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Lignans are traditionally defined as a class of secondary metabolites that are derived from the
dimersation of two or more phenylpropanoid units. Despite their common biosynthetic origins,
they boast a vast structural diversity. It is also well-established that this class of compounds
exhibits a range of potent biological activities. Owing to these factors, lignans have proven to be
a challenging and desirable synthetic target and have instigated the development of a number of
different synthetic methods, advancing our collective knowledge towards the synthesis of complex
and unique structures. Lignans are also well-known components of a number of widely eaten foods
and are frequently studied for their dietary impact. This book is based on the Special Issue of
the journal Molecules on ‘Lignans’. This collection of research and review articles describe topics
ranging in scope from recent isolation and structural elucidation of novel lignans, total syntheses
and strategies towards lignan synthesis, assessment of their biological activities and potential for
further therapeutic development. Research showing the impact of lignans in the food and agricultural
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The 13 research articles/communications, six reviews, and one perspective that comprise this
Special Issue on Lignans, highlight the most recent research and investigations into this diverse and
important class of bioactive natural products.
Lignans are traditionally defined as a class of secondary metabolites that are derived from the
oxidative dimerization of two or more phenylpropanoid units. Despite their common biosynthetic
origins, they boast a vast structural diversity. It is also well-established that this class of compounds
exhibit a range of potent biological activities. Owing to these factors, lignans have proven to be
a challenging and desirable synthetic target that has instigated the development of a number of
different synthetic methods, advancing our collective knowledge towards the synthesis of complex
and unique structures.
New lignans are constantly being found and this Special Issue details some of the most recently
discovered novel lignans—Liu et al. isolated three new dibenzocyclooctadiene lignans, heilaohulignans
A–C from Heilaohu, the roots of Kadsura coccinea, which have a long history of use in Tujia
ethnomedicine for the treatment of rheumatoid arthritis and gastroenteric disorders [1]. Heilaohulignan
C, in particular, demonstrated cytotoxic activity in a number of human cancer cell lines. Two new
lignan glycosides have also been found in the aerial portion of Lespedeza cuneata (Fabaceae), known
as Chinese bushclover, a plant that has been used in traditional medicine for the treatment of diseases
including diabetes, hematuria, and insomnia [2]. These newly-discovered compounds were tested for
their biological activities against human breast cancer cell lines, showing some cytotoxic activity.
A review detailing over 270 lignans isolated from Lauraceae, a valuable source of lignans and
neolignans is also presented, compiled by Li et al. [3]. Furthermore, Mexican Bursera plants have been
used in traditional medicine for treating various pathophysiological disorders and are a rich source of
lignans. An Italian research group have summarized the biological activities of lignans isolated from
selected Mexican Bursera plants in their review [4].
A subclass of lignans, norlignans lack a carbon present in the parent lignan structure, with
9-norlignans lacking a terminal carbon (C-9). An overview of the occurrence and biological activity
of all the 9-norlignans reported to date are given in the article by Eklund and Raitanen, which
also reports the semisynthetic preparation of a number of 9-norlignans using the natural lignan
hydroxymatairesinol, obtained from spruce knots, as the starting material [5].
As stated above, owing to their potent biological activities, lignans are a popular synthetic target.
A summary of the advances in lignan natural product synthesis over the last decade is outlined in the
review by Fang and Hu [6].
Davidson et al. have presented their work on their novel, efficient, convergent, and modular
synthesis of the well-known dibenzyl butyrolactone lignans through the use of the acyl-Claisen
rearrangement to stereoselectively prepare a key intermediate [7]. Not only were the natural products
able to be obtained, but the reported synthetic route also enabled the modification of these lignans
to give rise to 5-hydroxymethyl derivatives, which were then shown to have an excellent cytotoxic
profile which resulted in programmed cell death of Jurkat T-leukemia cells with less than 2% of the
incubated cells entering a necrotic cell death pathway.
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Advances in the synthesis of aryldihydronaphthalene and arylnapthalene lignans are also
detailed in this Special Issue through the concise synthesis of (+)-β- and γ-apopicropodophyllins
and dehydrodesoxypodophyllotoxin [8]. This was achieved using the key reaction involving
regiocontrolled oxidations of stereodivergent aryltetralin lactones, which were easily accessed from a
nickel-catalyzed reductive cascade approach.
As stated, lignans are formed from the oxidative dimerization of two or more phenyl propanoid
units. However, numerous oxidative transformations of lignans themselves have been reported in
the literature. Runeberg et al. provide an overview on the current findings in this field, focusing on
transformations targeting a specific structure, reaction, or an interconversion of the lignan skeleton [9].
The extensive analysis of the potent biological activities of lignans remains a popular avenue of
investigation. Antunez-Mojica et al. used a zebrafish embryo model to guide the chromatographic
fractionation of antimitotic secondary metabolites, ultimately leading to the isolation of several
podophyllotoxin-type lignans from the steam bark of Bursera fagaroides [10]. Subsequent to their
isolation, the biological effects on mitosis, cell migration, and microtubule cytoskeleton remodeling
of the isolated lignans were then further evaluated in zebrafish embryos through various methods.
Ultimately, it was demonstrated that the zebrafish model can be a fast and inexpensive in vivo model
to identify antimitotic natural products through bioassay-guided fractionation.
Pereira Rocha et al. combined the in silico prediction of biological activities of lignans
from Diphylleia cymosa and Podophyllum hexandrum with in vitro bioassays testing the antibacterial,
anticholinesterasic, antioxidant, and cytotoxic activities of these lignans [11]. In this study, the in silico
approach was validated and several ethnopharmacological uses and known biological activities of
lignans were confirmed, whilst it was shown that others should be investigated for new drugs with
potential clinical use.
To explore the differences in lignan composition profiles between various parts and genders
of Schisandra rubriflora and Schisandra chinesis (wuweizi), Szopa et al. used UHPLC-MS/MS [12].
Additionally, the anti-inflammatory activity of plant extracts and individual lignans was tested
in vitro for the inhibition of 15-lipooxygenase (15-LOX), phospholipases A2 (sPLA2), cyclooxygenase
1 and 2 (COX-1; COX-2) enzyme activities. The results of anti-inflammatory assays revealed higher
activity of S. rubriflora extracts, while individual lignans showed significant inhibitory activity against
15-LOX, COX-1 and COX-2 enzymes. Closely related, Chen et al. evaluated the quality and effect of
cultivated and wild growing methods on the lignan composition of Schisandra chinesis through the use
of UFLC-QTRAP-MS/MS in combination with multivariate statistical analysis, demonstrating that the
composition differs between plants grown in these conditions and the quality of cultivated wuweizi
was not as good as wild wuweizi [13].
While lignans have been shown to exhibit extensive potent biological activities, other factors need
to be considered for them to be potential drugs. The physicochemical properties of various lignans
subclasses were analyzed by Dr Lisa Pilkington to assess their Absorption, Distribution, Metabolism,
Excretion and Toxicity (ADMET) profiles and establish if these compounds are lead-like/drug-like
and thus have potential to be or act as leads in the development of future therapeutics [14]. Overall,
she established that lignans show a particularly high level of drug-likeness, an observation that,
coupled with their potent biological activities, demands future pursuit into their potential for use
as therapeutics.
Traditionally, health benefits attributed to lignans have included a lowered risk of heart disease,
menopausal symptoms, osteoporosis, and breast cancer. Rodriguez-Garcia et al. present a review that
focuses on the potential health benefits attributable to the consumption of different diets containing
naturally lignan-rich foods [15]. Current evidence endorses lignans as human health-promoting
molecules and, therefore, dietary intake of lignan-rich foods could be a useful way to bolster the
prevention of chronic illness, such as certain types of cancers and cardiovascular disease.
Lignan composition profiles of flaxseed, the richest grain source of lignans, was also studied,
assessing the relative impact of genetic and geographic parameters on the phytochemical yield and
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composition [16]. It was found that cultivar is more influential than geographic parameters on
the flaxseed phytochemical accumulation yield and composition. In addition, the corresponding
antioxidant activity of these flaxseed extracts was evaluated using both in vitro, and in vivo methods,
which confirmed that flaxseed extracts are an effective protector against oxidative stress and that
secoisolariciresinol diglucoside, caffeic acid glucoside, and p-coumaric acid glucoside are the main
contributors to the antioxidant capacity. A review of the use and effect of flaxseed as a food source
for dairy cows has also been presented [17], covering the gastrointestinal tract metabolism of lignans
in humans and animals. The review also provided an in-depth assessment of research towards
the impacts of flaxseed products on milk enterolactone concentration and animal health, and the
pharmacokinetics of enterolactone consumed through milk, which may have implications to both
ruminants and humans’ health.
With the rise in exploration of dietary lignans and their various effects, exemplified by the
aforementioned studies, the study by Durazzo et al. provides assessment and analysis of the
development and management of databases on dietary lignans, which includes a description of
the occurrence of lignans in food groups, the initial construction of the first lignan databases, and their
inclusion in harmonized databases at national and/or European level [18].
In addition to work into their notable biological activities, there has been a recent increase
in investigations exploring lignans in other roles. This includes gaining insight into the effects of
barrel-aging on spirits, whereby lignans present in the wooden barrels are released into the aging spirit.
To evaluate the impact of lignans in spirits, screening of a number of lignans was set up and served to
validate their presence in the spirit and release by oak wood during aging [19]. The most abundant,
and also the bitterest, lignan, (±)-lyoniresinol was detected and quantified in a large number of
samples to be above the gustatory threshold, suggesting its effect of increased bitterness in spirit taste.
Related to this, the molecular dynamics on wood-derived lignans were analyzed by intramolecular
network theory by Sandberg et al. [20]. These wood-derived lignan-based ligands called LIGNOLs
were studied, where it was found in the hydration studies that tetramethyl 1,4-diol is the LIGNOL
which was most likely to form hydrogen bonds to TIP4P solvent.
In summary, it can be seen in this Special Issue that research in natural lignans and lignin-derived
compounds continues to be a fruitful area of research. Scientists working across a large number of
disciplines continue to be attracted to work on lignans due to their relatively high natural abundance,
coupled with their highly potent and diverse range of biological activities.
Conflicts of Interest: The author declares no conflict of interest.
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Abstract: Heilaohu, the roots of Kadsura coccinea, has a long history of use in Tujia ethnomedicine
for the treatment of rheumatoid arthritis and gastroenteric disorders, and a lot of work has
been done in order to know the material basis of its pharmacological activities. The chemical
investigation led to the isolation and characterization of three new (1–3) and twenty known
(4–23) lignans. Three new heilaohulignans A-C (1–3) and seventeen known (4–20) lignans
possessed dibenzocyclooctadiene skeletons. Similarly, one was a diarylbutane (21) and two were
spirobenzofuranoid dibenzocyclooctadiene (22–23) lignans. Among the known compounds, 4–5, 7,
13–15 and 17–22 were isolated from this species for the first time. The structures were established,
using IR, UV, MS and NMR data. The absolute configurations of the new compounds were determined
by circular dichroism (CD) spectra. The isolated lignans were further evaluated for their cytotoxicity
and antioxidant activities. Compound 3 demonstrated strong cytotoxic activity with an IC50 value of
9.92 μM, compounds 9 and 13 revealed weak cytotoxicity with IC50 values of 21.72 μM and 18.72 μM,
respectively in the HepG-2 human liver cancer cell line. Compound 3 also showed weak cytotoxicity
against the BGC-823 human gastric cancer cell line and the HCT-116 human colon cancer cell line
with IC50 values of 16.75 μM and 16.59 μM, respectively. A chemiluminescence assay for antioxidant
status of isolated compounds implied compounds 11 and 20, which showed weak activity with IC50
values of 25.56 μM and 21.20 μM, respectively.
Keywords: lignans; heilaohu; tujia ethnomedicine; chemical characterization;
cytotoxicity; antioxidant
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1. Introduction
Kadsura coccinea (Lem.) A. C. Smith belongs to the medicinally important genus Kadsura from the
Schisandraceae family. It is an evergreen climbing shrub, which is mainly distributed in south-western
provinces of P. R. China [1]. Its leaves, fruits, stems and roots are used as medicine. The fruits have
unique shapes and high nutritional and medicinal values [2]. The stems and roots are called Heilaohu
in Tujia ethnomedicine for looking swarthy while dispelling wind effectively. The isolates of this plant
mainly contain lignans, triterpenoids and essential oils. Bioactive lignans and triterpenoids from this
plant are of special interest [3]. The compounds from genus Kadsura have been reported with different
bioactivities including anti-tumor [4,5], anti-HIV [6–8], anti-inflammatory [9,10], inhibition of nitric
oxide (NO) production [11,12] and other pharmacological effects.
The lignans from Heilaohu are very important due to their bioactivities and structural diversity.
The lignans from this plant can be divided into four different categories on the basis of skeleton types:
dibenzocyclooctadienes, spirobenzofuranoid dibenzocyclooctadienes, diarylbutanes, and aryltetralins
lignans. Dibenzocyclooctadiene (two benzene rings sharing an eight membered ring neighborhood) is
the most common basic skeleton in Heilaohu. Methoxy, hydroxyl and methylenedioxy are the most
frequently found substituents at benzene rings, while other important substituents including acetyl-,
angeloyl-, tigloyl-, propanoyl-, benzoyl-, cinnamoyl- and butyryl- groups are invariably presented
at C-1, C-6 or C-9 [13–15]. Spirobenzofuranoid dibenzocyclooctadienes are rare in other genera and
can be considered as the characteristic chemical constituents of genus Kadsura. This category features
a furan-ring at C-14, C-15 and C-16 positions and a ketonic group at the C-1 or C-3 position [3], and the
same connections on the eight membered ring located at the C-6 or C-9 position. Diarylbutanes and
aryltetralins have previously been reported but are not very common in genus Kadsura, and most of
them were found in the DCM (CHCl3) layer and EtOAc layer.
This work was conducted to further explore lignans from Heilaohu. The chemical investigation
led to the isolation and characterization of three new (1–3) and twenty known (4–23) lignans. The three
new Kadsura lignans A–C (1–3) and seventeen known lignans, schizandrin (4) [16], binankadsurin
A (5) [17], acetylbinankadsurin A (6) [18], isobutyroylbinankadsurin A (7) [19], isovaleroylbinankadsurin
A (8) [19], kadsuralignan I (9) [20], kadsuralignan J (10) [20], kadsuralignan L (11) [21], kadsulignan
N (12) [22], longipedunin B (13) [15], schisantherin F (14) [23], schizanrin D (15) [23], acetylgomisin R
(16) [24], intermedin A (17) [25], kadsurarin (18) [14], kadsutherin A (19) [25] and kadsuphilol A (20) [26]
possessed dibenzocyclooctadiene skeletons. Similarly, meso-dihydroguaiaretic acid dimethyl (21) [27] had
a diarylbutane type. Schiarianrin E (22) [28] and schiarisanrin A (23) [29] contained spirobenzofuranoid
dibenzocyclooctadiene lignan skeletons.
A literature survey revealed that kadsulignan I (9) exhibited inhibitory effects on LPS-induced
NO production in BV-2 cells with IC50 value of 21.00 μM [30]. Kadsuralignan L (11) demonstrated
moderate NO production inhibitory activity with an IC50 value of 52.50 μM [21]. Heilaohu has been
used for the treatment of rheumatoid arthritis in traditional medicine for a long time, and a few
of its isolated compounds have been used for their anti-inflammatory and cytotoxic activities [3].
With the aim of searching for natural compounds which are responsible for folk efficacy and medicinal
application as anti-cancer agents and as anti-inflammatory agents, we employed a chemiluminescence
assay for anti-oxidant activity to find out the anti-inflammatory properties of a compound. We also
used a cytotoxicity assay against cancer cell lines, namely HepG-2 human liver cancer cells, BGC-823
human gastric cancer cells and HCT-116 human colon cancer cells, after the chemical characterization
of compounds.
2. Results and Discussion
2.1. Structure Characterization of the Isolated Compounds from Heilaohu
Heilaohulignan A (1) (Figure 1) was obtained as an amorphous powder. Its molecular formula,
C26H32O8, was determined by [M + Na]+ ion peak at m/z 495.1998 (calcd. 495.1995) in HR-ESI-MS,
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showing 11 degrees of unsaturation. The UV data, with absorption maxima at λmax 242 nm, and its
IR spectrum, with absorption bands at 3419 (OH), 1645 (C=C) and 1463 cm−1 (aromatic moiety),
suggested that 1 is a dibenzocyclooctadiene lignan with a hydroxyl substitution.
Figure 1. Structures of heilaohulignans A–C (1–3).
The 1H- and 13C-NMR spectra of 1 (Table 1) indicated the presence of 12 aromatic carbons (δC
141.7 (C-1), 138.8 (C-2), 151.5 (C-3), 113.0 (C-4), 134.8 (C-5), 102.4 (C-11), 148.8 (C-12), 135.0 (C-13),
140.3 (C-14), 118.2 (C-15) and 122.9 (C-16)) and two aromatic proton singlets at δH 6.71 (1H, s) and
6.32 (1H, s), which were assignable to H-4 and H-11, respectively. A butane chain was deduced on the
cross-peaks of H-6 (δH 2.65, m), H-7 (δH 2.01, m), H-8 (δH 1.81, m) and H-9 (δH 4.73, s) in the 1H-1H
COSY spectrum. In addition, in the HMBC spectrum, correlations were found between H-9 and C-10,
C-8 and C-15, and between H-6 and C-4, C-7 and C-16. The functional moieties evident from the 1H-
and 13C-NMR data included one methylenedioxy, three methoxy groups and four methyl groups; the
presence of signals at δH 0.97 (d, J = 7.0 Hz, 3H), 1.09 (d, J = 7.0 Hz, 3H) and 2.61 (m, 1H), and δC 176.7
(C=O), 18.7 (CH3), 18.7 (CH3), 34.0 (CH) suggested the presence of an isobutyroyl group.
Table 1. 1H- (600 MHz) and 13C-NMR (150 MHz) data of compounds 1, 2, and 3 (CDCl3).
Number
1 2 3
δH (ppm) J (Hz) δC (ppm) δH (ppm) J (Hz) δC (ppm) δH (ppm) J (Hz) δC (ppm)
1 − 141.7 − 143.0 − 147.0
2 − 138.8 − 140.2 − 133.6
3 − 151.5 − 152.2 − 150.5
4 6.71 s 113.0 6.58 s 113.5 6.41 s 106.9
5 − 134.8 − 131.3 − 133.5
6 2.65 m 38.9 2.50 m, 3.03 m 34.6 2.66 m 38.6
7 2.01 m 35.1 2.04 m 43.0 2.12 m 34.8
8 1.81 m 43.0 − 80.9 2.10 m 41.7
9 4.73 s 82.8 − 207.3 5.62 s 82.9
10 − 134.8 − 135.4 − 136.0
11 6.32 s 102.4 6.52 s 100.7 6.54 s 103.0
12 − 148.8 − 148.7 − 148.9
13 − 135.0 − 136.9 − 136.1
14 − 140.3 − 141.7 − 141.1
15 − 118.2 − 117.7 − 119.0
16 − 122.9 − 121.6 − 117.1
17 1.01 d (7.3) 15.3 1.33 s 23.3 1.09 d (7.0) 19.8
18 1.17 d (7.3) 20.0 0.89 d (7.1) 14.8 1.61 dd (7.1, 1.1) 14.2
19 5.93 dd (8.9, 1.4) 101.0 5.96 s, 6.02 s 101.6 5.98 s, 5.93 s 101.2
1′ − 176.7 − 173.1 − 167.5
2′ 2.61 dt (13.9, 6.9) 34.0 2.43 m 41.5 − 127.6
3′ 0.97 d (7.0) 18.7 1.40 m, 1.62 m 26.8 6.02 d (1.5) 137.2
4′ 1.09 d (7.0) 18.7 0.86 t (7.4) 11.7 1.47 s 11.8
5′ − − 1.02 d (7.0) 16.9 0.97 d (7.1) 15.0
2-OCH3 3.96 s 59.6 3.80 s 60.6 3.84 s 60.7
3-OCH3 3.78 s 61.1 3.86 s 56.1 3.84 s 59.8
14-OCH3 3.89 s 56.0 3.88 s 59.8 3.90 s 55.8
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Further analysis of the HMBC spectrum (Figure 2) showed three methoxy groups (δH 3.96, 3.78,
3.89, 2-OCH3, 3-OCH3 and 14-OCH3, respectively), with two secondary methyl groups (δC 15.3 and
20.0) assignable to CH3-17 and CH3-18, respectively, and one methylenedioxy group (δH 6.07, 6.02, each
1H, d, J = 1.5 Hz) located between C-12 and C-13. The NMR data was similar to a known compound,
binankadsurin A (5) [17]. However, different carbon and proton chemical shifts for C-1′, C-2′, C-3′
and C-4′ indicated that the methyl group located at C-1 was substituted by an isobutyroyl group.
Thus, the planar structure of compound 1 was established.
Figure 2. Key HMBC and NOESY correlations of heilaohulignan A (1) and ROESY correlations of
heilaohulignans B–C (2–3).
The biphenyl group in 1 was found to have a twisted boat/chair configuration from its CD
spectrum (Figure S63), which showed a negative Cotton effect around 250 nm and a positive value
around 220 nm, favoring the S-biphenyl configuration as gomisin F [31,32] suggesting 1 possesses an
S-biphenyl configuration [28]. The observed NOESY correlations (Figure 2) of δH 6.71 (H-4) and δH
2.01 (H-7), δH 1.01 (H3-17), δH 6.32 (H-11) and δH 1.81 (H-8), δH 4.73 (H-9), indicated that CH3-17 was
α-oriented, and CH3-18 and H-9 as β-oriented. Hence, 7S, 8R, and 9R configurations were confirmed at
C-7, C-8, and C-9, respectively. Based on these data, the structure of 1 was unambiguously determined
and was named as heilaohulignan A.
Heilaohulignan B (2) (Figure. 1) was obtained as an amorphous powder. Its molecular formula
C27H32O9 was determined by [M + COOH]− ion peak at m/z 545.2028 (calcd. 545.2026) in HR-ESI-MS.
The UV absorption bands at 241 nm and IR absorption bands at 3446 (OH), 1704 (C=O) and
1457, 1579 cm−1 (aromatic ring) suggested 2 as a dibenzocyclooctadiene lignan possessing a hydroxy
group and an ester.
The 1H- and 13C-NMR spectra of 2 (Table 1) supported a dibenzocyclooctadiene lignan
basic skeleton with one methylenedioxy, three methoxy, and a 2-methylbutyryloxy (O-isovaleryl)
substituents. The 1H-NMR signals at δH 2.43 (m, H-2′), 1.40 (m, H-3′), 1.62 (m, H-3′), 0.86 (t, J = 7.4,
H-4′), 1.02 (d, J = 7.0, H-5′) and 13C-NMR signals at δC 173.1 (C-1), 41.5 (C-2′), 26.8 (C-3′), 11.7 (C-4′),
and 16.9 (C-5′) were assignable to a 2-methylbutyryloxy group. Comparison of the NMR data of 2
with a known lignan, kadoblongifolins A, showed great similarity [14]. The only difference was the
presence of a 2-methylbutyryloxy (O-isovaleryl) group at C-1 in 2.
The HMBC correlations (Figure 2) of methylenedioxy hydrogens (δH 5.96, 1H, s, OCH2O-19a, 6.02,
1H, s, OCH2O-19b) with carbons at δC 138.8 (C-12) and 151.5 (C-13) were used to locate its attachment
to C-12 and C-13. The methoxy groups were located at C-2, C-3, and C-14, with one secondary methyl
group (δC 14.8) assignable to CH3-18 and one quaternary methyl group (δC 23.3) assignable to CH3-17.
The keto group position was confirmed at C-9 by HMBC correlations of H-11 (δH 6.52) and H3-17
(δH 1.33) with C-9 (δC 207.3).
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The CD curve of 2 (Figure S64) showed a positive Cotton effect around 205 nm and a negative
Cotton effect around 254 nm, favoring the S-biphenyl configuration as gomisin F [31,32]. The ROESY
(Rotating Frame Overhauser Effect) spectrum (Figure 2) of 2 showed cross-correlation peaks between
δH 6.58 (H-4) and δH 0.89 (CH3-18); δH 2.04 (H-7) and δH 1.33 (CH3-17), which confirmed that CH3-17
was β-oriented and CH3-18 was α-oriented, thus supporting 7R and 8R configurations. The compound
2-methylbutyryl is derived from 2-methylbutyryl-CoA biosynthetically, in which the stereochemistry
of 2-methyl group is S. As stereochemistry is retained, the configuration in the 2-methylbutyryl
group was shown as S. Based on these spectral data, the structure of 2 was deduced and named as
heilaohulignan B.
Heilaohulignan C (3) (Figure 1) was obtained as a yellow oil. Its molecular formula, C27H32O8,
was determined by [M + Na]+ ion at m/z 507.1990 (calcd. 507.1995) in HR-ESI-MS, suggesting 12
degrees of unsaturation. The UV data, with absorption maxima at λmax 242 nm, and its IR spectrum,
with absorption bands at 3417 (-OH), 1700 (C=O) and 1613, 1503 cm−1 (aromatic moiety), suggested 3
as a dibenzocyclooctadiene lignan with a hydroxyl substitution.
The 1H- and 13C-NMR spectra of 3 (Table 1) indicated the presence of 12 aromatic carbons,
two aromatic protons, one methylenedioxy and three methoxy groups, suggesting the presence of
a biphenyl moiety. A butane chain was deduced on the cross-peaks of H-6 (δH 2.66, m), H-7 (δH
2.12, m), H-8 (δH 2.10, m) and H-9 (δH 5.62, s) in the 1H-1H COSY spectrum. In the HMBC spectrum
(Figure 2.), two methyl groups (CH3-17, CH3-18) exhibited correlations with C-8 and C-9, and three
methoxy groups at δH 3.84, 3.84 and 3.90 (2-OCH3, 3-OCH3 and 14-OCH3) showed correlations with
C-2, C-3, and C-14, respectively, confirming these substituted groups of positions undoubtedly. Thus,
the planar structure of compound 3 was the same as angloybinankadsurin A [15]. However, the
chemical shifts of C-4′ and C-5′ of 3 were around 4–5 ppm different from the known, which led to
doubt about the stereochemistry of 3.
The biphenyl group in 3 was determined to have an S-biphenyl configuration from its CD
spectrum (Figure S65), identical to that of 1 and 2. However, the ROESY experiment (Figure 2) revealed
that cross-correlation peaks between δH 6.41 (H-4) and δH 0.97 (H3-5′); δH 6.54 (H-11) and δH 2.12 (H-7),
δH 5.62 (H-9); δH 5.62 (H-9) and δH 1.09 (H3-17), δH 2.12 (H-7); δH 1.61 (H3-18) and δH 1.47 (H3-4′)
confirmed that CH3-17 was β-oriented and CH3-18 was α-oriented, which were essentially different
from the known angloybinankadsurin A [15], where CH3-17 and CH3-18 are both α-oriented. Thus R,
S, and R configurations were confirmed at C-7, C-8, and C-9, respectively. The ROESY correlation
peaks between δH 6.02 (H-3′) and δH 0.97 (H3-5′), and comparison of data in the literature supported
Z-configuration for the double bond in the angeloyloxy moiety. Based on these spectral data, the
complete structure of 3 was established and it was named as heilaohulignan C.
The spectroscopic data of known compounds (Figures S20–S59) were in good agreement
with those reported in the literature. Thus, the known compounds were identified as
schizandrin (4), binankadsurin A (5), acetylbinankadsurin A (6), isobutyroylbinankadsurin A (7),
isovaleroybinankadsurin A (8), kadsuralignan I (9), kadsuralignan J (10), kadsuralignan L (11),
kadsulignan N (12), longipedunin B (13), schisantherin F (14), schizanrin D (15), acetylgomisin R (16),
intermedin A (17), kadsurarin (18), kadsutherin A (19), kadsuphilol A (20), meso-dihydroguaiaretic
acid dimethyl ether (21), schiarianrin E (22), and schiarisanrin A (23) (Figure S1).
For the chemical characterization of dibenzocyclooctadienes, there was little to distinguish among
different compounds whether the substituents linked to C-1 or C-6/C-9. When the substituents such
as acetyl-, angeloyl-, tigloyl-, propanoyl-, benzoyl-, cinnamoyl- and butyryl- groups connected to
C-6/C-9, δH-6/9 was displayed over 5.5 ppm and the relationship with C-1′ could be found in HMBC,
while δH-6/9 would be revealed around 4.7 ppm if substituents attached to C-1. For spirobenzofuranoid
dibenzocyclooctadienes, δC-1/3 with a ketonic group at 195 ppm nearby and δC-16 around 65 ppm could
be classified in 13C-NMR. In addition, δC-20 around 78 ppm (CH2) is a typical signal in this compound.
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2.2. Cytotoxic Activity of Isolated Compounds
Compounds 1–23 were assayed for their cytotoxic activity against the HepG-2 human liver
cancer cell line, the BGC-823 human gastric cancer cell line and the HCT-116 human colon cancer
cell line. The results are summarized in Table 2: heilaohulignan C (3) showed good cytotoxicity in
HepG-2 human liver cancer cells with IC50 values of 9.92 μM, and weak cytotoxicity against BGC-823
human gastric cancer cells and HCT-116 human colon cancer cells with IC50 values of 16.75 μM and
16.59 μM, respectively. Meanwhile, in the HepG-2 human liver cancer cell line, kadsuralignan I (9)
and longipedunin B (13) revealed weak cytotoxicity with IC50 values of 21.72 μM and 18.72 μM,
respectively. The remaining compounds showed no cytotoxicity against the three cancer cell lines.
Compounds 3, 9 and 20 demonstrated good activity against all cells. Compounds 1–20, bearing the
same dibenzocyclooctadiene skeleton, indicate that spatial configuration and the relative configuration
of structures may have an impact on bioactivities.
Table 2. Cytotoxicity data of compounds 3, 9 and 13.
Compound
Cell Lines
Hep G-2 HCT-116 BGC-823
3 9.92 16.59 16.75
9 21.72 NO NO
13 18.72 NO NO
Taxol ≤0.10 ≤0.10 ≤0.10
Results are expressed as IC50 in μM; Taxol used as a positive control; ‘NO′ = no activity.
2.3. Antioxidant Activity of Isolated Compounds
Compounds 1–23 were assayed for their antioxidant activity using a chemiluminescence assay.
As shown in Table 3, kadsuralignan L (11) showed weak activity with an IC50 value of 25.56 μM,
and kadsuphilol A (20) with an IC50 value of 21.20 μM. The remaining compounds exhibited no
antioxidant activity.
Table 3. Antioxidant activity data of compounds 11 and 20.




Results are expressed as IC50 in μM; Vitamin E used as a positive control.
3. Materials and methods
3.1. Plant Material
Heilaohu were collected from Huaihua City of Hunan Province, China. The plant was identified
by Wei Wang. It has been deposited at Sino-Pakistan TCM (Traditional Chinese Medicine) and
the Ethnomedicine Research Center, School of Pharmacy, Hunan University of Chinese Medicine,
Changsha, China.
3.2. General and Solvents
The HR-ESI-MS spectra were performed on Waters UHPLC-H-CLASS/XEVO G2-XS Qtof, Waters
Corporation, Milford, MA, USA. NMR data were recorded on Bruker AV-600 spectrometers (Bruker
Technology Co., Ltd., Karlsruhe, Germany) with TMS (Tetramethylsilane) as an internal standard.
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Column chromatographic silica gel (80–100 mesh, 200–300 mesh and 300–400 mesh) was purchased
from Qingdao Marine Chemical Inc., Qingdao, China. Semipreparative HPLC was performed on
an Agilent 1100 liquid chromatograph (Agilent Technologies, Santa Clara, CA, USA) with an Agilent
C18 (34 mm × 25 cm) column. Fractions were monitored by TLC, and spots were visualized by
heating silica gel plates sprayed with 5% H2SO4 in vanillin solution. Petroleum ether (PE), hexane,
ethyl acetate (EtOAc), ethanol, n-butanol (n-BuOH), methanol (MeOH) and dichloromethane (CH2Cl2)
were purchased from Shanghai Titan Scientific Co., Ltd, Shanghai, China. Acetonitrile (HPLC grade)
and methanol (HPLC grade) were from Merck KGaA, 64271 Darmstadt, Germany.
3.3. Experimental Procedures
Heilaohu (200 kg) was extracted twice with 80% ethanol for 2 h under reflux extraction. All extract
solvents were evaporated under vacuum to obtain a crude extract (6 kg). Half of the extracts (3 kg)
were suspended in water and partitioned with PE, CH2Cl2, EtOAc and n-BuOH, respectively.
The CH2Cl2 layer (945 g) was crudely separated on a silica gel column (6 kg, 25 cm × 75 cm)
using gradient elution with cyclohexane/ethyl acetate/methanol (80:1:0, 20:1:0, 10:1:0, 5:1:0, 1:1:0,
0:1:0, 0:0:1, v:v) to afford twelve fractions. Fraction 5 (49.5 g) was subjected to a silica gel column
(8 cm × 45 cm, 800 g), and eluted with cyclohexane/CH2Cl2 /EA (1:0:0, 80:1:0, 40:1:0, 20:1:0, 10:1:0,
5:1:0, 3:1:0, 2:1:0, 1:1:0, 0:1:0, 0:40:1, 0:20:1, 0:10:1, 0:5:1, v:v:v) to obtain twelve sub-fractions (E1–E12).
Sub-fraction E6 (2.0 g) was repeated purified by a silica gel column (3 cm × 60cm, 40 g) eluted with
hexane/CHCl3/acetone (10:20:1, 20:10:1, 20:20:1, 40:10:1, v:v:v) to yield 2 (3 mg). Fraction 8 (40 g) was
chromatographed by column chromatography on a silica gel (5 cm× 80 cm, 400 g) using the gradient
system (CH2Cl2/methanol, 40:1, 20:1, 10:1, 5:1, 3:1, 1:1, 0:1, v:v) to afford ten fractions (H1–H10).
Sub-fraction H7 (PE/CHCl3/methanol, 80:1:0, 15.0 g) was repeat purified by a silica gel column (4 cm
× 45cm, 100 g) eluted with PE/CHCl3/methanol (40:1:0, 20:1:0, 10:1:0, 5:1:0, 3:1:0, 2:1:0, 1:1:0, 0:1:0,
0:40:1, 0:20:1, 0:10:1, 0:0:1, v:v:v) to afford 6 (800 mg). Sub-fraction H8 (15.0 g) was repeat purified
by a silica gel column (4cm × 60 cm, 450 g) eluted with PE/acetone (40:1, 20:1, 10:1, 5:1, 3:1, 2:1:0,
1:1, v:v) to yield 5 (300 mg). Fraction 9 (53.9 g) was chromatographed by column chromatography on
a silica gel (7cm× 60 cm, 500 g) using the gradient system (PE/EA,10:1, 5:1, 3:1, 2:1, 1:1, 0:1, v:v) to
afford fourteen fractions (I1–I14). Sub-fraction I10 (0.5 g) was repeated purified by an RP-18 column
eluted with methanol/water (40%, 50%, 60%, 70%, 80%, 90%, 100%) to yield 4 (5 mg). Sub-fraction
I10-4 was purified by semi preparative HPLC with 73% MeOH-H2O to obtain 17 (5 mg, tR = 20.6 min).
Sub-fraction I10-6 was purified by semi preparative HPLC with 71% MeOH-H2O to obtain 18 (15 mg,
tR = 41.3 min). Sub-fraction I12 was purified by semi preparative HPLC with 72% MeOH-H2O to yield
19 (15 mg, tR = 78.1 min) and 20 (25 mg, tR = 29.0 min).
The EtOAc layer (530 g) was separated into eight fractions (fraction 1–8) on a 80–100 mesh silica
gel column (6.5 kg), using a step gradient elution with PE/EtOAc (10:0, 20:1, 9:1, 8:2, 7:3, 6:4, 1:1, 0:10).
Fraction 3 (90 g) was applied to a silica gel column (200–300 mesh, 4.5 kg) with cyclohexane/EtOAc
(10:0, 95:5, 90:1, 85:15, 8:2, 7:3, 6:4, 1:1), so as to afford 10 sub-fractions. Sub-fractions were subjected
to repeated silica gel columns (isocratic elution and step gradient elution) and Sephadex LH-20
(MeOH/H2O = 1:1) to give compounds 1 (11.9 mg), 7 (7.7 mg) and 8 (2.1 g), and the mini-fractions were
conducted to semi preparative HPLC (MeOH-H2O) to gain compound 3 (14.6 mg) (77% MeOH-H2O),
9 (28.4 mg) (80% MeOH-H2O), 10 (35.6 mg) (80%MeOH/H2O), 13 (7.3 mg) (76%MeOH-H2O) and
22 (9.0 mg) (80%MeOH-H2O). Fraction 4 (60 g) was purified by a silica gel column (300–400 mesh,
4 kg) with PE/EtOAc (10:0, 10:1, 9:1, 8:2,7:3, 6:4, 1:1) to provide 12 sub-fractions. Fraction 5 (50 g) was
chromatographed on a silica gel (300–400 mesh, 3.5 kg) to obtain 12 sub-fractions. Sub-fractions from
fraction 4 and 5 were fractionated under the same chromatography conditions to obtain compounds 11
(130.1 mg), 12 (29.6 mg), 14 (7.3 mg), 15 (23.2 mg), 16 (2.7 mg), 21 (1.3 mg) and 23 (4.8 mg). The solvents
of recrystallization of 7, 8 and 9 were MeOH (HPLC grade), cyclohexane and hexane, respectively.
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3.4. Spectroscopic Data of New Compounds
Heilaohulignan A (1): Amorphous powder, [α]25D − 160.0 (c = 0.0125, CHCl3), UV (MeOH) λmax (log ε):
242 (4.57) nm, IR (KBr) νmax 3419, 1645, 1463, 1101, 721, 655 cm−1; 1H- and 13C-NMR data, Table 1;
+HR-ESI-MS m/z 495.1998 ([M + Na]+, calcd. 495.1995).
Heilaohulignan B (2):Amorphous powder, [α]25D + 40.0 (c = 0.10, CHCl3), UV (MeOH) λmax (log ε):
241(4.58) nm, IR (KBr) νmax 3446, 2932, 2360, 1704, 1457, 1102; 1H- and 13C-NMR data, Table 1;
−HR-ESI-MS m/z 545.2028 ([M + COOH]−, calcd. 545.2026).
Heilaohulignan C (3): Yellow oil, [α]25D + 48.0 (c = 0.09, CH3OH), UV (MeOH) λmax (log ε): 241 (4.59)
nm; IR (KBr) νmax 3417, 2945, 1700, 1457, 1368, 1248, 1108, 1025, 1H- and 13C-NMR data, Table 1;
+HR-ESI-MS m/z 507.1990 ([M + Na]+, calcd. 507.1995).
3.5. Cytotoxicity Assay
Cell viability was determined by MTT assay [33]. Taxol was used as a positive control. HepG-2
human liver cancer cells, BGC-823 human gastric cancer cells and HCT-116 human colon cancer
cells were seeded at 6 × 103 cells/well in 96-well plates. Cells were allowed to adhere overnight,
and then the media were replaced with fresh medium containing selected concentrations of the natural
compounds dissolved in DMSO. After 48 h incubation, the growth of the cells was measured. The effect
on cell viability was assessed as the percent cell viability compared with the untreated control group,
which were arbitrarily assigned 100% viability. The compound concentration required to cause 50% cell
growth inhibition (IC50) was determined by interpolation from dose–response curves. All experiments
were performed in triplicate.
3.6. Antioxidant Assay
Chemiluminescence (CL) [34] was applied to the antioxidant assay process. Chemiluminescence
(CL) is a sensitive and accurate method for the measurement of the ability of samples to inhibit
the generation of reactive oxygen species (ROS). The positive control was Vitamin E. In our study,
we used phorbol 12-myristate 13-acetate (PMA) as stimulus for the production of different ROS by
the phagocytic cells. PMA is activator of protein kinase C and an activator of nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase. Neutrophils stimulated with PMA give rise to robust
chemiluminescence signals by a consequent increase in ROS production. The results were monitored
by an Enspire Multimode Plate Reader, Perkin Elmer (EnSpire 2300, PerkinElmer, Singapore) as counts
per second (CPS). Briefly, 40 μL diluted whole blood (1:25 dilution in sterile PBS, pH 7.4) or 40 μL poly
morphonuclear neutrophils (PMN) (1 × 106/mL) suspended in hanks balanced salt solution (HBSS++),
were incubated with different concentrations of compounds. The cells were stimulated with 40 μL
of PMA followed by lucigenin as an enhancer (0.5 mM), and then HBSS++ was added to adjust the
final volume to 200 μL. The final concentrations of the samples in the mixture were 2.5 μM, 5 μM,
10 μM, 20 μM and 40 μM. Tests were performed in white 96-well microplates which were incubated at
22 ◦C for 30 min. Control wells contained HBSS++ alone, lucigenin with PMA and cells but no test
compounds, and cells with positive control. The inhibition percentage (%) for each concentration was
calculated using the following formula:
Inhibition percentage (%) = 100 − (CPS test / CPS control) × 100
4. Conclusions
Phytochemical investigation on DCM and EtOAc fractions from Heilaohu were carried out.
Twenty-three lignans were isolated and identified by spectroscopic techniques such as 1D-, 2D-NMR
and HR-ESI-MS, including three new dibenzocyclooctadiene lignans, heilaohulignans A–C (1–3),
together with 20 known compounds. Among the known compounds, 12 compounds (4–5, 7, 13–15
and 17–22) were isolated from this species for the first time.
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All isolated compounds were evaluated for their cytotoxicities and antioxidant bioassays. The new
dibenzocyclooctadiene heilaohulignans A and B (1–2) did not exhibit potential activity on evaluation
of cytotoxicity and antioxidant activity. Heilaohulignan C (3) demonstrated good cytotoxicity with
IC50 value of 9.92 μM against HepG-2 human liver cancer cell line, as well as weak cytotoxicity
against BGC-823 human gastric cancer cells and HCT-116 human colon cancer cells with IC50 values of
16.75 μM and 16.59 μM, respectively. Compounds 9 and 13 revealed weak cytotoxicity with IC50 values
of 21.72 μM and 18.72 μM, respectively in HepG-2 human liver cancer cells. The chemiluminescence
assay implied that compounds 11 and 20 showed weak activity with IC50 values of 25.56 μM and
21.20 μM, respectively. Consequently, the underlying cytotoxicity and antioxidant mechanisms of
dibenzocyclooctadiene lignans, as well as their main active constituents, need to be further investigated
and clarified, providing the material basis on the relationship between traditional uses and modern
pharmacological activities.
Supplementary Materials: The following are available online. Figure S1 is structures of compounds 1–23 isolated
from Heilaohu. Figures S2–S19 are NMR data of new compounds (1–3); Figures S20–S59 are 1H- and 13C-NMR of
known compounds (4–23); Figures S60–S62 HRESIMS spectrum of new compounds (1–3); Figures S63–S65 are CD
spectrum of new compounds (1–3).
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Abstract: Lespedeza cuneata (Fabaceae), known as Chinese bushclover, has been used in traditional
medicines for the treatment of diseases including diabetes, hematuria, and insomnia. As part of a
continuing search for bioactive constituents from Korean medicinal plant sources, phytochemical
analysis of the aerial portion of L. cuneata led to the isolation of two new lignan glycosides (1,2)
along with three known lignan glycosides (3–7) and nine known flavonoid glycosides (8–14).
Numerous analysis techniques, including 1D and 2D NMR spectroscopy, CD spectroscopy, HR-MS,
and chemical reactions, were utilized for structural elucidation of the new compounds (1,2).
The isolated compounds were evaluated for their applicability in medicinal use using cell-based
assays. Compounds 1 and 4–6 exhibited weak cytotoxicity against four human breast cancer cell lines
(Bt549, MCF7, MDA-MB-231, and HCC70) (IC50 < 30.0 μM). However, none of the isolated compounds
showed significant antiviral activity against PR8, HRV1B, or CVB3. In addition, compound 10
produced fewer lipid droplets in Oil Red O staining of mouse mesenchymal stem cells compared to
the untreated negative control without altering the amount of alkaline phosphatase staining.
Keywords: Lespedeza cuneata; lignan glycoside; flavonoid glycoside; cytotoxicity; adipocyte and
osteoblast differentiation
1. Introduction
Lespedeza cuneata (Dum. Cours.) G. Don. (Fabaceae), known as Chinese bushclover, is a warm-season,
perennial legume that is widely distributed in Korea, China, and India [1]. This plant has been used
in folk medicine for the treatment of diseases, including diabetes, hematuria, and insomnia, as well
as for the protection of the kidneys, liver, and lungs [2,3]. Previous pharmacological studies of this
medicinal plant have revealed that extracts of L. cuneata exhibit inhibition of inflammatory mediators
in Lipopolysaccharide (LPS)-activated RAW264.7 cells and paw edema in carrageenan-stimulated
rats [4], as well as hepatoprotective and antidiabetic effects [1,2,5,6]. A recent study of L. cuneata extract
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reported its in vitro cytotoxic effects against several cancer cell lines including HeLa, Hep3B, A549, and
Sarcoma180 [7]. In terms of phytochemical components, it is a rich source of various compounds such as
steroids, flavonoids, phenolics [3,6,8], phenylpropanoids [2,9], lignans [5,9], and phenyldilactones [10].
Among the constituents, lignans, and flavonoids are the main components of L. cuneata, and the lignans
were found to have hepatoprotective [5] and anti-ulcerative colitis activities [9], and the flavonoids
were reported to show hepatoprotective [6] and NO-inhibitory effects [11].
As part of a continuing search for bioactive constituents from Korean medicinal plant
sources [12–14], the methanol (MeOH) extract of the aerial portion of L. cuneata was found to
exhibit cytotoxic effects on human ovarian carcinoma cells [15]. In our recent study, bioassay-guided
fractionation and repeated chromatography of the MeOH extract of L. cuneata resulted in isolation
of (−)-9′-O-(α-L-rhamnopyranosyl)lyoniresinol, which suppresses the proliferation of A2780 human
ovarian carcinoma cells through induction of apoptosis [15]. In the current study investigating bioactive
compounds from the aerial portion of L. cuneata, further phytochemical analysis was carried out, which
led to the isolation of two new lignan glycosides (1,2) along with three known lignan glycosides (3–7)
and nine known flavonoid glycosides (8–14). Numerous analysis techniques, including 1D and 2D
NMR spectroscopy, CD spectroscopy, HR-MS, and chemical reactions, were utilized for structural
elucidation of the new compounds (1,2). Subsequently, we investigated the possible therapeutic effects
of the isolated compounds using various cell-based assays. In this paper, we describe the isolation and
structural characterization of compounds 1–14 (Figure 1), as well as the evaluation of their applicability
to medicinal use including their cytotoxicity, antiviral activity, and their effects on the regulation of
adipocyte and osteoblast differentiation.
Figure 1. Chemical structures of compounds 1–14. Glc, glucopyranosyl; Rha, rhamnopyranosyl;
Ara(f), arabinofuranosyl.
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2. Results and Discussion
2.1. Isolation of the Compounds
The dried aerial portion of L. cuneata was extracted with 80% MeOH to produce the methanolic
extract, which was sequentially solvent-partitioned with hexane, CH2Cl2, EtOAc, and n-BuOH to
obtain each solvent fraction. Phytochemical analysis of the EtOAc fraction using repeated column
chromatography and high performance liquid chromatography (HPLC) purification led to the isolation
of two new lignan glycosides (1,2) along with three known lignan glycosides (3–7) and nine known
flavonoid glycosides (8–14) (Figure 1).
2.2. Structure Elucidation of the Compounds
Compound (1) was isolated as a colorless gum with an optical rotation of ([α]25D +24.0 (c 0.05,
MeOH). The molecular formula was determined to be C26H36O10 from the molecular ion peak [M + H]+
at m/z 509.2384 (calculated for C26H37O10 509.2387) in positive mode High-resolution electrospray
ionisation mass spectrometry (HRESIMS) and the NMR spectroscopic data (Table 1). The infrared (IR)
spectrum exhibited absorptions of hydroxy groups (3351 cm−1) and phenyl rings (1521 and 1455 cm−1).
The 1H NMR spectrum (Table 1) showed signals from two sets of aromatic protons, one at δH 6.67
(1H, d, J = 8.0 Hz, H-5), 6.56 (1H, d, J = 2.0 Hz, H-2), and 6.53 (1H, dd, J = 8.0, 2.0 Hz, H-6) and
another at δH 6.66 (1H, d, J = 8.0 Hz, H-5’), 6.54 (1H, d, J = 2.0 Hz, H-2’), and 6.53 (1H, dd, J = 8.0,
2.0 Hz, H-6’), as well as two methoxy groups at δH 3.74 (3H, s) and 3.73 (3H, s). The characteristic
NMR data of 1, combined with heteronuclear single quantum correlation (HSQC) data, also showed
signals for four methylenes at δH 3.77 (1H, dd, J = 10.0, 6.0 Hz, H-9’a) and 3.33 (1H, m, H-9’b)/δC
69.7 (C-9’), δH 3.69 (1H, m, H-9a), and 3.48 (1H, dd, J = 11.0, 7.0 Hz, H-9b)/δC 62.6 (C-9), δH 2.67
(1H, dd, J = 14.0, 7.0 Hz, H-7a) and 2.56 (1H, dd, J = 14.0, 8.5 Hz, H-7b)/δC 35.6 (C-7), and δH 2.60
(2H, m, H-7’)/δC 35.8 (C-7’), and two methines at δH 2.07 (1H, m, H-8’)/δC 40.7 (C-8’) and 1.94 (1H,
m, H-8)/δC 44.1 (C-8), which are indicative of a secoisolariciresinol-type lignan [16,17]. In addition,
characteristic rhamnose NMR signals were observed at δH 4.63 (1H, d, J = 1.5 Hz, H-1”) and 1.25 (3H,
d, J = 6.0 Hz, H-6”), δC 102.0, 73.7, 72.4, 72.2, 69.9, and 17.8 [18]. These data suggest that compound
1 is a secoisolariciresinol-type lignan glycoside, and the 1H and 13C NMR spectra of 1 were highly
similar to those of (−)-secoisolariciresinol-O-α-L-rhamnopyranoside [19]. The planar gross structure
of 1 was established based on the 1H-1H correlation spectroscopy (COSY) and Heteronuclear multiple
bond correlation (HMBC) spectral data (Figure 2). However, the absolute stereochemistry of 1 was
not identical to (−)-secoisolariciresinol-O-α-L-rhamnopyranoside because compound 1 showed a
positive optical rotation ([α]25D +24.0, c 0.05, MeOH) similar to chaenomiside F (compound 3) ([α]
25
D
+30.0, c 0.1, MeOH) [20] and (−)-secoisolariciresinol-O-α-L-rhamnopyranoside showed a negative
rotation ([α]20D −49.5, c 0.30, acetone) [19]. Enzymatic hydrolysis was carried out to further confirm
the absolute configuration of compound 1, which yielded an aglycone and a rhamnose. The aglycone
was determined to be (+)-secoisolariciresinol (1a) through LC/MS analysis with an m/z signal of 361.2
[M − H]− and a positive optical rotation ([α]25D +30.0, c 0.02, acetone) [16]. The CD spectrum of 1a
showed positive Cotton effects at 209, 223, and 288 nm, and negative effects at 216 and 230 nm, which
is the first report of an experimental CD spectrum of (+)-secoisolariciresinol. The coupling constant
(J = 1.5 Hz) of the anomeric proton of the rhamnose revealed the α-configuration of the anomeric
proton [21]. The identity of L-rhamnose was established through LC/MS analysis of the rhamnose
obtained from the enzymatic hydrolysis [22,23]. Thus, the structure of compound 1 was determined to
be (+)-secoisolariciresinol-O-α-L-rhamnopyranoside.
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Figure 2. 1H-1H COSY ( ) and key HMBC ( ) correlations for 1 and 2.
Table 1. 1H and 13C NMR data of 1 and 2 in CD3OD (δ in ppm, 800 MHz for 1H and 200 MHz for 13C) a.
Position
1 2
δH δC δH δC
1 133.6 s 132.2 s
2 6.56 d (2.0) 113.0 d 6.54 d (2.0) 111.9 d
3 6.67 α d (8.0) 115.5 d 6.65 d (8.0) 114.2 d
4 145.4 s 144.5 s
5 148.9 s 147.5 s
6 6.53 dd (8.0, 2.0) 122.6 d 6.52 dd (8.0, 2.0) 121.3 d
7 2.67 dd (14.0, 7.0);2.56 dd (14.0, 8.5) 35.6 t
2.69 dd (14.0, 6.5);
2.53 dd (14.0, 9.0) 34.5 t
8 1.94 m 44.1 d 1.92 m 42.5 d
9 3.69 m;3.48 dd (11.0, 7.0) 62.6 t
3.71 m;
3.48 dd (11.0, 7.0) 61.2 t
1’ 133.6 s 131.4 s
2’ 6.54 d (2.0) 113.0 d 6.28 s 105.3 d
3’ 148.8 s 147.6 s
4’ 145.4 s 133.4 s
5’ 6.66 α d (8.0) 115.5 d 147.6 s
6’ 6.53 dd (8.0, 2.0) 122.6 d 6.28 s 105.3 d
7’ 2.60 m 35.8 t 2.60 m 35.2 t
8’ 2.07 m 40.7 d 2.08 m 39.3 d
9’ 3.77 dd (10.0, 6.0);3.33 m 69.7 t
3.79 dd (10.0, 6.0);
3.35 m 67.9 t
1” 4.63 d (1.5) 102.0 d 4.64 d (1.5) 100.7 d
2” 3.82 dd (3.5, 1.5) 72.2 d 3.81 dd (3.5, 1.5) 71.0 d
3” 3.68 dd (9.5, 3.5) 72.4 d 3.68 dd (9.5, 3.5) 71.1 d
4” 3.38 t (9.5) 73.7 d 3.38 t (9.5) 72.5 d
5” 3.62 dq (9.5, 6.0) 69.9 d 3.62 dq (9.5, 6.0) 68.7 d
6” 1.25 d (6.0) 17.8 q 1.25 d (6.0) 16.5 q
3-OCH3 3.73 β s 55.8 q 3.72 s 54.7 q
3’-OCH3 3.74 β s 55.8 q 3.74 s 55.1 q
5’-OCH3 3.74 s 55.1 q
a J values are in parentheses and reported in Hz; 13C NMR assignments based on 1H-1H COSY, HSQC, and HMBC
experiments; α, β Exchangeable peaks.
Compound 2 was obtained as a colorless gum with a positive optical rotation value of [α]25D +27.5
(c 0.04, MeOH). The molecular formula of 2 was determined to be C27H38O11 from the molecular ion
peak at m/z 537.2343 [M − H]− (calculated for C27H37O11 537.2336) in the negative mode HRESIMS
and the NMR spectroscopic data (Table 1). The ultraviolet (UV) and IR spectra of 2 were almost
identical to those of 1. The 1H and 13C NMR spectra (Table 1) were also quite similar to those of 1,
with a noticeable difference being that the proton signals for a 1,3,4-trisubstituted aromatic ring in 1
were absent and the proton signals for a typical 1,3,4,5-tetrasubstituted aromatic ring (δH 6.28 (2H, s))
19
Molecules 2018, 23, 1920
and an overlapped signal for two methoxyl groups (δH 3.74 (6H, s)) was present in 2. In light of these
data, compound 2 was also deduced to be one of the secoisolariciresinol-type lignans like compound 1,
and the differences in the structure of 2 compared to compound 1 were confirmed through analysis of
the 1H-1H COSY and HMBC data (Figure 2). Specifically, an HMBC correlation from the methoxyl
group (δH 3.74) to C-3’/C-5’ (δC 147.6) was observed, which led to the assignment of the methoxyl
group at C-3’/C-5’. The similarity between the characteristic CD curves of 1 (positive at 206, 229,
and 285 nm and negative at 217 nm) and 2 (positive at 205, 233, and 283 nm and negative at 221 nm)
revealed that the absolute configuration of 2 was identical to compound 1 as the 8S and 8’S form,
which was also supported by the positive optical rotation value ([α]25D +27.5, c 0.04, MeOH) of 2 like
that of 1. Enzymatic hydrolysis was conducted to further confirm the absolute configuration of 2,
which yielded an aglycone (2a) and a rhamnose. As expected, the aglycone (2a) was determined to be
(+)-seco-5’-methoxy-isolariciresinol using LC/MS analysis with an m/z signal of 393.2 [M + H]+ and a
positive optical rotation value of 2a ([α]25D +25.5, c 0.02, acetone) [16]. The characteristic small coupling
constant (J = 1.5 Hz) of the anomeric proton of the rhamnose at δH 4.64 indicated the α-configuration
of the rhamnose [21], and L-rhamnose was confirmed using LC/MS analysis of the rhamnose obtained
from the enzymatic hydrolysis of 2 [22,23]. Accordingly, the structure of compound 2 was determined
to be (+)-seco-5’-methoxy-isolariciresinol-9’-O-α-L-rhamnopyranoside.
The known compounds were identified as chaenomiside F (3) [16,20], (+)-isolariciresinol
9-O-β-D-glucoside (4) [5], lariciresinol 9-O-β-D-glucopyranoside (5) [24], isovitexin (6) [25], vitexin
(7) [26], nicotiflorin (8) [27], isoquercetin (9) [28], quercimelin (10) [29], avicularin (11) [30], rutin
(12) [28], myricitrin (13) [31], and betmidin (14) [32,33], through comparison of their spectroscopic data,
including 1H and 13C NMR, and physical data with previously reported values, as well as through
LC/MS analysis.
2.3. Cytotoxic Activity of Isolated Compounds against Human Tumor Cell Lines
Based on the cytotoxic activity of the MeOH extract of L. cuneata in our recent study [15],
the cytotoxic activities of the isolated compounds (1–14) were evaluated by determining their inhibitory
effects on human tumor cell growth in human breast cancer cells (Bt549, MCF7, MDA-MB-231 and
HCC70), using a sulforhodamine B (SRB) bioassay [12,34]. The results (Table S1) demonstrated that
compound 1 showed cytotoxicity against Bt549, MDA-MB-231, and HCC70 cell lines with IC50 values
ranging from 24.38–26.16 μM. Compounds 4 and 5 exhibited cytotoxicity against MCF7 (IC50: 28.08 μM)
and HCC70 (IC50: 24.81 μM) cell lines, respectively, and compound 6 showed cytotoxic activity against
MCF7, MDA-MB-231, and HCC70 cell lines with IC50 values ranging from 27.57–29.18 μM (Table S1).
However, other compounds were inactive (IC50 > 30.0 μM). Although recent studies of L. cuneata
extract have reported that the extract showed cytotoxic effects against various cancer cell lines [7,15],
the isolated compounds (1–14) did not appear to be responsible for the cytotoxicity.
2.4. Antiviral Activity of the Isolated Compounds against PR8, HRV1B, and CVB3 Infection
Recently, many studies exploring antiviral natural products and organic synthetic compounds
have reported that a variety of flavonoids exhibit potent antiviral activity by inhibiting the early stages
of viral infection, viral protein expression, and neuraminidase activity [35–37]. Therefore, we assessed
the isolated compounds (1–14) for their antiviral activity against PR8, HRV1B, and CVB3 infection in
A549, Vero, and HeLa cells, respectively. Less than 10% of the cells survived in the positive-control
group (cells with virus only) after 48 hours of infection. In addition, cells treated with compounds
1–14 (10 μM) also had less than 10% survival. Because we could not identify any significant differences
between the control and test groups, these results suggest that the compounds do not show significant
antiviral activity against PR8, HRV1B, or CVB3.
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2.5. Regulatory Effects of Compound 10 on Differentiation into Adipocytes and Osteoblasts
Mesenchymal stem cells (MSCs) in the bone marrow are pluripotent cells, which differentiate
into osteocytes as well as adipocytes. Since microenvironmental changes such as hormones, immune
responses, and metabolism cause alterations in the regulation of MSC differentiation, where alterations
in the expression of the related genes might disturb the balance between osteoprogenitor and
adipocyte progenitor cells in osteoporosis patients [38], natural products that are able to suppress
MSC differentiation toward adipocytes and/or promote osteogenic differentiation of MSC would be
promising in the management of postmenopausal osteoporosis. The biological activity of compound
10 was additionally tested regarding its effects on the differentiation of mouse MSCs into adipocytes
or osteoblasts, since large amounts of compound 10 was isolated among the isolated compounds.
Compound 10 was added to the MSC culture media during adipocyte differentiation. Compound
10 slightly reduced the formation of lipid droplets and resulted in somewhat fewer Oil Red O
(ORO)-stained cells compared to the normally differentiated adipocytes (Figure 3A). However,
ALP staining and ALP activity in the compound 10-treated cells did not increase during the MSC
differentiation into osteoblasts, in contrast to the positive control group treated with oryzativol A
(Figure 3B). These results demonstrate that compound 10 marginally suppressed adipogenesis of MSCs
but did not influence osteogenesis.
Figure 3. Reciprocal effects of compound 10 on the differentiation of MSCs into adipocytes or
osteoblasts. Mouse mesenchymal stem cells (C3H10T1/2) were treated with 10 μM compound 10. After
adipogenic differentiation, the cells were stained with Oil Red O (ORO), and the number of stained
lipid droplets was quantitatively evaluated (A). After osteoblast differentiation, the cells were stained
for ALP levels, and the ALP activity was measured (B). Ctrl represents untreated negative control.
For the positive controls, 40 micrograms of resveratrol (Res) was used for adipogenesis and 5 μM of
oryzativol A (OryA) was added for osteogenesis. * denotes 0.01 ≤ p ≤ 0.05 and *** denotes p < 0.001.
3. Materials and Methods
3.1. Plant Material
The aerial portions of L. cuneata were collected from Mt. Bangtae, Inje, Kangwon Province,
Republic of Korea, in October 2016. The plant materials were identified by one of the authors,
Prof. S. Lee. A voucher specimen (YKM-2016) was deposited at the herbarium of the School of
Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
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3.2. Extraction and Isolation
The dried aerial portions of L. cuneata (4.2 kg) were extracted three times with 4.2 L of 80% MeOH
for three days at room temperature and filtered. The resultant filtrate was evaporated under reduced
pressure using a rotavap to obtain the MeOH extract (401.8 g), which was suspended in distilled H2O
(2 L) and successively solvent-partitioned with hexane, CH2Cl2, EtOAc, and n-BuOH (2.0 L × 3 for each)
to yield the hexane- (20.6 g), CH2Cl2- (0.7 g), EtOAc- (12.7 g), and n-BuOH-soluble (69.3 g) fractions.
The EtOAc-soluble fraction (12.7 g) was subjected to Diaion HP-20 column chromatography with a
gradient solvent system of MeOH-H2O (0–100% MeOH) to afford six fractions (A–F). Fraction D (5.4 g)
was separated using RP-C18 column chromatography with a gradient solvent system of MeOH-H2O
(30–100% MeOH) to yield six sub-fractions (D1–D6). Sub-fraction D3 (2.8 g) was fractionated using
silica gel column chromatography with a gradient solvent system of CH2Cl2-MeOH-H2O (15:1:0–9:3:0.5
v/v/v) to produce 10 sub-fractions (D3-1–D3-10). Sub-fraction D3-7 (1.1 g) was separated using an
RP-C18 column with 60% MeOH to produce four sub-fractions (D3-71–D3-74). Sub-fraction D3-72
(506.7 mg) was subjected to silica gel column chromatography with a gradient solvent system of
CH2Cl2-MeOH-H2O (10:1:0–1:1:0.25, v/v/v) to give five sub-fractions (D3-721–D3-725). Sub-fraction
D3-722 (316.4 mg) was subjected to Sephadex LH-20 column chromatography with 100% MeOH to
produce 10 sub-fractions (D3-722A–D3-722J). Sub-fraction D3-722C (230.0 mg) was purified using
semi-preparative HPLC with a Phenomenex Luna phenyl-hexyl column (18% MeCN, flow rate:
2 mL/min) to yield compound 5 (1.4 mg, tR = 37.0 min). Sub-fraction D3-73 (158.8 mg) was subjected to
Sephadex LH-20 column chromatography with 100% MeOH to give 10 sub-fractions (D3-73A–D3-73J).
Compounds 2 (0.7 mg, tR = 49.5 min) and 3 (1.8 mg, tR = 41.5 min) were obtained from sub-fraction
D3-73B (24.5 mg) using semi-preparative HPLC with a Phenomenex Luna phenyl-hexyl column (18%
MeCN, flow rate: 2 mL/min). Compound 1 (7.6 mg, tR = 61.0 min) was isolated from sub-fraction
D3-73C (44.7 mg) using semi-preparative HPLC with a Phenomenex Luna phenyl-hexyl column (18%
MeCN, flow rate: 2 mL/min). Compound 14 (3.7 mg, tR = 20.5 min) was obtained from sub-fraction
D3-73I (8.2 mg) using semi-preparative HPLC with a Phenomenex Luna phenyl-hexyl column (21%
MeCN, flow rate: 2 mL/min). Sub-fraction D3-74 (127.6 mg) was subjected to Sephadex LH-20 column
chromatography with 100% MeOH to give eight sub-fractions (D3-741–D3-748). Compounds 9 (0.7 mg,
tR = 30.5 min) and 10 (32.8 mg, tR = 48.0 min) were isolated from sub-fraction D3-746 (42.3 mg)
using semi-preparative HPLC with a Phenomenex Luna phenyl-hexyl column (18% MeCN, flow rate:
2 mL/min). Sub-fraction D3-8 (515.0 mg) was subjected to RP-C18 column chromatography using a
gradient solvent system of 40–60% MeOH to produce four sub-fractions (D3-81–D3-84). Sub-fraction
D3-82 (346.7 mg) was subjected to silica gel column chromatography with a gradient solvent system
of CH2Cl2-MeOH (10:1–1:1, v/v) to give four sub-fractions (D3-821–D3-824). Sub-fraction D3-822
(54.8 mg) was applied to Sephadex LH-20 column chromatography with 100% MeOH to produce six
sub-fractions (D3-822A–D3-822F). Compound 4 (3.5 mg, tR = 39.0 min) was purified from sub-fraction
D3-822A (16.3 mg) using semi-preparative HPLC with a Phenomenex Luna phenyl-hexyl column
(15% MeCN, flow rate: 2 mL/min). Sub-fraction D3-824 (78.1 mg) was separated using Sephadex
LH-20 column chromatography with 100% MeOH to yield five sub-fractions (D3-824A–D3-824E).
Sub-fraction D3-824C (22.4 mg) was separated using semi-preparative HPLC with a Phenomenex Luna
phenyl-hexyl column (16% MeCN, flow rate: 2 mL/min) to obtain compound 8 (2.3 mg, tR = 72.5 min).
Sub-fraction D3-824D (37.3 mg) was separated using semi-preparative HPLC with a Phenomenex Luna
phenyl-hexyl column (14% MeCN, flow rate: 2 mL/min) to obtain compound 13 (0.5 mg, tR = 73.0 min),
and compound 13’s washing fraction D3-824DW (20.5 mg) was collected. Compound 11 (1.0 mg,
tR = 49.5 min) was purified using semi-preparative HPLC with a Phenomenex Luna phenyl-hexyl
column (18% MeCN, flow rate: 2 mL/min) from sub-fraction D3-824DW (20.5 mg). Sub-fraction
D3-10 (132.7 mg) was applied to Sephadex LH-20 column chromatography with 80% MeOH to
produce nine sub-fractions (D3-101–D3-109). Sub-fraction D3-108 (50.3 mg) was further separated
using semi-preparative HPLC with a Phenomenex Luna phenyl-hexyl column (38% MeOH, flow rate:
2 mL/min) to yield compound 12 (2.1 mg, tR = 72.0 min). Finally, compounds 6 (0.6 mg, tR = 37.0 min)
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and 7 (2.0 mg, tR = 39.0 min) were isolated from sub-fraction D3-109 (17.2 mg) using semi-preparative
HPLC with a Phenomenex Luna phenyl-hexyl column (20% MeCN, flow rate: 2 mL/min).
3.2.1. (+)-Secoisolariciresinol-O-α-L-rhamnopyranoside (1)
Colorless gum; [α]25D +24.0 (c = 0.05, MeOH); ESIMS (negative mode) m/z: 507 [M − H]−;
HRESIMS (positive mode) m/z: 509.2384 [M + H]+, calculated for C26H37O10, 509.2387; UV (MeOH)
λmax nm (log ε): 205 (2.29), 233 (3.43), 283 (0.76); IR (KBr) νmax cm−1: 3703, 3351, 2947, 2833, 2513,
2302, 2047, 1521, 1455; CD (MeOH) λmax nm (Δε): 206 (+19.2), 217 (−11.5), 229 (+10.3), 285 (+2.8); 1H
(CD3OD, 800 MHz) and 13C (CD3OD, 200 MHz) NMR spectroscopic data, see Table 1.
3.2.2. (+)-Seco-5’-methoxy-isolariciresinol-9’-O-α-L-rhamnopyranoside (2)
Colorless gum; [α]25D +27.5 (c = 0.04, MeOH); ESIMS (negative mode) m/z: 537 [M − H]−;
HRESIMS (negative mode) m/z: 537.2343 [M − H]−, calculated for C27H37O11, 537.2341; UV (MeOH)
λmax nm (log ε): 205 (2.29), 233 (3.43), 283 (0.76); IR (KBr) νmax cm−1: 3705, 3340, 2945, 2831, 2512,
2302, 2045, 1516, 1453; CD (MeOH) λmax nm (Δε): 205 (+11.5), 221 (−23.4), 233 (+13.8), 283 (+3.1); 1H
(CD3OD, 800 MHz) and 13C (CD3OD, 200 MHz) NMR spectroscopic data, see Table 1.
3.3. Enzymatic Hydrolysis of Compounds 1,2
A solution of each compound (1.0 mg) in H2O (1 mL) was individually hydrolyzed with
naringinase (10 mg, from Penicillium sp.; ICN Biomedicals Inc., Irvine, CA, USA) at 40 ◦C for 36 h.
Each reaction mixture was extracted with CH2Cl2 to yield the individual CH2Cl2 extract and a water
phase. The CH2Cl2 extracts from compounds 1 and 2 were chromatographically separately with a
Phenomenex Strata® C18-E column (2 g) using a gradient solvent system from 100% H2O to 100%
MeOH to give aglycones 1a (0.3 mg) and 2a (0.3 mg), respectively. The aglycone of 1a was determined
to be (+)-secoisolariciresinol using LC/MS analysis with an m/z signal of 361.2 [M − H]− and a
positive optical rotation ([α]25D +30.0, c 0.02, acetone) [16]. The CD spectrum of 1a showed positive
Cotton effects at 209, 223, and 288 nm and negative effects at 216 and 230 nm. The aglycone of 2a
was determined to be (+)-seco-5’-methoxy-isolariciresinol using LC/MS analysis with an m/z signal
of 393.2 [M + H]+ and a positive optical rotation ([α]25D +25.5, c 0.02, acetone) [16]. After drying the
water phase in vacuo, the residue was dissolved in anhydrous pyridine (200 μL) followed by the
addition of L-cysteine methyl ester hydrochloride (0.6 mg). The reaction mixture was incubated at
60 ◦C for 1 h, then O-tolyl isothiocyanate (15 μL) was added and the mixture was incubated at 60 ◦C
for 1 h. The reaction product was directly analyzed using LC/MS (0−35% MeCN for 30 min, flow rate:
0.3 mL/min) with an analytical Kinetex column (2.1 × 100 mm, 5 μm) (Agilent Technologies, Santa
Clara, CA, USA). The L-rhamnose in compounds 1 and 2 was identified through comparison of the
retention times with those of authentic sample (tR = L-rhamnose 25.6 min).
3.4. Cytotoxicity Assay
A sulforhodamine B (SRB) bioassay was used to determine the cytotoxicity of each isolated
compound against four cultured human tumor cell lines [12,34]. The assays were performed at the
Korea Research Institute of Chemical Technology. All the cell lines used, Bt549, MCF7, MDA-MB-231,
and HCC70, are human breast cancer cells. Etoposide (purity ≥ 98%, Sigma, St. Louis, MO, USA) was
used as a positive control. The half maximal inhibitory concentrations (IC50) of cancer cell growth are
expressed as the mean from three distinct experiments.
3.5. Antiviral Activity Assay
Influenza A/PR/8 virus (PR8), human rhinovirus 1B (HRV1B), and coxsackievirus B3 (CVB3)
were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA). PR8, CVB3,
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and HRV1B were replicated in A549, Vero, and HeLa cells, respectively, at 37 ◦C. Antiviral activity was
evaluated with the SRB method using cytopathic effect (CPE) reduction as previously reported [39].
3.6. Oil Red OStaining
At 6–8 days after differentiation, the adipocytes were fixed with 10% neutral buffered formalin
(NBF) and stained with 0.5% Oil Red O (Sigma, St. Louis, MO, USA). To stop the reaction, cells were
washed with distilled water three times. Stained cells were resolved with 1 mL of isopropanol and the
colorimetric changes was measured at 520 nm to evaluate intra-cellular triglyceride content.
3.7. Alkaline Phosphatase (ALP) Staining and Activity
At 7–9 days after osteogenic differentiation, the medium was removed, and the cells were washed
with 2 mM MgCl2 solution. After incubation with AP buffer (100 mM Tris−HCl, pH 9.5, 100 mM NaCl,
and 10 mM MgCl2) for 15 min, the cells were treated in AP buffer containing 0.4 mg/mL of nitro-blue
tetrazolium (NBT, Sigma) and 0.2 mg/mL of 5-bromo-4-chloro-3-indolyl phosphate (BCIP, Sigma) for
15 more minutes. To stop the reaction, the cells were exposed to 5 mM EDTA (pH 8.0) and fixed with
10% NBF for 1 h.
The differentiation into osteoblast was evaluated regarding ALP activity. The ALP activity was
determined using an Alkaline Phosphatase Assay Kit (ab83369; Abcam, Cambridge, MA, USA). Briefly,
the cell lysates were incubated with p-nitrophenyl phosphate (p-NPP) solution at RT for 1 h in the dark.
After stopping the reaction, the optical density was measured at 405 nm using a SpectraMax M2/M2e
Microplate Readers (Molecular Devices, San Jose, CA, USA).
4. Conclusions
In the present study, phytochemical analysis of the aerial portion of L. cuneata led to the isolation
of two new lignan glycosides (1,2) along with three known lignan glycosides (3–7) and nine known
flavonoid glycosides (8–14). All the isolated compounds were evaluated for their applicability for
medicinal use using cell-based assays. Compounds 1 and 4–6 exhibited weak cytotoxicity against the
breast cancer cell lines (Bt549, MCF7, MDA-MB-231 and HCC70) (IC50 < 30.0 μM), while none of the
isolated compound showed significant antiviral activity against PR8, HRV1B, or CVB3. In a mouse
mesenchymal stem cell line, treatment with compound 10 resulted in fewer lipid droplets compared to
the untreated negative without altering the amount of alkaline phosphatase staining.
Supplementary Materials: Supplementary materials are available online. General experimental procedures,
1D NMR, 2D NMR, HRESIMS, CD data of 1 and 2, LC/MS analysis of 1 and 2, and Table S1 are available free of
charge on the Internet.
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1. Introduction
Lignans are widely distributed in the plant kingdom, and show diverse pharmacological
properties and a great number of structural possibilities. The Lauraceae family, especially the genera
of Machilus, Ocotea, and Nectandra, is a rich source of lignans and neolignans, and neolignans represent
potential chemotaxonomic significance in the study of the Lauraceae. Lignans and neolignans are
dimers of phenylpropane, and conventionally classified into three classes: lignans, neolignans, and
oxyneolignans, based on the character of the C–C bond and oxygen bridge joining the two typical
phenyl propane units that make up their general structures [1]. Usually, lignans show dimeric
structures formed by a β,β’-linkage (8,8’-linkage) between two phenylpropanes units. Meanwhile, the
two phenylpropanes units are connected through a carbon–carbon bond, except for the 8,8’-linkage,
which gives rise to neolignans. Many dimers of phenylpropanes are joined together through two
carbon–carbon bonds forming a ring, including an 8,8’-linkage and another carbon–carbon bond
linkage; such dimers are classified as cyclolignans. When the two phenylpropanes units are linked
through two carbon–carbon bonds, except for the 8,8’-linkage, this constitutes a cycloneolignan.
Oxyneolignans also contain two phenylpropanes units which are joined together via an oxygen
bridge. Herein, lignans and neolignans are classfied into five groups: lignans, cyclolignans, neolignans,
cycloneolignans, and oxyneolignans on the basis of their carbon skeletons and cyclization patterns.
The majority of lignans isolated from Lauraceae have shown only minor variations on well-known
structures; for example, a different degree of oxidation in the side-chain and different substitutions
in the aromatic moieties, including hydroxy, methoxy, and methylenedioxy groups. Since the
nomenclature and numbering of the lignans and neolignans in the literature follow different rules,
the trivial names or numbers of the compounds were used to represent them. Furthermore, the
semi-systematic names of compounds and their corresponding names in the literature are summarized
in the Supporting Information. Herein, we give a comprehensive overview of the chemical structures
of lignans and neolignans isolated from Lauraceae.
2. Lignans
This section covers lignans formed by an 8,8’-linkage between two phenyl propane units,
which are subclassified according to the pattern of the oxygen rings as depicted in Figure 1.
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The semi-systematic names of those lignans without trivial names and their corresponding names in
found in the literature are given in Table SI-1 (Supporting Information).
Figure 1. Subtypes of classical lignans.
2.1. Simple Lignans
Machilin A (1) was first obtained from the CHCl3-soluble portion of the methanolic extract
of the bark of Machilus thunbergii collected at Izu Peninsula, together with meso-dihydroguaiaretic
acid (2). The absolute structure of machilin A (1) was determined to be 2S and 3R (meso-form) [2].
Yu and Ma et al. also reported that the bark of M. thunbergii contained machilin A (1) and
meso-dihydroguaiaretic acid (2). Furthermore, meso-dihydroguaiaretic acid (2) was found to have
significant neuroprotective activity against glutamate-induced neurotoxicity in primary cultures
of rat cortical cells and exerted diverse hepatoprotective activity, perhaps by serving as a potent
antioxidant [3,4]. Activity-guided fractionation of the dichloromethane extract of the bark of
M. thunbergii not only led to the isolation of machilin A (1) and meso-dihydroguaiaretic acid (2),
but also meso-austrobailignan-6 (3) and meso-monomethyl dihydroguaiaretic acid (4). It was reported
that meso-dihydroguaiaretic acid (4) showed potent inhibitory activity against DNA topoisomerase
I and II in vitro at a concentration of 100 μM with inhibition ratios of 93.6 and 82.1%, respectively.
Furthermore, meso-austrobailignan-6 (3) was referred to as threo-austrobailignan-6 (10) in the article [5].
Two diastereomeric dibenzylbutane lignans ((5) and (6)) which exhibited selective inhibition against
COX-2 (cyclooxygenase) were obtained from the leaves of Ocotea macrophylla Kunth, which were
collected in Nocaima county, Colombia [6]. Besides machilin A (1) and meso-dihydroguaiaretic acid (2),
oleiferin C (7) also were found in the stem bark of M. thunbergii collected at Ulleung-Do, Kyungbook,
Korea. Moreover, meso-dihydroguaiaretic acid (2) and oleiferin C (7) induced an apoptotic effect in
HL-60 cells via caspase-3 activation [7]. meso-Dihydroguaiaretic acid (2), threo-dihyidroguaiaretic acid
(8), sauriol B (9), and threo-austrobailignan-6 (10) were isolated from the ethanolic extract of the bark of
Nectandra turbacensis (Kunth) Nees [8]. The leaves and root bark of N. turbacensis (Kunth) Nees collected
in the city of Santa Marta (Magdalena, Colombia) contained meso-monomethyl dihydroguaiaretic
acid (4), threo-dihyidroguaiaretic acid (8), austrobailignan-5 (11), and schineolignin B (17) [9]. Lignan
12 was first obtained from the leaves of Apollonias barbujana collected in San Andrésy Sauces [10].
Compounds 13–16 were found to occur in the trunk wood of N. puberula. Proof of the absolute structure
of compound 13 relied on its acid catalyzed cyclization into (-)-galbulin, a tetralin-type neolignan of
known absolute stereochemistry [11] (Figure 2).
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Figure 2. Chemical structures of simple lignans.
2.2. 7,7’-Epoxylignans
Nectandrin A (19) and nectandrin B (20) were first isolated from leaves and stems of Nectandra
rigida Nees, along with galgravin (18) [12]. Nectandrin A (19) and nectandrin B (20), together with
machilin F (21), machilin G (22), machilin H (23), and machilin I (25) were found to occur in the
methanolic extract of the bark of M. thunbergii Sieb. et Zucc [13]. Galgravin (18), henricine (26), and
veraguensin (29) were found in the leaves and root bark of N. turbacensis (Kunth) Nees [9]. Zuonin
B (24), machilin F (30), and nectandrin B (20) were obtained from the stem bark of M. thunbergii [7].
Galgravin (18) and veraguensin (29), together with the 2,5-phenyl ring disubstituted lignans 27
and 28 were described for the first time from an ethanolic extract of the leaves Ocotea foetens [14].
Veraguensin (29) was first reported to be isolated from Ocotea veraguensis [15,16], and this compound
was also found in N. puberula [11]. Verrucosin (30) was first gained from the benzene extract of
branch wood of Urbanodendron verrucosum, together with austrobailignan-7 (31) and calopiptin (32).
The structure of verrucosin (30) was established by comparison with the synthetic racemate and
by the preparation of a dimethyl ether followed by a comparison of spectral data with published
data to determine the absolute structure [17]. (+)-Galbacin (33), (+)-galbelgin (34), nectandrin A (19),
nectandrin B (20), and machilin-G (22) were found to occur in the dichloromethane extract of the
bark of M. thunbergii Sieb. et Zucc. Furthermore, nectandrin B (20) showed potent inhibitory activity
against DNA topoisomerase I and II in vitro at a concentration of 100 μM, with inhibition ratios of 79.1
and 34.3%, respectively [3–5]. Beilschminol B (35) was first obtained from the roots of Beilschmiedia
tsangii [18]. Odoratisol C (36), odoratisol D (37), and machilin-I (25) were obtained from the air-dried
bark of the Vietnamese medicinal plant M. odoratissima Nees [19] (Figure 3).
2.3. 7,9’-Epoxylignans
(-)-Parabenzoinol (38) was isolated from the fresh leaves of Parabenzoin trilobum Nakai, and its
structure was elucidated by X-ray crystallographic analysis [20]. Actifolin (39) was identified in the
stems of Lindera obtusiloba; moreover, its effect on tumor necrosis factor (TNF)-α and interleukin (IL)-6
as well as its inhibitory activity against histamine release were examined using human mast cells.
Actifolin (39) suppressed the gene expressions of proinflammatory cytokines, TNF-α, and IL-6 in
human mast cells [21,22] (Figure 4).
2.4. Lignan-9,9’-Olides
(-)-Parabenzlactone (40) and acetylparabenzylactone (41) were found in the fresh leaves of P.
trilobum Nakai [23]. 5,6-Dihydroxymatairesinol (42) was found to occur in the methanolic extract of
the stems of L. obtusilob [21] (Figure 4).
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Figure 3. Chemical structures of 7,7’-epoxylignans.
2.5. 2.9,2’.9’-Diepoxylignans
The chromene dimer 43 was obtained from the ethanolic extract of the leaves of Cinnamomu
mparthenoxylon (Jack) Meisn [24] (Figure 4).
Figure 4. Chemical structures of 7,9’-epoxylignans, lignan-9,9’-olides, and 2.9,2’.9’-diepoxylignans.
2.6. 7.9’,7’.9-Diepoxylignans
The ethanol/H2O (9:1) extract of the fruits of L. armeniaca contained magnolin (44) and eudesmin
(45) [25]. Phytochemical studies revealed the presence of sesamin (46) and O-methylpiperitol (47) in the
ethanolic extract of the fruit of calyces of N. amazonurn [26]. Sesamin (46) was also found to occur in the
CH2Cl2 extract of the bark of M. thunbergii Sieb. et Zucc [3,4]. Magnolin (44), eudesmin (45), sesamin
(46), and O-methylpiperitol (47) were all found to occur in Persea pyrifolia Nees and Mart. ex Nees [27].
Phytochemical investigations of the methanolic extract of the leaves of A. barbujana resulted in the
isolation of demethylpiperitol (48) [10]. The ethanolic extract of Pleurothyrium cinereum also contained
(+)-demethylpiperitol (48), as well as (+)-de-4”-O-methylmagnolin (49), which was found to be a potent
COX-2/5-LOX dual inhibitor and platelet-activating factor (PAF)-antagonist (COX-2: IC50 = 2.27 μM;
5-LOX: IC50 = 5.05 μM; PAF: IC50 = 2.51 μM) (49) [6,28]. (+)-Syringaresinol (50) was isolated from the
stems of C. reticulatum Hay [29]. (+)-De-4”-O-methylmagnolin (49) and (+)-syringaresinol (50) both
were found to occur in the methanolic extract of the stems of Actinodaphne lancifolia [30]. The leaves of
C. macrostemon Hayata [31] and the stems of C. burmanii [32] both contained (+)-syringaresinol (50) and
yangambin (51), which showed various pharmacological effects. Moreover, C. burmanii also contained
(+)-sesamin (46) [32]. (+)-Demethoxyexcelsin (52), (+)-piperitol (53), and (+)-methoxypiperitol (54) were
obtained from the bark and wood of N. turbacensis, together with (+)-sesamin (46) [33]. Epiyangambin
(55), episesartemin (56), and yangambin (51) were isolated from the leaves of O. duckei, and yangambin
(51) represented the major constituent [34]. Kwon et al. reported the isolation of (+)-syringaresinol (50)
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and pluviatilol (57) from the stems of L. obtusilob, and pluviatilol (57) showed cytotoxicity against a
small panel of human tumor cell lines [21]. (+)-5-Demethoxyepiexcelsin (58) and (+)-epiexcelsin (59)
were reported to be found in Litsea verticillata Hance, and (+)-5- demethoxyepiexcelsin (58) showed
moderate anti-HIV activity with an IC50 value of 16.4 μg/mL (42.7 μM) [35]. (+)-Xanthoxyol (60),
(+)-syringaresinol (50), and pluviatilol (57) were obtained from the stems of L. obtusiloba Blume.
The effect of these compounds on tumor necrosis factor (TNF)-α and interleukin (IL)-6 as well as their
inhibitory activity against histamine release were examined using human mast cells. Pluviatilol (57)
inhibited the release of histamine from mast cells [22]. 4-Keto-pinoresinol (61) was isolated from the
ethanolic extract of the leaves and twigs of Litsea chinpingensis [36] (Figure 5).
Figure 5. Chemical structures of 7.9’,7’.9-diepoxylignans.
3. Cyclolignans
There are three main types of cyclolignans isolated from nature, including 2,7’-cyclolignans,
2,2’-cyclolignans, and 7,7’-cyclolignans. Cyclolignans are not so common in Lauraceae. We have only
retrieved less than 10 2,7’-cyclolignans isolated from Lauraceae. The semi-systematic names of those
cyclolignans without trivial names and their corresponding names in the literature are given in Table
SI-1 (Supporting Information).
2,7.’-Cyclolignans
(-)-Isoguaiacin (62) and (+)-guaiacin (63) were isolated from the extract of the bark of M. thunbergii
Sieb. et Zucc. These two compounds showed significant neuroprotective activities against
glutamate-induced neurotoxicity in primary cultures of rat cortical cells [3,4]. (+)-Otobaphenol (64) and
cyclolignans 65 and 66 were isolated from the ethanolic extract of P. cinereum [28]. Cinnamophilin A
(67) was first reported to be obtained from the methanolic extract of roots of Cinnamomum philippinense
(Merr.) Chang [37]. (-)-Aristoligone (68), (-)-aristotetralone (69), and (-)-cagayanone A (70) were
obtained from the ethanolic extract of the leaves and twigs of L. chinpingensis [36] (Figure 6).
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Figure 6. Chemical structures of 2,7’-cyclolignans.
4. Neolignans
Neolignans are widely distributed in the Lauraceae family, especially in the genera of Aniba,
Nectandra, and Ocotea. The types of neolignans isolated from Lauraceae include 8,1’-neolignans,
8,3’-neolignans, 7,1’-neolignans, and 7,3’-neolignan (Figure 7). 3,3’-neolignans, which also exist in
nature, have not been isolated from Lauraceae. The semi-systematic names of the abovementioned
neolignans without trivial names and their corresponding names in the literature are given in Table SI-2
and SI-3 (Supporting Information).
Figure 7. Subtypes of neolignans.
4.1. 8,1’-Neolignans
Burchellin (71) was first isolated from the trunk wood of Aniba burchellii Kosterm [38]. Burchellin
(71) has also been found in the benzene extract of the trunk of an unclassified Aniba species collected
in the vicinity of Manaus, Amazonas, along with compounds 72 and 73 [39,40]. Compounds 72 and
74 were obtained as a mixture from an unclassified Amazonian Nectandra species. As the analogous
values for the mixture of compounds 72 and 74 were substantially identical to those of pure compound
72, including the ORD (optical rotatory dispersion) curves, then the two compounds should have the
same absolute configuration [41]. 3’-Methoxyburchellin (75) was first isolated from the stem bark of
O. veraguensis [16]. Benzene extract of the trunk wood of Aniba terminalis [42] and ethanolic extract of
the trunk wood of an Aniba species collected 130 km north of Manaus, Amazonas [43] both contained
burchellin (71) and compound 76. The trunk wood of Ocotea catharinensis yielded compound 77 [44,45].
Inspection of Aniba simulans revealed the occurrence of compounds 78–80 [46,47]. Armenin A (81) and
armenin B (82) were first obtained from the benzene extract of the trunk wood of Licaria armeniaca [48].
The fruits of L. armeniaca yielded compounds 76 and 78 [25]. Compounds 74, 78 and armenin C
(83) were isolated from the fruits of Aniba riparia [49]. Compound 85 was isolated from the benzene
extract of trunk wood of an unclassified Aniba species [50]. Canellin B (86) was first obtained from
the benzene extract of the trunk wood of Licaria canella [51]. The trunk wood of an Amazonian Aniba
species contained armenin A (81), armenin B (82), C (83), canellin B (86), canellin D (87), canellin E
(88), porosin (90), and porosin B (91) [52]. Porosin (90) was first obtained from the wood of Ocotea
porosa [53]. Porosin B (91) was first obtained from the branch wood of U. verrucosum, and porosin (90)
also were found to exist in the same species [17]. The wood of Ocotea catharinensis yielded armenin
B (82), canellin B (86), ferrearin C (95), ferrearin E (96), and compounds 92 and 93. Moreover, the
structures of compound 92 and ferrearin C (95) were certified by single-crystal X-ray analysis [45].
Ferrearin A (99) and ferrearin B (100) were first isolated from the trunk wood of the Amazonian Aniba
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ferra Kubitzki, together with compounds 85 and 92. The relative structures of ferrearin A (99) and
ferrearin B (100) were elucidated as structures of 97 and 98 [54], then revised as ferrearin A (99) and
ferrearin B (100). Besides these two compounds, 3’-methoxyburchellin (75), compound (77), ferrearin C
(101), and ferrearin D (102) were found to occur in the trunk wood of Ocotea aciphylla [55,56]. Burchelin
(71), porosin (90), porosin B (91), and compounds 76, 89, 94, 103–106, 112, and 113 all were identified
in the trunk wood of O. porosa, collected from the Forest Reserve of the Botanical Institute, Sâo Paulo,
Brazil [57,58]. Fifteen 8,1’-neolignans have been reported to be found in the bark and leaves of O. porosa
harvested near Santa Maria, State of Rio Grande do Sul, Brazil, including burchellin (71), porosin (90),
porosin B (91), and compounds 76, 89, 94, and 105–113 [59] (Figure 8).
Figure 8. Chemical structures of 8,1’-neolignans.
4.2. 8,3’-Neolignans
The benzene extract of trunk wood of Licaria aritu Ducke [60] and the EtOH/H2O (9:1) extract
of the fruits of N. glabrescens contained licarin A (114) and licarin B (115) [26]. Licarin A (114) was
also isolated from N. rigida Nees and is responsible for the major cytotoxic activity of crude extract
of N. rigida Nees, displaying ED50 vs. KB cancer cell line at 7.0 μg/mL [12]. Machilin B (116) was
obtained from the methanolic extract of the bark of M. thunbergii [2], as well as licarin A (114) and
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licarin B (115). Licarin A (114) showed significant neuroprotective activities against glutamate-induced
neurotoxicity in primary cultures of rat cortical cells and induced an apoptotic effect in HL-60 cells via
caspase-3 activation [4,7]. Licarin A (114) and licarin D (117) were found in branch wood of the shrub
U. verrucosum [17]. Obovatifol (118), odoratisol-A (119), and (-)-licarin A (114) were obtained from the
air-dried bark of the Vietnamese medicinal plant Machilius odoratissima Nees [19]. Besides licarin A
(114) and licarin B (115), machilusol A (120), machilusol B (122), machilusol C (123), machilusol D (124),
machilusol E (125), machilusol F (126), and acuminatin (127) were isolated from the stem wood of
Machilus obovatifolia. Machilusols A–F showed moderate cytotoxic activity [61]. The dichloromethane
extract of the bark of M. thunbergii Sieb. et Zucc also contained (-)-acuminatin (127), together with
licarin A (114). (-)-Acuminatin exerted diverse hepatoprotective activities, perhaps by serving as a
potent antioxidant [3,5]. Dihydrodehydrodiconifery alcohol (129) was found in the ethanolic extract of
the leaves and twigs of L. chinpingensis [36]. Compound 130 was first obtained from the benzene extract
of the trunk of an Aniba species collected in the vicinity of Manaus, Amazonas, along with acuminatin
(127) and licarin D (116) [40]. A. burchellii Kosterm contains compounds 130 and 131. The determination
of their absolute stereochemistry relied on spectra and a preparation by thermolysis as well as the acid
isomerization of burchellin (71) [62]. Denudatin B (132), as well as (+)-licarin A (114), liliflol B (121),
and (+)-acuminatin (127), have been found in leaves of Nectandra amazonum Nees [63]. Mirandin A
(133) was proved to be the major neolignan of an unclassified Nectandra species, which grew at Rosa de
Maio, a locality on the Manaus-Itacoatiara highway, Amazonas [41]. (+)-Mirandin A (133), (-)-licarin A
(114), and (-)-licarin B (115) also were found to occur in the ethanolic extract of P. cinereum [28]. Licarin
C (128), mirandin A (133), mirandin B (134), and compounds 135 and 146 were obtained from the
benzene extract of Nectundru mirunda trunk wood [64]. Compounds 136 and 137 were found in the
stem bark of O. veraguensis [16]. Furthermore, compound 136 also was found in the trunk wood of an
Aniba species collected 130 km north of Manaus, Amazonas [43], and compound 137 was obtained
from the wood of O. catharinensis [44] and the fruits of O. veraguensis [65]. Compounds 135, 138, 139,
141, and 143–145 were isolated from the benzene extract of Anibu simulans trunk wood [46]. The extract
of EtOH/H2O (9:1) of fruits of L. armeniac also provided compounds 136 and 138 [25]. Obovaten (142),
perseal D (159), perseal C (160), and obovatinal (161) were first obtained from the leaves of Persea
obovatifolia; together with obovatifol (118), these compounds showed significant cytotoxicity against
P-388, KB16, A549, and HT-29 cancer cell lines in vitro [66,67]. Compound 148 was isolated from the
benzene extract of the trunk wood of A. terminalis [42]. Lancifolins A–F (149–154) were obtained from
branches of the shrub Aniba lancifolia Kubitzki et Rodrigues [68]. Neolignan ketone 156 was found to
exist in the chloroform extract of the bark of Ocotea bullata [69]. Ocophyllals A (157) and ocophyllals B
(158), which have a C-1’ formyl side chain instead of a propenyl group, as well as (+)-licarin B (115)
were observed to occur in the ethanolic extract from leaves of O. macrophylla [70]. Licarin A (114),
licarin B (115), (7R,8S,1’R)-7,4’-epoxy-1’-methoxy-3,4-methylenedioxy-8,3’-neolign-8’-ene-6’(1’H)-one
(140), and compounds 130, 147, 155, 162, and perseal F (163) were obtained from O. porosa [57–59].
Compound 162 also was found to occur in the dichloromethane extract of the bark of M. thunbergii SIEB.
et ZUCC [5]. Meanwhile, perseal F (163) and perseal G (164) were present in the chloroform-soluble
portion of the stem wood of M. obovatifolia [71] (Figure 9).
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Figure 9. Chemical structures of 8,3’-neolignans.
4.3. 7,1’-Neolignans
Licaria chrysophylla gave a considerable proportion of chrysophyllin A (165), which was the
first type of 7,1’-neolignan to be obtained. Chrysophyllin B (166), chrysophyllon I-A (167), and
chrysophyllon I-B (168) were also identified in L. chrysophylla [72,73]. The trunk wood of an Amazonian
Aniba species collected in the vicinity of Manaus, Amazonas also contained chrysophyllin A (165) and
chrysophyllin B (166) [52] (Figure 10).
4.4. 7,3’-Neolignans
Chrysophyllon II-A (169) and chrysophyllon II-B (170) belonging to the category of 7,3’-neolignans,
both were found to occur in the bark, wood, and fruit calyces of L. chrysophylla [73] (Figure 10).
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Figure 10. Chemical structures of 7,1’-neolignans.
5. Cycloneolignans
Cycloneolignans are responsible for the chemotaxonomic characteristics of some genera in the
Lauraceae family, such as Aniba, Licaria, and Nectandra. Most cycloneolignans isolated from Lauraceae
belong to the categories of 7.3’,8.1’-cycloneolignans and 7.3’,8.5’-cycloneolignans (Figure 11). Only
two 7.1’,8.3’-cycloneolignans have been reported to be obtained from O. bullata. The semi-systematic
names of those cycloneolignans without trivial names and their corresponding names in the literature
are given in Table SI-4 (Supporting Information).
Figure 11. Subtypes of cycloneolignans.
5.1. 7.3’,8.1’-Cycloneolignans
Guianin (171) was first obtained from the wood of Aniba guianensis Aubl [74]. Meanwhile,
2’-epiguianin (172) was isolated from the leaves of O. macrophylla Kunth, which showed inhibition
activity against the platelet-activating factor (PAF)-induced aggregation of rabbit platelets with an
IC50 value of 1.6 μM [70]. Fourteen 7.3’,8.1’-cycloneolignans, including 3’-methoxyguianin (173)
and compounds 174–176 and 178–187, were isolated from the trunk wood of O. porosa collected
from the mountainous Atlantic forest region of São Paulo State, where it is known as ‘canela
parda’ [75,76]. Compound 192 was first obtained from the trunk wood of O. porosa collected from
the Forest Reserve of Instituto BottInico (SHo Paulo, SP), along with guianin (171) and 2’-epiguianin
(172) [58]. Compound 191 was first obtained from the benzene extract of A. burchellii Kosterm,
together with guianin (171) [62]. Compounds 193–195 and 229 were found to be present in the
benzene extract of the trunk of a unclassified Aniba species collected from the Ducke Forest Reserve,
Manaus, Amazonas, as well as guianin (171) and 3’-methoxyguianin (173) [40]. Compounds 184,
194–198, and 202–207 were obtained from seed coat and dried fruit pulp of O. veraguensis. Since the
author did not describe how to determine the absolute configuration of these compounds, their
name should contain the addition of the prefix ‘rel’ [65]. Otherwise, compounds 188, 191, and
208–210 were isolated from the petrol and chloroform extract of the stem bark of O. veraguensis [16].
The trunk bark of O. catharinensis contained compounds 200, 208, 209, as well as canellin-C (212)
and 5-methoxycanellin-C (213), and the contents of all these compounds in the bark were over
0.01% [44,45]. Compounds 214–216, 218, and 228 were found to occur in the trunk wood of an Aniba
species collected 130 km north of Manaus, Amazonas [43]. The benzene extract of trunk wood
pertaining to an unclassified Aniba species collected from the Ducke Forest Reserve, Manaus yielded
217, 219, 221, 222, 224, and methoxycanellin A (226) [50,77]. Compound 189 was first obtained from
the ethanolic extract of wood of Ocotea costulatum, along with compound 221 [78]. The trunk wood
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of the Amazonian A. ferra Kubitzki contained rel-(7S,8R,1’S,2’S,3’R)-1’,2’-dihydro-2’-hydroxy-3,3’,5’-
trimethoxy-4,5-methylenedioxy-7.3’,8.1’-cycloneolign-8’-ene- 4’(3’H)-one (199) and methoxycanellin
A (226) [54]. Canellin A (225) and canellin C (212) were first obtained from the trunk wood
of L. canella [51]. These two compounds have also been reported to be found in the trunk
wood of L. rigida Kosterm. However, the relative structures of the compounds shown in the
abovementioned article were different from those shown in other articles—the methyl occupied
an exo-configuration and the aryl adopted an endo-configuration [79]. The trunk wood of
the central Brazilian O. aciphylla also yielded canellin-A (225), as well as compound 208 and
3’-methoxyguianin (173) [55,56]. 2’-Epiguianin (172), compounds 177, 190–192, 211, 220, 223, 227, and
rel-(7R,8R,1’S,3’S)-5’-methoxy-3,4-methylenedioxy-7.3’,8.1’-cycloneolign-8’-ene-2’,4’(1’H,3’H)-dione
(229) were obtained from the bark and leaves of O. porosa [59]. Compounds 194, 201, 230, and 231
were found in the extract of EtOH/H2O (9:1) of the fruits of L. armeniaca [25]. The chloroform extract
of the trunk wood of L. armeniaca yielded compound 232 [80] (Figure 12).
 
Figure 12. Chemical structures of 7.3’,8.1’-cycloneolignans.
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5.2. 7.3’,8.5’-Cycloneolignans
Macrophyllin B (233) was purified from an unclassified Nectandra species collected at Rosa
de Maio, a locality on the Manaus-Itacoatiara highway (8 km), Amazonas [41]. Nectamazins A–C
(234–236), macrophyllin B (233), denudanolide D (237), and kadsurenin C (238) isolated from leaves
of N. amazonum Nees showed inhibition activity against the platelet-activating factor (PAF)-induced
aggregation of rabbit platelets [63]. A phytochemical exploration of the leaves of O. macrophylla
afforded ocophyllols A–C (239–241). Their absolute configurations were established by derivatizing
them with (R)-and (S)-MTPA, and then analyzing the NMR data, as well as by a comparison of their
circular dichroism (CD) data with that of a related compound whose absolute configuration was
previously established by single-crystal X-ray analysis. Moreover, ocophyllols A–C (239–241) showed
some inhibition activity against the platelet-activating factor (PAF)-induced aggregation of rabbit
platelets [70]. Cinerin B (242), cinerin C (243), cinerin A (244), and cinerin D (245) were isolated from
the leaves of P. cinereum. Again, their CD data was used to determine the absolute configuration of
these compounds. Cinerin C (243) was the first known macrophyllin-type cycloneolignan, which
was isolated from the trunk wood of Licaria macrophylla Kosterm and named as macrophyllin A [81].
Cinerin A–D also showed some inhibition activity against the platelet-activating factor (PAF)-induced
aggregation of rabbit platelets [82]. Compound 246 and macrophyllin B (233) were identified in the
ethanolic extract of leaves of P. cinereum [28] (Figure 13).
Figure 13. Chemical structures of 7.3’,8.5’-cycloneolignans.
5.3. 7.1’,8.3’-Cycloneolignans
Ocobullenone (247) was the first naturally occurring bicyclooctanoid found to exhibit the 7.1’, 8.3’
linkage, and it was isolated from the chloroform extract of the bark of O. bullata [83]. Iso-ocobullenone
(248) was also isolated from the chloroform extract of the bark of O. bullata, and its structure was
confirmed by single-crystal X-ray analysis [69] (Figure 14).
Figure 14. Chemical structures of 7.1’,8.3’-cycloneolignans.
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6. Oxyneolignans
An ether oxygen atom provides the linkage between the two phenylpropane units, giving rise to
oxyneolignans. Oxyneolignans are rarely distributed in Lauraceae. Less than 10 oxyneolignans have
been found to occur in the Lauraceae family, belonging to two categories: 7.3’,8.4’-dioxyneolignans
and 8,4’-oxyneolignans (Figure 15).
Figure 15. Subtypes of oxyneolignans.
6.1. 7.3’,8.4’-Dioxyneolignans
The trunk wood of L. rigida Kosterm contained eusiderin (249) and eusiderin B (250) [79].
The trunk wood of an unclassified Aniba species collected at the Ducke Forest Reserve, Manaus
also yielded the benzodioxane-type neolignan eusiderin (249), eusiderin-F (251), and eusiderin-G
(252) [50,77]. Eusiderin (249) was also found to be present in the ethanolic extract of wood of
O. costulatum [78] (Figure 16).
Figure 16. Chemical structures of 7.3’,8.4’-dioxyneolignans.
6.2. 8,4’-Oxyneolignans
Machilin C (253), D (254), and E (255) were first obtained from the methanolic extract of the bark
of M. thunbergii [2]. Odoratisol B was obtained from the air-dried bark of the Vietnamese medicinal
plant M. odoratissima Nees. This compound showed the same relative structure as machilin C (253),
but was termed odoratisol B in the article [19]. Perseal A (256) and perseal B (257), which have a C-1’
formyl side chain instead of a propenyl group, were isolated from the chloroform-soluble fraction of
the leaves of P. obovatifolia. They showed significant cytotoxicity against P-388, KB 16, A549, and HT-29
cancer cell lines [67] (Figure 17).
 
Figure 17. Chemical structures of 8,4’-oxyneolignans.
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7. Uncommon Lignans
This section covers lignans and neolignans that contain uncommon skeletons. The molecular
backbone of compounds 258–267 consists of a unique C6–C3 unit, and an ether oxygen atom provides
the linkage between the phenyl and propyl groups. The semi-systematic names of those uncommon
lignans without trivial names and their corresponding names in the literature are given in Table SI-5
(Supporting Information).
Compounds 258–261 were isolated from the benzene extract of A. simulans trunk wood [46].
Compounds 259 and 260 were also found in the fruits of L. armeniaca [25] and the trunk wood of
N. mirunda, respectively [64]. Compound 262 was isolated from the benzene extract of the trunk wood
of A. terminalis [42]. Compounds 263 and 264 have been found in the trunk bark of O. catharinensis [45].
The stem bark of O. veraguensis also yielded compound 263 [16]. Chrysophyllon III-A (265) and
chrysophyllon III-B (266) have been found in trunk wood, bark, and fruit calyces of L. chrysophylla [73].
Compound 267 was obtained from the bark and leaves of O. porosa [59]. (+)-9’-O-trans-feruloyl-5,5’-
dimethoxylariciresinol (268), which showed cytotoxicity against a small panel of human tumor cell
lines with ED50 values around 10 μg/mL, was isolated from the stems of L. obtusiloba Blume [21,22].
Turbacenlignan A (269), a 7,8-secolignan, was isolated from the leaves and root bark of N. turbacensis
(Kunth) Nees [9]. Cinnaburmanin A (270) was isolated from the roots of C. burmanii [84] (Figure 18).
Figure 18. Chemical structures of uncommon neolignans.
8. Conclusions
A renewed interest in compounds isolated from natural resources has led to an enormous
class of pharmacologically active compounds. Lignans and neolignans have been revealed to show
significant pharmacological activities, including antitumor, anti-inflammatory, immunosuppression,
cardiovascular, antioxidant, and antiviral activities [85,86]. The Lauraceae family, especially the genera
of Machilus, Ocotea, and Nectandra, represents a rich source of lignans and neolignans. Moreover,
neolignans are responsible for the potential chemotaxonomic significance found in the study of
Lauraceae. Studies on lignans and neolignans in Lauraceae were mainly carried out in the 1980s. There
have been more studies concerning the identification of lignans and neolignans in Lauraceae, but less
on the biological activities of these compounds. Among the lignans and neolignans isolated from
Lauraceae, the biological activities of sesamin and yangambin have been studied more, while there
are relatively few articles published on other compounds. Sesamin, a 7.9’,7’.9-diepoxylignan present
in many species in the Lauraceae family such as N. amazonurn, M. thunbergii, P. pyrifolia, C. burmanii,
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and N. turbacensis, showed significant anticancer properties [87]. Yangambin (51) which was the major
constituent of O. duckei, showed diverse biological activities [88]. Therefore, it is extremely urgent to
expand the scope of research on the lignans and neolignans in Lauraceae, with the aim of discovering
all biological activities of these compounds.
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Abstract: The genus Bursera belongs to the family Burseraceae and has been used in traditional
Mexican medicine for treating various pathophysiological disorders. The most representative
phytochemicals isolated from this genus are terpenoids and lignans. Lignans are phenolic metabolites
known for their antioxidant, apoptotic, anti-cancer, anti-inflammatory, anti-bacterial, anti-viral,
anti-fungal, and anti-protozoal properties. Though the genus includes more than 100 species, we
have attempted to summarize the biological activities of the 34 lignans isolated from selected Mexican
Bursera plants.
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1. Introduction
The genus Bursera Jacq. ex L. (family Burseraceae, order Sapindales), named after the Danish
botanist Joachim Burser (1583–1639), is a monophyletic genus [1] that includes about 105 species of
small trees and shrubs distributed from Southern U.S. to Peru and the Caribbean, particularly in
Mexico (ca. 92 species) [2]. These plants are characterized by the production of resins that are exuded
from the trunk and leaves and provide a chemical defense against specialized herbivores [3]. Once
dried, the resin obtained by Bursera spp. is called “copal”, a term which is also used to describe a large
group of resins characterized by hardness and a relative high melting point, which also is found in
other plants [4]. The loss of the essential oils and the oxidation and polymerization processes transform
copal into amber.
The phytochemistry of this genus is characterized by the presence of volatile metabolites such
as simple hydrocarbons and terpenoids as well as phenolics [5–8]. Among the compounds present
in the volatile fraction, heptane, α- and β-pinene, β-phellandrene, and limonene are among the most
frequent [5], whereas β-caryophyllene and germacrene D are the most common sesquiterpenes in the
genus Bursera [8]. Cembrane and verticillane diterpenoids are often present [9–11]. Pentacyclic
triterpenoids are largely present in the resin of several species, and the study of triterpenoidic
composition of resins is important to define the botanical origin of archaeological samples of copal [12].
In Bursera microphylla resin, malabaricane triterpenoids were also found [11]. Leaves and branches of
some Bursera also contain flavonoids [13–15] and luteolin 3′-O-rhamnoside is very common [13].
Lignans are naturally occurring plant phenolics, biosynthetically derived from phenylpropanoids,
that are important components in foods and medicines; their chemical and biological properties
have been reviewed [16]. The aim of this review is to summarize literature findings on the botanical
characterization, distribution, ethnopharmacology, and biological activities of Mexican Bursera that
produce lignans. Different Bursera species have been sorted according to, and synonyms are those
reported in, the Plant List Database [17]. Unless otherwise specified, common names are those reported
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by Lemos and Rivera [18]. The phytochemistry was analyzed by data reported in the SciFinder database.
Images of the species reported in this paper can be found on the Enciclovida web site [19].
2. Genus Bursera
Members of this genus are typically small- to medium-sized trees or shrubs, mostly dioecious,
succulent, and with resin canals in vascularized tissues. Their leaves are deciduous, imparipinnate, or
sometimes unifoliolate or trifoliolate (occasionally bipinnate). Their flowers are small, almost always
unisexual, three- to six-merous. Their fruit is a dehiscent two- to three-valve drupe with a fleshy to
coriaceous skin, and with a pyrene (the stone or pit that contains the seed), cartilaginous to bony,
enveloped totally or partially by an arillate structure.
The taxonomy of the genus Bursera is based on morphological characteristics of fruit, bark, and
leaves, as well as molecular data. Currently, there are two recognized subgenera: one subgenus
named Bursera (previously called section Bursera) that includes species commonly known with the
general vernacular name of “cuajiotes”, and the other is called Elaphrium (previously called section
Bullockia) that comprises species with the general common name of “copales” [20–22]. The most
conspicuous difference between the subgenera is the bark: in subgenus Bursera, it tends to be colorful
and exfoliating, whereas in Bursera subgenus Elaphrium, it is likely to be complete (not exfoliating),
and grey or reddish grey. However, although bark helps in species identification because it is easy to
see, whether the bark is complete or exfoliating is not an absolute difference between the two groups.
Setting the bark aside, the most reliable distinction between the two subgenera is the number of locules
in the ovary (three in subg. Bursera vs. two in Elaphrium), and the number of valves in the fruit
(three in subg. Bursera vs. two in Elaphrium) [20,21]. Another distinguishing trait is the presence of
well-developed cataphylls (small bract-like leaves that appear before “true leaves” and are short-lived)
in subgenus Elaphrium and absent or very inconspicuous in subgenus Bursera [23]. Toledo further
divided section Bursera into three groups that can be distinguished by the color of the exfoliating
bark: mulatos, red cuajiotes, and yellow cuajiotes [24]. Furthermore, the section Bullockia was divided
into two groups: pseudoaril-covered fruits group and partially covered fruits group [24]. In 1980,
Gillet changed the name of section Bullockia into Elaphrium due to the fact that some characteristics
of this section resemble those of Elaphrium tomentosum Jacq. [25]. Phylogeny studies by Becerra and
Venable allowed the recognition of four different groups in section Bursera: the simaruba group (massive
trees, trilobate cotyledons, red exfoliating bark, poor producing resin (mulatos)), the microphylla group
(medium-sized trees or shrubs, multilobate cotyledons, yellow to red exfoliating bark, highly resinous),
the fagaroides group (medium-sized trees or shrubs, multilobate cotyledons, highly resinous), and
the fragilis group (medium-sized trees, multilobate cotyledons, red exfoliating bark, highly resinous
(cuajiotes)) [22]; and two groups in Elaphrium: copallifera (seed completely or at least two-thirds covered
by pseudoaril) and glabrifolia (seed partially covered or at least less than two-thirds by pseudoaril) [5].
Bursera’s flowers are small and inconspicuous, with few species-specific characteristics, occurring
during bursts during the dry season. Thus, in their natural habitats, it is often easier to recognize them
by their bark and leaf characteristics as well as the locations where they grow. The Bursera genus is
closely related to the other two resin producing Burseraceae: Boswellia and Commiphora, and they differ
mostly in their geographic distribution. Boswellia and Commiphora are present in desert parts of tropical
Africa, Arabia, Pakistan, and India, whereas Bursera is distributed from the Southern U.S. to Peru and
the Caribbean, and particularly in Mexico. The Bursera section shares some similarities with Boswellia,
whereas Elaphrium is similar to Commiphora [26].
2.1. Traditional Uses, Phytochemistry, and Biological Activities
Most of the Bursera species that produce lignans are widely used by the Mexican native population.
Although different Bursera species are used for different health issues, they are traditionally attributed
medicinal properties including providing relief from pain, inflammation, rheumatism, and can help
treat illnesses such as colds, skin tumors, polyps, and venereal diseases [27–30]. The following are
46
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reported lignan-producing Bursera plants from Mexico listed according to the subgenus they belong
to and sorted alphabetically. Traditional uses, when found, and biological properties of the isolated
compounds are described for each species.
2.2. Subgenus Elaphrium
2.2.1. Bursera citronella McVaugh and Rzed.
B. citronella (synonyms: none reported) is also known as xochicopal (Náhuatl name) or lináloe, and
as almárciga in Spanish [31]. It is a 10 m tree with grey trunk bark and unifoliate or trifoliolate leaves,
distributed in Western Mexico (Michoacan, Colima, Jalisco, and Guerrero). It belongs to the subsection
glabrifolia [5]. The resin is mostly used as incense. It has been reported that B. citronella is used as
antitussive in several regions in Mexico [32].
The phytochemistry of B. citronella has been studied by Koulman who isolated two lignans:
hinokinin (1) and savinin (2) (Figure 1) [33]. Biological activities of hinokinin have been recently
reviewed [34]. Cytotoxicity of hinokinin (1) has been tested by several authors [35–38]. Hinokinin
(1) has been shown to have anti-inflammatory [39–42], immunosuppressive [43,44], antibacterial [45],
and antiviral [46] properties. Hinokinin (1) was tested for several other biological activities,
such as antispasmodic [47], neurite outgrowth-promoting in PC12 cells [48], antileukemic [49],
antiproliferative [50], and neuroprotective activities [51]. This compound showed an interesting
activity against Trypanosoma cruzi, [52–56], but with a low parasite selectivity [57]. Hinokinin has
been chosen as a trypanosomicidal marker in P. cubeba [58]. In order to ascertain the safety of this
compound toward mammalian cells, several studies have been performed [59–61]. The authors found
that hinokinin did not increase DNA damage, demonstrating the absence of mutagenic and genotoxic
activities. On the other hand, the results on the antimutagenic potential of this compound showed a
strong inhibitory effect against some direct and indirect-acting mutagens.
Figure 1. Structures of dibenzyl butyrolactone lignans isolated from Bursera spp.
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Savinin (2), also called hibalactone [62], was isolated for the first time from Juniperus spp. [63].
It has been tested for different biological activities, such as cytotoxicity against several tumor
cell lines [36,64–66]. Savinin (2) was shown to have an anti-inflammatory activity in several
assays [40,44,67–69], but also interesting antinociceptive, anxiolytic, and antioxidant activities [70,71].
2.2.2. Bursera cuneata (Schltdl.) Engl.
B. cuneata (synonym: Elaphrium cuneatum Schltdl. L.) is a tree that grows up to 10 m in height with
no-peeling grey-reddish bark. It has imparipinnate leaves of coriaceous texture with 3 to 13 leaflets,
6.5 cm long and 2.3 cm wide, and margin roughly serrated. Their flowers are clustered in inflorescences
up to 8 cm long. Its flowers are white and its fruits are up to 1.2 cm long with a black pit, almost
completely covered by a yellow or orange pseudoaril. It is native to Mexican oak-tropical deciduous
forest transition zones from Jalisco to Oaxaca and is often known as copal or copalillo [72]. Although
B. cuneata is characterized by seeds covered by pseudoaril, Becerra and Venable did not classify it into
the copallifera group [22]. No medical uses have been reported for this species, but it is largely used as
incense during sacred ceremonies and to prepare handcrafted objects.
Koulman isolated three lignans from this species: hinokinin (1), savinin (2), and cubebin (3)
(Figure 1) [33]. Cubebin was first isolated by Chatterjee in 1968 from Piper cubeba [73] and then from
several Aristolochia spp. Biological activities of cubebin have been recently reviewed by Cunha et al. [16].
In particular, trypanocidal activity of this compound against free amastigote forms of Trypanosoma cruzi
has been studied by de Souza et al. [52], and Bastos et al. showed it is inactive against trypomastigote
forms [74]. Notably, cubebin (3) is usually the starting material for the semi-synthetic preparation
of hinokinin (1) and other lignans [52]. Recently, cubebin was proven to induce vasorelaxation via
nitric oxide activation without prostacyclin involvement [75]. Because of its therapeutic potential,
the effects of cubebin on mutagenicity and genotoxicity has been deeply studied by several research
groups [76]. The authors found that cubebin (3) was cytotoxic at high doses (280 μM), but at lower
concentrations, no cytotoxic, mutagenic, or proliferative effects were observed for this compound.
The mutagenicity of cubebin (3), alone or in combination with doxorubicin (DXR), using standard
(ST) and high bioactivation (HB) crosses of the wing Somatic Mutation And Recombination Test
(SMART) in Drosophila melanogaster was also studied [77]. Even in this case, the effect of cubebin was
dose-dependent. At lower doses (<1 mM), it reduces DXR toxicity, whereas at higher doses (>2.0 mM),
it is cytotoxic. The biological activities of cubebin have been recently reviewed [78].
2.2.3. Bursera excelsa (Kunth) Engl.
B. excelsa (synonyms: Bullockia sphaerocarpa and Elaphrium excelsum) is commonly known
as tecomajaca, or copal santo, pom (in the Maya language) [79] and tecomahaca in the Náhuatl
language [29]. It belongs to the copallifera group. These are trees up to 8 m tall with grey non-peeling
bark. Their leaves are 11 to 23 cm long and 6 to 10.5 cm wide, with winged raquis and 9 to
15 leaflets, hairy and margin conspicuously toothed. Their flowers are small, yellow, and densely
hairy. Traditionally, it is used to treat tumors and muscle spasms [29]. It is widely distributed
across Mexico from the state of Sinaloa to Chiapas. The phytochemistry of B. excelsa has been
extensively studied [8,12,13]. Regarding lignan composition, Koulman isolated three compounds
from this species: 3,4-dimethoxy-3′,4′-methylenedioxylignano-9,9′-lactone (4), 3,4-dimethoxy-3′,4′-
methylenedioxylignano-9,9′-epoxylignan-9′-ol (DME) (5), and guayadequiol (6) (Figure 1) [33].
Compound 4 was named iso-bursehernin “ . . . since the only difference between this compound and
bursehernin is the placement of the aromatic groups in relation to the lactone ring” and compound 5
was named DME [33]. Iso-bursehernin (also called kusunokinin) was isolated from several plants, such
as Cinnamomun camphora [80], Virola spp. [81,82], and from different species of Haplophyllum [83–85].
Compounds 4 and 5 were identified as active glioma inhibitors in a bioassay-guided isolation process
from Piper nigrum fruits [86] and 4 selectively docked to Leishmania mexicana pyruvate kinase in a study
to find potential antiprotozoal polyphenolic plant extracts [87]. Kusunokinin isolated from P. nigrum
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showed potent cytotoxic activity on breast cancer cells (MCF-7 and MDA-MB-468) with IC50 values of
1.18 and 1.62 μg/mL, respectively, but demonstrated lower cytotoxicity on normal breast cell lines
(IC50 higher than 11 μg/mL). Cell cycle studies showed that this compound induced cell apoptosis and
drove cells toward the G2/M phase. Moreover, it decreased topoisomerase II and Bcl-2. The authors
observed an increasing in p53, p21, bax, cytochrome c, and caspase-8, -7, and -3 activities, except
caspase-9, suggesting that kusunokinin has potent anticancer activity through the extrinsic pathway
and G2/M phase arrest [88].
Lignans that contain a methylenedioxy group show high antifeedant or deterrent activity against
insects. Polar substituents on the aromatic rings, such as hydroxyl or glycosyl groups, reduce this
activity. Guayadequiol (6) was isolated for the first time from Bupleurum salicifolium [89]. No biological
data for this compound have been reported. The hexane extract of B. excelsa was shown to possess
in vivo anti-inflammatory activity [29].
2.2.4. Bursera graveolens (Kunth) Triana and Planch.
B. graveolens (synonyms: Amyris caranifera, A. graveolens, B. andersonii, B. pilosa, B. tatamaco,
Elaphrium graveolens, E. pilosum, Terebinthus graveolens, and T. pilosa) is called copal and
mizquixochicopalli in Náhuatl language [90]. Its Spanish common name is palo santo and it is native
to the tropical dry forests from the Yucatan Peninsula of Mexico, south to Peru, and the Galapagos
Islands of Ecuador. These are trees and sometimes shrubs up to 15 m tall, highly fragrant, with grey
bark. Their leaves are imparipinnate, sometimes bipinnate, up to 30 cm long and 18 cm wide, with
7 to 11 leaflets. The leaflets are 3 to 9 cm long and 1 to 4 cm wide, of acuminate apex, and margin
roughly serrated. Their small flowers are yellowish, white, or green and their fruits glabrous and are
up to 1.0 cm long. Their seeds are black and about two-thirds covered by an orange-red pseudoaril.
Traditionally, the alcoholic extract of the bark is used for rheumatism, and the bark infusion, as a
digestive and for respiratory problems. In recent years, the resin and oils have been extracted from the
wood by the perfume industry. From the active methanol extract of stems, Nakanishi et al. isolated
a new aryltetralin lignan, burseranin (7), and picropolygamain (8) (Figure 2) along with known
triterpenes, lupeol and epi-lupeol [91]. The two isolated lignans 7 and 8 showed important cytotoxic
activity against the human HT1080 fibrosarcoma cell line. Both compounds exhibited potent inhibitory
effects in comparison with adriamycin as a positive control (5.5 and 1.9 μg/mL vs. 0.1 μg/mL).
Picropolygamain (8) was isolated for the first time in 1985 from Commiphora incisa resin [92] and later
from Bursera simaruba [93]. This compound was shown to be active against LNCaP (androgen-sensitive
human prostate adenocarcinoma) cell line (ED50 1.1 μg/mL) during tests aimed at developing an
in vivo Hollow Fiber Assay [94].
Figure 2. Aryltetraline lignans (picro series) isolated from Bursera spp.
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2.2.5. Bursera penicillata (Sessé and Moç. ex DC.) Engl.
B. penicillata (synonyms: Amyris penicillata, Bursera mexicana, Elaphrium delpechianum, E. mexicanum,
E. penicillatum, Terebinthus delpechiana, and T. mexicana) belongs to the section glabrifolia. Its common
names are coyoluche, torote incienso, and torote copal [95]. These are trees up to 12 m tall of grey or reddish
grey bark, and are very fragrant, even sometimes from a distance. Their leaves are imparipinnate, 12
to 38 cm long, rachis-winged, and with 3 to 15 leaflets. The leaf blades are finely pubescent on both
surfaces and the margins strongly toothed. Their flowers are small, white, and arranged in few to
many inflorescences up to 14 cm long. Fruits are 1 to 1.3 cm long, 0.8 to 1.1 cm wide with a black
pit, and partially covered by a red, orange, or pale pseudoaril. Endemic to Northwest Mexico, this
species prospers in tropical deciduous forests and sporadically thornscrub and transition areas to oak
woodland, from Southeastern Sonora and Southwest Chihuahua to Michoacan. According to Gentry,
the leaves are used to treat the common cold and the gum is used for toothaches. It is also used as
incense [96]. Koulman reported the presence of savinin (2) in this species [33].
2.2.6. Bursera submoniliformis Engl.
B. submoniliformis (synonyms: Bursera subsessiliformis Engl. and Elaphrium submoniliforme (Engl.)
Marchand ex Engl.) is commonly known as copal chino. These trees are up to 12 m tall with grey
to reddish gray bark. Their leaves are imparipinnate, up to 20 cm long and 7 cm wide, with 9 to
17 leaflets. The leaflets are velvety, 1.3 to 5 cm long, 0.5 to 2 cm wide, and have toothed margins.
They have small white flowers that are arranged in inflorescences. Fruits are 7.5 to 12 mm long with
a black pit almost or completely covered by a yellow or orange pseudoaril. Endemic to Mexico, this
species inhabits tropical deciduous forests at altitudes of 500 to 1600 m of the Balsas and Papaloapan
river basins in the states of Mexico, Michoacan, Guerrero, Puebla, Morelos, and Oaxaca. It belongs
to the subsection copallifera. The gum resin is used to alleviate pain associated with flatulence and
tooth-ache [97]. The only reference about the phytochemistry of B. submoniliformis is by Koulman, who
reported the presence of savinin (2) in this species [33].
2.3. Section Bursera
2.3.1. Bursera aptera Ramirez
B. aptera (synonyms: Elaphrium apterum and Terebinthus aptera) belongs to the section fagaroides. Its
common names are cuajiote verde [98,99] and cuajiote blanco (Náhuatl names). The species is distributed
in Guerrero, Morelos, Oaxaca, and Puebla regions in Mexico [2]. These are shrubs or trees up to 10 m
high with green trunks and bark that exfoliates in yellow or beige papyrus-like sheets. The leaves
are glabrous, 2.5–7.5 cm long comprising 4 to 9 pairs of leaflets up to 15 mm long and 6 mm wide.
The flowers are reddish, yellow, or white and the fruits are small, up to 7 mm long, greyish red when
mature, and with a pit completely covered by a yellow or white papery pseudoaril.
Nieto-Yañez et al. evaluated the anti-leishmanial activity of a B. aptera methanolic extract.
The extract showed strong activity against Leishmania mexicana both in the in vitro and in vivo tests.
The gas chromatography-mass spectrometry (GC-MS) phytochemical analysis of the extract showed
the presence of 11 compounds. Most of these compounds were fatty acids and fatty acid esters, but
they revealed the presence of podophyllotoxin (19) (Figure 3) [100].
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Figure 3. Aryltetraline lignans isolated from Bursera spp.
2.3.2. Bursera arida (Rose) Standl.
B. arida (synonyms: Elaphrium aridum Rose and Terebinthus arida Rose) is endemic in the states of
Oaxaca and Puebla [2]. It is commonly known as zapotillo [99]. These are small trees, often shrubs, of
reddish-brown exfoliating bark with leaves up to 2.5 cm long and 1 cm wide, comprising 3 to 11 leaflets.
Their flowers are very small, reddish, and solitary. Their fruits are solitary or in pairs, over short and
pilose peduncles 1 to 2 mm long, with a seed completely covered by a pale yellow pseudoaril [101]. It
belongs to the microphylla subsection. Traditionally, the plant latex is topically used for healing wounds
and skin eruptions [102] in the Tehuacán-Cuicatlán valley. Bursera arida has different medicinal uses
such as a disinfectant, cough suppressant, and antidepressant [103].
The phytochemistry of B. arida was studied by Ionescu, who prepared a chloroform extract
of the stems, leaves, twigs, and bark, and found naringenin, β-sitosterol, betulonic acid, and four
lignans: (+)-3-hydroxymethyl-5-methoxy-6,7-methylenedioxy-1-(3′,4′-methylenedioxybenzene)-l,2,3,
4-tetrahydronaphthalene-2-carboxylic acid lactone (9) (Figure 3), (+)-3-hydroxymethyl-6,7-
methylenedioxy-1-(3′,4′-methylenedioxybenzene)-3,4-dihydronaphthalene-2-carboxylic acid lactone
(10) (Figure 4), (+)-3-hydroxymethy1-6,7-methylenedioxy-1-(5′-methoxy-3′,4′-methylenedioxybenzene)-
3,4-dihydronaphthalene-2-carboxylic acid lactone (11) (Figure 4), and 2,3-bis-(3,4-
methylenedioxybenzyl)butane-l,4-diol diacetate (12) (Figure 5) [104]. Compound 12 has the
structure of ariensin.
Figure 4. 7′,8′-Dehydro-aryltetraline lignans isolated from Bursera spp.
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Figure 5. Dibenzylbutane diol lignans isolated from Bursera spp.
2.3.3. Bursera ariensis (Kunth) McVaugh and Rzed.
B. ariensis (synonyms B. panosa Engl., B. sessiflora Engl., E. ariensis Kunth, and E. brachypodium
Rose). These are trees and sometimes shrubs between 2 and 8 m tall with greenish-gray trunks and
bark that exfoliates in papery sheets that are yellowish or beige, sometimes with orange tones, with
whitish resin that darkens upon contact with air. Their leaves are hairy especially when young, 5 to
22 cm long, and 2 to 7 cm wide, with a winged rachis and 5 to 9 leaflet pairs. Their flowers can be
solitary but often develop in conglomerates at the end of branches of reddish-yellow color. Their fruits
are 6 to 8 mm long, growing in thick conglomerates, with a pit completely covered by a yellow or
orange pseudoaril. It is distributed in Mexico (Chiapas, Guerrero, Jalisco, and Oaxaca regions) where
it is commonly known as guande and cuajiote blanco (Náhuatl name) [101] and used to treat colds and
inflammation. It belongs to the fagaroides group and is poorly studied. From the acetonic extract of the
bark, Hernandez isolated a new lignan named ariensin (12) [105]. Ariensin was shown to be active
against the RAW246.7 murine cell line (IC50 9.8 μM) [11].
2.3.4. Bursera fagaroides (H.B.K.) Engl.
B. fagaroides, or “fragrant bursera” (B. obovata Turcz., B. schaffneri S. Wats) [2] is a dioecious shrub
or tree, occasionally hermaphrodite, 0.5 to 10 m high, and highly resinous. The trunk is green with a
bark that exfoliates in yellowish-gray papery sheets. The leaves are most often compound, with 5 to
13 leaflets, although occasionally they are unifoliolate or trifoliolate. They have whitish-green or yellow
flowers, with a few of them arranged in small inflorescences or solitary. Male flowers are most often
5-merous (sometimes 3- and 4-). Female flowers are 3-merous. Fruits are typically 0.5 to 0.8 cm long
with short peduncles no more than 2 mm long that terminate in a sharp point. When the pits mature,
they are covered by a yellow or red pseudoaril. It is commonly known as cuajiote amarillo (in Morelos)
or pima bajo [106]. This species belongs to the fagaroides group. Three subspecific variants of this species
were recognized by McVaugh and Rzedowski (1965). B. fagaroides var. fagaroides, commonly known
as xixote and jiote [72], are most often shrubs with leaves with serrated margins and are distributed
in Northern, Central, and Western Mexico. B. fagaroides var. purpusii (common name aceitillo) [107]
are most often trees with leaves of entire margin (not toothed) distributed throughout Southeastern
Mexico. B. fagaroides var. elongata, common Mayo name to’oro sahuali [95], is from Northwestern
Mexico, and has been classified by recent molecular studies as a separate taxon not belonging within
B. fagaoides [108].
Bursera fagaroides is used to alleviate inflammation, skin tumors, and warts, and is perhaps the
most studied Bursera species in terms of its chemistry and biological effects. The first report about
B. fagaroides phytochemistry dates back to 1969, when Bianchi et al. isolated β-peltatin A-methyl ether
(13) and the new 5′-demethoxy-β-peltatin A-methyl ether (14) (Figure 3) that showed activity against
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the Walker carcinoma 256 (WA16) tumor system from the chloroform extract of this plant. The ethanol
extract from the dried exudate of Bursera fagaroides showed significant cytotoxic activity against the
HT-29 (human colon adenocarcinoma) cell line. From this extract, Velazquez-Jimenez et al. isolated
two aryltetraline lignans: (−)-deoxypodophyllotoxin (15) and (−)-morelensin (16) (Figure 3), and
two dibenzylbutirolactone lignans: (−)-yatein (17) and (−)-5′-desmethoxy yatein (18) or bursehernin]
(Figure 1) [109]. The authors determined the absolute configuration of these compounds by comparing
the vibrational circular dichroism spectra of known podophyllotoxin and deoxypodophyllotoxin with
those obtained by density functional theory calculations. Morelensin (16) was shown to be cytotoxic
and antiproliferative against several cancer cell lines [35,110]. Yatein (17) was shown to be cytotoxic and
antiproliferative to several cancer cell lines [111–114]. For example, it was tested against HL-60 (human
promyelocytic leukemia cells), SMMC-7721 (human hepatoma), A-549 (human lung adenocarcinoma),
MCF-7 (human breast cancer), and SW480 (human colon adenocarcinoma) cell lines using the MTT
(3-(4,5-dimethylthiazol-2)2,5-difeniltetrazolium bromide) method as previously reported [115], with
cisplatin as the positive control [116]. Yatein (17) showed significant cytotoxic activity against all tested
cell lines being superior to cisplatin. Chen et al. tested yatein [117] against DLD-1 (human colorectal
carcinoma), CCRF-CEM (human lymphoblastic leukemia), and IMR-32 (human neuroblastoma) cell
lines. The study showed that yatein possesses similar cytotoxic activity to doxorubicin (positive control)
against DLD-1 and CCRF-CEM cell lines [117]. Other studies showed that it is able to suppress herpes
simplex virus type 1 (HSV-1) replication in HeLa cells in a plaque reduction assay. Doussot et al. studied
the lignan profile and the antiproliferative activity of ethanol extracts from plants belonging to different
species of Linum, Callitris, and Juniperus. They compared the activity of deoxypodophyllotoxin (15),
podophyllotoxin (19), and yatein (17) against six human cancer cell lines: A549, U373 (glioblastoma),
T98G (glioma), Hs683 (oligodendro-glioma), MCF7 (breast cancer), and SKMEL-28 (melanoma).
The most active compound was deoxypodophyllotoxin (IC50 < 0.01 μM against all cell lines, not
tested against U373), followed by podophyllotoxin (IC50 = 0.03 μM against all cell lines except U373
(IC50 > 100 μM). Yatein (17) showed an antiproliferative activity, but to a lesser extent (IC50 = 30.9, not
tested, 26.5, 29.8, 31.9, and 39.6 μM, respectively) [118]. The inhibitory effect of yatein (17) on HSV-1
replication was concentration-dependent with an IC50 value of 30.6 ± 5.5 μM [119]. Furthermore,
yatein (17) was demonstrated to be a potent CYP3A4 inhibitor and this study is of particular importance
as 17 and other methylenedioxyphenol compounds were found to induce herb-drug interactions in
clinical situations [120]. Yatein (17) showed other important biological activities, such as anti-platelet
aggregation [121], and was shown to have moderate inhibitory activity against cytochrome P450 [122].
The bioactivity-guided separation of the hydroalcoholic extract of B. fagaroides var. fagaroides by
Rojas-Sepúlveda et al. led to, besides the already isolated lignans, podophyllotoxin (19), burseranin (7),
and acetyl podophyllotoxin (20) (Figure 3). All the isolated compounds were found to be active against
tumor cell lines tested, especially 5′-demethoxy-β-peltatin A-methyl ether (14), which exhibited greater
activity than camptothecin and podophyllotoxin against PC-3 (ED50 = 1.0 × 10−5 μg/mL) and KB
(ED50 = 1.0 × 10−5 μg/mL) cell lines [123]. Furthermore, the cytotoxic and antitumor activity of the
ethanol extract (70%) of B. fagaroides bark against L5178Y lymphoma cell line was tested. The antitumor
activity was studied on BALB/c mice (2 × 104 cells L5178Y i.p). Treated animals (at 50 mg/kg/day
over 15 days) showed a significant increase in survival compared with those treated with the placebo
or without treatment [124].
Podophyllotoxin and deoxypodophyllotoxin are secondary metabolites of many plants [125].
The biological activities and the importance of podophyllotoxin (19), as the lead compound in the
development of new anticancer agents, are well known [126–128]. The problem connected with its use
is the scarce amount isolated from natural sources. For this reason, biotechnological production of this
lignan has been studied [129]. Deoxypodophyllotoxin (15) is a promising anticancer agent [130,131].
Other diarylbutane lignans were isolated by Morales-Serna et al. from the chloroform extract
of B. fagaroides resin, named by the author as 9′-acetyl-9-pentadecanoyl-dihydroclusin (21) (correctly,
a hexadecanoyl derivative), 2,3-demethoxy-secoisolintetralin monoacetate (22), and dihydroclusin
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monoacetate (23), together with two known lignans: 2,3-demethoxy-secoisolintetralin diacetate
(24) and dihydroclusin diacetate (25) [132] (Figure 5). Recently, Antúnez Mojica et al. isolated
three new aryldihydronaphtalene-type lignans from the dichloromethane stem bark extract of
B. fagaroides var. fagaroides: 7′,8′-dehydropodophyllotoxin (26), 7′,8′-dehydroacetylpodophyllotoxin
(27), and 7′,8′-dehydro-trans-p-cumaroyl podophyllotoxin (28) (Figure 4), along with six known
lignans: podophyllotoxin (19), acetylpodophyllotoxin (20), 5′-demethoxy-β-peltatin A methylether
(14), acetylpicropodophyllotoxin (29) (Figure 2), burseranin (7), and hinokinin (1) [133]. The cytotoxic
activity of the new isolated compounds 26–28 against the cancer cell lines KB, PC-3, MCF-7, and
HF-6 was evaluated, which showed that all of them displayed good activity against KB, PC-3, and
HF-6, but were not active against the MCF-7 cell line. When compared with podophyllotoxin (19)
(ED50 = 2.10 × 10−4 μM), compounds 26 and 28 were most active against the PC-3 cell line displaying
similar toxicity (ED50 = 2.4 × 10−5 and 2.42 × 10−5 μM, respectively), whereas compound 27 was less
active (ED50 = 0.06 μM). Lignans 26–28 showed moderate activity against KB and HF-6 cell lines when
compared to 19. The cytotoxic activity of the other isolated compounds was already proven [123].
Acetylpicropodophyllotoxin (29) was previously isolated from Hernandia ovigera and it is a potent,
selective inhibitor of type I insulin-like growth factor receptor (IGF-IR) [134].
Ornithine decarboxylases (ODC) are enzymes that catalyze the decarboxylation of ornithine to
produce putrescine in the biosynthesis of polyamines. Polyamine metabolism is closely related with
the progression of growth, proliferation, and cell regeneration. The in vitro effect of an ethanolic extract
from the stem bark of Bursera fagaroides on ODC activity, and on the growth of Entamoeba histolytica, was
studied by Rosas-Arreguín et al. using metronidazole and G418 as positive controls [135]. The authors
found growth inhibition, with IC50 values in the order of 0.05 mg/mL. The ODC activity was inhibited
by 12% at 4.0 mg/mL.
Gutiérrez-Gutiérrez et al., considering the use in Mexican traditional medicine of B. fagaroides as an
antidiarrheic, investigated the in vitro anti-giardial activities of four podophyllotoxin-type lignans from
Bursera fagaroides var. fagaroides: 5′-demethoxy-β-peltatin A methylether (14), acetylpodophyllotoxin
(20), burseranin (7), and podophyllotoxin (19) [136]. They found that all lignans affected Giardia
adhesion, but only compounds 14, 19, and 20 caused growth inhibition.
2.3.5. Bursera microphylla A. Gray
B. microphylla, or “elephant tree” (Elaphrium microphyllum (A. Gray) Rose, Terebinthus microphylla
(A. Gray) Rose), is commonly known as xoop (Seri name) and torote blanco [95]. It is typically a small
tree that grows up to 10 m tall, with a thickened trunk and thickened lower branches, with light gray
to white peeling bark, with younger branches having a reddish color. The leaves are 3 to 8 cm long
and have 7 to 35 small, linear, and glabrous leaflets. The leaflets are up to 1.5 cm long. The flowers are
yellowish white or greenish and inconspicuous. The fruits are brownish red at maturity with a black
pit completely covered by a yellow-orange pseudoaril [26]. It belongs to the microphylla group. The Seri
Indians from Sonora, Mexico use the bark, leaves, flowers, and fruits to treat a variety of maladies such
as inflammation, diarrhea, and venereal diseases. The first lignan isolated from Bursera microphylla was
burseran (30) (Figure 1) [137]. Cole et al. showed that burseran has cytotoxic activity against human
epidermoid carcinoma of the nasopharynx (9KB cell line) in a Cancer Chemotherapy National Service
Center (CCNSC) test (ED50 < 10 μg/mL) acting as a spindle poison. Tomioka et al. synthetized cis (H8′
α) and trans burseran and tested them in a cilia regeneration test in Tetrahymena, that is a useful model
for studying the antitubulinic activity of spindle poisons [138]. Both trans and cis burseran have shown
inhibitory activity, but the antitumor activity was higher for trans burseran [139]. An analysis of the
chemical composition of the methanol extract of B. microphylla resin from the Sonora Desert (Mexico),
revealed the presence of several known lignans: ariensin (12), burseranin (7), dihydroclusin diacetate
(25), picropolygamain (8), desmethoxy-yatein (18), hemiariensin (31) (Figure 5), and dihydroclusin
9′-acetate (23); and two new ones: podophyllotoxin butanoate (32) and dihydroclusin 9-acetate (33)
(Figures 3 and 5) [11,140]; in addition to burseran (30). Compound 32 was already known as a
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synthetic derivative of podophyllotoxin [141] but it was new as a natural product. Burseran (30) and
dihydroclusin diacetate (25) were tested against human cancer cell lines: A549 (lung cancer), HeLa
(cervix cancer), and PC-3 (prostate cancer), and on murine cell lines M12.C3.F6 (B cell lymphoma)
and RAW264.7 (macrophages transformed by virus Abelson leukemia); which were found to be more
active against murine cell lines in micromolar range (IC50 13.8, 36.3, and 2.5 μM, respectively). The
anti-proliferative activities of dihydroclusin 9-acetate (31), dihydroclusin 9′-acetate (23), burseranin (7),
picropolygamain (8), and hemiariensin (31) were evaluated on the human cancer cell lines A549, LS
180, and HeLa, and on the human non-cancer cell line ARPE-19. None of the evaluated compounds
had statistically significant anti-proliferative effects with respect to dimethyl sulfoxide (DMSO) control
on LS 180, A549, and ARPE cell lines. However, burseranin (7) and picropolygamain (8) had an
interesting anti-proliferative activity on the gynecological cancer cell line, HeLa, with IC50 values of
21.72 ± 1.03 and 9.31 ± 1.01 μM, respectively [140].
2.3.6. Bursera morelensis Ramírez
B. morelensis (synonym: Elaphrium morelense (Ramírez) Rose) is widely distributed in Mexico [101],
where it is commonly known as coabinillo [99]. It is a tree up to 13 m tall with red bark that exfoliates in
thin sheets. Its leaves are 5 to 11 cm long and 1.5 to 4.5 cm wide, with 15 to 51 linear leaflets. The flowers
are yellow, pink, greenish, or white. The fruits are 0.5 to 1 cm long, with a pit completely covered
by a pale yellow pseudoaril. It belongs to the microphylla group. The only two papers describing
the phytochemistry of B. morelensis address the composition and the anti-inflammatory activity of
the essential oil [142] and the isolation of deoxypodophyllotoxin (15) and morelensin (16) from the
resin [110]. Morelensin (16), although highly active against the KB (epidermoid carcinoma) cancer
cells, demonstrated only marginal activity against the porcine stable (PS) kidney cell line [110].
2.3.7. Bursera roseana Rzed., Calderón & Medina
B. roseana (synonyms: Bursera acuminata (Rose) Engl. and Terebinthus acuminata Rose) is a 12–20 m
high tree with bark peeling in reddish-orange stripes. It is imparipinnate with 3 to 7 (sometimes 9)
leaflets with a hairy underside but a bright and glabrous upper side. The leaflets are typically of oval
shape, 4.5 to 15 cm long and 2 to 6 cm wide, ending in a long point. The flowers are white or greenish
and the is fruit is glabrous, 0.9 to 1.2 cm long, with a pit completely covered by a pale pseudoaril [143].
This species grows in moist canyons in the transition zone between highland pine-oak forest and
lowland tropical subdeciduous forest. It is common in Nayarit, Zacatecas, Aguascalientes, Jalisco,
Colima, Michoacán, Estado de México, and Guerrero [143]. It belongs to the simaruba group. The
only phytochemical study on this species was reported by Koulman, who found 5′-desmethoxy
yatein [bursehernin or (−)-trans-methylpluviatolide [144] (+)-trans-methylpluviatolide, which has been
called dextrobursehernin [145] (18)], morelensin (16), deoxypodophyllotoxin (15), and β-peltatin-A
methylether (13). Bursehernin (18) was studied by Ito et al. for its inhibitory effects on Epstein-Barr
virus early antigen activation induced by 12-O-tetradecanoylphorbol 13-acetate in Raji cells [146].
The data reported demonstrated that bursehernin (18) was slightly weaker than β-carotene, which
is commonly used in cancer prevention studies [147] so it might be a valuable antitumor promoter.
Bursehernin (18) is able to inhibit the growth of Neisseria gonorrhoeae [148]. The trypanocidal activity of
racemic mixtures of cis- and trans-bursehernin was evaluated in vitro against trypomastigote forms of
two strains of Trypanosoma cruzi, and results showed that the racemic cis-stereoisomer was inactive,
whereas the racemic trans-stereoisomer displayed trypanocidal activity, with an IC50 ~89.3 μM. These
results were different from those obtained for pure (−)-trans-methylpluviatolide by Bastos et al., but
the difference could be ascribed to the use of the racemic mixture [74].
2.3.8. Bursera schlechtendalii Engl.
B. schlechtendalii (synonyms: Bursera jonesii Rose, Elaphrium jonesii (Rose) Rose, Terebinthus jonesii
(Rose) Rose, and Terebinthus schlechtendalii (Engl.) Rose) is a small tree or shrub, 4–6 m high, with a
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strong turpentine smell, and known as sak chakaj. It has a glossy greyish pink bark that peels off in thin
papery sheets; the branches are thick and stout. The leaves are simple (unifoliolate), often less than 6
cm long and 2.5 cm wide. The flowers are small, usually solitary, with yellow or reddish petals, and
the fruits are 4 to 8 mm long with a pit completely covered by a yellow or red pseudoaril. It is used
to treat the flu. It is found at altitudes of 200–400 m on dry rocky hillsides or in thickets in Southern
Mexico and Guatemala. It belongs to the fagaroides group. In 1972, McDoniel et al. isolated from stems
and leaves the chloroform extract of Mexican B. schlechtendalii Engl. yatein (17) and bursehernin (18).
2.3.9. Bursera simaruba (L.) Sarg.
B. simaruba or “gumbo-limbo” (Bursera simaruba var. yucatanensis Lundell) is commonly known as
yala-guito [99]. It is a 6–15 m high tree with a peeling reddish bark that reveals a smooth grey underbark.
The leaves are compound, bright, and mostly glabrous when mature. Leaves have 3 to 13 leaflets, 4
to 9 cm long and 1.8 to 3.5 cm wide. The small flowers have pink, pale yellow-green, or white petals
and are arranged in inflorescences. The fruits are glabrous, red to brownish, 1 to 1.5 cm long, ending
in a point, with a pit completely covered by a red pseudoaril. This is perhaps the most widespread
species of Bursera, occurring from Southern Florida and the Caribbean, along both coasts of Mexico,
to South America. Taken orally or as curative baths, the leaves and bark are attributed a variety of
medicinal properties. It belongs to the simaruba group. In 1992, Peraza-Sánchez and Peña-Rodriguez
isolated picropolygamain (8), which showed activity in the brine shrimp assay (LC50 = 52.2 ppm).
Further in vitro evaluation against three human tumor cell lines (A-549, lung), MCF-7 (breast), and
HT-29 (colon) showed that 8 has cytotoxic activity comparable to that of Adriamycin [93]. Noguera
et al. isolated the anti-inflammatory β-peltatin A-methyl ether (13) from the leaf hexane extract of
B. simaruba. It inhibited the carrageenan-induced rat paw edema, in a dose- and time-dependent
manner (three hours = 9.55%, five hours = 34.37%, and seven hours = 35.6%) [149]. Maldini et al.
studied the methanolic extract of Bursera simaruba bark and isolated 11 compounds, including lignans
yatein (17), β-peltatin-O-β-D-glucopyranoside (34) (Figure 3), hinokinin (1), and bursehernin (18) [149].
3. Conclusions
Lignans are phenolic secondary metabolites characterized by a large variety of biological activities.
Among these, the cytotoxic and anti-proliferative ones are perhaps the most common and most studied.
Literature analysis of Mexican plants producing lignans Burseara spp., revealed that the most common
lignan types are dibenzyl butyrolactones (nine compounds), picro aryltetraline derivatives (three
compounds), aryltetraline derivatives (nine compounds), 7′,8′-dehydro-aryltetraline derivatives (five
compounds), and dibenzylbutane diols (eight compounds). Notably, all the examined Elaphrium
subgenus species produce only dibenzyl butyrolactones and picro aryltetraline derivatives, whereas
Bursera subgenus produce all lignan types. The most common compound, up to now, appears to be
bursehernin (18), which is present in five species belonging to the Bursera section. Hinokinin (1) and
savinin (2) are also widespread (four species), both in the Elaphrium and Bursera sections. Compounds
3, 8, 12, 13, 15, 16, 17, and 33 were isolated from three species.
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Abstract: Lignans, neolignans, norlignans and norneolignans constitute a large class of phenolic
natural compounds. 9-Norlignans, here defined to contain a β–β’ bond between the two
phenylpropanoid units and to lack carbon number 9 from the parent lignan structure, are the most
rarely occurring compounds within this class of natural compounds. We present here an overview of
the structure, occurrence and biological activity of thirty-five 9-norlignans reported in the literature
to date. In addition, we report the semisynthetic preparation of sixteen 9-norlignans using the natural
lignan hydroxymatairesinol obtained from spruce knots, as starting material. 9-Norlignans are shown
to exist in different species and to have various biological activities, and they may therefore serve
as lead compounds for example for the development of anticancer agents. Hydroxymatairesinol is
shown to be a readily available starting material for the preparation of norlignans of the imperanene,
vitrofolal and noralashinol family.
Keywords: lignans; norlignans; 9-norlignans; semisynthesis; hydroxymatairesinol; bioactivity
1. Introduction
Many secondary metabolites, including lignans, flavonoids, and coumarins are formed from
phenylpropanoids originating from the well-known shikimic acid pathway. The parent structures are
usually further oxidized and arranged into various structures. Norlignans, a subclass of lignans lacking
one or more carbon atoms, seem to be a rather unknown class of natural products. Compared to
other phenylpropanoids their occurrence, biosynthetic pathway, and their properties are much
less reported in the literature. Especially 9-norlignans (lacking carbon 9 from the parent lignan
skeleton) with guaiacyl (3-methoxy-4-hydroxyphenyl) moieties have rarely been reported in the
literature, although they would be expected to be common norlignans as guaiacyl lignans are
the most abundant class of lignans. To the best of our knowledge, (+)-imperanene, vitrofolal E
and F, noralashinol A and C are the only guaiacyl type 9-norlignans which have been reported as
plant constituents [1–4]. The unnatural enantiomer, (−)-R-imperanene, dehydroxyimperanenes and
dihydrodehydroxy-imperanenes have also been synthesized [5,6]. Normally, common substitution
patterns are found in norlignans, but the more rare 2,4,5-trisubstituted phenyl moieties seem to be
present in several 9-norlignans. In this paper we review the occurrence and properties of natural
compounds belonging to the class of 9-norlignans, and in addition, we report the semisynthesis of
9-norlignans from the natural lignan hydroxymatairesinol.
1.1. Classification and Nomenclature of Norlignans
The term lignan is defined as two phenyl propane units coupled together by a β–β’ bond, and if
the same structural units are coupled in any other ways the product is called a neolignan. If the
coupling between the units contains an ether function (fundamental parent structures) the compound
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is called an oxyneolignan. According to the present recommendations by the International Union
of Pure and Applied Chemistry (IUPAC), the prefix nor (modification of the fundamental parent
structure) is used when the lignan, neolignan or oxyneolignan lack one or more carbon atoms [7].
However, in the literature there are today over 60 compounds named as norlignans although the
major part of these are lacking the β–β’coupling, which is the definition for the fundamental parent
structure named lignan. In our opinion most of these structures should be named as norneolignans
or noroxyneolignans (prefix nor + fundamental parent structure). The choice of the numbering of
the lost carbon is also somewhat confusing. Numbering of the modified carbon skeleton (in this
case nor) should be performed so that the modification is expressed by the lowest locant (number,
unprimed). However, the choice of locants for the removal of a carbon atom (nor) is preferred in
the order: unprimed, higher number. Consequently, there is a conflict when assigning structures
to 9 or 7-norlignans or norneolignans. Although the exact definition of different norlignans seems
a bit confusing and vague, we here define a norlignan as a plant-derived compound consisting of
two phenylpropane units coupled in the propane moiety with a β–β’ bond and missing one or more
carbon atoms.
Moreover, we consider 9-norlignans to be derived from a parental lignan skeleton and thus to
have a detectable β–β’ coupling and to lack one (or more, in the case of di(bis)norlignans) of the
terminal carbon atoms (carbon 9). In Figure 1, the fundamental structures of different norlignan and
norneolignan structures coupled in the propane moiety are displayed (oxyneolignans and others are
excluded, dotted lines in red indicate the missing carbon-9, the bold lines indicate the coupling in the
propane moiety).
Figure 1. Fundamental structures for the lignan and different 9-norlignan and 9-norneolignan
structures. Dotted (red lines) lines indicate the missing carbon-9 atom.
1.2. 9-Norlignans
According to the definition above, approximately 25 naturally occurring 9-norlignans can be
found in the literature. These are yateresinol (1) [8], pachypostaudin A and B (2,3) [9], aglacin H
(4) [10], vitrofolal A,B,E, and F (5,6,7,8) [2,11] descuraic acid (9) [12], cestrumoside (glycoside)
(10) [13], (−)-justiflorinol (11) [14], (+)-virgatyne (12) [15], the arylnaphthalene derivative 13 [16]
and the lactone 14 [17], compound 15 [18], S-(+)-imperanene (16) [1], 3-methoxy-imperanene (18) [19],
noralashinol A and C (19,20) [3,4], tectonoelin A and B (21,22) [20], peperotetraphin (23) [21] the related
cyclobutane carboxylates 24 and 25 [22] and hyperione A and B (26,27) [23] (Figure 2). In addition,
some related 9-norlignans have been synthesized and some 9-norlignan like compounds have also
been reported [6,24,25]. In Figure 3, the structures of compounds 28–35 are shown.
66





Figure 2. The structures of previously reported 9-norlignans with natural origin.
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Figure 3. Structures of synthetic 9-norlignans and 9-norlignan related compounds.
1.3. Occurrence and Biological Activity
Yateresinol (1) was first isolated from the heartwood of Libocedrus yateensis in 1979 by Ertman
et al. [8]. It has also been found in Cryptomerica japonica D. Don and found to be part of the wood
discoloring substances in sapwood [26]. Studies of butt-rot sugi wood suggested that the norlignans
may be important for antifungal properties but no clear effect has been shown [27]. Yateresinol has
been tested for cytotoxicity towards the human HL60 and Hepa G2 cancer cell lines [28] but was
shown to be inactive with the half maximal inhibitory concentration (IC50) values >20 μg/mL.
The two 9,9′-bisnorlignans 2 and 3 (pachypostaudin A and B) have been isolated from stem bark
of Pachypodanthium staudtii Engl. et. Diels [9]. The same bisnorlignans have also been isolated
from bark of the related species Pachypodanthium confine Engl. et Diels [29]. Both species are trees
growing in the tropical zone of west and central Africa, and have been used in traditional African
medicine. However, no biological activity of the bisnorlignans has been reported. Aglacin H (4) has
been isolated from the bark of Aglaia cordata collected in Indonesia [10]. No other sources, and no
chemical and biological properties for this norlignan have so far been reported. Norlignans from Vitex
species, namely vitrofolal A, B, E, and F (compounds 5–8) are norlignans of the arylnaphthalene type.
These compounds were first isolated from Vitex rotundifolia [2,11]. Compounds 5–8 have later also
been isolated from the seeds [30] and 7 from the roots of Vitex negundo [31,32]. Compounds 7 and
8 have also been isolated from the fruits of Vitex cannabifolia [33]. Vitrofolal E (7) was also recently
reported in the stem and bark of Syringa pinnatifolia [2,34]. Vitrofolals have been shown to have various
biological activities. Compound 7 was shown to have antibacterial activity against methicillin-resistant
Staphylococcus aureus at concentrations above 64 μg/mL [2]. Compounds 7 and 8 have also been
reported to have antioxidant activity by inhibition of lipid peroxidation using the ferric thiocyanate
method, and by scavenging of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH). In both assays 7
and 8 showed comparable or slightly higher antioxidative activity than α-tocopherol, L-cysteine and
butylated hydroxyanisole (BHA) [33,35]. Vitrofolal E (7) has also been shown to have moderate activity
in the in vitro cholinesterase inhibition assay [31] and to have tyrosinase inhibitory activity in the same
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μM-range compared to known inhibitors [32]. Vitrofolal F (8) has been shown to have α-chymotrypsin
(serine protease) inhibitory effect and has thus been suggested as a specific natural inhibitor of this
enzyme [36]. The aryldihydronaphthoic acid derivative, descuraic acid (9), was isolated from seeds of
Descurainia Sophia (L.) Webb ex Prantl, an annual/biennial herb [12]. Despite the structural similarities
with vitrofolals, no biological properties of this compound have been published to date, however it is
used in traditional medicine to alleviate common cold symptoms and to prevent asthma and oedema.
The 9-norlignan glycoside cestrumoside (10), was recently identified from methanol extract of Cestrum
diurnum L. leaves [13]. No biological effects for this compound were reported, although several
species of this plant have been used in traditional Chinese medicine, especially for treatment of burns
and swellings. However, recently 10 was claimed to be a protein kinase C inhibitor in an animal
feed additive [37]. A study of the cytotoxic effects of the arylnaphthalene lignans from Vietnamese
Acanthaceae, Justicia patentiflora revealed the structure of justiflorinol (11). However, the cytotoxic
evaluation showed that 11 does not have the same cytotoxic effect as structurally related lignans found
in this plant species [14]. Justiflorinol has also been isolated from leaves of Piper sanguineispicum and
tested for its antileishmanial activity and for cytotoxicity on MCF7 and Vero cells. No significant
biological activity was found [38]. (+)-Virgatyne (12) has been found in whole plant extracts of the
Taiwanese annual plant Phyllantus virgatus Frost. F. (Euphorbiaceae) [15]. This plant has traditionally
been used to protect the liver and 12 was tested for anti-hepatitis B virus in a MS-G2 cell line, but was
shown to be completely inactive [39].
Different liverwort species have been shown to contain dihydronaphthalene and naphthalene
lignans and norlignans. The arylnaphthalene derivative 13 was first isolated from Pellia epiphylla
and the structure was confirmed by chemical synthesis [16]. The same compound (13) was later
found in Jamesoniella autumnalis [40], Bazzania trilobata [41], Lepidozia reptans [42], Lepidozia incurvata,
Chiloscyphus polyanthos and Jungermannia exsertifolia ssp. cordifolia. In the last three species conjugates
with malic acid, shikimic acid and α-L-rhamnose were also isolated [43], but so far no biological
activity has been reported.
The butyrolactone 9-norlignan (14) has been isolated from a methanol-water extract of leaves of
Cestrum parqui, originally a South American shrub, but frequently occurring also in the Mediterranean
region. Green cestrum (Cestrum parqui) has been shown to have phytotoxic effects and has been
studied as a natural herbicide. Compound 14 showed phytotoxic effects on Lactuca sativa (lettuce) and
Lycopersicon esculentum (tomato) by reducing the development of the plant [17].
Compound 15 was first identified in alkaline extraction (pulping) of Norway spruce (Picea abies)
roots. Later it was also shown to be a degradation product of the abundant guaiacyl type
dibenzylbutyrolactone lignan hydroxymatairesinol [18]. The degradation process has been studied
in detail and 15 can be obtained by alkaline treatment of hydroxymatairesinol in nearly quantitative
yields [5]. The carboxylic acid has not been reported as a constituent in other plants, but the
corresponding alcohol ((−)-imperanene (17)), although the other enantiomer (+)-imperanene 16,
has been found in the rhizomes of Imperata cylindrica. (+)-Imperanene was shown to have platelet
aggregation inhibitory effects and gave a complete inhibition, at 6 × 10−4 M concentration, of rabbit
platelet aggregation induced by thrombin [1]. (+)-Imperanene, 3-methoxyimperanene (18) and their
glucosides have also been detected in rum distillate wastewater. In the same report, these compounds
were shown to be inhibitors of human tyrosinase activity (IC50 = 1.85 mM). (+)-Imperanene showed
the highest activity, indicating that the guaiacyl (3-methoxy-4-hydroxyphenyl) substitution pattern
is important for the activity [19]. Contrary to many other norlignans, imperanene has been a target
for several synthetic works. Noralashinol C (19) and noralashinol A (20), structurally related to the
arylnaphthalene norlignans vitrofolals, have been isolated from stem barks of Syringa pinnatifolia.
Compound 20 seems to be the acetal of 7 (possibly formed by reaction with methanol). Compound 19
was inactive in a cytotoxicity assay using HepG2 hepatic cancer cells and 20 was inactive in the NO
production inhibitory assay [3,4]. Tectonoelin A and B (21,22), and compound 14 have been isolated
from the leaves of Tectona grandis and shown to have growth inhibition activity in the etiolated wheat
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coleoptiles bioassay test [20]. Interestingly, both green cestrum and teak leaves seem to contain these
rare norlignans and display herbicidal effects. Cyclobutane-type norlignans peperoteraphin (23) and
two related isomers (24,25) have been isolated from Peperomia tetraphylla (whole plant). Compounds 24
and 25 were tested for cytotoxicity in human liver cancer cell lines HepG2, human lung cancer cell lines
A549, and human cervical cancer cell lines Hela. Moderate activity with IC50 values around 50 μM
for all cell lines, were detected [21,22]. Hyperione A and B (26,27) have been isolated from Hypericum
chinense (whole herb). Hypericum species are known for their antibacterial activity but compounds 26
and 27 showed no antibacterial activity [23]. The occurrence and biological activities of 9-norlignans
are summarized in Table 1.
Table 1. 9-Norlignans, their occurrence and biological activity.
Compound Number Occurrence Bioactivity References
Yateresinol 1 Libocedrus yateensis, Cryptomericajaponica Antifungal [8,26]
Pachypostaudin A 2 Pachypodanthium staudtii,
Pachypodanthium confine [9,29]Pachypostaudin B 3
Aglacin H 4 Aglaia cordata [10]
Vitrofolal A 5
Vitex rotundifolia, Vitex negundo,










Descuraic Acid 9 Descurainia Sophia [12]
Cestrumoside 10 Cestrum diurnum L. [13]
(−)-Justiflorinol 11 Justicia patentiflora, Pipersanguineispicum [14,38]









Lactone 14 Cestrum parqui Phytotoxic effects [17]
Compound 15 Picea abies [18]
(+)-Imperanene 16 Imperata cylindrica, sugarcane rumdistillate
Platelet aggregation inhibitory
effect, tyrosinase inhibitory effect [1,19]
3-Methoxy-Imperanene 18 Sugarcane rum distillate Tyrosinase inhibitory effect [19]
Noralashinol C 19 Syringa pinnatifolia [3,4]Noralashinol A 20
Tectonoelin A 21 Tectona grandis Herbicidal activity [20]Tectonoelin B 22
Peperoteraphin 23




Hyperione A 26 Hypericum chinense [23]Hyperione B 27
In addition to these compounds, some 9-norlignan-like compounds (although containing
additional carbon atoms) have been isolated (Figure 3). Pouzolignan D (28) and K (29) were isolated
from the aerial parts of Pouzolzia zeylanica (L.) Benn. var. microphylla (wedd.) W.T. Wang [24] and
dysosmanorlignans A (30) and B (31) from the roots of Dysosma versipellis [25]. No biological activity
has been reported for these compounds.
Several of these naturally occurring lignans have been the topic for total synthesis, however,
the synthetic methods are excluded from this literature review. Some semisynthetic methods as
well as the synthesis of interesting derivatives related to the presented norlignans will be discussed
briefly. For example, the synthesized dehydroxy- and dihydrodehydroxyimperanene isomers have
been evaluated for their plant growth regulatory effects, for larvicidal, antifungal, antibacterial and
cytotoxic activity, and compared to dihydroguaiaretic acid isomers. In most studies compounds
32–35 were less or equally active as dihydroguaiaretic acids. In the cytotoxicity study, using HL-60
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and HeLa cells, compound 35 showed the highest activity with IC50 values at approximately 6 μM,
suggesting that norlignans may serve as lead compounds for anticancer agents [6].
As previously mentioned, imperanene derivatives can also be synthesized from the natural lignan
hydroxymatairesinol and these compounds can be further transformed to vitrofolal and noralashinol
type norlignans. To expand the substrate scope for investigation of 9-norlignans and to perform
structure–activity relationship studies, we have undertaken the semisynthetic preparation of 15
different 9-norlignans with different functionalities using hydroxymatairesinol as starting material.
In this strategy we chose to introduce flexibility or rigidity to the basic skeleton. We also varied the
functionality at carbon-9 by the preparation of the carboxylic acid, the ester and the alcohol. In addition,
the skeleton was also aromatized by oxidation and two different substitution patterns at the aromatic
moieties were prepared. The semisynthesis of these compounds from hydroxymatairesinol is presented
in detail below.
2. Results
Semisynthesis of Norlignan Derivatives from Hydroxymatairesinol
The knots of Norway spruce (Picea abies (L.) H. Karst) have been shown to contain about
10% (w/w) of the dibenzylbutyrolactone hydroxymatairesinol (36, Scheme 1). Methods for the
separation of knots and the subsequent isolation of hydroxymatairesinol were developed during
the last decade. Today hydroxymatairesinol is isolated on kg-scale, which certainly makes it one
of the most readily available lignans in pure form for further studies. In our previous studies,
we have shown that hydroxymatairesinol is degraded to norlignan derivative 15 by strong alkali.
This retro-aldol-type reaction probably involves a formation of a quinone methide intermediate and
the loss of formaldehyde [5].
During degradation, two of the stereocentra of hydroxymatairesinol are destroyed, but the third
retains the R-configuration without isomerization, yielding an optically pure product in excellent
yields, usually over 95%. Further esterification and reduction of the obtained product (37), by lithium
aluminium hydride (LAH) affords the 9-norlignan (−)-imperanene (17), as previously reported.
However, the structure of 15 offers many possibilities for modification of the structure, which enabled
the preparation of a set of derivatives for structure-activity relationship (SAR) studies of their biological
effects (Scheme 1). The double bond was shown to be susceptible for protonation and Friedel–Crafts
ring closing to yield two diastereomers of the 6’-7-cyclo-9-norlignan (aryltetralin-type) 38 in a 3:4
ratio. The two diastereomers were not separable by column chromatography. Further modification
of the carboxylic acid to the ester 39 and the alcohol 40 was performed equally as in the case of
15 [5]. Oxidation of the cyclonorlignan 39 by 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) was
utilized to aromatize the aliphatic ring to obtain the corresponding arylnaphthalene vitrofolal-type
norlignan 41. This structure was also transformed into the acid 42 and the alcohol 43 by hydrolysis
and reduction, respectively. Oxidation of 38 or 40 by DDQ was proven to be unsuccessful. In the
case of 38, the structure was easily decarboxylated during the oxidation. The double bond of 15 was
also reduced by catalytic hydrogenation in a batch reactor using ethanol, Pd/C and hydrogen at a
slightly elevated pressure (2 bar) to give 44. Again, the ester 45 and the alcohol 46 were prepared
equally as for the other structures (Scheme 1). The permethylated derivative 48 was obtained by
methylation with MeI in dry acetone and K2CO3. The acid 47 and the alcohol 49 were prepared
accordingly. With these simple chemical modifications, we obtained a set of compounds (derivatives of
imperanenes, vitrofolals and noralashinols) with some structural alterations. In this strategy we chose
to introduce both flexibility, by reducing the double bond, and rigidity by introducing the aliphatic
ring, at the basic skeleton of imperanene. The nonflexible cyclic structures with a half-boat structure
38–40 adopted a certain non-planar conformation, and were therefore aromatized to yield a planar
structure (compounds 41–43) resembling bioactive 9-norlignans of the vitrofolal and noralashinol
family. Finally, we chose to prepare the carboxylic acid with an ionizable group, the ester containing
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the carbonyl function and the alcohol, for comparison of the effects of the functionality at C-9’. Some of
the derivatives were also submitted to methylation of the free phenolic groups for comparison of
the 3-methoxy-4-hydroxyphenyl and 3,4-dimethoxyphenyl moieties. The liverwort norlignan 13 was
obtained from 42 by treatment with AlCl3 in pyridine.
 
 
Scheme 1. Preparation of various 9-norlignans from hydroxymatairesinol. This generalized
scheme shows the fundamental chemical transformations. For more detailed information on the
interconversions and transformations including reaction conditions, see the supplementary material.
Compounds 15, 44, 48, 37, 38, 40 and 41 have previously been evaluated as inhibitors of multidrug
resistance protein 1 (MRP1)-mediated transport using human erythrocytes as model. This was
part of a larger study on polyphenolic compounds comprising lignans, norlignans, stilbenes and
flavonoids. Compound 15 was shown to be the most active one, with moderate activity at
IC50 = 50 μM. The structure-activity relationship study showed that the carbonyl function at C-9’
is crucial for the activity. Furthermore, none of the norlignans showed detrimental effects up to
200 μM, indicating a large therapeutic width. These compounds could therefore be interesting as
possible agents reversing multidrug resistance and to potentially sensitize cancer cells to anticancer
drugs [44]. A similar set of compounds (15, 38, 40, 41, 44 and 48) were tested for estrogen and
antiestrogen activity in the yeast estrogen assay. Compounds 40, 41 and 48 showed antiestrogenic
effects, albeit at quite high concentrations (100–500 μM) [45]. Some of these norlignans were
also studied for antimicrobial effects in comparison with the effective stilbene trans-pinosylvin
(trans-3,5-dihydroxystilbene) and its monomethylated derivative (trans-3-hydroxy-5-methoxystilbene).
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Although some effects were observed, it was concluded that the norlignans were ineffective against
Salmonella infantis, Listeria monocytogenes and Candida tropicalis [46].
3. Discussion and Conclusions
Norlignans of the C-9 type are an uncommon group of polyphenols in nature. Many of these
compounds can be found in plants used in traditional Asian medicine, however published scientific
data of their bioactivities is in general rather scarce. In most cases, their biological effects have been
tested in a few assays mainly for antioxidant, cytotoxic and antimicrobial activities. Clearly, a more
broad and systematic screening of bioactivity should be conducted to evaluate these compounds as
potential bioactive agents. 9-Norlignans belonging to the vitrofolal-, noralashinol-, and imperanene
families have however been shown to be bioactive and some of them could find potential in
treatment of cancer. Furthermore, these 9-norlignans have been shown to inhibit specific enzymes,
which warrants further investigations of these compounds. In our semisynthetic approach using
hydroxymatairesinol as starting material for the preparation of 9-norlignans, we have developed simple
chemical transformations to unsaturated, saturated, cyclic and aromatic structures closely resembling
those of the vitrofolal, noralashinol and imperanene family. The unsaturated compounds 15, 17 and 37
could also be seen as polyphenolic compounds with both trans-stilbene-like, and lignan-like structures,
which could make them interesting as antimicrobial compounds. The cyclic structures were obtained
in high yields by treatment with formic acid or trifluoroacetic acid. However, this Friedel–Crafts-type
reaction can also be performed in aqueous conditions, using mineral acids. The aromatization was
introduced by reaction with DDQ with moderate yields. DDQ was superior for this reaction due to its
benzylic hydride abstraction properties, yielding dehydrogenation of the product, rather than oxidative
polymerization. Hydrogenation of the double bond was facile, proceeding in high yields. To broaden
the substrate scope of the semisynthetic 9-norlignans, the initial carboxylic acid (of compound 15) was
esterified and reduced by conventional methods, in relatively high yields. By these interconversions the
carboxylic acid, the methyl ester and the alcohol derivatives were obtained for all the basic structures.
Some structures were also methylated at the phenolic positions, which gave us 16 norlignans with
different structures available for screening of biological activity. This semisynthetic route is not
restricted to these compounds and it offers numerous additional chemical modifications and functional
group interconversions. The biological testing of some selected semisynthetic 9-norlignans showed
that none of these compounds were highly active. However, compound 15 showed moderate activity
as an inhibitor of MRP1-mediated transport. The activity was decreased for all other derivatives,
which indicated that the double bond and the carboxylic acid function were important for the activity.
Due to the limited scope of biotesting for these semisynthetic 9-norlignans, no generalized results
of their bioactivity or results on structure-activity relationships can be proposed, without further
screening of biological activity.
4. Materials and Methods
All commercially available chemicals were used as supplied by the manufacturers.
Hydroxymatairesinol was isolated from Norway spruce (Picea abies (L.) Karst) knots by previously
described methods [5]. Knots of Norway spruce were separated, ground and freeze-dried prior
to extraction in a Soxhlet apparatus. The raw extract obtained with acetone-water (9:1 v/v),
after the removal of lipophilic extractives with hexane was purified by flash chromatography (eluent
CH2Cl2:EtOH 98:2 v/v) to yield hydroxymatairesinol.
GC analyses were performed on a standard gas chromatograph (Agilent Technologies, model 6850,
Santa Clara, CA, USA) equipped with a HP-5 column and a flame ionization (FI) detector. The samples
were silylated using hexamethyldisilazane-chlorotrimethylsilane in pyridine, prior to analyses.
Gas chromatography-mass spectrometry (GCMS) analyses were performed essentially the same
way (Agilent Technologies, model 7890A+5975C). High-resolution mass spectrometry (HRMS) were
recorded using a Micro Q-TOF (Bruker, Billerica, MA, USA) with electrospray ionization (ESI)
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operated in positive mode or with a ZAB-Spec high-resolution MS-ESI instrument (Fisons Instruments,
Ipswich, UK).
1H- and 13C-NMR spectra were recorded on an Avance instrument (Bruker) at 600.13 and
150.90 MHz, respectively. 2D NMR experiments (1H-1H COSY, HSQC, HMBC) were recorded
using standard pulse sequences and chemical shifts are reported downfield from tetramethylsilane.
Optical rotations were measured with a digital polarimeter model 241 (Perkin Elmer, Waltham, MA,
USA) using a 1 dm, 1 mL cell.
The inhibition of multidrug resistance protein 1-mediated transport was studied by
measurement of 2′,7′-bis-(carboxypropyl)-5(6)-carboxyfluorescein (BCPCF) efflux in human
erythrocytes. Erythrocytes were loaded with 2′,7′-bis-(carboxypropyl)-5-(6)-carboxyfluorescein
acetoxymethyl ester (BCPCF-AM) and incubated with or without the norlignans (10–200 mM).
The extracellular BCPCF fluorescence intensity was then measured and the IC50 values for BCPCF
efflux were determined from dose-response curves. The detailed experimental procedure and
results have previously been published [44]. The estrogen and antiestrogen activity was determined
using the yeast estrogen assay consisting of a transformed yeast strain (Saccharomyces cerevisiae).
Cells were pre-cultured and diluted in a medium containing chlorophenol red-β-D-galactopyranoside.
The suspensions with compounds were incubated in 96-well plates for three days before the absorbance
at 540 nm was measured. Estrogenic or anti-estrogenic activity was calculated by subtraction of
absorbance at 620 nm from that of 540 nm. Dose curves were plotted and the IC50 values were
calculated. 17β-Estradiol was used as reference. A more detailed description has been published by
Aehle et al. [45].
The antimicrobial activity tests were performed with Listeria monocytogenes L211, Salmonella infantis
EELA72 and Candida tropicalis 4068 using an automated incubator and turbidity reader to monitor the
microbial growth. The compounds were studied at equimolar concentrations (0.1–1 mM). The growth
was calculated by subtraction of the turbidity of the test culture from that of the control and expressed
as growth inhibition percentages. The detailed experimental procedure and results have previously
been published [46].
Supplementary Materials: The following are available online. Full experimental procedures for compounds
36–50, including analytical data.
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Abstract: Lignans comprise a family of secondary metabolites existing widely in plants and also
in human food sources. As important components, these compounds play remarkable roles in
plants’ ecological functions as protection against herbivores and microorganisms. Meanwhile,
foods rich in lignans have revealed potential to decrease of risk of cancers. To date, a number of
promising bioactivities have been found for lignan natural products and their unnatural
analogues, including antibacterial, antiviral, antitumor, antiplatelet, phosphodiesterase inhibition,
5-lipoxygenase inhibition, HIV reverse transcription inhibition, cytotoxic activities, antioxidant
activities, immunosuppressive activities and antiasthmatic activities. Therefore, the synthesis of
this family and also their analogues have attracted widespread interest from the synthetic organic
chemistry community. Herein, we outline advances in the synthesis of lignan natural products in the
last decade.
Keywords: natural products; total synthesis; lignan
1. Introduction
Lignans are a family of secondary metabolites widely distributed in plants and human food
sources. The story of lignans can traced back to 1942, when Harworth introduced the term for the first time
to describe this family [1]. It is known that lignans have remarkable ecological functions in plants, providing
protection against herbivores and microorganisms [2–7]. The consumption of foods rich in lignans has
potential to decrease of risk of cancers [8–11]. During its long research history, this family has exhibited
attractive pharmacological activities [12–19], such as antibacterial [20], antiviral [21–24], antitumor [25–27],
antiplatelet [28,29], phosphodiesterase inhibition [30,31], 5-lipoxygenase inhibition [32–34], HIV
reverse transcription inhibition [35–37], cytotoxic [38], antioxidant [39], immunosuppressive [40]
and antiasthmatic properties [31].
Lignan compounds have dimeric structures formed through a β,β′-linkage between two
phenylpropane units with different degrees of oxidation on the side-chain and variable substitution
patterns on the phenyl ring. Traditionally, lignans are divided into two classes: classical lignans and
neolignans. It should be noted that the term lignan in the literature refers to classical lignans in most
cases. Regarding the classification of classical lignans, four different types are reported. The first one
arranged classical lignans into three subgroups: acyclic lignan derivatives, arylnaphthalene derivatives
and dibenzocyclooctadiene derivatives [41]. The second type includes six subgroups: dibenzylbutanes,
dibenzylbutyrolactones, arylnaphthalenes, dibenzocyclooctadienes, substituted tetrahydrofurans
and 2,6-diarylfurofurans [9,14]. The third one is comprised of eight subgroups: furofurans, furans,
dibenzylbutanes, dibenzylbutyrolactones, aryltetralins, arylnaphthalenes, dibenzocyclooctadienes
and dibenzylbutyrolactols [8,42–45]. The fourth one includes seven subgroups of lignan scaffolds:
cyclobutanes, tetrahydrofurans, furofurans, dibenzylbutanes, aryltetralins, cycloheptenes and
dibenzocyclooctadienes [46].
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The synthesis of lignans and their analogues is an active field in the synthetic organic
chemistry community. Tremendous synthetic efforts on this family have been well documented by
reviews [9–14,41,47–51]. In recent years, several nice reviews have outlined progress of particular
topics related to the synthesis of furofuran lignans [48], arylnaphthalene lactone analogues [47] and
aryltetralin glycosides [49]. The present review will focus on the papers on the synthesis of lignans
published from 2008–2018. In order to avoid unnecessary duplication, we will not discuss works
already presented in previous reviews.
For the convenience of introduction of advances in the synthesis of lignans, we discuss three
subgroups in present review, namely, acyclic lignan derivatives, dibenzocyclooctadiene derivatives
and arylnaphthalene derivatives.
2. Advances in the Synthesis of Acyclic Lignan Derivatives
In the last decade, synthetic progress in acyclic lignan derivatives is related to lignans featuring
dibenzyl tetrahydrofuran, dibenzylbutyrolactone, and diphenyltetrahydrofuranfurofuran skeletons.
The synthesis of the acyclic lignan derivative (±)-paulownin (Scheme 1) was accomplished by
Angle and coworkers in 2008 [52]. The key step is a formal [3 + 2]-cycloaddition between silyl ether 1
and aldehyde 2 in the presence of BF3OEt2 and 2,6-di-tert-butyl-4-methylphenol (DBMP), generating
aryl tetrahydrofuran 3. After oxidation and removal of the protecting group, the resulting product
4 was connected with imidate 5, generating lactone 6. The synthesis of (±)-paulownin was finished
through photocyclization under a medium-pressure Hanovia lamp [53].
 
Scheme 1. Synthesis of (±)-paulownin. Adapted from Angle et al. [52].
In 2011, Barker and coworkers reported the total synthesis of (+)-galbelgin (Scheme 2) [54].
A stereoselective aza-Claisen rearrangement developed in their lab [55] afforded a reliable access
to the original two stereocenters in chiral amide 8. The subsequent nucleophilic addition from 11,
reduction, hydroxyl protection and double bond oxidative cleavage led to the formation of aldehyde
10. The second nucleophilic addition from 11 afforded 12 with four adjacent stereocenters established.
Methoxymethyl (MOM) group deprotection and cyclization completed the synthesis of (+)-galbelgin.
i
 
Scheme 2. Synthesis of (+)-galbelgin. Adapted from Barker et al. [54].
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She and coworkers reported the total synthesis of beilschmin A and gymnothelignan N in
2014 (Scheme 3) [56]. Alcohol 14 was prepared by hydroxyl protection of chiral amide 13 and
subsequent reduction. Aldehyde 16 was obtained after homologation and reduction. The nucleophilic
addition of 17 and oxidation afforded ketone 18. Dibenzyl tetrahydrofurans 20 was obtained after a
highly stereoselective introduction of a methyl group, deprotection and reduction. The synthesis of
beilschmin A was finished after the methylation. Inspired by a biosynthetic proposal from She’s group,
the challenging seven-membered ring skeleton in gymnothelignan N was constructed by an oxidative
Friedel-Crafts reaction of compound 20 using phenyliodonium diacetate (PIDA) as the oxidant, finally
affording gymnothelignan N.
 
Scheme 3. Synthesis of beilschmin A and gymnothelignan N. Adapted from She et al. [56].
In 2015, Lump and coworkers reported a bioinspired total synthesis of (±)-tanegool and
(±)-pinoresinol (Scheme 4) using [2 + 2] photodimerization and oxidative ring-opening as key
steps [46]. The synthesis started with the esterification of ferulic acid. The resulting product 22
went through [2 + 2] photodimerization and reduction, generating diol 23 smoothly. The synthesis of
(±)-tanegool through the expected oxidative ring-opening of 23 was achieved under different oxidative
conditions. Moreover, synthesis of (±)-pinoresinol was also accomplished. Using the same strategy,
trans-diester 26 was prepared from cis-diester 25. Reduced product 27 was submitted to an oxidative
ring-opening treatment using FeCl3·6H2O as the oxidant, finishing the synthesis of (±)-pinoresinol
through an oxidative ring opening and two 5-exo-trig cyclization pathway.
As powerful synthetic tools, photoredox-catalyzed tranformations have received considerable
attention in recent decades [57–59]. In 2015, MacMillian and coworkers developed an enantioselective
α-alkylation of aldehydes using a combination of photoredox catalysis and enamine catalysis
and achieved the asymmetric synthesis of (−)-bursehernin through this strategy (Scheme 5) [60].
Using Ru(bpy)3Cl2, chiral amine 33 and a compact fluorescent lamp (CFL) light source, the α-alkylation
of aldehyde 28 with bromonitrile 29 generated chiral aldehyde 30 in excellent yields and excellent
enantioselectivity. Subsequent reduction and cyclization afforded lactone 31. The synthesis of
(−)-bursehernin was achieved by a highly stereoselective alkylation between 31 and bromide 32.
In 2017, Soorukram and coworkers reported the asymmetric synthesis of ent-fragransin C1
(Scheme 6) [61]. Ketone 36 was produced by the nucleophilic addition of the aryllithium species generated
from 35 to chiral Weinreb amide 34. The following stereoselective reduction led to the formation of
alcohol 37. After hydroxyl protection, double bond oxidative cleavage and nucleophilic addition from
aryllithium 39, compound 40 was furnished in good diastereoselectivity. Followed by the deprotection
and cyclization treatments, the tetrahydrofuran ring in 41 was established. Finally, the synthesis of
ent-fragransin C1 was accomplished through debenzylation under hydrogenation conditions.
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Scheme 4. Bioinspired synthesis of (±)-tanegool and (±)-pinoresinol. Adapted from Lump et al. [46].
 
Scheme 5. Asymmetric synthesis of (−)-bursehernin. Adapted from MacMillian et al. [60].
 
Scheme 6. Asymmetric synthesis of ent-fragransin C1. Adapted from Soorukram et al. [61].
Based on a tandem nucleophilic addition/Ru-catalyzed isomerization/SET oxidation/radical
dimerization strategy [62], Jahn and coworkers reported a bioinspired total synthesis of multiple
lignans in 2018 (Scheme 7) [63]. Using bromide 42 as the substrate, a smooth unprecedented tandem
1,2-nucleophilic addition/Ru-catalyzed isomerization/SET oxidation/radical dimerization afforded
1,4-diketone 43 with acceptable diastereoselectivity. After the reduction, three different treatments of
43 led to the formation of 44 and 45 in varied ratios. With the removal of double t-butyldimethylsilyl
(TBS) protecting groups, the synthesis of (±)-fragransin A2 and (±)-odoratisol was achieved. Through
the same strategy, Jahn and coworkers completed the synthesis of (±)-galbelgin, (±)-grandisin,
(±)-galbacin, (±)-veraguensin, and (±)-beilschmin B.
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Scheme 7. Bioinspired synthesis of seven acyclic lignans. Adapted from Jahn et al. [63].
A Ni-catalyzed cyclization/cross-coupling strategy was developed and applied for the synthesis
of (±)-kusunokinin, (±)-dimethylmetairesinol, (±)-bursehernin and (±)-yatein by Giri and coworkers
in 2018 (Scheme 8) [64]. Ligand 48 was used for the Ni-catalyzed cyclization/cross-coupling between
iodide 46 and aryl zinc reagent 47 followed by Jones oxidation, generating lactone 49 readily.
Compound 49 was then connected with bromide 50 in a good diastereoselective manner, completing
the synthesis of (±)-kusunokinin. The syntheses of (±)-dimethylmetairesinol, (±)-bursehernin and
(±)-yatein were accomplished using the same protocol.
 
Scheme 8. Synthesis of four acyclic lignans. Adapted from Giri et al. [64].
3. Advances in Synthesis of Dibenzocyclooctadiene Serivatives
Dibenzocyclooctadiene derivative lignans feature a particular eight-membered ring containing a
chiral biaryl axis. Members of this subgroup possess various substitution patterns with two aryl rings
and different stereocenters on the aliphatic bridge.
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In 2010, an interesting Ni-catalyzed enantioselective Ullmann coupling of bis-ortho-substituted
arylhalides was developed and applied to the asymmetric synthesis of (+)-isoschizandrin by Lin and
coworkers (Scheme 9) [65]. With the application of chiral ligand 56, the Ni-catalyzed enantioselective
Ullmann coupling of bromide 51 gave the axial chiral biaryl dial 52 with acceptable enantioselectivity.
Aldehyde 55 was prepared after monoprotection, Wittig reaction and deprotection operations.
The synthesis of (+)-isoschizandrin was accomplished according to Molander’s cyclization protocol [66].
 
Scheme 9. Asymmetric synthesis of (+)-isoschizandrin. Adapted from Lin and Xu et al. [65].
Based on a double organocuprate oxidation strategy, Spring and coworkers reported the total
synthesis of (±)-deoxyschizandrin in 2012 (Scheme 10) [67]. Symmetrical 1,3-diene 58 was prepared by
the homo-coupling of alkenyl iodide 57 through a mild metalation, magnesio-cuprate transmetalation
and subsequent oxidation using 61 as the oxidant [68]. Subsequent hydrogenation afforded 59 as a
mixture of two diastereoisomers. After iodination, the expected iodide 60 was obtained. The synthesis
of (±)-deoxyschizandrin was completed by an intramolecular organocuprate oxidation process,
including metalation, magnesio-cuprate transmetalation and oxidation with 61.
 
Scheme 10. Synthesis of (±)-deoxyschizandrin. Adapted from Spring et al. [67].
In 2013, the RajanBabu group reported a general synthetic approach to multiple
dibenzocyclooctadienes lignans via an interesting borostannylative cyclization (Scheme 11) [69].
In the presence of PdCl2(PPh3)2 and [B-Sn] reagent 70, chiral diynyl precursor 62 was converted
into dibenzocyclooctadiene 64 through a borostannylative cyclization and a subsequent acidification
process [70].
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Scheme 11. Synthesis of five dibenzocyclooctadienes lignans. Adapted from RajanBabu et al. [69].
The Subsequent hydrogenation afforded 65 as the major product. After the deprotection and
oxidation, the general intermediate 66 was prepared. The synthesis of (−)-ananolignan C was
achieved through two successive diastereoselective reductions of 66. Meanwhile, the synthesis of
(−)-ananolignan B was accomplished from the treatment of 66 with LiAl(OtBu)3H and subsequent
acetylation. The stereoselective hydrogenation of (−)-ananolignan B led to the formation of
(−)-ananolignan D. The following configuration inversion of the hydroxyl group and actylation
led to the synthesis of (−)-ananolignan F. In addition, (−)-interiotherin C can also be formed through
the esterification of 69 and angeloyl chloride 71.
Synthesis of other three lignans was reported by RajanBabu and coworkers in the same paper
(Scheme 12) [69]. Oxidative cleavage of the right-bottom double bond of 64 was applied for the
formation of ketone 72. Diol 74 was obtained from the debenzylation and methyllithium 1,2-addition
of 72. After hydroxyl oxidation, diastereoselective reduction and benzoyl protection steps, compound
76 was obtained. Starting from 76, synthesis of schizanrin F was achieved by TBS deprotection,
oxidation, diastereoselective reduction and acetylation process. Starting from diol 74 again, compound
78 can be prepared by TBS deprotection, oxidation and double diastereoselective reduction. Finally,
the synthesis of kadasuralignan B and tiegusanlin D was accomplished through acetylation and
benzoylation of 78, respectively.
 
Scheme 12. Synthesis of another three dibenzocyclooctadienes lignans. Adapted from RajanBabu et al. [69].
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In 2018, a mild and asymmetric synthetic route to (−)-gymnothelignan L was developed by She
and coworkers through a Suzuki-Miyaura coupling and a bioinspired desymmetric transannular
Friedel-Crafts cyclization strategy (Scheme 13) [71]. Iodide 80 was obtained from iodination of
compound 79. The Suzuki-Miyaura coupling of 80 and arylboronic acid 84 formed biphenyl compound
81, which was transformed into 82 using DIBAL-H as the reducing agent. Under acidic conditions,
a bioinspired desymmetric transannular Friedel-Crafts cyclization of 82 occurred readily, generating 83.
After removal of the benzyl protecting group, the synthesis of (−)-gymnothelignan L was completed.
At almost the same time, a similar strategy was applied in total synthesis (−)-gymnothelignan V by
Soorukram and coworkers [72].
 
Scheme 13. Bioinspired asymmetric synthesis of (-)-gymnothelignan L. Adapted from She et al. [71].
4. Advances in the Synthesis of Arylnaphthalene Derivatives
In the literature, the arylnaphthalene derivative lignan subgroup includes arylnaphthalenes and
aryltetralins. Structurally, these lignans have a substituted naphthalene core. It should be mentioned
that, due to their excellent biological characters, several clinically used antitumor drugs are derived
from the well-known member, podophyllotoxin, and its glycosides [49].
 
Scheme 14. Asymmetric synthesis of (−)-plicatic acid. Adapted from Deng et al. [73].
In 2009, Deng and coworkers reported an asymmetric total synthesis of (−)-plicatic acid
(Scheme 14) [73]. The enantioselective epoxidation of trisubstitued olefin 85 was applied for the
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introduction of the original chiral stereocenters. Excellent enantioselectivity was obtained from the
application of chiral (S,S)-TADOOH 86. Intramolecular Friedel-Crafts reaction of 87 formed the
six-membered ring of 88 effectively. Subsequent silylation and intramolecular Barbier reaction under
SmI2/NiI2 conditions afforded a diastereoselective access to diol 90. After Fleming-Tamao- Kumada
oxidation [74,75], 91 was furnished. The synthesis of (−)-plicatic acid was completed following
hydration and global debenzylation.
The stereoselective aza-Claisen rearrangement strategy developed by Barker and coworkers
was not only effective for asymmetric synthesis of (+)-galbelgin (Scheme 2), but also for asymmetric
synthesis of (−)-cyclogalgravin, and (−)-pycnanthulignenes A and B (Scheme 15) [54]. Through the
aza-Claisen rearrangement strategy, alcohol 9 (Scheme 2) was prepared and submitted to hydroxyl
protection and double bond oxidation, generating aldehyde 92. The addition from aryllithium 11 gave
compound 93. The synthesis of (−)-cyclogalgravin was achieved through cyclization. Employing same
protocol, Barker’s group also finished an asymmetric synthesis of (−)-pycnanthulignenes A and B.
 
Scheme 15. Asymmetric synthesis of (−)-cyclogalgravin. Adapted from Barker et al. [54].
In 2012, Hong and coworkers reported the enantioselective total synthesis of (+)-galbulin using
an organocatalytic asymmetric Michael-Michael-aldol cascade (Scheme 16) [76]. Under the promotion
of Jørgensen-Hayashi catalyst 96, ketoaldehyde 97 was readily prepared from the asymmetric
Michael-Michael-aldol cascade of 94 and 95. Compound 99 was produced by reduction, oxidation and
epoxidation treatments of 97. Following epoxide ring-opening and aromatization, compound 101 was
obtained. The synthesis of (+)-galbulin was finally accomplished through selective methylation and
dehydroxylation processes.
 
Scheme 16. Enantioselective synthesis of (+)-galbulin. Adapted from Hong et al. [76].
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Peng and coworkers reported in 2013 the synthesis of sacidumlignan A employing Ueno-Stork
radical cyclization and skeletal rearrangement strategy (Scheme 17) [77]. Alcohol 103 was connected
with ethyl propenyl ether in the presence of bromine, readily generating 104. The Ueno-Stork radical
cyclization of 104 was enabled by Bu3SnH and AIBN.
 
Scheme 17. Synthesis of sacidumlignan A. Adapted from Peng et al. [77].
The resulting 105 was submitted to a skeletal rearrangement, affording arylnaphthalene 106.
The synthesis of sacidumlignan A was achieved after benzyl deprotection.
The same year, Peng and coworkers also reported the total synthesis of (±)-cyclogalgravin and
(±)-galbulin (Scheme 18) [78]. Cyclic acetal 108 was obtained from Ueno-Stork radical cyclization
of 107. Diol 110 was prepared by an oxidation, methylation and reduction process. Subsequent
selective hydroxyl protection, dehydroxylation, deprotection and oxidation led to the generation
of aldehyde 111. Next an intramolecular Friedel-Crafts reaction was applied for the synthesis
of (±)-cyclogalgravin. The synthesis of (±)-galbulin was readily achieved by the stereoselective
hydrogenation of (±)-cyclogalgravin.
 
Scheme 18. Synthesis of (±)-cyclogalgravin and (±)-galbulin. Adapted from Peng et al. [78].
In 2013, Argade and coworkers reported a novel strategy to construct arylnaphthalene frameworks
via Pd-promoted [2 + 2 + 2] cyclization (Scheme 19), which enabled the synthesis of justicidin B and
retrojusticiding B [79]. Through a Pd-promoted [2 + 2 + 2] cyclization process, aryne precursor 112
was connected with diene 113, generating arylnaphthalene 114. After the regioselective hydrolysis of
the ester group, the synthesis of justicidin B was achieved through a chemoselective reduction of the
acid group using BH3·SMe2 and subsequent lactonization. Meanwhile, the synthesis of retrojusticidin
B was achieved through the reduction of 115 and subsequent lactonization.
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Scheme 19. Synthesis of justicidin B and retrojusticiding B. Adapted from Argade et al. [79].
Shia and coworkers reported in 2015 the synthesis of three arylnaphthalene derivative lignans
using a Mn(III)-mediated free radical cyclization cascade (Scheme 20) [80]. Knoevenagel condensation
of α-cyano ester 116 with aldehyde 117 and subsequent reduction was applied for the generation
of α-cyano ester 118. The following oxidative free radical cyclization cascade enabled by Mn(OAc)3
afforded access to compound 119. The synthesis of retrojusticidin B was accomplished after decyanation
and aromatization operations. Using the same strategy, the synthesis of justicidin E and helioxanthin
was completed.
 
Scheme 20. Synthesis of arylnaphthalene derivative lignans. Adapted from Shia et al. 2015 [80].
In 2015, Narender and coworkers reported an interesting Ag-promoted radical addition/
cyclization process for the construction of highly substituted α-naphthol skeletons (Scheme 21) and the
synthesis of three arylnaphthalene lignans [81]. Through the Ag-promoted radical addition/cyclization
between ketoester 120 and aryl propiolate 121, polysubstituted arynaphthol 122 was readily prepared.
The synthesis of diphyllin was finished under known reductive-lactonization conditions [82].
The synthesis of justicidin A was then achieved through methylation of diphyllin. The synthesis
of taiwanin E was also accomplished.
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Scheme 21. Synthesis of arylnaphthalene lignans. Adapted from Narender et al. [81].
In 2017 Ham and coworkers reported the synthesis of seven arylnaphthalene derivative
lignans based on a strategy involving Hauser-Kraus annulation and Suzuki-Miyaura cross-coupling
(Scheme 22) [83]. In the presence of LiHMDS, the Hauser-Kraus annulation between cyanophthalide
123 and γ-crotonolactone 124 and subsequent protection treatment gave arylnaphthalene 125.
The synthesis of diphllin was finished by the subsequent Suzuki-Miyaura cross-coupling of 126
and potassium aryltrifluoroborate 127. Justicidin A was produced by the methylation of diphllin.
The syntheses of taiwannin E, chinensinaphthol justicidin C, justicidin D and cilinaphthalide B were
also finished.
 
Scheme 22. Synthesis of seven arylnaphthalene lignans. Adapted from Ham et al. [83].
Hajra and coworkers reported the enantioselective total synthesis of (−)-podophyllotoxin and
natural analogues in 2017 (Scheme 23) [84]. The L-proline-catalyzed asymmetric cross aldol reaction
between 6-bromopiperonal 128 and aldehyde 129 introduced original stereocenters with excellent
diastereoselectivity and excellent stereoselectivity at gram scale. Lactone 130 was obtained after reduction,
lactonization and TBS protection operations. Z-Benzylidene lactone 132 was prepared through an
aldol reaction between 130 and aldehyde 131, and subsequent elimination. The intramolecular Heck
reaction between trisubstituted Z-alkene motif and the bulky bromoarene motif in 132 happened
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smoothly, generating compound 133 in good yields. Notably, under different hydrogenation conditions,
three stereoselective pathways of 133 led to the synthesis of (−)-podophyllotoxin, (−)-picropodophyllin,
(+)-isopicropodophyllin, respectively. Meanwhile, the synthesis of (+)-isopicropodophyllone was
achieved through the oxidation of (+)-isopicropodophyllin. The synthesis of (−)-isopodophyllotoxin
can be accomplished through a TBS deprotection and reductive Heck reaction process from 132.
 
Scheme 23. Synthesis of (−)-podophyllotoxin and three natural analogues. Adapted from Hajra et al. [84].
Czarnocki and coworkers reported in 2018 the total synthesis of (+)-epigalcatin using a
photocyclization process under continuous flow UV irradiation conditions (Scheme 24) [85]. Diester
134 was condensed with aldehyde 120 at basic conditions, affording E,E-bisbenzylidenesuccinic acid
135. Through an amidation process, L-prolinol was introduced in amide 136 as a chiral auxiliary.
Eight-membered ring compound 137 was prepared via following hydrolysis and macrolactonization.
Under continuous flow irradiation with UV light, the photocyclization of 137 furnished 138
smoothly [86]. Remove of the chiral auxiliary, hydrogenation of the double bond and simultaneous
reduction of formyl group led to the formation of ester 139. The synthesis of (+)-epigalcatin was
achieved through subsequent reductive transformations of the methyl ester of 139 into a methyl group
via three steps.
 
Scheme 24. Synthesis of (+)-epigalcatin. Adapted from Czarnocki et al. [85].
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Peng and coworkers reported the total synthesis of (−)-podophyllotoxin and four natural
analogues using a Ni-catalyzed reductive cascade in 2018 (Scheme 25) [87]. The asymmetric
conjugated addition of 141 to chiral α,β-unsaturated amide 140 introduced the first stereocenter.
Enol ether 144 was obtained after subsequent reduction, oxidation, acetal formation and elimination.
β-Bromoacetal 145 was produced using 2,4,4,6-tetrabromo-2,5-cyclohexadienone (TBCD). With the
application of the Ni-catalyzed reductive cascade [88], both 146 and 147 were produced in moderate
yields. After the hydration and oxidation of 146, the synthesis of (+)-deoxypicropodophyllin
was accomplished. (+)-Isodeocypodophyllotoxin can be synthesized from the epimerization at
C9a of (+)-deoxypicropodophyllin under basic conditions. With the radical bromination under
visible-light irradiation [89], and further oxidation treatments, the synthesis of (−)-epipodophyllotoxin
and (−)-podophyllotoxone was achieved in a stepwise fashion. The stereoselective reduction of
(−)-podophyllotoxone using L-Selectride gave (−)-podophyllotoxin. Additionally, compound 147
can be transformed into Meyer’s 150 intermediate for synthesis of (−)-picropodophyllin and
(−)-picropodophyllone through three regular operations [90].
 
Scheme 25. Synthesis of (−)-podophyllotoxin and four natural analogues. Adapted from Peng et al. [87].
The Ni-catalyzed cyclization/cross-coupling has been verified as a suitable strategy for not
only the synthesis of multiple acyclic lignan derivatives (Scheme 8) but also the synthesis of
(±)-dimethylretrodendrin and (±)-collinusin (Scheme 26) by Giri and coworker [64]. Lactone 49
was obtanied from the Ni-catalyzed cyclization/cross-coupling process (Scheme 8). The stereoselective
aldol reaction between 49 and aldehyde 117 and following intramolecular Friedel-Crafts reaction led
to the formation of (±)-dimethylretrodendrin.
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Scheme 26. Synthesis of (±)-dimethylretrodendrin and (±)-collinusin. Adapted from Giri et al. [64].
In the presence of 153, the Ni-catalyzed cyclization/cross-coupling of 46 and 151 and
following oxidation gave lactone 152. The synthesis of (±)-collinusin was completed by subsequent
intramolecular nucleophilic addition and dehydration.
In 2018, Belozerova and coworkers reported the synthesis of sevanol via an oxidative dimerization
strategy (Scheme 27) [91]. Chiral ester 156 was prepared by esterification of acid 154 and chiral alcohol
155. After the removal of two MOM protecting groups of 156, compound 157 was submitted to
FeCl3-promoted oxidative dimerization, affording sevanol after the hydrolysis of all three ester groups.
 
Scheme 27. Synthesis of sevanol. Adapted from Belozerova et al. [91].
Aria and coworkers reported total synthesis of (±)-isolariciresinol using a tandem Michael-aldol
reaction in 2018 (Scheme 28) [92]. Alcohol 160 was obtained as a diastereomeric mixture from the
tandem Michael-aldol reaction of dithiane 158, lactone 124 and aldehyde 159 under basic conditions.
After the cleavage of the dithiane substituent and TBS, the following cyclization furnished 162 as the
major product.
Ester 163 was prepared from methanolysis of the lactone ring and TBS protection operations.
The synthesis of (±)-isolariciresinol was achieved through the subsequent reduction and
deprotection treatments.
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Scheme 28. Synthesis of (±)-isolariciresinol. Adapted from Aria et al. [92].
Barker and coworkers reported in 2017 the first total synthesis of (±)-ovafolinins A and B through
the acyl-Claisen rearrangement developed in their lab and a cascade cyclization enabled by bulky
protecting groups (Scheme 29) [93]. Notably, (±)-ovafolinins A and B have polycyclic skeletons rarely
found in lignans. The acyl-Claisen rearrangement between acid chloride 165 and allylic morpholine
166 afforded amide 167 as a single diastereoisomer and in excellent yields. Alcohol 168 was prepared
by hydration and reduction. Phenol 169 was introduced through a Mitsunobu reaction. Alcohol 170
was obtained after the oxidative cleavage of the double bond and following reduction. The subsequent
t-butyldiphenylsilyl (TBDPS) protection, debenzylation and oxidation led to the formation of compounds
171 and 172 through a cascade cyclization enabled by the TBDPS group. The synthesis of (±)-ovafolinins
A and B was achieved after subsequent hydrogenation and deprotection.
i
 
Scheme 29. Synthesis of (±)-ovafolinins A and B. Adapted from Barker et al. [93].
Taking advantage of the above achievement, Barker and coworkers reported the first asymmetric
total synthesis of (+)-ovafolinins A and B (Scheme 30). Starting from acid chloride 165 again, chiral
amide 174 was first prepared. Stereoselective allylation and dihydroxylation of the double bond
led to the generation of lactone 176. After the reduction and oxidative cleavage of the 1,2-diol motif,
lactone 177 was formed by Fétizon oxidation. The introduction of the benzyloxymethyl group and the
following reduction led to the formation of 179. After TBDPS protection, Mitsunobu reaction with 181
and debenzylation, alcohol 180 was obtained. Chiral 172 was formed through a cascade cyclization
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under oxidative conditions. Finally, the first asymmetric synthesis of (+)-ovafolinins A and B was
achieved after deprotection operations. Based on optical rotation comparisons between the synthetic
samples and the natural compounds, Barker’s group demonstrated that natural ovafolinins A and
B were both isolated in scalemic mixtures. And the original stereochemical assignment of natural
ovafolinin B was corrected.
 
Scheme 30. Asymmetric synthesis of (+)-ovafolinins A and B. Adapted from Barker et al. [93].
Recently, we developed a new asymmetric synthetic route to (+)-ovafolinins A and B
(Scheme 31) [94]. Starting from benzyl syringaldehyde 182, bromide 183 was prepared after reduction
and bromination. The diastereoselective alkylation of (S)-Taniguchi lactone 184 introduced two adjacent
stereogenic centers in excellent stereoselectivity, affording lactone 185. Subsequent double benzyl
protection opened the lactone ring and generated ester 186. Compound 189 was obtained from the
reduction and connected with 188 through Mitsunobu reaction. After oxidative cleavage of double
bond, aldehyde 190 was obtained. The polycyclic skeleton in 191 was constructed through a double
Friedel-Crafts reaction of 190. The synthesis of (+)-ovafolinin B was accomplished through the global
debenzylation. And the synthesis of (+)-ovafolinin A was achieved through subsequent benzylic
oxidation cyclization enabled by Cu(OAc)2.
t
 
Scheme 31. Asymmetric synthesis of (+)-ovafolinins A and B. Adapted from Hu et al. 2018 [94].
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5. Conclusions
In this review, we have summarized the advances in the synthesis of lignan natural products
reported from 2008 to 2018. Synthetic progress in three areas was outlined: acyclic lignan derivatives,
dibenzocycooctadiene derivative and arylnaphthalene derivatives. Novel synthetic methodologies
had been applied for construction of challenging structures existing in lignan natural products. As the
result, many elegant synthetic approaches to lignans had been developed. However, as a long term
program, the promising biological features and development of concise synthetic approaches to
lignan natural products and their analogues are continuing to attract more and more interest from the
pharmaceutical industry and the organic synthesis community.
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62. Jagtap, P.R.; Ford, L.; Deister, E.; Pohl, R.; Císařová, I.; Hodek, J.; Weber, J.; Mackman, R.; Bahador, G.; Jahn, U.
Highly functionalized and potent antiviral cyclopentane derivatives formed by a tandem process consisting
of organometallic, transition-metal-catalyzed, and radical reaction steps. Chem. Eur. J. 2014, 20, 10298–10304.
[CrossRef] [PubMed]
96
Molecules 2018, 23, 3385
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Abstract: Dibenzyl butyrolactone lignans are well known for their excellent biological properties,
particularly for their notable anti-proliferative activities. Herein we report a novel, efficient,
convergent synthesis of dibenzyl butyrolactone lignans utilizing the acyl-Claisen rearrangement to
stereoselectively prepare a key intermediate. The reported synthetic route enables the modification of
these lignans to give rise to 5-hydroxymethyl derivatives of these lignans. The biological activities of
these analogues were assessed, with derivatives showing an excellent cytotoxic profile which resulted
in programmed cell death of Jurkat T-leukemia cells with less than 2% of the incubated cells entering
a necrotic cell death pathway.
Keywords: lignans; dibenzyl butyrolactones; anti-proliferative; acyl-Claisen; stereoselective synthesis
1. Introduction
Dibenzyl butyrolactone lignans 1 are a class of lignans which have been reported to exhibit
a range of biological activities, including, but not limited to neuroprotective [1], anti-cancer [2,3],
anti-inflammatory [2,4], and anti-aging effects (see Figure 1) [5]. Perhaps the most notable of these
biological properties is their reported potent anti-proliferative activities; examples of this class include
(−)-matairesinol 2 and (−)-arctigenin 3 which, along with their synthesized derivatives, have been
shown to exhibit excellent activity against various cancer cell lines, including pancreatic, breast,
endometrial, colorectal, lung, and bladder cancers [6–12].
Owing to their anti-cancer properties and their classification as drug-like compounds [13]
extensive work has gone into the study of these compounds and their related analogues to explore
and establish structure–activity relationships and the possible use of these lignans as lead compounds
for therapeutics. Whilst previous work has explored the synthesis of these lignans and analogues
thereof [14–16], mainly focusing on changing the substituents on the aryl rings [17], one area that has
not been extensively investigated is the synthesis of C-5 substituted analogues of these butyrolactone
lignans, represented by 4.
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Figure 1. General structures of butyrolactone lignan 1, natural dibenzylbutyrolactone lignans,
(−)-matairesinol 2 and (−)-artigenin 3, and 5-hydroxymethyl analogues 4.
We have previously shown that the acyl-Claisen rearrangement can be used to prepare
disubstituted morpholine pentenamides 5 with high diastereoselectivity at the C-3 and C-4 positions
which correspond to the benzyl groups in the lactone scaffold (Figure 2) [18–22]. Furthermore, in our
efforts to a prepare a number of different lignan scaffolds [18–36], we have used amides such as
5 to prepare compounds including tetrahydrofuran lignans (e.g., galbelgin 6), aryltetralins (e.g.,
ovafolinin 7) and aryl dihydronaphthalene lignans (e.g., (−)-pycananthuligene B 8).
 
Figure 2. Use of amide 5, the product of an acyl-Claisen rearrangement to access a number of lignan
scaffolds and natural products 6–8.
We wished to explore the usage of this methodology to synthesise butyrolactone lignans, as well
as probe the effect of adding a substituent at the C-5 position on the biological activity. The route
would be convergent and modular, allowing for simple modification of aromatic groups resulting in
the synthesis of a number of analogues.
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2. Results and Discussion
In order to utilise the acyl-Claisen rearrangement to prepare the desired lactones,
the corresponding allylic morpholines and acid chlorides first needed to be synthesised. Allylic
morpholines 9a and 9b were synthesised in five steps from 4-allyl-1,2-dimethoxybenzene 10 and
safrole 11 (Scheme 1), respectively. Firstly, allylic benzenes 10 and 11 were dihydroxylated
using catalytic osmium tetroxide giving 12 and 13, followed by periodate cleavage to give
aldehydes 14 and 15. Aldehydes 14 and 15 were immediately used in a Wittig reaction with
(carbethoxymethylene)-triphenylphosphorane to exclusively give the E-isomer of α,β-unsaturated
esters 16 and 17, in 55% and 56% yields, respectively, over three steps. The esters 16 and 17 were then
reduced to allylic alcohols 18 and 19 using di-iso-butyl aluminium hydride (DIBAL-H) in excellent
yields. Alcohols 18 and 19 were then converted to the corresponding allylic morpholines 9a and 9b,
by first generating a mesylate in situ, which then underwent substitution to give allylic morpholines
9a and 9b.
 
Scheme 1. (a) OsO4 (0.1–0.3 mol%), N-methylmorpholine-N-oxide (3 eq.), tBuOH/H2O (1:1), 4 days;
(b) NaIO4 (1.2 eq.), MeOH/H2O (3:1), 0.5–2 h; (c) Ph3PCHCO2Et (1.1 eq.), CH2Cl2, 16 h; (d) 18:
DIBAL-H (3 eq.), CH2Cl2, −78 ◦C, 10 min, 19: DIBAL-H (2.2 eq.), toluene, −10 ◦C, 10 min; (e) Et3N
(3 eq.), MsCl (1.2 eq.), morpholine (1.5 eq.), CH2Cl2, 0 ◦C, 2–18 h.
The required acid chlorides were then synthesised in four or five steps from commercially
available benzaldehydes—piperonal 20, 3,4,5-trimethoxybenzaldehyde 21 and vanillin 22 (Scheme 2).
Benzaldehydes 20–22 first underwent a Wittig reaction with (carbethoxymethylene)triphenylphosphorane
to give α,β-unsaturated esters 23–25 which were then hydrogenated using Pd on Carbon (10% w/w),
giving saturated esters 26–28 in 88–94% yield over two steps. The phenol in 28 was protected as the
benzyl ether, 29, in 83% yield. Esters 26, 27, and 29 were hydrolysed using NaOH in methanol/water
to the corresponding carboxylic acids 30, 31, and 32, respectively, in 94–99% yields. Finally, chlorination
of acids 30–32, along with commercially available 3,4-dimethoxyphenyl propionic acid 33, using oxalyl
chloride gave acid chlorides 34a–d in quantitative yields.
Acyl-Claisen rearrangements were undertaken using two allylic morpholines 9a and 9b which
were reacted individually with the four acid chlorides 34a–d, using TiCl4·2THF as the Lewis acid,
providing eight morpholine amides 35aa–bd in 42–95% yields. All amides 35aa–bd were obtained
as single diastereomers with a syn-configuration between the C-2 and C-3 substituents (Scheme 3).
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All amides 35aa–bd then underwent dihydroxylation using osmium tetroxide and N-methylporpholine
N-oxide (NMO) to give cyclized 5-hydroxymethyllactones 4aa–bd.
 
Scheme 2. (a) Ph3PCHCO2Et (1.1 eq.), CH2Cl2, 3–20 h; (b) H2, Pd/C (10% w/w), ethyl acetate, 1–2 h;
(c) BnBr, K2CO3, CH3CN, 65 h; (d) NaOH (4 eq.), MeOH/H2O, 2.5 h; (e) (COCl)2 (2 eq.), CH2Cl2,
1.5–4 h.
In all cases it was observed that only the 3,4-trans-4,5-trans-lactone was obtained. This configuration
was confirmed through NOESY NMR analysis, depicted in Figure 3 with 4bb. We propose that only
this isomer was obtained due to the preferential cyclisation of the 3,4-anti diol 36, leaving the polar
uncyclised 3,4-syn diols 37 which were difficult to isolate. Upon dihydroxylation of amide 35bb at
a larger scale and following isolation of lactone 4bb by column chromatography, a small sample of the
corresponding uncyclised diol 37 was able to be isolated. This diol 37 was subsequently cyclised using
2 M H2SO4 in methanol to give the corresponding C-5 epimer, epi-4bb, confirming this hypothesis
(Scheme 4).
 
Figure 3. Selected NOESY correlations showing trans,trans-relationship of hydroxymethyl lactone
lignan analogue 4bb.
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Scheme 3. (a) TiCl4·2THF (100 mol%), iPr2NEt (1.5 eq.), acid chloride (1.2 eq.), CH2Cl2, 18–24 h;
(b) OsO4 (8 mol %), NMO (3 eq.), tBuOH/H2O (1:1), 3–7 days; (c) LiAlH4 (1.5 eq.), THF, 0.5–2 h;
(d) NaIO4 (1.2 eq.), MeOH/H2O (3:1), 0.25–1 h; (e) Ag2CO3/Celite (2 eq.), toluene, reflux, 2–3 h; (f) H2,
Pd/C (10% w/w), MeOH, 10 min.
Finally, to deprotect the benzyl-protected lactones 4ad and 4bd to their respective alcohols, they
were subjected to hydrogenolysis to give 4ae and 4be in excellent yields. Transformation of C-5
hydroxymethyl analogues 4 into dibenzylbutryolactone lignans 1 was achieved via reduction using
LiAlH4, to the corresponding triols 38aa–bd, followed by periodate cleavage, forming lactols 39aa–bd.
These lactols 39aa–bd were then oxidised using Fetizon’s reagent [37,38] to give racemic samples of
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dibenzyl butyrolactone lignans 1aa–bd, including known natural products arcitin 1aa, bursehernin
1ab, (3R*,4R*)-3-(3′′,4′′-dimethoxybenzyl)-4-(3′,4′,5′-trimethoxybenzyl)dihydrofuran-2(3H)-one 1ac,
kusunokinin 1ba, hinokinin 1bb, and isoyatein 1bc. Additionally, phenolic lignans, buplerol 1ae, and
haplomyrfolin 1be were produced by the debenzylation of 1ad and 1bd, respectively.
 
Scheme 4. Synthesis of epi-4bb.
Several of the synthesised compounds were then tested for their anti-microbial and cytotoxic
activities. All tested compounds were found to be inactive against Staphlycoccus aureus and Escherichia.
coli, showing no to little antimicrobial activity, while the compounds were shown to exhibit
antiproliferative effects against Jurkat T-leukaemia cells, while also showing effects on cell cycle
progression (Figure 4). While the synthesised naturally-occurring dibenzyl butyrolactones, arcitin 1aa,
bursehernin 1ab, and (3R*,4R*)-3-(3′′,4′′-dimethoxybenzyl)-4-(3′,4′,5′-trimethoxybenzyl)dihydrofuran-
2(3H)-one 1ac, boasted the best activities, 5-hydroxymethyl analogue 4bb had similar potency.
Compound 4bb was shown to have the best activity of all of the 5-hydroxymethyl analogues tested,
inducing apoptosis, evidenced by the presence of cells in the early and predominantly in the late
apoptotic cell cycle (Figure 4). Additionally the compounds demonstrated an effect on cell cycle
progression. A significantly greater number of 4N cells were present following treatment with
compound 4bb in particular causing a significant increase in 4N cells (Figure 4D,E). During the
cell cycle, DNA is replicated in the S-phase, going from 2N in G1, to 4N by the end of this phase.
The DNA content in cells then remains at 4N during G2 and M phases, before cytokinesis at the
M-phase. The observation that there was in increase in 4N cells indicates that it is likely these cells
have arrested in G2/M and will not re-enter next G1-phase after this mitotic slippage. This is in-line
with published cell cycle data following treatment with other lignans [39,40]. Furthermore, our
compounds showed minimal levels of necrosis, less than 2% (except 4ba with 7%), suggesting that
the cells are in fact entering programmed cell death cycles, which is considered the most effective and
non-inflammatory mechanism of cancer-cell death.
In conclusion, the synthesis of dibenzyl butyrolactone lignans utilising the acyl-Claisen
rearrangement has been accomplished and represent a new, modular, and convergent method
towards the synthesis of this class of natural products. Furthermore, this route gives rise to the
previously-unexplored 5-hydroxymethyl derivatives 4 of these natural products. The biological
activities of this new set of derivatives were assessed, with one derivative in particular, 4bb, showing
a superior cytotoxic profile and resulting in cell cycle arrest and programmed cell death of Jurkat
T-leukaemia cells with less than 2% of the incubated cells entering a necrotic cell death pathway.
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Figure 4. (A) Cell survival (by a measure of metabolic activity) of Jurkat T-cell leukaemia cells incubated
with 100 μM of lignans and lignan analogues for 48 h. The data represents means of triplicate
experiments and is shown as means ± SEM (n = 3). The positive control (not shown) had a growth
of 100%. Significance of the compound activity compared to the control is expressed: (*) p-value
<0.05; (**) p-value <0.01; (***) p-value <0.001. (B) Dotplot showing the viability of Jurkat T-leukaemia
cells after incubation with 100 μM 4bb for 24 h followed by labelling with annexin V/propidium
iodide and analysis using flow cytometry. Cells in the bottom-left quadrant represent viable cells,
bottom-right quadrant are positive for annexin V and are in early apoptosis, top-right quadrant are
double positive for annexin V and propidium iodide and are in late apoptosis, and top-left quadrant
are only positive for propidium iodide and are undergoing necrosis. (C) Negative control showing the
viability of vehicle-(DMSO) treated Jurkat T-leukaemia cells. (D) Cell cycle analysis of unsynchronized
cells incubated in the presence of 100 μM 4bb or E: vehicle for 24 h. DNA content of the cells was
determined by flow cytometry. Percentage of cells in each stage of the cell cycle (average of three
replicates ± SD is reported).
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3. Experimental Section
3.1. General Methods
All reactions were carried out with oven-dried glassware and under a nitrogen atmosphere in
dry, freshly distilled solvents unless otherwise noted. Diisopropylethylamine was distilled from CaH2
and stored over activated 4Å molecular sieves. All melting points for solid compounds, given in
degrees Celsius (◦C), were measured using a Reicher–Kofler block and are uncorrected. Infrared (IR)
spectra were recorded using a Perkin Elmer Spectrum1000 FT-IR spectrometer. The NMR spectra were
recorded on a 400 MHz spectrometer. Chemical shifts are reported relative to the solvent peak of
chloroform (δ 7.26 for 1H and δ 77.16 ± 0.06 for 13C). The 1H-NMR data was reported as position (δ),
relative integral, multiplicity (s, singlet; d, doublet; dd, doublet of doublets; ddd, doublet of doublet
of doublets; dt, doublet of triplets; dq, doublet of quartets; t, triplet; td, triplet of doublets; q, quartet;
m, multiplet), coupling constant (J, Hz), and the assignment of the atom. The 13C-NMR data were
reported as position (δ) and assignment of the atom. The NMR assignments were performed using
COSY, HSQC and HMBC experiments. High-resolution mass spectroscopy (HRMS) was carried out by
electrospray ionization (ESI) on a MicroTOF-Q mass spectrometer. Fetizon’s reagent was prepared
following a literature procedure [41]. Unless noted, chemical reagents were used as purchased.
3.2. Synthetic Methods
3.2.1. General Procedure A: Acyl-Claisen
To a stirred suspension of TiCl4·2THF (1 mmol) in CH2Cl2 (5 mL), under an atmosphere of
nitrogen, was added a solution of allylic morpholine (1 mmol) in CH2Cl2 (2.5 mL) followed by
dropwise addition of iPr2NEt (1.5 mmol). After stirring for 10 min a solution of acid chloride (1.2 mmol)
in CH2Cl2 (2.5 mL) was added dropwise and the resultant mixture stirred for the specified time.
The reaction mixture was quenched with aqueous NaOH (12 mL, 1 M) and the aqueous phase extracted
with CH2Cl2 (3 × 10 mL). The combined organic extracts were washed with brine (6 mL), dried
(MgSO4), the solvent removed in vacuo and the crude product purified by column chromatography.
3.2.2. General Procedure B: Dihydroxylation
To a stirred solution of morpholine pentenamide (1 mmol) in tBuOH/H2O (1:1, 20 mL) or
tBuOH/H2O/THF (1:1:1, 30 mL) was added NMO (3 mmol). A solution of OsO4 (0.08 mmol, 2.5%
w/v in tBuOH) was then added dropwise and the resultant mixture stirred for the specified time.
The mixture was quenched with saturated aqueous Na2SO3 (30 mL) and stirred for a further 1 h.
The aqueous phase was extracted with ethyl acetate (3 × 20 mL), the combined organic extracts washed
with aqueous KOH (5 mL, 1 M), dried (MgSO4), the solvent removed in vacuo and the crude product
purified by column chromatography.
3.2.3. General Procedure C: Lithium Aluminum Hydride Reduction
To a stirred suspension of LiAlH4 (1.4 mmol) in THF (10 mL), under an atmosphere of nitrogen
at 0 ◦C, was added a solution of lactone (1 mmol) in THF (10 mL) and the mixture stirred for the
specified time. After warming to room temperature, the mixture was quenched with the addition of
water (30 mL) and the aqueous phase extracted with ethyl acetate (3 × 40 mL). The combined organic
extracts were washed with brine (25 mL), dried (MgSO4), and the solvent removed in vacuo.
3.2.4. General Procedure D: Periodate Cleavage
To a stirred solution of triol (1 mmol) in MeOH/H2O (3:1, 50 mL) was added NaIO4 (1.2 mmol)
and the resultant mixture stirred for the specified time. The reaction mixture was quenched with brine
(40 mL) and extracted with ethyl acetate (3 × 80 mL). The organic layers were combined, washed with
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water (2 × 40 mL), dried (MgSO4), and solvent removed in vacuo to give the crude product which was
purified by column chromatography if necessary.
3.2.5. General Procedure E: Fétizon’s Oxidation
To a stirred solution of lactol (1 mmol) in toluene (60 mL), under an atmosphere of nitrogen, was
added Fétizon′s reagent (2 mmol) and heated at reflux for the specified time. The reaction mixture
was allowed to cool and filtered, the solvent removed in vacuo and the crude product purified by
column chromatography.
3.2.6. General Procedure F: Benzyl Deprotection
To a stirred solution of benzyl ether (1 mmol) in MeOH (30 mL) was added 10% palladium
on carbon (20% w/w) and the resultant mixture stirred under and atmosphere of hydrogen for the
specified time. The reaction mixture was filtered through celite, washed with methanol (3 × 20 mL),
the solvent removed in vacuo and the crude product purified by column chromatography if necessary
(The 1H and 13C-NMR spectra of compounds in the Supplemental Materials).
(E)-Ethyl 4-(3′,4′-dimethoxyphenyl)but-2-enoate (16). To a stirred solution of NMO (7.9 g, 67.3 mmol) in
H2O/tBuOH (1:1, 80 mL) was added 4-allyl-1,2-dimethoxybenzene 10 (3.86 mL, 22.4 mmol). A solution
of OsO4 (0.6 mL, 0.059 mmol, 2.5% w/v in tBuOH) was then added dropwise and the resulting mixture
stirred at room temperature for 4 days. The mixture was then quenched with saturated aqueous
Na2SO3 (100 mL) and stirred for 1 h. The mixture was extracted with ethyl acetate (3 × 50 mL),
the organic layers combined, washed with aqueous KOH (1 M, 20 mL), and dried (MgSO4). Solvent
was removed in vacuo to give 12 (4.8 g, quant.) as a white solid which was used without further
purification. To a stirred solution of diol 12 (4.8 g, 22.8 mmol) in methanol/H2O (3:1, 100 mL) was
added NaIO4 (5.9 g, 27.4 mmol) and stirred for 30 min. The reaction mixture was then quenched with
addition of brine (50 mL) and extracted with ethyl acetate (3 × 40 mL). The organic extracts were
combined, washed with water (2 × 20 mL), and dried (MgSO4). Solvent was removed in vacuo to
give 14 (2.68 g, 65%) as a pale-yellow oil which was used without further purification. To a stirred
solution of 2-(3,4-dimethoxyphenyl)acetaldehyde 14 (2.68 g, 14.8 mmol) in CH2Cl2 (100 mL), under
an atmosphere of nitrogen, was added (carbethoxymethylene)triphenylphosphorane (5.7 g, 16.3 mmol)
and the resulting mixture stirred for 16 h. Solvent was removed in vacuo and the crude product
purified by column chromatography (3:1, hexanes, ethyl acetate) to give the title compound 16 (3.13 g,
84%) as a colourless oil. Rf = 0.56 (2:1 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 1.27 (3H, t,
J = 7.2 Hz, 1-OCH2CH3), 3.45 (2H, dd, J = 1.5, 6.7 Hz, 4-H), 3.86 (6H, s, 3′, 4′-H), 4.17 (2H, q, J = 7.2 Hz,
1-OCH2CH3), 5.80 (1H, td, J = 1.6, 15.5 Hz, 2-H), 6.67 (1H, d, J = 1.9 Hz, 2′-H), 6.71 (1H, dd, J = 1.9,
8.1 Hz, 6′-H), 6.81 (1H, d, J = 8.1 Hz, 5′-H), 7.07 (1H, td, J = 6.7, 15.5 Hz, 3-H). δC (100 MHz; CDCl3)
14.3 (1-OCH2CH3), 38.1 (C-4), 55.9, 56.0 (3′, 4′-OCH3), 60.3 (1-OCH2CH3), 111.5 (C-5′), 112.1 (C-2′),
120.8 (C-6′), 122.2 (C-2), 130.2 (C-1′), 147.6 (C-3), 147.9 (C-4′), 149.1 (C-3′), 166.6 (C-1). Values are in
agreement with literature data [42].
(E)-4-(3′,4′-Dimethoxyphenyl)but-2-en-1-ol (18). To a stirred solution of ester 16 (1.0 g, 4.0 mmol) in
CH2Cl2 (20 mL), under an atmosphere of nitrogen at −78 ◦C, was added DIBAL (12 mL, 1 M in
cyclohexane) and the resulting mixture stirred for 10 min. The reaction mixture was quenched with
addition of 2 M HCl until gas evolution ceased, the organic phase separated and the aqueous phase
further extracted with CH2Cl2 (3 × 10 mL). The organic layers were combined then washed with water
(10 mL) and dried (MgSO4). Solvent was removed in vacuo and the crude product purified by column
chromatography (1:1 hexanes, ethyl acetate) to give the title compound 18 (0.76 g, 92%) as a colourless
oil. Rf = 0.18 (2:1, hexanes, ethyl acetate). δH (400 MHz; CDCl3) 3.30 (2H, d, J = 6.6 Hz, 4-H), 3.82 (3H, s,
4′-OCH3), 3.83 (3H, s, 3′-OCH3), 4.08 (2H, d, J = 5.6 Hz, 1-H), 5.64–5.69 (1H, m, 2-H), 5.78–5.83 (1H, m,
3-H), 6.68 (1H, s, 2′-H), 6.69 (1H, d, J = 8.0 Hz, 6′-H), 6.77 (1H, d, J = 8.0 Hz, 5′-H). δC (100 MHz; CDCl3)
38.2 (C-4), 55.8 and 55.9 (3′ and 4′-OCH3), 63.3 (C-1), 111.4 (C-5′), 112.0 (C-2′), 120.4 (C-6′), 130.2 (C-2),
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131.6 (C-3), 132.7 (C-1′), 147.4 (C-4′), 148.9 (C-3′). IR: νMAX (film)/cm-1; 3391 (broad), 2933, 2835, 1591,
1512, 1463, 1417, 1258, 1232, 1137, 1025, 971, 852, 806, 762. HRMS (ESI+) Found [M + Na]+ 231.0995;
C12H16NaO3 requires 231.0992.
(E)-4-(4-(3′,4′-Dimethoxyphenyl)but-2-en-1-yl)morpholine (9a). To a stirred solution of alcohol 18 (0.73 g,
3.5 mmol) in CH2Cl2 (20 mL), under an atmosphere of nitrogen at 0 ◦C, was added Et3N (1.5 mL,
10.5 mmol) and stirred for 5 min. MsCl (0.48 mL, 4.2 mmol) was added and stirred for 10 min.
Morpholine (0.50 mL, 5.3 mmol) was added and the mixture brought to room temperature and stirred
for 2 h. Saturated aqueous NaHCO3 (20 mL) and water (4 mL) was then added and the aqueous layer
further extracted with CH2Cl2 (3 × 20 mL). The organic layers were then combined, dried (MgSO4)
and the solvent removed in vacuo. The crude product was purified by column chromatography
(1:1 hexanes, ethyl acetate) to give the title compound 9a (0.60 g, 62%) as a colourless oil. Rf = 0.31
(1:2 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 2.41–2.44 (4H, m, O(CH2CH2)2N), 2.96 (2H, d, J =
6.8 Hz, 1-H), 3.30 (2H, d, J = 6.7 Hz, 4-H), 3.68–3.71 (4H, m, O(CH2CH2)2N), 3.83 (6H, s, 3′, 4′-OCH3),
5.52–5.57 (1H, m, 3-H), 5.71–5.78 (1H, m, 2-H), 6.67–6.70 (2H, m, 2′ and 6′-H), 6.78 (1H, d, J = 7.9 Hz,
5′-H). δC (100 MHz; CDCl3) 38.5 (C-4), 53.6 (O(CH2CH2)2N), 55.8, 56.0 (3′, 4′-OCH3), 61.1 (C-1), 67.0
(O(CH2CH2)2N), 111.4 (C-5′), 111.9 (C-2′), 120.3 (C-6′), 127.1 (C-3), 132.8 (C-1′), 133.8 (C-2), 147.5 (C-4′),
149.0 (C-3′). IR: νMAX (film)/cm−1; 2934, 2851, 1591, 1453, 1260, 1138, 1028, 976, 864, 805, 763. HRMS
(ESI+) Found [M + H]+ 278.1762; C16H24NO3 requires 278.1751.
(E)-Ethyl 4-(3′,4′-methylenedioxyphenyl)but-2-enoate (17). To a stirred solution of NMO (8.67 g, 74.0 mmol)
in H2O/tBuOH (1:1, 80 mL) was added safrole 11 (4.0 mL, 27 mmol). A solution of OsO4 (0.75 mL,
0.074 mmol, 2.5% w/v in tBuOH) was added dropwise and the resultant mixture stirred at room
temperature for 17 h. The reaction mixture was quenched with saturated aqueous Na2SO3 (100 mL)
and stirred for 1 h. The mixture was extracted with ethyl acetate (3 × 50 mL), the organic layers were
combined, washed with aqueous KOH (1 M, 20 mL) and dried (MgSO4). Solvent was removed in
vacuo to give diol 13 (5.2 g, quant.) as a white solid which was used without further purification.
To a stirred solution of diol 13 (5.2 g, 27 mmol) in methanol/H2O (3:1, 100 mL) was added NaIO4
(6.8 g, 32 mmol) and stirred for 2 h. The mixture was then quenched with addition of brine (50 mL)
and extracted with ethyl acetate (3 × 50 mL). The organic extracts were combined, washed with water
(2 × 20 mL), brine (10 mL), and dried (MgSO4). Solvent was removed in vacuo to give aldehyde
15 (4.4 g, quant.) as a yellow oil which was used without further purification. To a stirred solution
of 2-(3,4-methylenedioxyphenyl)acetaldehyde 15 (4.4 g, 27 mmol) in CH2Cl2 (50 mL), under an
atmosphere of nitrogen, was added (carbethoxymethylene)triphenylphosphorane (10.4 g, 30 mmol)
and the resulting mixture stirred for 16 h. Solvent was removed in vacuo and the crude product
purified by column chromatography (19:1, hexanes, ethyl acetate) to give the title compound 17 (3.54 g,
56%) as a colourless oil. Rf = 0.73 (2:1 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 1.27 (3H, t,
J = 7.2 Hz, 1-OCH2CH3), 3.42 (2H, dd, J = 6.6, 1.6 Hz, 4-H), 4.17 (2H, q, J = 7.2 Hz, 1-OCH2CH3), 5.78
(1H, dt, J = 15.5, 1.6 Hz, 2-H), 5.93 (2H, s, OCH2O), 6.61 (1H, dd, J = 8.0, 2.0 Hz, 6′-H), 6.64 (1H, d, J =
2.0 Hz, 2′-H), 6.74 (1H, d, J = 8.0 Hz, 5′-H), 7.04 (1H, dt, J = 15.5, 6.6 Hz, 3-H). δC (100 MHz; CDCl3)
14.4 (1-OCH2CH3), 38.2 (C-4), 60.4 (1-OCH2CH3), 101.1 (OCH2O), 108.5 (C-5′), 109.4 (C-2′), 121.9 (C-6′),
122.4 (C-2), 131.5 (C-1′), 146.5 (C-4′), 147.5 (C-3), 148.0 (C-3′), 166.6 (C-1). Values are in agreement with
literature data [43].
(E)-4-(3′,4′-Methylenedioxyphenyl)but-2-en-1-ol (19). To a stirred solution of ester 17 (3.2 g, 13.7 mmol)
in toluene (100 mL), under an atmosphere of nitrogen at −10 ◦C, was added DIBAL (30 mL, 1 M
in toluene) and the resultant mixture stirred for 10 min. The reaction mixture was quenched with
addition of 2 M HCl until gas evolution ceased, the organic layer was separated and the aqueous phase
further extracted with CH2Cl2 (3 × 50 mL). The organic layers were combined, washed with brine
(30 mL) and dried (MgSO4). Solvent was removed in vacuo and the crude product purified by column
chromatography (3:1 hexanes, ethyl acetate) to give the title compound 19 (2.59 g, 98%) as a pale yellow
oil. Rf = 0.42 (hexanes, ethyl acetate). δH (400 MHz; CDCl3) 1.41 (1H, br s, 1-OH), 3.30 (2H, d, J =
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6.6 Hz, 4-H), 4.12 (2H, br d, J = 4.5 Hz, 1-H), 5.64–5.72 (1H, m, 2-H), 5.77–5.85 (1H, m, 3-H), 5.92 (2H, s,
OCH2O), 6.63 (1H, dd, J = 7.9, 1.9 Hz, 6′-H), 6.67 (1H, d, J = 1.9 Hz, 2′-H), 6.73 (1H, d, 7.9 Hz, 5′-H). δC
(100 MHz; CDCl3) 38.4 (C-4), 63.6 (C-1), 101.0 (OCH2O), 108.3 (C-5′), 109.2 (C-2′), 121.4 (C-6′), 130.4,
131.8 (C-2, 3), 133.9 (C-1′), 146.0, 147.8 (C-3′, 4′). Values are in agreement with literature data [43].
(E)-4-(4-(3′,4′-Methylenedioxyphenyl)but-2-en-1-yl)morpholine (9b). To a stirred solution of alcohol 19
(1.66 g, 8.6 mmol) in CH2Cl2 (15 mL), under an atmosphere of nitrogen at 0 ◦C, was added Et3N
(3.6 mL, 25.9 mmol) and stirred for 5 min. MsCl (1.2 mL, 10.4 mmol) was added and stirred for 10 min.
Morpholine (1.3 mL, 13.8 mmol) was added and the mixture brought to room temperature and stirred
for 18 h. Saturated aqueous NaHCO3 (25 mL) and water (5 mL) was added and the aqueous layer
further extracted with CH2Cl2 (3 × 30 mL). The organic layers were combined, dried (MgSO4) and the
solvent removed in vacuo. The crude product was purified by column chromatography (2:1 hexanes,
ethyl acetate) to give the title compound 9b (1.4 g, 60%) as a pale yellow oil. Rf = 0.39 (1:2 hexanes,
ethyl acetate). δH (400 MHz; CDCl3) 2.43 (4H, br t, J = 4.7 Hz, NCH2CH2O), 2.96 (2H, d, J = 6.5 Hz,
1-H), 3.28 (2H, d, J = 7.0 Hz, 4-H), 3.71 (4H, t, J = 4.7 Hz, NCH2CH2O), 5.49–5.56 (1H, m, 2-H), 5.69–5.76
(1H, m, 3-H), 5.91 (2H, d, J = 2.0 Hz, OCH2O), 6.61 (1H, dd, J = 7.5, 2.0 Hz, 6′-H), 6.65 (1H, d, J = 2.0 Hz,
2′-H), 6.72 (1H, d, J = 7.5 Hz, 5′-H). δC (100 MHz; CDCl3) 38.7 (C-4), 53.7 (NCH2CH2O), 61.2 (C-1),
67.1 (NCH2CH2O), 100.9 (OCH2O), 108.3 (C-5′), 109.1 (C-2′), 121.4 (C-6′), 127.4 (C-2), 133.7 (C-3), 134.1
(C-1′), 146.0 (C-4′), 147.8 (C-3′). IR: νMAX (film)/cm−1; 2855, 1739, 1488, 1242, 1115, 1036, 926, 864, 736.
HRMS (ESI+) Found [M + H]+ 262.1428; C15H20NO3 requires 262.1438.
(E)-Ethyl-3-(3′,4′-methylenedioxyphenyl)prop-2-enoate (23). To a stirred solution of piperonal
20 (5.0 g, 33 mmol) in CH2Cl2 (100 mL), under an atmosphere of nitrogen, was added
(carbethoxymethylene)triphenylphosphorane (12.8 g, 37.0 mmol) and the resulting mixture stirred for
20 h. Solvent was then removed in vacuo and the crude product purified by column chromatography
(3:1, hexanes, ethyl acetate) to give the title compound 23 (6.97 g, 95%) as a white solid. Rf = 0.68
(2:1 hexanes, ethyl acetate). Melting point: 62–64 ◦C. δH (400 MHz; CDCl3) 1.32 (3H, t, J = 7.2 Hz,
1-OCH2CH3), 4.25 (2H, q, J = 7.2 Hz, 1-OCH2CH3), 6.00 (2H, s, -OCH2O-), 6.25 (1H, d, J = 15.9 Hz, 2-H),
6.80 (1H, d, J = 8.0 Hz, 5′-H), 7.00 (1H, dd, J = 1.4, 8.0 Hz, 6′-H), 7.02 (1H, d, J = 1.4 Hz, 6′-H), 7.58 (1H,
d, J = 15.9 Hz, 3-H). δC (100 MHz; CDCl3) 14.5 (1-OCH2CH3), 60.5 (1-OCH2CH3), 101.7 (-OCH2O-),
106.6 (C-5′), 108.7 (C-2′), 116.4 (C-2), 124.5 (C-6′), 129.1 (C-1′), 144.4 (C-3), 148.5 (C-4′), 149.7 (C-3′),
167.3 (C-1). Values are in agreement with literature data [44].
(E)-Ethyl-3-(3′,4′,5′-trimethoxyphenyl)prop-2-enoate (24). To a stirred solution of 3,4,5-
trimethoxybenzaldehyde 21 (3.0 g, 15.3 mmol) in CH2Cl2 (100 mL), under an atmosphere of
nitrogen, was added (carbethoxymethylene)triphenylphosphorane (5.9 g, 16.8 mmol) and the resulting
mixture stirred for 3 h. Solvent was then removed in vacuo and the crude product purified by column
chromatography (3:1, hexanes, ethyl acetate) to give the title compound 24 (4.0 g, 94%) as a white
solid. Rf = 0.52 (2:1 hexanes, ethyl acetate). Melting point: 64–66 ◦C. δH (400 MHz; CDCl3) 1.34
(3H, t, J = 7.2 Hz, 1-OCH2CH3), 3.87 (3H, s, 4′-OCH3), 3.88 (6H, s, 3′-OCH3), 4.26 (2H, q, J = 7.2 Hz,
1-OCH2CH3), 6.34 (1H, d, J = 15.9 Hz, 2-H), 6.75 (2H, s, 2′-H), 7.60 (1H, d, J = 15.9 Hz, 3-H). δC
(100 MHz; CDCl3) 14.5 (1-OCH2CH3), 56.3 (3′-OCH3), 60.6 (1-OCH2CH3), 61.1 (4′-OCH3), 105.3 (C-2′),
117.7 (C-2), 130.1 (C-1′), 140.2 (C-4′), 144.7 (C-3), 153.6 (C-3′), 167.1 (C-1). Values are in agreement with
literature data [45].
3-(3′,4′,5′-Trimethoxyphenyl)propionic acid (31). To a stirred solution of 24 (5.4 g, 19.4 mmol) in ethyl
acetate (30 mL) was added 10% palladium on activated carbon (0.54 g, 10% w/w). The solution was
flushed with an atmosphere of hydrogen and stirred for 2 h. The reaction mixture was then filtered
through a plug of celite and washed with ethyl acetate, solvent was then removed in vacuo to give
saturated ester 27 (5.23 g, 96%) which was then used without further purification.
To a stirred solution of ester 27 (5.1 g, 17.9 mmol) in methanol (30 mL) was added aqueous NaOH
(72 mL, 1 M, 4 eq.) and stirred for 20 min. The mixture was then extracted with CH2Cl2 (10 mL) and
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the aqueous layer acidified with aqueous 2 M HCl. The aqueous phase was then extracted with ethyl
acetate (3 × 50 mL), dried (MgSO4) and solvent removed in vacuo to give the title compound 31 (4.6 g,
quant.) as a white solid. Rf = 0.15 (2:1 hexanes, ethyl acetate). Melting point: 104–105 ◦C. δH (400 MHz;
CDCl3) 2.68 (2H, t, J = 7.8 Hz, 2-H), 2.90 (2H, t, J = 7.8 Hz, 3-H), 3.82 (3H, s, 4′-OCH3), 3.84 (6H, s,
3′-OCH3), 6.43 (2H, s, 2′-H). δC (100 MHz; CDCl3) 31.1 (C-2), 35.8 (C-3), 56.2 (3′-OCH3), 61.0 (4′-OCH3),
105.4 (C-2′), 136.0 (C-1′), 136.7 (C-4′), 153.4 (C-3′), 178.8 (C-1). Values are in agreement with literature
data [46].
3-(3′,4′-Methylenedioxyphenyl)propionic acid (30). To a stirred solution of 23 (6.92 g, 31.4 mmol) in ethyl
acetate (30 mL) was added 10% palladium on activated carbon (0.69 g, 10% w/w). The solution was
flushed with an atmosphere of hydrogen and stirred for 1 h. The reaction mixture was then filtered
through a plug of celite and washed with ethyl acetate, solvent was then removed in vacuo to give
saturated ester 26 (6.9 g, 99%) which was then used without further purification.
To a stirred solution of ester 26 (6.74 g, 30.0 mmol) in methanol (30 mL) was added aqueous NaOH
(121 mL, 1 M, 4 eq.) and stirred for 2.5 h. The mixture was then extracted with ethyl acetate (10 mL) and
the aqueous layer acidified with aqueous 2 M HCl. The aqueous phase was then extracted with ethyl
acetate (3 × 50 mL), dried (MgSO4) and solvent removed in vacuo to give the title compound 30 (5.5 g,
94%) as a white solid. Rf = 0.44 (2:1 hexanes, ethyl acetate). Melting point: 80–82◦C. δH (400 MHz;
CDCl3) 2.64 (2H, t, J = 7.7 Hz, 2-H), 2.88 (2H, t, J = 7.7 Hz, 3-H), 5.93 (2H, s, -OCH2O-), 6.66 (1H, dd, J =
7.9, 1.4 Hz, 6′-H), 6.70 (1H, d, J = 1.4 Hz, 2′-H), 6.74 (1H, d, J = 7.9 Hz, 5′-H). δC (100 MHz; CDCl3) 30.5
(C-2), 36.1 (C-3), 101.0 (-OCH2O-), 108.4 (C-2′), 108.9 (C-5′), 121.2 (C-6′), 134.1 (C-1′), 146.2 (C-3′), 147.8
(C-4′), 179.1 (C-1). Values are in agreement with literature data [47].
3-(3′-Methoxy-4′-benzyloxyphenyl)propionic acid (32). To a stirred solution of vanillin 22
(3.0 g, 19.7 mmol) in CH2Cl2 (100 mL), under an atmosphere of nitrogen, was added
(carbethoxymethylene)triphenylphosphorane (7.56 g, 21.7 mmol) and the resulting mixture stirred for
18 h. Solvent was then removed in vacuo and the crude product purified by column chromatography
(2:1, hexanes, ethyl acetate) to give a 2:1 mixture of E and Z isomers of unsaturated ester 25 (4.13 g,
94%) as a yellow oil which was used immediately.
To a stirred solution of unsaturated ester 25 (4.13 g, 18.6 mmol) in ethyl acetate (30 mL) was added
10% palladium on activated carbon (0.4 g, 10% w/w). The solution was flushed with an atmosphere
of hydrogen and stirred for 2 h. The reaction mixture was then filtered through a plug of celite and
washed with ethyl acetate, solvent was then removed in vacuo to give saturated ester 28 (3.9 g, 94%)
as a yellow oil which was then used without further purification. To a stirred solution of phenol 28
(3.75 g, 16.7 mmol) in acetonitrile (40 mL), under an atmosphere of nitrogen, was added K2CO3 (6.9 g,
50.0 mmol) and stirred for 10 min. Benzyl bromide (6.0 mL, 50.0 mmol) was then added and the
resulting mixture allowed to stir for 65 h. The reaction mixture was then quenched with addition of
water (50 mL) and extracted with CH2Cl2 (3 × 30 mL). The organic phases were combined, washed
with water (2 × 10 mL) and dried (MgSO4). Solvent was then removed in vacuo and the crude product
purified by column chromatography (9:1 hexanes, ethyl acetate) to give benzyl ether 29 (4.38 g, 83%)
as a colourless oil which was used immediately. To a stirred solution of ester 29 (4.3 g, 13.7 mmol) in
methanol (30 mL) was added aqueous NaOH (55 mL, 1 M, 4 eq.) and stirred for 2.5 h. The mixture
was then acidified with aqueous 2 M HCl, extracted with ethyl acetate (3 × 50 mL), dried (MgSO4)
and solvent removed in vacuo to give the title compound 32 (3.85 g, 98%) as a white solid. Rf = 0.30
(2:1 hexanes, ethyl acetate). Melting point: 99–100◦C. δH (400 MHz; CDCl3) 2.66 (2H, t, J = 7.7 Hz, 2-H),
2.90 (2H, t, J = 7.7 Hz, 3-H), 3.88 (3H, s, 3′-OCH3), 5.13 (2H, s, 7′-H), 6.68 (1H, dd, J = 8.2, 2.0 Hz, 6′-H),
6.76 (1H, d, J = 2.0 Hz, 2′-H), 6.81 (1H, d, J = 8.2 Hz, 5′-H), 7.27–7.32 (1H, m, 11′-H), 7.34–7.39 (2H, m,
10′-H), 7.41–7.45 (2H, m, 9′-H). δC (100 MHz; CDCl3) 30.4 (C-2), 35.9 (C-3), 56.1 (3′-OCH3), 71.3 (C-7′),
112.4 (C-2′), 114.5 (C-5′), 120.3 (C-6′), 127.4 (C-9′), 127.9 (C-11′), 128.7 (C-10′), 133.5 (C-1′), 137.4 (C-8′),
146.9 (C-4′), 149.8 (C-3′), 178.8 (C-1). Values are in agreement with literature data [48].
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3-(3′,4′-Methylenedioxyphenyl)propanoyl chloride (34b). To a stirred solution of carboxylic acid 30 (0.22 g,
1.2 mmol) in CH2Cl2 (3 mL), under an atmosphere of nitrogen, was added oxalyl chloride (0.2 mL,
2.3 mmol) dropwise and the mixture stirred for 4 h. The solvent was removed in vacuo to give the
title compound 34b (0.24 g, quant.) as a green oil, which was placed under nitrogen and used without
further purification.
3-(3′,4′-Dimethoxyphenyl)propanoyl chloride (34a). To a stirred solution of carboxylic acid 33 (0.24 g,
1.2 mmol) in CH2Cl2 (5 mL), under an atmosphere of nitrogen, was added oxalyl chloride (0.2 mL,
2.3 mmol) dropwise and the mixture stirred for 2.5 h. The solvent was removed in vacuo to give the
title compound 34a (0.26 g, quant.) as a yellow oil, which was placed under nitrogen and used without
further purification.
3-(3′,4′,5′-Trimethoxyphenyl)propanoyl chloride (34c). To a stirred solution of carboxylic acid 31 (0.25 g,
1.2 mmol) in CH2Cl2 (3 mL), under an atmosphere of nitrogen, was added oxalyl chloride (0.2 mL,
2.3 mmol) dropwise and the mixture stirred for 1.5 h. The solvent removed in vacuo to give the title
compound 34c (0.27 g, quant.) as a green crystalline solid, which was placed under nitrogen and used
without further purification.
3-(3′,4′-Methylenedioxyphenyl)propanoyl chloride (34d). To a stirred solution of carboxylic acid 32 (0.33 g,
1.2 mmol) in CH2Cl2 (3 mL), under an atmosphere of nitrogen, was added oxalyl chloride (0.2 mL,
2.3 mmol) dropwise and the mixture stirred for 4 h. The solvent was removed in vacuo to give the title
compound 34d (0.35 g, quant.) as a yellow oil, which was placed under nitrogen and used without
further purification.
(2R*,3S*)-2-(3′,4′-Methylenedioxybenzyl)-3-(3′′,4′′-dimethoxybenzyl)-1-morpholinopent-4-en-1-one (35ab).
Using general procedure A: Morpholine 9a (0.57 g, 2.06 mmol), acid chloride 34b (0.52 g, 2.47 mmol)
and reaction time of 24 h. The crude product was purified by column chromatography (2:1 hexanes,
ethyl acetate) to give the title compound 35ab (0.39 g, 42%) as a pale-yellow amorphous solid. Rf =
0.58 (1:3, hexanes, ethyl acetate). Melting point: 114–116 ◦C. δH (400 MHz; CDCl3) 2.57 (1H, dd, J =
13.6, 9.0 Hz, 7′′-HA), 2.66–2.73 (1H, m, 3-H), 2.77–2.85 (2H, m, 7′-HA, OCHACH2N), 2.85–2.94 (4H,
m, 2-H, 7′-HB, 7′′-HB, OCH2CHAN), 3.06 (1H, ddd, J = 13.3, 7.9, 3.3 Hz, OCH2CHBN), 3.27–3.41 (3H,
m, OCHCCHCN, OCHBCH2N), 3.53–3.60 (1H, m, OHDCH2N), 3.67–3.75 (1H, m, OCH2CHDN), 3.85
(3H, s, 4′′-OCH3), 3.86 (3H, s, 3′′-OCH3), 4.88 (1H, dd, J = 16.9, 1.8 Hz, 5-HA), 4.98 (1H, dd, J = 10.3,
1.8 Hz, 5-HB), 5.85 (1H, ddd, J = 16.9, 10.3, 9.5 Hz, 4-H), 5.90 (1H, d, J = 1.3 Hz, OCHAO), 5.91 (1H, d,
J = 1.3 Hz, OCHBO), 6.60 (1H, dd, J = 7.8, 1.6 Hz, 6′-H), 6.64 (1H, d, J = 1.6 Hz, 2′-H), 6.65–6.68 (2H,
m, 2′′, 6′′-H), 6.70 (1H, d, J = 7.8 Hz, 5′-H), 6.77 (1H, d, J = 8.7 Hz, 5′′-H). δC (100 MHz; CDCl3) 37.4
(C-7′), 38.3 (C-7′′), 42.0 (OCH2CHCDN), 46.4 (OCH2CHABN), 46.6 (C-2), 48.5 (C-3), 56.0 (3′, 4′-OCH3),
66.4 (OCHABCH2N), 67.0 (OCHCDCH2N), 101.0 (OCH2O), 108.4 (C-5′), 109.6 (C-2′), 111.1 (C-5′′), 112.4
(C-2′′), 116.8 (C-5), 121.3 (C-6′′), 122.0 (C-6′), 132.3 (C-1′′), 133.6 (C-1′), 139.3 (C-4), 146.2 (C-4′), 147.5
(C-4′′), 147.7 (C-3′), 148.9 (C-3′′), 172.6 (C-1). IR: νMAX (film)/cm-1; 2963, 1631, 1515, 1488, 1442, 1236,
1031, 925, 807, 730. HRMS (ESI+) Found [M + H]+ 454.2241; C26H32NO6 requires 454.2224.
(2R*,3S*)-2-(3′,4′,5′-Trimethoxybenzyl)-3-(3′′,4′′-dimethoxybenzyl)-1-morpholinopent-4-en-1-one (35ac).
Using general procedure A: Morpholine 9a (0.47 g, 1.7 mmol), acid chloride 34c (0.53 g, 2.0 mmol) and
a reaction time of 19 h. The crude product was purified by column chromatography (1:1 hexanes, ethyl
acetate) to give the title compound 35ac (0.50 g, 58%) as a yellow oil. Rf = 0.38 (1:3 hexanes, ethyl
acetate). δH (400 MHz; CDCl3) 2.59 (1H, dd, J = 13.6, 9.2 Hz, 7′′-HA), 2.67–2.74 (1H, m, 3-H), 2.78
(1H, ddd, J = 11.4, 7.8, 3.0 Hz, NCH2CHAO), 2.82–2.96 (5H, m, 2-H, 7′-H, 7′′-HB, NCHACH2O), 3.06
(1H, ddd, J = 13.2, 7.8, 3.0 Hz, NCHBCH2O), 3.25–3.40 (3H, m, NCHBCH2O, NCHCCHCO), 3.54–3.61
(1H, m, NCHDCH2O), 3.67–3.73 (1H, m, NCH2CHDO), 3.80 (3H, s, 4′-OCH3), 3.82 (6H, s, 3′-OCH3),
3.85 (3H, s, 4′′-OCH3), 3.86 (3H, s, 3′′-OCH3), 4.90 (1H, dd, J = 17.0, 1.8 Hz, 5-HA), 5.00 (1H, dd, J =
10.2, 1.8 Hz, 5-HB), 5.87 (1H, ddd, J = 17.0, 10.2, 9.1 Hz, 4-H), 6.37 (2H, s, 2′-H), 6.66–6.70 (2H, m, 2′′,
6′′-H), 6.78 (1H, d, J = 8.7 Hz, 5′′-H). δC (100 MHz; CDCl3) 38.1 (C-7′), 38.3 (C-7′′), 42.0 (NCHCDCH2O),
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46.4 (NCHABCH2O), 46.5 (C-2), 48.7 (C-3), 56.0 (3′′, 4′′-OCH3), 56.3 (3′-OCH3), 61.0 (4′-OCH3), 66.4
(NCH2CHABO), 66.9 (NCH2CHCDO), 106.2 (C-2′), 111.1 (C-5′′), 112.5 (C-2′′), 116.8 (C-5), 121.2 (C-6′′),
132.3 (C-1′′), 135.6 (C-1′), 136.8 (C-4′), 139.2 (C-4), 147.5 (C-4′′), 148.8 (C-3′′), 153.3 (C-3′), 172.6 (C-1). IR:
νMAX (film)/cm-1; 2940, 1632, 1589, 1459, 1236, 1123, 1028, 913, 735. HRMS (ESI+) Found [M + Na]+
522.2474; C28H37NNaO7 requires 522.2462.
(2R*,3S*)-2-(3′,4′-Dimethoxybenzyl)-3-(3′′,4′′-dimethoxybenzyl)-1-morpholinopent-4-en-1-one (35aa). Using
general procedure A: Morpholine 9a (0.53 g, 1.91 mmol), acid chloride 34a (0.52 g, 2.29 mmol) and
a reaction time of 24 h. The crude product was purified by flash chromatography (1:3 hexanes, ethyl
acetate) to give the title compound 35aa (0.63 g, 77% yield) as a pale-yellow amorphous solid. Rf = 0.42
(19:1 CH2Cl2, methanol). Melting point: 98–101 ◦C. δH (400 MHz; CDCl3) 2.55–2.63 (1H, m, 7′′-HA),
2.85–2.93 (1H, m, 7′′-HB), 2.67–2.85 (3H, m, 3-H, OCH2CHABN), 3.29-3.37 (4H, m, OCH2CHCDN,
OCHABCH2N), 2.85–3.06 (3H, m, 2-H, 7′-H), 3.50–3.67 (2H, m, OCHCDCH2N), 3.83, 3.84, 3.85, 3.86
(12H, s, 3′, 4′, 3′′, 4′′-OCH3), 4.89 (1H, dd, J = 17.1, 1.7 Hz, 5-H), 4.99 (1H, dd, J = 10.3, 1.9 Hz, 5-H),
5.82–5.91 (1H, m, 4-H), 6.67–6.69 (4H, m, 2′, 6′, 2′′, 6′′-H), 6.75–6.78 (2H, m, 5′, 5′′-H). δC (100 MHz;
CDCl3) 37.2 (C-2), 38.2 (C-7′′), 41.9, 46.5 (OCH2CH2N), 46.2 (C-7′), 48.5 (C-3), 55.8, 55.9 (3′, 4′, 3′′,
4′′-OCH3), 66.3, 66.8 (OCH2CH2N), 111.0, 111.3 (C-5′, 5′′), 112.4, 112.6 (C-2′, 2′′), 116.6 (C-5), 120.9,
121.2 (C-6′, 6′′), 132.2, 132.3 (C-1′, 1′′), 139.2 (C-4), 147.3, 147.6 (4′, 4′′-OCH3), 148.7, 148.8 (3′, 3′′-OCH3),
172.6 (C-1). IR: νMAX (film)/cm−1; 2935, 1628, 1591, 1462, 1260, 1155, 1027, 912, 857, 765. HRMS (ESI+)
Found [M + H]+ 470.2537; C27H36NO6 requires 470.2537
(2R*,3S*)-2-(3′-Methoxy-4′-benzyloxybenzyl)-3-(3′′,4′′-dimethoxybenzyl)-1-morpholino-pent-4-en-1-one
(35ad). Using general procedure A: Morpholine 9a (0.47 g, 1.7 mmol), acid chloride 34d (0.62 g,
2.0 mmol) and a reaction time of 22 h. The crude product was purified by column chromatography (2:1
hexanes, ethyl acetate) to give the title compound 35ad (0.59 g, 64%) as a yellow oil.
Rf = 0.58 (1:3, hexanes, ethyl acetate). δH (400 MHz; CDCl3) 2.57 (1H, dd, J = 13.5, 9.0 Hz, 7′′-HA),
2.62–2.68 (1H, m, 3-H), 2.68–2.74 (1H, m, OCHACH2N), 2.75–2.82 (1H, m, OCH2CHAN), 2.83–2.92 (4H,
m, 2-H, 7′-H, 7′′-HB), 2.99 (1H, ddd, J = 13.3, 7.6, 3.2 Hz, OCH2CHBN), 3.20–3.32 (3H, m, OCHBCH2N,
OCHCCHCN), 3.50–3.55 (1H, m, OCHDCH2N), 3.61–3.67 (1H, m, OCH2CHDN), 3.84 (3H, s, 3′-OCH3),
3.85 (3H, s, 4′′-OCH3), 3.85 (3H, s, 3′′-OCH3), 4.88 (1H, dd, J = 17.1, 1.9 Hz, 5-HA), 4.97 (1H, dd, J = 10.3,
1.9 Hz, 5-HB), 5.13 (1H, s, 7′′′-H), 5.85 (1H, ddd, J = 17.1, 10.3, 9.0 Hz, 4-H), 6.59 (1H, dd, J = 8.1, 1.9 Hz,
6′-H), 6.65–6.68 (2H, m, 2′′-H, 6′′-H), 6.69 (1H, d, J = 1.9 Hz, 2′-H), 6.74 (1H, d, J = 8.1 Hz, 5′-H), 6.77
(1H, d, J = 8.5 Hz, 5′′-H), 7.25–7.30 (1H, m, 4′′′-H), 7.32–7.37 (2H, m, 3′′′-H), 7.38–7.42 (2H, m, 2′′′-H).
δC (100 MHz; CDCl3) 37.4 (C-7′), 38.3 (C-7′′), 41.9 (OCH2CHCDN), 46.3 (OCH2CHABN), 46.5 (C-2), 48.6
(C-3), 56.0, 56.2 (3′, 3′′, 4′′-OCH3), 66.4 (OCHABCH2N), 66.9 (OCHCDCH2N), 71.2 (C-7′′′), 111.1 (C-5′′),
112.4 (C-2′′), 113.3 (C-2′), 114.6 (C-5′), 116.7 (C-5), 120.9 (C-6′), 121.3 (C-6′′), 127.3 (C-2′′′), 127.9 (C-4′′′),
128.7 (C-3′′′), 132.4 (C-1′′), 133.1 (C-1′), 137.3 (C-1′′′), 139.3 (C-4), 146.7 (C-4′), 147.5 (C-4′′), 148.8 (C-3′′),
149.7 (C-3′), 172.7 (C-1). IR: νMAX (film)/cm−1; 2936, 1736, 1633, 1513, 1454, 1261, 1140, 1028, 915, 733.
HRMS (ESI+) Found [M + Na]+ 568.2671; C33H39NNaO6 requires 568.2670.
(2R*,3S*)-2-(3′,4′-Dimethoxybenzyl)-3-(3′′,4′′-methylenedioxybenzyl)-1-morpholinopent-4-en-1-one (35ba).
Using general procedure A: Morpholine 9b (0.25 g, 0.96 mmol), acid chloride 34a (0.26 g, 1.2 mmol)
and a reaction time of 21 h. The crude product was purified by column chromatography (1:1 hexanes,
ethyl acetate) to give the title compound 35ba (0.36 g, 83%) as a yellow oil.
Rf = 0.50 (1:3 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 2.56 (1H, dd, J = 13.4, 9.0 Hz, 7′′-HA),
2.62–2.70 (1H, m, 3-H), 2.75–2.94 (6H, m, 2-H, 7′-H, 7′′-HB, NCHACHAO), 3.05 (1H, ddd, J = 13.6, 7.9,
3.1 Hz, NCHBCH2O), 3.28–3.41 (3H, m, NCH2CHBO, NCHCCHCO), 3.51–3.57 (1H, m, NCH2CHDO),
3.58–3.64 (1H, m, NCHDCH2O), 3.83 (3H, s, 3′-H), 3.84 (3H, s, 4′-H), 4.89 (1H, dd, J = 17.2, 1.9 Hz,
5-HA), 4.99 (1H, dd, J = 10.2, 1.9 Hz, 5-HB), 5.86 (1H, ddd, J = 17.2, 10.2, 9.1 Hz, 4-H), 5.92 (1H, d,
J = 1.4 Hz, OCHAO), 5.92 (1H, d, J = 1.4 Hz, OCHBO), 6.58 (1H, dd, J = 7.9, 1.6 Hz, 6′′-H), 6.64 (1H, d,
J = 1.6 Hz, 2′′-H), 6.66–6.70 (2H, m, 2′, 6′-H), 6.71 (1H, d, J = 7.9 Hz, 5′′-H), 6.76 (1H, d, J = 8.1 Hz, 5′-H).
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δC (100 MHz; CDCl3) 37.3 (C-7′), 38.5 (C-7′′), 42.0 (NCHABCH2O), 46.3 (NCHCDCH2O), 46.5 (C-2),
48.8 (C-3), 56.1 (3′, 4′-OCH3), 66.4 (NCH2CHABO), 66.9 (NCH2CHCDO), 101.0 (OCH2O), 108.1 (C-5′′),
109.6 (C-2′′), 111.4 (C-5′), 112.7 (C-2′), 116.8 (C-5), 121.0 (C-6′), 122.1 (C-6′′), 132.4 (C-1′), 133.7 (C-1′′),
139.2 (C-4), 145.9 (C-4′′), 147.6 (C-4′), 147.8 (C-3′′), 149.0 (C-3′), 172.7 (C-1). IR: νMAX (film)/cm−1; 2908,
1740, 1630, 1515, 1441, 1237, 1029, 923, 730. HRMS (ESI+) Found [M + Na]+ 476.2042; C26H31NNaO6
requires 476.2044.
(2R*,3S*)-2-(3′,4′-Methylenedioxybenzyl)-3-(3′′,4′′-methylenedioxybenzyl)-1-morpholinopent-4-en-1-one
(35bb). Using general procedure A: Morpholine 9b (0.5 g, 1.91 mmol), acid chloride 34b (0.49 g,
2.30 mmol) and a reaction time of 30 min. The crude product was purified by column chromatography
(1:1 hexanes, ethyl acetate) to give the title compound 35bb (0.798 g, 95%) as a pale-yellow solid. Rf =
0.68 (1:3 hexanes, ethyl acetate). Melting point: 131–133 ◦C. δH (400 MHz; CDCl3) 2.54 (1H, dd, J =
13.5, 8.9 Hz, 7′′-HA), 2.61–2.69 (1H, m, 3-H), 2.78–2.93 (6H, m, 2-H, 7′-H, 7′′-HB, NCHACHAO), 3.06
(1H, ddd, J = 13.2, 7.8, 3.1 Hz, NCHBCH2O), 3.29–3.41 (3H, m, NCH2CHBO, NCHCCHCO), 3.53–3.61
(1H, m, NCH2CHDO), 3.66–3.74 (1H, m, NCHDCH2O), 4.89 (1H, dd, J = 17.0, 1.9 Hz, 5-HA), 4.99
(1H, dd, J = 10.2, 1.9 Hz, 5-HB), 5.85 (1H, ddd, J = 17.0, 10.2, 9.1 Hz, 4-H), 5.90 (1H, d, J = 1.4 Hz,
3′-OCHAO), 5.91 (1H, d, J = 1.4 Hz, 3′-OCHBO), 5.92 (1H, d, J = 1.5 Hz, 3′′-OCHAO), 5.93 (1H, d,
J = 1.5 Hz, 3′′-OCHBO), 6.55–6.61 (2H, m, 6′, 6′′-H), 6.62–6.64 (2H, m, 2′, 2′′-H), 6.70, 6.71 (2 × 1H,
2 × d, J = 8.0 Hz, 5′, 5′′-H). δC (100 MHz; CDCl3) 37.4 (C-7′), 38.5 (C-7′′), 42.0 (NCHCDCH2O), 46.4
(NCHABCH2O), 46.5 (C-2), 48.8 (C-3), 66.4 (NCH2CHABO), 67.0 (NCH2CHCDO), 101.0 (2 × OCH2O),
108.2, 108.4 (C-5′, 5′′), 109.6 (C-2′, 2′′), 116.8 (C-5), 122.1 (C-6′, 6′′), 133.6 (C-1′, 1′′), 139.2 (C-4), 145.9,
146.2 (C-4′, 4′′), 147.6, 147.7 (C-3′, 3′′), 172.6 (C-1). IR: νMAX (film)/cm−1; 2897, 1630, 1487, 1440, 1244,
1036, 925, 808, 730. HRMS (ESI+) Found [M + Na]+ 460.1722; C25H27NNaO6 requires 460.1731.
(2R*,3S*)-2-(3′,4′,5′-Trimethoxybenzyl)-3-(3′′,4′′-methylenedioxybenzyl)-1-morpholinopent-4-en-1-one (35bc).
Using general procedure A: Morpholine 9b (0.25 g, 0.96 mmol), acid chloride 34c (0.27 g, 1.2 mmol) and
a reaction time of 18 h. The crude product was purified by column chromatography (1:1 hexanes, ethyl
acetate) to give the title compound 35bc (0.40 g, 86%) as a pale-yellow solid. Rf = 0.55 (1:3 hexanes,
ethyl acetate). Melting point: 104–106 ◦C. δH (400 MHz; CDCl3) 2.56 (1H, dd, J = 13.4, 9.0 Hz, 7′′-HA),
2.62–2.70 (1H, m, 3-H), 2.75–2.95 (6H, m, 2-H, 7′-H, 7′′-HB, NCHACHAO), 3.06 (1H, ddd, J = 13.2, 7.7,
3.0 Hz, NCHBCH2O), 3.25–3.40 (3H, m, NCH2CHBO, NCHCCHCO), 3.54–3.60 (1H, m, NCH2CHDO),
3.65–6.71 (1H, m, NCHDCH2O), 3.80 (3H, s, 4′-OCH3), 3.82 (6H, s, 3′-OCH3), 4.90 (1H, dd, J = 17.2,
1.9 Hz, 5-HA), 5.00 (1H, dd, J = 10.2, 1.9 Hz, 5-HB), 5.85 (1H, ddd, J = 17.2, 10.2, 9.0 Hz, 4-H), 5.92 (1H,
d, J = 1.4 Hz, OCHAO), 5.93 (1H, d, J = 1.4 Hz, OCHBO), 6.36 (2H, s, 2′-H), 6.59 (1H, dd, J = 7.9, 1.6 Hz,
6′′-H), 6.65 (1H, d, J = 1.6 Hz, 2′′-H), 6.72 (1H, d, J = 7.9 Hz, 5′′-H). δC (100 MHz; CDCl3) 38.1 (C-7′),
38.5 (C-7′′), 42.0 (NCHCDCH2O), 46.4 (C-2, NCHABCH2O), 48.9 (C-3), 56.4 (3′-OCH3), 61.1 (4′-OCH3),
66.4 (NCH2CHABO), 67.0 (NCH2CHCDO), 101.0 (OCH2O), 106.2 (C-2′), 108.2 (C-5′′), 109.6 (C-2′′), 116.9
9 (C-5), 122.1 (C-6′′), 133.6 (C-1′′), 135.6 (C-1′), 136.9 (C-4′), 139.1 (C-4), 145.9 (C-4′′), 147.7 (C-3′′), 153.3
(C-3′), 172.6 (C-1). IR: νMAX (film)/cm−1; 2922, 1632, 1589, 1490, 1240, 1120, 1036, 925, 730. HRMS
(ESI+) Found [M + Na]+ 506.2145; C27H33NNaO7 requires 506.2149.
(2R*,3S*)-2-(3′-Methoxy-4′-benzyloxybenzyl)-3-(3′′,4′′-methylenedioxybenzyl)-1-morpholinopent-4-en-1-one
(35bd). Using general procedure A: Morpholine 9b (0.25 g, 0.96 mmol), acid chloride 34d (0.35 g,
1.2 mmol) and a reaction time of 18 h. The crude product was purified by column chromatography
(1:1 hexanes, ethyl acetate) to give the title compound 35bd (0.45 g, 88%) as a yellow oil.
Rf = 0.67 (1:3 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 2.54 (1H, dd, J = 13.5, 8.9 Hz, 7′′-HA),
2.61–2.70 (2H, m, 3-H, NCH2CHAO), 2.73–2.91 (5H, m, 2-H, 7′-H, 7′′-HB, NCHACH2O), 2.99 (1H,
ddd, J = 13.2, 7.7, 3.0 Hz, NCHBCH2O), 3.20–3.35 (3H, m, NCH2CHBO, NCHCCHCO), 3.53 (1H, ddd,
J = 11.0, 5.5, 2.5 Hz, NCH2CHDO), 3.62 (1H, ddd, J = 13.0, 5.5, 2.5 Hz, NCHDCH2O), 3.84 (3H, s,
3′-OCH3), 4.88 (1H, dd, J = 17.0, 1.9 Hz, 5-HA), 4.98 (1H, dd, J = 10.2, 1.9 Hz, 5-HB), 5.13 (2H, s, 7′′′-H),
5.84 (1H, ddd, J = 17.0, 10.2, 9.1 Hz, 4-H), 5.91 (1H, d, J = 1.4 Hz, OCHAO), 5.92 (1H, d, J = 1.4 Hz,
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OCHBO), 6.57 (1H, dd, J = 8.0, 1.9 Hz, 6′′-H), 6.59 (1H, dd, J = 8.2, 1.8 Hz, 6′-H), 6.64 (1H, d, J = 1.8 Hz,
2′′-H), 6.69 (1H, d, J = 1.9 Hz, 2′′-H), 6.71 (1H, d, J = 8.0 Hz, 5′′-H), 6.75 (1H, d, J = 8.2 Hz, 5′-H),
7.25–7.30 (1H, m, 4′′′-H), 7.32–7.37 (2H, m, 3′′′-H), 7.38–7.43 (2H, m, 2′′′-H). δC (100 MHz; CDCl3) 37.4
(C-7′), 38.5 (C-7′′), 41.9 (NCHCDCH2O), 46.3 (NCHABCH2O), 46.4 (C-2), 48.8 (C-3), 56.2 (3′-OCH3), 66.3
(NCH2CHABO), 66.9 (NCH2CHCDO), 71.2 (C-7′′′), 100.9 (OCH2O), 108.1 (C-5′′), 109.6 (C-2′′), 113.2
(C-2′), 114.5 (C-5′), 116.7 (C-5), 121.0 (C-6′), 122.1 (C-6′′), 127.3 (C-2′′′), 127.9 (C-4′′′), 128.6 (C-3′′′),
133.1 (C-1′) 133.6 (C-1′′), 137.3 (C-1′′′), 139.2 (C-4), 145.9 (C-4′′), 146.7 (C-4′), 147.6 (C-3′′), 149.7 (C-3′),
172.6 (C-1). IR: νMAX (film)/cm−1; 2920, 1630, 1489, 1231, 1114, 1034, 913, 729. HRMS (ESI+) Found
[M + Na]+ 552.2354; C32H35NNaO6 requires 552.2357.
(3R*,4R*)-3-(3′,4′-Methylenedioxybenzyl)-4-(3′′,4′′-dimethoxybenzyl)-5-(hydroxymethyl)dihydrofuran-2(3H)-
one (4ab). Using general procedure B: Amide 35ab (0.38 g, 0.84 mmol) in tBuOH/H2O and a reaction
time of 3 days. The crude product was purified by column chromatography (1:1 hexanes, ethyl acetate)
to give the title compound 4ab (180 mg, 54%) as a white foam. Rf = 0.50 (19:1 CH2Cl2, methanol). δH
(400 MHz; CDCl3) 1.79 (1H, t, J = 6.4 Hz, 6-OH), 2.36–2.44 (1H, m, 4-H), 2.51 (1H, dd, J = 13.7, 7.9 Hz,
7′′-HA), 2.58 (1H, dd, J = 13.7, 6.6 Hz, 7′′-HB), 2.68 (1H, ddd, J = 9.3, 7.0, 5.5 Hz, 3-H), 2.85 (1H, dd, J =
14.0, 7.0 Hz, 7′-HA), 2.92 (1H, dd, J = 14.0, 5.5 Hz, 7′-HB), 3.15 (1H, ddd, J = 12.5, 6.4, 5.1 Hz, 6-HA), 3.54
(1H, ddd, J = 12.5, 6.4, 2.5 Hz, 6-HB), 3.83 (3H, s, 3′′-OCH3), 3.85 (3H, s, 4′′-OCH3), 4.19 (1H, ddd, J =
8.0, 5.1, 2.5 Hz, 5-H), 5.92 (1H, d, J = 1.5 Hz, OCHAHBO), 5.93 (1H, d, J = 1.5 Hz, OCHAHBO), 6.47 (1H,
d, J = 2.0 Hz, 2′′-H), 6.57–6.60 (2H, m, 6′ and 6′′-H), 6.61 (1H, d, J = 1.5 Hz, 2′-H), 6.71 (1H, d, J = 7.8 Hz,
5′-H), 6.77 (1H, d, J = 8.1 Hz, 5′′-H). δC (100 MHz; CDCl3) 35.3 (C-7′), 38.7 (C-7′′), 41.6 (C-4), 47.6 (C-3),
56.0 (3′′-OCH3, 4′′-OCH3), 63.2 (C-6), 84.1 (C-5), 101.2 (OCH2O), 108.3 (C-5′), 109.7 (C-2′), 111.4 (C-5′′),
112.0 (C-2′′), 121.0 (C-6′′), 122.5 (C-6′), 130.3 (C-1′′), 131.6 (C-1′), 146.6 (C-4′), 148.0 (C-4′′), 148.1 (C-3′),
149.3 (C-3′′), 177.7 (C-2). IR: νMAX (film)/cm−1; 3496 (broad), 2936, 2254, 1760, 1515, 1489, 1442, 1239,
1025, 909, 809, 766. HRMS (ESI+) Found [M + Na]+ 423.1427; C22H24NaO7 requires 423.1414.
(3R*,4R*)-3,4-bis(3′,4′-Dimethoxybenzyl)-5-(hydroxymethyl)dihydrofuran-2(3H)-one (4aa). Using general
procedure B: Amide 35aa (0.29 g, 0.61 mmol), in tBuOH/H2O and a reaction time of 6 days. The crude
product was purified by flash chromatography (1:1 hexanes, ethyl acetate) to give the title compound
4aa (0.18 g, 70%) as a colourless oil. Rf = 0.32 (19:1 CH2Cl2, methanol). δH (400 MHz; CDCl3) 2.39–2.44
(1H, m, 4-H), 2.53 (1H, dd, J = 13.7, 7.3 Hz, 7′′-HA), 2.58 (1H, dd, J = 13.7, 6.5 Hz, 7′′-HB), 2.64 (1H, br s,
6-OH), 2.71 (1H, ddd, J = 9.3, 6.7, 5.7 Hz, 3-H), 2.88 (1H, dd, J = 14.0, 6.7 Hz, 7′-HA), 2.94 (1H, dd, J =
14.0, 5.5 Hz, 7′-HB), 3.16 (1H, dd, J = 12.6, 4.9 Hz, 6-HA), 3.53 (1H, dd, J = 12.6, 2.4 Hz, 6-HB), 3.81, 3.83,
3.84 (12H, s, 3′, 4′, 3′′, 4′′-OCH3), 4.15 (1H, ddd, J = 8.0, 4.9, 2.4 Hz, 5-H), 6.49 (1H, d, J = 1.9 Hz, 2′′-H),
6.57 (1H, dd, J = 8.1, 1.9 Hz, 6′′-H), 6.66–6.68 (2H, m, 2′, 6′-H), 6.73–6.80 (2H, m, 5′, 5′′-H). δC (100 MHz;
CDCl3) 35.0 (C-7′), 38.5 (C-7′′), 41.6 (C-4), 47.5 (C-3), 55.8 (3′, 4′, 3′′, 4′′-OCH3), 62.9 (C-6), 84.0 (C-5),
111.2, 111.4 (C-5′, 5′′), 112.1 (C-2′′), 112.6 (C-2′), 120.9 (C-6′′), 121.4 (C-6′), 130.4 (C-1′, 1′′), 147.9 (C-4′,
4′′), 149.0 (C-3′, 3′′), 178.0 (C-2). IR: νMAX (film)/cm−1; 3505 (br), 2938, 1761, 1591, 1514, 1465, 1259,
1156, 1025, 910, 808, 766, 647. HRMS (ESI+) Found [M + H]+ 417.1909; C23H29O7 requires 417.1908.
(3R*,4R*)-3-(3′,4′,5′-Trimethoxybenzyl)-4-(3′′,4′′-dimethoxybenzyl)-5-(hydroxymethyl)dihydrofuran-2(3H)-one
(4ac). Using general procedure B: Amide 35ac (0.45 g, 0.90 mmol) in tBuOH/H2O/THF and a reaction
time of 3 days. The crude product was purified by column chromatography (1:1 hexanes, ethyl acetate)
to give the title compound 4ac (0.17 g, 42%) as a pale-yellow solid.
Rf = 0.31 (19:1 CH2Cl2, methanol). Melting point: 141–142 ◦C. δH (400 MHz; CDCl3) 1.68 (1H, t, J =
6.5 Hz, 6-OH), 2.38–2.46 (1H, m, 4-H), 2.55 (1H, dd, J = 13.8, 8.2 Hz, 7′′-HA), 2.65 (1H, dd, J = 13.8, 5.9
Hz, 7′′-HB), 2.72 (1H, ddd, J = 9.7, 6.3, 5.7 Hz, 3-H), 2.90 (1H, dd, J = 14.0, 6.3 Hz, 7′-HA), 2.95 (1H, dd,
J = 14.0, 5.7 Hz, 7′-HB), 3.15 (1H, ddd, J = 12.4, 5.1, 5.4 Hz, 6-HA), 3.54 (1H, ddd, J = 12.4, 6.5, 2.5 Hz,
6-HB), 3.82 (6H, s, 4′, 3′′-OCH3), 3.83 (6H, s, 3′-OCH3), 3.85 (3H, s, 4′′-OCH3), 4.20 (1H, ddd, J = 8.2,
5.1, 2.5 Hz, 5-H), 6.38 (2H, s, 2′-H), 6.49 (1H, d, J = 2.0 Hz, 2′′-H), 6.58 (1H, dd, J = 8.1, 2.0 Hz, 6′′-H),
6.76 (1H, d, J = 8.1 Hz, 5′′-H). δC (100 MHz; CDCl3) 35.7 (C-7′), 38.6 (C-7′′), 41.8 (C-4), 47.7 (C-3), 56.0,
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56.1 (3′′, 4′′-OCH3), 56.3 (3′-OCH3), 61.0 (4′-OCH3), 63.2 (C-6), 83.9 (C-5), 106.5 (C-2′), 111.5 (C-5′′),
112.2 (C-2′′), 121.0 (C-6′′), 130.3 (C-1′′), 133.7 (C-1′), 137.2 (C-4′), 148.2 (C-4′′), 149.3 (C-3′′), 153.5 (C-3′),
177.7 (C-2). IR: νMAX (film)/cm−1; 3527 (br), 2938, 1761, 1590, 1514, 1237, 1126, 1026, 735. HRMS (ESI+)
Found [M + Na]+ 469.1839; C24H30NaO8 requires 469.1833.
(3R*,4R*)-3-(3′-Methoxy-4′-benzyloxybenzyl)-4-(3′′,4′′-dimethoxybenzyl)-5-(hydroxymethyl)dihydrofuran-
2(3H)-one (4ad). Using general procedure B: Amide 35ad (0.59 g, 1.1 mmol) in tBuOH/H2O and
a reaction time of 7 days. The crude product was purified by column chromatography (1:1 hexanes,
ethyl acetate) to give the title compound 4ad (0.30 g, 56%) as a cloudy oil. Rf = 0.27 (19:1 CH2Cl2,
methanol). δH (400 MHz; CDCl3) 1.57 (1H, t, J = 6.5 Hz, 6-OH), 2.34–2.42 (1H, m, 4-H), 2.50 (1H, dd, J =
13.5, 8.0 Hz, 7′′-HA), 2.59 (1H, dd, J = 13.5, 6.0 Hz, 7′′-HB), 2.70 (1H, ddd, J = 9.7, 6.2, 5.6 Hz, 3-H), 2.90
(1H, dd, J = 14.1, 6.2 Hz, 7′-HA), 2.94 (1H, dd, J = 14.1, 5.6 Hz, 7′-HB), 3.10 (1H, ddd, J = 12.5, 6.5, 5.2
Hz, 6-HA), 3.48 (1H, ddd, J = 12.5, 6.5, 2.7 Hz, 6-HB), 3.80 (3H, s, 3′′-OCH3), 3.86 (6H, s, 3′, 4′′-OCH3),
4.18 (1H, ddd, J = 8.3, 5.2, 2.7 Hz, 5-H), 5.12 (2H, s, 7′′′-H), 6.46 (1H, d, J = 2.0 Hz, 2′′-H), 6.56 (1H, dd,
J = 8.0, 2.0 Hz, 6′′-H), 6.61 (1H, dd, J = 8.1, 2.0 Hz, 6′-H), 6.72 (1H, d, J = 2.0 Hz, 2′-H), 6.75 (1H, d, J =
8.0 Hz, 5′′-H), 6.79 (1H, d, J = 8.1 Hz, 5′-H), 7.25–7.30 (1H, m, 4′′′-H), 7.31–7.36 (2H, m, 3′′′-H), 7.39–7.42
(2H, m, 2′′′-H). δC (100 MHz; CDCl3) 35.1 (C-7′), 38.6 (C-7′′), 41.7 (C-4), 47.6 (C-3), 56.0 (3′′, 4′′-OCH3),
56.2 (3′-OCH3), 63.3 (C-6), 71.3 (C-7′′′), 84.0 (C-5), 111.5 (C-5′′), 112.1 (C-2′′), 113.3 (C-2′), 114.3 (C-5′),
121.0 (C-6′′), 121.6 (C-6′), 127.4 (C-2′′′), 128.0 (C-4′′′), 128.7 (C-3′′′), 130.3 (C-1′′), 131.1 (C-1′), 137.2
(C-1′′′), 147.2 (C-4′), 148.2 (C-4′′), 149.3 (C-3′′), 150.0 (C-3′), 177.8 (C-2). IR: νMAX (film)/cm−1; 3523
(br), 2935, 1761, 1514, 1261, 1025, 911, 730. HRMS (ESI+) Found [M + Na]+ 515.2023; C29H32NaO7
requires 515.2040.
(3R*,4R*,5S*)-4-(3′′,4′′-Dimethoxybenzyl)-3-(4′-hydroxy-3′-methoxybenzyl)-5-(hydroxymethyl)dihydrofuran-
2(3H)-one (4ae). Using general procedure F: Benzyl ether 4ad (0.27 g, 0.55 mmol) gave the title
compound 4ae (0.19 g, 88%) as a yellow solid. Rf = 0.43 (19:1 CH2Cl2, methanol). Melting point:
183–185 ◦C. δH (400 MHz; CDCl3) 1.63 (1H, t, J = 6.5 Hz, 6-OH), 2.34–2.43 (1H, m, 4-H), 2.53 (1H, dd,
J = 13.8, 8.1 Hz, 7′′-HA), 2.62 (1H, dd, J = 13.8, 6.1 Hz, 7′′-HB), 2.69 (1H, dt, J = 9.5, 6.0 Hz, 3-H), 2.92
(2H, d, J = 6.0 Hz, 7′-H), 3.13 (1H, ddd, J = 12.5, 6.5, 5.3 Hz, 6-HA), 3.51 (1H, ddd, J = 12.5, 6.5, 2.5 Hz,
6-HB), 3.82 (3H, s, 3′-OCH3), 3.84 (3H, s, 3′′-OCH3), 3.85 (3H, s, 4′′-OCH3), 4.19 (1H, ddd, J = 8.0, 5.3,
2.5 Hz, 5-H), 5.52 (1H, s, 4′-OH), 6.46 (1H, d, J = 2.0 Hz, 2′′-H), 6.57 (1H, dd, J = 8.1, 2.0 Hz, 6′′-H), 6.63
(1H, dd, J = 8.0, 1.9 Hz, 6′-H), 6.66 (1H, d, J = 1.9 Hz, 2′-H), 6.76 (1H, d, J = 8.1 Hz, 5′′-H), 6.83 (1H,
d, J = 8.0 Hz, 5′-H). δC (100 MHz; CDCl3) 35.1 (C-7′), 38.6 (C-7′′), 41.6 (C-4), 47.7 (C-3), 56.0, 56.1 (3′,
3′′, 4′′-OCH3), 63.4 (C-6), 84.1 (C-5), 111.5 (C-5′′), 111.9 (C-2′), 112.1 (C-2′′), 114.4 (C-5′), 121.0 (C-6′′),
122.3 (C-6′), 129.7 (C-1′), 130.4 (C-1′′), 144.7 (C-4′), 146.8 (C-3′), 148.2 (C-4′′), 149.3 (C-3′′), 177.8 (C-2).
IR: νMAX (film)/cm−1; 3438 (br), 2937, 1755, 1514, 1236, 1155, 1025, 907, 723. HRMS (ESI+) Found
[M + Na]+ 425.1564; C22H26NaO7 requires 425.1571.
(3R*,4R*)-3,4-bis(3′,4′-Methylenedioxybenzyl)-5-(hydroxymethyl)dihydrofuran-2(3H)-one (4bb). Using
general procedure B: Morpholine amide 35bb (0.322 g, 0.74 mmol) in tBuOH/H2O/THF and a reaction
time of 5 days. The crude product was then purified by column chromatography (2:1 hexanes, ethyl
acetate) to give the title compound 4bb (0.145 g, 51%) as a pale-yellow oil.
Rf = 0.59 (1:3 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 1.72 (1H, br, 6-OH), 2.32–2.41 (1H, m, 4-H),
2.47 (1H, dd, J = 13.7, 8.1 Hz, 7′′-HA), 2.56 (1H, dd, J = 13.7, 6.2 Hz, 7′′-HB), 2.65 (1H, ddd, J = 9.0, 7.5,
5.3 Hz, 3-H), 2.85 (1H, dd, J = 14.0, 7.5 Hz, 7′-HA), 2.96 (1H, dd, J = 14.0, 5.3 Hz, 7′-HB), 3.15 (1H, dd,
J = 12.6, 4.9 Hz, 6-HA), 3.54 (1H, dd, J = 12.6, 2.5 Hz, 6-HB), 4.18 (1H, ddd, J = 7.7, 4.9, 2.5 Hz, 5-H),
5.93–5.95 (4H, m, 2 × OCH2O), 6.45–6.49 (2H, m, 2′′, 6′′-H), 6.60 (1H, dd, J = 7.8, 1.7 Hz, 6′-H), 6.63 (1H,
d, J = 1.7 Hz, 2′-H), 6.70 (1H, d, J = 7.8 Hz, 5′′-H), 6.73 (1H, d, J = 7.8 Hz, 5′-H). δC (100 MHz; CDCl3)
35.4 (C-7′), 38.9 (C-7′′), 41.8 (C-4), 47.6 (C-3), 63.3 (C-6), 83.9 (C-5), 101.1, 101.2 (2 × OCH2O), 108.4
(C-5′), 108.6 (C-5′′), 109.2 (C-2′′), 109.6 (C-2′), 121.9 (C-6′′), 122.4 (C-6′), 131.5 (C-1′, 1′′), 146.6 (C-4′, 4′′),
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148.0, 148.1 (C-3′, 3′′), 177.6 (C-2). IR: νMAX (film)/cm−1; 3432 (br), 2922, 1760, 1503, 1490, 1444, 1247,
1038, 927, 811. HRMS (ESI+) Found [M + H]+ 385.1279; C21H21O7 requires 385.1282.
(3R*,4R*)-3-(3′,4′-Dimethoxybenzyl)-4-(3′′,4′′-methylenedioxybenzyl)-5-(hydroxymethyl)dihydrofuran-2(3H)-
one (4ba). Using general procedure B: Morpholine amide 35ba (0.336 g, 0.74 mmol) in tBuOH/H2O/
THF and a reaction time of 4 days. The crude product was then purified by column chromatography
(1:3 hexanes, ethyl acetate) to give the title compound 4ba (0.103 g, 34%) as a pale yellow oil.
Rf = 0.48 (1:3 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 1.68 (1H, t, J = 6.6 Hz, 6-OH), 2.33–2.42 (1H,
m, 4-H), 2.48 (1H, dd, J = 13.7, 7.9 Hz, 7′′-HA), 2.56 (1H, dd, J = 13.7, 6.3 Hz, 7′′-HB), 2.68 (1H, ddd, J =
9.3, 6.9, 5.4 Hz, 3-H), 2.89 (1H, dd, J = 14.0, 6.9 Hz, 7′-HA), 2.96 (1H, dd, J = 14.0, 5.4 Hz, 7′-HB), 3.15
(1H, ddd, J = 12.5, 6.6, 5.2 Hz, 6-HA), 3.52 (1H, ddd, J = 12.5, 6.6, 2.6 Hz, 6-HB), 3.85 (3H, s, 3′-OCH3),
3.86 (3H, s, 4′-OCH3), 4.18 (1H, ddd, J = 7.9, 5.2, 2.6 Hz, 5-H), 5.93 (1H, d, J = 1.4 Hz, OCHAO), 5.94 (1H,
d, J = 1.4 Hz, OCHBO), 6.44 (1H, d, J = 1.6 Hz, 2′′-H), 6.47 (1H, dd, J = 7.8, 1.6 Hz, 6′′-H), 6.67 (1H, d, J =
2.2 Hz, 2′-H), 6.68–6.72 (2H, m, 6′, 5′′-H), 6.79 (1H, d, J = 8.0 Hz, 5′-H). δC (100 MHz; CDCl3) 35.2 (C-7′),
38.8 (C-7′′), 41.7 (C-4), 47.6 (C-3), 56.0 (3′, 4′-OCH3), 63.4 (C-6), 83.8 (C-5), 101.3 (OCH2O), 108.5 (C-5′),
109.2 (C-2′′), 111.3 (C-5′′), 112.5 (C-2′), 121.6 (C-6′), 121.9 (C-6′′), 130.3 (C-1′), 131.5 (C-1′′), 146.7 (C-4′′),
148.1 (C-4′, 3′′), 149.2 (C-3′), 177.7 (C-2). IR: νMAX (film)/cm−1; 3472 (br), 2933, 1760, 1516, 1490, 1242,
1157, 1028, 925, 810, 730. HRMS (ESI+) Found [M + Na]+ 423.1423; C22H24NaO7 requires 423.1414.
(3R*,4R*)-3-(3′,4′,5′-Trimethoxybenzyl)-4-(3′′,4′′-methylenedioxybenzyl)-5-(hydroxymethyl)dihydrofuran-2(3H)-
one (4bc). Using general procedure B: Morpholine amide 35bc (0.372 g, 0.77 mmol) in tBuOH/H2O/THF
and a reaction time of 4 days. The crude product was then purified by column chromatography (1:3
hexanes, ethyl acetate) to give the title compound 4bc (0.084 g, 25%) as a pale-yellow oil.
Rf = 0.38 (1:3 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 1.69 (1H, t, J = 6.6 Hz, 6-OH), 2.36–2.45 (1H,
m, 4-H), 2.53 (1H, dd, J = 13.8, 7.6 Hz, 7′′-HA), 2.59 (1H, dd, J = 13.8, 6.8 Hz, 7′′-HB), 2.70 (1H, ddd, J =
9.5, 6.7, 5.4 Hz, 3-H), 2.87 (1H, dd, J = 14.0, 6.7 Hz, 7′-HA), 2.93 (1H, dd, J = 14.0, 5.4 Hz, 7′-HB), 3.22
(1H, ddd, J = 12.7, 6.6, 5.0 Hz, 6-HA), 3.58 (1H, ddd, J = 12.7, 6.6, 2.5 Hz, 6-HB), 3.82 (3H, s, 4′-OCH3),
3.84 (6H, s, 3′-OCH3), 3.85 (3H, s, 4′′-OCH3), 4.19 (1H, ddd, J = 7.9, 5.0, 2.5 Hz, 5-H), 5.94 (1H, d, J =
1.4 Hz, OCHAO), 5.94 (1H, d, J = 1.4 Hz, OCHBO), 6.37 (2H, s, 2′-H), 6.46 (1H, d, J = 1.8 Hz, 2′′-H),
6.48 (1H, dd, J = 7.9, 1.8 Hz, 6′′-H), 6.70 (1H, d, J = 7.9 Hz, 5′′-H). δC (100 MHz; CDCl3) 36.0 (C-7′),
38.8 (C-7′′), 41.9 (C-4), 47.6 (C-3), 56.3 (3′-OCH3), 61.1 (4′-OCH3), 63.3 (C-6), 83.8 (C-5), 101.3 (OCH2O),
106.5 (C-2′), 108.5 (C-5′′), 109.2 (C-2′′), 121.9 (C-6′′), 131.4 (C-1′′), 133.6 (C-1′), 137.1 (C-4′), 146.7 (C-4′′),
148.2 (C-3′′), 153.5 (C-3′), 177.7 (C-2). IR: νMAX (film)/cm−1; 3475 (br), 2941, 1760, 1591, 1490, 1445,
1244, 1127, 1036, 926. HRMS (ESI+) Found [M + Na]+ 453.1519; C23H26NaO8 requires 453.1520.
(3R*,4R*)-3-(3′-Methoxy-4′-benzyloxybenzyl)-4-(3′′,4′′-methylenedioxybenzyl)-5-(hydroxymethyl)dihydrofuran-
2(3H)-one (4bd). Using general procedure B: Morpholine amide 35bd (0.405 g, 0.77 mmol) in tBuOH/H2O/
THF and a reaction time of 5 days. The crude product was then purified by column chromatography (1:3
hexanes, ethyl acetate) to give the title compound 4bd (0.205 g, 56%) as a pale-yellow oil.
Rf = 0.58 (1:3 hexanes, ethyl acetate). δH (400 MHz; CDCl3) 1.64 (1H, t, J = 6.6 Hz, 6-OH), 2.31–2.40 (1H,
m, 4-H), 2.46 (1H, dd, J = 13.7, 7.9 Hz, 7′′-HA), 2.53 (1H, dd, J = 13.7, 6.3 Hz, 7′′-HB), 2.67 (1H, ddd, J =
9.2, 7.2, 5.3 Hz, 3-H), 2.87 (1H, dd, J = 14.0, 7.2 Hz, 7′-HA), 2.95 (1H, dd, J = 14.0, 5.3 Hz, 7′-HB), 3.13
(1H, ddd, J = 12.6, 6.6, 5.1 Hz, 6-HA), 3.48 (1H, ddd, J = 12.6, 6.6, 2.6 Hz, 6-HB), 3.86 (3H, s, 3′-OCH3),
4.17 (1H, ddd, J = 7.8, 5.1, 2.6 Hz, 5-H), 5.13 (2H, s, 7′′′-H), 5.93 (1H, d, J = 1.4 Hz, OCHAO), 5.94 (1H, d,
J = 1.4 Hz, OCHBO), 6.43 (1H, d, J = 1.6 Hz, 2′′-H), 6.45 (1H, dd, J = 7.9, 1.6 Hz, 6′′-H), 6.64 (1H, dd, J =
8.2, 2.0 Hz, 6′-H), 6.68–6.70 (2H, m, 2′, 5′′-H), 6.81 (1H, d, J = 8.2 Hz, 5′-H), 7.27–7.30 (1H, m, 4′′′-H),
7.32–7.36 (2H, m, 3′′′-H), 7.40–7.44 (2H, m, 2′′′-H). δC (100 MHz; CDCl3) 35.3 (C-7′), 38.8 (C-7′′), 41.8
(C-4), 47.6 (C-3), 56.1 (3′-OCH3), 63.4 (C-6), 71.3 (C-7′′′), 83.8 (C-5), 101.3 (OCH2O), 108.5 (C-5′′), 109.2
(C-2′′), 113.0 (C-2′), 114.4 (C-5′), 121.5 (C-6′), 121.9 (C-6′′), 127.5 (C-2′′′), 128.0 (C-4′′′), 128.7 (C-3′′′),
131.0 (C-1′), 131.5 (C-1′′), 137.3 (C-1′′′), 146.7 (C-4′′), 147.2 (C-4′), 148.1 (C-3′′), 150.0 (C-3′), 177.7 (C-2).
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IR: νMAX (film)/cm−1; 3471 (br), 2940, 1743, 1504, 1490, 1366, 1230, 1036, 926, 735. HRMS (ESI+) Found
[M + Na]+ 499.1729; C28H28NaO7 requires 499.1727.
(3R*,4R*,5S*)-4-(3′′,4′′-Methylenedioxybenzyl)-3-(4′-hydroxy-3′-methoxybenzyl)-5-(hydroxymethyl)
dihydrofuran-2(3H)-one (4be). Using general procedure F: Benzyl ether 4bd (0.02 g, 0.04 mmol) and
a reaction time of 1 h. The crude product was then purified by column chromatography (1:3 hexanes,
ethyl acetate) to give the title compound 4be (0.017 g, quant.) as a colourless oil. Rf = 0.52 (1:3 hexanes,
ethyl acetate). δH (400 MHz; CDCl3) 1.74 (1H, br, 6-OH), 2.33–2.42 (1H, m, 4-H), 2.48 (1H, dd, J = 13.7,
8.0 Hz, 7′′-HA), 2.57 (1H, dd, J = 13.7, 6.2 Hz, 7′′-HB), 2.67 (1H, ddd, J = 9.4, 6.9, 5.5 Hz, 3-H), 2.88 (1H,
dd, J = 14.0, 6.9 Hz, 7′-HA), 2.94 (1H, dd, J = 14.0, 5.5 Hz, 7′-HB), 3.15 (1H, br d, J = 12.6 Hz, 6-HA), 3.52
(1H, br d, J = 12.6 Hz, 6-HB), 3.86 (3H, s, 3′-OCH3), 4.18 (1H, ddd, J = 8.0, 5.0, 2.5 Hz, 5-H), 5.54 (1H,
s, 4′-OH), 5.93 (1H, d, J = 1.4 Hz, OCHAO), 5.94 (1H, d, J = 1.4 Hz, OCHBO), 6.45 (1H, d, J = 1.9 Hz,
2′′-H), 6.47 (1H, dd, J = 7.7, 1.9 Hz, 6′′-H), 6.63 (1H, dd, J = 8.0, 1.9 Hz, 6′-H), 6.67 (1H, d, J = 1.9 Hz,
2′-H), 6.70 (1H, d, J = 7.7 Hz, 5′′-H), 6.84 (1H, d, J = 8.0 Hz, 5′-H). δC (100 MHz; CDCl3) 35.3 (C-7′), 38.8
(C-7′′), 41.7 (C-4), 47.7 (C-3), 56.1 (3′-OCH3), 63.4 (C-6), 83.9 (C-5), 101.3 (OCH2O), 108.6 (C-5′′), 109.2
(C-2′′), 111.8 (C-2′), 114.5 (C-5′), 121.9 (C-6′′), 122.3 (C-6′), 129.6 (C-1′), 131.5 (C-1′′), 144.7 (C-4′), 146.7
(C-3′), 146.8 (C-4′′), 148.1 (C-3′′), 177.8 (C-2). IR: νMAX (film)/cm −1; 3449 (br), 2933, 1754, 1516, 1490,
1246, 1036, 926, 812. HRMS (ESI+) Found [M + Na]+ 409.1246; C21H22NaO7 requires 409.1258.
(±)-Arcitin (1aa). Using general procedure C: Lactone 4aa (0.16 g, 0.39 mmol) and a reaction time of
2 h to give triol 38aa (0.17 g, quant.) as a colourless oil. Then using general procedure D: Triol 38aa
(0.16 g, 0.37 mmol) and a reaction time of 2.5 h to give lactol 39aa (0.14 g, 97%) which was used without
further purification. Then using general procedure E: Lactol 39aa (0.054 g, 0.14 mmol) and a reaction
time of 3 h. The crude product was purified by column chromatography (1:1, hexanes, ethyl acetate) to
give the title compound 1aa (0.05 g, 88%) as a pale yellow amorphous solid. Rf = 0.45 (19:1, CH2Cl2,
methanol). Melting point: 114–116 ◦C [lit. [49] 113 ◦C]. δH (400 MHz; CDCl3) 2.45–2.68 (4H, m, 8, 7′,
8′-H), 2.92 (1H, dd, J = 14.3, 6.8 Hz, 7-HA), 2.97 (1H, dd, J = 14.3, 5.5 Hz, 7-HB), 3.82 (3H, s, 3′-OCH3),
3.83 (3H, s, 3-OCH3), 3.85–3.90 (7H, m, 4, 4′-OCH3, 9′-HA), 4.13 (1H, t, J = 7.0 Hz, 9′-HB), 6.49 (1H,
d, J = 1.9 Hz, 2′-H), 6.55 (1H, dd, J = 8.1, 1.9 Hz, 6′-H), 6.66 (1H, dd, J = 8.1, 1.9 Hz, 6-H), 6.69 (1H, d,
J = 1.9 Hz, 2-H), 6.75 (1H, d, J = 8.1 Hz, 5-H), 6.77 (1H, d, J = 8.1 Hz, 5′-H). δC (100 MHz; CDCl3) 34.5
(C-7), 38.2 (C-7′), 41.1 (C-8′), 46.6 (C-8), 55.8, 55.9 (3, 4, 3′, 4′-OCH3), 71.2 (C-9′), 111.1 (C-5), 111.4 (C-5′),
111.9 (C-2′), 112.4 (C-2), 120.6 (C-6′), 121.4 (C-6), 130.2 (C-1), 130.5 (C-1′), 147.9 (C-4′), 148.0 (C-4), 149.1
(C-3, 3′), 178.7 (C-9). IR: νMAX (film)/cm−1; 2956, 1753, 1588, 1513, 1257, 1236, 1153, 1137, 1019, 825,
764. HRMS (ESI+) Found [M + H]+ 387.1806; C22H27O6 requires 387.1802. Values are in agreement
with literature data [50].
(±)-Bursehernin (1a). Using general procedure C: Lactone 4ab (0.114 g, 0.28 mmol) and a reaction
time of 30 min to give triol 38ab (0.111 g, 97%) as a cloudy oil. Then using general procedure D: Triol
38ab (0.111 g, 0.27 mmol) and a reaction time of 1 h to give lactol 39ab (0.093 g, 91%) which was used
without further purification. Then using general procedure E: Lactol 39ab (0.093 g, 0.25 mmol) and
a reaction time of 2 h. The crude product was purified by column chromatography (1:1, hexanes, ethyl
acetate) to give the title compound 1ab (0.06 g, 65%) as a pale-yellow oil. Rf = 0.66 (19:1, CH2Cl2,
methanol). δH (400 MHz; CDCl3) 2.41–2.62 (4H, m, 8, 7′, 8′-H), 2.88 (1H, dd, J = 14.0, 6.9 Hz, 7-HA),
2.96 (1H, dd, J = 14.0, 5.1 Hz, 7-HB), 3.82 (3H, s, 3-OCH3), 3.83–3.86 (4H, m, 4-OCH3, 9′-HA), 4.10 (1H,
dd, J = 9.1, 6.9 Hz, 9′-HB), 5.91 (1H, d, J = 1.4 Hz, OCHAO), 5.92 (1H, d, J = 1.4 Hz, OCHBO), 6.42 (1H,
d, J = 1.5 Hz, 2′-H), 6.44 (1H, dd, J = 7.9, 1.5 Hz, 6′-H), 6.66 (1H, d, J = 1.9 Hz, 2-H), 6.67–6.70 (2H, m, 6,
5′-H), 6.78 (1H, d, J = 8.0 Hz, 5-H). δC (100 MHz; CDCl3) 34.7 (C-7), 38.4 (C-7′), 41.2 (C-8′), 46.6 (C-8),
55.9 (3, 4-OCH3), 71.2 (C-9′), 101.1 (OCH2O), 108.4 (C-5′), 108.8 (C-2′), 111.2 (C-5), 112.3 (C-2), 121.4
(C-6), 121.6 (C-6′), 130.2 (C-1), 131.7 (C-1′), 146.4 (C-4′), 148.0 (C-3′), 148.1 (C-4), 149.2 (C-3), 178.7 (C-9).
IR: νMAX (film)/cm−1; 2907, 1764, 1514, 1489, 1442, 1240, 1025, 923, 808, 730. HRMS (ESI+) Found
[M + Na]+ 393.1317; C21H22NaO6 requires 393.1309. Values are in agreement with literature data [51].
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(±)-4-O-Methyl traxillagenin (1ac). Using general procedure C: Lactone 4ac (0.119 g, 0.27 mmol) and
a reaction time of 45 min to give triol 38ac (0.11 g, 90%) as a cloudy oil. The using general procedure
D: Triol 38ac (0.11 g, 0.24 mmol) and a reaction time of 15 min. The crude product was purified by
column chromatography (1:2 hexanes, ethyl acetate) to give lactol 39ac (0.06 g, 60%) as a colourless oil.
Then using general procedure E: Lactol 39ac (0.06 g, 0.15 mmol) and a reaction time of 3 h. The crude
product purified by column chromatography (1:1, hexanes, ethyl acetate) to give the title compound
1ac (0.044 g, 73%) as a white solid. Rf = 0.61 (19:1, CH2Cl2, methanol). Melting point: 126 ◦C. δH
(400 MHz; CDCl3) 2.44–2.66 (4H, m, 8, 7′, 8′-H), 2.91 (1H, dd, J = 14.1, 6.6 Hz, 7-HA), 2.98 (1H, dd,
J = 14.1, 5.4 Hz, 7-HB), 3.79 (6H, s, 3′-OCH3), 3.80 (6H, s, 4′-OCH3), 3.83 (3H, s, 3-OCH3), 3.84 (3H, s,
4-OCH3), 3.87 (1H, dd, J = 9.2, 7.3 Hz, 9′-HA), 4.14 (1H, dd, J = 9.2, 7.0 Hz, 9′-HB), 6.19 (2H, s, 2′-H), 6.63
(1H, dd, J = 8.0, 2.0 Hz, 6-H), 6.70 (1H, d, J = 2.0 Hz, 2-H), 6.75 (1H, d, J = 8.0 Hz, 5-H). δC (100 MHz;
CDCl3) 34.6 (C-7), 39.0 (C-7′), 41.2 (C-8′), 46.7 (C-8), 56.0 (3, 4-OCH3), 56.2 (3′-OCH3), 60.9 (4′-OCH3),
71.3 (C-9′), 105.7 (C-2′), 111.2 (C-5), 112.6 (C-2), 121.4 (C-6), 130.3 (C-1), 133.8 (C-1′), 137.0 (C-4′), 148.1
(C-4), 149.2 (C-3), 153.5 (C-3′), 178.7 (C-9). IR: νMAX (film)/cm−1; 2938, 1764, 1590, 1509, 1460, 1237,
1123, 1014, 731. HRMS (ESI+) Found [M + Na]+ 439.1716; C23H28NaO7 requires 439.1727. Values are in
agreement with literature data [52].
(±)-4′-O-Benzyl buplerol (1ad). Using general procedure C: Lactone 4ad (0.505 g, 1.02 mmol) and
a reaction time of 3 h to give the triol 38ad (0.472 g, 93%) as a cloudy oil. Then using general procedure
D: Triol 38ad (0.472 g, 0.95 mmol) and a reaction time of 30 min to give lactol 39ad (0.416 g, 94%)
as a white solid which was used without further purification. Then using general procedure E:
Lactol 39ad (0.416 g, 0.90 mmol) and a reaction time of 1.5 h. The crude product was purified by
column chromatography (1:1, hexanes, ethyl acetate) to give the title compound 1ad (0.374 g, 90%) as
a pale-yellow oil. Rf = 0.52 (1:1, hexanes, ethyl acetate). δH (400 MHz; CDCl3) 2.42–2.66 (4H, m, 8, 7′,
8′-H), 2.91 (1H, dd, J = 14.1, 6.2 Hz, 7-HA), 2.95 (1H, dd, J = 14.1, 5.7 Hz, 7-HB), 3.827, 3.829 (6H, 2 × s,
3, 3′-OCH3), 3.85 (3H, s, 4-OCH3), 3.83–3.88 (1H, m, 9′-HA), 4.11 (1H, dd, J = 8.7, 7.0 Hz, 9′-HB), 5.12
(2H, s, Ph-CH2), 6.48 (1H, dd, J = 8.0, 2.0 Hz, 6′-H), 6.51 (1H, d, J = 2.0 Hz, 2′-H), 6.64 (1H, dd, J = 8.2,
2.0 Hz, 6-H), 6.68 (1H, d, J = 2.0 Hz, 2-H), 6.76 (1H, d, J = 8.2 Hz, 5-H), 6.77 (1H, d, J = 8.0 Hz, 5′-H),
7.27–7.32 (1H, m, Ph-p-H), 7.33–7.38 (2H, m, Ph-m-H), 7.40–7.44 (2H, m, Ph-o-H). δC (100 MHz; CDCl3)
34.6 (C-7), 38.3 (C-7′), 41.2 (C-8′), 46.7 (C-8), 56.0 (3, 3′-OCH3), 56.1 (4-OCH3), 71.3, 71.4 (C-9′, Ph-CH2),
111.3 (C-5), 112.5 (C-2), 112.6 (C-5′), 114.5 (C-5′), 120.7 (C-6′), 121.5 (C-6), 127.4 (Ph-o-C), 128.0 (Ph-p-C),
128.7 (Ph-m-C), 130.3 (C-1), 131.3 (C-1′), 137.3 (Ph-i-C), 147.2 (C-4′), 148.1 (C-4), 149.2 (C-3), 149.9 (C-3′),
178.8 (C-9). IR: νMAX (film)/cm−1; 2935, 1763, 1512, 1260, 1233, 1140, 1014, 736, 697. HRMS (ESI+)
Found [M + Na]+ 485.1934; C28H30NaO6 requires 485.1935.
(±)-Buplerol (1ae). Using general procedure F: Lactone 1ad (0.336 g, 0.73 mmol) and a reaction time of
3.5 h to give the title compound 1ae (0.271 g, quant.) as a white solid. Rf = 0.33 (1:1, hexanes, ethyl
acetate). Melting point: 101–103 ◦C. δH (400 MHz; CDCl3) 2.42–2.66 (4H, m, 8, 7′, 8′-H), 2.90 (1H, dd,
J = 14.1, 6.8 Hz, 7-HA), 2.97 (1H, dd, J = 14.1, 5.3 Hz, 7-HB), 3.81 (3H, s, 3-OCH3), 3.83 (3H, s, 3′-OCH3),
3.86 (4H, m, 4-OCH3), 3.87 (1H, dd, J = 8.9, 7.1 Hz, 9′-HA), 4.13 (1H, dd, J = 9.3, 7.1 Hz, 9′-HB), 5.51 (1H,
s, 4′-OH), 6.43 (1H, d, J = 1.9 Hz, 2′-H), 6.52 (1H, dd, J = 8.0, 1.9 Hz, 6′-H), 6.64–6.67 (2H, m, 2, 6-H), 6.77
(1H, d, J = 8.6 Hz, 5-H), 6.80 (1H, d, J = 8.0 Hz, 5′-H). δC (100 MHz; CDCl3) 34.7 (C-7), 38.5 (C-7′), 41.3
(C-8′), 46.7 (C-8), 55.9, 56.0 (3, 3′, 4-OCH3), 71.4 (C-9′), 111.1, 111.2 (C-5, 5′), 112.5 (C-2), 114.6 (C-2′),
121.5 (C-6, 6′), 129.9 (C-1′), 130.4 (C-1), 144.6 (C-4′), 146.7 (C-3′), 148.1 (C-4), 149.2 (C-3), 178.9 (C-9). IR:
νMAX (film)/cm−1; 3417, 2938, 1760, 1513, 1236, 1148, 1023, 812, 795. HRMS (ESI+) Found [M + Na]+
395.1462; C21H24NaO6 requires 395.1465. Values are in agreement with literature data [53].
(±)-Kusunokinin (1ba). Using general procedure C: Lactone 4ba (0.082 g, 0.20 mmol) and a reaction
time of 1 h to give the triol 38ba (0.083 g, quant.) as a cloudy oil. Then using general procedure D: Triol
38ba (0.083 g, 0.20 mmol) and a reaction time of 15 min to give lactol 39ba (0.064 g, 84%) which was
used without further purification. Then using general procedure E: Lactol 39ba (0.056 g, 0.15 mmol)
and a reaction time of 1 h. The crude product was purified by column chromatography (2:1, hexanes,
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ethyl acetate) to give the title compound 1ba (0.051 g, 91%) as a colourless oil. Rf = 0.48 (1:1, hexanes,
ethyl acetate). δH (400 MHz; CDCl3) 2.44–2.65 (4H, m, 8, 7′, 8′-H), 2.84 (1H, dd, J = 14.1, 7.0 Hz, 7-HA),
2.95 (1H, dd, J = 14.1, 5.1 Hz, 7-HB), 3.82 (3H, s, 3′-OCH3), 3.85 (3H, s, 4′-OCH3), 3.87 (1H, dd, J =
9.2, 7.2 Hz, 9′-HA), 4.14 (1H, dd, J = 9.2, 7.0 Hz, 9′-HB), 5.92 (1H, d, J = 1.4 Hz, OCHAO), 5.93 (1H, d,
J = 1.4 Hz, OCHBO), 6.48 (1H, d, J = 2.0 Hz, 2′-H), 6.55–6.60 (3H, m, 2, 6, 6′-H), 6.71 (1H, d, J = 7.7 Hz,
5-H), 6.76 (1H, d, J = 8.2 Hz, 5′-H). δC (100 MHz; CDCl3) 34.9 (C-7), 38.4 (C-7′), 41.3 (C-8′), 46.6 (C-8),
55.9 (3′-OCH3), 56.0 (4′-OCH3), 71.4 (C-9′), 101.1 (OCH2O), 108.3 (C-5), 109.6 (C-2), 111.4 (C-5′), 111.8
(C-2′), 120.8 (C-6′), 122.4 (C-6), 130.6 (C-1′), 131.5 (C-1), 146.6 (C-4), 148.0 (C-3, 4′), 149.2 (C-3′), 178.6
(C-9). IR: νMAX (film)/cm−1; 2908, 1764, 1515, 1489, 1442, 1242, 1024, 912, 809, 729. HRMS (ESI+) Found
[M + Na]+ 393.1301; C21H22NaO6 requires 393.1309. Values are in agreement with literature data [50].
(±)-Hinokinin (1bb). Using general procedure C: Lactone 4bb (0.12 g, 0.31 mmol) and a reaction time
of 30 min to give the triol 38bb (0.12 g, quant.) as a cloudy oil. Then using general procedure D:
Triol 38bb (0.121 g, 0.31 mmol) and a reaction time of 10 min to give lactol 39bb (0.096 g, 86%) which
was used without further purification. Then using general procedure E: Lactol 39bb (0.089 g, 0.25
mmol) and a reaction time of 1 h. The crude product was purified by column chromatography (1:1,
hexanes, ethyl acetate) to give the title compound 1bb (0.08 g, 90%) as a pale-yellow oil. Rf = 0.73 (1:1,
hexanes, ethyl acetate). δH (400 MHz; CDCl3) 2.41–2.62 (4H, m, 8, 7′, 8′-H), 2.83 (1H, dd, J = 14.1, 7.2
Hz, 7-HA), 2.98 (1H, dd, J = 14.1, 5.0 Hz, 7-HB), 3.85 (1H, dd, J = 9.2, 7.1 Hz, 9′-HA), 4.12 (1H, dd, J =
9.2, 6.9 Hz, 9′-HB), 5.91–5.94 (4H, m, 2 × OCH2O), 6.44–6.47 (2H, m, 2′, 6′-H), 6.59 (1H, dd, J = 7.9,
1.8 Hz, 6-H), 6.62 (1H, d, J = 1.8 Hz, 2-H), 6.69 (1H, d, J = 8.4 Hz, 5′-H), 6.72 (1H, d, J = 7.9 Hz, 5-H). δC
(100 MHz; CDCl3) 34.9 (C-7), 38.4 (C-7′), 41.4 (C-8′), 46.6 (C-8), 71.2 (C-9′), 101.1 (2 × OCH2O), 108.4
(C-5, 5′), 108.9 (C-2′), 109.5 (C-2), 121.6 (C-6′), 122.3 (C-6), 131.5 (C-1), 131.7 (C-1′), 146.4 (C-4), 146.6
(C-4′), 148.0 (C-3, 3′), 178.5 (C-9). IR: νMAX (film)/cm−1; 2901, 1764, 1488, 1441, 1242, 1015, 924, 808,
728. HRMS (ESI+) Found [M + Na]+ 377.0986; C20H18NaO6 requires 377.0996. Values are in agreement
with literature data [54].
(±)-Isoyatein (1bc). Using general procedure C: Lactone 4bc (0.076 g, 0.18 mmol) and a reaction time
of 1 h to give the triol 38bc (0.077 g, >99%) as a cloudy oil. Then using general procedure D: Triol
38bc (0.077 g, 0.18 mmol) and a reaction time of 1 h to give lactol 39bc (0.057 g, 80%) which was used
without further purification. Then using general procedure E: Lactol 39bc (0.05 g, 0.12 mmol) and
a reaction time of 3 h. The crude product was purified by column chromatography (1:1, hexanes, ethyl
acetate) to give the title compound 1bc (0.8 mg, 16%) as a pale-yellow oil. Rf = 0.55 (1:1, hexanes, ethyl
acetate). δH (400 MHz; CDCl3) 2.46–2.64 (4H, m, 8, 7′, 8′-H), 2.86 (1H, dd, J = 14.1, 7.0 Hz, 7-HA), 2.98
(1H, dd, J = 14.1, 5.1 Hz, 7-HB), 3.81 (6H, s, 3′-OCH3), 3.82 (3H, s, 4′-OCH3), 3.89 (1H, dd, J = 9.2, 7.0 Hz,
9′-HA), 4.19 (1H, dd, J = 9.2, 6.8 Hz, 9′-HB), 5.93 (1H, d, J = 1.5 Hz, OCHAO), 5.94 (1H, d, J = 1.5 Hz,
OCHBO), 6.20 (2H, s, 2′-H), 6.58 (1H, dd, J = 7.9, 1.8 Hz, 6-H), 6.61 (1H, d, J = 1.8 Hz, 2-H), 6.71 (1H,
d, J = 7.9 Hz, 5-H). δC (100 MHz; CDCl3) 34.9 (C-7), 39.2 (C-7′), 41.4 (C-8′), 46.6 (C-8), 56.2 (3′-OCH3),
61.0 (4′-OCH3), 71.4 (C-9′), 101.2 (OCH2O), 105.7 (C-2′), 108.3 (C-5), 109.6 (C-2), 122.4 (C-6), 131.5
(C-1), 133.8 (C-1′), 137.0 (C-4′), 146.7 (C-4), 148.1 (C-3), 153.5 (C-3′), 178.5 (C-9). IR: νMAX (film)/cm−1;
2938, 1763, 1590, 1489, 1443, 1241, 1122, 1011, 927, 813, 732. HRMS (ESI+) Found [M + Na]+ 423.1400;
C22H24NaO7 requires 423.1414. Values are in agreement with literature data [55].
(±)-4′-O-Benzyl haplomyrfolin (1bd). Using general procedure C: Lactone 4bd (0.18 g, 0.38 mmol) and
a reaction time of 20 min to give the triol 38bd (0.18 g, quant.) as a cloudy oil. Then using general
procedure D: Triol 38bd (0.18 g, 0.38 mmol) and a reaction time of 20 min to give lactol 39bd (0.13 g,
76%) as a white solid which was used without further purification. Then using general procedure
E: Lactol 39bd (0.13 g, 0.28 mmol) and a reaction time of 2 h. The crude product was purified by
column chromatography (3:1, hexanes, ethyl acetate) to give the title compound 1bd (0.12 g, 94%) as
a colourless oil. Rf = 0.65 (1:1, hexanes, ethyl acetate). δH (400 MHz; CDCl3) 2.43–2.64 (4H, m, 8, 7′,
8′-H), 2.84 (1H, dd, J = 14.1, 7.0 Hz, 7-HA), 2.94 (1H, dd, J = 14.1, 5.1 Hz, 7-HB), 3.83 (3H, s, 3′-OCH3),
3.87 (1H, dd, J = 9.1, 7.2 Hz, 9′-HA), 4.14 (1H, dd, J = 9.1, 7.0 Hz, 9′-HB), 5.12 (2H, s, 7′′-H), 5.91 (1H, d,
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J = 1.4 Hz, OCHAO), 5.93 (1H, d, J = 1.4 Hz, OCHBO), 6.49–6.52 (2H, m, 2′, 6′-H), 6.57 (1H, dd, J = 7.9,
1.8 Hz, 6-H), 6.59 (1H, d, J = 1.8 Hz, 2-H), 6.70 (1H, d, J = 7.9 Hz, 5-H), 6.78 (1H, d, J = 8.5 Hz, 5′-H),
7.27–7.32 (1H, m, 4′′-H), 7.33–7.38 (2H, m, 3′′-H), 7.41–7.45 (2H, m, 2′′-H). δC (100 MHz; CDCl3) 34.8
(C-7), 38.4 (C-7′), 41.3 (C-8′), 46.5 (C-8), 56.0 (3′-OCH3), 71.2 (C-7′′), 71.3 (C-9′), 101.1 (OCH2O), 108.3
(C-5), 109.6 (C-2), 112.4 (C-2′), 114.4 (C-5′), 120.7 (C-6′), 122.4 (C-6), 127.4 (C-2′′), 128.0 (C-4′′), 128.6
(C-3′′), 131.2 (C-1), 131.5 (C-1′), 137.2 (C-1′′), 146.6 (C-4), 147.1 (C-4′), 148.0 (C-3), 149.9 (C-3′), 178.6
(C-9). IR: νMAX (film)/cm−1; 2907, 1765, 1504, 1489, 1443, 1244, 1140, 1034, 911, 809, 730. HRMS (ESI+)
Found [M + Na]+ 469.1612; C27H26NaO6 requires 469.1622.
(±)-Haplomyrfolin (1be). Using general procedure F: Lactone 1bd (0.119 g, 0.27 mmol) and a reaction
time of 1.5 h. The crude product was purified by column chromatography (1:1 hexanes, ethyl acetate)
to give the title compound 1be (0.086 g, 91%) as a colourless oil. Rf = 0.47 (1:1 hexanes, ethyl acetate).
δH (400 MHz; CDCl3) 2.43–2.63 (4H, m, 8, 7′, 8′-H), 2.84 (1H, dd, J = 14.1, 7.0 Hz, 7-HA), 2.95 (1H, dd,
J = 14.1, 5.2 Hz, 7-HB), 3.83 (3H, s, 3′-OCH3), 3.86 (1H, dd, J = 9.1, 7.2 Hz, 9′-HA), 4.13 (1H, dd, J = 9.1,
7.0 Hz, 9′-HB), 5.63 (1H, s, 4′-OH), 5.91 (1H, d, J = 1.4 Hz, OCHAO), 5.92 (1H, d, J = 1.4 Hz, OCHBO),
6.46 (1H, d, J = 1.9 Hz, 2′-H), 6.51 (1H, dd, J = 8.0, 1.9 Hz, 6′-H), 6.58 (1H, dd, J = 7.8, 1.7 Hz, 6-H), 6.60
(1H, d, J = 1.7 Hz, 2-H), 6.70 (1H, d, J = 7.8 Hz, 5-H), 6.80 (1H, d, J = 8.0 Hz, 5′-H). δC (100 MHz; CDCl3)
34.8 (C-7), 38.3 (C-7′), 41.4 (C-8′), 46.5 (C-8), 55.9 (3′-OCH3), 71.3 (C-9′), 101.1 (OCH2O), 108.3 (C-5),
109.6 (C-2), 111.2 (C-2′), 114.6 (C-5′), 121.4 (C-6′), 122.4 (C-6), 129.9 (C-1′), 131.5 (C-1), 144.5 (C-4′), 146.5
(C-4), 146.7 (C-3′), 147.9 (C-3), 178.7 (C-9). IR: νMAX (film)/cm−1; 3468, 2921, 1762, 1515, 1489, 1443,
1243, 1035, 907, 725. HRMS (ESI+) Found [M + Na]+ 379.1151; C20H20NaO6 requires 379.1152. Values
are in agreement with literature data [56].
4. Biological Assay Methods
4.1. Cell Culture
Jurkat E61 cells (ECACC) were maintained at 37 ◦C in RMPI media (Lonza) supplemented with
10% Foetal Bovine Serum (FBS) (Lonza) (10% RPMI) in a humidified environment of 5% CO2 in air.
Cells were routinely passaged to maintain a cell density of between 1 × 105 and 1 × 106/mL.
4.2. Drug Treatments
Lignans were diluted to stock concentrations of 30 mM in DMSO and further diluted to the
working concentration in 10% RPMI. The DMSO diluted to the appropriate concentration was used as
the vehicle-control. Cells were seeded at the relevant density per well depending upon the assay to be
performed, in 100 μL volume of fresh 10% RPMI. Trypan blue exclusion method was used to assess
viability prior to experiments and cell viability was always >95%. Lignans were added at 100 μL/well
to the relevant wells. Cells were incubated at 37 ◦C in a humidified environment of 5% CO2 in air
for the indicated times. Dead cell controls were included in subsequent viability assays by treating
cells with 50 μL/well EtOH (final concentration 50%) for 48 h. Apoptotic controls were included in
subsequent apoptosis assays by exposing cells to a heat shock at 43 ◦C for 2 h. Positive controls for
cell cycle analysis were included by treating cells with 0.5 μM camptothecin for 4 h to induce cell
cycle arrest.
4.3. MTS Assay
Following treatments at a cell density of 1 × 105 cells/well, the samples were centrifuged at
500 g for 5 min and the supernatant was removed. A 100 μL/well volume of fresh 10 % RPMI was
added. A 20 μL volume of MTS solution (Promega, G1112) was added to each well and the plate
was incubated in the dark for 1 h at 37 ◦C. The absorbance was detected at 490 nm on a Synergy HT
plate reader.
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4.4. Annexin V/PI Assay
Following treatments at a cell density of 1 × 105 cells/well, the samples were centrifuged at 500 g
for 5 min and the supernatant was removed. Cells were washed in 500 μL DPBS before addition
of 100 μL of 1 × Annexin V binding buffer (BD Biosciences). A 5 μL volume of FITC-conjugated
Annexin V (BD Biosciences) and 10 μL Propidium Iodide (BD Biosciences) was added and the cells
were incubated in the dark for 20 min. Samples were diluted by addition of 400 μL 1 × Annexin
V binding buffer before immediate analysis on an Accuri C6 Flow Cytometer (Becton Dickinson,
Oxford, UK).
4.5. Cell Cycle Analysis
Following treatments at a cell density of 5 × 106/well, cells were centrifuged at 500 g for 5 min
and the supernatant was removed. The remaining cell pellet was vortexed while simultaneously
adding 500 μL of 70% ethanol dropwise, fixing the cells and minimising clumping. The samples were
incubated at 4 ◦C for 30 min, and then centrifuged at 1000 g for 5 min. The supernatant was discarded,
and the pellet was re-suspended in 500 μL DPBS. The samples were centrifuged again at 1000 g for
5 min, and the supernatant was removed a final time. The pellet was resuspended in 50 μL RNase
A (100 μg/mL stock; Roche, UK) and 200 μL PI (50 μg/mL stock; Sigma, UK). The samples were
analyzed on an Accuri C6 flow cytometer (Becton Dickinson) and data was modelled and interpreted
using ModFit Analysis Software, version 5.0 (Verity Software House).
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Abstract: Herein, we present an expeditous synthesis of bioactive aryldihydronaphthalene lignans
(+)-β- and γ-apopicropodophyllins, and arylnaphthalene lignan dehydrodesoxypodophyllotoxin.
The key reaction is regiocontrolled oxidations of stereodivergent aryltetralin lactones, which were
easily accessed from a nickel-catalyzed reductive cascade approach developed in our group.
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1. Introduction
Lignans are a class of secondary metabolites in various plants, and most of them
have demonstrated interesting biological properties [1,2], thus attracting the attention of the
synthetic chemists [3,4]. Some of 2,7′-cyclolignans such as 7,8,8′,7′-tetrahydronaphthalene (THN),
7′,8′-dihydronaphthalene (DHN) and 7′-arylnaphthalene types are exemplified in Scheme 1a. Hong
and co-workers used organocatalytic domino Michael–Michael–aldol reactions to construct THN
skeleton of galbulin and realized its first enantioselective synthesis [5]. Barker and co-workers
completed the first asymmetric synthesis of (−)-cyclogalgravin based on a key construction of C2–C7′
bond from in situ generated quinoid intermediate [6]. Notably, the other two structurally distinct class
of lignans could also be obtained from a common precursor in their syntheses. Ramana et al. proposed
a dehydrative cyclization of an aldehyde intermediate to build the DHN unit of sacidumlignan B,
whose subsequent aromatization led to the synthesis of sacidumlignan A [7]. We were also involved in
this fascinating field and achieved the synthesis of these three molecules through Ueno–Stork radical
cyclization and Friedel–Crafts reaction [8,9]. However, almost all of the above syntheses applied
stepwise strategies (i.e., a sequence of C2–C7′, C8–C8′, then C1–C7 bonds formation in our previous
routes) for construction of the central core [10].
2. Results and Discussion
Recently, we completed a new synthesis of podophyllotoxin [11,12], an aryltetralin lignan used
as building block for the chemotherapeutic drugs etoposide and teniposide. The key reaction is
a Ni-catalyzed reductive tandem coupling [13–19] of dibromide A that led to the simultaneous
construction of C8–C8′ and C1–C7 bonds in THN framework of B (Scheme 1b). We envision that this
Molecules 2018, 23, 3037; doi:10.3390/molecules23113037 www.mdpi.com/journal/molecules125
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aryltetralin lactone could serve as an advanced intermediate for the unified synthesis of the titled
arylnaphthalene, DHN and THN lignans C, by means of the regioselective late-stage oxidation. Herein,
we disclosed the preliminary results.
Scheme 1. (a) Several arylnaphthalene lignans and their DHN and THN derivatives; (b) Our
synthetic logic.
Starting from the commercially available 6-bromopiperonal and 3,4,5-trimethoxyphenyl bromide,
the chiral β-bromo acetal 1 was straightforwardly prepared as in gram-scale according to a known
route [11]. Under a fully intramolecular reductive nickel-catalysis ligated by ethyl crotonate (Scheme 2),
diastereodivergent (+)-deoxypicropodophyllin (2) and (+)-isodeoxypodophyllotoxin (3) were obtained
in 50% overall yield after a conversion of acetal moiety to the corresponding lactone. With aryltetralin
lactones 2 and 3 in hand, the designed regiocontrolled oxidation in central aliphatic ring could be
executed (vide infra).
 
Scheme 2. Reductive tandem cyclization for tetralin lactones.
First of all, the increase of an unsaturation degree at either C8–C8′ or C7′–C8′ location was pursued
in order to get (+)-β-apopicropodophyllin (5) and (+)-γ-apopicropodophyllin (6) quickly. As shown
in Scheme 3, the introduction of a phenylselenyl group at C8′ position of (+)-deoxypicropodophyllin
(2) was done by an initial enolization and subsequent quench with phenylselenyl bromide (PhSeBr)
at −78 ◦C. The generated products as two diastereoisomers (4a and 4b) were separated by column
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chromatography on silica gel in 95% overall yield. The α-phenylselenide 4a is supposed to adopt a
pseudo-boat conformation, where the hydrogen atom at C8 is arranged cis to the -SePh. The requisite
syn-elimination of phenylselenoxide in situ generated from oxidation of 4a [20], eventually provided
(+)-β-apopicropodophyllin (5) with in vivo insecticidal activity against the fifth-instar larvae of
Brontispa longissima [21]. Its 1H NMR spectral data (Table S2) and optical rotation were in agreement
with the reported data by Toste and Meyers [22,23]. The structure was later unambiguously confirmed
by its single-crystal analysis (Figure 1) [24]. In contrast, the hydrogen atom at C7′ is oriented at
cis-position of C8′-PhSe in the favored half-chair conformer of β-phenylselenide 4b. Thus, a double
bond within C7′–C8′ was formed upon the subjection of 4b to m-CPBA, therefore affording to
(+)-γ-apopicropodophyllin (6) in 88% yield. As shown in Table S3, 1H NMR spectra of the synthetic 6
was accord with the literature [25].
Syn-elimination






Scheme 3. Regiodivergent oxidation of (+)-deoxypicropodophyllin (2).
 
Figure 1. X-ray crystal structure of (+)-β-apopicropodophyllin (5), selected H atoms have been omitted
for clarity.
Next, the potential aromatization within tetralin lactone was investigated. As shown in Scheme 4,
one-step conversion of (+)-isodeoxypodophyllotoxin (3) to dehydrodesoxypodophyllotoxin (7) was
realized in 56% yield promoted by a mixture of N-bromosuccinimide (NBS) and dibenzoyl peroxide
(BPO) in refluxing CCl4. The plausible mechanism of this tandem reaction would be radical
bromination [26] catalyzed by BPO occurs firstly, and a fast elimination of the resulting labile
benzylbromide followed by further oxidation, providing the central benzene ring in 7. 1H NMR
spectra data (Table S4) of synthetic dehydrodesoxypodophyllotoxin was consistent with previous
report [27].
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Scheme 4. One-step conversion of tetralin to arylnaphthalene skeleton.
3. Materials and Methods
3.1. General Procedure
For product purification by flash column chromatography, SiliaFlash P60 (particle size: 40–63 μm,
pore size 60A) and petroleum ether (bp. 60–90 ◦C) were used. All solvents were purified and
dried by standard techniques and distilled prior to use. All of experiments were conducted under
an argon or nitrogen atmosphere in oven-dried or flame-dried glassware with magnetic stirring,
unless otherwise specified. Organic extracts were dried over Na2SO4 or MgSO4, unless otherwise
noted. 1H and 13C-NMR spectra were taken on a Bruker AM-400, AM-600 and Varian mercury
300 MHz spectrometer with TMS as an internal standard and CDCl3 as solvent unless otherwise noted.
HRMS were determined on a Bruker Daltonics APEXII 47e FT-ICR spectrometer with ESI positive ion
mode. The X-ray diffraction studies were carried out on a Bruker SMART Apex CCD area detector
diffractometer equipped with graphite-monochromated Cu-Kα radiation source. Melting points were
measured on Kofler hot stage and are uncorrected.
3.2. Synthesis of C9a-PhSe-Deoxypicropodophyllin (4a and 4b)
A solution of 2 [11] (100 mg, 0.25 mmol) in THF (8 mL) under argon was cooled to −78 ◦C,
followed by the addition of freshly prepared LDA (0.5 mmol, 2.0 equiv). The stirred solution was
maintained at this temperature for 20 min, and a solution of PhSeBr (118 mg, 0.5 mmol, 2.0 equiv)
in THF (3 mL) was then added. The resulting mixture was stirred for 20 min at −78 ◦C, and then
quenched by water (1 mL). The mixture was extracted with EtOAc (2 × 30 mL). The combined
organic layers were washed with water (2 × 8 mL) and brine (8 mL) respectively, dried over Na2SO4,
filtered and concentrated under reduced pressure. The crude product was purified by flash column
chromatography (petroleum ether/EtOAc = 4:1 → petroleum ether/EtOAc =2:1) on silica gel to afford
4a (90 mg, 65% yield) as a white solid and 4b (42 mg, 30% yield) as a white solid. Characterization data
for 4a: Rf = 0.42 (petroleum ether/EtOAc = 1:1); 1H-NMR (400 MHz, CDCl3): δ = 7.48 (d, J = 8.0 Hz,
1H), 7.47 (d, J = 8.0 Hz, 1H), 7.40 (t, J = 7.2 Hz, 1H), 7.28 (t, J = 7.2 Hz, 2H), 6.68 (s, 1H), 6.61 (s, 2H), 6.56
(s, 1H), 5.88 (d, J = 1.2 Hz, 1H), 5.87 (d, J = 1.2 Hz, 1H), 4.49 (s, 1H), 4.10 (dd, J = 9.2, 7.6 Hz, 1H), 3.85
(s, 3H), 3.84 (s, 6H), 3.75 (dd, J = 5.2, 4.0 Hz, 1H), 3.48 (dd, J = 16.4, 8.4 Hz, 1H), 3.32–3.27 (m, 1H), 2.62
(d, J = 16.4 Hz, 1H) ppm; 13C-NMR (100 MHz, CDCl3): δ = 176.7, 152.9 (2C), 147.2, 146.9, 137.7 (2C),
137.3, 134.6, 131.8, 129.9, 129.1 (2C), 126.1, 126.0, 109.3, 108.8, 106.8 (2C), 101.0, 73.3, 60.9, 56.2 (2C), 53.9,
51.3, 41.5, 35.0 ppm; HRMS (ESI): calcd. for C28H30NO7Se+ [M + NH4]+: 572.1182, found: 572.1186.
3.3. Synthesis of (+)-β-Apopicropodophyllin (5)
To a stirred solution of 4a (90 mg, 0.076 mmol) in CH2Cl2 (4 mL) was added m-CPBA (77%, 34.0 mg,
0.15 mmol, 2.0 equiv) at 0 ◦C followed by the addition of NaHCO3 (12.6 mg, 0.15 mmol, 2.0 equiv).
After stirring for 15 min, the reaction mixture was extracted with CH2Cl2 (3 × 20 mL). The combined
organic layers were washed with saturated aqueous NaHCO3 (4 × 5 mL), water (5 mL) and brine (5 mL)
respectively, then dried over Na2SO4, filtered and concentrated under reduced pressure. The resulting
residue was purified by flash column chromatography (petroleum ether/EtOAc = 3:1 → petroleum
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ether/EtOAc = 1:1) on silica gel to afford (+)-β-apopicropodophyllin (5) (56 mg, 88% yield) as a
white solid. Rf = 0.37 (petroleum ether/EtOAc = 1:1); [α]
20
D = +92.04 (c = 1.00, CHCl3), [α]
23
D = +65.1
(c = 2.72, CHCl3)] [23]; m.p. 188–190 ◦C; 1H-NMR (300 MHz, CDCl3): δ = 6.72 (s, 1H), 6.63 (s, 1H),
6.37 (s, 2H), 5.954 (s, 1H), 5.947 (s, 1H), 4.90 (d, J = 17.4 Hz, 1H), 4.82 (d, J = 17.4 Hz, 1H), 4.81 (s, 1H),
3.86 (dd, J = 22.2, 3.9 Hz, 1H), 3.79 (s, 3H), 3.78 (s, 6H), 3.65 (dd, J = 22.2, 3.6 Hz, 1H) ppm; 13C-NMR
(100 MHz, CDCl3): δ = 172.2, 157.2, 153.2 (2C), 147.3, 147.0, 138.3, 137.1, 129.7, 128.2, 123.8, 109.6, 107.7,
105.6 (2C), 101.3, 71.0, 60.8, 56.2 (2C), 42.8, 29.2 ppm.
This product (5 mg) was dissolved in EtOAc (1 mL) and hexane (2 mL). After three days, colorless
single crystals were obtained by slow evaporation of solvents at room temperature.
3.4. Synthesis of (+)-γ-Apopicropodophyllin (6)
To a stirred solution of 4b (42 mg, 0.16 mmol) in CH2Cl2 (3 mL) was added m-CPBA (77%, 72.0 mg,
0.32 mmol, 2.0 equiv) at 0 ◦C followed by the addition of NaHCO3 (26.9 mg, 0.32 mmol, 2.0 equiv).
After stirring for 15 min, the reaction mixture was extracted with CH2Cl2 (3 × 20 mL). The combined
organic layers were washed with saturated aqueous NaHCO3 (4 × 5 mL), water (5 mL) and brine (5 mL)
respectively, then dried over Na2SO4, filtered and concentrated under reduced pressure. The resulting
residue was purified by flash column chromatography (petroleum ether/EtOAc = 3:1 → petroleum
ether/EtOAc = 1:1) on silica gel to afford (+)-γ-apopicropodophyllin (6) (26 mg, 88% yield) as a white
solid. Rf = 0.23 (petroleum ether/EtOAc = 1:1); [α]
20
D = +27.03 (c = 1.00, CHCl3), [α]
19
D = +25.0 (c = 1,
CHCl3)] [28]; m.p. 206–208 ◦C; 1H-NMR (300 MHz, CDCl3): δ = 6.77 (s, 1H), 6.52 (brs, 3H), 5.97 (s, 2H),
4.70 (t, J = 8.7 Hz, 1H), 4.01 (t, J = 8.7 Hz, 1H), 3.92 (s, 3H), 3.83 (s, 6H), 3.39 (td, J = 15.9, 8.7 Hz, 1H), 2.94
(dd, J = 15.0, 6.9 Hz, 1H), 2.79 (dd, J = 15.6, 15.3 Hz, 1H) ppm; 13C-NMR (150 MHz, CDCl3): δ = 168.1,
152.7, 148.7 (2C), 147.3, 146.8, 138.1, 130.7 (2C), 129.9, 129.6, 119.9, 109.5, 108.6, 101.6 (2C), 70.9, 61.0,
56.2 (2C), 35.8, 33.3 ppm.
3.5. Synthesis of Dehydrodesoxypodophyllotoxin (7)
An oven-dried 10 mL round-bottom flask was charged with NBS (17.8 mg, 0.1 mmol, 1.0 equiv)
and BPO (2.4 mg, 0.01 mmol, 0.1 equiv) at room temperature under argon, followed by the addition
of a solution of 3 (40.0 mg, 0.1 mmol) in CCl4 (3 mL). The reaction mixture was stirred for 2 h at
82 ◦C. The reaction solvent was then evaporated in vacuo. The resulting residue was purified by
flash column chromatography (petroleum ether/EtOAc = 5:1 → petroleum ether/EtOAc = 2:1) on
silica gel to afford dehydrodesoxypodophyllotoxin (7) (22.2 mg, 56% yield) as a white solid. Rf = 0.45
(petroleum ether/EtOAc = 1:1); m.p. 271–273 ◦C; 1H-NMR (400 MHz, CDCl3): δ = 7.70 (s, 1H), 7.21
(s, 1H), 7.12 (s, 1H), 6.55 (s, 2H), 6.09 (s, 2H), 5.38 (s, 2H), 3.97 (s, 3H), 3.84 (s, 6H) ppm; 13C-NMR
(150 MHz, CDCl3): δ = 169.6, 153.0 (2C), 150.0, 148.7, 140.5, 139.8, 137.8, 134.6, 130.34, 130.30, 119.1,
118.7, 107.3 (2C), 103.8, 103.6, 101.8, 68.0, 61.0, 56.1 (2C) ppm.
4. Conclusions
In summary, a two-phase strategy was developed for the unified synthesis of
(+)-β-apopicropodophyllin (5), (+)-γ-apopicropodophyllin (6), and dehydrodesoxypodophyllotoxin
(7). In phase I, their tetrahydronaphthalene (THN) backbone was constructed by a Ni-catalyzed
reductive cascade. In phase II, regioselective oxidation of stereodivergent tetralin lactone (2 and 3)
gave arylnaphthalene lignan 7 and its dihydronaphthalene (DHN) congeners (5 and 6) efficiently.
Supplementary Materials: The following are available online. Copies of 1H-, 13C-NMR, and crystallographic
information files (CIFs) for 5.
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Abstract: Numerous oxidative transformations of lignan structures have been reported in the literature.
In this paper we present an overview on the current findings in the field. The focus is put on transformations
targeting a specific structure, a specific reaction, or an interconversion of the lignan skeleton. Oxidative
transformations related to biosynthesis, antioxidant measurements, and total syntheses are mostly
excluded. Non-metal mediated as well as metal mediated oxidations are reported, and mechanisms
based on hydrogen abstractions, epoxidations, hydroxylations, and radical reactions are discussed for
the transformation and interconversion of lignan structures. Enzymatic oxidations, photooxidation,
and electrochemical oxidations are also briefly reported.
Keywords: lignans; oxidation
1. Introduction
Lignans constitute a group of natural phenolics found in plant species. They have been identified in
around 70 families in the plant kingdom, for example in trees, grasses, grains, and vegetables. Lignans are
found in roots, rhizomes, stems, leaves, seeds, and fruits, from where they are usually isolated through
extraction with an appropriate solvent. They have a diverse structure built up from two phenyl propane
units with different degrees of oxidation in the propane moiety and different substitution patterns in the
aromatic rings. Lignans have been shown to have a wide range of biological activities such as antibacterial
and insecticidal effects in plants, and anti-cancerous, antiviral, anti-inflammatory, immunosuppressive,
anti-diabetic, and antioxidant properties in mammals [1–6]. In addition, many lignans have been
found in different foods and feeds, and have been associated with health benefits, such as antioxidant
activity and anticancer properties [7–10]. The structure and occurrence of lignans have previously
been extensively reviewed in the literature. In some of these reviews the chemical transformations and
oxidative degradations have partially been described, mainly for determination of structures [6,11–16].
More recently, advances in the chemistry of lignans, including transformations and interconversions of
different lignans, were reviewed by Ward [17]. Although synthetic modifications and interconversions
have been extensively reported for lignans, a specific overview on oxidative transformations has not
been published. Oxidative transformations of lignan structures can be found in various fields: in total
synthesis, in biosynthesis, in antioxidant studies, in oxidative degradations, and as part of targeted
chemical transformations. In this paper, we report an overview on oxidative transformations of lignan
structures, where the focus is put on transformations targeting a specific structure, a specific reaction,
or an interconversion of the lignan skeleton. Oxidative transformations related to studies of biosynthetic
routes, antioxidant activities, and total syntheses for coupling phenylpropane units (creating the lignan
skeleton) are mostly excluded. The purpose of this paper is to exemplify the transformations induced
by different reagents or oxidation methods (Table 1). The presented text, figures, and schemes should
be taken as representative examples rather than a comprehensive review of the literature. However,
the most relevant literature in the field is cited.
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Table 1. Various methods for oxidative transformations of lignans.
Non-Metal Ox. Oxidative Transformation Yields Ref.





mCPBA Epoxidation, Baeyer-Villiger oxidation,
oxidation of ethoxy-THF-lignans to lactones
~70–90% [29,38–42]
peroxyl radical (ROO.) Antioxidative radical scavenging to phenoxyl




Same as above No data [46–63]
DPPH Same as above, radical 5-5 couplings to dimers
and oxidation of benzylic alcohol to ketone
No data [6,51,64–67]
TEMPO Oxidation of benzylic alcohol to ketone 60% [68]
BAIB and PIFA phenolic hydroxyl oxidation to quinone type
structures, Ar-Ar-coupling to
dibenzocyclooctadienes, nucleophilic attack at
ipso- or benzylic position
~10–80% [69–74]





Benzylic alcohol oxidation to carbonyl,
9,9′-diol oxidation to lactols
>90% [80–89]




N-Bromosuccinimide (NBS) Brominations (arylic or benzylic), benzylic CH2
to ketone, benzylic ring closure and
aromatization
75–90% [35,101–107]
Dimethyldioxirane (DMDO) Oxidative ring opening of furan rings ~80% [108]
Nitrobenzene Oxidative degradation to vanillin and
vanillic acid
80–100% [109–111]
Metal-Mediated Ox. Oxidative Transformation Yields Ref.
Cr-(VI)
(CrO3, PCC, PDC)
Oxidation of benzylic alcohols to ketones,




Pd, Au Oxidation of benzylic alcohols in presence of
free phenolic into (mainly) ketone
No data [121–126]
MoOPH α-Hydroxylation ~25–95% [113,127–131]
MoCl5 Ar-Ar-coupling to dibenzocyclooctadienes ~50–90% [132,133]
VoF3; V2O5; Tl2O3; RuO5 Ar-Ar-coupling to dibenzocyclooctadienes,
benzylic ring closure
~50–100% [134–147]
MTO (catalyst) Aromatic demethylation and quinone
formation and simultaneous benzylic alcohol
oxidation to ketones, benzylic cleavage,
benzylic hydroxylation, oxidation of benzylic
alcohol to ketone
~40–100% [148–150]
Pb(OAc)4 Benzylic acetoxylation ~30–70% [151]
CeCl3 α-Hydroxylation 71% [152]
Other Oxidations Oxidative Transformation Yields Ref.
Enzymatic ox.
peroxidase Benzylic ring closure 37–99% [153–155]
HRP Radical 4-O-5 coupling 3.6% [156]
SDH Oxidation of diol to lactone No data [157]
P450/CPR1 Arylic hydroxylation and rearrangement No data [158]
CYP Benzylic hydroxylation 90% [159]
Electrochemical ox.
Demethylation, quinone formation, and
benzylic ring closure
No data [160]
Ar-Ar-coupling to dibenzocyclooctadiene >80% [161]
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2. Non-Metal-Mediated Oxidations
2.1. 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (or DDQ)
2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) has been used to promote benzylic
functionalization of lignans by abstraction of a hydride from the benzylic position. The benzylic cation
can then be a target for either intramolecular ring closure or nucleophilic attack. The nucleophilicity of
the solvent can direct the reaction towards either benzylic ring closure to aryltetralins, or to aryl-aryl
coupling to cyclooctadienes, or toward nucleophilic attack by the solvent. In the latter case, a nucleophilic
solvent such as AcOH can function as an oxygen donor. As an example, (−)-dehydroxycubebin was
oxidized by DDQ in AcOH, and reacted by either benzylic ring closure to an aryltetralin (1), or by
O-acetylation through nucleophilic attack at the benzylic position (2) [18] (Scheme 1). When the solvent
was changed to the more acidic and less nucleophilic trifluoroacetic acid (TFA), aryl-aryl coupling to
a dibenzocyclooctadiene (3) was favored [19–27].
 
Scheme 1. Oxidation of dehydroxycubebin by DDQ. AcOH promotes benzylic functionalization while
TFA promotes aryl-aryl coupling.
Another example of benzylic O-acetylation is shown in Scheme 2. Tomioka et al. reported that the
dibenzocyclooctadiene lignan known as (+)-isostegane could be O-acetylated at the benzylic position
by DDQ in acetic acid, forming (+)-steganacin (Scheme 2) [28].
 
Scheme 2. Benzylic O-acetylation of (+)-isostegane by 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone
(DDQ) in AcOH.
A DDQ/TFA-mediated reaction of an epoxy-lignan (5), formed through mCPBA epoxidation of
an olefinic lignan (4), did not form the cyclooctadiene as expected. Instead, TFA-induced epoxide
opening and methyl or benzyl group rearrangement to two intermediates preceded DDQ mediated
ring closure to 6 and 7 (Scheme 3) [29]. One intermediate underwent the previously described ring
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closure to a cyclooctadiene, while the other went through benzylic ring closure to a cyclohexanone,
with subsequent ring closure to a benzofuran.
 
Scheme 3. TFA- and DDQ-mediated rearrangement and oxidative ring closure of an epoxide lignan.
DDQ has also been used for benzylic dehydrogenation of lignan structures to olefins, and in some cases
further aromatization to naphthalene type lignans [23,30–32]. One example of benzylic olefin formation
is visualized in Scheme 4 by the DDQ oxidation of the natural lignan hydroxymatairesinol (HMR) [33,34].
Due to different stereoelectronic properties at the benzylic alcohol for the hydroxymatairesinol epimers,
the oxidation reaction resulted in different major products, of which oxomatairesinol had the highest yield.
A range of minor products, which are not shown here, were also formed in the reactions.
 
Scheme 4. Oxidation of hydroxymatairesinol (HMR) by DDQ is dependent on the stereochemistry of
the benzylic alcohol position. The major products are shown here. A range of minor products were
also formed in the reactions.
An example of DDQ-mediated aromatization of lignans is shown in Scheme 5, for the aromatization
of isodeoxypodophyllotoxin [35].
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Scheme 5. DDQ-mediated aromatization of isodeoxypodophyllotoxin.
When gmelinol reacted with three equivalents of DDQ it underwent benzylic hydride abstraction and
C-C-bond rearrangement, followed by an oxidative ring opening of an ether bridge to form an aldehyde,
and finally, another benzylic hydride abstraction and formation of olefin (8) [36]. The reaction is visualized
in Scheme 6.
 
Scheme 6. Oxidation of gmelinol with three equivalents DDQ.
DDQ-mediated epimerization followed by nucleophilic ring closure at the benzylic position is
visualized in Scheme 7 on a lignan (9) synthesized from gmelinol [37]. The epimerization step may
go through benzylic hydride abstraction, leading to adjacent C-C bond cleavage and regeneration.
One epimer (10) is favored as it can undergo nucleophilic attack at the positively charged benzylic
position, forming product 11.
 
Scheme 7. DDQ-mediated epimerization and nucleophilic ring closure.
2.2. Meta-Chloroperoxybenzoic Acid (mCPBA)
Epoxidation of olefinic lignans with mCPBA has been reported, as previously shown in
Scheme 3 [29,38].
The Bayer-Villiger oxidation of ketones with mCPBA has also been reported for lignans.
The 3,7-dioxobicyclo[3,3,0]octane lignan 12 gave the corresponding dilactone product 13 (Scheme 8) [39,40].
In the total synthesis of taiwanin E, the last two steps consist of Baeyer-Villiger of an aldehyde (14) to the
corresponding formate (15), followed by hydrolysis by MeOH and K2CO3 to the alcohol (Scheme 9) [41].
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Scheme 8. Baeyer-Villiger oxidation of a diketone to a dilactone.
 
Scheme 9. Baeyer-Villiger oxidation of an aldehyde to the corresponding formate, which was further
hydrolyzed to the alcohol (taiwanin E).
In addition, mCPBA and Lewis acid mediated oxidation of an ethoxy-THF-lignan (16) to a lactone
(17) has been reported (Scheme 10) [42].
 
Scheme 10. Lewis acid and mCPBA mediated oxidation of an ethoxytetrahydrofuran to the corresponding lactone.
2.3. Oxidations by Peroxyl Radical
Radical scavenging of peroxyl radicals has been utilized for measuring antioxidant activity
for natural phenolics, including flavonoids [43,44] and lignans [45,46]. The antioxidant activity of
lignans is caused by their efficiency to scavenge radicals through hydrogen abstraction, forming
phenoxyl radicals. However, in the process, the lignan structure is oxidized and undergoes various
transformations. The highly antioxidant active lignan known as secoisolariciresinol was oxidized
by two ethyl linoleate peroxide radicals induced by azobisisobutyronitrile (AIBN) to a quinone-like
intermediate (18), which formed the lignan lariciresinol through trans-selective ring closure. As a side
reaction, a peroxyl radical also undertook radical coupling at the ipso-position of the phenoxyl radical
intermediate to 19 (Scheme 11) [45,46].
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Scheme 11. Peroxyl radical mediated oxidation of the lignan secoisolariciresinol.
2.4. Azo Compounds (AAPH, AIBN and ABTS)
2,2′-Azobis(2-amidinopropan) dihydrochloride (AAPH or ABAP), azobisisobutyronitrile (AIBN),
and 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) are radical initiators often used in
studies of oxidative stability of drugs and proteins, and of antioxidative activity in, among others,
food supplements and natural products [47–49]. These azo compounds undergo thermal degradation
under release of N2, and formation of two amidino propane (from AAPH) or isobutyronitrile (from
AIBN) radicals. These radicals can be transformed into other reactive radical species depending on the
reaction environment, for example by oxygen addition into peroxyl radicals [50].
Studies on antioxidant activity on a range of lignans have been done using AAPH, but only in
some cases the major oxidation products have been characterized [51–56]. Upon radical scavenging,
the lignans form phenoxyl radicals with their radical delocalized over the phenolic ring, followed by
radical coupling at either the ipso- or meta-position, or through the para phenoxyl radical. Alternatively,
a second radical reaction yields a quinone methide intermediate that reacts further through an ionic
mechanism, as shown in Scheme 11 for 18. As an example, secoisolariciresinol primarily reacted
through an aryl-aryl coupling, the so called 5-5 coupling, to dimer 20, and through phenoxyl or
meta-coupling with an amidino propane radical from AAPH to 21 and 22 respectively [57]. Further
hydrolysis of the meta-coupled amidino propane unit formed a furanone product (23). Lariciresinol
was also formed through a similar mechanism as described above (in Scheme 11) for peroxyl radicals.
Uniquely for secoisolariciresinol, an alternative radical scavenging path is possible. In this path,
an intermediate with alkoxyl radicals on one or both aliphatic hydroxyls, reacts through radical
coupling with another hydroxyl radical, forming dimer 24, or with water, forming hydroperoxides (25)
(Scheme 12).
As described in the previous chapter, AIBN has been used as a radical initiator for peroxyl radicals
in antioxidant studies on lignans [46]. As shown in Scheme 11, a possible antioxidant product is
formed through ipso-coupling of the lignan with an AIBN derived peroxide. AIBN has also been used
in total synthesis of a range of lignans, in aryl halide and Ru3SnH/AIBN initiated radical aryl-aryl
couplings [58], and in (Me3Si)3SiH/AIBN promoted radical conversion of a thionocarbonate to a lignan
lactone [59]. The radical initiator ABTS has also been used for antioxidant studies on lignans [60–63],
in the so called trolox equivalent antioxidant capacity (TEAC) assays [163]. However, no systematic
study on the formed oxidation products by AIBN or ABTS has been done, excluding the product 19.
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Scheme 12. Oxidation products formed from secoisolariciresinol after 2,2′-Azobis(2-amidinopropan)
dihydrochloride (AAPH)-mediated radical scavenging.
2.5. 2,2-Diphenyl-1-picrylhydrazyl (DPPH)
DPPH is a stable nitrogen centered free radical that is commonly used for antioxidant assays [64,65].
It has been vastly used for antioxidant assays on lignans [6,66]. Eklund et al. [51] and Smeds et al. [67]
investigated the antioxidant mechanism for the DPPH-initiated radical scavenging of different lignans.
Upon radical scavenging, the lignan intermediates underwent further radical abstractions or aryl
couplings to form dimers and oligomers by 5-5′- or 5-O-4′-couplings. An example is shown in
Scheme 13 for the reaction between HMR and DPPH. The two major reaction paths, following the
initial radical abstraction, were the intramolecular radical coupling forming an aryl-aryl dimer (26),
or a second radical abstraction and rearrangement to the lignan oxomatairesinol. Further coupling of
the dimeric structure also formed larger oligomers.
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Scheme 13. Reaction products of HMR with the free radical DPPH.
2.6. 2,2,6,6-Tetramethyl-1-piperidinyloxy (TEMPO)
The free radical organocatalyst TEMPO has been used in combination with a number of different
oxidants. For decades it has been used for oxidation of primary and secondary alcohols [164–166].
Surprisingly, TEMPO has not been widely used for the oxidation of lignans. However, a TEMPO-catalyzed
oxidation of the benzylic hydroxyl on podophyllotoxin to the corresponding ketone (podophyllotoxone)
has been reported (Scheme 14) [68]. Sodium periodate (NaIO4) was used as the oxidant in the presence
of NaBr as the co-catalyst.
 
Scheme 14. 2,2,6,6-Tetramethyl-1-piperidinyloxy (TEMPO)-mediated oxidation of the benzylic alcohol
of podophyllotoxin.
2.7. Hypervalent Iodine Reagents
The hypervalent iodine reagents BAIB, PIFA, IBX, DMP, and NaIO4 have been used in numerous
studies for mild oxidation of lignan structures. Efficient oxidation of primary and benzylic alcohols
into carbonyls, and phenolics into quinones have been reported. In addition, PIFA has been used for
arylic coupling to form benzocyclooctadienes.
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2.7.1. [Bis(acetoxy)iodo]benzene (BAIB or PIDA) and [Bis(trifluoroacetoxy)iodo]benzene (PIFA)
Diphyllin was oxidized by BAIB or PIFA through phenolic hydroxyl oxidation and nucleophilic
attack to a para-quinone type product (27) (Scheme 15) [69].
 
Scheme 15. Bis(trifluoroacetoxy)iodo benzene (PIFA) or Bis(acetoxy)iodo benzene (BAIB)-mediated
oxidation of diphyllin.
Lignans have also been ring closed to cyclooctadienes by PIFA in TFE (Scheme 16, upper reaction
path). The initial step is believed to be cyclization to a spirodienone intermediate (28) that undergoes
rearrangement to the cyclooctadiene product (29). In the cases where a lignan has a para-hydroxyl
group, in addition to the cyclooctadiene product, nucleophilic addition at ipso-position to 30 was
reported when using a more nucleophilic solvent such as methanol (Scheme 16, lower reaction
path) [70–73]. Other minor products were also formed.
 
Scheme 16. Lignan oxidation by PIFA in TFE or MeOH. With TFE as the solvent, the major reaction was
formation of the cyclooctadiene. In methanol, nucleophilic attack occurred as an additional reaction.
BAIB has also been utilized in the total synthesis of the natural lignan (±)-tanegool. The synthesis
started from ferulic acid. Firstly, a diarylcyclobutanediol intermediate (31) was made through a three-step
synthesis, involving para-nitro-esterification of the carboxylic acid, light induced [2 + 2] coupling,
and finally reduction of the para-nitro esters with LAH. This intermediate was then oxidatively ring
opened to a di-para-quinone methide (32) by BAIB in TFE and acetone, followed by 5-exo-trig cyclization,
by one of the hydroxyls, to 33. The cyclization was stereoselective due to steric hindrance of the bulky
aromatic rings. Finally, hydration by addition of water gave (±)-tanegool (Scheme 17) [74].
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Scheme 17. Total synthesis of (±)-tanegool involving BAIB mediated oxidative ring opening.
2.7.2. 3-Iodobenzoic Acid (IBX)
A green and selective demethylation reaction, using IBX as the primary oxidant, has been reported
for a number of lignans [75]. The substrates underwent oxidation to an o-quinone structure, followed
by reduction by sodium hydrosulfite to the catechol products. The reaction was selective towards
demethylation of phenolic methoxyl groups, leaving methyl esters intact. Scheme 18 shows the IBX
oxidation of a methyl ester norlignan (34). The reaction mixture was acetylated prior to purification
through silica gel column chromatography, giving 35. The same reaction was also successful on the
lignans hydroxymatairesinol (product yield= 55%), conidendrin (product yield= 70%), and lariciresinol
(product yield = 40%), yielding demethylated products.
 
Scheme 18. Selective 3-Iodobenzoic Acid (IBX)-mediated demethylation of a norlignan.
When an aliphatic or benzylic alcohol was present, alcohol oxidation to a carbonyl outweighed
the demethylation reaction [76]. Scheme 19 shows the selective oxidation of the benzylic alcohol in
a synthetic lignan (37) to the corresponding ketone (38). Alternatively, after removal of the protective
group, the product was oxidized to the diketone (36). Both of these reactions left the methoxyl groups
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intact [77]. Benzylic alcohol oxidations by IBX have also been reported on other lignans under similar
reaction conditions. Both epi-aristoligone and magnolone have been prepared by this method [78,79]
(Scheme 19).
 
Scheme 19. Oxidation of benzylic alcohols by IBX.
2.7.3. Dess-Martin Periodinane (DMP)
DMP has been reported as an agent for mild and selective oxidation of alcohols to aldehydes and
ketones. It has a higher solubility compared to its precursor IBX, and lacks the danger of explosion [80].
Oxidation of lignans baring benzylic or aliphatic hydroxyls to the corresponding ketones by DMP
have been described for various lignans [81–86]. An example is shown in Scheme 20 for oxidation of
isopicrosteganol to the atropisomers of picrosteganone [87]. Scheme 21a shows the oxidation of an
aliphatic primary diol (39) with DMP [88]. The reaction quantitatively forms a lactol known as cis-cubebin
through subsequent ring closure of the aldehyde. A similar ring closure has been reported by DMP
oxidation of a lignan baring a hydroxyl group and a carboxylic acid (40), forming a hydroxy-butyrolactone
(41, Scheme 21b) [89].
 
Scheme 20. Dess-Martin oxidation of the benzylic alcohol to the ketone.
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Scheme 21. Dess-Martin oxidation of (a) diol 39 to cis-cubebin; (b) hydroxyacid 40 to hydroxybutyrolactone 41.
2.7.4. Sodium Periodate (NaIO4)
In 1955, Adler et al. [90] reported NaIO4 mediated oxidation of guaiacyl or syringyl groups,
giving demethylation followed by formation of o-quinones. When a syringyl lignan (42) with aliphatic
hydroxyls was oxidized with NaIO4, it formed a 5-methoxyl o-quinone structure (43) with an ether
bridge to the ortho-position (Scheme 22) [91]. For lignans without aliphatic hydroxyls, as for 44,
the o-quinone structures were formed without the ether bridge (45, Scheme 23) [92–94].
 
Scheme 22. NaIO4-mediated oxidation to an ether bridged o-quinone structure.
 
Scheme 23. NaIO4-mediated oxidation of syringyl-lignan forming an o-quinone structure.
In the total synthesis of sylvone, the final steps consisted of the so-called Lemieux–Johnson
oxidation. A vicinal diol (47) was formed from an alkene (46) by OsO4, and then a NaIO4-mediated
oxidative cleavage of the vicinal diol gave the ketone (sylvone) and formaldehyde (Scheme 24) [95].
Lemieux-Johnson oxidation has been used on other lignans as well, giving ketone products in high
yields, as shown in Scheme 24 [96–100].
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Scheme 24. Lemieux-Johnson oxidation in the synthesis of sylvone (upper). Other lignan structures
where the same methodology has been applied (position for oxidation marked in red). The isolated
overall yields for both steps are given (lower).
2.8. N-Bromosuccinimide (NBS)
The Wohl-Ziegler reaction using NBS and a radical initiator to promote arylic or benzylic
bromination has been widely used, and also applied to lignans. Tomioka et al. reported a benzylic
bromination of (−)-stegane by NBS in CCl4, using benzoyl peroxide (BPO) as the radical initiator [101].
The formed 4-bromostegane yielded (−)-steganone after hydrolysis in aqueous THF, with an overall
yield of 85% (Scheme 25). By further acetylation, the desired product (−)-steganacin was obtained in
72% yield. Similar results were also achieved starting from stegane, a stereoisomer of (+)-isostegane [35].
 
Scheme 25. Wohl-Ziegler bromination of (+)-isostegane followed by hydrolysis to (−)-steganol.
By using a solvent with increased polarity, NBS can also be used to oxidize alcohols to aldehydes
and ketones [102]. This has been imposed on a photolytic NBS-mediated oxidation of lignan 48,
using dioxane as the solvent, forming a benzylic ketone (49) product in high yield (Scheme 26) [103].
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The reaction was proposed to proceed through bromination of the benzylic position, followed by
hydrolysis by water to a hydroxyl, and finally oxidation to the corresponding ketone.
 
Scheme 26. UV and NBS-mediated formation of the benzylic ketone (49).
When a similar method was applied to deoxypodophyllotoxin by a reaction with NBS in DMF,
only arylic bromination occurred (50, Scheme 27) [104]. To get the benzylic ketone, NBS-BPO oxidation
in CCl4 followed by hydrolysis was employed. The product epipodophyllotoxine was further
oxidized by pyridinium chlorochromate (PCC) to podophyllotoxone. Interestingly, in addition to
epipodophyllotoxine, the NBS-mediated reaction also yielded dehydroxypodophyllotoxin through
oxidative aromatization [105].
 
Scheme 27. Reaction of deoxypodophyllotoxin with NBS in DMF and CCl4, and further oxidation of
epipodophyllotoxine by PCC to the corresponding ketone (podophyllotoxone).
A similar naphthalene type lignan, known as justicidin B, was formed through NBS-treatment of
jatrophan in CCl4 (Scheme 28) [106,107]. The reaction includes trans-cis-isomerization, oxidative ring
closure, and dehydrogenation.
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Scheme 28. Synthesis of justicidin B by NBS-oxidation of jetrophan.
2.9. Dimethyldioxirane (DMDO or DMD)
A highly selective ring opening of asarinin to a diastereomerically pure product (52) when using
DMDO has been reported (Scheme 29) [108]. With one equivalent of DMDO, a selective ring opening
was achieved at the C-7 with R configuration, while the other furan ring remained unaltered (51).
DMDO was highly reactive towards the substrate, and the reaction needed to be performed at −20 ◦C.
If more than one equivalent of DMDO was used, the reaction was believed to go through a radical
mechanism yielding a mixture of products. However, after acetylation of the product, ring opening of
the second furan ring was achieved under the same conditions as previously used, only with a slightly
lower yield.
 
Scheme 29. Selective ring opening of asarinin by DMDO.
2.10. Nitrobenzene
Reports from the 1950s and 1960s show oxidative degradation of lignans to vanillin, vanillic acid,
and syringaldehyde, using nitrobenzene as the oxidant. Nitrobenzene oxidation of thujaplicatin and
dihydroxythujaplicatin, which are lignans found in western red cedar, gave vanillin as the sole product,
but only in approximately 2% yield [109,110]. Thujaplicatin methyl ether, with the meta-hydroxyl
protected as a methoxyl group, gave around 4% of both vanillin and syringaldehyde upon nitrobenzene
oxidation. Another study systematically oxidized a range of lignans under the following conditions:
180 ◦C, 60 ml of 2 M NaOH and 8 mL nitrobenzene per gram of lignan. The reaction time was 2 h.
The results are listed in Table 2 [111]. Similarly, nitrobenzene has also been used for the production of
vanillin from industrial lignin [167].
Table 2. Results of nitrobenzene-mediated oxidative degradation of lignans.
Lignan Vanillin % Vanillic Acid % Conversion %
Pinoresinol 31 9 81
Lariciresinol 63 5 100
Olivil 83 3 100
Matairesinol 15 2 100
Conidendrin 1 - -
Isoolivil 3 - -
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3. Metal-Mediated Oxidations
Oxidation of lignans using metal reagents could be divided into methods which use equimolar
amounts or catalytic amounts of the metal oxidant.
Catalytic reactions usually employ transition metals in heterogenous or homogenous conditions
and may be sensitive for different functional groups or heteroatoms. Equimolar metal oxidants
are widely used for all types of oxidation of lignans, and may involve one-electron oxidations or
ionic mechanisms.
3.1. Chromium (VI) Oxidations
There are many examples of Chromium (VI) oxidation of benzylic alcohols to ketones in different
lignan structures. Acyclic matairesinol derivatives, [112–114], cyclooctadiene structures (53–56) [87,115],
and podophyllotoxin derivatives have all been oxidized by CrO3 or PCC to the corresponding ketone
in relatively high yields (60–95%) [103,105,116,117] (Scheme 30).
 
Scheme 30. Oxidation of the benzylic alcohol to the corresponding ketone by Cr(VI) oxidants.
The dotted line corresponds to either the existence of the bond or the absence of the bond.
Cr(VI) mediated oxidation of primary alcohols in the lignan structures (57) has also been performed.
Oxidation by PCC or CrO3 led to lactones and carboxylic acids (58 and 59) [118–120] (Scheme 31).
There are no literature examples where chromium (VI) oxidants have successfully been used
for oxidation of lignans in the presence of free phenolic groups. Therefore, it can be concluded that
chromium mediated oxidations cannot be performed when phenolic groups are present in the structure.
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Scheme 31. Oxidation of the primary alcohols by Cr(VI) oxidants. The dotted line corresponds to
either the existence of the bond or the absence of the bond.
3.2. Palladium and Gold Mediated Oxidations
Oxidation of benzylic alcohols in the presence of free phenolic groups has been achieved
by transition metal catalysis. Hydroxymatairesinol (HMR) has been shown to undergo catalytic
dehydrogenation in mild conditions, using palladium on different supporting materials [121]
(Scheme 32). The major oxidation product was oxomatairesinol, however, hydrogen formed during
the dehydrogenation partially reacted with HMR by hydrogenolysis to give a significant amount
of matairesinol as a side product. Later on, it was shown that the same transformation could
also be performed using gold as a catalyst [121]. This method was much more selective towards
oxomatairesinol [123] and showed faster conversion in the presence of oxygen [124–126]. It is
noteworthy that one diastereomer of HMR gave oxomatairesinol much more selectively and with
higher conversion rates, but some conidendrin was also formed as a side product depending on the
conditions of the reaction.
 
Scheme 32. Palladium and gold catalyzed oxidation (dehydrogenation) of hydroxymatairesinol.
3.3. Molybdenium Mediated Oxidations
Hydroxylation at the α-position of butyrolactone lignans (60) has been performed directly
on the deprotonated ester by molecular oxygen [127,128]. However, this reaction proceeded
much faster and with better selectivity when molybdenum reagents were used. For this purpose,
oxodiperoxymolybdenum (pyridine) (hexamethylphosphoric triamide), MoO5·Py·HMPA(MoOPH),
also known as Vedejs’ reagent was used [113,129–131]. The stereoselectivity of the oxidation was very
much dependent on the base and the conditions used for the deprotonation. For example, if KHMDS was
used, the diastereomeric excess of one isomer was just 11% [113,130]. At the same time, when KHMDS
was used together with 18-crown-6, the selectivity raised to 64–99% [130,131] (Scheme 33).
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Scheme 33. Molybdenum catalyzed α-hydroxylation of butyrolactone lignans. The dotted line
corresponds to either the existence of the bond or the absence of the bond.
Molybdenum reagents have also been used for the preparation of 2-2′-cyclolignan structures.
Oxidative coupling of two aryls was performed with molybdenum pentachloride (MoCl5) [132,133].
The formation of the cyclooctadiene structure proceeded with excellent yields when the substrates
were non-functionalized aliphatics, but the yields decreased dramatically with increasing degree of
functionalization (Scheme 34).
 
Scheme 34. Ar-Ar oxidative coupling by MoCl5.
3.4. Vanadium, Thallium and Ruthenium Oxidations
Oxidative coupling has also been reported using V, Tl, and Ru. Vanadinum oxofluoride in the
presence of trifluoroacetic acid has shown good selectivity for the Ar-Ar oxidative coupling, forming
the cyclooctadiene lignan structure Isostegnane in high yield [134] (Scheme 35).
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Scheme 35. Ar-Ar oxidative coupling by VOF3.
Later it was also shown that thallium oxide (Tl2O3) or ruthenium oxide (RuO2) also work well as
oxidants in this reaction [135,136]. In fact, the reactions with ruthenium oxide showed higher yields
than reactions with thallium oxide, and vanadium oxofluoride reactions showed slightly lower yields
in the vast majority of the reported reactions [137–141]. High stereoselectivity was observed in most
cases (Scheme 36).
In many of these reactions, 2-7′-cyclolignans (74) and (77) were formed as minor products by
oxidation of the benzylic positions [140,142–144] (Scheme 37).
Interestingly, these reactions also proceeded in the presence of a free phenolic group. Yields up to
90% of 79 were obtained with matairesinol derivatives (78) [137,144–146] (Scheme 38).
It has also been reported by Planchenault et al. [145,147] that some metal oxidants other than Mo,
V, Ru, and Tl, such as Mn(OAc)3, Ce(OH)4, Re2O7, Fe(OH)(OAc)2, Co3O4, Ag(OCOCF3)2, CrO3, IrO2,
Pr6O11, SeO2, TeO2 etc., are possible to use for high yield preparations of cyclooctadiene-lignans.
 
Scheme 36. Ar-Ar oxidative coupling by VOF3, RuO2, or Tl2O3.
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Scheme 37. Ru, Tl, and V mediated oxidative cyclizations, forming 2-2′ and 2-7′cyclolignans.
 
Scheme 38. Oxidative coupling of matairesinol derivatives in the presence of free phenolic groups.
3.5. Methyl Trioxo-Rhenium (MTO) Catalyzed Oxidations
MTO catalyzed oxidations are interesting because of the diversity of possible transformations.
For example, podophyllotoxin and related structures (81) were oxidized to quinone structures (80 and 82)
by MTO [148] (Scheme 39). The reaction proceeded via demethylation, hydroxylations, and at the
same time, the benzylic alcohol was oxidized.
 
Scheme 39. Oxidation of podophyllotoxin and related structures by Methyl Trioxo-Rhenium (MTO).
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When asaranin and sesaminin were treated with MTO in similar conditions, the reaction resulted
in cleavage at the benzylic position to yield lactones (83 and 84) [149]. (Scheme 40).
 
Scheme 40. Oxidation of asaranin and sesaminin with MTO.
MTO catalyzed reactions with lariciresinol, matairesinol and hydroxymatairesinol resulted in
multiple benzylic hydroxylations, demethylations, oxidations, and cleavage of water [150] (Scheme 41,
structures 85–90).
 
Scheme 41. Oxidation of lariciresinol, matairesinol, and hydroxymatairesinol by MTO (major products shown).
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3.6. Other Metal Mediated Lignan Oxidations
Oxidative acetoxylation of matairesinol derivatives 91 and 93 has been accomplished using lead
acetate [151] (Scheme 42). In the reactions of the trans-butyrolactone derivatives (91), one diastereomer
of the 7-acetoxy product (92) was formed in high yield (60–73%). In the reaction of the cis lactone
(93) in the same conditions, the reaction resulted in a mixture of the 7-acetoxy product (94) and the
2′-7-cyclolignan (95).
 
Scheme 42. Lead acetate acetoxylation of matairesinol derivatives.
In addition to molybdenum initiated α-hydroxylation of esters, cerium trichloride catalyzed
α-hydroxylation has also been reported [152]. This method did not require deprotonation of theα-position.
Coordination of cerium to two α-carbonyls directed the position of the oxidation. (Scheme 43).
 
Scheme 43. Cerium trichloride mediated α-hydroxylation.
4. Other Oxidation Methods
4.1. Enzymatic Oxidations
Although enzymatic oxidations have mostly been studied for elucidation of biosynthetic routes
for many lignans, some attempts for targeted oxidations in vitro have been reported.
Laccases are copper-containing oxidases which have been used in, among others, wood, pulp,
and paper industries [168]. They play a key role in the dimerization of 4-hydroxycinnamic acids in
the biosyntheses of natural lignans [22,169]. Lignans have also been used as substrates in laccase
activity studies [170,171]. Laccase oxidations of lignans baring guaiacyl groups have led to efficient
polymerization [172–174]. The mechanism is believed to involve hydrogen atom abstraction to form
phenoxyl radicals, which then undergo intermolecular radical couplings [175].
Peroxidases are another group of oxidases which are also involved in the biosynthesis of lignans
through β-β coupling of two phenylpropanoid units [22,169,176,177]. They typically use hydrogen
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peroxide as cofactor in the oxidation reactions. A range of different peroxidases has been used for
selective ring closure of butyrolactone lignans (ex. 100) with up to quantitative yields of the aryltetralin
product (ex. 101) (Scheme 44). The reactions were performed with both immobilized cell cultures
and freely suspended plant cell cultures, and in absence of foreign hydrogen peroxide. Although the
reaction worked also in hexane, quantitative ring closure only occurred when the reaction was done in
B5 medium [153,154]. A similar reaction, but with H2O2 as a cofactor and ethanol as solvent, has also
been reported on the same lignan [155].
 
Scheme 44. Enzymatic, peroxidase-mediated ring closure.
A study of 4-O-5 units in softwood lignin used pinoresinol, among others, as a lignin model
compound. A pinoresinol dimer (102) coupled through a 4-O-5 bond, was synthesized using horseradish
peroxidase (HRP) and a hydrogen peroxide-urea complex (Scheme 45) [156]. Although sufficient for
the study, the isolated yield was very low.
 
Scheme 45. Peroxidase and H2O2- mediated 4-O-5-coupling.
In the biosynthesis of matairesinol, secoisolariciresinol is oxidized by an enzyme known as
secoisolariciresinol dehydrogenase (SDH) [178,179]. The reaction proceeds through an oxidative ring
closure of the diol to a lactol, and further oxidation to the lactone. In a study on the mode of catalysis
of SDH, the reaction was done in vitro, in a 5 mM scale, using isolated SDH and NAD+ in a Tris-HCl
buffer (Scheme 46) [157].
Enzymatic oxidation of sesamin has been studied in vitro, using yeast cells expressing some of
the enzymes found in sesame seeds [158]. Yeast strains containing a combination of a P450 enzyme
(CYP92B14) and Sesamum indicum cytochrome P450 oxidoreductase 1 (CPR1) in a synthetic defined (SD)
medium gave, via oxidation and rearrangement, sesaminol and sesamolin (Scheme 47), two lignans
found in sesame seeds.
Escherichia coli expressing human hepatic enzymes (CYP) have been used for the bioconversion
of deoxypodophyllotoxin into epipodophyllotoxin (Scheme 48) [159]. The objective of the study was
to investigate a possible route for industrial production of epipodophyllotoxin, which is a valuable
precursor for the pharmaceutical industry. High conversions were achieved, but the reactions were done
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in scales up to only 0.5 μmols. The high cost of up scaling was presented as the bottleneck that needed
to be tackled before a possible industrial production. A large scale isolation of deoxypodophyllotoxin,
from wild chervil (Anthriscus sylvestris), had already been accomplished [180].
 
Scheme 46. Enzymatic transformation of secolariciresinol into matairesinol.
 
Scheme 47. Enzymatic transformation of sesamin into sesaminol and sesamolin.
 
Scheme 48. Enzymatic bioconversion of deoxypodophyllotoxin into epipodophyllotoxin.
4.2. Electrochemical Oxidations
An acetoxy lignan (104) (Scheme 49) has been electrochemically oxidized to an o-quinone (105) at
a constant anode potential of 0.725 V using a platinum gauze working electrode, a platinum wire counter
electrode and an Ag/Ag+ reference electrode. The electrolyte was a solution of 0.01 M tetrabutylammonium
tetraboroflourate in acetonitrile, with solid potassium carbonate as a buffer. The product was not isolated,
but further reduced to a catechol, which was isolated and characterized [160].
Dibenzocyclooctadienes have been synthesized by electrochemical oxidation of butyrolactone
lignans (106) (Scheme 50). A platinum working electrode, a platinum counter electrode, a Ag/AgBr,
Et4NBr reference electrode, and a 0.1 M Et4NClO4-CH3CN supporting electrolyte was used. The products
(107) were obtained in high yields, more than 80% in both cases [161].
The lignan hibalactone has been electrochemically oxidized using voltammetry with
a three-electrode system, consisting of a glassy carbon working electrode, a platinum counter electrode,
156
Molecules 2019, 24, 300
and a Ag/AgCl counter electrode. The lignan showed a single quasi-reversible electro-oxidation, with
the alkene bonded to the lactone ring being the most probable site of oxidation [181]. The lignans
epi-guaiacin, guaiacin, verrucosin, and nectandrin B have been isolated from Iryanthera juruensis fruits
and electrochemically oxidized during an investigation of their antioxidative properties (Figure 1).
A glassy carbon working electrode, a carbon counter electrode, and a Ag/AgCl reference electrode
were used [182]. Honokiol and magnolol were electrochemically oxidized using an acetylene black
nanoparticle-modified glassy carbon electrode as a working electrode, with a platinum wire counter
electrode and a saturated calomel reference electrode. The results indicated that the oxidation of
honokiol was reversible and involved two electrons. The oxidation of magnolol was irreversible [183].
 
Scheme 49. Electrochemical oxidation of an acetoxy lignan to an o-quinone.
 
Scheme 50. Synthesis of dibenzocyclooctadienes by electrochemical oxidation of butyrolactone lignans.
 
Figure 1. The structures of the lignans hibalactone, epi-guaiacin, guaiacin, verrucosin, nectandrin B,
honokiol and magnolol, the glycoside etoposide, and the flavonolignan silybin.
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Foodstuff and plant extracts containing phenolic compounds including lignans have been
electrochemically oxidized during the determination of the phenolic content [184–187] and the
antioxidant capacity [188,189]. The drug etoposide, which is a semisynthetic epipodophyllotoxin
glycoside, has been oxidized electrochemically using a carbon paste working electrode, a Ag/AgCl/3
M KCl reference electrode, and a platinum wire counter electrode, with a supporting electrolyte of
varying pH. The oxidation involves the transfer of two electrons and proceeds in one voltammetric
oxidation step at a pH < 4.0 and two voltammetric oxidation steps at a pH > 4.0. In the first and
reversible oxidation step, one electron is transferred, resulting in a stable radical. The product in
the second oxidation step is an unstable cation, which rapidly converts into the o-quinone [190].
The flavonolignan silybin and its derivatives has been electrochemically oxidized using various
methods [191–195].
4.3. Photooxidations
The lignans hydroxymatairesinol, allohydroxymatairesinol, α-conidendrin, and oxo-matariresinol
have been used as substrates for light-irradiation experiments in different solvents. The products of
light-irradiation of hydroxymatairesinol that were either isolated or detected were allohydroxymatairesinol,
oxomatairesinol, α-conidendrin, allo-7′-methoxymatairesinol, 7′-methoxymatairesinol, and vanillin
(Scheme 51). The irradiation of allo-hydroxymatairesinol formed the reaction products hydroxymatairesinol,
oxomatairesinol, α-conidendrin, allo-7′-methoxymatairesinol, 7′-methoxymatairesinol, and vanillin.
Oxomatairesinol was formed from the irradiation of hydroxymatairesinol, and vanillin from the irradiation
of oxomatairesinol [162].
 
Scheme 51. The photooxidation reactions of hydroxymatairesinol.
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5. Conclusions
Lignans are oxidatively transformed in a number of processes and conditions. In nature, oxidations
are mostly related to biosynthetic pathways, or processes where lignans act as primary antioxidant
scavenging free radicals. When it comes to targeted oxidative transformations or studies between
lignans and oxidants, the reports in the literature can be divided into non-metal mediated and metal
mediated oxidations. The oxidative transformations include the oxidation of alcohols, both primary and
benzylic, or benzylic functionalization by halogenation, hydroxylation, dehydrogenation, or by ring
closing reactions. Oxidative Ar-Ar couplings forming cyclooctadienes have been extensively reported
and can be quite selectively accomplished with several reagents in high yields. α-Hydroxylations
and epoxidations have also been reported, although to a much lesser extent and these reactions may
warrant further investigations. Radical mediated oxidations often result in polymerization or radical
addition reactions giving a wide range of products with poor selectivity, especially in the presence of
free phenolic groups. Although there are over 200 papers reporting the oxidative transformations of
lignans, we can conclude that there is still room for further investigations, especially concerning the
selectivity. In addition, electrochemical oxidations and photooxidations are rather unexplored and
could be a future area of research.
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Are Total and Individual Dietary Lignans Related to Cardiovascular Disease and Its Risk Factors in
Postmenopausal Women? A Nationwide Study. Nutrients 2018, 10, 865. [CrossRef]
9. Kiyama, R. Biological effects induced by estrogenic activity of lignans. Trends Food Sci. Technol. 2016, 54,
186–196. [CrossRef]
10. Bobe, G.; Murphy, G.; Albert, P.S.; Sansbury, L.B.; Lanza, E.; Schatzkin, A.; Cross, A.J. Dietary lignan
and proanthocyanidin consumption and colorectal adenoma recurrence in the Polyp Prevention Trial.
Int. J. Cancer 2012, 130, 1649–1659. [CrossRef]
11. Hearon, W.M.; MacGregor, W.S. The Naturally Occurring Lignans. Chem. Rev. 1955, 55, 957–1068. [CrossRef]
12. Rao, C. Chemistry of Lignans; Andhra University Press: Visakhapatnam, India, 1978.
13. Ayres, D.C.; Loike, J.D. Lignans: Chemical, Biological, and Clinical Properties; Phillipson, J.D., Ayres, D.C.,
Baxter, H., Eds.; Cambridge University Press: Cambridge, UK, 1990; ISBN 0521304210.
14. Whiting, D.A. Lignans, neolignans, and related compounds. Nat. Prod. Rep. 1987, 4, 499–525. [CrossRef]
[PubMed]
15. Ward, R.S. Lignans, neolignans and related compounds. Nat. Prod. Rep. 1999, 16, 75–96. [CrossRef]
159
Molecules 2019, 24, 300
16. Kariyappa, A.K.; Ramachandrappa, R.K.; Seena, S. Lignans: Insight to Chemistry and Pharmacological
Applications-An Overview. Chem Sci Rev Lett. 2015, 4, 1157–1165.
17. Ward, R.S. Recent Advances in the Chemistry of Lignans. Stud. Nat. Prod. Chem. 2000, 24, 739–798.
[CrossRef]
18. Pelter, A.; Ward, R.S.; Venkateswarlu, R.; Kamakshi, C. Oxidative transformations of lignans - reactions of
dihydrocubebin and a derivative with DDQ. Tetrahedron 1991, 47, 1275–1284. [CrossRef]
19. Venkateswarlu, R.; Kamakshi, C.; Moinuddin, S.G.; Subhash, P.V.; Ward, R.S.; Pelter, A.; Hursthouse, M.B.;
Light, M.E. Transformations of lignans, Part V. Reactions of DDQ with a gmelinol hydrogenolysis product
and its derivatives. Tetrahedron 1999, 55, 13087–13108. [CrossRef]
20. Ward, R.S.; Hughes, D.D. Oxidative cyclisation of cis- and trans-2,3-dibenzylbutyrolactones using phenyl
iodonium bis(trifluoroacetate) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone. Tetrahedron 2001, 57,
5633–5639. [CrossRef]
21. Charlton, J.L.; Chee, G.-L. Asymmetric synthesis of lignans using oxazolidinones as chiral auxiliaries.
Can. J. Chem. 1997, 75, 1076–1083. [CrossRef]
22. Magoulas, G.; Papaioannou, D.; Magoulas, G.E.; Papaioannou, D. Bioinspired Syntheses of Dimeric
Hydroxycinnamic Acids (Lignans) and Hybrids, Using Phenol Oxidative Coupling as Key Reaction,
and Medicinal Significance Thereof. Molecules 2014, 19, 19769–19835. [CrossRef]
23. Satyanarayana, P.; Venkateswarlu, S.; Viswanatham, K.N. Oxidative aryl-aryl, aryl-benzyl coupling
of lignans-reactions of phyllanthin and haloderivatives with TTFA, DDQ, Li/THF: synthesis of
dibenzocyclooctadiene system and phyltetralin. Tetrahedron 1991, 47, 8277–8284. [CrossRef]
24. Pelter, A.; Ward, R.S.; Jones, D.M.; Maddocks, P. Asymmetric synthesis of lignans of the dibenzylbutanediol
and tetrahydrodibenzocyclooctene series. J. Chem. Soc. Perkin Trans. 1 1993, 2631–2637. [CrossRef]
25. Pelter, A.; Ward, R.S.; Jones, D.M.; Maddocks, P. Asymmetric syntheses of lignans of the dibenzylbutyrolactone,
dibenzylbutanediol, aryltetraun and dibenzocyclooctadiene series. Tetrahedron: Asymmetry 1992, 3, 239–242.
[CrossRef]
26. Chattopadhyay, S.K.; Rao, K.V. Chemistry of saururus cernuus IV: cyclooctadiene systems derived from
austrobailignan-5. Tetrahedron 1987, 43, 669–678. [CrossRef]
27. Venkateswarlu, R.; Kamakshi, C.; Moinuddin, S.G.; Subhash, P.V.; Ward, R.S.; Pelter, A.; Coles, S.J.;
Hursthouse, M.B.; Light, M.E. Transformations of lignans. Part 4: Oxidative and reductive rearrangements
of dibenzocyclooctadiene and spirodienone lignans. Tetrahedron 2001, 57, 5625–5632. [CrossRef]
28. Tomioka, K.; Ishiguro, T.; Koga, K. First asymmetric total synthesis of (+)-steganacin determination of
absolute stereochemistry. Tetrahedron Lett. 1980, 21, 2973–2976. [CrossRef]
29. Chang, J.; Xie, J. Synthesis of some new lignans and the mechanism of intramolecular nonphenolic oxidative
coupling of aromatic compounds. Sci. China Ser. B Chem. 2000, 43, 323–330. [CrossRef]
30. Tilve, S.G.; Torney, P.S.; Patre, R.E.; Kamat, D.P.; Srinivasan, B.R.; Zubkov, F.I. Domino Wittig-Diels Alder
reaction: Synthesis of carbazole lignans. Tetrahedron Lett. 2016, 57, 2266–2268. [CrossRef]
31. Ward, R.S.; Satyanarayana, P.; Gopala Rao, B.V. Reactions of Aryltetralin Lignans with DDQ—An Example
of DDQ Oxidation of Allylic Ether Groups. Tetrahedron Lett. 1981, 22, 3021–3024. [CrossRef]
32. Yamaguchi, H.; Arimoto, M.; Tanoguchi, M.; Ishida, T.; Inoue, M. Studies on the constituents of the seeds
of Hernandia ovigera L. III. Structures of two new lignans. Chem. Pharm. Bull. (Tokyo) 1982, 30, 3212–3218.
[CrossRef]
33. Eklund, P.C.; Sjöholm, R.E. Oxidative transformation of the natural lignan hydroxymatairesinol with
2,3-dichloro-5,6-dicyano-1,4-benzoquinone. Tetrahedron 2003, 59, 4515–4523. [CrossRef]
34. Taskinen, A.; Eklund, P.; Sjöholm, R.; Hotokka, M. The molecular structure and some properties of
hydroxymatairesinol. An ab initio study. J. Mol. Struct. THEOCHEM 2004, 677, 113–124. [CrossRef]
35. Ishiguro, T.; Mizuguchi, H.; Tomioka, K.; Koga, K. Stereoselective reactions. VIII. Stereochemical requirement
for the benzylic oxidation of lignan lactone. A highly selective synthesis of the antitumor lignan lactone
steganacin by the oxidation of stegane. Chem. Pharm. Bull. 1985, 33, 609–617. [CrossRef]
36. Ward, R.S.; Pelter, A.; Jack, I.R.; Satyanarayana, P.; Rao, B.V.G.; Subrahmanyam, P. Reactions of paulownin,
gmelinol and gummadiol with 2,5-dichloro-5,6-dicyanobenzoquinone. Tetrahedron Lett. 1981, 22, 4111–4114.
[CrossRef]
160
Molecules 2019, 24, 300
37. Ward, R.S.; Pelter, A.; Venkateswarlu, R.; Kamakshi, C.; Subhash, P.V.; Moinuddin, S.G.; Hursthouse, M.B.;
Coles, S.J.; Hibbs, D.E. Transformations of lignans, part IV. Acid-catalysed rearrangements of gmelinol with
BF3-etherate and study of a product with a unique lignan skeleton formed by further oxidation with DDQ.
Tetrahedron 1999, 55, 13071–13086. [CrossRef]
38. Chang, J.B.; Xie, J.X. Synthesis of New Schizandrin Analogues. Chinese Chem. Lett. 2001, 12, 667–670.
39. Orito, K.; Sasaki, T.; Suginome, H. Photoinduced molecular transformations. 158. A total synthesis of
(.+-.)-methyl piperitol: An unsymmetrically substituted 2,6-diaryl-3,7-dioxabicyclo [3.3.0] octane lignan.
J. Org. Chem. 1995, 60, 6208–6210. [CrossRef]
40. Suginome, H.; Orito, K.; Yorita, K.; Ishikawa, M.; Shimoyama, N.; Sasaki, T. Photoinduced Molecular
Transformations. 157. A New Stereo- and Regioselective Synthesis of 2,6-Diaryl-3,7 dioxabicyclo[3.3.0]octane
Lignans Involving a β-Scission of Alkoxyl Radicals as the Key Step. New Total Syntheses of (±)-Sesamin,
(±)-Eudesmin, and. (+)-Yangambin. J. Org. Chem. 1995, 60, 3052–3064. [CrossRef]
41. Sato, Y.; Tamura, T.; Mori, M. Arylnaphthalene Lignans through Pd-Catalyzed[2+2+2] Cocyclization of
Arynes and Diynes: Total Synthesis of Taiwanins C and E. Angew. Chem. Int. Ed. 2004, 43, 2436–2440.
[CrossRef]
42. Peng, Y.; Xiao, J.; Xu, X.-B.; Duan, S.-M.; Ren, L.; Shao, Y.-L.; Wang, Y.-W. Stereospecific Synthesis of
Tetrahydronaphtho[2,3-b]furans Enabled by a Nickel-Promoted Tandem Reductive Cyclization. Org. Lett.
2016, 18, 5170–5173. [CrossRef]
43. Sang, S.; Tian, S.; Wang, H.; Stark, R.E.; Rosen, R.T.; Yang, C.S.; Ho, C.-T. Chemical studies of the antioxidant
mechanism of tea catechins: radical reaction products of epicatechin with peroxyl radicals. Bioorg. Med. Chem.
2003, 11, 3371–3378. [CrossRef]
44. Fujisawa, S.; Kadoma, Y. Comparative study of the alkyl and peroxy radical scavenging activities of
polyphenols. Chemosphere 2006, 62, 71–79. [CrossRef] [PubMed]
45. Spatafora, C.; Daquino, C.; Tringali, C.; Amorati, R. Reaction of benzoxanthene lignans with peroxyl radicals
in polar and non-polar media: Cooperative behaviour of OH groups. Org. Biomol. Chem. 2013, 11, 4291–4294.
[CrossRef] [PubMed]
46. Masuda, T.; Akiyama, J.; Fujimoto, A.; Yamauchi, S.; Maekawa, T.; Sone, Y. Antioxidation reaction mechanism
studies of phenolic lignans, identification of antioxidation products of secoisolariciresinol from lipid oxidation.
Food Chem. 2010, 123, 442–450. [CrossRef]
47. Betigeri, S.; Thakur, A.; Raghavan, K. Use of 2,2′-Azobis(2-Amidinopropane) Dihydrochloride as a Reagent
Tool for Evaluation of Oxidative Stability of Drugs. Pharm. Res. 2005, 22, 310–317. [CrossRef] [PubMed]
48. Pisoschi, A.M.; Negulescu, G.P. Methods for Total Antioxidant Activity Determination: A Review.
Biochem. Anal. Biochem. 2011, 1. [CrossRef]
49. Amorati, R.; Zotova, J.; Baschieri, A.; Valgimigli, L. Antioxidant Activity of Magnolol and Honokiol: Kinetic
and Mechanistic Investigations of Their Reaction with Peroxyl Radicals. J. Org. Chem. 2015, 80, 10651–10659.
[CrossRef]
50. Werber, J.; Wang, Y.J.; Milligan, M.; Li, X.; Ji, J.A. Analysis of 2,2’-Azobis (2-Amidinopropane) Dihydrochloride
Degradation and Hydrolysis in Aqueous Solutions. J. Pharm. Sci. 2011, 100, 3307–3315. [CrossRef]
51. Eklund, P.C.; Långvik, O.K.; Wärnå, J.P.; Salmi, T.O.; Willför, S.M.; Sjöholm, R.E. Chemical studies on
antioxidant mechanisms and free radical scavenging properties of lignans. Org. Biomol. Chem. 2005, 3, 3336.
[CrossRef]
52. Hosseinian, F.S.; Muir, A.D.; Westcott, N.D.; Krol, E.S. Antioxidant capacity of flaxseed lignans in two model
systems. J. Am. Oil Chem. Soc. 2006, 83, 835. [CrossRef]
53. Kang, M.-H.; Naito, M.; Sakai, K.; Uchida, K.; Osawa, T. Mode of action of sesame lignans in protecting
lowdensity lipoprotein against oxidative damage in vitro. Life Sci. 1999, 66, 161–171. [CrossRef]
54. Hodaj, E.; Tsiftsoglou, O.; Abazi, S.; Hadjipavlou-Litina, D.; Lazari, D. Lignans and indole alkaloids from the
seeds of Centaurea vlachorum Hartvig (Asteraceae), growing wild in Albania and their biological activity.
Nat. Prod. Res. 2017, 31, 1195–1200. [CrossRef] [PubMed]
55. Alphonse, P.A.S.; Aluko, R.E. Anti-carcinogenic and anti-metastatic effects of flax seed lignan secolariciresinol
diglucoside (SDG). Discov. Phytomedicine 2015, 2, 12–17. [CrossRef]
161
Molecules 2019, 24, 300
56. Hosseinian, F.F.H. Antioxidant Properties of Flaxseed Lignans Using In Vitro Model Systems. Ph.D. Thesis,
University of Saskatchewan, Saskatoon, SK, Canada, 2006.
57. Hosseinian, F.S.; Muir, A.D.; Westcott, N.D.; Krol, E.S. AAPH-mediated antioxidant reactions of
secoisolariciresinol and SDG. Org. Biomol. Chem. 2007, 5, 644–654. [CrossRef] [PubMed]
58. Narasimhan, N.S.; Aidhen, I.S. Radical mediated intramolecular arylation using tributyltinhydride/aibn:
A formal synthesis of steganone. Tetrahedron Lett. 1988, 29, 2987–2988. [CrossRef]
59. Fischer, J.; Reynolds, A.J.; Sharp, L.A.; Sherburn, M.S. Radical Carboxyarylation Approach to Lignans.
Total Synthesis of (−)-Arctigenin, (−)-Matairesinol, and Related Natural Products. Org. Lett. 2004, 6,
1345–1348. [CrossRef] [PubMed]
60. Huang, X.-X.; Bai, M.; Zhou, L.; Lou, L.-L.; Liu, Q.-B.; Zhang, Y.; Li, L.-Z.; Song, S.-J. Food Byproducts
as a New and Cheap Source of Bioactive Compounds: Lignans with Antioxidant and Anti-inflammatory
Properties from Crataegus pinnatifida Seeds. J. Agric. Food Chem. 2015, 63, 7252–7260. [CrossRef]
61. Chen, J.-J.; Wei, H.-B.; Xu, Y.-Z.; Zeng, J.; Gao, K. Antioxidant Lignans from the Roots of Vladimiria muliensis.
Planta Med. 2013, 79, 1470–1473. [CrossRef]
62. Lee, E.-J.; Chen, H.-Y.; Hung, Y.-C.; Chen, T.-Y.; Lee, M.-Y.; Yu, S.-C.; Chen, Y.-H.; Chuang, I.-C.; Wu, T.-S.
Therapeutic window for cinnamophilin following oxygen–glucose deprivation and transient focal cerebral
ischemia. Exp. Neurol. 2009, 217, 74–83. [CrossRef] [PubMed]
63. Mocan, A.; Schafberg, M.; Cris, an, G.; Rohn, S. Determination of lignans and phenolic components of
Schisandra chinensis (Turcz.) Baill. using HPLC-ESI-ToF-MS and HPLC-online TEAC: Contribution of
individual components to overall antioxidant activity and comparison with traditional antioxidant assays.
J. Funct. Foods 2016, 24, 579–594. [CrossRef]
64. Sharma, O.P.; Bhat, T.K. DPPH antioxidant assay revisited. Food Chem. 2009, 113, 1202–1205. [CrossRef]
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Abstract: By using a zebrafish embryo model to guide the chromatographic fractionation
of antimitotic secondary metabolites, seven podophyllotoxin-type lignans were isolated
from a hydroalcoholic extract obtained from the steam bark of Bursera fagaroides.
The compounds were identified as podophyllotoxin (1), β-peltatin-A-methylether (2),
5′-desmethoxy-β-peltatin-A-methylether (3), desmethoxy-yatein (4), desoxypodophyllotoxin
(5), burseranin (6), and acetyl podophyllotoxin (7). The biological effects on mitosis, cell migration,
and microtubule cytoskeleton remodeling of lignans 1–7 were further evaluated in zebrafish embryos
by whole-mount immunolocalization of the mitotic marker phospho-histone H3 and by a tubulin
antibody. We found that lignans 1, 2, 4, and 7 induced mitotic arrest, delayed cell migration, and
disrupted the microtubule cytoskeleton in zebrafish embryos. Furthermore, microtubule cytoskeleton
destabilization was observed also in PC3 cells, except for 7. Therefore, these results demonstrate that
the cytotoxic activity of 1, 2, and 4 is mediated by their microtubule-destabilizing activity. In general,
the in vivo and in vitro models here used displayed equivalent mitotic effects, which allows us to
conclude that the zebrafish model can be a fast and cheap in vivo model that can be used to identify
antimitotic natural products through bioassay-guided fractionation.
Keywords: Bursera fagaroides; podophyllotoxin-type lignans; cell cycle; cell migration; epiboly;
microtubules; F-actin; cancer; lignans
1. Introduction
Lignans are a big family of secondary metabolites biosynthesized in plants through the shikimic
acid pathway that represent an important class of compounds in cancer research studies [1,2].
One of the most representative groups of lignans are the aryltetralin lignans [3]. Into this group
of compounds, podophyllotoxin (1) is the most known because of its use as an effective antiviral for
genital warts treatment. Podophyllotoxin inhibits tubulin polymerization inducing the mitotic arrest
of cancer cells [4]. In vitro, it binds to the colchicine binding site [5,6]. Because of the unacceptable
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gastrointestinal toxicity, many semisynthetic podophyllotoxin derivatives were developed and tested
for anticancer activity [7]. Etoposide and teniposide are glycosylated derivatives of podophyllotoxin
developed in the 1970s. These derivatives are used in many clinical chemotherapeutic regimens,
because of their easy administration and good toleration. However, the action mechanism through
which they exert their effect is different from that of podophyllotoxin (1), since these semisynthetic
drugs break DNA by the interaction with the topoisomerase II enzyme [1].
Our research team has characterized an interesting traditional Mexican medicinal plant named
Bursera fagaroides, which is popularly used as an antitumoral. Our previous studies described the
isolation of seven aryltetralin-type lignans including podophyllotoxin (1), β-peltatin-A-methylether
(2), 5′-desmethoxy-β-peltatin-A-methylether (3), desmethoxy-yatein (4), desoxypodophyllotoxin (5),
burseranin (6), and acetyl podophyllotoxin (7) [8], as well as three aryldihydronaphtalene-type lignans,
i.e., 7′,8′-dehydropodophyllotoxin (8), 7′,8′-dehydroacethyl podophyllotoxin (9), and 7′,8′-dehydro
trans-p-cumaroylpodophyllotoxin (10) (Figure 1) [9]. The cytotoxic evaluation of these compounds
indicated that all lignans showed potent cytotoxic activity against a panel of four human cancer cell
lines (KB, HF-6, MCF-7, and PC-3), being selective against prostate cancer cells (PC-3).
 trans p  
Figure 1. Glycosylated derivatives of podophyllotoxin (etoposide and teniposide) and
podophyllotoxin-type lignans 1–10: podophyllotoxin (1), β-peltatin-A-methylether (2),
5′-desmethoxy-β-peltatin-A-methylether (3), desmethoxy-yatein (4), desoxypodophyllotoxin
(5), burseranin (6), acetyl podophyllotoxin (7), 7′,8′-dehydropodophyllotoxin (8), 7′,8′-dehydroacethyl
podophyllotoxin (9), and 7′,8′-dehydro trans-p-cumaroylpodophyllotoxin (10), isolated from the steam
bark of Bursera fagaroides.
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Other studies proved that lignans 3 and 7 are more potent than the semisynthetic podophyllotoxin
drug etoposide (14.1 and 7.6 μg/mL, respectively) in the human breast cancer cell line BT-549 [10].
Additionally, compounds 3, 6, and 7 showed anti-giardial activity in vitro, provoking morphological
alterations in Giardia parasite [11]. In a deeper molecular recognition study of lignans 3, 7, and 9,
the action mechanism consisting in disrupting microtubule networks and cell cycle arrest in G2/M
phase in the human carcinoma lung cell line A549 was demonstrated. Also, we established that these
compounds interact with the tubulin colchicine binding site with a high binding constant (Kb) [6].
Recently, in vivo studies performed with the aryldihydronaphtalene-type lignans (8–10) in the
developing zebrafish embryo model, demonstrated that these compounds promote mitotic arrest,
delay cell migration and disrupt microtubules [9].
Continuing the study of this important medicinal plant, in this work, we analyzed the
hydroalcoholic extract of B. fagaroides steam bark, employing developing zebrafish embryos as a model
with the aim to identify compounds able to affect the tubulin cytoskeleton and to find a faster and
easier biological model to discover new destabilizing anticancer drugs.
2. Results and Discussion
2.1. In Vivo Analysis of Mitotic Arrest in Zebrafish Embryos
Histone H3 phosphorylated at serine 10 (H3S10ph) has long been used to identify mitotic
cell nuclei in cultured cell lines [12] as well as in whole embryos such as those of Xenopus and
zebrafish [13–15]. In particular, 24 h-old zebrafish embryos have been used to screen the effects of
small chemical molecules on the cell cycle and the induction of mitotic arrest using whole-mount
immunohistochemistry of H3S10ph [16].
First, we evaluated the effect of a B. fagaroides hydroalcoholic extract (HA) on mitotic arrest
in whole 24 h post fertilization (hpf) zebrafish embryos. Nocodazole and aphidicolin were used
as controls of inhibition of DNA polymerase and tubulin depolymerization, respectively [17,18].
The aphidicolin-treated embryos exhibited considerably fewer H3S10ph-positive nuclei compared
with the control embryos incubated with the vehicle (DMSO). In contrast, nocodazole-treated embryos
appeared to have substantially more H3S10ph-positive nuclei compared with the control embryos
(Figure S1).
The HA extract of B. fagaroides did not affect the number of mitotic cells, as measured by the
number of H3S10ph-positive nuclei with respect to that of the control (Figure 2, Figure S2, and Table S1).
Nevertheless, in our previous study, this extract showed potent in vitro cytotoxic activity and strong
in vivo antitumor activity against L5178Y lymphoma in mice [8]. Therefore, we considered that the
lack of effect of the HA extract in zebrafish embryos could be due to poor bioavailability because of
the low concentration of the active compounds present in the extract. For this reason, we decided to
test the effect of its chromatographic fractions. Therefore, successive chromatographic fractionations
of the HA extract were performed, which afforded four fractions, two of which (F-1 and F-2) were
analyzed (Figure S2). These two fractions were the most active when the fractionation was guided
by the cytotoxic activity. In contrast, F-3 and F-4 were not evaluated in this work because of their
lack of cytotoxic activity reported by Rojas et al. [8]. Fractions F-1 and F-2 increased the number
of H3S10ph-positive nuclei by 4.08- and 4.48-fold, respectively (Figure 2 and Table S1). The treated
embryos that exhibited increased H3S10ph levels also displayed abnormal morphology; these embryos
were curved ventrally (Figure S2), like the embryos treated with nocodazole.
172
Molecules 2019, 24, 8
Figure 2. Staining of mitotic nuclei by phospho-histone H3 (H3S10ph) in zebrafish embryos
treated with the hydrocoholic extract fractions and the pure compounds: Podophyllotoxin (1),
β-peltatin-A-methylether (2), 5′-desmethoxy-β-peltatin-A-methylether (3), desmethoxy-yatein (4),
desoxypodophyllotoxin (5), burseranin (6), and acetyl podophyllotoxin (7). The fold changes were
determined in comparison with the control (DMSO-treated). Values represent means ± s.d. * Significant
differences (p < 0.001). These results are also shown in Table S1.
Chromatographic purification of fractions F-1 and F-2 afforded seven lignans identified as
podophyllotoxin (1), β-peltatin-A-methylether (2), 5′-desmethoxy-β-peltatin-A-methylether (3),
desmethoxy-yatein (4), desoxypodophyllotoxin (5), burseranin (6), and acetyl podophyllotoxin (7) by
direct comparison with authenticated samples obtained in previous work (Figure 1) [8].
Next, we analyzed the effect of all the isolated podophyllotoxin-type lignans (1–7) on the H3S10ph
marker and morphology in zebrafish embryos (Figure 3). The results showed that compounds 1, 2,
4, and 7 significantly increased the H3S10ph levels, by 2.95-, 3.89-, 4.44- and 2.88-fold, respectively
(Figure 2 and Table S1).
In contrast, compounds 3, 5, and 6 did not affect the number of mitotic cells or the circularity of
the embryos. Zebrafish embryos treated with podophyllotoxin (1) exhibited H3S10ph levels 2.95-fold
higher than those of the control embryos (Figure 2). Many semisynthetic derivatives of podophyllotoxin
with anticancer activity have been described, such as etoposide. We asked whether etoposide had
any effect in this model. The results revealed that etoposide appeared to slightly decrease the number
of H3S10ph-positive nuclei compared with control embryos, but this difference was not statistically
significant (Figure 2 and Table S1).
This difference could be attributed to the mechanism of action by which these compounds
act. It is well known that etoposide interacts with DNA and inhibits DNA-topoisomerase II, while
podophyllotoxin (1) and its congeners (3, 6, and 7) inhibit tubulin assembly [6].
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Figure 3. Whole-mount immunolocalization of H3S10ph in zebrafish embryos treated with B.
fagaroides lignans. Wild-type 24 h post-fertilization zebrafish embryos were immunostained for
H3S10ph after a 6 h treatment with different compounds. (A) Dimethyl sulfoxide (control),
(B) Aphidicolin, (C) Nocodazole, (D) Podophyllotoxin (1), (E) β-peltatin-A-methylether (2), (F)
5′-desmethoxy-β-peltatin-A-methylether (3), (G) Desmethoxy-yatein (4), (H) Desoxypodophyllotoxin
(5), (I) Burseranin (6), (J) Acetyl podophyllotoxin (7). The images were visualized by confocal
microscopy. Scale bar, 500 μm.
2.2. Characterization of Compounds that Affect Cell Migration in the Zebrafish Model
Previous studies have shown that when the microtubule cytoskeleton is compromised in early
zebrafish embryos by ultraviolet light radiation or by nocodazole treatment, epiboly migration
is severely affected [19,20]. The effect on epiboly migration has been used to screen libraries of
compounds that destabilize microtubules [21]. By using this approach, we analyzed the effect of pure
174
Molecules 2019, 24, 8
lignans (1–7) on epiboly migration in zebrafish embryos. Embryo treatment started at the sphere stage,
and all treatment groups were fixed at the same time point when the control DMSO-treated embryos
reached 90% of epiboly. Compounds 1, 2, 4, and 7 induced epiboly delay and larger blastoderm cells
and nuclei, as evidenced by phalloidin alexa and SYTOX green staining of the embryos (Figure 4).
These effects show similarities to those of nocodazol treatment, although this destabilizing microtubule
compound showed a more penetrant phenotype. Compounds 3 and 5 delayed epiboly too but did not
show effects on the size of blastoderm cells or in their nuclei (Figure 4).
Figure 4. Immunolocalization of actin filaments and nuclei in zebrafish embryos after treatment with
lignans (1)–(7), dimethyl sulfoxide (negative control), Aphidicolin, and Nocodazole (positive controls).
Sphere-stage zebrafish embryos were treated with different compounds until control embryos reached
90% epiboly, fixed, processed for actin and nuclei staining, and visualized by confocal microscopy.
Scale bar, 250 μm.
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2.3. In Vivo and In Vitro Analysis of Compounds that Affect Microtubules
To corroborate that these lignans possess microtubule destabilizing activity, we decided to perform
a tubulin immunolocalization assay in embryos treated with lignans 1–7. Starting from the sphere
stage, embryos in all treatment groups were fixed when they reached 50% of epiboly. This stage was
chosen to perform tubulin immunolocalization since the yolk cells present large and conspicuous
microtubules that are readily visualized by confocal microscopy [22].
The results showed that, again, compounds 1, 2, 4, and 7 induced microtubules destabilization
similar to nocodazol (Figure 5). On the other hand, zebrafish embryos treated with compound 3
showed some degree of disorganized microtubules, and compound 5-treated embryos presented
less abundant arrays of microtubules, although neither treatment showed the degree of microtubule
destabilization found in embryos treated with compounds 1, 2, 4, and 7 (Figure 5).
Finally, we asked if the identified lignans also destabilize the microtubule cytoskeleton in cancer
cells when exposed in vitro to these compounds. Specifically, we tested the effect of the pure lignans
1–7 in the PC3 human prostate cancer cell line, as this was the most susceptible cancer cell line when
evaluated by Rojas et, al. [8]. We found that 1, 2, and 4 destabilized microtubules; in contrast 3, 5, 6,
and 7 did not affect the microtubule cytoskeleton (Figure 6).
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Figure 5. Whole-mount immunolocalization of yolk cell microtubules in zebrafish embryos after
treatment with lignans (1)–(7). Sphere-stage zebrafish embryos were treated with different compounds
until all embryos reached 50% epiboly; they were then fixed, processed for microtubule fluorescent
immunolocalization, and visualized by confocal microscopy. Scale bar, 25 μm.
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Figure 6. Whole-mount immunolocalization of cancer PC3 cells microtubules as viewed by confocal
microscopy after treatment with DMSO (control) and lignans (1)–(7). Scale bar, 100 μm.
These results indicated that six of the seven B. fagaroides lignans showed equivalent effects to those
observed in whole zebrafish embryos. Only acetyl podophyllotoxin (7) presented a dissimilar effect in
both systems, severely affecting microtubules in zebrafish embryos (Figure 4) without showing any
effect on the microtubule cytoskeleton of PC3 cells in the assay (Figure 6).
In general, lignans with major conformational mobility, such as 1, 2, 4, and 7, isolated in this work,
showed a better in vivo effect than the planar lignans 8–10 isolated previously [9].
3. Materials and Methods
3.1. Plant Material, Extraction, and Isolation
The bark of B. fagaroides (Kunth) Engl., was collected in the village of Capula between Zacapu and
Quiroga, Michoacán, Mexico. Its identification was made in the herbarium of the Instituto Mexicano
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del Seguro Social (registration number-12 051 IMSSM) and the Institute of Botany, University of
Guadalajara (IBUG-140 748). The voucher specimens were deposited in both herbariums.
The bark of B. fagaroides (1700 g) was dried at room temperature, and the dry material was
extracted by triplicate with hexane, followed by MeOH/H2O 70:30 to yield 40.5 g hydroalcoholic
extract (HA). Then, the extract was fractionated by percolation, eluting with mixtures of
n-hexane/acetone/MeOH with increasing polarity, to yield: F-1, 1.09 g (8:2:0), F-2, 1.45 g (6:4:0),
F-3, 16 g (0:100:0), and F-4, 18.5 g (0:1:1).
The fractionation of F-1 led to the purification of podophyllotoxin (1) (4.92 mg),
β-peltatin-A-methylether (2) (3.5 mg), and 5′-desmethoxy-β-peltatin-A-methylether (3) (7.9 mg), while
desmethoxy-yatein (4) (8.7 mg), desoxypodophyllotoxin (5) (4.3 mg), burseranin (6) (15 mg), and acetyl
podophyllotoxin (7) (6.2 mg) were obtained from F-2. This procedure was performed by RP–HPLC as
described by Rojas-Sepulveda et al. [8]. The pure lignans were characterized by direct comparison
(1H NMR, co-TLC, Table S2) with authenticated samples available in our laboratory [8].
3.2. Fish Maintenance and Strains
Zebrafish (Danio rerio) embryos were obtained from natural crosses from wild-type and
AB–TU–WIK hybrid lines. Embryo stages were determined by morphological criteria [23].
Zebrafish were handled in compliance with the local animal welfare regulations, EU Directive
2010/63/EU indications [24], and zebrafish use was approved by the Ethics Committee of Instituto de
Biotecnología, UNAM.
3.3. Chemical Treatment of Zebrafish Embryos
Treatments were performed as previously described [9,16]. In brief, the compounds for the
chemical treatments were diluted in anhydrous DMSO (276855, Sigma-Aldrich, Saint Louis, MO, USA).
Plant extracts and pure compounds for screening were tested at a standard final concentration of
200 μg/mL in water. The control compounds were aphidicolin (10 μg/mL, A0781, Sigma-Aldrich,
Saint Louis, MO, USA) and nocodazole (10 μg/mL, M1404, Sigma-Aldrich, Saint Louis, MO, USA).
Etoposide was obtained from Sigma-Aldrich (E1383). To test the effect on mitotic arrest, 10 zebrafish
embryos of 24 h of postfertilization age, for each treatment, were incubated at 28 ◦C in egg water
(60 μg/mL of “Instant Ocean” sea salts in distilled water) for 6 h in 48-well plates [25]. Three microliters
of each compound stock solution were added to a total volume of 300 μL at the beginning of the
incubation. Control embryos were treated with DMSO alone at 1% final concentration (v/v) and
processed for immunohistochemistry as described below. To test the effect on cell migration and on
F-actin, zebrafish embryos at sphere stage were incubated until the control embryos reached 90%
epiboly to bud stage. Finally, to test the effect on the tubulin cytoskeleton, zebrafish embryos at sphere
stage were incubated until the control embryos reached 60% epiboly. Embryos in all treatments were
stage-matched, fixed, and processed as described below.
3.4. Immunofluorescense and Immunohistochemistry
Whole-mount fluorescent immunostaining against the mitotic marker serine 10 phospho-histone
H3 (H3S10ph) in zebrafish embryos was used as previously described [13]. For immunohistochemistry,
embryos were processed as for fluorescent immunostaining except that after overnight incubation with
the primary anti-phospho-histone H3 antibody, the embryos were processed with R.T.U. Vectastain
Universal Quick Kit (PK-7800, Vector, Burlingame, CA, USA) and developed in diaminobenzidine
with nickel contrast substrate (SK-4100, Vector, Burlingame, CA, USA). For the analysis of the effects
on microtubules, the embryos were incubated with the different compounds, fixed at 60% epiboly, and
processed as described.
The primary antibody used was a mouse anti-α-tubulin monoclonal antibody (T9026,
Sigma-Aldrich, Saint Louis, MO, USA), and a goat anti-mouse coupled to Alexa Fluor 647 (A21235,
Molecular Probes, Eugene, OR, USA) was used as a secondary antibody. For the analysis of cell
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migration, all embryos were fixed at the same time when the controls reached the tail bud stage.
Afterwards, they were washed three times, stained for 1 h at room temperature with SYTOX orange
(S11368, Molecular Probes, Eugene, OR, USA) diluted 1:2000 in blocking buffer to visualize DNA
and nuclei, and counter-stained with phalloidin Alexa Fluor 488 (A12379, Molecular Probes, Eugene,
OR, USA). The embryos were then washed three times, mounted, and imaged by confocal microscopy.
3.5. Fluorescence Microscopy
Th fluorescent signals corresponding to H3S10ph-positive cells in whole zebrafish embryos
where imaged by fluorescence microscopy with a 5× objective, 0.15 N.A. Plan-Neofluar under a
Zeiss Axioscop Microscope. Image stack (10 to 14 images per embryo) corresponding to different
focal planes were acquired with a CoolSNAP cfd CCD camera (Roper Scientific, Tucson Arizona, AZ,
USA), controlled by MicroManager 1.5 software (NIH, Bethesda, MD USA). Image resolution was
1392 × 1040, and stack images were saved in 8-bit multi-image TIFF file.
3.6. Confocal Laser Scanning Microscopy
Zebrafish embryos stained with the specified fluorescent dyes were visualized on a Zeiss LSM
510 META confocal inverted microscope (Carl Zeiss, Jena, Germany) with a Plan-Neofluar 10× (0.3
N.A.) objective, a Plan-Neofluar 20× (0.5 N.A.) objective, or a Plan-Neofluar 40× objective (0.75 N.A.).
Double-stained embryos (SYTOX orange and Phalloidin Alexa Fluor 488) were simultaneously excited
at 488 nm and 543 nm and visualized on a FluoView FV1000 confocal microscope coupled to an
up-right BX61WI Olympus microscope with a Plan FLN 10× (0.3 N.A.) objective or a Plan FLN 20×
(0.75 N.A.) objective. The pinhole aperture was maintained at 105. Serial optical sections were obtained
with a z-step of 8 μm. The images were processed with the public domain software ImageJ [26] the LSM
Image Browser from Zeiss and Adobe Photoshop. To quantify the H3S10ph-positive nuclei in each
embryo, focused images were made binary by thresholding to highlight in black the H3S10ph-positive
nuclei and in white the background, and automatically quantified by the “analyze particles” command
in ImageJ software. Embryo contour was delineated on each image, and the circularity was measured
in Image J. The Student´s t-test was performed in Microsoft Excel for statistical analysis.
3.7. Immunofluorescence of α-Tubulin in PC3 Cells
PC3 cells were grown in RPMI medium supplemented with 10% FCS. In total, 3 × 104 cells were
cultured in 24-well culture plates containing slides and allowed to attach overnight at 37 ◦C in 5% CO2.
The cells were then treated with compounds 1–7 at their IC50 values (0.95, 0.085, 1.0 × 10−5, 1.7 × 10−3,
2.0 × 10−3, 2.0 × 10−3, and 5.0 × 10−3 μg/mL, respectively) at 37 ◦C for 72 h. The cells were fixed
with PFA (paraformaldehyde) 4% in PEM buffer (PIPES 100 mM pH 6.9, EGTA 5 mM, MgCl2 2 mM).
After 15 min, PFA/NaHCO3 was added, and the cells incubated for 45 min at room temperature. The
slides were rinsed with PBS and treated with 0.1% Triton X-100 (Sigma Aldrich, Saint Louis, MO,
USA), then incubated with a primary anti-α-tubulin antibody (1:300, Sigma Aldrich, Saint Louis, MO,
USA) overnight at 4 ◦C. A secondary anti-mouse Alexa Fluor 647 antibody (1:1000, Molecular Probes,
Eugene, OR, USA) was added, and the slides were incubated for 1 h at 37 ◦C. The cells were stained
with 0.4 μg/mL of 4, 6-diamidino-2-phenylindole (DAPI, Molecular Probes, Eugene, OR, USA) in PBS
for 10 min, mounted, and imaged by confocal microscopy as recently described [27].
4. Conclusions
In this work, following a bioassay-guided fractionation by using the zebrafish model, we isolated
seven antimitotic active lignans (1–7) from an antitumoral hydroalcoholic extract of B. fagaroides.
We found by using immunoassays in zebrafish embryos that 1, 2, 4, and 7 lignans induced mitotic
arrest, delayed cell migration, and disrupted the microtubule cytoskeleton. These results enabled
us to demonstrate that microtubule destabilization is the mechanism of action through which these
compounds exert their cytotoxic activity.
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Furthermore, microtubule array disruption was demonstrated also in PC3 cells. In general,
equivalent antimitotic effects were observed in both in vivo and in vitro models.
Finally, we can conclude that the in vivo zebrafish model developed in this work is a suitable,
faster, and cheap model to identify antimitotic natural products through bioassay-guided fractionation.
Supplementary Materials: Whole-mount immunolocalization of phospho-histone-H3 (H3S10ph) in zebrafish
embryos. Table quantification of H3S10ph by the extract and fractions. 1H NMR table of pure compounds (1–7).
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Abstract: This paper reports the in silico prediction of biological activities of lignans from Diphylleia
cymosa and Podophyllum hexandrum combined with an in vitro bioassays. The extracts from the
leaves, roots and rhizomes of both species were evaluated for their antibacterial, anticholinesterasic,
antioxidant and cytotoxic activities. A group of 27 lignans was selected for biological activities
prediction using the Active-IT system with 1987 ligand-based bioactivity models. The in silico
approach was properly validated and several ethnopharmacological uses and known biological
activities were confirmed, whilst others should be investigated for new drugs with potential clinical
use. The extracts from roots of D. cymosa and from rhizomes and roots of P. hexandrum were very
effective against Bacillus cereus and Staphylococcus aureus, while podophyllotoxin inhibited the growth
of Staphylococcus aureus and Escherichia coli. D. cymosa leaves and roots showed anticholinesterasic
and antioxidant activities, respectively. The evaluated extracts showed to be moderately toxic to
THP-1 cells. The chromatographic characterization indicated that podophyllotoxin was the major
constituent of P. hexandrum extract while kaempferol and its hexoside were the main constituents of
D. cymosa leaves and roots, respectively. These results suggest that the podophyllotoxin could be the
major antibacterial lignan, while flavonoids could be responsible for the antioxidant activity.
Keywords: lignans; in silico studies; podophyllotoxin; antibacterial activity; acetylcholinesterase
inhibitors; antioxidant activity; cytotoxicity
1. Introduction
Lignans are a large group of phenylpropanoid dimers with a different degree of oxidation
in the side-chain and a different substitution in the aromatic group [1,2]. They are classified in
groups according to their oxygenation and cyclization patterns. The most prominent member of this
group of natural products is podophyllotoxin (PTOX, 1). Its antitumour activity prompted several
studies, and resulted in the introduction of successful clinical drugs. This aryltetralin lignan is a
Molecules 2018, 23, 3303; doi:10.3390/molecules23123303 www.mdpi.com/journal/molecules183
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lead compound for the semi-synthetic derivatives etoposide (27), teniposide (28), and etopophos
(29) (Figure 1), which have an important role in cancer therapy [3,4]. In addition, analogues of
podophyllotoxin (1) were evaluated for the treatment of rheumatoid arthritis, psoriasis, and malaria
with good results [3,5]. Furthermore, there are reviews published referring to the semisynthesis of
PTOX derivatives, applications, mode of action and structure-activity relationships [6–8].
Arylnaphatalene lignans such as diphyllin (24) and its glycosides 25 and 26 (Figure 1) were isolated
from some traditional medicinal plants and have been reported to possess a wide range of pharmacological
activities, including antitumour, anti-leshmania, antifungal, antiviral and antibacterial [9,10].
Currently, there are few plant sources of podophyllotoxin (1) and its related lignans occur in
a particular taxonomic group, but in low amounts. Podophyllotoxin (1) is still obtained from wild
Podophyllum populations, and this is a major constraint in supplying the lignan to the pharmaceutical
industry that is under pressure to meet demand. To overcome this situation, several studies focussing
on its production by biotechnological strategies and synthetic approaches have been reported [11,12].
Podophyllotoxin (1) is found in the rhizomes, roots and leaves of both Podophyllum hexandrum
Royle and Diphylleia cymosa Michaux (Berberidaceae), while the occurrence of diphyllin (24) is reported
in the latter species but not in Podophyllums [13]. P. hexandrum and D. cymosa are herbaceous perennials
found growing in moist shady conditions [14], and are known for their medicinal use in American
and Asian cultures. Both genera are taxonomically closely related, and some common features are
their habitat, morphology, karyotype and chemical profile, whilst the differences are related to floral
biology [13,15,16]. A study based on four molecular markers and morphology confirms the close
relationship between Diphylleia and Podophyllum [17]. P. hexandrum is sometimes treated as a monotypic
genus Sinopodophyllum [18].
P. hexandrum is commonly named as the Himalayan Mayapple or Indian Mayapple and Indian
Podophyllum. There are ethnobotanical records based on its healing properties in Asian culture for
the treatment of skin cancers as well as due to its purgative, emetic, cytotoxicity, antitumour and
antileukaemic properties [11,19]. Overall, the parts used for medicinal purposes are mainly the
rhizomes, roots and fruits. D. cymosa has been called the Southern Mayapple and Umbrella Leaf [20].
There is an account that describes the American Cherokee Indians using an infusion of the plant as a
diuretic, antiseptic, diaphoretic and for the treatment of smallpox [21]. According to an earlier clinical
study, the resin demonstrated none of the biological properties associated with Podophyllum [22].
Considerable interest has been centered on P. hexandrum due to the PTOX content and its related
lignans. With regard to D. cymosa, the species has been investigated less than the Podophyllums and
only a few studies have been reported [13,23,24].
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Figure 1. Chemical structures of lignans and podophyllotoxin derivatives [13,25].
This paper reports on the evaluation of ethanolic extracts from the leaves and roots of D. cymosa,
and from the rhizomes and roots of P. hexandrum for the antibacterial activity, inhibition of AChE,
as well as for the antioxidant activity and cytotoxicity combined with an in silico target fishing approach.
The latter was used to predict new activities for known lignans from both species. The lignans profiling
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was based on the chromatographic analyses (UPLC-DAD-ESI-MS/MS) which were included with the
aim of identifying the major phenolic components in the extracts (Figure 2).
Figure 2. Workflow of the methodology performed in this study.
2. Results
A growing amount of work has been applied to investigating P. hexandrum due to its content
of PTOX (1) and related lignans. However, it is surprising to note that studies into D. cymosa are
extremely limited when compared with the Podophyllum species, even though this species is endemic
in the Southern Appalachian Mountains of the Eastern North America [22,26].
There has been a decrease in the wild populations of P. hexandrum in India due to the over
collection of rhizomes and roots of this species [27]. In addition, the species shows a short season
of availability, and thus plants are limited in the field. A number of studies have been undertaken
to achieve mass propagation [28] as well as to establish plant derived-cultures for the production
of podophyllotoxin [29,30], whereas their low yields were far from meeting commercial needs.
Enhancement of the lignan was attempted by other systems, including transgenic cultures, addition
of a precursor feeding to the culture medium, the use of an elicitor such as methyl jasmonate,
and the production by endophytes [11]. With regard to the latter, there are reports on the production
of PTOX (1) by the endophytic fungi Fusarium solani [31] and Trametes hirsuta [32] isolated from
P. hexandrum. These species of endophytes could be a promising source for large-scale production of
PTOX, whereas the yields must be improved.
2.1. Chromatographic Profiling by UPLC-DAD-ESI-MS/MS
Several lignans have been already reported for D. cyomsa and P. hexandrum. From the leaves and roots
of D. cymosa, Broomhead and Dewick [13] isolated the lignans PTOX (1), 4′-demethyl-podophyllotoxin
(6), 4′-demethyldesoxypodophyllotoxin (9), diphyllin (24), diphyllin glucoside (25), diphyllin diglucoside
(26) and 4′-demethyldesoxypodophyllotoxin 4-O-glucoside (10) (Figure 1), this being the only study
reporting the isolation and characterization of compounds from D. cymosa.
A phytochemical study of P. hexandrum led to the isolation of the lignans PTOX (1),
4′-demethylpodophyllotoxin (6), 4′-demethyldesoxypodophyllotoxin (9), PTOX glucoside (3),
desoxy-podophyllotoxin (deoxypodophyllotoxin, 5), 4′-demethylpodophyllotoxin glucoside (7),
4′-demethylisopicropodophyllone (15), podophyllotoxone (11), 4′-demethylpodophyllotoxone
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(12), picropodophyllotoxin (13), isopicropodophyllone (14), 4′-demethyldeoxypodophyllotoxin
(4′-demethyldesoxypodophyllotoxin, 9), α-peltatin (18) and β-peltatin (19) (Figure 1) [13].
In this study, the chemical characterization of D. cymosa and P. hexandrum was performed using
UPLC-DAD-ESI-MS. The obtained chromatographic profiles indicated the presence of compounds of
different polarities in the EtOH extracts of D. cymosa and P. hexandrum (Figure 3). The crude extracts
as well as lignans previously isolated from P. hexandrum such as PTOX (1), deoxypodophyllotoxin
(5), 4′-demethylpodophyllotoxin (6), podophyllotoxone (11), α-peltatin (18) and β-peltatin (19) were
evaluated in the same chromatographic conditions. The UV and ESI+-MS spectra for the reference
compounds podophyllotoxin (1) and α-peltatin (18) are presented in Figure 4 (Figure 4A,B). The UV
and MS spectra for all reference compounds and identified chromatographic peaks are available in the
Supplementary Material.
The chromatographic profile obtained by UPLC-DAD for the EtOH extracts of D. cymosa leaves
(Figure 3A), D. cymosa roots (Figure 3B) and P. hexandrum rhizomes and roots (Figure 3C) showed peaks
with UV absorption spectra with λmax around 260–290 nm which is compatible with the chemical
structure of lignans due to conjugation of the aromatic rings. It was possible to identify peaks with
UV absorption pattern characteristic of aryltetralin lignans related to podophyllotoxin (peaks 4, 8, 11
and 13, λmax at 290 nm) and peltatins (peaks 6 and 10, λmax at 275 nm), and arylnaphtalene lignans,
such as diphyllin (peaks 5, 7 and 12; λmax at ca. 260 nm). Peaks with UV spectra characteristic of
other phenolic compounds were also identified, such as phenolic acids (peak 1, λmax at 246, 295 and
326 nm) and flavonoids (peaks 2, 3 and 9, λmax at 265 and ca. 350 nm), which are compounds with
more conjugated chromophores.
UPLC-ESI-MS/MS analyses were carried out in order to identify the major constituents of the
extracts (Table 1). Chromatographic peak 1 (RT = 1.96 min) showed m/z at 353 and 355 in the negative
and positive ionization modes, respectively. The UV absorption profile of compound 1 was indicative
of phenolic acids (λmax ~ 295 and 326 nm). The fragmentation of the parent ion at m/z 353 in a MS2
experiment in the negative mode afforded daughter ions at m/z 191 [M − H − caffeoyl]−, 179 [M −
H − quinic]−, and 173 [quinic acid − H − H2O]− suggesting the identity of compound 1 as one of
the regioisomers of caffeoylquinic acid. The fragmentation pattern of caffeoylquinic acids have been
extensively described [33].
The chromatographic peaks 2, 3 and 9 had a UV absorption profile indicative of flavonols, with
λmax ~ 255–265 and 350 nm. MS spectra associated to peak 2 (RT = 2.91 min) showed a peak of
[M − H]− at m/z 463 and [M + H]+ at m/z 465. The MS2 fragmentation of the parent ion at at m/z 465
in the positive mode afforded a daughter ion at m/z 303 [M + H − hexose]+, indicating that peak 2
could correspond to a hexoside of the flavonol quercetin. The observed fragmentation pattern of the ion
at m/z 303 generated a peak at m/z 165, which is indicative of the presence of a hydroxyl group at C3
of flavonols. A similar UV absorption profile was observed for peak 3 (RT = 3.17 min), which showed
a MS spectra with a peak of [M − H]− at m/z 447 and [M + H]+ at m/z 449. The MS2 fragmentation of
the parent ions at m/z 447 and m/z 449 afforded daughter ions at m/z 285 [M − H − hexose] and 287
[M + H − hexose] in the negative and positive ionization modes, respectively. The 16 a.m.u. difference
observed between peaks 2 and 3, along with the similarity in the UV spectra and in the fragmentation
pattern obtained in MS2 experiments, suggest that peak 2 is a hexoside of the flavonol kaempferol.
This is the major peak observed in the chromatogram of D. cymosa leaves (Figure 3A). The compound
corresponding to peak 9 (RT = 4.53 min) showed a UV and MS profiles similar to those observed for
peak 3. The MS spectra registered for this compound presented a peak at m/z 285 corresponding to
the deprotonated molecule [M − H]−. The fragmentation pattern of the parent ion at m/z 285 was
similar to that observed for peak 3, suggesting that peak 9 corresponds to the aglicone kaempferol.
This flavonol is the major constituent of the EtOH extract of D. cymosa roots.
Analysis of the UV and MS spectra associated with peaks 4 (RT = 3.73 min) and 8 (RT = 4.46 min)
showed λmax at 290 nm, indicative of aryltetralin lignans. MS spectra associated with peaks 4 and 8
showed signals of [M + H]+ at m/z 577 and 415, respectively. The same pattern was observed in the
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negative ionization mode, with signals of [M − H]− at m/z 575 and 459 [M − H + formiate]− for peaks
4 and 8, respectively. The difference of 162 Da between the two compounds indicates the presence
of a hexose residue. The fragmentation of the parent ion at m/z 415 in the positive ionization mode
generated the daughter ion at m/z 247 which is compatible with the neutral loss of a trimethoxybenzyl
group (C9H12O3). These results, along with the analysis of the isolated lignan podophyllotoxin in the
same conditions, allowed the identification of compound 8 as podophyllotoxin (1) and compound 4 as
an O-hexosyl derivative of podophyllotoxin. PTOX (1) is the major component of the EtOH extract
of P. hexandrum rhizomes and roots. On the other hand, this lignan was not found in the extract of
D. cymosa roots.
Chromatographic peaks 5 (RT = 3.84 min), 7 (RT = 4.11 min) and 12 (RT = 5.52 min) showed
UV spectra similar to those observed for arylnaphtalene lignans (λmax at 275 nm). The MS spectra
registered for these compounds showed peaks at m/z 543, for compounds 5 and 7, and m/z 379
for compound 12, corresponding to the deprotonated molecules [M − H]− in the negative mode.
The difference of 162 Da between the compound 12 and compounds 5 and 7 indicates the presence of
a hexose residue in the latter. The fragmentation of ion at m/z 379 in the negative mode originated
the daughter ions at m/z 319 and 391. These fragments were reported for the lignan diphyllin [34],
which suggest that compound 12 is diphyllin (24) while compounds 5 and 7 are O-hexosyl derivatives
of diphyllin.
In the UPLC profile of the EtOH extract of rhizomes and roots of P. hexandrum, the peak eluted at
3.84 min (peak 5′) showed a different UV absorption profile, with λmax at 287 nm, characteristic
of aryltetralin lignans. The MS spectra associated with this compound showed a peak at m/z
399 [M − H]− and 401 [M + H]+ in the negative and positive ionization modes, respectively. Analysis
of the lignan 4′-demethylpodophyllotoxin (6) in the same conditions allowed us to assign this lignan
as the compound responsible for peak 5′.
The compound corresponding to peaks 6 (RT = 3.92 min) and 10 (RT = 4.62 min) showed
UV absorption pattern similar to what is described for peltatins. The MS spectra associated with
chromatographic peak 6 peak showed peaks at m/z 399 and 401 for the deprotonated and protonated
molecules, respectively. The MS2 fragmentation of the parent ion at m/z 401, in the positive
ionization mode, generated the daughter ion at m/z 247 which is compatible with the neutral loss of
a trimethoxybenzyl group (C9H12O3). These results, along with the analysis of the lignan α-peltatin
(18) in the same conditions, allowed the identification of compound 6 as α-peltatin (18). The MS
spectra associated with peak 10 showed peaks at m/z 413 and 415 for the deprotonated and protonated
molecules, respectively. The analysis of the isolated lignan β-peltatin (19) in the same conditions,
allowed the identification of compound 10 as β-peltatin (14).
Figure 3. Chromatographic profiles obtained by UPLC-DAD for the EtOH extracts of D. cymosa leaves
(A) and roots (B) and P. hexandrum rhizomes and roots (C).
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Figure 4. UV, ESI/MS and ESI-MS/MS in the positive ionization mode spectra obtained for
podophyllotoxin (A) and α-peltatin (B).
The UV spectra observed for the compound of peak 11 was very similar to that observed for
peaks 4 and 8, suggesting that compound 11 (RT = 4.86) is an aryltetralin lignan. The MS spectrum
registered for this compound presented peaks at m/z 411 and 413 in the negative and positive modes,
respectively. The MS2 fragmentation of the parent ion at m/z 413 was very similar to that observed for
the lignan podophyllotoxone (11) (RT = 5.28 min), suggesting that the compound corresponding to
peak 11 could be its isomer isopicropodophyllone (14).
The peak 13 (RT = 5.78), which is only present in the EtOH extract of P. hexandrum rhizomes and
roots, showed UV spectra compatible with aryltetralin lignans and the MS spectra presented peaks at
m/z 444 [M − H + formiate]− and 399 [M + H]+. These results, along with the results obtained for the
purified compound allowed the identification of compound 13 as desoxypodophyllotoxin (5).
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2.2. In Silico Prediction of Biological Activity of Lignans
The Active-IT system was composed, at the time the calculations were run, of 1987 biological
activity datasets modeled with SVM and Naïve Bayes machine learning methods. About 1815 datasets
were obtained directly from the PubChem Bioassay database and the remaining 172 datasets were
obtained from different sources, including the combination of several PubChem datasets. Some of these
modeled datasets were reported before, such as AMES [35], AChE [36] and antifungal/antibacterial
activities [37], however most remain unpublished. The complete description of all modeled datasets is
far beyond the scope of this paper and will not be discussed in detail.
The target fishing approach was performed using the Active-IT programme [36]. Before being
able to perform predictions of biological activities of the lignans with the Active-IT system, we first
made an ultimate validation using some known activities of these compounds. About 12 of the 27
lignans (compounds from 1 to 27) used in this study appear in one or more datasets from the PubChem
Bioassay. Among the 1815 PubChem PubChem Bioassay datasets within the Active-IT system about
243 have one or more lignans of the series, with a total of 309 activity points, with 128 classified as
active and 181 classified as inactive. For example, the podophyllotoxin (1) appears in 195 different
datasets. As expected, the activity predictions of lignans using these models produced excellent results
with an AUC of 0.96 for SVM and 0.82 for Naïve Bayes (Figure 5A and Table 2).
Therefore, we decided the best approach for validation was to re-build all of these 243 models,
excluding the lignans that appear in each dataset and repeat the prediction. The details of all these
models, as well as their internal validation are included in the Supplementary Material (Table S3).
The calculated values Pa-Pi of lignans that were excluded from the models are shown in Table S4 of
the Supplementary Material. As expected the prediction was a little worse, but the results are still very
good, considering most datasets have a cell-based format, with an AUC of 0.71 for SVM and 0.73 for
Naïve Bayes (Figure 5A and Table 2). It is worth pointing out that while the SVM method experienced
a large decrease in AUC (0.25 AUC units) the Naïve Bayes had a far smaller decrease (0.09 AUC units).
This is an evidence that the Naïve Bayes method has a smaller dependence from the input and is less
unresponsive to small variations of the dataset composition. The SVM has a lower resilience as it is
much more dependent on the input dataset.
However, the validation with AUC only tells us whether the global prediction was accurate or not.
In the chemoinformatics it is more important to define whether the most probable active compounds
appear in the highest positions in the ranking.
Table 2. Results of the area under the ROC curve (AUC) for biological activity prediction of lignans.
Only models with AUC > 0.5 were considered. For activity classes the experimental data points were
merged into 125 activity classes. In this case, all 27 lignans have had their activity predicted and were
used to build the activity class score.
Method Dataset







Naïve Bayes NEW a 0.730 ± 0.037 292 0.767 ± 0.054 125
Naïve Bayes OLD b 0.816 ± 0.031 292 0.803 ± 0.050 125
SVM NEW a 0.710 ± 0.037 305 0.673 ± 0.062 125
SVM OLD b 0.962 ± 0.014 305 0.868 ± 0.041 125
a Datasets where all lignans were excluded; b Datasets that include some lignans.
Several metrics can be used to decide the better cutoff to be applied in a classification schema.
We used the three metrics based on a contingency matrix to decide the best cutoff to be used:
(1) F-score is a measure of the accuracy of the test, calculated by the harmonic mean of recall or
sensitivity [TP/(TP + FN)] and precision [TP/(TP + FP)];
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(2) Matthews Correlation Coefficient (MCC) is a balanced measure of the quality of binary
classification and is the most informative single score to establish the quality of a binary classifier
prediction in a confusion matrix context [38];
(3) Enrichment Factor (EF) is a measure of how many more active compounds we find relative to a
random distribution, it is calculated from the proportion of true active compounds selected in
relation to the proportion of true active compounds in the entire dataset [39].
The complete results of Pa-Pi values calculated for all lignans, as well the predictions made, are
included in the Supplementary material (Table S4). The best cutoff for the classification of lignan
compounds as active or inactive was Pa-Pi ≥ 0.15 for both SVM and Naïve Bayes methods, using a
positive lower limit of Pa-Pi as an additional filter. In Table 3 are presented a summary of the results
when this threshold value is applied. In this table it is possible to note that SVM outperforms Naïve
Bayes method for both datasets in the prediction of active compounds, and both methods present
a higher specificity as few inactive compounds are misclassified as active (low false positive rate).
This draws attention to the fact that the misclassified inactive compounds are almost the same for
datasets with (OLD) or without the lignans (NEW) and, despite the fact that there are several active
missed, both methods present a good precision as most of the compounds predicted as active are
really active. Both methods lost performance when the lignans are deleted from the modeling dataset,
but the effect is more pronounced in SVM, as discussed before for AUC results.
The main approach used in this work to make predictions about the biological activities of lignans
was the grouping of several models in activity classes and this procedure must be validated as well.
The 243 datasets used in the validation were classified in 137 activity classes, with the more populated
being the models associated with leukemia cancer with 16 different datasets. From these 137 activity
classes only 125 showed a predominance of active (47 cases) or inactive compounds (78 cases), and 12
showed an equal number of active and inactive. Thus, the predominance of active or inactive lead
us to classify 47 classes as “probable active” as the lignans are prone to be active and 78 classes as
“probable inactive” as the lignans are prone to be inactive.
To make the prediction, all 27 lignans were submitted to 243 models and the activity class score
was calculated as described in the Material and Methods section. To build this score, the individual
Pa-Pi values were not taken in account, only the number of cases where the value of Pa-Pi is above the
threshold and with a positive minimum value.
Table 3. Validation of biological activity prediction of lignans. For all methods the threshold was
defined at Pa-Pi = 0.15. Compounds with Pa-Pi better or equal to the threshold are classified as active
and compounds with Pa-Pi below the threshold are classified as inactive. Compounds with a Pa-Pi
minimum below zero are classified as inactive, no matter the mean Pa-Pi. In the rows named as
“Both” the compound was predicted as active if any method predicted it as active. The metrics F-score,
MCC and EF were used to define the best threshold (full data not shown).
Method Dataset TP FP TN FN F-Score MCC EF
Naïve Bayes NEW a 30 17 151 94 0.35 0.19 1.54
SVM NEW a 46 21 159 79 0.48 0.30 1.66
Both NEW a 60 33 148 68 0.54 0.31 1.56
Naïve Bayes OLD b 51 17 151 73 0.53 0.36 1.81
SVM OLD b 106 18 162 19 0.85 0.75 2.06
Both OLD b 112 33 148 16 0.82 0.68 1.87
a Datasets where all lignans were excluded; b Datasets that include some lignans.
The best threshold was determined by analyzing the value of MCC for each threshold (Table 3),
being Pa-Pi ≥ 0.3 for Naïve Bayes and Pa-Pi ≥ 0.25 for SVM. The score of each activity class, in these
cases, was calculated by the number of lignans classified as active among all the models belonging to
the same class divided by the number of lignans used in the calculations (27) and the square root of the
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number of models of this class. The division by the square root of the number of models works like a
normalization process because as the number of models in the same class increases more compounds
are prone to be predicted as active for this class. From our experience, if we divided by the number of
models, those classes with a large number of models are penalized, and if we take only the number
of compounds the classes with a large number of models are privileged. The division by square root
brings some balance to the prediction.
Using this approach we reconstructed the ROC curves using the scores of activity classes and
the results are show in the Figure 5B and Table 3. As we can see the values of AUC metric although
a little smaller than those obtained when we use the Pa-Pi scores of each individual compound are
high enough to say that this approach sounds viable and allow us to use it to classify the whole set
of lignans instead of analyzing a much larger number of results when we consider each compound
independently. It is worth noting that all lignans were used in this activity class validation and not only
those for which experimental results are available. Another interesting result was that for Naïve Bayes




Figure 5. Validation of biological activities prediction of lignans. (A) ROC curves obtained in the
prediction using all 309 experimental data available for lignans. The values of Pa-Pi scores were used
to rank each data point. (B) ROC curves obtained for prediction after grouping the experimental data
in 125 activity classes (12 classes with an equal number of active and inactive were not considered).
The rank was built with an activity class score calculated with the number of lignans with Pa-Pi scores
above the threshold, divided by the square root of the number of models belonging to the same class.
193
Molecules 2018, 23, 3303
A partial list of predicted biological activities as well as the targets associates with the diseases are
described in the supplementary material (Table S1 for SVM, Table S2 for Naïve Bayes and Table S3 for
results when both methods are taken together). In Table 4 is presented a summary about the activities
predicted until the 50 position in the ranking of 753 activity classes using both machine-learning
methods (Table S3 of the Supplementary Material).
2.3. Antibacterial Activity
Infectious diseases, especially those caused by bacteria, are a major concern in several countries
mostly due to antimicrobial resistance, which is a global public health issue that could hold back the
control of many bacterial diseases [40]. Therefore, the search for new antimicrobial compounds from
natural sources is immensely valuable. The in silico target fishing showed a probable antibacterial
activity for aryltetralin lignans, as presented previously.
In our study, the ethanolic extracts from roots of D. cymosa and from rhizomes and roots of
P. hexandrum were the most effective extracts against Gram-positive bacteria, reaching total inhibition of
the microbial growth against B. cereus and proeminent inhibition rates (58.43 ± 2.7% and 67.56 ± 0.8%,
respectively) against S. aureus (Table 5). PTOX also presented antibacterial activity against S. aureus
(53.34 ± 8.8%) and E. coli (51.57 ± 9.08%). No antibacterial activity of the extracts and PTOX was
observed against the Gram-negative pathogens EHEC, P. aeruginosa and Salmonella Typhi.
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24.76 ± 5.8 0 34.30 ± 2.33 0 23.18 ± 9.94 24.88 ± 3.93
D. cymosa
(roots)




58.43 ± 2.7 100.66 ± 0.28 49.28 ± 6.97 18.53 ± 5.21 22.51 ± 15.91 42.52 ± 6.40
Podophyllotoxin 53.34 ± 8.8 0 51.57 ± 9.08 33.00 ± 7.76 30.19 ± 9.39 31.62 ± 7.54
2.4. Anticholinesterasic Activity
We evaluated the AChE inhibitory activity of D. cymosa and P. hexandrum extracts as well as of
PTOX. All extracts showed promising inhibition of AChE activity in the quantitative assay. The EtOH
extract of leaves from D. cymosa showed the higher percentage of inhibition at 400 μg/mL (Table 6).
In the bioautographic assay, the extract of P. hexandrum showed a higher intensity of white spots, and
this result did not correspond to the quantitative assay. This may have happened due to the possibility
of false-positive results when the evaluated extract presents some classes of secondary metabolites,
such as tannins and phenolics, which do not directly inhibit the enzyme but can induce enzymatic
denaturation [57,58]. On the other hand, the in silico studies did not confirm the AChE inhibition
activity (position 577 in 753 models) by the group of 27 lignans investigated in the present study.
Table 6. In vitro evaluation of antioxidant and anticholinesterase activity of ethanolic extracts from
D. cymosa, P. hexandrum and podophyllotoxin.
Samples









D. cymosa (leaves) 19.48 ± 5.90 133.94 ± 25.60 >50 + 64.22 ± 4.87 368.0 ± 13.8
D. cymosa (roots) 20.76 ± 1.76 43.77 ± 6.69 10.20 ± 1.46 - 40.86 ± 3.70 100.0 ± 5.3
P. hexandrum
(rhizomes and roots)
30.70 ± 2.12 24.66 ± 4.45 13.66 ± 1.35 ++++ 47.04 ± 3.17 338.9 ± 15.1
Podophyllotoxin >200 >200 >50 - 32.73 ± 5.38 400 ± 10.3
Quercetin 0.3 ± 0.1 NA NA NA NA NA
Pyrogallol NA 1.14 ± 0.15 NA NA NA NA
Propylgalate NA NA <20 NA NA NA
Physostigmine NA NA NA ++++ 89.81 ± 1.16 NA
- not active; + slight inhibition, ++++ strong inhibition.
2.5. Antioxidant Activity
Although, inhibition of AChE is still considered as the main therapeutic strategy to treat
Alzheimer’s disease, other events are implicated in the physiopathology of this disease. The role
of oxygen reactive species (ROS) have been extensively investigated. Therefore, we evaluated the
antioxidant potential of the EtOH extracts of D. cymosa leaves, roots and P. hexandrum rhizomes
and roots.
The extract of leaves from D. cymosa showed antioxidant activity only in the β-carotene/linoleic
acid co-oxidation assay, while the extract of roots showed promising antioxidant activity in all
evaluated models. The extract of P. hexandrum roots and rhizomes presented significant antioxidant
potential in all evaluated models. However, the isolated lignan PTOX (1) showed no antioxidant
activity (Table 6).
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2.6. Cytotoxicity
The results of the cytotoxicity assay, performed in THP-1 cells using the SRB method, indicated a
moderate toxicity for the extracts of leaves from D. cymosa and of roots and rhizomes from P. hexandrum,
which showed cell viability lower than 80% at 200 and 400 μg/mL, with CC50 of 368.0 ± 13.8 and
338.9 ± 15.1 μg/mL (Table 6). On the other hand, the extract of roots from D. cymosa was cytotoxic
at all tested concentrations, with a CC50 value of 100.0 ± 5.3 μg/mL. The lignan PTOX (1) showed
a CC50 value of 400.0 ± 10.3 μg/mL (Table 6). In silico prediction indicated a small probability of
lignans to present THP-1 cytotoxicity (position 316 in 753 activity classes).
3. Discussion
A broad range of biological activities have been associated with lignans, thus making them
an interesting class of secondary metabolites. Even though lignans are known for their toxicity,
other biological activities of lignan-rich plant extracts are worth investigating.
The chromatographic characterization of the phenolic content of the EtOH extracts of D. cymosa
leaves, D. cymosa roots and P. hexandrum rhizomes and roots indicated a similar chemical composition
for the three extracts. The caffeoylquinic acid was only identified in D. cymosa leaves, while PTOX
hexoside, deoxypodohyllotoxin (5) and 4′-demethylpodohyllotoxin (6) were only found in P. hexandrum.
PTOX was found in the EtOH extracts of D. cymosa leaves and P. hexandrum rhizomes and roots, being
the major constituent of the latter. The EtOH extract of roots from D. cymosa showed the best antioxidant
potential among the evaluated extracts. These results can be explained by the presence of kaempferol as
the major constituent of this extract. Numerous studies have shown that flavonoids, such as quercetin
and kaempferol, and their heterosides have a wide range of biological activities, including antioxidant,
anti-inflammatory and antimicrobial activities [59,60]. Recently, Wang and co-workers [61] observed a
DPPH and ABTS radical scavenging activity for kaempferol as well as an inhibition of concanavalin A
(Con A)-induced NO or ROS production in LPS-induced RAW 264.7 macrophage cells [61]. In another
study, kaempferol was able to scavenge the superoxide anion, hypochlorous acid, chloramine and
nitric oxide [62] as well as showed scavenging ability on superoxide anion produced by electrochemical
reduction of oxygen [63].
The lignan content of Podophyllum and Diphylleia species varies both qualitatively and
quantitatively, according to the data previously published. UPLC-DAD-MS methods are largely
employed for the identification and quantification of lignans in the aforementioned species [64–67].
Sharma and Arora identified four aryltetralin lignans in the MeOH extract of rhizomes from
P. hexandrum [64]. In another study, Sharma and Kumar evaluated the extracts of leaves and
roots of P. hexandrum obtained from different locations by HPLC-ESI-MS, and found that the
podophyllotoxin content was twice as high in the roots in comparison with the content found in
the leaves of P. hexandrum found in high altitudes [65]. Avula e coworkers evaluated the content of
podophyllotoxin (1), 4′-demethylpodophyllotoxin (6), α-peltatin (18) and β-peltatin (19) in samples
from P. peltatum. 4′-demethylpodophyllotoxin (6) and α-peltatin (18) were the main lignans observed
for this species, while the content of PTOX varied from 0.004–0.77% when plants colletcted from
various colonies within the same site were evaluated [66]. UPLC-ESI-MS methods can also be
employed for the pharmacokinetic studies. The lignans podophyllotoxin (1), 4-epi-podophyllotoxin
(2), and 4′-demethylpodophyllotoxin (6) were simultaneously evaluated in rat plasma using a
UPLC-ESI-MS method after oral administration of the EtOH extract of Diphylleia sinensis, 367 mg/kg,
to Wistar rats [67]. It is noteworthy to mention that this is the first report of the characterization of
flavonoids and caffeoylquinic acid in D. cymosa.
Some predictions of biological activities observed in this study were in accordance with the
ethnopharmacological uses for both plant species, as well as for the other isolated podophyllum lignans.
However, some new predict activities such as angiogenesis, osteoporosis, myotonic dystrophy and
autoimmune diseases were also observed (Table 4). A reasonable agreement could be noted between
predictions made with SVM and Naïve Bayes modeling methods, although the use of both methods
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can produce results that are more reliable, as indicated in the validation step. Thus, all predictions
discussed below will be based in a unique rank of 753 activity classes, where the best rank between
both methods and the averaged rank were used to produce the final ordered list.
The in silico approach showed a high probability of lignans have an anti-inflammatory activity
(position 1 in 753 activity classes). This activity has been described before for lignans [11]. The most
probable target related with this activity is NF-κB activation. The nuclear factor NF-κB pathway has
been considered a classical proinflammatory signaling pathway [68].
The cytotoxic activity of lignans has been much explored, as well as their mechanism of action.
The results from in silico prediction showed a low cytotoxicity against THP-1 cells (316/753), which is
in accordance with our experimental results. Podophyllotoxin have been evaluated in several
models using THP-1 cells, with moderate to low toxicity reported. The effect of podophyllotoxin
on IL-1β and TNF expression was evaluated using THP-1 cells at 10 μM and no cytotoxicity was
observed [69]. However, according with our calculations, lignans could present cytotoxicity against
human lymphoblastic (position 2 in 753 activity classes), isogenic chicken DT 40 (position 19 in 753
activity classes), HEK293 (position 32 in 753 activity classes) and MAGI-CCR5 (position 50 in 753
activity classes) cells. Derivatives have been synthetized [11] to obtain new antitumour compounds.
Many targets involved in cancer therapy have also been predicted as potential targets for lignans,
such as AP1 endonuclease (position 6 in 753 activity classes), tumor antigen p53 (position 7 in 753
activity classes), GLI family zinc (position 11 in 753 activity classes), RecQ-like DNA helicase 1 (position
14 in 753 activity classes). Other targets can be found in Table 4 and Table S3 of Supplementary Material.
The lignans also showed high probability to be active against Salmonella typhimurum (position 3 in
753 activity classes), Mycobacterium tuberculosis (position 4 in 753 activity classes), Staphylococcus aureus
(position 23 in 753 activity classes), Pseudomonas aeruginosa (position 18 in 753 activity classes) and
Escherichia coli (position 52 in 753 activity classes). In this study, all these microorganisms were
evaluated, with the exception of M. tuberculosis. These predictions are in agreement with ours
in vitro results from the antibacterial assay. The activity against M. tuberculosis is consistent with
the ethnopharmacological use in the Eastern world folk medicine [42].
Regarding the in vitro antibacterial activity, the ethanolic extracts from rhizomes and roots of
P. hexandrum and from roots of D. cymosa were the most effective samples against Gram-positive
bacteria. PTOX (1) showed significative activity against S. aureus and E. coli, while no antibacterial
activity was observed against the other Gram-negative pathogens. The antibacterial activity of
lignans have already been reported. Nanjundaswamy and coleagues [70] reported a relevant
antibacterial activity of two synthetic precursors of PTOX against E. coli, P. aeruginosa and Salmonella
Typhi. Other authors have also indicated antibacterial activity of extracts from the rhizomes of
P. hexandrum [71] and analogues of PTOX against P. aeruginosa [72], contrasting the results of the
present study. This finding supports the ethnopharmacologial uses of both plant species. No mention
of antimicrobial activity from D. cymosa was reported so far.
Interestingly, PTOX did not elicit a higher inhibition of the growth of most of the evaluated
microorganisms, in comparison with the crude extracts. This is probably due to the synergistic effect
of secondary metabolites in the crude extracts.
Considering S. typhimurum, one target related to the predicted activity is the PhoP regulation.
This target is composed by two genes PhoP and PhoQ, associated with virulence, survival inside the
macrophages and defensing resistance of S. typhimurum [73]. Against M. tuberculosis, the possible
target is a transaminase BioA, an enzyme involved in biotin biosynthesis, representing a potential
target to develop new antitubercular agents [74]. The putative target involved in the activity against
S. aureus is the Quorum sensing (QS), defined by Reuter and co-workers [75] as the exchange of
chemical signals in bacterial populations, that depends on the bacterial density. QS is responsible for
virulence in the clinically relevant bacteria. It has been suggested as a promising target for developing
new anti-infective compounds. It was not found a specific target related to E. coli.
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The extracts of roots from D. cymosa and rhizomes and roots of P. hexandrum showed the best
antioxidant potential, while the extract of leaves from D. cymosa showed an anticholinesterasic activity.
All the extracts showed moderate toxicity to the THP-1 cells, and the cytotoxic activity observed for the
extracts of leaves of D. cymosa and rhizomes and roots of P. hexandrum were similar to that observed
for PTOX (1), which did not exhibit antioxidant and anticholinesterase activity. These results indicate
that PTOX (1) could be the major cytotoxic lignan in these extracts, while other phenolic constituents
could be responsible for the antioxidant and anticholinesterase activities observed. However, in the
extract of roots of D. cymosa, which showed the lowest CC50 value, the lignan PTOX (1) was not found,
indicating that other unidentified minor compound is the responsible for the observed cytotoxicity.
According to the in silico prediction (position 49 in 753 models), the lignans can act DNA
damage-inducible transcript 3 protein (C/EBP homologous protein, CHOP) which has been
proposed as a target of treatments for some neurodegenerative diseases as Alzheimer’s diseases [52].
Furthermore, according to Naïve Bayes prediction (Table S2 in the Supplementary Material) the lignans
can possibly act over the protein Tau indicating a potential application to treat the Alzheimer’s disease
and other diseases [76].
Another important effect of lignans is the immunosuppressive activity what can be associated
to their uses as therapeutic agents against psoriasis and rheumatoid arthritis, as well to prevent the
acute rejection of transplanted organs [77,78]. One putative target that could explain this activity is the
sphingosine 1-phosphate receptor 1, predict as potential target for lignans (position 20 in 753 activity
class), due to its involvement in immune system modulation [79].
The anti-viral activity of lignans is well known since it was first cited in 1942 as a treatment for
veneral wart (Condyloma acuminatum), an ailment caused by a papilloma virus [80]. There have been
reported effects against HIV, herpes simplex, influenza, vaccinia viruses, and measles [42]. These results
also confirm our in silico predictions as the activities against HIV-1 and herpes appear in position 9
and 42, respectively, among 753 activity classes.
The hypolipidemic properties of lignans, as reported by Iwasaki and co-workers [81] are in
consonance with our prediction as potential target for these compounds the 1-acylglycerol-3-phosphate
O-acyltransferase, a protein activator of the lipase Atgl [82], predict in position 41 among 753 activity classes.
There are no reports in literature of the evaluation of the anticholinesterase activity of
Berberidaceae plants or of the lignan PTOX (1), but other lignans have already demonstrated in vitro
AChE inhibitory activity [83]. In the study by Hung and co-workers [84], sixteen lignans were isolated
from Schizandra chinensis and were evaluated for the inhibition of AChE in vitro. Among the evaluated
compounds, only five were active with IC50 lower than 15 μM. Schisandrin was evaluated in vivo
by Itoh et al. [85] and was active at 3 mg/kg. El-Hassan et al. [86] demonstrated that Syringaresinol
inhibited AChE in vitro with an IC50 value of 200 μg/mL. Still exploring the investigation of AChE
inhibition activity by lignans, Salleh et al. [87], isolated five lignans from the stem extract of Beilschmiedia
pulverulenta, which were evaluated in vitro in the microplate inhibition assay for the AChE, showing
have IC50 values in the range of 179.8 to 504 μM.
Regarding the antioxidant capacity of these compounds, studies by Wang et al. [88] evaluated the
ability of the extracts of S. chinensis and S. sphenanthera to scavenge the DPPH radical. The authors
suggested that variations in lignan content between the extracts lead to different antioxidant activities.
The S. chinensis species showed higher activity due to the higher content of the lignans Schisandrol A
and B and Schinsandrin B.
In a study by Dar et al. [63], the antioxidant capacity of PTOX (1) was evaluated in the DPPH
sequestration and the TBARS lipid peroxidation assays. In both experiments, PTOX presented IC50
value higher than 250 μg/mL.
These results, along with the data found in literature, indicates that PTOX (1) is probably not
involved in the antioxidant activity observed for P. hexandrum and D. cymosa extracts, but other lignans
or other phenolic constituents may account for the observed activity.
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4. Materials and Methods
4.1. Plant Material
The leaves and roots of D. cymosa plants were collected at the University of Nottingham
(Nottingham, UK) in June, July and August 1995. The authentication of plants was confirmed by Julian
MH Shaw (Senior Registrar, Horticultural Taxonomy, Royal Horticultural Society, Wisley, Working,
UK). Dried rhizomes and roots of P. hexandrum were purchased from United Chemical and Allied
Products, Calcutta, India. Both plants were kindly provided by Dr Paul M. Dewick (University of
Nottingham, Nottingham, UK). The purified lignans used in this study were isolated and identified in
a previous work [24].
4.2. Preparation of Extracts
Powdered material (4.8 g) of D. cymosa (leaves and roots) and P. hexandrum (rhizomes and roots)
was extracted with 150 mL ethanol 92.8◦ by sonication for 10 min at room temperature. The solutions
were filtered and the solvent was removed under reduced pressure in a rotary evaporator. The process
was repeated three times, and the combined extracts were dried in a water bath (40 ◦C) to yield the
ethanolic crude extracts. The latter were 15.83% yield for leaves and 14.03% for roots of D. cymosa
respectively, as well as 8.33% for rhizomes and roots of P. hexandrum. All samples were stored at 4 ◦C
in amber flasks until required.
4.3. Chromatographic Characterization of D. cymosa and P. hexandrum Extracts by UPLC-DAD-ESI-MS/MS
The UPLC-ESI-MS profiles were obtained in a UPLC system coupled with DAD and ESI-TQ-MS
detectors. The samples were prepared at 1.0 mg/mL using MeOH, centrifuged (10,000 rpm, 10 min)
and then filtered through 0.22 μm PTFE filters. A portion of 3 μL of each sample was injected into the
chromatographic system.
4.3.1. Chromatographic Conditions
The elution was carried out using a gradient elution of 0.1% formic acid in deionized water with
(A) and 0.1% formic acid in acetonitrile (B), in a gradient elution from 5 to 36.5% of B in 3.5 min,
36.5–54.5% from 3.5 to 7.5 min, 54.5 to 95% from 7.5 to 9.0 min, with a final isocratic period at 95% B
from 9.0 to 10.0 min. The analyses were performed in an Acquity-HSS-ODS (150 × 4.0 mm, 1.8 μm)
C-18 column at 40 ◦C.
4.3.2. Mass Spectrometric Conditions
The mass spectrometer (Waters TQ-XS, Milford, DE, USA) was operated in negative and positive
electrospray ionization modes and spectra were recorded by scanning the mass range from m/z 100
to 1000 in both MS and MS/MS modes. Nitrogen was used as drying, nebulising and collision gas.
Drying gas flow rate was 12 L/min. The heated capillary temperature was set at 350 ◦C and nebulizer
pressure at 45 psi. The source parameters such as capillary voltage (VCap), fragmentor, skimmer and
octapole voltages were set at 3500 V, 175 V, 65 V and 750 V, respectively. For the MS/MS analysis,
a ramp of collision energies, from 15 to 70 eV, was used. The obtained data were processed using the
MassLynx (version B 04.00) software (Waters, Milford, DE, USA).
4.4. In Silico Studies
4.4.1. In Silico Prediction of Biological Activity of Lignans
The molecular descriptors used to build the models were the multi-conformational 3-point
pharmacophore fingerprints produced by in-house software 3D-Pharma [89]. Each conformation
of each compound was treated separately, and its heavy atoms were converted to potential
pharmacophore points (PPP) which could be one or more of the following six types: hydrogen
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bond donor, hydrogen bond acceptor, positively charged, negatively charged, aromatic and lipophilic.
For each conformation all combinations of three pharmacophore points in the 3D space (triplets) were
calculated to compose a pharmacophore fingerprint. The union of uni-conformational fingerprints
produce a unique modal fingerprint for each compound [90] which was used for all subsequent
calculations. In the cases where the datasets were obtained from PubChem Bioassay the conformations
were downloaded from PubChem Compound [91], in all other cases the conformations were
produced with OMEGA software from OpenEye with standard options limited to a maximum of 10
conformations [92,93].
The multi-conformation (modal) pharmacophore fingerprint of active and inactive compounds
of each dataset were submitted to the in-house software ExCVBA [94] to build and validate machine
learning models using support vector machine (SVM) and Naïve Bayes approaches. Each dataset
was used to produce SVM and Naïve Bayes ensemble of models through recurrent stratified random
partition of the original dataset to produce a training set composed of 70% of the original dataset and a
validation set composed of 30% of the original dataset. This process was repeated at least 30 times and
the average scores of each compound over the models in which it appears in the validation set was
used to assess the modeling performance with the area under the Receiver Operating Characteristic
curve (AUC-ROC), as well for activity prediction of new compounds, as described below.
The calculation of AUC-ROC was performed as defined in Equation (1) with the rank sum of
active compounds, which is also called Mann-Whitney U test:










where ri is the rank of the jth active, Na, and Ni are the number of active and inactive compounds,
respectively. When ties occur between active and inactive the rank of the active were scaled by
interpolation to avoid any bias. The expected standard error of AUC in this paper follows the
proposition of Nicholls [95] (Equation (2)), based on Hanley [96] approximation for an ‘typical’
ROC curve:
AUC = w ± t95%
√
w2(1 − w)/(1 + w)
Na
+
w(1 − w)2/(2 − w)2
Ni
(2)
where w is the observed AUC. In the estimation of t-statistic at 95% (t95%) the number of degrees of
freedom, ν, follows the proposition of Nicholls [97] (Equation (3)), from the variances of actives and
inactives and using the Welch–Satterthwaite formula:














The SVM models were built with LibSVM [98] software with linear kernel option. The cost C,
which is a penalty parameter applied to misclassified compounds on the training data, was selected
with exponentially growing sequences from 2−12 to 2+6, by means of a 5-fold cross-validation (CV)
using the Power Metric [39,99] at χ = TPR + FPR = 0.5 as an optimization objective metric to assure early
recovery of active compounds. The Naïve Bayes model was produced using Perl module from CPAN
repository [100] which was incorporated into the ExCVBA software (NEQUIM, Belo Horizonte, Brazil).
In the prediction phase the modal multi-conformational pharmacophore fingerprints of the new
compounds were submitted to SVM or Naïve Bayes model ensemble and the average raw scores
obtained were converted into probabilities through comparison with the score distribution of active
and inactive compounds used to build the models (validation sets only), producing a measure of
belonging to these two subsets [101].
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Considering the SVM or Naïve Bayes score of the new compound as the threshold, the probability
of it being active (Pa) is equal to the fraction of active compounds with a worse score (FNR) than
the compound under prediction (Equation (4)) and the probability of being inactive (Pi) is equal
to the fraction of inactive compounds with a better score (FPR) than the lignan under prediction









where Na and Ni are the number of active compounds and the number of inactive compounds; FN is
the number of active compounds with worse scores than the threshold; and FP is the number of
inactive compounds with better scores than the threshold. For each model ensemble, the difference
between the Pa and Pi (Pa-Pi) was used to evaluate the potential activity of the modeled compounds.
Although the variance of Pa-Pi, as well its limits, can be analytically estimated from the variances of
Pa and Pi, as described before [36], in this work we used a new approach, as described below.
The variance of the SVM or Naïve Bayes scores of each compound when it appears in the
validation sets and the standard error of the mean (SEM) (Equation (6)) were used to build a better





where SD is the standard deviation, defined as the root mean squared of the variance. Accordingly,
the limits of scores, computed at 95% of confidence interval, were estimated by Equation (7):
scorelimits = scoremean ± t95% ∗ SEM (7)
The values of mean score were used to calculate the mean value of Pa and Pi, while the maximum
and minimum values were used to estimate their upper and lower limits, as exemplified in the Figure 6.
In the prediction phase, the scores of each unseen compound over all 30 models of the ensemble
are averaged and the limits are calculated with 95% of confidence interval. The average score is used
to calculated the Pa-Pi mean from the average value of Pa minus the average value of Pi. The upper
limit of the score is used to calculate the upper limit of Pa-Pi, using the higher value of Pa minus the
lowest value of Pi, whereas the lower limit is used to calculate the lowest value of Pa-Pi, using the
lower value of Pa minus the higher value of Pi. The limits of Pa-Pi calculated in this way provide a
better confidence interval of the prediction, although much larger than the analytical estimate it is
more useful as it can be used as an applicability domain approximation, likewise the proposition of
Norinder and co-workers [102]. If the new compound looks like an outlier the score variance over all
30 models can be very large and this will reflect in the range of values of Pa-Pi. If the lower value of
Pa-Pi falls below zero the compound cannot be predicted as active.
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Figure 6. Variation of Pa and Pi probabilities with the SVM score in the model for agonists of the P53
signaling pathway (AID = 720552) together with its upper and lower limits. Calculation of the limits of
Pa-Pi for each new compound involve the upper and lower limits of the score over all 30 models of the
ensemble. Maximum Pa-Pi will be calculated from the higher value of Pa minus lower value of Pi and
minimum Pa-Pi will be calculated from the lower value of Pa minus higher value of Pi. If this value
falls below zero the compound is considered inactive.
4.4.2. In Silico Prediction of Putative Activity Classes of Lignans
To predict potential biological activities of lignans used in this study, all 1987 datasets of Active-IT
system were grouped into 924 activity classes. This grouping approach will make it easier to predict the
larger datasets of compounds with a common substructure. To make the prediction of most probable
activity classes all data points are filtered with a pre-defined threshold and, additionally, a positive
minimum limit of Pa-Pi. In the next step, the instances that pass the filters are counted. The final
activity class score is calculated by the sum of instances that pass the filter among all models belonging
to the same class, divided by the number of compounds and by the square root of the number of
models of the same class.
4.5. Evaluation of Antibacterial Activity
Antibacterial susceptibility was performed using the modified microdilution method for
bacteria [36,103], against Gram-positive (Staphylococcus aureus ATCC 25923 and Bacillus cereus ATCC
11778) and Gram-negative recognized pathogens (Escherichia coli ATCC 11775, Enterohemorrhagic
E. coli ATCC 43895-EHEC, Pseudomonas aeruginosa ATCC 10145 and Salmonella choleraesuis subs.
choleraesuis sorotype Typhi BM/Panama-TY2).
The experiments were performed in 96 well microplates. The extracts and isolated substance
solubilized in DMSO (VetecTM) at 50 mg/mL were diluted in Mueller Hinton Broth (MHB, Difco) at a
concentration of 500 μg/mL. The bacterial isolates, criopreserved at −80 ◦C were grown in Tryptic Soy
Agar (TSA, Acumedia®) plates, at 37 ◦C for 18–24 h. The inoculum was adjusted in saline solution in a
spectrophotometer at 625 nm, to a concentration of 1–5 × 108 CFU/mL and then diluted in MHB to
1–5 × 105 CFU/mL.
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Volumes of 100 μL of the inoculum were added to wells containing 100 μL of the extracts at
500 mg/mL, in triplicate (one well intended for extract control), resulting in a final concentration
of 250 μg/mL. Chloramphenicol at 50 μg/mL and 0.5% DMSO were used as positive and negative
controls, respectively. Evaluation of microbial growth was carried out by adding the inoculum to a
well containing only MHB. Sterility of the culture medium was also confirmed by incubation in the
assay plate. Assays were performed in triplicate. The microplates were incubated at 37 ◦C for 24 h.
As an indicator of microbial growth, 20 μL of 2,3,5-triphenyltetrazolium chloride (TTC, Sigma-Aldrich,
St. Louis, MO, USA) at 5 mg/mLwere added to each well. The plates were incubated at 37 ◦C for
3 h and then the TTC was solubilized with 100 μL of sodium lauryl sulfate solution in isopropanol
7 μg/mL and measured in a microplate reader at 485 nm. The result was expressed as the percentage
of inhibition compared with the microbial growth control [104], and was considered positive for
antibacterial activity for those extracts with an inhibition higher than 50%.
4.6. Inhibition of Acetylcholinesterase
4.6.1. Bioautographic Assay
The bioautographic assay was performed by thin layer chromatography (TLC) according to
the method proposed by Marston, Kissling and Hostettman [105]. The extracts were solubilized
in methanol (Merck) at 20 mg/mL, and a portion of 10 μL of this solution was applied on a TLC
plate (silica gel 60 F254, Merck, Darmstadt, Germany), which was eluted with CHCl3:MeOH (9:1).
The acetylcholinesterase enzyme (Electropardus electricous type VI-S, Sigma-Aldrich, St. Louis, MO,
USA) solution was prepared by diluting 1 KU of the enzyme in 30 mL of Tris/HCl buffer, pH 7.8,
with the addition of 30 mg of bovine serum albumin (BSA). The enzyme solution was sprayed on the
TLC plate and incubated in a humid chamber at 37 ◦C for 20 min. The substrate solution was prepared
using 1-naphthyl acetate (2.5 mg/mL) and Fast Blue B salt (2.5 mg/mL), and sprayed on the TLC plate
after the incubation period. The purple staining shows the enzymatic activity and the appearance of
white bands after 5 min indicates inhibition of AChE activity. The result was expressed by the intensity
of the white bands observed.
4.6.2. Microplate Assay
AChE inhibition assay was performed on a 96-well microplate according to Ellman’s method [106]
with adaptations. Initially, the extracts were solubilized on MeOH, at 20 mg/mL, and diluted to
4 mg/mL using Tris/HCl buffer solution (50 mM, pH 8.0). A portion of 25 μL of the samples
(4 mg/mL) were added to the wells of the microplate, as well as 50 μL of 0.1% BSA solution in
Tris/HCl Buffe (pH 8.0), 125 μL of DTNB in Tris/HCl (3 mM) containing NaCl (10 mM) and MgCl2
(20 mM). Subsequently, 25 μL of the ATCI aqueous solution (15 mM) was added to all wells. Then,
a background reading was performed at 405 nm using microplate reader (Multiskan Go, Thermo
Scientific, Whaltham, MA, USA). The enzymatic reaction was initiated after the addition of 25 μL of
AChE solution (AChE from Electropardus electricous type VI-S, 0.2 U/mL, Sigma-Aldrich, St. Louis,
MO, USA) in Tris/HCl buffer (50 mM, pH 8.0) containing 0.1% BSA. The kinetic cycle was performed
in a period of 25 min, with readings at 5 min intervals, at 405 nm. Physostigmine (Eserine, Sigma,
St. Louis, MO, USA) was employed as the positive control. A blank was performed in the same
assay conditions using MeOH. The assay was performed in triplicate and the % of inhibition (%I) was
calculated according to the following equation: %I = [(a − b)/a] × 100, where a = ΔA/min of control;
b = ΔA/min of test sample; ΔA = change in absorbance between time x and time zero. Extracts with
enzyme %I higher than 40% at 400 μg/mL were considered promising.
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4.7. Evaluation of Antioxidant Activity
4.7.1. β-Carotene/Linoleic Acid Co-Oxidation Assay
The evaluation of the antioxidant activity using the β-carotene/linoleic acid co-oxidation system
was performed according to Duarte-Almeida et al. [107], with adaptations. The extracts were
solubilized in MeOH (2.2 mg/mL) and further diluted to concentrations ranging from 3.125 to
200 μg/mL. An aliquot of 25 μL of sample solutions were added in the 96-well microplate. 25 mg
of linoleic acid and 100 mg Tween 20 (Sigma, St. Louis, MO, USA) were added to a round-bottom
flask containing 1 mL of a β-carotene solution (1 mg/mL, Sigma, St. Louis, MO, USA) in chloroform.
The latter was removed in a rotatory evaporator and, then, 50 mL of aerated water was added to
the flask, affording the β-carotene emulsion. Portions of 250 μL of the freshly prepared emulsion
were added to the wells corresponding to the odd columns of a microplate. A blank emulsion was
prepared as described above, without the addition of the β-carotene solution, and portions of 250 μL
were added to the even columns of the microplate. MeOH and quercetin (20 μg/mL, Sigma, St. Louis,
MO, USA) were employed as negative and positive controls, respectively. Readings were performed
immediately at 470 nm. After the first reading, the microplate was incubated at 45 ◦C and the kinetic
cycle was performed with readings at 15 min intervals for a total of 120 min. The antioxidant activity
was expressed as % of inhibition of lipid peroxidation (%I), using the formula (I% = Ac (initial abs
− Final abs) − Aam (final abs − Initial abs)/Ac × 100). Assays were performed in triplicate and
IC50 values were determined by non-linear regression using GraphPad Prism, version 6.0 (GraphPad
Software, San Diego, CA, USA). It was considered promising when the extracts exhibited IC50 values
lower than 50 μg/mL.
4.7.2. DPPH Radical Scavenger Activity
The evaluation of the antioxidant activity using the 2,2-diphenyl-1-picrylhydrazyl radical (DPPH)
was performed according to the method proposed by Mensor et al. [108], with adaptations. The samples
were dissolved in MeOH at concentrations ranging from 1.0 to 200 μg/mL. A portion of 250 μL of
each sample was added to a 96-well microplate. MeOH and pyrogallol (50 μg/mL) were employed
as negative and positive controls, respectively. Then, 100 μL of either MeOH (blank wells) or DPPH
solution (120 μg/mL, reaction wells) was added to the microplate. The reading was performed on a
microplate reader (EL808IU-Biotek model, Biotek, Winooski, VT, USA), at 5 min intervals for a total
of 45 min, at 515 nm. The percentage of radical scavenging activity (%RSA) was calculated using the
following equation: % RSA = ((AC − AS)/AC) × 100, where AC is the absorbance of control and AS is
the absorbance of samples taken at 35 min. The results were expressed in EC50 (effective concentration
for 50% capture of the radicals) determined by non-linear regression using GraphPad Prism, version
6.0. In this assay, extracts showing EC50 values lower than 15 μg/mL were considered promising.
4.7.3. Thiobarbituric Acid Reactive Substances (TBARS) Assay
The evaluation of antioxidant activity using the TBARS assay [109], with adaptations. Briefly,
the samples were solubilized in methanol (50.0 to 31.25 μg/mL) and a portion of 25 μL of each extract
solution was added to 10 mL test tubes in triplicate (two reaction tubes and one control). The tubes
corresponding to the blank, negative and positive controls were prepared by adding 25 μL of deionized
water, MeOH or propylgalate (Sigma, St. Louis, MO, USA, 0.1 mM), respectively. The phospholipid
liposomes were prepared using bovine brain extract type VII (Sigma Aldrich, St. Louis, MO, USA,
10 mg/mL) in phosphate buffered saline (PBS) solution. The suspension was subjected to an ultrasonic
bath until the formation of the liposomes. Then, 50 μL of the liposome suspension was added to
the tubes corresponding to the blank, negative and positive controls, and sample reaction tubes.
In sequence, 125 μL of PBS was added to all tubes. The lipid peroxidation was initiated by the addition
of 25 μL of FeCl3 solution (Vetec, Rio de Janeiro, Brazil, 1 mM) and 25 μL of ascorbic acid solution
(Vetec, Rio de Janeiro, Brazil, 1 mM) in the tubes corresponding to the negative control, positive control
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and sample reaction. The blank tubes were prepared by adding 75 μL of deionized water. All tubes
were incubated for 20 min at 37 ◦C, and after that, 25 μL of BHT (di-tert-butyl methyl phenol, 2% in
ethanol), 125 μL of thiobarbituric acid (Merck, Darmstadt, Germany, 1% in 50 mM NaOH), and 125 μL
of hydrochloric acid (1%) were added in all tubes. All tubes were shaken vigorously and incubated for
30 min at 80–90 ◦C. Then, 500 μL of n-butanol (Vetec) was added to all tubes which were shaken and
placed in the centrifuge for 10 min at 3600 rpm. The butanolic phase was removed and transferred to a
96-well microplate, and the absorbance was recorded on a Multiskan Go microplate reader (Thermo
Scientific, Whaltham, MA, USA) at 532 nm. The percentage of inhibition (%I) of lipid peroxidation
was calculated as: %I = ((AC − AS)/AC) × 100 where AC is the absorbance of control, AS is the
absorbance of samples. Assays were performed in triplicate and IC50 values were determined by
non-linear regression using GraphPad Prism, version 6.0 (GraphPad Software, San Diego, CA, USA).
Extracts showing IC50 values lower than 50 μg/mL were considered promising.
4.8. Evaluation of Cytotoxicity in THP-1 Cells
The assay was performed following the sulforhodamine B (SRB) method [110]. THP-1 cells (acute
human monocytic leukemia cells, ATCC TIB-202) were cultured in a RPMI medium supplemented
with 10% fetal bovine serum. A cell suspension was prepared at the density of 1 × 106 cells/mL with
2 μL of PMA (phorbol myristyl acetate, Sigma, St. Louis, MO, USA, 30 μg/mL). A portion of 100 μL of
this suspension was transferred to the wells of a microplate. The plate was incubated at 37 ◦C, in a
5% CO2 atmosphere, for about 12 to 16 h to allow cells to adhere. After that, 100 μL of each sample
(400, 200, 100, 50 and 25 μg/mL) were added to the wells. The plate was then incubated at 37 ◦C for
18 h. After incubation, 100 μL of cold trichloroacetic acid (TCA, 10%) solution was added in each well.
The plate was incubated at 4 ◦C for 1 h. The supernatant was discarded and the wells were washed
three times with 200 μL of distilled water. Then, the wells were allowed to dry for 24 h. After this
period, 100 μL of sulforhodamine B solution (0.057%) was added to each well and the plate was kept at
room temperature for 30 min. After that, the wells were washed with 200 μL of 1% acetic acid solution,
four times. The plate was allowed to dry for 24 h. In sequence, 100 μL of 10 mM Tris Base solution
(pH 10.5) was added to all wells. The plate was then stirred for 5 min inside the microplate reader.
The optical density was measured at 510 nm in a microplate reader. A toxicity control of the sample
diluent was performed. Cell viability was calculated according to the formula (A − B/C − B) × 100,
where A, B and C corresponds to the absorbance measured for the samples, blank and negative control,
respectively. The extracts were considered non-toxic when cell viability was higher than 80%.
4.9. Statistical Analysis
The results were expressed as mean ± SD of three independent experiments and IC50 values
were determined by non-linear regression using GraphPad Prism, version 6.0 (GraphPad Software,
San Diego, CA, USA). The statistical significance of differences was evaluated using one-way ANOVA
in comparison with control groups. Results were considered different when p < 0.05.
5. Conclusions
In this study the extracts from the leaves and roots of D. cymosa and from the rhizomes and
roots of P. hexandrum showed antibacterial activity against B. cereus and S. aureus. On the other hand,
podophyllotoxin inhibited the growth of S. aureus and E. coli. It is important to highlight that the
antimicrobial activity of D. cymosa was not reported before. D. cymosa leaves showed anticholinesterase
and antioxidant activities, while the extracts of roots showed antioxidant activities in all evaluated
models. The extracts from the rhizomes and roots of P. hexandrum presented antioxidant activities in
two models used except in the DDPH assay. Additionally, the evaluated extracts from both species
were shown to be moderately toxic to THP-1 cells.
According to the chromatographic profiles, the presence of PTOX (1), deoxypodophyllotoxin
(5), 4′-demethylpodophyllotoxin (6), podophyllotoxone (11), α-peltatin (18) and β-peltatin (19)
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were characterized in the EtOH extracts of D. cymosa and P. hexandrum. These lignans were
previously isolated from both Berberidaceae species. Podophyllotoxin (1) was the major constituent of
P. hexandrum extract while kaempferol and its hexoside were the main constituents of D. cymosa leaves
and roots, respectively. To the best of our knowledge, this is the first report of the characterization of
flavonoids and caffeoylquinic acid in D. cymosa.
Furthermore, it might be useful to investigate whether D. cymosa could be a possible source of
podophyllotoxin, and how this could be achieved in the future.
Our Active-IT system proved to be very useful in predicting a broad spectra of biological activities.
It was well validated in relation to both the direct score of probabilities to be active or inactive and
indirect activity class score. Both approaches produced AUC-ROC values higher than 0.7, even for
datasets where no information about lignans was provided. In particular, our in silico studies using
machine learning methods was very effective in confirming both ethnopharmacological uses and
biological activities of D. cymosa and P. hexandrum extracts. Moreover, the prediction results suggest
that extracts of D. cymosa and P. hexandrum could provide insights in the research against Alzheimer’s,
antimicrobial and anti-inflammatory diseases. In addition, new predicted activities against diseases
related to the endocrine system, lipidic disorders, neuropathies, osteoporosis, as well as antiangiogenic
should be investigated in the search for new drugs with a clinical use. The aforementioned activities
and their associated targets should be more fully explored with the aim of obtaining new uses for
known lignans as well as to contributing to the understanding of the mechanism of the actions of
these natural compounds from D. cymosa and P. hexandrum. It would be desirable if the new predicted
activities could attract more attention from researchers and students, and hopefully the results would
be helpful to the worldwide community.
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Abstract: Schisandra rubriflora is a dioecious plant of increasing importance due to its lignan
composition, and therefore, possible therapeutic properties. The aim of the work was lignan profiling
of fruits, leaves and shoots of female (F) and male (M) plants using UHPLC-MS/MS. Additionally,
the anti-inflammatory activity of plant extracts and individual lignans was tested in vitro for the
inhibition of 15-lipooxygenase (15-LOX), phospholipases A2 (sPLA2), cyclooxygenase 1 and 2 (COX-1;
COX-2) enzyme activities. The extracts of fruits, leaves and shoots of the pharmacopoeial species,
S. chinensis, were tested for comparison. Twenty-four lignans were monitored. Lignan contents in
S. rubriflora fruit extracts amounted to 1055.65 mg/100 g DW and the dominant compounds included
schisanhenol, aneloylgomisin H, schisantherin B, schisandrin A, gomisin O, angeloylgomisin O and
gomisin G. The content of lignan in leaf extracts was 853.33 (F) and 1106.80 (M) mg/100 g DW.
Shoot extracts were poorer in lignans—559.97 (F) and 384.80 (M) mg/100 g DW. Schisantherin B,
schisantherin A, 6-O-benzoylgomisin O and angeloylgomisin H were the dominant compounds in
leaf and shoot extracts. The total content of detected lignans in S. chinensis fruit, leaf and shoot extracts
was: 1686.95, 433.59 and 313.83 mg/100 g DW, respectively. Gomisin N, schisandrin A, schisandrin,
gomisin D, schisantherin B, gomisin A, angeloylgomisin H and gomisin J were the dominant lignans
in S. chinensis fruit extracts were. The results of anti-inflammatory assays revealed higher activity of
S. rubriflora extracts. Individual lignans showed significant inhibitory activity against 15-LOX, COX-1
and COX-2 enzymes.
Keywords: Schisandra rubriflora; Schisandra chinensis; red-flowered Chinese magnolia vine; Chinese
magnolia vine; lignans; phytochemical analysis; UHPLC-MS/MS; anti-inflammatory activity; LOX;
COX; sPLA2
1. Introduction
Schisandra rubriflora (Franch.) Rehd. et Wils, is a rare and little-known plant species of the genus
Schisandra beyond East Asian phytotherapy. S. rubriflora occurs at natural sites in the western Sichuan
province of China. It is an endemic species that occurs only in this region [1,2]. S. rubriflora cultivations
outside the East Asian region are rare, but attempts have recently been made to grow this species in
Europe, including Poland [2,3].
S. rubriflora is a dioecious vine reaching about 3–4 meters in height [1]. S. rubriflora leaves are
characterized by elliptical to obovate-elliptical shape, 7–11.5 cm long and 2.5–5.5 cm wide. The leaves
Molecules 2018, 23, 3103; doi:10.3390/molecules23123103 www.mdpi.com/journal/molecules214
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are sharp-edged, rarely blunt-edged, and leaf blade edges are finely serrated. Mature berry-shaped
fruits of S. rubriflora, collected in the hanging ears, are dark red in color, the size of peas, sitting on
about 5–8 cm long stalks [1].
Schisandra chinensis (Turcz.) Baill. is a related species, much better known in terms of medicinal
properties, for which cultivation methods have been developed (with cultivations in Europe and
America) [1,4,5]. The description of the raw material, i.e., the fruit of the Chinese magnolia
vine—Schisandrae chinensis fructus—appeared for the first time in 2008 in the European Pharmacopoeia
6 [6]. The raw material has been used for many years in the official health care of Asian countries [7–10].
It is a pharmacopoeial species also known in the USA [11]. A World Health Organization (WHO)
monograph is also devoted to this plant [12]. Schisandrae chinensis fruit extracts show valuable,
proven, therapeutic properties. These include: anti-inflammatory, anti-tumor, and anti-ulcer properties,
anti-bacterial and anti-fungal activity; additionally, they can act hepatoprotectively, adaptogenically
and ergogenically; these extract also have antioxidant and detoxification properties [4,13,14].
Scientific information about therapeutic properties of S. rubriflora fruits is less available, and its
monograph is not listed in any of the world pharmacopoeias [2]. This species is known in the traditional
Chinese medicine as a sedative and toning agent, and its fruits are still consumed locally. There are
indications regarding the use of this species in the treatment of hepatitis, chronic gastroenteritis
and neurasthenia [2,15]. The biological activity of compounds contained in the fruit of this species,
described only by Chinese research groups, is limited mainly to the anti-HIV-1 properties, resulting
from the inhibition of HIV-1 replication in H9 lymphocytes [16,17]. According to available sources,
compounds belonging to the group of dibenzocyclooctadiene lignans as well as nortriterpenoids
and bisnortriterpenoids are both responsible for anti-HIV-1 activity [16,18,19]. Furthermore, extracts
from S. rubriflora shoots have been shown to effectively reduce the level of GPT (glutamin-pyruvate
transaminase) in the blood, which may be useful in the treatment of liver and bile duct diseases [2,20].
Valuable biological properties and therapeutic applications resulting from them are conditioned
by the unique chemical composition of S. chinensis [4,21]. Lignans are the main group of secondary
metabolites specific to this genus, among which the main role is played by dibenzocyclooctadiene
lignans [21,22]. The majority of scientific research has focused on this group of metabolites. They
are referred to as “schisandra lignans” due to the characteristic, complicated chemical structure of
these compounds as well as the occurrence limited only to this genus. Schisandrin, gomisin A,
deoxyschisandrin and schisantherin A and B are listed as the most important from the group of
dibenzocyclooctadiene lignans (Figure 1). Recent studies have reported the identification of ever
new structures from the group of lignans and their derivatives [22–24]. The available data show that
dibenzocyclooctadiene lignans, and their derivatives, specific only for S. rubriflora, such as schirubrin
A-D, rubrilignans A and B or rubrisandrin A and B are also present in S. rubriflora [16,18,25].
There are several studies on the anti-inflammatory activity of S. chinensis fruit extracts [26,27]
and some individual lignans [28–31], but there are no studies on S. chinensis leaf and shoot extracts.
importantly, these investigations have not yet been performed in S. rubriflora species. Moreover, there
are no studies comparing the results obtained for complex plant material to the results obtained for
pure lignans. In this work, we attempt to assess the anti-inflammatory potential of plant extracts and
compare it with anti-inflammatory properties of pure lignan samples.
The present study introduces phytochemical characteristics of lignan contents using the
UHPLC-MS/MS method in S. rubriflora, including the division of the material into female (F) and male
(M) specimens of soil-grown plants. The results were compared to the analyses of pharmacopoeial
species–S. chinensis—performed for comparison purposes.
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Figure 1. Example structural formulas of abundant S. rubriflora dibenzocyclooctadiene lignans: (a)
schisandrin; (b) gomisin A; (c) deoxyschisandrin; (d) schisantherin A; (e) schisantherin B. Structural
formulas drown in: ACD/ChemSkech (Freeware), version 12.00, Advanced Chemistry Development,
Inc., Toronto, ON, Canada, www.acdlabs.com, 2010.
Moreover, the anti-inflammatory potential of S. rubriflora fruits, leaves and shoots of F and M
specimens was studied for the first time using estimations based on the inhibition of eicosanoid-
generating enzymes; these included cyclooxygenases (COX-1 and COX-2), lipoxygenase (LOX) and
secretory phospholipase A2 (sPLA2), reducing the concentrations of prostanoids and leukotrienes.
Additionally, the analyses involved individual lignans as well as an artificially created “average sample
of S. rubriflora lignan composition”. Comparative studies with S. chinensis shoot, leaf and fruit extracts
were also conducted in this study.
2. Results
2.1. Schisandra Rubriflora Lignan Profile
The UHPLC-MS/MS method was used for both qualitative and quantitative analyses of the extracts
tested (Tables S1 and S2, Figure S1). Twenty-four lignans were quantified in all analyzed samples,
representing four lignan groups: dibenzocyclooctadiene lignans (schisantherin A and B, schisandrin,
schisandrin C, gomisin A, D, G, J, N, O, 6-O-benzoylgomisin O, schisandrin A, rubrisandrin A,
epigomisin O, schisanhenol, rubriflorin A, angeloylgomisin H and O), aryltetralin lignan (wulignan A1),
dibenzylbutane lignans (pregomisin, mesodihydroguaiaretic acid), tetrahydrofuran lignan (fragransin
A2) and dihydrobenzofuran neolignans (licarin A and B) [32–34].
The total lignan content in the analyzed fruit extracts of S. rubriflora was 1055.65 mg/100 g DW.
Quantitatively dominant compounds were: Schisanhenol (268.02 mg/100 g DW), aneloylgomisin
H (185.10 mg/100 g DW), schisantherin B (118.07 mg/100 g DW), schisandrin A (104.32 mg/100 g
DW), gomisin O (103.64 mg/100 g DW), angeloylgomisin O (76.88 mg/100 g DW) and gomisin G
(66.39 mg/100 g DW) (Table 1).
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The presence of twenty-four and twenty-three lignans was found in the analyzed extracts of
female (F) and male (M) S. rubriflora specimens, respectively (Table 1). No fragransin A2 was found in
leaf extracts of male specimens. The total contents of the tested group of compounds in leaf extracts
were: F—853.33 mg/100 g DW and M—1106.80 mg/100 g DW.
Qualitatively dominant compounds in F leaf extracts were: Schisantherin B (291.47 mg/100 g
DW), schisantherin A (226.80 mg/100 g DW), 6-O-benzoylgomisin O (134.51 mg/100 g DW)
and angeloylgomisin H (100.83 mg/100 g DW). Qualitatively dominant in M leaf extracts were:
6-O-benzoylgomisin O (564.62 mg/100 g DW), angeloylgomisin H (129.28 mg/100 g DW), gomisin D
(116.51 mg/100 g DW), schisantherin A (107.17 mg/100 g DW), schisantherin B (104.28 mg/100 g DW)
and angeloylgomisin O (48.80 mg/100 g DW) (Table 1).
The presence of twenty-four and twenty-three lignans were found in the analyzed shoot extracts
of female (F) and male (M) S. rubriflora specimens, respectively. These were the same compounds that
were identified in fruit and leaf extracts (Table 1). The total contents of the tested group of compounds
in shoot extracts were: F—559.97 mg/100 g DW and M—384.80 mg/100 g DW.
Qualitatively the dominant compounds in F shoot extracts were: Schisantherin B (239.11 mg/100 g
DW), angeloylgomisin H (105.80 mg/100 g DW), schisantherin A (84.35 mg/100 g DW) and
6-O-benzoylgomisin O (72.38 mg/100 g DW). Fragransin A2 was not found in these extracts.
Qualitatively dominant compounds in M shoot extracts were: schisantherin B (169.04 mg/100 g
DW), angeloylgomisin H (74.73 mg/100 g DW) and 6-O-benzoylgomisin O (52.18 mg/100 g DW)
(Table 1).
2.2. Schisandra Chinensis Lignan Profile
The UHPLC-MS/MS analysis of lignans in fruit, leaf and shoot extracts of Schisandra chinensis
was performed for comparative purposes. When comparing the results, qualitative similarities and
quantitative differences were found between the extracts tested (Table 2). In all analyzed samples,
twenty-four lignans were quantified, representing four lignan groups: dibenzocyclooctadiene lignans
(schisantherin A and B, schisandrin, schisandrin C, gomisin A, D, G, J, N, O, 6-O-benzoylgomisin O,
schisandrin A, rubrisandrin A, epigomisin O, schisanhenol, rubriflorin A, angeloylgomisin H and O),
aryltetralin lignan (wulignan A1), dibenzylbutane lignans (pregomisin, mesodihydroguaiaretic acid)
and tetrahydrofuran lignan (fragransin A2). In addition, dihydrobenzofuran neolignans (licarin A
and B) were also found in the analyzed extracts (Table 2).
The total contents of detected lignans in fruit, leaf and shoot extracts were equal to: 1686.95,
433.59 and 313.83 mg/100 g DW, respectively. Qualitatively the dominant compounds in S. chinensis
fruits were: gomisin N (259.05 mg/100 g DW), schisandrin A (212.50 mg/100 g DW), schisandrin
(206.08 mg/100 g DW), gomisin D (195.22 mg/100 g DW), schisantherin B (195.82 mg/100 g
DW), gomisin A (177.94 mg/100 g DW), angeloylgomisin H (161.90 mg/100 g DW) and gomisin
J (142.35 mg/100 g DW). Fragrasin A2 was not detected in the fruit extract (Table 2).
The amounts of individual compounds were lower in leaf and shoot extracts than in fruit extracts.
Rubriflorin A was detected only in trace amounts in the leaf extract. The dominant lignans in both
leaf and shoot extracts were: Schisantherin B, gomisin A, gomisin N and angeloylgomisin H, and
their quantities were equal to 102.47 and 35.27; 73.82 and 36.29; 55.06 and 62.69; and 47.34 and
44.84 mg/100 g DW, respectively (Table 2).
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Table 2. The lignan contents (mg/100g DW) ± SD (n =5) in fruit, leaf and shoot extracts of Schisandra
chinensis.
Lignans Fruits Leaves Shoots
Wulignan A1 0.15 ± 0.03 0.03 ± 0.001 0.04 ± 0.001
Rubrisandrin A 0.03 ± 0.002 0.04 ± 0.001 0.03 ± 0.001
Rubriflorin A 0.01 ± 0.001 traces 0.01 ± 0.001
Schisandrin 206.08 ± 22.32 32.51 ± 3.14 32.87 ± 4.14
Gomisin D 195.22 ± 15.63 9.62 ± 1.96 11.33 ± 1.12
Gomisin J 142.35 ± 19.12 18.06 ± 3.11 13.22 ± 0.54
Gomisin A 177.94 ± 20.14 73.82 ± 8.41 36.29 ± 2.41
Gomisin G 44.56 ± 5.44 12.18 ± 2.14 11.69 ± 1.44
Licarin B 0.37 ± 0.02 0.03 ± 0.001 0.03 ± 0.001
Epigomisin O 3.16 ± 0.09 1.01 ± 0.07 0.91 ± 0.80
Gomisin O 4.08 ± 1.21 5.35 ± 0.55 4.45 ± 0.12
Mesodihydroguaiaretic acid 0.46 ± 0.09 0.38 ± 0.06 0.42 ± 0.07
Schisantherin A 31.32 ± 3.25 3.86 ± 0.98 2.22 ± 0.14
Schisantherin B 185.82 ± 20.39 102.47 ± 4.87 35.27 ± 3.12
Dehydroisoeugenol 0.16 ± 0.05 0.36 ± 0.09 0.41 ± 0.04
Schisanhenol 9.60 ± 1.88 1.00 ± 0.07 0.91 ± 0.02
Schisandrin A 212.50 ± 18.45 17.74 ± 1.02 13.89 ± 1.21
Fragransin A2 nd 0.02 ± 0.001 0.01 ± 0.001
Pregomisin traces traces traces
Gomisin N 259.05 ± 30.88 55.06 ± 4.52 62.69 ± 4.98
6-O-Benzoylgomisin O 33.64 ± 2.89 10.83 ± 2.01 7.48 ± 1.21
Schisandrin C 18.54 ± 2.15 37.20 ± 2.77 29.94 ± 4.23
Angeloylgomisin H 161.90 ± 15.65 47.34 ± 3.45 44.84 ± 2.27
Angeloylgomisin O 65.56 ± 5.99 4.67 ± 0.87 4.89 ± 0.84
Total content 1686.95 ± 185.67 433.59 ± 40.09 313.83 ± 28.70
Shaded parts indicates the highest quantities of given compounds. nd—not detected.
2.3. Anti-Inflammatory Activity
The following plant material extracts were tested for anti-inflammatory activity: Fruits and leaves
of Schisandra rubriflora and Schisandra chinensis as well as selected most abundant lignans present
in plant samples: 6-O-benzoylgomisin O, schisandrin, gomisin D, gomisin N and schisantherin A.
Extracts from the shoots were not assayed for their anti-inflammatory activity, due to the relatively low
lignan contents, determined in phytochemical studies, compared to leaf and fruit extracts (Tables 1
and 2).
The tests were based on the in vitro inhibition of 15-lipooxygenase (15-LOX), phospholipase A2
(sPLA2), cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes.
Plant material extracts showed moderate inhibition of 15-LOX and relatively high inhibitory
activity against COX-1, COX-2 and sPLA2 (Table 3). Evaluation of 15-LOX inhibition showed that
S. rubriflora fruit and leaf extracts moderately inhibited this enzyme: 22%—fruits, 38%—F leaves,
42%—M leaves at 17.5 μg/mL. For S. chinensis, the activity was lower: 25%—fruits (17.5 μg/mL) and
31%—leaves (175.0 μg/mL) (Table 3).
The sPLA2 enzyme inhibition assay showed that fruit and leaf extracts of S. rubriflora inhibited its
activity to about 62–65% at 175.0 μg/mL. Inhibition percentage for fruit and leaf extracts of S. chinensis
was lower: 25% and 49%, respectively (at 175.0 μg/mL) (Table 3).
The most promising results were obtained for in vitro inhibitory COX-1 and COX-2 enzyme
activities. S. rubriflora fruit extracts (at 17.4 μg/mL) inhibited COX-1 and COX-2 activities in 71% and
48%, respectively. Leaf extracts showed higher activity at 175.0 μg/mL, and the inhibition was 86%
and 82% (F), and 96% and 90% (M), respectively (Table 3). S. chinensis extracts exhibited lower activity.
The percentage of COX-1 and COX-2 inhibition was 59% and 66% for fruits, and 69% and 77% for
leaves, respectively (Table 3).
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Evaluation of anti-inflammatory properties of individual lignan solutions and the average sample
of lignan composition (MIX) (Table S3) showed that they were not active against the sPLA2 enzyme
(Table 4). All studied lignans, i.e., 6-O-benzoylgomisin O, schisandrin, gomisin D, gomisin N and
schisantherin A, as well as their MIX sample, showed from 49% to 57% 15-LOX inhibitory activity at
0.175 μg/mL (Table 4). The highest inhibition for COX-1 was estimated for schisandrin—62% at 1.75
μg/mL, schisantherin A—74% at 0.175 μg/mL, and for the average sample of lignan composition—61%
at 1.75 μg/mL (Table 4). The highest inhibition for COX-2 was detected for schisandrin—54% at
1.75 μg/mL, gomisin D—62% at 1.75 μg/mL, gomisin N—70% at 0.175 μg/mL and for the MIX
sample—56% at 0.175 μg/mL (Table 4).
3. Discussion
Twenty-four lignans were identified from four chemical lignan groups in all analyzed samples of
both plant species: Dibenzocyclooctadiene lignans (schisantherin A and B, schisandrin, schisandrin
C, gomisin A, D, G, J, N, O, 6-O-benzoylgomisin O, schisandrin A, rubrisandrin A, epigomisin
O, schisanhenol, rubriflorin A, angeloylgomisin H and O), aryltetralin lignan (wulignan A1),
dibenzylbutane lignans (pregomisin, mesodihydroguaiaretic acid), and tetrahydrofuran lignan
(fragransin A2). In addition, the presence of dihydrobenzofuran neolignans (licarin A and B) was also
found in the analyzed extracts. Until now, there have been no reports on the detection of so many
lignan compounds in S. rubriflora fruit, leaf and shoot extracts, including the differentiation on male
and female specimens (Table 1, Tables S1 and S2, Figure S1).
Schisanhenol was quantitatively predominant in the analyzed S. rubriflora fruit extracts
(268.02 mg/100 g DW), and its content was: 1.45-, 2.27-, 2.57-, 2.59-, 3.48- and 4.04-fold higher,
respectively, than the content of the remaining dominant compounds: Angeloylgomisin H,
schisantherin B, schisandrin A, gomisin O, angeloylgomisin O and gomisin G (Table 1).
Twenty-four and twenty-three lignans were found in both leaf and shoot extracts of F and
M S. rubriflora specimens, respectively. Fragransin A2 was found in the extracts from leaves and
shoots of F specimens, while it was not detected in analogous extracts from M specimens. The total
content of lignans in leaf extracts of F specimens was 1.30-fold lower compared to the content in
leaf extracts of M specimens (Table 1). The following compounds were predominant in F specimen
leaf extracts: schisantherin A and B, 6-O-benzoylgomisin O, and angeloylgomisin H. The contents
of schisantherin A and B were: 2.12- and 2.80-fold higher, respectively, compared to their contents
in leaf extracts of M. specimens. The contents of 6-O-benzoylgomisin O and angeloylgomisin H
in leaf extracts of M specimens were: 4.20-, 1.28-fold higher, respectively, than in leaf extracts
of F specimens (Table 1). The most dominant compounds in leaf extracts of M specimens were:
6-O-benzoylgomisin O, angeloylgomisin H, gomisin D, angeloylgomisin O, schisantherin A and B.
Gomisin D and angeloylgomisin O contents in leaf extracts of M. specimens were: 7.08-, 2.84-fold
higher, respectively, than in leaf extracts of F specimens (Table 1).
The total lignan content in shoot extracts of F specimens was 1.46-fold higher than in the extracts
from M specimens (Table 1). The quantitatively dominant compounds in shoot extracts of F specimens
were: Schisantherin B, angeloylgomisin H, schisantherin A, and 6-O-benzoylgomisin O: 1.41-, 1.42-,
3.48- and 1,39-fold higher, respectively, compared to shoot extracts of M specimens. Schisantherin
B, angeloylgomisin H, and 6-O-benzoylgomisin O were predominant in the extracts of M specimens
(Table 1).
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This work presents for the first time such a wide determination of lignan contents in the extracts
of S. rubriflora, taking into account the division into the material originating from female (F) and
male (M) specimens (leaves and shoots and fruits). Studies on lignan composition of S. rubriflora
were performed before only by Chinese teams [16–18,25,35]. Importantly, these studies were only
qualitative, no quantitative data were found, and the authors did not distinguish extracts in terms
of gender. In 2006, Chen et al. [18] isolated fruit extracts of S. rubriflora and detected following
compounds by the 1H NMR method: schisanhenol, schisandrin, deoxyschisandrin, schisantherin B,
angeloylgomisin P, tigloylgomisin P, gomisin M1, M2, O and J as well as specific rubrisandrins A and B.
In 2010, Xiao et al. [17] identified the following lignans in fruit extracts based on the 1H and 2H-NMR
spectroscopy: Gomisin G and O, angeloylgomisin P, wulignan A2, epiwulignan A1 and rubrisandrin C.
Mu et al. [16] conducted in 2011 an isolation and structure elucidation of the following lignans from
S. rubriflora fruit extracts using preparative HPLC and 13C-NMR: Schisandrin, schisandrin A and C,
rubschisantherin, angeloygomisin Q, benzoylgomisin Q, gomisin J, Q, C, B, K, N, S, T, isogomisin O,
wilsonilignangomisin G, marlignan L and G. Moreover, the latter authors detected for the first time two
new lignans in the fruit extract, i.e., rubrilignans A and B. In comparison to those results, the current
study identified eight additional new compounds in fruit extracts: Gomisin A, 6-O-benzoylgomisin O,
angeloylgomisin H and O, pregomisin, mesodihydroguaiaretic acid and licarin A and B.
Extracts from aerial parts of S. rubriflora were studied by Li et al. [25] using 1H- and 13C-NMR
and they found the following compounds: gomisin K, M1 and R, dimethylgomisin J, angeloylgomisin
K3 and R, interiotherin B, schisantherin D, mesodihydroguaiaretic acid, dihydroguaiaretic acid and
pregomisin. Li et al. [35] detected rubriflorin A and B in stem extracts. In the present study, additional
nineteen compounds were detected both in shoot and leaf extracts: Schisantherin A and B, schisandrin,
schisandrin C, gomisin A, D, G, J, N, O, 6-O-benzoylgomisin O, schisandrin A, rubrisandrin A,
epigomisin O, schisanhenol, angeloylgomisin H and O, wulignan A1 and fragransin A2. Moreover,
our study included quantitative estimation and division on female and male plants, which had not
been done before (Table 1).
A comparative lignan profiling of extracts from fruits, leaves and shoots of S. chinensis using the
UHPLC-MS MS method (Tables 2 and 5) was carried out in the present study. The total content of
the tested group of compounds in S. rubriflora fruit extracts was 1.60-fold lower than in S. chinensis
fruit extracts. The total lignan contents in S. rubriflora fruit extracts of F specimen was: 1.97-, 2.55-fold
higher, respectively, than in S. chinensis leaf extracts (Table 1). The total lignan content in extracts from
F and M shoots of S. rubriflora was: 1.78- and 1.23-fold higher, respectively, than in S. chinensis shoot
extracts (Table 1).
Schisanhenol, schisantherin B, schisandrin A, gomisin O and angeloylgomisin H were
predominant in S. rubriflora fruit extracts in terms of quantity (Table 3). The contents of schisanhenol,
gomisin O and angeloylgomisin H in S. rubriflora fruit extracts was: 27.92- and 1.14-fold higher,
respectively, than in S. chinensis fruit extracts (Table 1). The total content of schisantherin B and
schisandrin A in S. rubriflora fruit extracts was: 1.57- and 2.04-fold lower, respectively, than in S.
chinensis fruit extracts (Table 1).
Schisantherin A and schisantherin B, 6-O-benzoylgomisin O and angeloylgomisin H were among
the quantitatively predominant compounds in S. rubriflora leaf extracts (Table 2). The quantities of
these compounds in F and M leaf extracts of S. rubriflora were: 58.76- and 27.76-; 2.84- and 1.02-; 12.42-
and 52.13-; and 2.13- and 2.73-fold higher, respectively than in S. chinensis leaf extracts (Table 5).
Similarly as in leaf extracts, schisantherin A and schisantherin B, 6-O-benzoylgomisin O and
angeloylgomisin H were among the quantitatively predominant compounds in S. rubriflora shoot
extracts (Table 2). The quantities of these compounds in F and M leaf extracts of S. rubriflora were:
38.00- and 10.93-; 6.78- and 9.68-; 6.98- and 52.13-; and 2.36- and 1.67-fold higher, respectively, than in
S. chinensis shoot extracts (Table 5).
Different compounds were proved to be dominant in S. chinensis extracts. The quantities of
schisandrin, gomisin D, gomisin J, gomisin A, schisandrin A, gomisin N and schisandrin C in
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S. chinensis fruit extracts were: 31.37-; 55.46-; 26.36-; 157.25-; 2.04-; 13.49- and 3.47-fold higher,
respectively, than in S. rubriflora fruit extracts (Table 5). The dominant compounds in S. chinensis
leaf and shoot extracts included schisandrin, gomisin A, gomisin N and schisandrin C. The amount
of these lignans in leaf extracts, in comparison to their quantities in F and M leaf extracts, were:
3.99- and 5.71-; 11.53- and 17.58-; 32.95- and 24.91-; and 84.55- and 195.79-fold higher, respectively.
Correspondingly, the quantities of these compounds in shoot extracts, compared to S. rubriflora F and
M shoot extracts, were: 8.20- and 14.61-; 12.14- and 22.00-; 77.40- and 58.05; and 106.93- and 332.67-fold
higher, respectively (Table 5).
Table 5. The comparison of the amounts (mg/100g DW) of the dominant lignans in the studied S.
rubriflora and S. chinensis extracts.
Lignans




F M F M
Schisandrin 6.57 8.15 5.69 4.01 2.25 206.08 32.51 32.87
Gomisin D 3.52 16.45 116.51 8.25 20.26 195.22 9.62 11.33
Gomisin J 5.40 0.97 0.76 0.46 0.36 142.35 18.06 13.22
Gomisin A 0.75 6.40 4.20 2.99 1.65 177.94 73.82 36.29
Gomisin G 66.39 11.13 8.23 5.25 3.67 44.56 12.18 11.69
Schisantherin A 27.19 226.80 107.17 84.35 24.27 31.32 3.86 2.22
Schisantherin B 118.07 291.47 104.28 239.11 169.04 185.82 102.47 35.27
Schisanhenol 268.02 2.05 2.73 1.13 2.53 9.60 1.00 0.91
Schisandrin A 104.32 0.22 0.38 0.12 0.50 212.50 17.74 13.89
Gomisin N 19.20 1.58 2.21 0.81 1.08 259.05 55.06 62.69
6-O-Benzoylgomisin O 35.28 134.51 564.62 72.38 52.18 33.64 10.83 7.48
Schisandrin C 4.96 0.44 0.19 0.28 0.09 18.54 37.20 29.94
Angeloylgomisin H 185.10 100.83 129.28 105.80 74.73 161.90 47.34 44.84
Total content 1055.65 853.33 1106.80 559.97 384.80 1686.95 433.59 313.83
The present study determined the complex in vitro anti-inflammatory activity of fruit and leaf
extracts of S. rubriflora and S. chinensis. Moreover, the analyses were also performed on individual most
abundant lignans (6-O-benzoylgomisin O, schisandrin, gomisin D, gomisin N and schisantherin A) and
a synthetic average sample of lignan composition mixture (MIX) (representing mean concentrations
of 16 most abundant lignans from fruit and leaf extracts of S. rubriflora and S. chinensis; see Table S3).
In most cases, dose-dependent inhibition of selected enzymes by plant extracts or lignan solutions
was observed. However, the most pronounced exceptions were found for 15-LOX inhibition (and
partially COXs), especially by lignan solutions. An inverse dose-dependence in case of plant extracts
can be contributed to a relatively wide confidence interval between dilutions (overlapping SDs),
and thus the lack of significant difference. However, more interesting is an inverse dose-dependent
inhibition of 15-LOX by lignan solutions. This is a clear deviation from the competitive inhibition
mechanism. The observed dependencies allow us to suggest the occurrence of another mechanism,
namely inhibitor acceleration of the enzyme by lignans. Known mechanisms of inhibitor acceleration
rely on allostery and multiple active sites [36]. This assumption could be partially supported by the
results for plant extracts, providing also some arguments for significant participation of lignans in
their anti-inflammatory properties, albeit of low confidence (as mentioned earlier). This hypothesis
should be confirmed in further studies. On the other hand, plant secondary metabolism is so rich and
complicated that it is difficult to conclude that particular antioxidant properties, or anti-inflammatory
in this case, are driven only by one compound group. Further, a parallel occurrence of components
inhibiting as well as increasing the activity is possible due to the natural complexity of such a
plant extract.
Previously, there were studies involving anti-inflammatory properties of certain schisandra
lignans, but they were conducted on different models. Gomisin N, J and schisandrin C were proved
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to exert anti-inflammatory effect by reducing nitric oxide (NO) production from lipopolysaccharide-
stimulated (LPS) RAW 264.7 cells [28]. Schisantherin A was shown to be an anti-inflammatory agent
that down-regulated NF-κB and MAPK signaling pathways in LPS-treated RAW 264.7 cells [29].
Another study [30] demonstrated that schisandrin, deoxyschisandrin, schisandrin B and C and
schisantherin A reduced LPS-induced NO production in RAW 264.7 cells. In addition, schisandrin
was shown to exert a protective effect on LPS-induced sepsis [31]. In vitro studies performed by
Guo et al. [31] showed that anti-inflammatory properties of schisandrin resulted from NO production
inhibition, prostaglandin E2 (PGE2) release, COX-2 and inducible nitric oxide synthase (iNOS)
expression, which in turn was caused by the inhibition of nuclear factor kappa B (NF-κB), c-Jun
N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) activities in the RAW 264.7
macrophage cell line.
Moreover, extracts from S. chinensis fruits were tested for the anti-inflammatory activity by
Huyke et al. [26]. Non-polar S. chinensis fruit extracts showed that the dose-dependent COX-2
inhibition (at 20 μg/mL) catalyzed prostaglandin production [26].
Lim et al. [27] conducted in vitro tests on such representative schisandra lignans as schisandrin,
schisandrin A and C, gomisin B, C, G and N, as well as on methanolic extracts of S. chinensis fruits,
for 5-lipoxygenase (5-LOX) inhibitory activity. The tested compounds inhibited 5-LOX-catalyzed
leukotriene production by A23187-treated rat basophilic leukemia (RBL-1) cells at concentrations
of 1–100 μM. Compounds, such as schisandrin and gomisins showed moderate inhibitory activity
(IC50 < 10 μM) against 5-LOX-catalyzed leukotriene production, but they were significantly less active
against COX-2-catalyzed PGE2 and inducible NO production [27].
We have also proved in our study the high anti-inflammatory potential of S. chinensis fruit extracts
against COX-1 and COX-2 enzyme activities (Table 3). Positive results were also obtained for leaf
extracts (Table 3). Moreover, the inhibitory activity against 15-LOX and sPLA2 enzymes has been
demonstrated for the first time. To the best of our knowledge, the extracts from fruits and leaves
of S. rubriflora have not yet been studied for anti-inflammatory activity. The obtained results from
S. rubriflora plant materials showed a higher activity in comparison to S. chinensis (Table 3).
We have demonstrated, based on the results of individual lignan analyses, that 6-O-
benzoylgomisin O, schisandrin, gomisin D, gomisin N and schisantherin A display significant 15-LOX,
COX-1 and COX-2 inhibitory activities, and that they are virtually inactive against sPLA2 (Table 4).
Our study also analyzed for the first the anti-inflammatory activity of 6-O-benzoylgomisin O and
gomisin D.
4. Materials and Methods
4.1. Plant Material
Plant material was obtained as part of cooperation with Clematis—Źródło Dobrych Pnączy Spółka
z o.o. spółka jawna with a registered office in Pruszków (address: ul. Duchnicka 27, 05-800 Pruszków,
Poland) [37]. Plant species were identified by dr. eng. Szczepan Marczyński (owner of the Clematis
arboretum). For the purpose of comparative phytochemical analysis, fruits and leaves and shoots
(stems with leaves) of about 10 years old female (F) (100 individuals) and male (M) (50 individuals)
S. rubriflora (Franch.) Rehd. et Wils specimens, and about 10 years old monoecious specimens of S.
chinensis Turcz. Baill (100 individuals) were collected and dried. Leaves and shoots were harvested in
May, fruits in September 2017. The fruits were lyophilized and the leaves and shoots were air-dried
(about 25–30 ◦C). Dry plant material was pulverized in a mixing ball mill (MM 400, Retch, Haan,
Germany).
4.2. Plant Sample Extraction
Methanol extracts were prepared from fruits, shoots and leaves of F and M S. rubriflora plants.
The samples (0.3 g, 5 replicates) were extracted with 3 mL of methanol (grade-HPLC, Merck, Darmstadt,
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Germany). The extraction process was carried out twice in an ultrasonic bath (Sonic 2, POLSONIC
Palczyński Sp.J., rsaw, Poland) for 20 min. The obtained extracts were centrifuged for 5 min (4000 rpm)
in a centrifuge (Centrifuge MPW–223E, MPW Med. Instruments, Warsaw, Poland). The centrifuged
extracts were filtered using sterilizing syringe filters (Millex®GP, 0.22 μm, Filter Unit, Millipore,
Bedford, MA, USA).
4.3. UHPLC–MS/MS Lignan Targeted Profiling
Lignan-targeted profiling was carried out in methanolic extracts of S. rubriflora and S. chinensis
by means of ultra-high performance liquid chromatography coupled to a tandem mass spectrometer
(UHPLC-MS/MS). An external standard addition method was used. Filtered plant extracts were
aliquoted in two 45 μL portions. To the first, 5 μL of methanol was added, while to the second 5 μL of
the standard lignan solution (all monitored compounds). Samples were analyzed on a UHPLC Infinity
1260 (Agilent, Wolbrom, Germany) coupled to a quadrupole tandem mass spectrometer 6410 QQQ
LC/MS (Agilent, Santa Clara, CA, USA). Samples were separated on an analytical column (Kinetex
C18 150 × 4.6 mm, 2.7 μm) in a gradient mode of 50% methanol in water (A) versus 100% methanol
(B) with 0.1% of formic acid. A linear gradient was applied, 20% to 65% of B in 22 min at 0.5 mL/min
at 60 ◦C; the injection volume was 2 μL. Standard lignan substances were purchased from ChemFaces
Biochemical Co. Ltd. (Wuhan, China). The studied lignans and their structures and synonymous
names are listed in Table S1. Lignans were analyzed in the MRM mode after ESI ionization (Table S2).
In addition to lignans, whose standards were commercially available (Tables S1 and S2, Figure S1),
compounds from the dibenzocyclooctadiene lignan group (angeloylgomisins H and O) were also
identified based on the UHPLC-MS/MS result analysis for the tested extracts. The identification was
based on analyzing fragmentation ions of these compounds visible in mass spectra. The quantitative
analysis of angeloylgomisyn H and O was based on their content conversion, according to schisandrin
standard curve (UHPLC-MS/MS)—the main compound from the dibenzocyclooctadiene lignan group;
according to pharmacopoeial requirements, the raw material should be standardized based on the
content of this compound [3].
4.4. Anti-Inflammatory Activity
Plant material methanolic extracts of fruits and leaves of S. rubriflora (F and M) and S. chinensis
were tested for anti-inflammatory activity. Additionally, the following most abundant lignans present
in the plant samples were analyzed for anti-inflammatory activity: 6-O-benzoylgomisin O, schisandrin,
gomisin D, gomisin N and schisantherin A (No: L10, L1, L16, L14, L6; Tables S1, S2 and Figure S1,
respectively); in addition, the mixture of lignans, representing the average plant sample composition
(MIX) (mean concentrations of 16 most abundant lignans of fruit and leaf extracts of S. rubriflora and S.
chinensis; see Table S3), underwent analogous analysis.
The plant extracts (concentrations: 175.0 and 17.5 μg/mL, Table 3) and solutions of selected lignans
(concentrations: 1.75 and 0.175 μg/mL, Table 4) were serially diluted in methanol. The tests were based
on in vitro inhibition of 15-lipooxygenase (15-LOX), phospholipases A2 (sPLA2), cyclooxygenase-1
(COX-1) and cyclooxygenase-2 (COX-2) enzymes.
4.4.1. Inhibitory Activity against 15-Lipooxygenase (15-LOX)
Samples were tested for their inhibitory activity against 15-LOX using an assay kit (760700,
Cayman Chem. Co., Ann Arbor, MI, USA), according to the manufacturer’s instructions; arachidonic
acid at 0.91 mM was the substrate; nordihydroguaiaretic acid (NDGA) at 100 μM served as a
positive control inhibitor. The kit measures the concentration of hydroperoxides produced in the
lipooxygenation reaction using purified soy 15-lipooxygenase standard at pH 7.4 in 10 mM Tris-HCl
buffer. The reagent’s colorimetric composition is vendor proprietary. The measurements were carried
out in 96-well plate using a Synergy II reader (Biotek, Winooski, VT, USA) at 490 nm. The end-point
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absorbance was recorded after 5-min incubation of enzyme and inhibitor followed by 15-min incubation
after substrate addition and 5-min incubation after chromogen addition.
4.4.2. Inhibitory Activity against Cyclooxygenase-1 and Cyclooxygenase-2 (COX-1 and COX-2)
Samples were tested for their ability to inhibit COX-1 and COX-2 using the COX-1 (ovine) and
COX-2 (human) inhibitor assay kit (701050, Cayman Chem. Co.), according to the manufacturer’s
instructions; arachidonic acid at 1.1 mM was the substrate; ibuprofen at 10 μM served as a positive
control inhibitor. The kit measures the peroxidase component of COXs. The appearance of oxidized
N,N,N’,N’-tetramethyl-p-phenylenediamine (TMPD) was monitored kinetically for 5 min in a 96-well
plate format at 590 nm using a Synergy II reader.
4.4.3. Inhibitory Activity against Phospholipases A2 (sPLA2)
Inhibition of sPLA2 activity was tested using an assay kit (10004883, Cayman Chem. Co.),
according to the manufacturer’s instructions; diheptanoyl thio-PC at 1.44 mM was the substrate;
thioetheramide-PC at 100 μM served as a positive control inhibitor. Human recombinant Type V sPLA2
was used. Free thiols released by cleavage of the diheptanoyl thio-PC ester bond were measured
kinetically using DTNB (5-5’-dithio-bis-(2-nitrobenzoic acid), Ellman’s reagent) in a 96-well plate
format at 420 nm using a Synergy II reader. The percent of inhibition was calculated according to
Equation (1):
%Inh = [(IA−Inhibitor)\IA] × 100 (1)
where: %Inh—percent of inhibition; IA—100% enzyme activity (without inhibitor); Inhibitor—enzyme
activity with inhibitor added.
All samples were assayed in triplicate, including 100% enzyme activity, positive control inhibitor
and tested extracts and lignan solutions.
4.4.4. Statistical Analysis
Quantitative results are expressed in mg/100 g DW (dry weight) as the mean ± SD (standard
deviation) of three or five samples (n = 3, n = 5) in the experiments that were repeated three times.
5. Conclusions
The present study is the first comparative, complex, qualitative and quantitative analyses of S.
rubriflora and S. chinensis lignan composition derived from different groups. The contents of shoot
and fruit extracts of both plant species were determined for the first time using the UHPLC-MS/MS
method. The study identified and characterized twenty-four lignans representing four chemical
groups: dibenzocyclooctadiene lignans (schisantherin A and B, schisandrin, schisandrin C, gomisin
A, D, G, J, N, O, 6-O-benzoylgomisin O, schisandrin A, rubrisandrin A, epigomisin O, schisanhenol,
rubriflorin A, angeloylgomisin H and O), aryltetralin lignan (wulignan A1), dibenzylbutane
lignans (pregomisin, mesodihydroguaiaretic acid), tetrahydrofuran lignan (fragransin A2) and
dihydrobenzofuran neolignans (licarin A and B). Qualitative and quantitative differences in lignan
composition were recorded depending on the origin of samples (fruit, leaf and shoot) as well as
plant species.
Additionally, the current work determined for the first time the anti-inflammatory activity, based
on the in vitro inhibition of 15-lipooxygenase (15-LOX), phospholipases A2 (sPLA2), cyclooxygenases
1 and 2 (COX-1; COX-2) enzymes, of fruit and leaf extracts of the analyzed species as well as
individual lignans: 6-O-benzoylgomisin O, schisandrin, gomisin D, gomisin N and schisantherin
A; furthermore, a mixture of lignans representing an average plant sample composition was also tested.
The results revealed a high competitiveness of S. rubriflora in relation to known, pharmacopoeial plant
species—S. chinensis.
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Based on our research, we suggest to consider the extracts of S. rubriflora (fruit, leaf and shoot), as a
rich, valuable source of lignans with a promising anti-inflammatory potential. The objects of interest
exhibited very interesting differences and showed new research directions involving these compounds,
e.g., phenolic composition and other biological activities of S. rubriflora would be worth investigating.
Supplementary Materials: The following are available online, Figure S1: Exemplary UHPLC–MS/MS MRM
chromatogram of lignan standard mixture at 100 ug/mL. Table S1: The standard lignan substances used in the
performer studies. Table S2: The monitored fragmentation reactions (multiple reactions monitoring, MRM) for
studied lignans. Table S3: Quantitative composition of “average sample lignan composition” (MIX) at 1.75 μg/mL.
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Abstract: Schisandrae Chinensis Fructus, also called wuweizi in China, was a widely used folk medicine
in China, Korea, and Russia. Due to the limited natural resources and huge demand of wuweizi,
people tend to cultivate wuweizi to protect this species. However, the quality of wild and cultivated
herbs of the same species may change. Little attention has been paid to comparing wild and cultivated
wuweizi based on simultaneous determination of its active components, such as lignans and organic
acids. An analytical method based on UFLC-QTRAP-MS/MS was used for the simultaneous
determination of 15 components, including 11 lignans (schisandrin, gomisin D, gomisin J,
schisandrol B, angeloylgomisin H, schizantherin B, schisanhenol, deoxyschizandrin, γ-schisandrin,
schizandrin C, and schisantherin) and 4 organic acids (quinic acid, D(−)-tartaric acid, L-(−)-malic acid,
and protocatechuic acid) in wuweizi under different ecological environments. Principal components
analysis (PCA), partial least squares discrimination analysis (PLS-DA), independent sample t-test,
and gray relational analysis (GRA) have been applied to classify and evaluate samples from different
ecological environments according to the content of 15 components. The results showed that the
differential compounds (i.e., quinic acid, L-(−)-malic acid, protocatechuic acid, schisandrol B) were
significantly related to the classification of wild and cultivated wuweizi. GRA results demonstrated
that the quality of cultivated wuweizi was not as good as wild wuweizi. The protocol not just
provided a new method for the comprehensive evaluation and quality control of wild and cultivated
wuweizi, but paved the way to differentiate them at the chemistry level.
Keywords: Schisandrae Chinensis Fructus; wild; cultivated; multiple bioactive components;
simultaneous quantitation
1. Introduction
Schisandrae Chinensis Fructus (wuweizi) is the dried ripe fruit of the magnolia plant
Schisandra chinensis (Turcz.) Baillon. Wuweizi was a folk medicine in China, Korea, and Russia,
which was used as a sedative and tonic. With the ability to replenish vital energy and promote
fluid production, benefitting the kidneys and tranquilizing the mind, wuweizi was used to treat
seminal emission, excessive sweating, diarrhea, insomnia, fatigue, and neurasthenia in clinics [1,2].
Existing research studies have shown that lignans with a dibenzocyclooctadiene skeleton and organic
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acids are major types of phytochemicals in wuweizi [3,4]. It has been demonstrated that lignans have
abundant bioactivities, including antihepatotoxic, antioxidant, antitumor, nervous system protection,
and anticancer properties [5–7]. Organic acids have the beneficial pharmacological effects of arresting
coughs and removing phlegm [2,8,9].
With the deeper understanding on the effectiveness of wuweizi, many industries, such as medicine,
prescriptions, health products, and food and beverage, have a wide range of applications for this
species. Various kinds of products, such as beverages, fermented wine, jam, tea, jelly, and dye,
have aroused the demand for wuweizi. Due to excessive logging of unsustainable wild resources,
the wild resources of wuweizi in northeast China have rapidly decreased and cannot meet the
increasing demand of the markets. Therefore, planting cultivars has become a trend throughout
northeast China. Unlike the wild ecological environment, the cultivated ecological environment is an
artificial intervention. When plants face adversity, specialized metabolites accumulate significantly
more than usual [10]. It is generally believed that most of the bioactive components isolated from herbs
belong to specialised metabolites [11]. Varied ecological environments can lead to plants producing
and accumulating various specialized metabolites, which cause uneven qualities of wuweizi. It is
the amount or proportion among the medicinal constituents that mainly contribute to the quality
difference for herbal medicine of the same species [12,13].
Nowadays, wuweizi is officially documented in Chinese, Japanese, European, Korean,
and Russian pharmacopoeias, and other worldwide pharmacopoeial monographs [2]. Schisandrin is
the quality indicator in the Chinese and United States pharmacopoeia. In addition, the content
of lignans as the sum of the percentages of schisandrin, schisandrol B, deoxyschisandrin,
and γ-schisandrin shall not be less than 0.95% by HPLC for quality control, as has been listed in
the United States pharmacopeia. The control of several simple components may provide certain
guidance, but for the multi-component and multi-target medicinal plants, there are still some
limitations [14] because the pharmacological effect of wuweizi was usually a comprehensive effect of
various kinds of compounds. For example, lignans and organic acids all have pharmacological effects,
but they take different effects. However, most reports of quantitative analysis were focused on each
particular class of compounds or certain active ingredients for the quality control of wuweizi [4,15–18].
The analysis of particular lignans alone was not sufficient for further study of the wuweizi quality
control. Therefore, it is necessary to study the differences between wild and cultivated wuweizi and
comprehensively evaluate the quality of them based on the simultaneous determination of lignans and
organic acids.
The aim of this paper is to evaluate the quality of wild and cultivated wuweizi based on the
simultaneous determination of multiple bioactive constituents combined with multivariate statistical
analysis. A reliable method based on ultra-fast performance liquid chromatography coupled with triple
quadrupole-linear ion trap mass spectrometry (UFLC-QTRAP-MS/MS) was used to simultaneously
determine the content of 15 constituents, including 11 lignans and 4 organic acids in 12 batches of
wuweizi samples from different ecosystems. Furthermore, principal component analysis (PCA) was
introduced to get a good overview of the sample distribution. Partial least squares-discriminant
analysis (PLS-DA) and t-tests were performed to show the difference of each compound between two
types of wuweizi according to the contents of the tested constituents. Gray relational analysis (GRA)
was carried out for the comprehensive evaluation. The protocol not just provided a new method for
the comprehensive evaluation and quality control of wild and cultivated wuweizi, but allowed for
differentiation of them at the chemistry level.
2. Results and Discussion
2.1. Optimization of Extraction Conditions
The orthogonal experiment was carried out to obtain a satisfactory extraction efficiency of major
compounds in samples. Extraction solvent, material-solvent ratio, and ultrasonic time were optimized
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through 9 extraction experiments. The orthogonal table of levels and factors was shown in Table S1.
The total peak area was calculated for evaluation of the orthogonal experiment, and the results were
shown in Table S2. Finally, the optimum extraction conditions were achieved through ultrasonic
extraction with a 40:1 ratio of methanol for 40 min at room temperature.
2.2. Optimization of UFLC Conditions
The peak area of schisandrin, theoretical plate number, resolution, and retention time
were taken into consideration to investigate the different chromatographic columns, flow rates,
column temperatures and mobile phases. Three kinds of columns, including an Agilent ZORBAX
SB-C18 column (250 mm × 4.6 mm, 5 μm), a XBridge C18 (100 mm × 4.6 mm, 3.5 μm), and a SynergiTM
Hydro-RP 100Å (100 mm × 2.0 mm, 2.5 μm), were all compared to test samples. The results showed
that the separation effect of three types of chromatographic columns were quite different, and the
last one had the desirable resolution, peak shape, and retention time. Consequently, the column of
SynergiTM Hydro-RP 100Å (100 mm × 2.0 mm, 2.5 μm) was employed for this analysis. To achieve
an efficient and rapid analysis, several UFLC parameters, including different kinds of mobile phases
(methanol/water, acetonitrile/water, acetonitrile/0.1% aqueous formic acid, acetonitrile containing
0.1% formic acid solution/water, and acetonitrile containing 0.1% formic acid solution/0.1% aqueous
formic acid), flow rates (0.3 mL/min, 0.35 mL/min and 0.4 mL/min), and column temperatures (30, 35,
and 40 ◦C) were examined systematically. When acetonitrile aqueous solution was used for gradient
elution, the shape of the peaks were better. When the flow rate was 0.40 mL/min, the resolution
was better. The results of resolution under three column temperatures were all satisfactory, however,
the column temperature of 40 ◦C had a higher theoretical plate number. Finally, it was determined that
a gradient elution using water as eluent A and acetonitrile as eluent B at a flow rate of 0.4 mL/min
under the column temperature of 40 ◦C resulted in the desired separation in a short analysis time.
2.3. Optimization of MS Conditions
In order to develop a sensitive and accurate quantitative method, individual solutions of all
standard compounds (about 100 ng/mL) were examined separately with infusion mode by a full-scan
mass spectrometry method in both positive and negative modes. After trial and error inspection,
we found that lignans show maximum sensitivity under the positive ion mode. However, organic acids
display desirable results in the negative ion mode. ESI, the electrospray ionizationsource of MS,
could obtain abundant fragment ions of compounds. MRM (multiple reaction monitoring) is suitable
for the quantification of components as a promising technology for the sensitivity and robustness.
MRM transition from the MS/MS spectrum was chosen when the most abundant fragment ions
appeared. For example, compounds 1, 2, 3, and 4 the showed most intense ion for [M − H]−.
All the optimum values, including retention time (tR), mass data (m/z), precursor and product ions,
fragmentor voltage (FV), and collision energy (CE) for each compound are summarized in Table 1.
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Table 1. Precursor/product ion pairs and parameters for MRM of the target compounds.







FV (V) CE (eV)
1 Quinic acid 0.79 191.1[M − H]− 191.1 85.02 −120 −26
2 D(−)-Tartaric acid 0.82 149.0[M − H]− 149.0 87 −55 −16
3 L-(−)-Malic acid 0.84 133.0 [M − H]− 133.0 114.9 −80 −14
4 Protocatechuic acid 1.11 153.0 [M − H]− 153.0 106 −85 −16
5 Schisandrin 5.65 433.3[M + H]+ 433.3 415.34 146 13
6 Gomisin D 5.75 553.3[M + Na]+ 553.3 507.32 21 35
7 Gomisin J 5.92 389.3[M + H]+ 389.3 287.1 156 27
8 Schisandrol B 6.11 417.3[M + H]+ 417.3 399.2 131 15
9 Angeloylgomisin H 6.67 501.3[M + H]+ 501.3 401.2 146 11
10 Schizantherin B 7.34 515.3[M + H]+ 515.3 415.2 56 11
11 Schisanhenol 7.63 403.2[M + H]+ 403.2 340.2 1 27
12 Deoxyschizandrin 8.83 417.3[M + H]+ 417.3 316.18 241 31
13 γ-schisandrin 9.50 401.3[M + H]+ 401.3 300.15 231 31
14 Schizandrin C 9.85 385.2[M +H]+ 385.2 285.16 201 29
15 Schisantherin 11.96 537.4[M + H]+ 537.4 282.3 56 15
2.4. UFLC Method Validation
All method validations of quantification were performed using the UFLC-QTRAP-MS/MS
technique. Each standard calibration curve was constructed by plotting the peak areas (Y) against the
corresponding concentrations (X), which achieved appropriate determination coefficients (r2 > 0.9991),
and the test range covered the concentrations of investigated compounds in samples. The limits
of detection (LOD) and limits of quantification (LOQ) were in the ranges of 0.49–2.95 ng/mL and
1.38–12.65 ng/mL of 15 analytes, respectively. The relative standard deviation (RSD) values of intra-day
and inter-day variations of 15 components ranged from 0.67% to 3.09% and 0.15% to 2.63%, respectively.
The RSD of repeatability and stability tests of the 15 analytes were less than 5%, and the overall
recoveries varied between 95.62% and 99.97%, with RSDs less than 4.12%, demonstrating that this
method was validated for all kinds of analytes. The detailed results of each method validation were
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2.5. Quantification of Lignans and Organic Acids
Twelve batches of cultivated and wild wuweizi were collected from Heilongjiang, Jilin,
and Liaoning and dealt with using the same processing method (sun drying). Sample information
is listed in Table 3. The validated analytical method of UFLC-QTRAP-MS/MS was successfully
applied to the simultaneous determination of 11 lignans and 4 organic acids in wuweizi. Each sample
was determined three times and the quantitative results of 15 compounds are presented in Table 4.
Total ion chromatograms of the representative wild and cultivated samples are shown in Figure S1.
Typical MRM chromatograms are shown in Figure 1. The histogram (Figure 2) suggests lignans were
found in higher concentrations in wild than cultivated-type. However, the content of organic acids
was slightly higher in the cultivated-type. It was clearly shown that the total contents of 15 compounds
varied from 25,598.77 μg/g to 35,179.73 μg/g. The total contents of each type of constituent was
also calculated, and 11 lignans ranged from 14,960.30 μg/g to 22,853.62 μg/g, and in the following
order: (highest) S1 (wild) > S6 (wild) > S3 (wild) > S5 (wild) > S4 (wild) > S10 (cultivated) > S2
(wild) > S8 (cultivated) > S7 (cultivated) > S11 (cultivated) > S9 (cultivated) > S12 (cultivated) (lowest).
The four organic acids ranged from 9075.64 μg/g to 13,646.81 μg/g. By comparing the amounts, it was
found that the compounds of wuweizi from different ecosystems were quite different. In this study,
the contents of lignans were similar to previous studies [4,15–18]. However, the contents of organic
acids were slightly lower than the reported, which may be related to the harvest period, processing,
and origin [19].
Table 3. Detailed information of samples.
Sample No. Habitats GPS Records Harvesting Time
Processing
Method
S1 Mulan, Heilongjiang 45
◦56′54” N,
128◦02′14” E 10 August 2017 sun drying
S2 Jingyu, Jilin 42
◦23′11” N,
126◦48′28” E 14 August 2017 sun drying
S3 Jingyu, Jilin 42
◦23′11” N,
126◦48′28” E 17 August 2017 sun drying
S4 Xinbin, Liaoning 41
◦43′53” N,
125◦02′01” E 14 August 2017 sun drying
S5 Hengren, Liaoning 41
◦15′13” N,
125◦22′15” E 10 August 2017 sun drying
S6 Baoqing, Heilongjiang 46
◦19′29” N,
132◦11′22” E 20 August 2017 sun drying
S7 Jingyu, Jilin 42
◦23′11” N,
126◦48′28” E 16 August 2017 sun drying
S8 Jingyu, Jilin 42
◦23′11” N,
126◦48′28” E 17 August 2017 sun drying
S9 Jingyu, Jilin 42
◦23′11” N,
126◦48′28” E 20 August 2017 sun drying
S10 Fengcheng, Liaoning 41
◦48′19” N,
123◦27′47” E 10 August 2017 sun drying
S11 Shuangyang, Jilin 43
◦31′22” N,
125◦39′31” E 10 August 2017 sun drying
S12 Heihe, Heilongjiang 50
◦14′37” N,
127◦31′16” E 16 August 2017 sun drying
235




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Molecules 2019, 24, 1335
 
Figure 1. Representative extract ion chromatograms (XIC) of MRM chromatograms of
15 investigated compounds.
Figure 2. Histogram of the mean accumulative contents of different types of wuweizi from 12 batches.
2.6. PCA of the Samples
To evaluate the differences of components in wuweizi of two types, unsupervised PCA was
performed. 12 Samples were set as observations, while the contents of 15 compounds were set as
variables. The score scatter plot and the loading plot were displayed in Figure 3. In Figure 3, all samples
were separated into two relative clusters, i.e., wild and cultivated wuweizi. This classification
indicated that the content and distribution of chemical constituents varied between different types of
wuweizi. The first and second principal components described 59.4% and 17.6% of the variability in
the original observations, respectively, and the first two principal components accounted for 77.0% of
the total variance.
Figure 3. Score scatter plot of PCA processed data acquired from wild and cultivated wuweizi scanned
by both positive and negative ion modes. Each of the green triangles represent a batch of wild wuweizi,
while the blue squares represent a batch of cultivated ones.
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2.7. PLS-DA of the Samples
The selected initial data was further processed by PLS-DA in order to reveal differences in the
chemical composition among wild and cultivated wuweizi. The results were shown in Figure 4.
Model parameters were set as follows: confidence level was 95%, R2Y = 0.967, and Q2 = 0.924,
and the parameters showed that the established PLS-DA model was effective. The PLS-DA score
plot displayed that the two clusters representing the wild and cultivated groups were well separated,
thereby indicating the remarkable differences between the two types.
 
Figure 4. Score scatter plot (A) and VIP (B) by PLS-DA processed data obtained from wild and
cultivated wuweizi scanned by positive and negative ion mode.
The VIP (variable importance for the projection) plot summarizes the importance of the variables
both to explain X and to correlate to Y. The VIP plot is arranged from high to low, and the VIP-values
greater than 1 indicated important variables, and four potential biological markers of quinic acid,
L-(−)-malic acid, protocatechuic acid, and schisandrol B have high contributions to classification.
2.8. T-test
More than two-thirds of bioactive components quantified in this study showed a significant
difference between two types of wuweizi, according to the T-test (Figure 5). Quantitation of
major compounds, including protocatechuic acid, gomisin D, angeloylgomisin H, schisanhenol,
and γ-schisandrin, showed strikingly higher levels (p < 0.01) in wild-type, while quinic
acid and L-(−)-malic acid showed lower contents (p < 0.01) compared with cultivated-type.
Secondly, quantitation of schisandrin, gomisin J, schisandrol B, and schizandrin C displayed highly
contents (p < 0.05) in wild wuweizi than its cultivated-type.
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Figure 5. The contents of 15 compounds in wild and cultivated wuweizi (* p < 0.05; ** p < 0.01).
2.9. Gray Relational Analysis (GRA)
Because the contents of the 15 target components of lignans and organic acids in samples were
different, it is difficult to judge the quality of samples intuitively. Therefore, gray relational analysis
was carried out for comprehensive evaluation. It could be seen that the quality of wild wuweizi was
better according to the results shown in Table S4. The quality sequencing of the samples was in the
following order: S1 (wild) > S6 (wild) > S3 (wild) > S4 (wild) > S5 (wild) > S2 (wild) > S10 (cultivated)
> S12 (cultivated) > S8 (cultivated) > S11 (cultivated) > S7 (cultivated) > S9 (cultivated).
3. Materials and Methods
3.1. Plant Materials
Twelve batches of cultivated and wild wuweizi dealing with the same processing method were
studied in this research. The botanical origin of materials was authenticated by Prof. Xunhong Liu
of the Nanjing University of Chinese Medicine. Voucher specimens were deposited at Herbarium
in Nanjing University of Chinese Medicine. These samples were collected from Heilongjiang, Jilin,
and Liaoning at around August 2017, dealing with sun drying for about 20 days. All batches of
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wuweizi were ripe when they were collected. Wild wuweizi grew under forests, valleys, and besides
streams, places which were shady and moist. Cultivated wuweizi grew in arable land, which had
enough sunshine and wind, or low-lying and rainy land. Detailed information is shown in Table 3.
3.2. Chemicals and Reagents
The reference compounds of L-(−)-malic acid (3), deoxyschizandrin (12), γ-schisandrin (13),
schisandrin (5), schisantherin (15) were purchased from National Institutes for Food and Drug Control
(Beijing, China). Quinic acid (1), D(-)-Tartaric acid (2), gomisin D (6), gomisin J (7), schizandrin C
(14), schisandrol B (8), angeloylgomisin H (9), schizantherin B (10), and schisanhenol (11) were
purchased from Nanjing Liangwei biotechnology Co., Ltd. (Nanjing, China). Protocatechuic acid (4)
was purchased from Nanjing Spring and Autumn Biological Engineering Co., Ltd., China. The purity of
all compounds by HPLC analysis was greater than 98%. The structures of the 15 reference compounds
are shown in Figure 6. Formic acid of MS grade, acetonitrile, and methanol of HPLC grade were
purchased from Merck (Darmstadt, Germany). Ultrapure water was prepared using a Milli-Q water
purification system (Millipore, Bedford, MA, USA).
  
Quinic acid (1) D(-)-Tartaric acid (2) L-( )-Malic acid (3) Protocatechuic acid (4) Schisandrin (5) 
 
  
Gomisin D (6) Gomisin J (7) Schisandrol B (8) Angeloylgomisin H (9) Schizantherin B (10) 
 
Schisanhenol (11) Deoxyschizandrin (12) -schisandrin (13) Schizandrin C (14) Schisantherin (15) 
Figure 6. Chemical structures of 15 reference substances.
3.3. Preparation of Standard Solutions
A mixed standard stock solution containing 15 reference standards was prepared in methanol and
their concentrations were as follows: 1, 26.60 μg/mL; 2, 0.10 μg/mL; 3, 29.52 μg/mL; 4, 12.77 μg/mL;
5, 9.31 μg/mL; 6, 1.01 μg/mL; 7, 0.93 μg/mL; 8, 5.35 μg/mL; 9, 2.26 μg/mL; 10, 2.21 μg/mL; 11,
1.20 μg/mL; 12, 2.40 μg/mL; 13, 4.60 μg/mL; 14, 1.47 μg/mL; 15, 7.17 μg/mL. This standard stock
solution was then diluted with methanol to a series of appropriate concentrations to generate the
calibration curves. The solutions were stored at 4 ◦C for a day prior to LC-MS analysis.
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3.4. Preparation of Sample Solutions
The dried fruits were pulverized into powders and screened through the 50-mesh sieve.
Each sample (0.5 g) was accurately weighed and extracted by ultrasonication (500 W, 40 kHz) in
20 mL methanol for 40 min. After cooling down at room temperature, methanol was added to
compensate for the weight lost during extraction. After centrifugation (12,000 rpm, 10 min) and
filtering (0.22 μm membrane filter), the supernatants were stored in a sample plate at 4 ◦C prior to
LC-MS analysis.
3.5. Chromatographic and Mass Spectrometric Conditions
The mass spectrometry detection was performed using an API5500 triple quadrupole mass (AB
SCIEX, Framingham, MA, USA). The MS was equipped with an electrospray ionization (ESI) source
operating in MRM and under both positive and negative ion modes. The MS parameters were set
as follows: gas temperature 550 ◦C; pressures of nebulizer of MS, 5500 V (positive) and −4500 V
(negative); GSI flow 65 L/min; CUR flow 30 L/min and all MS data were acquired and analyzed using
the Analyst 1.5.2 software (AB SCIEX, Framingham, MA, USA). The cone voltage and collision energy
parameter of each compound were individually optimized.
The chromatographic analysis was performed on a Shimadzu SIL-20A XR system (Shimadzu,
Kyoto, Japan), consisting of a binary solvent delivery system and an automatic sampler. A SynergiTM
Hydro-RP 100Å column (100 mm × 2.0 mm, 2.5 μm, (Phenomenex, Los Angeles, CA, USA) was
used for eluting samples. The mobile phase was composed of water (A) and acetonitrile (B) using
a gradient elution of 30%–52% B at 0–4 min, 52%–75% B at 4–8 min, 75%–90% B at 8–11 min, 90%–30%
B at 11–15 min, 30% B at 15–17.10 min. The column temperature was 40 ◦C, the flow rate kept at
0.4 mL/min, and the sample injection volume was 1 μL.
3.6. Validation of the Method
3.6.1. Linearity, LOD, and LOQ
The linearity of the calibration curves was obtained by plotting the peak areas (Y) against the
corresponding concentrations (X) of each analyte. The lowest concentration of standard solution
for calibration use was diluted with methanol to a series of appropriate concentrations. The LODs
and LOQs of 15 analytes were determined using a series of diluted standard solutions until the
signal-to-noise (S/N) ratios were about 3 and 10, respectively.
3.6.2. Precision, Repeatability, Stability, Accuracy
The analysis method developed in this study was validated for precision (the intra- and inter-day),
repeatability, stability, and accuracy. The intra-day and inter-day variability tests were determined
by measuring the mixed standard solutions in six replicates in a day and once a day during three
consecutive days, respectively. To evaluate the repeatability, six different analytical sample solutions
prepared from the same sample (sample 1) were parallel processed and analyzed. To confirm the
stability, the sample solution mentioned above was stored at room temperature and analyzed at 0,
2, 4, 8, 12, and 24 h, respectively. All the variations were expressed in RSD. A recovery test was
used to evaluate the accuracy of this method. A certain amount of the 15 standards with low (80%),
medium (100%), and high (120%) levels were added into a known amount of samples (0.25 g), and then
extracted and analyzed with the same procedures. To be specific, a recovery test was conducted
by standard protocol and calculated by the formula: (%) = (found amount– original amount in
sample)/spiked amount × 100%.
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3.7. Multivarite Statistical Analysis
Multivariate statistical analysis was performed using the Simca-P 13.0 software (for Windows,
Umetrics AB, Umeå, Sweden) by PCA and PLS-DA. PCA and PLS-DA were used to evaluate the
variations of the two types of wuweizi according to the contents of the 15 components. PCA is
an unsupervised pattern recognition method used for analyzing, classifying, and reducing the
dimensionality of numerical datasets in a multivariate problem [20,21], and it has been widely used
for the quality control of herbal medicines [22–24]. PLS-DA is good for highlighting the differences
between two groups. It is possible to identify and select the important markers in samples via
multivariate analysis of LC/MS data, even at low concentration levels [25]. Data of the contents
of 15 compounds in wild and cultivated samples were listed. When the contents of investigated
components were below the quantitation limit or not detected in the samples, the values of such
elements were considered to be 0. All experimental data were statistically analyzed by independent
sample t-test (SPSS 16.0 for Windows, IBM, Armonk, NY, USA). The columns were charted by Origin
pro 8 (Origin Lab, Northampton, MA, USA), showing the difference of each compound between two
types of wuweizi. GRA provides a reliable guarantee for the quality evaluation of traditional Chinese
medicine on the basis of the contents of the 15 index constituents [26].
4. Conclusions
An analytical method based on UFLC-QTRAP-MS/MS was used for the simultaneous
determination of 15 components, including 11 lignans and 4 organic acids, in wuweizi under different
ecosystems (wild and cultivated). Multivariate statistical analyses, such as PCA, PLS-DA, independent
sample t-test, and GRA, have been successfully applied to comprehensively analyze and evaluate
the wuweizi under different ecosystems according to the contents of the 15 components. The data of
content determination showed that lignans had higher contents in wild-type, while cultivated-type
contained more organic acids. This phenomenon is probably ascribed to environmental stress (such as
water, soil strength, and nutrient status), which can have a great influence on the accumulation of the
active compounds of medicinal plants. PCA and PLS-DA results showed that there are great difference
between wild and cultivated wuweizi, and 4 different compounds (protocatechuic acid, quinic acid
and L-(−)-malic acid, and schisandrol B) were significantly related to sample classification. It could
be seen that the quality of the samples collected from the wild environment was better according
to the GRA results. Wild wuweizi usually suffered more stress than cultivated-type and produced
more specialized metabolites, even though the quality indicator of the two types all conformed to the
requirements of Chinese pharmacopoeia. Findings from this research may provide a new method for
the comprehensive evaluation and quality control of wuweizi from different ecosystems. It may also
provide a basis for differentiating wild and cultivated wuweizi at the chemistry level.
Supplementary Materials: The following are available online. Table S1: Levels and factors of orthogonal table.
Table S2: Result of L9(3)3 orthogonal experiment. Table S3: Recoveries and relative standard deviations (RSD) of
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the representative wild and cultivated samples.
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Abstract: The physicochemical properties of classical lignans, neolignans, flavonolignans and
carbohydrate-lignan conjugates (CLCs) were analysed to assess their ADMET profiles and establish
if these compounds are lead-like/drug-like and thus have potential to be or act as leads in the
development of future therapeutics. It was found that while no studied compounds were lead-like,
a very large proportion (>75%) fulfilled all the requirements to be deemed as present in drug-like
space and almost all compounds studied were in the known drug space. Principal component
analysis was an effective technique that enabled the investigation of the relationship between the
studied molecular descriptors and was able to separate the lignans from their sugar derivatives and
flavonolignans, primarily according to the parameters that are considered when defining chemical
space (i.e., number of hydrogen bond donors, acceptors, rotatable bonds, polar surface area and
molecular weight). These results indicate that while CLCs and flavonolignans are less drug-like,
lignans show a particularly high level of drug-likeness, an observation that coupled with their potent
biological activities, demands future pursuit into their potential for use as therapeutics.
Keywords: lignans; chemometrics; neolignans; flavonolignans; chemical space; drug-like
1. Introduction
Lignans are a class of secondary metabolites that are derived from the oxidative dimerisation of
two or more phenylpropanoid units [1]. Despite their common biosynthetic precursors, lignans show
vast structural diversity due to the numerous potential coupling modes of the phenoxy radicals [2].
The nature of the molecular linkage of the phenylpropanoids provides the most fundamental level of
classification of lignans into two main subclasses—classical lignans and neolignans—although there
exist other smaller subclasses, including flavonolignans and coumarolignans [1,3–6].
Classical lignans are phenylpropane dimers that have a β-β′ linkage and there six main subtypes
of classical lignans—dibenzylbutanes, dibenzylbutyrolactones, arylnaphthalenes/aryltetralins,
dibenzocyclooctadienes, substituted tetrahydrofurans, and 2,6-diarylfurofurans (Figure 1) [3,6,7].
Neolignan was a classification initially coined by Gottlieb to distinguish phenylpropanoid dimers that
did not contain the β-β′ (also referred to as an 8-8′) phenylpropane linkage characteristic of classical
lignans [8,9]. Neolignans have more varied structures than classical lignans; there are 15 subtypes
designated by the nature and position of the linkage between the phenylpropane units [3,6,10], the most
common subtypes being benzofurans, 1,4-benzodioxanes, alkyl aryl ethers, biphenyls, cyclobutanes,
8-1′-bicyclo[3.2.1]octanes, 8-3′-bicyclo[3.2.1]octanes and biphenyl ethers, examples of which are shown
in Figure 1.
Lignans have been found in more than 70 plant families and an extensive range of localities within
plants, from roots to leaves, seeds and flowers [1,3–5,11]. Most importantly, this class of compound
has exhibited several potent, significant, biological activities, including anticancer [3,4,12,13],
antimicrobial [4], antiviral [12–15], immunosuppressive [4], anti-inflammatory [4], antioxidant [3,4,16],
and hepaprotective [15–17] actions as well as cancer [18,19] and osteoporosis [20] prevention
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properties; activities that have contributed an ever-increasing interest in lignans and their
synthesis [3–5,7,11,15,21–41].
 
Figure 1. Examples of the six types of classical lignans, the eight types of neolignans investigated in
this study, a flavonolignan and carbohydrate-lignan conjugate (CLC).
Throughout human history, plants with a high lignan content have been utilised to treat illnesses
and ailments, playing a vital role in traditional folk medicine [5,11]. These lignan-containing plants
have been documented in medical pharmacopoeias from a large number of cultures including English,
Korean, Native American, Chinese, Japanese, South American and Tibetan. For many, the uptake of
modern medicine has supplanted the need and use of traditional medicines, however the continued
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use of folk medicine exists in a large number of cultures including Ayurvedic, Unani, Siddhi, Kampo,
Jamu and in traditional Chinese medicine [4]. Furthermore, traditional medicine has been a critical
source of inspiration in the pursuit of modern drug therapies, with a number of presently-used
medicines being engendered by compounds of natural origins–circa 40% of commercially-available
drugs are either natural products or derivatives thereof [5]. In this capacity, lignans constitute an
important class of compounds that provide a starting point for the development of therapeutic
agents [1,3,5,11,21,42–44].
Potentially the most well-known example of a lignan as a currently-utilised and lead compound
is the aryltetralin lactone, podophyllotoxin (Figure 2) [11,21,45]. It has been known for centuries that
the plants of the Podophyllum genus possess medicinal properties. These plants have particularly
been used by the indigenous peoples of the Himalayas and North America [45]. Podophyllotoxin
was first isolated in 1880 from one of these plants [46], and is a cytotoxic compound that binds
to tubulin, thereby inhibiting microtubule assembly during mitosis and thus interrupts the cell
cycle [47–49]. Podophyllotoxin has a mode of action and level of potency that lends it to be a
possible cancer chemotherapeutic, however this possibility was tempered by the discovery that
it exhibits high levels of gastrointestinal toxicity [50]. Podophyllotoxin, however, has been approved
for use as a topically-administered treatment for genital warts. Additionally, podophyllotoxin was
used as a lead compound for antitumour agents [51], resulting in the development of etoposide,
its water-soluble phosphate ester prodrug, etopophos and teniposide as anticancer agents that are all
in current use to treat a range of cancers, including testicular, lung and ovarian cancer, lymphoma,
leukemia, neuroblastoma and various types of brain tumours [45,50,52]. It should be noted that
etoposide, etopophos and teniposide exhibit an alternative mode of action to their lead compound,
podophyllotoxin, in that they are potent DNA topoisomerase II inhibitors [50–52].
Figure 2. Structure of podophyllotoxin and three of its most notable derivatives; etoposide, etopophos
and teniposide.
Podophyllotoxin provides an inspiring example of the potential that lignans possess as a
foundation for the development of medicines to target diseases and conditions, many of which
that have an unmet need for cures and treatments.
While potent biological activity, which many lignans possess, is the most critical property
of a potential drug or lead compound, it is also important to assess the Absorption, Distribution,
Metabolism, Excretion and Toxicity (ADMET) profiles of these compounds to evaluate their likelihood
of being effective drug leads [53]. To do this, the physicochemical properties of the compounds
can be calculated–these molecular descriptors can subsequently be assessed against various existing
and verified benchmarks. Drug-like chemical space is defined by the Lipinski’s rule of five–the
most widely used and recognised set of parameters that are used to assess properties of potential
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therapeutics. Compounds that fall within these boundaries are indicated to be able to be orally
absorbed [54,55]. The two other definitions of chemical space are lead-like space and known drug space
(KDS). Compounds within lead-like chemical space are typically compounds that are less complex,
hence have low molecular weights and lower lipophilicities (LogP) [56]—lead-like compounds have very
low limits for these parameters as they generally increase during the optimisation process in medicinal
chemistry; lead-like compounds are more likely to become real therapeutics once modified [57,58].
KDS is defined by criterion that includes all small organic compounds that have been assessed in
human clinical trials and were/are subsequently in medical use [59]. The upper limits for each chemical
space referred to in this study are provided (Table 1).
Table 1. Definition of lead-like, drug-like and known drug space (KDS) in terms of molecular descriptors.
Descriptor Lead-Like Space Drug-Like Space Known Drug Space
Molecular weight (g mol−1) 300 500 800
Lipophilicity (Log P) 3 5 6.5
Hydrogen bond donors 3 5 7
Hydrogen bond acceptors 3 10 15
Polar surface area (Å2) 60 140 180
Rotatable bonds 3 10 17
We wished to assess the ADMET profile of lignans and related compounds to explore their position
in the predefined chemical spaces, as well as if there are notable differences within, and between,
these groups. Presented herein is the result of the investigation into the physicochemical properties of
traditional lignans, neolignans, flavonolignans and sugar derivatives of lignans (carbohydrate-lignan
conjugates; CLCs) to establish if these compounds are lead-like/drug-like and thus have potential to be
or act as leads in the development of future therapeutics.
2. Methodology
Representative compounds for each of the main subclasses of lignan and neolignan
compounds were found by doing a substructure search using Scifinder and choosing the
ten lignan compounds with the highest number of references. There were six subclasses
of classical lignans (dibenzylbutanes, dibenzylbutyrolactones, arylnapthalenes/aryltetralins,
dibenzocyclooctadienes, substituted tetrahydrofurans and 2,3-diarylfurans) and eight subclasses
of neolignans (benzofurans, 1,4-benzodioxanes, alkyl aryl ethers, biphenyls, cyclobutanes,
8-1′-bicyclo[3.2.1]octanes, 8-3′-bicyclo[3.2.1]octanes and biphenyl ethers) included in this
study–examples of these subclasses are given in Figure 1 and the compound details (name, class
and CAS number) of each compound included in this study are given in the Supplementary
Information. Furthermore, additional lignan-like compounds were also found–flavonolignans and
sugar derivatives (carbohydrate-lignan conjugates, CLCs) of classical lignan and neolignan subclasses.
In total, 16 different groups of compounds were studied, each group consisting of ten compounds.
Hence, 160 compounds were included in this representative study.
The 3D structures of the compounds were drawn using ChemBioDraw as part of the ChemOffice
software package [60]. The structures were then optimised using the MM2 [61] force field in
Chem3D [60]. The molecular descriptors were calculated using QikProp 4.42 [62], which has been
shown to be an accurate and reliable tool for the calculation of the molecular descriptors analysed in
this study [63].
Following generation of the molecular descriptors for all the compounds in the study, the mean,
median and standard deviation of each descriptor was calculated (see Section 3.1). Graphs of the
distributions of these molecular descriptors were generated with R (version 3.2.2) [64] and R Studio
(version 0.99.486) [65] using the ggplot2 package [66]. Compounds were categorised as lead-like,
drug-like and in KDS for each of the parameters by comparing the values for the descriptors against
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those stated in Table 1 and including them in the chemical space if the calculated value was less than
or equal to the stipulated benchmark.
Principal Component Analysis (PCA) was carried out using all compounds and parameters
included in this study (see Section 3.2) using R (version 3.2.2) [64] and R Studio (version 0.99.486) [65].
PCA analysis was performed using the prcomp function as part of the stats package, by singular value
decomposition of the centred and scaled data matrix [64]. Results of this analysis were visualised
using the factoextra package (version 1.0.5) [67].
3. Results and Discussion
3.1. Molecular Descriptors
Using the aforementioned methods, ten molecular descriptors were calculated for each of the
160 compounds studied. Molecular weight, lipophilicty (LogP), the number of hydrogen bond donors,
hydrogen bond acceptors and rotatable bonds and polar surface area (PSA) have been extensively
used in the assessment of a molecules’ suitability to be considered as a drug [68]. The other molecular
descriptors—dipole moment, polarisability, ionisation potential and water solubility (LogS) have been
used less extensively, however their association with desirable characteristics has led them to being
increasingly examined in recent times [63,69,70].
To analyse the molecular descriptors, summary statistics–the mean, median and standard deviation
for each of these parameters—for each compound type, as well as for all 160 compounds (all classical
lignans, neolignans, flavonolignans and CLCs) were calculated and are in the table provided (Table 2).
Table 2. Mean, standard deviation (std dev) and median values of the compound types for the ten
molecular descriptors analysed in this study.
Compound Type
Molecular Weight (g mol−1) Lipophilicity (LogP) Hydrogen Bond Donors
Mean Std Dev Median Mean Std Dev Median Mean Std Dev Median
Overall 381.5 70.4 372.4 3.0 1.3 3.1 1.8 1.9 2.0
Classical lignans and neolignans 361.2 42.3 364.4 3.3 1.0 3.4 1.4 1.3 1.0
Flavonolignans 478.6 7.0 482.4 1.6 0.6 1.5 4.1 0.7 4.0
CLCs 567.4 67.5 534.6 0.4 1.1 0.5 6.1 2.1 5.5
Dibenzylbutanes 354.8 36.1 346.4 3.2 1.1 3.2 2.5 1.5 2.0
Dibenzylbutyrolactones 369.6 31.4 372.4 2.5 0.7 2.5 1.6 0.8 2.0
Arylnapthalenes/Aryltetralins 348.2 23.6 350.3 3.1 0.8 3.1 0.7 0.9 0.0
Dibenzocyclooctadienes 413.3 17.8 416.5 3.9 0.7 3.7 0.7 0.8 0.5
Substituted tetrahydrofurans 362.2 28.1 350.4 3.6 0.5 3.6 0.7 0.9 0.0
2,6-Diarylfurofurans 377.8 24.2 371.4 2.7 0.6 2.9 1.0 0.9 1.0
Benzofurans 351.2 21.6 352.4 3.4 1.1 3.1 2.1 1.3 2.5
1,4-Benzodioxanes 352.0 37.3 359.4 3.3 1.2 3.5 1.6 1.4 1.5
Alkyl aryl ethers 387.0 15.5 377.4 3.1 1.4 2.7 2.4 1.8 3.0
Biphenyls 313.8 62.6 298.4 3.5 1.6 3.9 2.4 1.5 2.0
Cyclobutanes 371.6 51.1 372.4 3.7 0.9 3.9 1.0 1.4 0.0
8-1′-Bicyclo[3.2.1]octanes 377.8 15.3 373.4 3.3 0.6 3.2 0.4 0.8 0.0
8-3′-Bicyclo[3.2.1]octanes 381.4 30.0 386.4 3.5 0.5 3.6 0.8 0.4 1.0
Biphenyl ethers 296.5 27.4 287.3 3.1 1.1 2.6 1.3 0.8 1.5
Hydrogen Bond Acceptors Polar Surface Area (Å2) Rotatable Bonds
Mean Std Dev Median Mean Std Dev Median Mean Std Dev Median
Overall 6.3 3.4 6.0 79.5 37.1 70.2 7.0 3.8 6.0
Classical lignans and neolignans 5.4 1.7 5.8 68.3 22.5 66.9 6.4 3.1 6.0
Flavonolignans 9.0 0.8 9.7 158.5 11.4 159.2 7.1 0.7 7.0
CLCs 16.6 3.8 14.9 156.9 29.3 142.1 15.1 5.0 14.5
Dibenzylbutanes 4.9 1.5 5.0 71.2 22.2 69.1 11.0 1.9 11.0
Dibenzylbutyrolactones 6.5 1.2 6.0 90.8 13.6 87.9 7.6 1.5 8.0
Arylnapthalenes/Aryltetralins 4.7 1.5 5.3 61.6 15.4 69.4 3.4 1.9 3.0
Dibenzocyclooctadienes 5.1 0.8 4.9 51.2 11.9 49.4 5.0 1.6 5.0
Substituted tetrahydrofurans 4.9 0.5 4.7 50.6 12.6 47.8 3.4 1.6 4.0
2,6-Diarylfurofurans 6.8 0.5 6.4 66.3 14.0 66.6 3.3 2.2 4.0
Benzofurans 5.1 1.8 6.4 69.2 25.2 80.7 7.1 2.5 8.5
1,4-Benzodioxanes 5.0 1.4 4.5 70.7 23.8 59.3 5.8 1.7 6.0
Alkyl aryl ethers 6.7 1.6 7.2 76.9 27.8 80.9 12.1 1.3 12.5
Biphenyls 4.1 3.1 2.6 63.2 28.4 56.2 8.4 2.3 7.0
Cyclobutanes 4.5 1.5 4.3 66.8 36.4 59.6 4.6 1.6 5.0
8-1′-Bicyclo[3.2.1]octanes 6.3 0.7 6.0 69.5 8.5 66.5 4.7 1.3 5.0
8-3′-Bicyclo[3.2.1]octanes 6.7 0.8 6.5 71.8 7.6 72.9 5.8 1.4 6.0
Biphenyl ethers 4.1 1.5 4.5 76.1 26.2 84.4 7.1 1.8 7.5
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Table 2. Cont.
Dipole Moment (D) Water Solubility (LogS) Ionisation Potential (eV)
Mean Std Dev Median Mean Std Dev Median Mean Std Dev Median
Overall 4.1 1.9 3.9 −4.1 1.4 −4.1 9.0 0.4 9.0
Classical lignans and neolignans 4.1 1.9 4.0 −4.2 1.4 −4.2 9.0 0.4 9.0
Flavonolignans 4.0 2.5 3.2 −4.4 0.8 −4.4 9.1 0.2 9.1
CLCs 4.7 1.9 3.9 −2.5 1.3 −2.4 9.0 0.2 9.0
Dibenzylbutanes 4.1 1.2 3.9 −3.4 1.2 −3.0 9.1 0.2 9.0
Dibenzylbutyrolactones 5.5 2.2 4.7 −2.6 0.6 −2.6 9.2 0.2 9.2
Arylnapthalenes/Aryltetralins 5.1 2.8 4.9 −3.5 1.3 −3.5 8.4 0.2 8.4
Dibenzocyclooctadienes 2.6 1.0 2.5 −5.6 0.9 −5.4 8.6 0.3 8.5
Substituted tetrahydrofurans 3.5 1.6 3.8 −5.4 1.1 −5.0 9.0 0.3 9.0
2,6-Diarylfurofurans 2.7 1.3 2.8 −3.9 1.0 −4.4 8.9 0.3 9.0
Benzofurans 3.0 0.9 3.1 −4.7 1.1 −4.4 8.7 0.2 8.7
1,4-Benzodioxanes 3.9 2.0 3.8 −4.9 1.2 −4.7 9.0 0.2 9.1
Alkyl aryl ethers 4.0 1.5 4.4 −4.2 1.9 −3.2 9.1 0.1 9.1
Biphenyls 3.6 1.7 3.5 −3.5 0.9 −4.0 8.7 0.2 8.8
Cyclobutanes 3.7 1.8 3.9 −5.8 1.5 −5.4 9.2 0.5 9.0
8-1′-Bicyclo[3.2.1]octanes 4.9 1.2 5.2 −3.5 0.5 −3.5 8.9 0.5 8.8
8-3′-Bicyclo[3.2.1]octanes 4.5 1.8 4.5 −4.1 0.7 −4.3 9.0 0.6 8.9
Biphenyl ethers 5.3 2.1 4.9 −3.6 0.6 −3.7 9.6 0.3 9.6
Polarisability (Å3)
Mean Std Dev Median
Overall 36.3 5.1 36.0
Classical lignans and neolignans 35.1 4.2 35.1
Flavonolignans 42.7 1.8 43.2
CLCs 45.6 4.6 46.5
Dibenzylbutanes 32.2 4.1 30.4
Dibenzylbutyrolactones 32.0 2.8 30.9
Arylnapthalenes/Aryltetralins 32.2 1.7 31.9
Dibenzocyclooctadienes 51.2 1.6 49.4
Substituted tetrahydrofurans 38.7 3.5 37.1
2,6-Diarylfurofurans 37.3 2.8 37.1
Benzofurans 35.3 1.8 35.1
1,4-Benzodioxanes 35.7 3.8 35.7
Alkyl aryl ethers 35.7 3.5 34.0
Biphenyls 31.0 3.7 29.9
Cyclobutanes 38.7 4.6 38.1
8-1′-Bicyclo[3.2.1]octanes 36.3 2.8 36.1
8-3′-Bicyclo[3.2.1]octanes 37.5 3.0 37.0
Biphenyl ethers 29.9 1.9 29.6
3.1.1. Molecular Weight
The molecular weights of the compounds in this study are approximately normally distributed
(Figure 3), with an overall mean of 381.5 g mol−1 and standard deviation of 70.4 g mol−1 (Table 2).
 
Figure 3. The statistical distribution of the molecular weight of all analysed compounds
(green = 300 g mol−1, compounds < 300 g mol−1 are in the lead-like space; yellow = 500 g mol−1,
compounds < 500 g mol−1 are in the drug-like space; red = 800 g mol−1, compounds < 800 g mol−1 are
in the KDS). Total number of compounds = 160.
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Unsurprisingly, the categories with the highest average molecular weights were CLCs and
flavonolignans, with mean molecular weights of 567.4 ± 67.5 and 478.6 ± 7.0 g mol−1, respectively.
By definition, flavonolignans are the result of a dimerisation of a phenyl propanoid unit and flavone
nucleus, a flavone moiety having a higher molecular weight than another phenyl propanoid unit that
forms the basis of a classical lignan/neolignan. The CLCs in this study are classical lignans/neolignans
with a least one additional saccharide unit attached. Of all of the sub-classes, flavonolignans had
the lowest standard deviation for molecular weight, indicative that the compounds of this type have
very similar molecular composition. Of the classical lignans and neolignans, dibenzyocyclooctadienes
had a significantly higher average than other classical lignans and neolignans (413.3 g mol−1 vs.
361.2 g mol−1). Conversely, biphenyls (313.8 ± 62.6 g mol−1) and biphenyl ethers (296.5 ± 27.4 g mol−1)
had the lowest molecular weights, on average. Looking at these compounds, they generally have
lower numbers of substituents on the aromatic ring and less elaboration of the sidechains, which could
account for this observation. Compounds in the KDS have molecular weights lower than 800 g mol−1
(red line in Figure 3); as can be seen, all of the compounds studied exist in KDS for this parameter.
Almost all (94.5%) of the compounds would be considered to be drug-like when considering molecular
weight, however only ~10% of compounds are also considered lead-like (<300 g mol−1).
3.1.2. The Octanol–Water Partition Coefficient (LogP)
Like the molecular weights, the lipophilicites (LogP values)—the octanol-water partition coefficient
of the molecules—are approximately normally distributed (mean = 3.0, standard deviation = 1.3, Table 2,
Figure 4). All compounds studied have a calculated LogP less than the benchmark for KDS (LogP = 6.5),
and all but one can be considered drug-like (LogP < 5) for this parameter. Approximately half of the
compounds had a calculated lipophilicity allowing it to be in lead-like space. The compound classes
that were calculated to exhibit the highest degree of lipophilicity were dibenzocyclooctadienes and
cyclobutanes (LogP = 3.9 ± 0.7 and 3.7 ± 0.9, respectively). Contrastingly, CLCs have the lowest
average calculated LogP (0.4 ± 1.1), thereby demonstrating a low affinity for non-aqueous systems
and the highest degree of hydrophilicity. Flavonolignans also had low LogP values (mean = 1.6) which
was notably lower than the classical lignans and neolignans studied (mean = 3.3).
Figure 4. The statistical distribution of the octanol–water partition coefficient (LogP) of all analysed
compounds (green = 3, compounds < 3 are in the lead-like space; yellow = 5, compounds < 5 are in the
drug-like space; red = 6.5, compounds < 6.5 are in the KDS). Total number of compounds = 160.
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3.1.3. Hydrogen Bond Donors and Acceptors
Ideally, compounds should not have too many hydrogen bond donors and acceptors; the number
of hydrogen bond donors should be lower than seven, five and three to be considered to be in KDS,
drug-like space and lead-like space, respectively. On average, the compounds in this study conform
reasonably well with the three aforementioned definitions used for the chemical spaces (mean = 3.0,
standard deviation = 1.3, Figure 5, Table 2) for hydrogen bond donors. As can be seen, most compounds
have three or less hydrogen bond donors (81.3%), allowing them to be classified in lead-like space and
the majority of compounds have less than two. There are a proportion of compounds that do have
more than three hydrogen bond donors–these compounds were mainly CLCs and flavonolignans,
with their mean number of hydrogen bond donors being 6.1 and 4.1, respectively. Dibenzylbutanes
and alkyl aryl ethers also had a significant percentage of compounds excluded from lead-like space
according to this parameter.
 
Figure 5. The statistical distribution of the hydrogen bond donors of all analysed compounds (green = 3,
compounds < 3 are in the lead-like space; yellow = 5, compounds < 5 are in the drug-like space; red = 7,
compounds < 7 are in the KDS). Total number of compounds = 160.
Only 15% of compounds were classified as being lead-like in terms of the number of hydrogen
bond acceptors (≤3 hydrogen bond acceptors)–much lower than that observed for the hydrogen bond
donors, although greater than 90% of compounds had ≤10 hydrogen bond acceptors, classifying them
as drug-like.
The number of hydrogen bond acceptors displayed a slightly-left skewed normal distribution
(Figure 6)–far different to the strongly-skewed distribution seen for the aforementioned number of
hydrogen bond donors (Figure 5). The overall mean number of hydrogen bond acceptors was 6.3,
although this was largely inflated due to the CLCs (hydrogen bond donors = 16.6 ± 3.8) and to a
lesser degree, flavonolignans (hydrogen bond donors = 9.0 ± 0.8); without these two compound types
included in the analysis, the mean decreased to 5.4 hydrogen bond acceptors. The only compounds
studied with greater than 15 hydrogen bond acceptors, thus not in KDS, were CLCs.
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Figure 6. The statistical distribution of the hydrogen bond acceptors of all analysed compounds
(green = 3, compounds < 3 are in the lead-like space; yellow = 5, compounds < 5 are in the drug-like
space; red = 15, compounds < 15 are in the KDS). Total number of compounds = 160.
3.1.4. Polar Surface Area (PSA)
The polar surface area (PSA) of all the compounds in the study was found to be 79.5 ± 37.1 Å2
(Figure 7, Table 2). This parameter is inherently-linked to the number of hydrogen bond acceptors and
donors, thus it is no surprise that CLCs had a much higher average polar surface area than the overall
average (PSA = 156.9 ± 29.3 Å2). CLCs, however, did not have the highest mean PSA–flavonolignans
had a marginally higher average PSA (158.5 ± 11.4 Å2). Of the classical lignans/neolignans,
the subclass with the highest PSA were dibenzylbutyrolactones (PSA = 90.8 ± 13.6 Å2); the compounds
with the lowest PSAs were dibenzylcyclooctadienes and substituted THF’s (mean = 51.2 Å2 and
50.6 Å2, respectively). The highest PSA at which oral absorption is able to occur has been reported
to be 140 Å2 – this value thereby benchmarks the upper PSA limit for drug-like space [71,72]. A large
proportion of studied compounds (88.1%) are in drug-like space when considering PSA, while nearly
all compounds are in KDS (PSA ≤ 180 Å2), while only a third of compounds were within the strict
bounds of lead-like space.
 
Figure 7. The statistical distribution of the polar surface area (PSA) of all analysed compounds
(green = 60, compounds < 60 Å2 are in the lead-like space; yellow = 140, compounds < 140 Å2 are in the
drug-like space; red = 180, compounds < 180 Å2 are in the KDS). Total number of compounds = 160.
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3.1.5. Rotatable Bonds
Looking at the general structures of classical lignan/neolignan types, it is apparent that most,
in addition to the aryl rings present, have additional ring cycles present in the structures (Figure 1).
The exceptions to this general rule are the biphenyl structures, dibenzylbutanes and alkyl aryl
ethers; this is reflected in the number of rotatable bonds (Table 2, Figure 8), where alkyl aryl
ethers and dibenzylbutanes have the largest average number of rotatable bonds of all the classical
lignans/neolignans (mean = 12.1 and 11.0, respectively). CLCs also had high counts for number of
rotatable bonds, whereas highly-constricted structures, with a more fused-ring scaffold had far lower
averages for this parameter, i.e., 3.3 ± 2.2 for 2,6-diarylfurofurans, and mean = 3.4 ± 1.6 for substituted
tetrahydrofurans and arylnapthalenes/aryltetralins.
Figure 8. The statistical distribution of the rotatable bonds of all analysed compounds (green = 3,
compounds < 3 are in the lead-like space; yellow = 10, compounds < 10 are in the drug-like space;
red = 17, compounds < 17 are in the known drug space). Total number of compounds = 160.
The number of rotatable bonds had the second-lowest proportion of compounds classified as
lead-like, (12.5%) indicating that this parameter (along with molecular weight with 10.6% in lead-like
space) is one of the more effective descriptors for eliminating potential drug candidates. Lu et al.
found that compounds were considered to be in privileged property space if they had ≤10 rotatable
bonds–hence, this is the benchmark used to define drug-like space for the number of rotatable bonds [72].
The number of rotatable bonds was the most discerning factor for inclusion of compounds in drug-like
space (85.0% of compounds met the criteria of ≤10 rotatable bonds, Table 3). However, 98.1% of the
compounds tested were within the bounds of KDS, with ≤17 rotatable bonds.
3.1.6. Other Molecular Descriptors
The calculated dipole moments of the compounds are approximately normally distributed,
with a mean of 4.1 ± 1.9 D (Table 2, Figure S1). The compounds with the lowest dipole moments
were dibenzocyclooctadienes (mean = 2.6 ± 1.0 D) and 2,6-diarylfurofurans (mean = 2.7 ± 1.3 D),
while dibenzylbutyrolactones and biphenyl ethers were the types that had the highest average dipole
moments (mean = 5.5 D and 5.3 D, respectively). Density functional theory (DFT) has previously
been applied to dipole moment measurements of compounds in KDS, a study which found that
compounds within KDS have dipole moments ≤10 [70]. Furthermore, it has been reported that to be
orally available, a drug should have a dipole moment <13 D. All the compounds in this study had
dipole moments below 10 D, indicating that all of the compounds lie within KDS for this parameter
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and would be orally-available, using dipole moments as a measure of this desirable characteristic in
drug therapeutics.
Intrinsically linked to lipophilicity (LogP), the water solubility (LogS) of a compound is an
important property to consider [73]. Akin to the dipole moment, the LogS of a compound can be
a signifier of oral-availability; it has been shown that the majority of orally available drugs have
a LogS between 0 and −7, centring between −4 and −3 [67]. The distribution of the calculated
hydrophilicity of the compounds in this study has an approximately normal distribution in those
ranges (Figure S2, Table 2). Using the above-mentioned range as the criterion for this parameter as
a yardstick of oral-availability, 97% are likely to be orally-available. The mean LogS was −4.1 ± 1.4
for all compounds and it can be noted that CLCs and dibenzylbutyrolactones (mean = −2.5 and
−2.6, respectively) have the highest LogS values and thus greater aqueous solubility. In contrast,
cyclobutanes (mean = −5.8 ± 1.5), dibenzylcyclooctadienes (mean = −5.6 ± 0.9), and substituted
tetrahydrofurans (mean = −5.4 ± 1.1), had lower mean hydrophilicity values, indicating a low affinity
for aqueous media.
The ionisation potential of the compounds were normally distributed but had very low variability
(mean = 0.9 and standard deviation = 0.4, for all compounds) and no significant differences between
compound groups (Table 2, Figure S3). Analogous to the findings for dipole moment and water
solubility, the studied compounds have a high degree of compliance with the benchmarks set for
ionisation potentials as an indicator of oral availability. All but two of the 160 compounds investigated
had an ionisation potential between 8 and 10 eV–it has been shown that orally administered commercial
drugs have ionisation potentials in this range [67]. Of importance to note is that these three descriptors
that have been particularly associated with oral availability; ionisation potential, LogS and dipole
moment, are very closely correlated in the PCA analysis (see following section for further discussion,
Figure 9), with these vectors all having similar bearings. Ionisation potential has also been shown to
predicate the redox stability of compounds and thus their ease of metabolism in the body [70].
Polarisability is defined as the ability of a compound to form instantaneous dipoles and can be
associated with the ability of the drug to permeate the cell [70]. It has previously been shown that there
is a high correlation between the polarisability and molecular weight of a compound (r2 = 0.90)–an
observation that accounts for why molecular weight is such a crucial parameter in chemical space
definition [74]. Evidently, this was also the case this study–the principal component analysis shows
very close alignment of the polarisability and molecular weight vectors, signifying a high correlation
between these parameters (see following section for further discussion, Figure 9). The mean calculated
polarisability of all the compounds was found to be 36.3 ± 5.1 Å3 with an approximately normal
distribution, with a slight right-skew (Table 2, Figure S4). CLCs and flavonolignans have high mean
polarisability values (45.6 ± 4.6 Å3 and 42.7 ± 1.8 Å3, respectively), although dibenzylcclooctadienes
had the highest average polarisability (51.2 ± 1.6 Å3). Biphenyls and biphenyl ethers had the lowest
average polarisabilities. Convention dictates that polarisability values should be ≤68 Å3 to be classified
as being in KDS [70] all of the compounds in this study met this criterion.
3.2. PCA (Principal Component Analysis)
After looking at the individual molecular descriptors separately, it was decided to conduct an
overall analysis using PCA (Principal Component Analysis). PCA is a statistical technique that
transforms the data into a series of new, uncorrelated, dimensions called principal components.
These principal components are made up by a combination of the variables studied (in this case,
the molecular descriptors). Conducting PCA and analysing these principal components allows for the
in-depth, simultaneous investigation of all the descriptors, their interactions and interrelationships.
Furthermore, PCA can be used to discover groupings of samples–in this study, compounds—and
identify the variables that distinguish these clusters of compounds.
A way to view and analyse the results of a PCA is to plot the principal components against each
other, producing a biplot (see Figure 9). In the biplot, the vectors/arrows indicate the direction of
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influence for each molecular descriptor studied and the data points represent each molecule studied.
The biplot given shows the first two principal components–the first principal component is displayed
on the x-axis and is the principal component that explains the highest amount of variability of the data,
while the second principal component is the dimension in which the data is second-most variable.
In the PCA for this study, nearly half of the variability in the data set is explained by principal
component one while principal component two accounts for ~20% of the variability. Thus, these
first two principal components account for ~70% of the variability seen in the data which means that
the PCA is an effective technique for this investigation, that captures much of the differences and
similarities of the compounds in terms of their molecular descriptors and can provide many useful
conclusions and observations.
Figure 9. Biplot representing the PCA analysis on the studied compounds and molecular descriptors.
The arrows represent molecular descriptors and the direction in which they hold influence. Each point
represents a molecule in this study (blue = classical lignans and neolignans, green = flavonolignans,
red = CLCs).
Looking at the molecular descriptors, it can be seen that dimension one (corresponding to principal
component one–the dimension in which data has the greatest variability; x-axis) is largely influenced
by the LogP values, number of hydrogen bond donors, acceptors, rotatable bonds and polar surface
area—Figure 9 shows these variables having a significant horizontal component to their direction,
with Figure 10 quantifying this contribution. The molecular weight of the compound is a significant
contributor to dimension one, but also strongly influences principal component two (y axis, as it also
has a large vertical component to its direction), along with the polarisability, ionisation potential,
dipole moment and LogS.
It can also be seen from this PCA, that the greater the LogP value (i.e., the greater the
lipophilicity), the lower the number of hydrogen bond donors, acceptors and polar surface area
for these compounds, as these vectors are in opposite direction to the LogP, signifying an inverse
relationship. This coincides with what one would anticipate—compounds with greater hydrogen
bond donors, acceptors and polar surface area are expected to be less lipophillic and have lower LogP
values. Furthermore, the number of hydrogen bond donors, acceptors and polar surface area are
highly correlated, as is signified through them acting in very similar directions in the biplot. This again
256
Molecules 2018, 23, 1666
concurs with what one would expect–a compound with the more hydrogen bond donors and acceptors
would be envisaged to have a greater polar surface area. As mentioned when these variables were
discussed, ionisation potential, dipole moment and LogS of a compound are shown to be highly
correlated. Additionally, LogS is aligned in the opposite orientation to the LogP vector–expected for
these two inversely-related measures.
It should also be noted that the variables that are the highest contributors to the first principal
component (number of hydrogen donors, acceptors, rotatable bonds, LogP, molecular weight and
polar surface area) are those that are considered when defining chemical spaces (Figure 10, Table 1).
Figure 10. Representation of the contributors to the first principal component.
Where the points are situated on a PCA plot, their relative positions, are a culmination of
their values for the various parameters and any observed groupings indicate similarities in the
physicochemical properties between compounds in that group. It is apparent that PCA with the ten
aforementioned descriptors are able to separate the compounds into groups–classical lignans and
neolignans (blue), flavonolignans (green) and CLCs (red). These compounds types are separated
on the x-axis–PC1–indicating that these groups can be separated by the variables that contribute to
this principal component. Therefore, this analysis can give general indications about the compound
classes. In general, it appears that CLCs have higher molecular weights, hydrogen bond acceptors,
hydrogen bond donors, rotatable bonds and polar surface areas and lower LogP values (lower
lipophilicities). Conversely, classical lignans and neolignans appear to be typified by higher
lipophilicities and lower numbers of hydrogen bond acceptors, donors and polar surface areas. In terms
of these descriptors, flavonolignans appear to be characterised between these two groups. Additionally,
all of the flavonolignans seems to be less variable, while both classical lignans/neolignans and CLCs
are significantly more variable. As the CLC group is composed of classical lignan/neolignan types
with additional saccharide unit(s), one can see the influence of the inclusion of a sugar moiety, on the
molecular descriptors. Furthermore, clemastanin B and secoisolariciresinol diglucoside represented by
155 and 160 in Figure 9, were the two compounds in the study that lie furthest to the right in the biplot
shown and were the two compounds in this study that contained two sugar units–this indicates that
the number of saccharide units in a CLC can also be differentiated using PCA.
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3.3. Lignans in Chemical Space
The proportion of all compounds studied in this investigation that lie within the benchmarks
for lead-like, drug-like and KDS as specified in Table 1 are shown, for each molecular descriptor and
when all molecular descriptors are taken into account (Table 3). Immediately apparent is that no
compound in this study fits in lead-like chemical space, when all of the molecular descriptors that define
lead-likeness are taken into account. While most compounds have ≤3 hydrogen bond donors and fulfil
the requirements for this parameter, the molecular weight, the number of hydrogen bond acceptors
and rotatable bonds are the parameters that limit the inclusion of lignans into lead-like space. To be
lead-like, lead structures generally possess low molecular complexity (i.e., low molecular weighs, along
with minimal numbers of hydrogen bond acceptors, hydrogen bond donors and rotatable bonds) [56].
Furthermore, these structures are more hydrophyllic and less drug-like, hence the strictest criterion for
the chemical spaces are those that define lead-like space. The purpose of lead structures is to offer a
simple scaffold, upon which further complexity can then be added, to provide drug-like compounds.
Rather than being lead-like, the majority of compounds–approximately 34 of those studied, are drug-like
in that they already have structures with greater complexity than one would expect from a lead
compound. The majority of the studied compounds fulfil the requirements to be considered drug-like,
thus by definition possess properties and characteristics that indicate they would be appropriate for
use as therapeutics. An even higher proportion of the compounds studied are in KDS, thus are in the
chemical space that is defined by known drugs.
Table 3. All compounds in this study and their inclusion within the defined chemical spaces.
Overall Lead-Like Space Drug-Like Space Known Drug Space
Molecular weight (g mol−1) 10.6% 94.4% 100%
Lipophilicity (Log P) 46.3% 99.4% 100%
Hydrogen bond donors 81.3% 96.3% 98.8%
Hydrogen bond acceptors 15.0% 93.8% 97.5%
Polar surface area (Å2) 33.1% 88.1% 98.8%
Rotatable bonds 12.5% 85.0% 98.1%
All criteria 0.0% 75.6% 97.5%
The success of podophyllotoxin as both a lead compound and as a drug were discussed
previously–podophyllotoxin itself is an approved therapeutic for genital warts and associated ailments,
while its structurally-related derivatives are clinically approved cancer treatments. Podophyllotoxin
is an aryltetralin lactone and as such can be classified as a dibenylbutryolactone or an aryltetralin.
For the purposes of this study, it was classified as a dibenzylbutyrolactone as it was apparent that its
molecular descriptors and structural scaffold were most similar to compounds of this type. Looking at
its molecular parameters, podophyllotoxin meets all the requirements of the Lipinski’s rule of five,
with a molecular weight =414.4 gmol−1, one hydrogen bond donor, eight hydrogen bond acceptors,
LogP = 2.31, PSA = 98.3 Å2 and only four rotatable bonds, hence meets all the requirements of being
drug-like, and therefore it is no surprise that it is an effective medicine. Furthermore, podophyllotoxin
has values for the other measures of oral availability, namely LogS, ionisation potential and dipole
moment, that signify it to be readily orally-available–a positive and desirable feature for therapeutics.
Podophyllotoxin is an excellent example of the potential of drug-like lignans for use a
medicines. Another example of a lignan currently in use is a dibenzylbutane, masoprocol,
a form of dihydroguaiaretic acid (Figure 1). Masoprocol is a lipoxygenase inhibitior and is an
antineoplastic medicine that is indicated to treat skin growths that result from exposure to the
sun [21,75,76]. Like podophyllotoxin, masoprocol fulfils all the criterion that dictate the requirements
of a drug-like compound.
Over 34 of the compounds included in this study, including podophyllotoxin and masoprocol, exist
in drug-like chemical space, exhibiting properties that allow them to be considered drug-like compounds
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and more likely to be successful therapeutics. There are numerous other lignans that also exhibit
potent biological activities and meet all the stipulated benchmarks to be considered drug-like, such
examples include arctigenin [77], matairesinol [78], sesamin [79] and schizandrin A (Figure 1) [80].
These compounds are just a few of the many hundreds of compounds yet to be fully explored, highlight
the vast prospects that lignans provide in medicinal chemistry.
3.4. Classical Lignans and Neolignans
There were 140 classical lignans and neolignans in this study which included the ten most
well-known (based on number of references for each compound) of each type. Summary statistics for
each of the parameters for the classical lignans/neolignans grouped together, and separate are given
in Table 2. Statistical distributions of each of the molecular parameters studied for the classical lignans
and neolignans are given (Figure 11, Figures S5–S13) and analysis of their positions in chemical spaces
are provided (Table 4, Tables S1–S15).
While some of the compound sub-classes are very similar in the characteristics studied, there
are some compound types that are notably different for various parameters. The compound
class that most frequently had markedly higher/lower averages than other lignans/neolignans
for the molecular descriptors was the dibenzocyclooctadienes (e.g., (+)-Schizandrin A, Figure 1).
Dibenzocyclooctadienes appear to have relatively high molecular weights, polarisability, polar surface
area and lipophilicity (LogP), while conversely having relatively low dipole moments and water
solubility (LogS). Cyclobutanes and substituted tetrahydrofurans also had high lipophilicities (LogP)
and low hydrophillicity measures (LogS), while substituted tetrehydrofurans also had high polar
surface areas and lower numbers of rotatable bonds. Arylnapthalenes and 2,6-diarylfurofurans
are highly fused scaffolds and this is reflected in their lower rotatable bonds count, compared to
other classical lignans and neolignans. Conversely, alkyl aryl ethers and dibenzylbutanes have a
less rigid/cyclic structural motif, hence have more rotatable bonds. As well as having a lower
amount of rotatable bonds, 2,6-diarylfurofurans also exhibit lower lipophilicities and a lower average
dipole moment. Dibenzylbutyrolactones also have lower LogP values and higher water solubilities
(LogS), along with higher polar surface areas and dipole moments. Biphenyl ethers are another type
that have higher relative calculated dipole moments, and along with biphenyls have lower average
molecular weights and polar surface areas. Benzofurans, 1,4-benzodioxanes, 8-1′-bicyclo-[3.2.1]octanes
and 8-3′-bicyclo[3.2.1]octanes were compound types that were not notably higher/lower than other
classical lignans and neolignans for the parameters investigated.
Overall, as stated previously, none of the classical lignans/neolignans in this study fulfil all the
requirements to be considered lead-like, although almost all (86.4%) are within the limits that define
drug-like space and all lignans are in KDS (Table 4).
The lead-like benchmarks that classical lignans and neolignans are least-frequently able to
realise are those concerning molecular weight (≤300 g mol−1; Figure S5), number of hydrogen
bond acceptors and the number of rotatable bonds (both ≤3; Figure S8 and Figure 11). In view
of the biosynthesis and definition of lignan structures, it is not surprising that very few of the
compounds meet the individual requirements for these parameters, and no compounds are able
to meet them all collectively. By definition, lignans and neolignans are the product of an oxidative
dimerisation of two or more phenyl propanoid units, which alone would have a weight of at least
240 g mol−1. These phenyl propanoid units are almost always oxygenated, often containing several
oxygen-containing substituents; the inclusion of more than three oxygen atoms, as is frequently the
case with naturally-occurring lignans, would not only increase the molecular weight above the cut-off
for lead-likeness, but would also exceed the number of allowable hydrogen bond acceptors.
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Table 4. All classical lignans and neolignans (not CLCs or flavonolignans) studied within the defined
chemical spaces.
Overall Lead-Like Space Drug-Like Space Known Drug Space
Molecular weight (g mol−1) 12.1% 100% 100%
Lipophilicity (Log P) 38.6% 99.3% 100%
Hydrogen bond donors 91.4% 99.3% 100%
Hydrogen bond acceptors 17.1% 100% 100%
Polar surface area (Å2) 37.9% 99.3% 100%
Rotatable bonds 14.3% 87.9% 100%
All criteria 0.0% 86.4% 100%
Conversely, it is apparent that lignans and neolignans are generally very drug-like and all are
within KDS (Table 4). The most discerning drug-like space parameter that ~13.5% of the compounds
violated were the number of rotatable bonds (criteria: ≤10 rotatable bonds, Figure 11). Related to
this, from this study, it can be stated that dibenzylbutanes (e.g., phyllanthin, Figure 12) are the
least drug-like of all the lignan sub-classes, largely owing to their high number of rotatable bonds–of
the ten dibenzylbutanes in this study, six are considered undrug-like. In contrast, compounds with
similar functional groups but having a more-fused ring scaffold (e.g., (−)-grandisin, Figure 12) are
more likely to be drug-like. In all other aspects lignans, in general, almost always fulfil every
other requirement that defines drug-like space and in several groups, namely dibenzylbutyrolactones,
arylnapthalenes/aryltetralins, substituted THFs, 2,6-diarylfurofurans, benzofurans, 1,4-benzodioxanes,
8-1′-bicyclo[3.2.1]octanes, 8-3′-bicyclo[3.2.1]octanes and biphenyl ethers, all members were considered
drug-like. The high-proportion of drug-likeness of classical lignans and neolignans, particularly these
aforementioned sub-classes, is a very notable and promising observation that promotes the justifiability
and importance of investigating lignans as drugs.
 
Figure 11. The statistical distribution of the rotatable bonds of the classical lignans and neolignans
(green = 3, compounds < 3 are in the lead-like space; yellow = 10, compounds < 10 are in the drug-like
space; red = 17, compounds < 17 are in the known drug space). Total number of compounds = 140.
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Figure 12. Structures of phyllanthin and (−)-grandisin.
Considering substituents on these core lignan scaffolds—while for most of the studied descriptors,
the most drug-like compounds would be those with no/few substituents on the core structures
which results in lower values for almost all of the parameters–this, however, is a rarity amongst
naturally-occurring lignans and it is very likely that the lipophilicity would increase, possibly
beyond acceptable levels. The addition of large polar groups (i.e., sugar moieties as for the CLC’s,
see Section 3.6) do have a significant effect on many of the properties of lignans, that largely
result in their exclusion from drug-like chemical space. In contrast, it can be seen that many of
the commonly-occurring, smaller, oxygenated substituents that feature in naturally-occurring lignans
(i.e., hydroxy, methoxy and methylenedioxy groups) are well-tolerated within drug-like chemical
space. This is evidenced by the fact that the parameters (i.e., molecular weight, lipophilicity,
hydrogen bond donors/acceptors and polar surface area) that would be most affected by the inclusion
of these moieties are very rarely (<1% of all lignans in the study) exceeded. It can therefore be said,
that naturally-occurring lignans do have an excellent balance of parameters and structures closely
analogous to these, with similar levels of substitution would be of interest.
Furthermore, as noted when discussing the individual molecular parameters, oral availability
can be linked to the dipole moment (ideally < 13 D), LogS (ideally between 0 and −7) and ionisation
potential (ideally between 8 and 10 eV). All classical lignans and neolignans had dipole moments under
the threshold of 13 D (Figure S10), while all but two and five of the 140 classical lignans and neolignans
had an ionisation potential and LogS within the above ranges, respectively (Figures S11 and S12). This
is predicates lignans and neolignans to have excellent oral bioavailability–an extremely desirable trait
of drugs.
3.5. Flavonolignans
As their name suggests, flavonolignans are a structurally very similar to classical lignans and
neolignans, however while lignans are formed through the oxidative dimerisation of two or more
phenyl propanoid units, the biosynthetic precursors of flavonolignans are a phenyl propanoid
unit and a flavone [81]. Flavonolignans are of particular interest to many, owing to their potent
biological activities that have been utilised worldwide, for millennia, particularly in the form of
silymarin. Silymarin (commonly known as milk thistle extract) is isolated from the seeds of milk
thistle, Silybum marianum, and is a complex mixture of, predominantly flavonolignan, compounds [82].
Silymarin is a popular liver protectant that has been used in traditional medicine for centuries and is
commonly available and used in present-day society [83,84].
Studying the earlier PCA, it is apparent through the close proximity of all flavonolignans in
the biplot, that they are all very structurally similar (Figure 9). Furthermore, it can be seen that
while flavonolignans are structurally similar to lignans, they are able to be separated on the basis
of their molecular descriptors. Flavonolignans are clustered to the right of almost all classical
lignans/neolignans and located higher on the y-axis on the PCA than many. One can use the
knowledge in which direction the molecular descriptors hold influence to discuss general trends
of this compound type. It can be surmised from the PCA, that flavonolignans generally have higher
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molecular weights, polarisability, number of hydrogen bond donors and acceptors. They also appear
to have lower lipophilicities (LogP). These observations are further corroborated by the results in
Table 2 (see Figure 13, Figures S14–S22 for analysis of each of the studied molecular descriptors for
flavonolignans alone).
The ten studied flavonolignans were also assessed in relation to the various criterion that define
the lead-like, drug-like and known drug spaces (Table 5). It is notable that flavonolignans are less
drug-like than classical lignans and neolignans, with no flavonolignans fulfilling all the requirements
for drug-likeness. The only constraint that flavonolignans exceeded was the polar surface area–no
flavonolignans had a PSA ≤ 140 Å2 and the mean PSA was 158.5 Å2 (Figure 13). It should be noted,
however, that all of the compounds had a PSA within the realm of KDS, and the flavonolignans were
all in KDS when considering all molecular descriptors.
Table 5. Flavonolignans studied within the defined chemical spaces.
Overall Lead-Like Space Drug-Like Space Known Drug Space
Molecular weight (g mol−1) 0% 100% 100%
Lipophilicity (Log P) 100% 100% 100%
Hydrogen bond donors 20% 100% 100%
Hydrogen bond acceptors 0% 100% 100%
Polar surface area (Å2) 0% 0% 100%
Rotatable bonds 0% 100% 100%
All criteria 0% 0% 100%
 
Figure 13. The statistical distribution of the polar surface area (PSA) of the flavonolignans (green = 60,
compounds < 60 Å2 are in the lead-like space; yellow = 140, compounds < 140 Å2 are in the drug-like
space; red = 180, compounds < 180 Å2 are in the KDS). Total number of compounds = 10.
Reviewing the additional gauges of oral availability; all flavonolignans meet the benchmarks set
for the dipole moment, LogS and ionisation potential, thus there is strong indication that flavonolignans
are orally available.
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3.6. CLCs; Carbohydrate-Lignan Conjugates
As the CLCs included in this study are saccharide-containing representatives of various types of
classical lignans and neolignans, the differences seen in the CLCs from lignans are due to the sugar
moiety. Through the principal component analysis, it was shown that CLCs can be differentiated
from both classical lignans/neolignans and flavonolignans on the basis of the molecular descriptors
that were included in this study (Figure 9). Analysis of the PCA suggests that the inclusion of a
saccharide unit to a lignan increases its mass, number of hydrogen bond donors, acceptors and number
of rotatable bonds, as well as its polarisability. They are also indicated to have lower lipophilicities
(LogP, Figure 14), and as shown through the comparison of means, a higher affinity for water and other
aqueous systems (Table 2, see Figure 14, Figures S23–S31 for the distributions of each of the molecular
descriptors).
The low calculated lipophilicities of CLCs are an asset in defining this compound type in
chemical space, with all of the CLCs studied having sufficiently low LogP values to be considered
lead-like (Figure 14), although interestingly this is the only parameter that any CLCs do not exceed
for lead-likeness–CLCs meet none of the other lead-like criteria (Table 6). The molecular descriptor
that was the most discriminating for CLCs was they number of hydrogen bond acceptors–no CLCs
had sufficiently low enough number of hydrogen bond acceptors to be considered either lead-like
or drug-like (Figure S25). Furthermore, only six out of ten CLCs in this study were in KDS for this
parameter. For the other molecular descriptors, very few compounds fell within the discerning bounds
of drug-like space, less than half of the CLCs within the limits for drug-like space for molecular weight
(Figure S23), number of hydrogen bond donors (Figure S24), number of rotatable bonds (Figure S27)
and polar surface area (Figure S26).
Table 6. CLCs studied within the defined chemical spaces.
Overall Lead-Like Space Drug-Like Space Known Drug Space
Molecular weight (g mol−1) 0% 10% 100%
Lipophilicity (Log P) 100% 100% 100%
Hydrogen bond donors 0% 50% 80%
Hydrogen bond acceptors 0% 0% 60%
Polar surface area (Å2) 0% 20% 80%
Rotatable bonds 0% 30% 70%
All criteria 0% 0% 50%
Figure 14. The statistical distribution of the octanol–water partition coefficient (LogP) of the CLCs
(green = 3, compounds < 3 are in the lead-like space; yellow = 5, compounds < 5 are in the drug-like
space; red = 6.5, compounds < 6.5 are in the KDS). Total number of compounds = 10.
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As a rule, CLCs are distinguished as having many alcohol moieties, which entails that they
have low lipophilicities and high molecular weights, number of hydrogen bond acceptors, number of
rotatable bonds and polar surface area. One must, however, mention that there is supposition that
drug-likeness is not a suitable measure of saccharides, which are adsorbed through active transport [85].
Saccharide-based drugs are atypical in KDS [59], and this is reflected in only half of the CLCs studied
being entirely in KDS.
4. Summary
In this study, 160 lignans and related compounds were analysed to study their physicochemical
properties, their general trends and the variability in these parameters between and within compound
types. Furthermore, these molecular descriptors allowed for the defining of these compounds in
various chemical spaces, particularly to highlight their drug-likeness. It was found, that while no
compounds in this study fulfilled all the requirements for six key molecular descriptors to be considered
to be lead-like, over 3/4 of the compounds were deemed to be in the drug-like space and nearly all
(~97.5%) were in the KDS. These results strongly advocate for the drug-likeness of the majority of lignan
compounds that should be further investigated as potential therapeutics. Notably, all compounds
from dibenzylbutyrolactones, arylnapthalenes/aryltetralins, substituted THFs, 2,6-diarylfurofurans,
benzofurans, 1,4-benzodioxanes, 8-1′-bicyclo[3.2.1]octanes, 8-3′-bicyclo[3.2.1]-octanes and biphenyl
ethers sub-classes were shown to drug-like, indicating that these sub-classes, in particular, should be
further studied for their potential as therapeutic agents.
A PCA analysis of the molecular descriptors particularly highlighted the complex
inter-relationships between these physicochemical properties–while the number of hydrogen bond
donors, acceptors, rotatable bonds and polar surface area appear to be strong, positive relationship,
they collectively have an inverse relationship with the lipophilicity (LogP) of compounds. The first
principal component is the dimension that accounts for the greatest variability in the data and it was
found that the largest contributors to this principal component were the variables that are considered
when defining the chemical spaces. PCA was also able to separate the groups of lignans (classical
lignans and neolignans), flavonolignans and CLCs–it was shown that flavnonolignans are more similar
to lignans, than their sugar-derivatives, with this separation being distinctive along the first principal
component. The differences seen between the different groups in the PCA were also reflected in the
differing proportions of lignans, flavonolignans and CLCs that were included in the chemical spaces,
particularly in the drug-like chemical space. Lignans were almost all (86.4%) drug-like and all were in
KDS, whereas no flavonolignans or CLCs were drug-like. All flavonolignans were in KDS and only
half of the CLCs were in KDS. This suggests that lignans, in general, have an excellent balance of
the often-paradoxical molecular properties, allowing them to be considered to be drug-like, whereas
flavonolignans and CLCs have larger values for the variables other than lipophilicity (i.e., polar surface
area, number of rotational bonds, hydrogen bond donors and acceptors, as they are further to the right
of the PCA plot) that exclude them from drug-like chemical space. This is particularly evident for the
CLCs, where LogP was the only parameter that all CLCs met the requirements for, to be classified as
present in drug-like chemical space.
Within the lignans, there were marked differences between different compound types, with
dibenzylcyclooctadienes proving to be the most distinctive compound type, exhibiting relatively
high molecular weights, polarisability, polar surface area and lipophilicity (LogP), while conversely
having relatively low dipole moments and water solubility (LogS). Overall, the results presented
here demonstrate that lignans are very drug-like. Coupled with their potent biological activities,
their physicochemical properties indicate there is significant value in their study as promising future
drug leads.
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Abstract: Dietary guidelines universally advise adherence to plant-based diets. Plant-based
foods confer considerable health benefits, partly attributable to their abundant micronutrient
(e.g., polyphenol) content. Interest in polyphenols is largely focused on the contribution of their
antioxidant activity to the prevention of various disorders, including cardiovascular disease and
cancer. Polyphenols are classified into groups, such as stilbenes, flavonoids, phenolic acids,
lignans and others. Lignans, which possess a steroid-like chemical structure and are defined as
phytoestrogens, are of particular interest to researchers. Traditionally, health benefits attributed to
lignans have included a lowered risk of heart disease, menopausal symptoms, osteoporosis and breast
cancer. However, the intake of naturally lignan-rich foods varies with the type of diet. Consequently,
based on the latest humans’ findings and gathered information on lignan-rich foods collected from
Phenol Explorer database this review focuses on the potential health benefits attributable to the
consumption of different diets containing naturally lignan-rich foods. Current evidence highlight
the bioactive properties of lignans as human health-promoting molecules. Thus, dietary intake of
lignan-rich foods could be a useful way to bolster the prevention of chronic illness, such as certain
types of cancers and cardiovascular disease.
Keywords: lignans; diet; antioxidants; health promotion; chronic diseases
1. Introduction
Polyphenol-rich diets are suggested to possess health benefits. Polyphenols are micronutrients
found in plants, and include flavonoids, stilbenes, phenolic acids, lignans and others [1]. They are
secondary plant metabolites implicated in protection against pathogens and ultraviolet radiation [2].
Given their diverse chemical structures, different polyphenol classes likely possess differing health
benefits [3]. It is therefore important to elucidate the specific potential benefits of each polyphenolic
compound. Significant interest has been elicited by lignans, due to their steroid-analogous chemical
structure. Accordingly, they are considered to be phytoestrogens. Lignans are bioactive compounds
exhibiting various biological properties, including anti-inflammatory, antioxidant and antitumor
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Molecules 2019, 24, 917
activities [4]. Additionally, some epidemiological studies have proposed that lignans decrease the
risk of cardiovascular disease, but their effects on other chronic diseases (e.g., breast cancer) remain
controversial [5].
Lignans are found in relatively low concentrations in various seeds, grains, fruits and vegetables,
and in higher concentrations in sesame and flax seeds [6]. Therefore, the level of lignan ingestion—and,
thus, lignan bioavailability, depends on the type of diet consumed [7,8] and can be highly variable.
The present review attempts to describe the potential beneficial effects of lignan intake on human
chronic disease, depending on the dietary source.
2. Biosynthesis, Classification and Presence of Lignans in Foods
Lignans are a type of secondary plant metabolite exhibiting diverse structures [9]. Plants derive a
complex array of secondary metabolites from only a handful of relatively simple propenyl phenols [10].
Biosynthesis of lignans is characterized by a remarkable increase in molecular complexity [10].
Lignans share common biosynthetic pathways, consist of two propyl-benzene units coupled by a
β,β′-bond [11], and thus belong to the group of diphenolic compounds [12].
Lignans may be organized into eight structural subgroups (according to the manner in which
oxygen is incorporated and the pattern of cyclization): Dibenzylbutyrolactol, dibenzocyclooctadiene,
dibenzylbutyrolactone, dibenzylbutane, arylnaphthalene, aryltetralin, furan and furofuran (Figure 1).
Each subgroup can be further subdivided according to lignan molecule oxidation level and identities
of non-propyl aromatic rings present on side chains [13,14].
dibenzylbutirolactol dibenzocyclooctadiene dibenzylbutirolactone dibenzylbutane
arylnapththalene aryltetralin furan furofuran
Figure 1. Structural subgroups of lignans (Ar=Aryl).
Of the eight lignan subclasses, synthesis of furofurans—which exhibit a
2,6-diaryl-3,7-dioxabicyclooctane skeleton—is initiated by the enantioselective dimerization
of two coniferyl alcohol units derived from the shikimate biosynthetic pathway (Figure 2) [14].
To date, 53 species of furofuran lignans have been reported in 41 genera of 27 plant families, including
Thymelaeaceae, Styracaceae, Scrophulariaceae, Saururaceae, Rutaceae, Rhizophoraceae, Piperaceae,
Pedaliaceae, Orobanchaceae, Myristicaceae, Magnoliaceae, Lauraceae, Lamiaceae, Geraniaceae,
Dioscoreaceae, Cyperaceae, Cupressaceae, Compositae, Combretaceae, Cactaceae, Aristolochiaceae,
Arecaceae, Araliaceae, Aquifoliaceae, Apocynaceae, Acoraceae and Acanthaceae. Furofuran lignans
are present in the bark, bulbs, leaves, seeds, stems and roots of these plants [14].
However, depending on the enzyme that catalyzes modification of the precursor metabolite,
a variety of lignans can be synthesized (Figure 2). The major lignans—which possess numerous
pharmacological properties—are artigenin, enterodiol, enterolactone, sesamin, syringaresinol,
medioresinol, (−)-matairesinol, (−)-secoisolariciresinol, (+)-lariciresinol and (+)-pinoresinol,
among others [15].
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Figure 2. Biosynthetic pathway of lignans. NGT (pinoresinol glucosyltransferase), PSS (piperitol/
sesamin synthase), PLR (pinoresinol/lariciresinol reductase), LGT (lariciresinol glycosyltransferase),
SGT (secoisolariciresinol glycosyltransferase), SID (matairesinol O-methyltransferase),
MMT (matairesinol O-methyltransferase), Glc (Glucoside).
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Currently, there is a growing interest in the presence of lignans in foodstuffs, given the potentially
beneficial bioactive properties of the former (anti-estrogenic, antioxidant and anti-carcinogenic
activities) [16]. The chief sources of dietary lignans are various vegetables and fruits, legumes,
whole grain cereals and oilseeds [16,17]. Among edible plant components, the most concentrated
lignan sources are sesame and flax seeds (Tables 1 and 2) [6]. Specifically, flax seeds contain
approximately 294.21 mg/100 g lignan, at present the maximal known content of any foodstuff.
Sesame seeds exhibit the second-highest lignan concentration, with sesaminol as the major constituent,
at 538.08 mg/100 g [6]. Flaxseed and cashew nuts are also relatively rich in lignans (containing 257.6
and 56.33 mg/100 g, respectively) [6].
Table 1. Lignan content of sesame seed (mg/100g food). Data collected from phenol explorer [18].
Seeds HMA HSE OXO ARC CYC CON DIM
Sesame seed 7.2 0.01 0.7 0.01 1.77 0.75 0.39
ISO LAR LAS MAT MED NOR SEC
1.61 10.37 0.08 29.79 4.15 0.08 0.1
SECS SES SEI SEN SYR TOD Total
0.01 538.08 102.86 133.94 0.2 2.47 834.57
Lignans: 7-Hydroxymatairesinol (HMA), 7-Hydroxysecoisolariciresinol (HSE), 7-Oxomatairesinol (OXO), Arctigenin
(ARC), Conidendrin (CON), Cyclolariciresinol (CYC), Dimethylmatairesinol (DIM), Isohydroxymatairesinol (IHM),
Isolariciresinol (ISO), Lariciresinol (LAR), Lariciresinol-sesquilignan (LAS), Matairesinol (MAT), Medioresinol
(MED), Nortrachelogenin (NOR), Secoisolariciresinol (SEC), Secoisolariciresinol-sesquilignan (SECS), Sesamin (SES),
Sesaminol (SEI), Sesamolin (SEN), Syringaresinol (SYR), Todolactol A (TOD).
Table 2. Lignan content of seeds (mg/100g food) [18].
LAR MAT MED SEC SYR Total
Other Seeds
Flaxseed 11.46 6.68 - 257.6 - 257.6
Sunflower seed 0.67 0.67 - 0.18 - 1.52
Nuts
Almond 0.03 3 × 10−4 - 0.07 - 0.10
Brazil nut - 0.01 - 0.77 - 0.78
Cashew nut 49.6 2.5 × 10−3 - 6.73 - 56.33
Chesnut 7.8 × 10−3 8.42 × 10−3 - 0.2 - 0.21
Hazelnut 0.01 3.3 × 10−3 - 0.05 - 0.06
Peanut 4.1 2.5 × 10−3 - 2.7 - 6.8
Pecan nut 8.4 × 10−3 3.15 × 10−3 - 0.01 - 0.02
Pistachio 0.12 1 × 10−4 - 0.04 - 0.16
Walnut 7.2 × 10−3 3.8 × 10−3 - 0.12 - 0.13
Pulses-Beans
Common bean white 0.12 1 × 10−3 - 0.08 8 × 10−3 0.2
Broad bean seed whole - 8.9 × 10−4 - 0.09 - 0.09
Mung bean - - - 0.18 - 0.18
Soy and soy products
Soy paste, miso 0.02 3.6 × 10−3 - 0.01 - 0.03
Soy flour - 7.5 × 10−3 - 0.3 - 0.3
Soy tempe 0.01 5 × 10−4 - 0.01 - 0.02
Soy tofu 0.04 7.27 × 10−5 8.5 × 10−3 9.91 × 10−3 0.04 0.09
Soy yogurt 0.01 3 × 10−3 - 0.02 - 0.03
Soyben edamame 0.07 - 0.02 0.07 0.2 0.3
Soybean sprout 0.03 5 × 10−4 0.01 0.03 0.05 0.12
Regarding cereal grains (Table 3), lignans are largely concentrated in their outer layers [19,20].
In cereal grains, the highest lignan concentration is found in the fiber-rich outer layers (seed coat
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and pericarp), as well as the aleurone layer, whereas the lowest concentration is found in the inner
endosperm [21,22].
Table 3. Lignan content of cereals (mg/100g food) [18].
LAR MAT MED SEC SYR Total
Cereal products
Bread (whole grain flour) 0.05 3.1 × 10−4 - 8.68 × 10−3 - 0.05
Bread (refined flour) 0.01 1.23 × 10−3 - 7.19 × 10−3 0.04 0.05
Bread, rye, whole grain flour 0.01 0.02 - 0.14 - 0.17
Breakfast cereals, bran 0.01 4.87 × 10−3 - 0.03 - 0.04
Breakfast cereals, corn - 1.67 × 10−3 - 5.5 × 10−3 - 0.007
Breakfast cereals, muesli 0.14 5.6 × 10−3 - 0.08 - 0.22
Breakfast cereal, oat - 0.06 - 0.02 - 0.08
Pasta - 1.85 × 10−3 - 2.3 × 10−3 - 0.004
Pasta Whole Grain - 1.5 × 10−3 - 5 × 10−3 - 0.006
Cereals
Barley, whole grain flour 0.08 3 × 10−3 0.01 0.03 0.16 0.28
Buckwheat, whole grain flour 0.36 1 × 10−3 0.03 0.13 0.24 0.76
Common wheat, germ - 9 × 10−3 - 0.02 - 0.02
Common wheat, refined flour 0.18 2.14 × 10−4 - 0.02 - 0.2
Common wheat, whole grain flour 0.1 9 × 10−4 0.03 0.02 0.37 0.52
Hard wheat, semolin - - - 2 × 10−3 - 0.002
Maize, whole grain 0.12 6.55 × 10−5 - 0.14 0.07 0.33
Oat, whole grain flour 0.18 0.07 0.04 0.01 0.35 0.65
Rye, whole grain flour 0.32 0.01 0.14 0.02 0.97 1.46
Ordering species by lignan content produces the following list: Dhurra < brown rice < red rice <
quinoa < millet < corn < amaranth < barley < buckwheat < wild rice < Japanese rice < spelt < oat <
triticale < wheat < rye [6]. Regarding vegetables (Table 4), the brassica family may contain between 185
and 2.321 mg /100 g of lignan, mainly pinoresinol. Peppers, French beans, carrots and courgettes also
exhibit a relatively high lignan content, ranging from 0.113 to 0.273 mg/100 g. Other foods, such as
spinach, white potatoes and mushrooms—contain below 0.1 mg/100 g of lignan. Fruits exhibit a lower
lignan content than seeds or vegetables (Tables 5 and 6), ranging from 11.57 mg/100 g for apricots to 0
mg/100 g for banana, with green grapes and kiwi fruit falling somewhere between these extremes [6].
Table 4. Lignan contents of vegetables (mg/100g food) [18].
LAR MAT MED SEC SYR Total
Cabbages
Broccoli 97.2 2.44 × 10−5 - 1.31 - 98.51
Brussel sprouts 49.3 4 × 10−5 - 1.06 - 50.36
Cauliflower 9.31 2.4 × 10−5 0.02 0.13 0.02 9.48
Collards 0.06 4 × 10−4 - 5.9 × 10−3 - 0.06
Green cabbage 0.03 3.5 × 10−5 - 9.2 × 10−3 - 0.03
Red cabbage 17.8 4.44 × 10−5 - 0.3 - 18.1
White cabbage 21.2 - - 0.31 - 21.51
Kale 59.9 1.2 - 1.9 - 63
Sauerkraut 11.6 - - 6.7 - 18.3
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Table 4. Cont.
LAR MAT MED SEC SYR Total
Fruit vegetales
Avocado 0.03 7.67 × 10−3 0.24 0.02 0.44 0.73
Eggplant purple 0.05 - 7 × 10−3 7.79 × 10−3 6 × 10−3 0.07
Black olive 0.03 5.62 × 10−3 - 5.75 × 10−3 - 0.04
Green olive 3.9 × 10−3 3.34 × 10−3 - 0.02 - 0.02
Green sweet pepper 12.32 - 1 × 10−3 0.22 4 × 10−3 12.54
Red sweet pepper 7.97 - - 0.24 - 8.21
Yellow sweet pepper 0.07 - - 5.5 × 10−3 - 0.07
Tomato (Cherry) 0.03 - 3 × 10−3 0.01 4.5 × 10−3 0.04
Tomato (Whole) 2.1 8.33 × 10−6 3.5 × 10−3 0.05 4.5 × 10−3 2.15
Gourds
Cucumber 3.55 - - 0.25 - 3.8
Pumpkin 0.01 2.5 × 10−5 - 0.1 - 0.11
Squash - - - 9 × 10−3 - 0.009
Zucchini 6.4 - - 0.62 - 7.02
Leaf vegetables
Arugula - 2 × 10−4 - 0.1 - 0.1
Chicory (green) 0.6 1.24 × 10−4 - 0.57 - 1.17
Lettuce (green) 0.3 2.24 × 10−4 - 0.18 - 0.48
Spinach 0.06 2.37 × 10−5 - 4.85 × 10−3 - 0.06
Broad bean pod - - - 0.02 - 0.02
Pod vegetables
Green bean 22 - - 0.67 - 22.67
Pulse vegetables
Fresh pea 0.05 - 3.5 × 10−3 7.56 × 10−4 - 0.0542
Root vegetables
Carrot 4.5 3.89 × 10−3 - 3.16 - 7.66
Celeriac - 3 × 10−5 - 0.02 - 0.02
Parsnip - 0.02 - 0.03 - 0.05
Radish 0.01 1.25 × 10−4 5.5 × 10−3 6.57 × 10−3 0.02 0.04
Swede - 7.43 × 10−5 - 4.93 × 10−3 - 0.005
Turnip root 0.1 - 4 × 10−3 9.83 × 10−3 0.03 0.14
Shoot vegetables
Asparagus 0.07 3.97 × 10−3 4 × 10−3 0.25 0.05 0.37
Fennel - 0.01 - 0.05 - 0.06
Stalks vegetables
Celery stalks - - - 5.99 × 10−3 - 0.005
Tubers
Potato 2.8 7.69 × 10−4 - 0.09 - 2.89
Sweet potato 0.07 0.1 - 0.12 - 0.29
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Table 5. Lignan contents of fruits berries (mg/100g food) [18].
HMA OXO CON CYC LAR LAS
Fruit Berries
Bilberry - - - 6.24 × 10−3 0.04 0.09
Blackberry - - - 7.96 × 10−3 0.15 0.15
Blackcurrant - - - 0.01 7.3 × 10−3 0.01
Cloudberry - - - - 0.65 0.25
Black grape - - - - 5.2 -
Green grape - - - - 1.88 -
Lingonberry - - 1.04 × 10−3 0.03 0.03 0.01
Strawberry 8.55 × 10−4 4.59 × 10−4 9.45 × 10−3 0.01 5.87 0.1
MAT MED SEC SECS SYR Total
Bilberry - 0.08 0.06 0.01 0.12 0.4
Blackberry 9.07 × 10−4 0.05 0.1 0.13 0.19 0.77
Blackcurrant 1.47 × 10−3 0.01 0.09 0.03 - 0.15
Cloudberry - 0.48 0.05 0.01 0.41 1.85
Black grape 0.11 - 0.09 - - 5.4
Green grape 0.09 - 0.28 - - 2.25
Lingonberry - 0.23 0.37 0.02 0.14 0.83
Strawberry 1.58 × 10−5 0.03 0.14 0.01 0.03 6.2
Table 6. Lignan contents of fruits (mg/100g food) [18].
LAR MAT MED SEC SYR Total
Fruits Citrus
Grapefruit 7.13 0.05 - 0.26 - 7.44
Lemon - - - 0.02 - 0.02
Orange 2.4 0.05 9.5 × 10−3 0.14 0.12 2.71
Tangerine 5.7 0.02 - 0.08 - 5.8
Fruits Drupes
Apricot 10.5 3.11 × 10−5 - 1.07 - 11.57
Nectarine 4.1 - - 0.61 - 4.71
Peach 6 1.71 × 10−4 - 0.83 - 6.83
Plum 0.31 2.22 × 10−4 1 × 10−3 0.09 - 0.4
Fruits-Gourds
Cantaloupe 1.8 × 10−3 - - 4.7 × 10−3 - 0.006
Melon 4.4 1.05 × 10−5 - 0.09 - 4.49
Watermelon 0.04 - 1 × 10−3 0.02 0.02 0.08
Fruits-Pomes
Apple 0.1 2.71 × 10−5 - 1.79 × 10−3 - 0.1
Pear 15.5 4.3 × 10−5 - 0.06 - 15.56
Fruits-Tropical
Banana 2.2 × 10−3 5.45 × 10−5 - 7.73 × 10−5 0.01 0.01
Kiwi 1.03 1.93 × 10−3 4.5 × 10−3 3.13 4 × 10−3 4.17
Mango - 1.06 × 10−3 - 0.01 - 0.01
Passion fruit - - - 0.02 - 0.02
Papaya - 2 × 10−3 - - - 0.002
Persimmon - - - 4 × 10−3 - 0.004
Pineapple 0.2 0.16 2 × 10−3 0.21 0.09 0.66
Pomegranate - 9 × 10−3 - 0.29 - 0.29
The highest lignan content is observed in non-alcoholic beverages, such as tea
(0.0392–0.0771 mg/100 g), which also contains other polyphenols (Table 7). Coffee is another
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important source of lignans, although concentration varies by type of coffee, ranging from 0.0187 to
0.0313 mg/100 g. Regarding alcoholic beverages, red wine contains an average of 0.080 mg/100 mL,
whereas white wine contains only approximately 0.022 mg/100 g [23].
Table 7. Lignan content of beverages (mg/100g drink and mg/100 mL wine) [18].
ISO LAR MAT SEC SYR Total
Alcoholic Beverages
Red Wine 0.07 7.56 × 10−3 5.51 × 10−3 0.04 3.43 × 10−3 0.12
White Wine 0.03 6.65 × 10−3 2.68 × 10−3 7.45 × 10−3 1.45 × 10−3 0.04
Dark Beer - - - 0.04 - 0.04
Beer - - - 0.03 - 0.03
Cider - - - 0.04 - 0.04
Scotch whisky - - - 4 × 10−3 - 0.004
Sherry - - - 0.02 - 0.02
Non-alcoholic Beverages
Cocoa - - - 0.03 - 0.03
Coffee - 9 × 10−4 4 × 10−4 8.67 × 10−3 - 0.009
Decaffeinated Coffe - 1.1 × 10−3 4.25 × 10−4 8.35 × 10−3 - 0.009
Roman camomile - - 5 × 10−4 1 × 10−3 - 0.001
Lemon juice - - - 2 × 10−3 - 0.002
Orange juice - 2 × 10−4 - 8 × 10−3 - 0.008
Soy milk - 6.17 × 10−3 5 × 10−5 2.25 × 10−3 - 0.008
Black Tea - 2 × 10−4 2.65 × 10−3 0.03 - 0.03
Green Tea - 1 × 10−4 3.38 × 10−3 0.03 - 0.03
Oolong Tea - - 1.8 × 10−3 0.02 - 0.02
Furthermore, the chief source of dietary fat in Mediterranean countries—extra virgin olive oil
(EVOO)—has garnered much interest regarding its beneficial properties, largely attributable to its
polyphenol profile (Table 8). Lignans are the second most abundant polyphenolic class present in
EVOO; of these, the most abundant across different EVOO types are pinoresinol (1.17–4.12 mg/ 100 g)
and 1-acetoxypinoresinol (0.27–6.69 mg/ 100 g) [7,24,25].
Table 8. Lignan content of oils (mg/100 g food) [18].
Fruit oils ACE LAR MAT PIN SEC Total
Extra virgin Olive Oil 0.66 3.43 × 10−3 7.5 × 10−5 0.42 2.5 × 10−4 1.08
Nut oils
Peanut, butter - 8.8 × 10−3 7.52 × 10−3 - 0.05 0.06
Other seed oils EPI EPL SES SEI SEO SEN SEL Total
Sesame seed oil 192.6 51.97 420.99 305.43 24.92 243.13 55.71 1294.75
Sesame seed black oil - - 644.5 226.92 21.55 287.33 43 1223.3
1-Acetoxypinoresinol (ACE), Episesamin (EPI), Episesaminol (EPL), Pinoresinol (PIN), Sesamol (SEO),
Sesamolinol (SEL).
Thus, given the presence of lignan in many common foodstuffs and beverages, its intake occurs
frequently, on a near-daily basis. For example, in a Dutch population, the major dietary sources of
lignan were fruits (7%), bread (9%), seeds and nuts (14%), vegetables (24%), and beverages (37%) [6].
Similarly, in a cohort of French women, the major dietary sources of lignan were vegetables and fruits
(0.2% from legumes, 0.6% from potatoes, 30% from vegetables, and 35% from fruits), followed by
alcoholic beverages (5%), coffee (5%), cereals (7%) and tea (11%) [6,26,27].
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3. Bioavailability
Only a handful of studies exist regarding post-consumption lignan bioavailability, including
only very limited human pharmacokinetic studies. After ingestion, plant lignans are metabolized by
intestinal bacteria, undergoing transformation to mammalian lignans (enterolactones and enterodiols
(Figure 3)) prior to absorption [16,28]. This apparently considerably decreases the risk of diverse types
of cancer, particularly of the colon, prostate and breast [16,29].
 
A B
Figure 3. Chemical structure of enterodiol (A) and enterolactone (B).
Many studies demonstrate a positive correlation between plant lignan intake and plasma
enterolignan levels [30]. After lignan ingestion, enterolactone and enterodiol are the first lignans
to become detectable in human biological fluids [28]. The half-lives of these compounds in plasma
are approximately 13 and 5 h, respectively [31], and they remain detectable even up to 8–10 h after
plant lignan consumption [32]. Furthermore, their intestinal metabolism into mammalian forms
appears indispensable for colonic absorption, and the colonic barrier is capable of conjugating
enterolignans [28,33].
The concentration of enterodiol and enterolactone in biological fluids varies significantly by
geographic region [28]. A study examining mammalian lignan pharmacokinetics in both men
and women after lignan solution intake found that enterodiol and enterolactone, respectively,
exhibit absorption half-lives of 3.4 and 8.4 h, reach maximum plasma concentrations of 65 and
42 mmol/L [28], exhibit elimination half-lives of 4.6 and 15.1 h, and exhibit maximum retention
times of 23.9 and 43.2 h [28,34]. Thus, while enterolactone is more rapidly absorbed than enterodiol,
the former attains a lower maximum plasma concentration [28].
During lignan metabolism, the initial (cytochrome P450-mediated) step involves conjugation
to glucuronic acid and sulfate, followed by enterohepatic recirculation [35]. Chaojie et al. (2013)
that glucuronidation of flax seed lignans significantly involves liver and intestinal microsomes [36].
Some studies demonstrate that flax seed-derived lignan metabolites distribute mainly to the intestine
(largely to the caecum), kidneys, uterus, prostate and liver [37]. Of these locations, the highest
concentration of lignan metabolites is observed in the liver [37].
Human breast cyst, prostatic, and seminal fluid (as well as prostate tissue) lignan concentration
has been determined [38,39]. As in circulation, the common mammary form of lignan is enterolignan,
while urinary forms are essentially monoglucuronides [28]. Furthermore, inter-individual variations in
gut microbiota and hepatic enzymes may modulate mammalian lignan metabolism and bioactivity [33].
Moreover, lignan bioavailability also depends on diet. For example, diets rich in flax seed
increase production of gut microbiota-derived enterolignans in a murine model, and lead to high
tissue and plasma concentrations of sulfate and glucuronide conjugates (the major flax-derived lignan
metabolites) [8,40].
Other studies have demonstrated that plant lignans, such as sesamin are quickly absorbed,
apparently from the small intestine and become detectable in systemic circulation within a few hours
after ingestion [22,41]. For example, lignans have been observed in porcine plasma 3 h after cereal
intake [42]. On the one hand, it has been empirically demonstrated that plant lignans are rapidly
absorbed from the small intestine after intake of a diet rich in cereals [22]. On the other hand,
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various factors—e.g., the use of oral antibiotics and inter-individual variations in gut microflora,
as well as diet—impact lignan pharmacokinetics [43]. For example, seed maturation state can alter
oral lignan bioavailability [44].
4. Lignan Content of Various Regional Diets
Dietary lignan consumption varies mainly with geographic location, but diet patterns are also
subject to cultural and ethnic group influences.
4.1. Mediterranean Diet
The traditional Mediterranean diet is predominantly plant-based, characterized by a low intake
of sweets; low meat products and red meat; a moderate intake of fish, poultry and fermented dairy
products; a high intake of unprocessed cereals, legumes, nuts, fruits and vegetables [45]; the use of
EVOO as the principal source of added fat; and moderate consumption of red wine [45]. Health benefits
of this diet are essentially attributable to increased consumption of fiber and bioactive compounds
(including antioxidants and functional fatty acids and lipids), as well as to a low intake of saturated
fats [45,46].
Lignan sources in the diet of a Mediterranean population included garlic, onions, vegetables,
including leafy greens, grains and seasonal fruits, including citrus, with each accounting for diverse
proportions (11–70%) and subtypes of total polyphenols consumed [47].
Indeed, many typical Mediterranean diet foods (e.g., cereals) exhibit a high concentration of both
lignans and other phenolic compounds [48].
Recently, the role of whole grain cereal intake in chronic disease prevention has been evaluated.
Numerous studies propose a connection between lignan intake—as part of a wholegrain-based
diet—and decreased incidence of chronic diseases, including cardiovascular disease, cancer and
diabetes [5].
Thus, the major dietary lignan sources in the Mediterranean diet are vegetables and fruits, legumes,
wholegrain cereals and oilseeds [3]. Additionally, another component of the Mediterranean diet,
the chestnut, represents an excellent source of calcium, antioxidants and phenolic compounds [16,49].
Furthermore, EVOO consumption is an essential part of the Mediterranean diet. In fact, regular EVOO
consumption is associated with a lower incidence of atherosclerosis, cardiovascular disease and
some types of cancer [50–52]. This effect may be attributable to the high concentrations of
(+)-1-acetoxypinoresinol and (+)-pinoresinol present in EVOO [53,54].
4.2. Northern Hemisphere Diet
This diet is observed in Northern and Nordic European regions, and is characterized by a high
level of consumption of seaweed, shellfish, fatty fish (such as mackerel, herring and salmon), lean meats,
rapeseed oil, legumes, nuts (such as almonds), vegetables, fruits (such as berries), whole grains (such as
oats), low-fat dairy, and restricted salt and sugar intake [55,56]. In Nordic countries, the major dietary
sources of plant lignans are vegetables, fruits and wholegrain cereals [57].
Among the many frequently-consumed plant species exhibiting a high lignan content,
some species occur mainly in the Northern Hemisphere (e.g., Cirsium spp. of the family Asteraceae) [58].
The vegetative structures of these plants contain triterpenes, polyacetylenes, phenolic acids, flavonoids
and alkaloids [58]. The most recent phytochemical studies of European Cirsium spp. demonstrate that
their seeds are rich sources of neolignans and lignans [58,59].
4.3. Indian Diet
Various categories of food products make up a significant portion of the typical Indian diet,
including fish, grapes, chocolate, oils, coffee, tea, biscuits and bread [60].
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The fruit of Morinda citrifolia (Indian mulberry) has been extensively traditionally utilized in the
treatment of cancer, diabetes, high blood pressure, diarrhea, headache and inflammation, largely due
to its high lignan content [61,62].
Sesame is a typical component of the Indian diet, and both sesame seeds and oil are rich
in lignans [63]. Sesame oil is recognized for both its notable resistance to oxidation and its
nutritional value [64–66]. Despite lignans comprising only a small proportion (0.5 to 1.0%) of total
sesame seed mass, the main sesame lignans—such as (+)-sesaminol, (+)-sesamolin and (+)-sesamin
glucosides—have garnered attention for their notable health-promoting properties (demonstrated both
in vitro and in vivo), including anti-inflammatory, antioxidant and anti-hypertensive activities [63].
Long-term intake of (+)-sesaminol has been proposed to inhibit the pathogenic extracellular
β-amyloid aggregation observed in Alzheimer’s Disease [67]. Similarly, (+)-sesamin exhibits protective
activity against prostate and breast cancers [68], and is a precursor to enterodiol and enterolactone
(which have been shown to possess anti-cancer, antidiabetic and anti-ageing properties [64]).
4.4. Asian Diet
The Asian diet is characterized by an elevated consumption of rice, noodles, spices and vegetables,
sesame seeds and oil [69]. Additionally, seafood, tofu and other soy products are commonly
consumed [70]. Many major plant sources of lignans occur in Asia; these are habitually included in the
diet, and in China are also used as medicinal plants. Such plants include Articum lappa, whose fruit
extracts and seeds are a rich source of bioactive lignans [70], including arctiin and arctigenin. These two
lignans exhibit anti-inflammatory activities (e.g., inhibition of lipopolysaccharide-induced nitric
oxide production and release of pro-inflammatory cytokines in murine macrophages in vivo) [70,71].
In addition, when tested on diverse cancer cell lines, arctigenin possesses potent apoptotic and
anti-proliferative activities [70,72].
Certain medicinal herbs are usually used as an aqueous infusion. Among them, Isodon spp. and
Tripterygium spp.
The genus Isodon comprises nearly 150 species found in the subtropical and tropical regions
of Asia and represents an excellent lignan source [73]. Some species, such as Isodon japonica,
have been used in traditional Chinese medicine to treat (for example) arthralgia, stomach-ache,
mastitis, gastritis and hepatitis [73,74]. Isodon rubescens has also been used in traditional medicine
for its hypotensive, antioxidant, immunological, antimicrobial, antitumor and anti-inflammatory
properties [73].
Tripterygium wilfordii Hook f., a traditional medicinal herb, may ameliorate symptoms of
rheumatoid arthritis and other autoimmune diseases [75]. Several phytochemical research studies have
isolated hundreds of bioactive compounds—including lignans—from the root of this plant [75,76].
Chinese traditional medicine has long made use of Schisandra chinensis Baill. fruit as a sedative
and antitussive tonic [77]. This fruit is additionally used in other countries in the production of
functional foods, jam and beverages. Dibenzocyclooctadiene lignans isolated from S. chinensis
exhibit anti-inflammatory and antioxidant properties, as well as improving cognitive functions
(e.g., memory) [77]. In addition, prior studies have reported that S. chinensis fruit extracts—in which the
major bioactive constituents are lignans—exert a neuroprotective effect and possess bioactivity which
may help prevent Alzheimer’s Disease [78]. Furthermore, S. chinensis fruit may have positive effects on
the liver, as well as on the gastrointestinal, immune, sympathetic and central nervous systems [79,80].
Lignan extracts have been shown to successfully suppress hepatocellular carcinoma cell proliferation
and to prevent chemical toxin-induced hepatic injury [79]. However, only 2% of the total S. chinensis
fruit is made up of lignans, and most of these are present in the seeds, which are usually removed
during manufacture of fruit-derived products [79].
The Schisandra glaucescens Diels vine is extensively distributed across the Southeastern Sichuan
and Western Hubei regions of China [81]. The stem of this vine has been used as an analgesic in diverse
conditions, including arthritis, rheumatism, and contusions. As yet, one sesquiterpenoid, 25 lignans
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and 43 triterpenoids have been isolated from S. glaucescens [81]. In addition, S. glaucescens berries are
thought to exert beneficial effects on the kidneys and lungs, relieving the symptoms of asthma for
example [82].
Crataegus pinnatifida has been employed by the functional foods industry. Some studies have
reported that it has the ability to protect against low-density lipoprotein (LDL) oxidation, to scavenge
free radicals, and to exert an anti-inflammatory effect [83,84]. C. pinnatifida is mostly consumed as fresh
fruit, processed juice or jam. Juice and jam manufacture results in a significant quantity of by-products,
including seeds and leaves [84].
Schisandra sphenanthera is mainly located in Southwest China. A diversity of triterpenoids and
lignans has been isolated from its leaves, stems, and fruit [85].
The roots, stems, fruit, and leaves of Kadsura coccinea are used medicinally, and its fruit, particularly,
exhibits significant medicinal and nutritional properties [86]. Its bioactive triterpenoids and lignans
have garnered interest for their reported bioactivities, including anti-inflammatory and anti-tumor
effects [86–88].
Zanthoxylum schinifolium has been employed to stimulate blood circulation, as well as in
the treatment of various diseases [89,90]. Due to its exceptional taste and characteristic aroma
(usually described as green, spicy, floral, and fresh), Z. schinifolium fruit is used as a spice in many
traditional Asiatic cuisines [89]. Prior pharmacological studies have demonstrated that the leaves and
fruit of this plant possess medicinal properties, including antitumor, anti-inflammatory, and antioxidant
activities, as well as inhibition of both platelet aggregation and monoamine oxidase production [89,91].
4.5. Latin-American Diet
The basis of the Latin-American diet consists of maize (corn), potatoes, peanuts and beans.
This diet also includes flax seed. As mentioned above, Linum usitatissimum L. (flax seed) represents
one of the best dietary sources of lignans, exhibiting a higher lignan content than legumes or grains [8].
Diets rich in flax seed are associated with a reduced risk of various diseases, including cardiovascular
disease, osteoporosis, diabetes, and prostate and breast cancers [8,92]. Likely mechanisms include
the ability to decrease circulating glucose, LDL and total cholesterol levels [93,94]. Furthermore,
L. usitatissimum has significant commercial applications, in the manufacture of linen fiber for
example [94]. In terms of lignans, flax seed contains mainly secoisolariciresinol and secoisolariciresinol
diglucoside, but matairesinol is also present in small quantities [95]. Indeed, >95% of total flax seed
mass consists of secoisolariciresinol diglucoside, which is predominantly localized in the seed’s fibrous
hull [96] rather than its interior [97].
Asian diet appears to facilitate the highest intake of lignans, in forms which also result in higher
bioavailability. This is due largely to a high level of vegetable consumption, as well as the use of
lignan-rich plant infusions in traditional medicine.
5. Human Studies Concerning Lignan Bioactivity
Recently, interest in identifying new sources of health-promoting natural compounds has
increased. However, there are few human epidemiological studies that evaluate lignans bioactivity.
Laboratory research, carried out on cell and animal models, concluded that lignans possess
antimicrobial, anti-inflammatory and anti-oxidant activities, among others.
About antimicrobial activity, various lignans have exhibited antiviral and antibacterial activity,
e.g., against Gram-positive bacteria through alteration of biofilm formation, bacteria metabolites,
membrane receptors and ion channels [98]. For instance, pinoresinol has demonstrated activity against
some virus [99].
Concerning anti-inflammatory activity, some lignans have the capacity to inhibit NF-kB activity
(transcription factor involves on the expression of inflammatory cytokines) on human mast cells
(HMC-1). Thus, reduced pro-inflammatory cytokines production. Furthermore, lignans are able to
suppress nitric oxide (NO) generation and decrease inflammatory cell infiltration [100–102].
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Regarding anti-oxidant activity, various bioactive natural compounds—including phenols from
grains, vegetables and fruits—are rich dietary sources of phytochemicals and vitamins, both of which
guard against oxidative stress [84,103]. A free radical formation is an inevitable byproduct of cellular
metabolism, and cells also require a certain level of reactive oxygen species (ROS) to carry out a normal
cellular process [70]. Nevertheless, accumulation and/or overproduction of ROS can damage cellular
constituents, including DNA [70], and play an important role in the pathogenesis of various severe
disorders, including chronic inflammation, cancer, neurodegeneration and atherogenesis [84].
Many studies have demonstrated the strong antioxidant activity of plant extracts,
attributable to several highly-effective antioxidants, including lignans (e.g., lariciresinol, matairesinol,
secoisolariciresinol, pinoresinol, and nortrachelogenin) [104]. Among the natural antioxidants,
lignans exhibit particularly high antioxidant efficiency and thus have potential as preventive and/or
therapeutic clinical tools [105].
In recent years, a significant effort has been devoted to analyzing the lignan consumption
of various populations (Table 9). Most studies have focused on post-menopausal women,
due to lignans being phytoestrogens that ameliorate menopausal symptoms and consequences
(e.g., climacteric symptoms, osteoporosis and estrogen-dependent cancers) [106].
5.1. Cancer
Various cohort studies have investigated dietary lignan anticancer bioactivity. As McCann et al.
(2010) describe in the “Western New York Exposures and Breast Cancer” study, lignan intake
among post-menopausal women with breast cancer significantly reduced the risk of mortality
from breast cancer (Hazard Ratio (HR) 0.29, 95% Confidence interval (CI) 0.11–0.76), as well as
significantly reducing the risk of all-cause mortality (HR 0.49, 95% CI 0.26–0.91) [107]. Other research
based on the Swedish Mammography Cohort (SMC) also detected a statistically significant inverse
association between breast cancer risk and lignan consumption among post-menopausal breast cancer
patients [108]. Interestingly, the “Ontario Women’s Diet and Health Study” reported that neither lignan
nor isoflavone consumption by a Canadian cohort correlated with a significant reduction in breast
cancer risk [109]. Nonetheless, some studies do propose that isoflavone consumption correlates with a
minor reduction in breast cancer risk in both pre- and post-menopausal women [109,110]. In addition,
a cohort study examining the association between flax seed and flax bread intake and breast cancer
risk demonstrated that flax seed intake was associated with a significant reduction in breast cancer risk
(Odds Ratio (OR) 0.82, 95% CI 0.69–0.97) [111]. Furthermore, Buck et al. (2011) demonstrated that high
serum enterolactone levels in post-menopausal breast cancer patients are associated with improved
overall survival rates [109,112].
Another study, based on data from the United States Cancer Center Support Grant, investigated
the association between individual breast cancer estrogen receptor (ER) status and lignan intake [113].
Higher lignan consumption was inversely correlated with the risk of ER− breast cancer among
premenopausal women (OR 0.16, 95% CI 0.03–0.44) and with the risk of ER+ breast cancer
among post-menopausal women (OR 0.64, 95% CI 0.42–1.00) [113]. Although this effect was
largely independent of specific lignan class, it predominantly correlated with matairesinol and
lariciresinol intake levels [113]. In addition, this study examined associations between breast tumor
subtype and dietary lignan intake, demonstrating that a reduction in premenopausal triple-negative
(HER2−PR−ER−) breast cancer risk (OR 0.16, 95% CI 0.04–0.62) was associated with higher lariciresinol
and pinoresinol intake [113]. This finding agrees with that of a German case-control study that
demonstrated a correlation between high intake of pumpkin and sunflower seeds (rich sources of
lariciresinol and pinoresinol) and a statistically significant reduction in post-menopausal ER+ breast
cancer risk (OR = 0.88, 95% CI = 0.77–0.99, p for trend = 0.02) [109,114].
Two recent meta-analyses have corroborated that high levels of plant lignan consumption correlate
with a modest reduction in post-menopausal breast cancer risk (13 studies; Risk Estimated (RE) 0.86,
95% CI 0.78–0.94) [115,116].
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Dietary lignan intake is also associated with a reduced risk for other cancer types (e.g., esophageal
and gastric adenocarcinoma, as well as colon cancer), but very few human studies have been conducted.
A Swedish study indicates that dietary lignan intake correlates with decreased risk of
gastroesophageal junction adenocarcinoma [117]. However, another Swedish study examining the
Swedish Cancer Registry database did not find a clear association between dietary lignan consumption
and development of gastric or esophageal adenocarcinoma [118]. Yet another (case-control) study
indicated that a diet rich in resveratrol, quercetin and lignans (characterized by low intake of milk,
but high intake of wholegrain bread, vegetables, wine and tea) may decrease the risk of developing
such cancers [103].
Regarding colorectal cancer, Zamora-Ros et al. (2015) evaluated the association of lignan and
flavonoid consumption with overall survival time and risk of recurrence in Barcelona (Spain) [119].
After a mean of 8.6 years’ follow-up, 77 of the 319 (24.1%) patients in the cohort had experienced
recurrence (excluding cases with metastasis that could not be resected), 133 of 409 (32.5%) patients had
died, and no association was noted between consumption of any flavonoid subclass or total lignans
and colorectal cancer risk [119].
Concerning prostate cancer risk, it has been studied its association with plasma enterolactone
concentrations. Wallström et al. (2018) evaluated a population of Swedish men with 1010 cases and
1817 controls. After a mean follow-up of 14.6 years; there were no significant associations between the
incidence of prostate cancer and plasma enterolactone (OR 0.99, 95% CI 0.77–1.280) [120]. Other study
carried out at Danish men, neither found an association between prostate cancer mortality and
plasma enterolactone [121]. However, two other pieces of research on humans, from 2003 and 2006,
obtained positive results based on dietary phytoestrogen intake [122,123]. A Swedish case-control
study indicated that lower prostate cancer risk is related to certain phytoestrogen-rich foods [123].
Given such mixed results, additional studies examining the effect of human lignan intake on
cancer risk are necessary. Specifically, most existing studies have not examined the relevance of the
specific dietary lignan source.
5.2. Cardiovascular Disease
Neolignans and flax lignans are reportedly relevant in diabetes, hypercholesterolemia and
cardiovascular disorders [124]. In addition, the anti-aging role of lignans has recently been
described [125]. Such lignan characteristics may be relevant to the reduction of cardiovascular
disease risk in post-menopausal women. Indeed, an inverse association exists between high lignan
consumption and the development of hypertension and cardiovascular disease [126]. Furthermore,
prospective and cross-sectional epidemiological evidence suggests that dietary lignan intake reduces
cardiovascular disease risk in post-menopausal women and elderly men by modifying traditional risk
factors [127].
Jacobs et al. (2000) demonstrated that the risk of mortality is inversely associated with whole
grain consumption in post-menopausal women [128]. Another study described how four weeks’
consumption of a whole grain cereal-rich diet exerted a reasonable cholesterol-lowering effect in
healthy post-menopausal women [17].
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Table 9. Association between naturally lignan-rich foods and health promotion.





Case-control study (2999 cases and 3370
controls)
FFQ
Consumption of flaxseed and flax bread was
associated with a significant reduction in breast
cancer risk (OR 0.82, 95% CI 0.69–0.97; and OR
0.77, 95% CI 0.67–0.89), respectively.
McCann et al.
(2012) [113]
Case-control study (638 cases and 611
controls) BioRepository at Roswell Park
Cancer Institute
FFQ
Lignan intakes were inversely associated with
risk of ER (−) breast cancer among
premenopausal women (OR 0.16, 95% CI
0.03–0.44) and particularly triple negative




Case-control study (2884 cases and 5509
controls)
FFQ
High and low consumption of soybeans, as
well as of sunflower and pumpkin seeds were
associated with significantly reduced breast
cancer risk compared to no consumption (OR
0.83, 95% CI 0.70–0.97; and OR 0.66, 95% CI
0.77–0.97, respectively).
Buck K et al.
(2011) [112]




Serum enterolactone was associated with a
significantly reduced risk of death only for
estrogen receptor-negative tumors (HR 0.27;
95% CI 0.08 to 0.87)
Buck K et al.
(2010) [116]
Meta-analyses Medline search to
identify epidemiologic studies
published between 1997 and
August 2009
Lignan exposure was not associated with




Breast cancer patients; National Death
Index
Food frequency questionnaire (FFQ),
DietSys (3.7)
Lignan intake among post-menopausal women
with breast cancer significantly reduced risk of
mortality from breast cancer (HR 0.29, 95% CI,
0.11–0.76), as well as significantly reducing risk




Meta-analy sesMedline, BIOSIS and
EMBASE databases publications up to
30 September 2008
Overall, there was little association between
high plant lignan intake and breast cancer risk
(11 studies, OR 0.93, 95% CI 0.83–1.03).
Cotterchio, M et
al. (2008) [109]
Ontario Cancer Registry; Controls:
Age-stratified random sample of
women
FFQ
Total phytoestrogen intake in pre-menopausal
women was associated with a significant
reduction in breast cancer risk among
overweight women (OR 0.51, 95% CI 0.30, 0.87).
Suzuki, R. et al.
(2008) [108]
Swedish Mammography Cohort




Receptor status of tumors:
Immunohistochemical
A significant 17% risk reduction for breast
cancer overall in high lignan intake was
observed, but no heterogeneity across Estrogen
Receptor/Progesterone Receptor subtypes.
Trock BJ et al.
(2006) [110]
Meta-analysis of 18 epidemiologic
studies
published from 1978 through 2004
High soy intake was discreetly associated with
reduction of breast cancer risk (OR 0.86, 95% CI:
0.75 to 0.99); association was not statistically
significant among women in Asian countries
(OR 0.89, 95% CI 0.71 to 1.12).
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Table 9. Cont.
Author, Year Methods Results
Gastroesophageal Cancer
Lin Y et al.
(2012) [117]
Case-control study (1995–1997); 806
controls, 181 cases of esophageal
adenocarcinoma, 255 cases of
gastroesophageal junctional
adenocarcinoma, and 158 cases of
esophageal squamous cell carcinoma.
Interviews and questionnaires; FFQ
No clear associations were found between risk
of esophageal carcinoma and lignan intake.
Lin Y et al.
(2012) [118]
Cohort study in Sweden, 81,670
(followed up 1998 to 2009). Cancer
cases: Swedish Cancer Register
FFQ
There was no statistically significant association






409 CRC cases in Barcelona (Spain).
FFQ; Phenol-Explorer database.
No associations were also observed with either




Case-control study (1010 cases and 1817
controls)




There were no significant associations between
plasma enterolactone and incidence of prostate
cancer (OR 0.99, 95% CI 0.77–1.280)
Eriksen AK et
al. (2017) [121]
1390 men diagnosed with prostate




No associations between plasma enterolactone
concentrations and prostate cancer
aggressiveness.
Hedelin M et al.
(2006) [123]
Swedish case-control study (1499
prostate cancer cases and 1130 controls)
FFQ
No association was found between dietary
intake of total or individual lignans or
isoflavonoids and risk of prostate cancer.
Bylund A. et al.
(2003) [122]
10 men with prostate cancer were
randomized to a daily supplement of
rye bran bread and 8 men of wheat
bread
Blood and urine samples.
Ultrasound-guided core biopsies of the
prostate.
In the rye group, there was a significant
increase in plasma enterolactone. However,
only small changes were observed in plasma







participants of the Multi-center National
Population Health Examination Surveys.
24-h Dietary recall and food databases.
In postmenopausal women, total and
individual lignan intakes (secoisolariciresinol,
pinoresinol, matairesinol) were not associated








molecule-1 (sICAM-1), CRP, insulin,
glucose, total cholesterol,
HDL-cholesterol and triacylglycerols.
Three-day weighed food record
No relationship between intake of pinoresinol,
lariciresinol or total lignans and sICAM-1
values was observed.
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Table 9. Cont.
Author, Year Methods Results
Jacobs DR. et al.
(2000) [128]
11,040 postmenopausal women enrolled
in the Iowa Women’s Health Study
Followed from baseline 1986−997.
Women who consumed on average 1.9 g
refined grain fiber/2000 kcal and 4.7 g whole
grain fiber/2000 kcal had a 17% lower mortality
rate (RR = 0.83, 95% CI = 0.73–0.94) than





A prospective study of Finnish men.
1889 men aged 42 to 60 years. Followed
up 12.2 years.
Multivariate analyses showed significant
associations between elevated serum










Increasing dietary lignans intake was
associated with better performance on the
MMSE (OR 1.49, 95% CI 0.94–2.38). Results





2028 participants of NHANES
2005-2008 and 2628 participants of
NHANES 1999-2004 (aged ≥18 years)
Inflammatory marker: CRP
Statistically significant inverse associations of
urinary lignan, enterodiol, and enterolactone
concentrations with circulating CRP counts
were observed in the
multivariate-adjusted models.
FFQ: Food Frequency Questionnaire; CI: Confidence Interval; HR: Hazard Ratio; OR: Odds Ratio; CVD:
Cardiovascular Disease; MMSE: Cognitive function Mini-Mental Examination; CRP: C-Reactive Protein.
However, a Warsaw population-based cross-sectional study conducted by the National Institute
of Cardiology demonstrated that total dietary lignan consumption does not correlate with the
occurrence of cardiovascular diseases, nor with cardiovascular risk factors (including central obesity,
hypercholesterolemia and hypertension) in post-menopausal women [126]. Nevertheless, this study
attributed a potentially-beneficial effect of lignan intake on hypercholesterolemia specifically to
lariciresinol [126].
In a Finnish population, the highest serum enterolactone concentrations correlated with a lower
risk of all-cause mortality, including from cardiovascular disease [129]. Enterolactone is a metabolite of
lariciresinol, pinoresinol, secoisolariciresinol and matairesinol, and very low matairesinol intake does
demonstrate an inverse relationship with endothelial dysfunction and vascular inflammation [127].
5.3. Other Diseases
Most studies have focused on the effects of lignan-rich food consumption in the prevention
of cancer and cardiovascular disease. However, some observational studies have investigated
the relationship between regular consumption of plant lignans and the risk of developing other
lifestyle-related diseases. A study based on the European Prospective Investigation into Cancer
and Nutrition cohort proposed that improved cognitive performance in post-menopausal women
is associated with higher dietary phytoestrogen consumption (predominantly lignans in Western
diets) [130]. Thus, it has been suggested that low-grade chronic inflammation contributes to the
prevalence of chronic lifestyle-related diseases. The relationship between lignan consumption
and inflammatory markers (e.g., C-reactive protein (CRP)) was studied in a United States cohort,
demonstrating that a beneficial inflammatory marker profile is associated with adult lignan
consumption [131].
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6. Conclusions
Taken together, reviewed data support the recently increased interest in lignan health-promoting
properties. Due to their various bioactive properties, dietary intake of lignan-rich foods may
prevent certain types of cancers (e.g., breast cancer in post-menopausal women and colon cancer).
Regarding chronic lifestyle-related diseases, some pieces of evidence indicate that lignan intake is
associated with a lower risk of developing cardiovascular disease. Nonetheless, further human studies
are warranted to evaluate lignan bioavailability resulting from different traditional dietary patterns,
in order to influence the rational promotion of healthy lignan-rich diets.
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Abstract: Flaxseeds are a functional food representing, by far, the richest natural grain source of lignans,
and accumulate substantial amounts of other health beneficial phenolic compounds (i.e., flavonols,
hydroxycinnamic acids). This specific accumulation pattern is related to their numerous beneficial effects
on human health. However, to date, little data is available concerning the relative impact of genetic and
geographic parameters on the phytochemical yield and composition. Here, the major influence of the
cultivar over geographic parameters on the flaxseed phytochemical accumulation yield and composition
is evidenced. The importance of genetic parameters on the lignan accumulation was further confirmed by
gene expression analysis monitored by RT-qPCR. The corresponding antioxidant activity of these flaxseed
extracts was evaluated, both in vitro, using ferric reducing antioxidant power (FRAP), oxygen radical
absorbance capacity (ORAC), and iron chelating assays, as well as in vivo, by monitoring the impact of
UV-induced oxidative stress on the lipid membrane peroxidation of yeast cells. Our results, both the
in vitro and in vivo studies, confirm that flaxseed extracts are an effective protector against oxidative
stress. The results point out that secoisolariciresinol diglucoside, caffeic acid glucoside, and p-coumaric
acid glucoside are the main contributors to the antioxidant capacity. Considering the health benefits of
these compounds, the present study demonstrates that the flaxseed cultivar type could greatly influence
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the phytochemical intakes and, therefore, the associated biological activities. We recommend that this
crucial parameter be considered in epidemiological studies dealing with flaxseeds.
Keywords: cultivar; environment; flax; flavonol; genetic; hydroxycinnamic acid; lignan; seed
1. Introduction
The consumption of fruit, vegetables, and grains has been associated with lower risks of
chronic and degeneration diseases [1]. Considering their numerous beneficial effects on human
health, during the last decades, there has been an increasing interest in their uses, and flaxseeds
are, therefore, considered as functional food [2]. Flaxseeds are the richest natural grain source
of lignan and accumulate a substantial amount of other phenolic compounds (e.g., flavonols,
hydroxycinnamic acids). In flaxseed, the foremost part of these phytochemicals is accumulated
under the form of a macromolecular complex (also known as lignan macromolecule) composed of
the lignan secoisolariciresinol diglucoside (SDG, Figure 1A) as the main component, and of flavonol
herbacetin diglucoside (HDG, Figure 1A), as well as hydroxycinnamic acid derivatives: p-coumaric
acid glucoside (CouG, Figure 1A), caffeic acid glucoside (CafG, Figure 1A), and ferulic acid glucoside
(FerG, Figure 1A), ester-linked together to hydroxymethylglutaryl spacers (Figure 1B) [3,4].
Figure 1. Structure of phenolic compounds involved in the lignan macromolecular complex.
(A) Structure of the complex components: (1) secoisolariciresinol (R = H), or secoisolariciresinol
diglucoside (SDG, R = β-D-glucose), (2) herbacetin (R = H) or herbacetin diglucoside (HDG,
R = β-D-glucose), (3) p-coumaric acid (R = H), or p-coumaric acid glucoside (CouG, R = β-D-glucose),
(4) caffeic acid (R = H) or caffeic acid glucoside (CafG, R = β-D-glucose), (5) ferulic acid (R = H) or
ferulic acid glucoside (FerG, R = β-D-glucose), (6) hydroxymethylglutaric acid (HMGA). (B) Schematic
representation of lignan macromolecule, where a unit of SDG or HDG is ester-linked to another unit,
thanks to HMGA, which can be replaced by one hydroxycinnamic acid glucoside (HCAG) unit (CouG,
CafG, or FerG) in terminal position of the chain.
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The beneficial effects of lignans on human health are well recognized [5,6]. Particularly,
the chemopreventive actions of SDG toward cancer, diabetes mellitus, and cardiovascular diseases
have been largely described [5,7,8]. The pharmacological activity of this compound is thought to
be due to its high antioxidant capacity [9–11] and to its phytoestrogenic activity [12]. Flavonols
and hydroxycinnamic acids, the other constituents of the flaxseed lignan macromolecule, also
display a wide range of health-promoting effects. The favorable actions on cardiovascular
health of vegetable-rich diets have been ascribed to flavonols, and hydroxycinnamic acids have
revealed powerful antioxidant properties and might be of particular interest for dermatologic
applications [13,14].
Although both in vivo and in vitro data are globally in favor of a chemopreventive effect of lignans,
epidemiological studies are much less conclusive, and the mechanism by which phytoestrogenic
lignans prevent cancers still remains unclear [7] and requires further elucidation. This could be
explained by the fact that our current knowledge concerning the genetic and environmental factors
affecting productivity and yield stability of these phenolic compounds, in flaxseeds, remains partial,
and little is known about the variation in antioxidant capacities of different flaxseed cultivars. Moreover,
no study has put efforts toward linking the lignan content of different cultivars and the expression of
genes involved in their biosynthetic pathway.
Herein we present a complete dataset concerning the relative impact of cultivar, edaphic, and
climatic parameters on productivity of the main constituents of the lignan macromolecule of flaxseeds,
in relation to their antioxidant capacities determined using both in vitro and in vivo systems. Such data
could be useful to predict, more precisely, the accumulation and, therefore, the nutritional intakes of
these compounds, with health benefits for pharmaceutical, nutraceutical, and/or cosmetic applications.
2. Materials and Methods
2.1. Chemicals
All chemicals were of analytical grade quality and purchased from Thermo (Illkirch, France).
The deionized water was produced using a milli-Q water purification system (Merck Millipore,
Molsheim, France). SDG and HDG standard were purchased from LGC Standards (Molsheim, France).
The hydroxycinnamic acid glucosides—p-coumaric acid glucoside, caffeic acid glucoside, ferulic acid
glucoside—were synthesized according to Beejmohun et al. (2004) [15] and Beejmohun et al. (2006) [16].
Prior to their use for HPLC or LC-MS analysis, all solutions were filtered through 0.45 μm nylon
syringe membranes (Merck Millipore, Molsheim, France).
2.2. Plant Materials and Cultivation
Flax cultivars Astral, Baïkal, Baladin, Barbara, and Oliver were provided by Laboulet Semences
(Airaines, France), Coopérative Linière Terre de Lin (Saint-Pierre-le-Viger, France) and Arvalis-Institut
Technique du Lin (Boigneville, France). Flax was grown up to seed at the following locations in
France: Eure (Gamaches-en-Vexin, GAM, 49◦16′14′’N/1◦37′02′’E/89 m), Somme (Airaines, AIR,
49◦57′57”N/1◦56′39”/70 m), and Eure-et-Loir (Chartres, CHA, 48◦27′21.05”N/1◦29′3.06”E/141 m).
Sowings were performed on March 30th of each year, with 450 seeds per m2. Fields were fertilized,
immediately after sowing, with 80 units of nitrogen, 60 units of potassium, and 60 units of phosphorus
per hectare (Figure S1). The soils of these sites were of clay loam type balanced, well-structured with
a granulometry of ca. 25% 2000–63 μm, 50% 63–2 μm, and 25% <2 μm particles, and a pH around
7.8. The final harvest took place on August 15th of each year at the same ripening stage for each
cultivar. Throughout the experiments, no visible disease or insect attack occurred at either location.
During the growing period, the experimental stations received 182.8 mm (year 2003), 305.0 mm (year
2004), 269.8 mm (year 2005) for GAM, 387.4 mm for AIR (year 2005), and 308.6 mm for CHA (year
2005) of rainfall over the growing period. The day temperatures at an elevation of 2 m averaged
15.72 ◦C (year 2003), 13.67 ◦C (year 2004), 13.96 ◦C (year 2005) for GAM, 13.48 ◦C for AIR (year 2005),
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and 14.45 ◦C for CHA (year 2005) over the growing period. All these meteorological characteristics are
displayed in Table S1 and Figure S2.
2.3. Gene Expression Analysis by RT-qPCR
Total RNA was extracted from 100 mg of frozen plant material in liquid nitrogen as described by
Hano et al. (2006) [17]. Expression patterns of LuDIR5, LuPLR1, and LuUGT74S1 were analyzed using
RT-qPCR, using specific primers described by Dalisay et al. (2015) [18]. For reverse transcription, 50 ng
of total RNA was incubated for 60 min at 50 ◦C with 1× RT buffer, 0.5 mM of each dNTP, 1 μM of
oligo-dT primers, 1 unit of RiboLock, and 4 units of Omniscript Reverse Transcriptase in a total volume
of 20 μL (Qiagen, Hilden, Germany). qPCR was performed with a PikoReal™ Real-Time PCR System
(Thermo Fisher Scientific, Villebon-sur-Yvette, France) using DyNAmo ColorFlash SYBR Green qPCR
(ThermoScientific) and specific primers. Two reference genes (CYC and ETIF5A) were used for data
normalization [19]. The qPCR parameters were as follows: an initial denaturation at 95 ◦C for 5 min,
then 40 three-step cycles of 94 ◦C for 10 s, primer annealing at 65 ◦C for 10 s, and extension at 72 ◦C for
30 s. After 40 cycles, an additional extension step was performed at 72 ◦C for 90 s. The presence of a
single amplicon was confirmed by the observation of a single peak in the melting curve obtained after
amplification. Expression levels were calculated and normalized using 2−ΔΔCt method [20]. Reactions
were performed in three biological and two technical replicates.
2.4. Extraction, HPLC, and LC-ESI-MS Analysis
Extractions (4 biological and 2 technical replicates), quantification of compounds was carried
out on a Varian liquid chromatographic system (Agilent Technology, Les Ulis, France), as well as
LC-ESI-MS analyses using a Waters 2695 Alliance coupled with a single quadrupole mass spectrometer
ZQ (Waters-Micromass, Manchester, UK), equipped with an electrospray ion source (ESI-MS), were
performed as described in Corbin et al. (2015) [21].
2.5. Determination of the Ferric-Reducing Antioxidant Power (FRAP)
Ferric-reducing antioxidant power (FRAP) was measured as described by Benzie & Strain,
(1996) [22] with little modification. Briefly, 10 μL of the extracted sample was mixed with 190 μL
of FRAP (10 mM TPTZ; 20 mM FeCl3·6H2O, and 300 mM acetate buffer pH 3.6; ratio 1:1:10
(v/v/v)). Incubation lasted 15 min at room temperature. Absorbance of the reaction mixture was
measured at 630 nm with a BioTek ELX800 Absorbance Microplate Reader (Thermo Fisher Scientific,
Villebon-sur-Yvette, France). Assays were made in triplicate and antioxidant capacity was expressed
as Trolox C equivalent antioxidant capacity (TAEC).
2.6. Determination of Oxygen Radical Absorbance Capacity (ORAC)
Oxygen radical absorbance capacity (ORAC) assay was performed as described by Prior et al.
(2003) [23]. Briefly, 10 μL of the extracted sample was mixed with 190 μL of fluorescein (0.96 μM)
in 75 mM phosphate buffer pH 7.4, and incubated for at least 20 minutes at 37 ◦C with intermittent
shaking. Then, 20 μL of 119.4 mM 2,2′-azobis-amidinopropane (ABAP, Sigma Aldrich, Saint-Quentin
Fallavier, France) was added and the fluorescence intensity was measured every 5 min for 2.5 h at 37 ◦C
using a fluorescence spectrophotometer (Bio-Rad, Marnes-la-Coquette, France) set with an excitation
at 485 nm and emission at 535 nm. Assays were made in triplicate, and antioxidant capacity was
expressed as Trolox C equivalent antioxidant capacity (TAEC).
2.7. Determination of the Iron-Chelating Capacity
The iron-chelating capacity was determined as described by Mladenka et al. (2011) [24]. Briefly,
10 μL of extract sample were mixed with ferrous iron at a final concentration of 50 μM in HEPES
(pH 6.8) buffer and 50 μL ferrozine (5 mM aqueous solution). All experiments were performed in
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96-well microplates. Each sample was measured with and without (blank) the addition of ferrozine.
Absorbance was measured at 550 nm immediately after addition of ferrozine, and 5 min later with a
BioTek ELX800 Absorbance Microplate Reader (Thermo Fisher Scientific, Villebon-sur-Yvette, France).
Chelating activity values were expressed in μM of fixed iron.
2.8. Yeast Cells Cultivation and Treatments
Yeast (Saccharomyces cerevisiae) strain MAV203 (Invitrogen, Thermo Fisher Scientific
Villebon-sur-Yvette, France) were used. Cells were grown aerobically at 30 ◦C in an orbital shaker
(150 rpm) in complete 2.0% (w/v) glucose YPD medium (Sigma Aldrich, Saint-Quentin Fallavier,
France). All extracts evaporated under nitrogen flow, dissolved in DMSO at 50 μg/mL, and added
to the cells 6 h before oxidative stress induction at a final concentration of 1 mg/mL. The final
concentration of DMSO applied on the cell was 1 % (v/v). For the control sample, DMSO to 0.1% of the
final volume, was added. Cells were irradiated with 106.5 J/m2 UV-C (254 nm) under a Vilber VL-6.C
filtered lamp (Thermo Fisher Scientific, Villebon-sur-Yvette, France), as described by Bisquert et al.
(2018) [25], and then incubated overnight at 30 ◦C before membrane lipid peroxidation determination.
2.9. Determination of Membrane Lipid Peroxidation Using Thiobarbituric Acid-Reactive Substances
(TBARS) Assay
Measurement of membrane lipid peroxide was carried out with the thiobarbituric acid (TBA;
Sigma Aldrich, Saint-Quentin Fallavier, France) method described by Hano et al. (2008) [26]. Briefly,
ca. 107 cells were ground using a mortar and pestle in distilled water, and centrifuged at 10,000×g
for 10 min. Supernatant fractions (75 μL) were mixed with 25 μL of 3% (w/v) SDS, 50 μL of 3% TBA
(w/v) in 50 mM NaOH, and 50 μL of 23% (v/v) of HCl throughout mixing between each addition.
The mixture was heated at 80 ◦C for 20 min. After cooling on ice, the absorbance at 532 nm (A532) was
measured, and non-specific absorbance at 600 nm (A600) was subtracted.
2.10. Statistical Treatment of Data
All data presented in this study are the means and the standard deviations of at least three
independent replicates. ANOVAs and Pearson correlations were performed using R software version
3.0.2. PCA was performed with XL-STAT2017 software (Addinsoft, Paris, France), with each parameter
considered as a discrete variable; the initial dataset was then converted into principal components
(PCs), and it was possible to graphically display the relationships among the considered parameters.
Gene expression and SDG content were represented using MeV4 software. All statistical tests were
considered significant at p < 0.05.
3. Results and Discussion
3.1. Influence of Genetic Variations on the Accumulation of the Main Constituents of the Lignan Macromolecule
The flax cultivars, herein studied, showed an SDG content ranging from 8.23 to 21.85 mg/g of
dry weight (DW) (Table 1). Barbara and Oliver are high SDG-producing cultivars, Baladin presents an
intermediate content, whereas Astral and Baïkal are poor in SDG, as compared to the other cultivars.
A similar range of variation in SDG content has been reported in a flax germplasm collection by
Diederichsen and Fu (2008) [27]. Lower SDG content was reported by Zimmermann et al. (2007,
2006) [28,29] for cultivars grown in Spain and Germany. Nevertheless, it should be noted that these
authors employed an extraction method based on acid hydrolysis, which is known to be potentially
destructive for SDG [30], leading to a possible underestimation in the actual contents. SDG is the
main component of the lignan macromolecule accumulated in flaxseed, but other compounds, such as
hydroxycinnamic acid glucosides (caffeic acid glucoside (CafG), p-coumaric acid glucoside (CouG),
and ferulic acid glucoside (FerG), as well as the flavonol herbacetin diglucoside (HDG), are also
incorporated in substantial amounts in this macromolecule [4,31,32]. Here, the whole set of these
298
Molecules 2018, 23, 2636
compounds was assayed. In our hands, CouG contents ranged from 4.78 to 10.48 mg/g DW, and FerG
content from 1.03 to 2.28 mg/g DW (Table 1). These results sound consistent with those described by
Westcott and Muir (1996), Jonhson et al. (2000), and Eliasson et al. (2003) [33–35] for cultivars grown
respectively in Canada, Denmark, and Sweden. To date, only semi-quantitative evaluation of the
HDG variations in flax cultivars have been studied through NMR [36], therefore, to the best of our
knowledge, the present work is the first study focusing on the quantitative variations in HDG contents
in linseed cultivars. Concerning the quantitative variations in CafG, only Wang et al. (2017) [37]
reported very low contents ranging from 2.40 to 8.70 μg/g DW for Chinese cultivars. Here, HDG
content ranged from 0.75 to 1.18 mg/g DW, and CafG contents from 0.80 to 1.90 mg/g DW (Table 1).
Table 1. Influence of the cultivar (C), cultivation site (L), and year (Y) on the accumulation of the main
constituents of the lignan macromolecule in flaxseeds.
Cultivar Location_Year SDG a HDG a FerG a CouG a CafG a
Astral AIR_05 12.85 ± 0.14 0.98 ± 0.06 1.65 ± 0.06 5.88 ± 0.09 0.85 ± 0.04
CHA_05 12.53 ± 0.11 1.05 ± 0.03 1.90 ± 0.08 6.05 ± 0.08 0.98 ± 0.06
GAM_03 11.73 ± 0.06 0.88 ± 0.04 1.58 ± 0.07 4.80 ± 0.08 1.23 ± 0.06
GAM_04 11.68 ± 0.09 1.10 ± 0.05 1.58 ± 0.04 4.78 ± 0.05 1.25 ± 0.05
GAM_05 13.48 ± 0.13 0.85 ± 0.01 1.57 ± 0.02 6.07 ± 0.22 0.87 ± 0.02
Barbara AIR_05 21.68 ± 0.17 0.93 ± 0.06 1.95 ± 0.03 10.48 ± 0.12 1.83 ± 0.04
CHA_05 20.88 ± 0.07 1.05 ± 0.03 2.18 ± 0.07 8.63 ± 0.65 1.63 ± 0.04
GAM_03 20.63 ± 0.10 0.95 ± 0.03 1.78 ± 0.03 9.95 ± 0.11 1.33 ± 0.06
GAM_04 21.85 ± 0.34 0.85 ± 0.03 1.78 ± 0.02 9.85 ± 0.26 1.53 ± 0.06
GAM_05 21.85 ± 0.81 0.88 ± 0.01 1.66 ± 0.01 9.84 ± 0.07 1.53 ± 0.01
Baladin AIR_05 16.03 ± 0.11 1.15 ± 0.03 2.10 ± 0.05 7.88 ± 0.07 1.48 ± 0.07
CHA_05 15.68 ± 0.19 1.18 ± 0.03 2.28 ± 0.07 7.58 ± 0.10 1.43 ± 0.09
GAM_03 18.20 ± 0.38 1.03 ± 0.03 2.03 ± 0.04 7.88 ± 0.12 1.33 ± 0.02
GAM_04 16.45 ± 0.13 1.08 ± 0.07 2.08 ± 0.02 7.33 ± 0.21 1.40 ± 0.08
GAM_05 16.20 ± 0.38 0.95 ± 0.01 1.92 ± 0.01 6.91 ± 0.04 1.19 ± 0.01
Baïkal AIR_05 8.33 ± 0.13 1.03 ± 0.04 1.75 ± 0.07 4.85 ± 0.07 0.85 ± 0.01
CHA_05 8.23 ± 0.07 1.18 ± 0.02 1.75 ± 0.05 4.85 ± 0.06 1.05 ± 0.03
GAM_03 8.23 ± 0.17 1.15 ± 0.05 1.88 ± 0.07 4.90 ± 0.07 0.80 ± 0.05
GAM_04 8.45 ± 0.10 1.05 ± 0.08 1.98 ± 0.03 4.98 ± 0.08 0.98 ± 0.04
GAM_05 8.40 ± 0.04 0.98 ± 0.01 1.79 ± 0.02 4.88 ± 0.05 0.83 ± 0.01
Oliver AIR_05 21.00 ± 0.25 0.75 ± 0.03 1.55 ± 0.03 10.15 ± 0.09 1.90 ± 0.05
CHA_05 19.50 ± 0.19 0.85 ± 0.03 1.33 ± 0.06 9.03 ± 0.26 1.75 ± 0.06
GAM_03 19.95 ± 0.11 0.98 ± 0.04 1.18 ± 0.06 9.38 ± 0.07 1.33 ± 0.06
GAM_04 19.93 ± 0.11 1.03 ± 0.07 1.03 ± 0.03 9.35 ± 0.09 1.45 ± 0.05
GAM_05 21.55 ± 0.37 0.83 ± 0.01 1.06 ± 0.01 9.12 ± 0.08 1.37 ± 0.01
F values Cultivar (C) 284.62 *** 4.06 * 19.18 *** 95.33 *** 14.76 ***
Location (L) 0.02 1.21 1.04 0.13 0.61
Year (Y) 0.03 2.09 0.68 0.02 0.48
C × L 194.69 *** 3.57 * 21.90 *** 75.96 *** 11.94 ***
C × Y 198.99 *** 4.58 * 17.25 *** 59.81 *** 11.19 ***
Y × L 0.02 1.484 0.536 0.062 0.441
C × L × Y 148.70 *** 4.23 * 16.18 *** 51.26 *** 9.62 ***
a All contents are given in mg/g DW. Values are mean ± SD of 4 independent replicates. ANOVA, F represents the
effect. Significance level: * p < 0.05; ** p < 0.01; *** p < 0.001.
In flaxseed, the lignan biosynthesis involves the dirigent protein (LuDIR5; Figure 2A)-mediated
stereoselective coupling of two E-coniferyl alcohol moieties, resulting in the formation of
(−)-pinoresinol [18,38]. The two following reaction steps leading to the conversion of (−)-pinoresinol to
(−)-lariciresinol, and (−)-lariciresinol to (+)-secoisolariciresinol, are catalyzed by the same bifunctional
enzyme pinoresinol–lariciresinol reductase (LuPLR1, Figure 2A) [17,39,40]. Secoisolariciresinol
is then glycosylated into SDG under the control of UDP-glycosyltransferase (LuUGT74S1,
Figure 2A) glycosylating the C-9 and C-9’ hydroxyl positions [41,42]. SDG is stored as a
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3-hydroxy-3-methylglutaryl ester-linked complex (HMG-SDG), as shown in Figure 1. Formation
of the HMG–SDG ester-linked oligomers, occurs by linking hydroxylmethylglutaryl (HMG) to C-6a
and C-6a’ position, via action of HMG CoA-transferase [43].
Figure 2. Expression profile of flax lignan biosynthetic gene and SDG accumulation in five flaxseed
cultivars. (A) Biosynthetic pathway leading to the formation of (+)-SDG in flaxseed. (B) Expression of
LuDIR5, LuPLR1, and LuUGT74S1 determined by RT-qPCR (normalized with CYC and ETIF5A reference
genes) visualized using MeV4 (n = 3) and SDG content measured by HPLC and visualized using
MeV4 (n = 3). (C) Pearson correlation matrix between (+)-SDG accumulation and the corresponding
biosynthetic gene expression. Significance level: * p < 0.05; ** p < 0.01; *** p < 0.001.
Correlation analysis between the different constituents of the flax lignan macromolecule revealed
significant positive correlations between the CafG, CouG, and SDG contents, on the one hand, and
between HDG and FerG, on the other hand (Table 2). This correlation was in agreement with our
previous results [36]. On the contrary, significant negative correlations were noted between the
SDG vs HDG and FerG yields (Table 2), which confirmed our previous observations [36]. From a
metabolic point of view, p-coumaric acid (Figure 1A) is a branch point leading to the biosynthesis
of either flavonoids or lignans [44]. Therefore, caffeic acid and p-coumaric acid (Figure 1A) could
be considered as more direct precursors for the HDG biosynthesis, whereas ferulic acid (Figure 1A)
constitutes a precursor for SDG biosynthesis. These biosynthetic links could explain, in part, the
observed correlations. Studying the possible metabolic channel regulation of the carbon allocation
between these two branches, during flaxseed development, could be of particular interest.
As a step forward, lignan biosynthetic gene expression analysis performed on immature flaxseed
(developmental stage 2; [17]) by RT-qPCR using the 3 specific genes involved in SDG biosynthesis
(LuDIR5, LuPLR1, and LuUGT74S1; Figure 2A,B) appeared in good agreement with the HPLC
quantification (Figure 2C). High expression of LuPLR1 was detected in high SDG-producing cultivars,
Barbara and Oliver, whereas Astral and Baïkal cultivars, accumulating lower SDG content, showed
a lower expression of these biosynthetic genes (Table 1). The steady state levels of the key LuPLR1
transcripts [40], and the two other biosynthetic genes (LuDIR5 and LuUGT74S1) are correlated with
the SDG content measured in the corresponding mature seeds (Figure 2C), confirming the great
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influence of genetic parameters (i.e., the cultivar), and indicated that most of the regulation occurred at
transcriptional level.
Table 2. Correlation analysis using Pearson correlation coefficient (PCC).







FerG −0.231 ns 0.510 **
CouG 0.966 *** −0.476 * −0.215 ns
CafG 0.835 *** −0.360 ns −0.063 ns 0.832 ***
FRAP 0.676 *** −0.624*** −0.545 ** 0.639 *** 0.671 ***










*** −0.482 * 0.806 *** 0.721 *** 0.774 *** 0.617 *** 0.875 ***
Significance level: * p < 0.05; ** p < 0.01; *** p < 0.001; ns: not significant.
3.2. Influence of Geographic Parameters on the Accumulation of the Main Constituents of Lignan Macromolecule
It is well accepted that environmental conditions, such as the climate of the culture year and
the location (soil conditions), could also greatly affect the accumulation of phenolic compounds,
as previously observed by Oomah et al. (1996) [45] for the accumulation of total flavonoids in flaxseeds.
Here, three different locations have been selected to provide access to the potential influence of edaphic
condition on lignan accumulation in flaxseed. Bordered by four different seas, three mountain ranges,
and the edge of the central European lowlands, France is known to be a country with very diverse
climatic conditions, resulting in very different weather patterns. Here, the three selected experimental
sites are representative of the major flax-growing areas in France, i.e., the western part, and the present
contrasting weather patterns. The CHA site is characterized by the highest temperatures and the
lowest rainfall during the seed maturation phase. On the contrary, AIR location presents the lowest
temperatures and the highest rainfall observed during the same period. The last location, GAM,
is considered as an intermediate in terms of climate. The impact of these different conditions, on the
composition and amount of the main constituents of the lignan macromolecule accumulated in the
seed of the five selected cultivars, are presented in Table 1. Analysis of the variance revealed that
cultivar was the main contributor for the observed variability (cultivars, C, Table 1). Edaphic factor
(location L, Table 1) has no significant effect on the accumulation of these phytochemicals, whereas
significant interactions with genetic factor were noted, but evidenced the prominent effect of genetic
background at a particular location according to F values (Table 1).
Nonetheless, the location constitutes a complex variable, differing by both climatic and edaphic
parameters, thus, to evaluate the sole contribution of climate, we decided to compare flaxseeds grown
at the same site, GAM (i.e., the same edaphic parameters) but in different cultivation years (i.e., different
climatic parameters). Here, we chose to consider three consecutive years with very contrasting weather
patterns and, for this reason, the 2003–2005 period was selected. Indeed, it must be noted that the
summer of 2003 was the hottest and driest in recent decades, and must be regarded as extremely
unusual. The 2003–2005 period was also the warmest period recorded in France since 1950, whereas
the low rainfall observed from June 2004 to December 2005 led to a dramatic soil water deficit for 2005,
with a soil humidity index close to 0.25 for GAM region (considering that a soil humidity index of 1
is for water-saturated soil whereas 0 is for water-depleted soil; see Table S1, Figure S2 for complete
meteorological condition descriptions). As flax is known to be a water-demanding crop during its
flowering period (i.e., June), we therefore decided to evaluate how these climate changes, leading to
water deficiency during this period, have affected the flaxseed metabolism. The results are reported in
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Table 1, and the analysis of the variance evidenced the genetic background (cultivars, C, Table 1) as
the sole significant factor influencing the SDG, FerG, CouG, and CafG content (Table 1). The climatic
parameters considered here (cultivation year, Y, Table 1) did not influence the accumulation of any
molecules in the analyzed cultivars, whereas significant interaction between genetic and climatic
parameters (C × Y, Table 1) was noted, but with lower F values as compared to genetic parameter
alone (C, Table 1), indicating that the main contributions have to be attributed to this latter parameter.
Our results are in good agreement with the results of Saastamoinen et al. (2013) [46], who also reported
a lower impact of the cultivation year compared to the cultivar parameter on SDG accumulation. On
the contrary, Wescott et al. (2002) [47] reported that the cultivation year could also influence SDG
yield. This apparently contradictory result can be due to the complexity of the climatic variable, that
could also be influenced by the nature of the soil considered (edaphic parameters). The nature of the
soil could greatly affect the influence of the drought period as its ability to retain water greatly relied
on its composition and granulometry. Indeed, a high soil ability to retain water could alleviate the
effect of temporary drought, and differences in this feature could explain such apparent discrepancies,
moreover, the rainfall regime differs between Scandinavian and Canadian summers, making it more
probable that drought occurs during the latter.
All these phytochemical profiles were subjected to principal component analysis. The resulting
biplot representation accounts for 99.43% (F1 + F2) of the initial variability of the data (Figure 3).
Discrimination occurs mainly in the first dimension, and SDG content was the main contributor for
this F1 axis that explains 89.43% of the initial variability. The concentrations of hydroxycinnamic
acid glucosides (particularly CouG) were the main contributors for the second dimension (F2 axis),
accounting for only 10% of the initial variability (Figure 3). PCA showed a significant grouping of
samples as a function of their SDG content. Using this analysis, the different cultivars could also
be easily discriminated. This PCA confirmed the prominence of the genetic background over the
environmental (edaphic and climatic) factors studied here.
Figure 3. Correlation circle for principal component analysis. The SDG, HDG, CafG, CouG, and FerG
contents for 5 cultivars (Astral, Baïkal, Baladin, Barbara, and Oliver) growing at 3 different locations
(GAM, AIR, and CHA) and over 3 different years (03 (2003), 04 (2004), or 05 (2005)) were submitted for
analysis by the PCA algorithm in Excel-XLSTAT software, using the Pearson correlation matrix (at a
significance level of p < 0.05).
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3.3. Evaluation and Comparison of In Vitro and In Vivo Antioxidant Capacities
To evaluate the influence of genetic and edaphic variables on the health benefit potential of these
flaxseeds, the antioxidant capacity of the corresponding extracts was then evaluated using both in vitro
and in vivo assays. On the basis of the chemical reaction involved, the major antioxidant capacity
assays can be roughly divided into two categories: i) hydrogen atom transfer (HAT) reaction-based
assay, such as ORAC assay, or ii) electron transfer (ET) reaction-based assay, such as FRAP assay
(Table 3).
In our hands, the antioxidant capacity of our flaxseed extracts revealed by these two different
assays ranged from 217.35 (Baladin, AIR_05) to 355.75 (Oliver, GAM_05) μM of Trolox C equivalent
antioxidant capacity (TEAC) using FRAP assay, and from 269.97 (Baïkal, GAM_04) to 375.76 (Oliver,
GAM_05) μM TEAC using ORAC assay (Table 3). The antioxidant capacity of polyphenolic compounds,
such as lignans, has been previously attributed to their capacity for HAT, from their OH groups to
the free radicals [48]. However, the radical scavenging capacity of these extracts occurring through an
ET-based mechanism cannot be excluded, according to the high antioxidant values calculated from the
FRAP assay (Table 3). Here these two in vitro antioxidant assays were significantly correlated with the
presence of SDG, CouG and CafG (Table 2).
Besides these two mechanisms involved in the scavenging of reactive oxygen species, transient
metal ion chelation is also considered as an antioxidant mechanism, since the Fenton reaction,
responsible for the hydroxyl radical formation and, subsequently, radical chain reaction propagation,
could be inhibited through this chelating mechanism [49,50]. Here, we evidenced that flaxseed
extracts displayed an efficient iron (Fe2+)-chelating activity, ranging from 7.18 μM (Baïkal, GAM_03)
to 14.72 μM (Oliver, GAM_04) of fixed iron (Table 3), that could also contribute to their antioxidant
activity, largely described in the literature [9,10]. In good agreement with the recent rationalization
of the iron-chelating capacity of SDG and its aglycone form secoisolariciresinol, high SDG quantities
associated with elevated contents of CouG and CafG, appeared to significantly contribute to the
development of a high iron-chelating capacity of the corresponding flaxseed extracts (Table 2).
It is necessary to emphasize that the assays described herein are strictly predictive results based
on the chemical reaction in vitro, however, they not necessary bear a great similarity to biological
systems. The validity of these data has to be, therefore, considered as limited to a strict chemical
sense with context interpretation. For this reason, in order to better reflect the in vivo situation,
the antioxidant activity of these extracts was further investigated for their capacity to inhibit membrane
lipid peroxidation induced by UV-C in yeast cells. Yeast cells have been proven to be an excellent model
to evaluate in vivo antioxidant capacity in a cellular oxidative stress context [51]. Indeed, baker’s yeast
(Saccharomyces cerevisiae) is an attractive and reliable model. This organism is a true eukaryote, and the
mechanisms of defense and adaptation to oxidative stress are well understood [25,52]. The in vivo
anti-lipoperoxidation activity (inhibition of malondialdehyde (MDA) formation), determined using the
TBARS assay, ranged from 21.68% (Baïkal, GAM_04) to 47.02% (Oliver, AIR_05) (Table 3). Interestingly,
a strong and significant correlation was observed between this cellular antioxidant capacity and
the SDG (PCC = 0.867), CouG (PCC = 0.806), and CafG (PCC = 0.721) contents (Table 2). However,
we can note that, since the contents of SDG, CouG, and CafG are highly correlated, these parameters
are not independent, and it is, therefore, difficult to definitely judge their respective contribution to
this biological activity (cellular antioxidant capacity) by single correlation analysis. In yeast models,
a similar protective effect against oxidative stress was previously observed on yeast cells treated with
thiamine [52] and melatonin [25]. To the best of our knowledge, this the first time that this system is
applied to characterize a flax extract. Our results are in agreement with those obtained using in vitro
assays, and highlighted the great in vivo antioxidant potential of flaxseed extracts as already proposed
by Wang et al. (2017) [37], using another cellular antioxidant assay in HepG2 cells.
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Table 3. Influence of the cultivar (C), cultivation site (L), and year (Y) on the in vitro and in vivo
antioxidant activities of flaxseed extracts.
Cultivar Location_Year FRAP a ORAC a Iron Chelation b
MDA
Inhibition c
Astral AIR_05 252.55 ± 2.45 281.55 ± 11.16 9.57 ± 0.25 37.10 ± 0.28
CHA_05 264.41 ± 10.28 317.87 ± 8.00 10.11 ± 0.41 36.95 ± 0.43
GAM_03 322.81 ± 1.41 263.13 ± 11.91 9.66 ± 0.12 38.47 ± 0.75
GAM_04 276.68 ± 4.33 312.34 ± 1.12 9.31 ± 0.53 37.71 ± 1.18
GAM_05 252.55 ± 5.23 263.92 ± 4.56 9.57 ± 0.22 38.17 ± 1.07
Barbara AIR_05 332.55 ± 4.57 339.45 ± 1.95 11.97 ± 0.19 45.95 ± 2.26
CHA_05 317.61 ± 9.33 341.29 ± 16.09 11.35 ± 0.72 44.58 ± 1.08
GAM_03 292.81 ± 5.84 329.45 ± 8.65 11.79 ± 0.06 43.05 ± 3.23
GAM_04 296.41 ± 8.20 336.55 ± 2.14 12.32 ± 0.53 46.41 ± 0.43
GAM_05 331.48 ± 5.23 309.45 ± 3.72 10.99 ± 0.28 45.65 ± 1.94
Baladin AIR_05 217.35 ± 4.67 286.82 ± 2.79 8.69 ± 0.31 33.44 ± 2.16
CHA_05 240.55 ± 6.31 334.18 ± 5.95 8.24 ± 0.44 33.28 ± 0.97
GAM_03 254.01 ± 2.30 307.61 ± 4.18 8.16 ± 0.43 32.06 ± 0.64
GAM_04 288.41 ± 11.27 321.82 ± 2.60 8.87 ± 0.06 28.85 ± 0.43
GAM_05 255.08 ± 14.24 281.03 ± 2.70 7.80 ± 0.59 34.50 ± 2.16
Baïkal AIR_05 262.01 ± 3.21 278.66 ± 5.76 8.42 ± 0.37 25.34 ± 1.18
CHA_05 274.95 ± 3.49 281.03 ± 2.79 8.16 ± 0.40 24.89 ± 1.19
GAM_03 227.61 ± 1.41 305.24 ± 2.32 7.18 ± 0.56 23.66 ± 1.62
GAM_04 243.75 ± 5.42 269.97 ± 4.09 7.62 ± 0.55 21.68 ± 3.13
GAM_05 243.78 ± 1.27 286.29 ± 2.51 8.07 ± 0.12 26.11 ± 0.86
Oliver AIR_05 350.68 ± 0.81 368.66 ± 21.39 14.45 ± 0.25 47.02 ± 2.16
CHA_05 306.28 ± 5.27 374.45 ± 6.42 14.54 ± 0.44 46.87 ± 1.19
GAM_03 302.41 ± 6.17 278.92 ± 5.39 13.74 ± 0.38 43.21 ± 0.75
GAM_04 355.75 ± 8.20 326.55 ± 2.70 14.72 ± 0.47 45.34 ± 2.37
GAM_05 343.08 ± 5.28 375.76 ± 7.91 14.10 ± 0.38 46.87 ± 1.40
F values Genetic (C) 11.91 *** 5.37 *** 188.00 *** 161.33 ***
Location (L) 0.02 1.05 0.04 0.03
Year (Y) 0.06 0.15 0.04 0.08
C × L 7.20 ** 4.59 ** 133.03 *** 105.31 ***
C × Y 7.34 ** 3.40 * 133.16 *** 130.60 ***
Y × L 0.03 0.64 0.04 0.06
C × L × Y 4.91 * 3.41 * 114.80 *** 109.27 ***
a expressed in mM of Trolox C equivalent antioxidant capacity (TEAC); b expressed in μM of fixed Fe2+; c expressed
in % inhibition of MDA formation relative to control cells; values are mean ± SD of 4 independent replicates.
ANOVA, F represents the effect. Significance level: * p < 0.05; ** p < 0.01; *** p < 0.001.
4. Conclusions
During the last decades, flaxseeds have emerged as one of the key sources of antioxidant
phytochemicals. Knowledge about the variation in the accumulation of these valuable constituents
is, hence, of particular interest. This study constitutes the first work devoted to the influence
of genetic, edaphic, and climatic parameters on the main compounds constituting the so-called
lignan macromolecule of flaxseeds, and the antioxidant activities of the obtained extracts. Our
results evidenced the predominant influence of genetic factors (cultivar) on the accumulation of
the constituents of the lignan macromolecule in flaxseeds. The results of gene expression suggest a
transcriptional regulation of this accumulation, knowledge of which would help to manipulate the
phenolic contents of flax. Elucidating the complete transcription regulation of lignan biosynthesis in
flax would, therefore, help to better control their accumulation. In our hands, other environmental
parameters, such as geographic and climatic variables, did not result in significant changes in the
lignan macromolecule accumulation. Both in vitro and in vivo antioxidant activity relied on SDG,
CafG, and CouG accumulations. Future works using purified compounds will be conducted to
further elucidate their respective contribution to the cellular antioxidant capacity observed with
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flaxseed extracts. Considering the health benefits of these compounds, the present study evidenced
the importance of a better knowledge of the flax cultivar type that could greatly influence the
phytochemical intakes and the associated biological activities. Therefore, we recommend that this
crucial parameter be considered in epidemiological studies dealing with flaxseeds.
Supplementary Materials: The following are available online, Table S1: Meteorological characteristics of the
cultivation site; Figure S1: Scheme describing cultivation conditions; Figure S2: Climatic data for the trial sites
Airaines (AIR), Gamaches-en-Vexin (GAM) and Chartres (CHA) for the years 2003 (03), 2004 (04), and 2005 (05).
Precipitations are expressed as cumulative monthly rainfall in mm, and temperatures are an average of daily
temperature in ◦C.
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Saso, L. In vitro analysis of iron chelating activity of flavonoids. J. Inorg. Biochem. 2011, 105, 693–701.
[CrossRef] [PubMed]
25. Bisquert, R.; Muñiz-Calvo, S.; Guillamón, J.M. Protective role of intracellular Melatonin against oxidative
stress and UV radiation in Saccharomyces cerevisiae. Front. Microbiol. 2018, 9, 1–11. [CrossRef] [PubMed]
26. Hano, C.; Addi, M.; Fliniaux, O.; Bensaddek, L.; Duverger, E.; Mesnard, F.; Lamblin, F.; Lainé, E. Molecular
characterization of cell death induced by a compatible interaction between Fusarium oxysporum f. sp. linii
and flax (Linum usitatissimum) cells. Plant Physiol. Biochem. 2008, 46, 590–600. [CrossRef] [PubMed]
27. Diederichsen, A.; Fu, Y.B. Flax Genetic Diversity as the Raw Material for Future Success. In Proceedings
of the International Conference on Flax and Other Bast Plants, Saskatoon, SK, Canada, 21–23 July 2008;
pp. 270–279.
28. Zimmermann, R.; Bauermann, U.; Morales, F. Effects of growing site and nitrogen fertilization on biomass
production and lignan content of linseed (Linum usitatissimum L.). J. Sci. Food Agric. 2006, 86, 415–419.
[CrossRef]
29. Zimmermann, R.; Bauermann, U.; Spedding, C. Effects of nitrogen fertilisation and two growing
sites on biomass production and lignan content of linseed (Linum usitatissimum L.): Second year.
Acta Agron. Hungarica 2007, 55, 173–181. [CrossRef]
30. Li, H.B.; Wong, C.C.; Cheng, K.W.; Chen, F. Antioxidant properties in vitro and total phenolic contents in
methanol extracts from medicinal plants. LWT-Food Sci. Technol. 2008, 41, 385–390. [CrossRef]
31. Struijs, K.; Vincken, J.P.; Verhoef, R.; van Oostveen-van Casteren, W.H.M.; Voragen, A.G.J.; Gruppen, H.
The flavonoid herbacetin diglucoside as a constituent of the lignan macromolecule from flaxseed hulls.
Phytochemistry 2007, 68, 1227–1235. [CrossRef] [PubMed]
306
Molecules 2018, 23, 2636
32. Struijs, K.; Vincken, J.P.; Verhoef, R.; Voragen, A.G.J.; Gruppen, H. Hydroxycinnamic acids are ester-linked
directly to glucosyl moieties within the lignan macromolecule from flaxseed hulls. Phytochemistry 2008, 69,
1250–1260. [CrossRef] [PubMed]
33. Westcott, N.D.; Muir, A.D. Variation in the concentration of the flax seed lignan concentration with variety,
location and year. In Proceedings of the 56th Flax Institute of the United States Conference, Fargo, ND, USA,
20–22 March 1996; pp. 77–80.
34. Johnsson, P.; Kamal-Eldin, A.; Lundgren, L.N.; Aman, P. HPLC method for analysis of secoisolariciresinol
diglucoside in flaxseeds. J. Agric. Food Chem. 2000, 48, 5216–5219. [CrossRef] [PubMed]
35. Eliasson, C.; Kamal-Eldin, A.; Andersson, R.; Aman, P. High-performance liquid chromatographic analysis
of secoisolariciresinol diglucoside and hydroxycinnamic acid glucosides in flaxseed by alkaline extraction.
J. Chromatogr. A 2003, 1012, 151–159. [CrossRef]
36. Ramsay, A.; Fliniaux, O.; Fang, J.; Molinie, R.; Roscher, A.; Grand, E.; Guillot, X.; Kovensky, J.; Fliniaux, M.A.;
Schneider, B.; et al. Development of an NMR metabolomics-based tool for selection of flaxseed varieties.
Metabolomics 2014, 10, 1258–1267. [CrossRef]
37. Wang, H.; Wang, J.; Qiu, C.; Ye, Y.; Guo, X.; Chen, G.; Li, T.; Wang, Y.; Fu, X.; Liu, R.H. Comparison of
phytochemical profiles and health benefits in fiber and oil flaxseeds (Linum usitatissimum L.). Food Chem.
2017, 214, 227–233. [CrossRef] [PubMed]
38. Corbin, C.; Drouet, S.; Markulin, L.; Auguin, D.; Lainé, É.; Davin, L.B.; Cort, J.R.; Lewis, N.G.; Hano, C. A
genome-wide analysis of the flax (Linum usitatissimum L.) dirigent protein family: From gene identification
and evolution to differential regulation. Plant Mol. Biol. 2018, 97, 73–101. [CrossRef] [PubMed]
39. von Heimendahl, C.B.I.; Schäfer, K.M.; Eklund, P.; Sjöholm, R.; Schmidt, T.J.; Fuss, E. Pinoresinol–lariciresinol
reductases with different stereospecificity from Linum album and Linum usitatissimum. Phytochemistry
2005, 66, 1254–1263. [CrossRef] [PubMed]
40. Renouard, S.; Tribalatc, M.; Lamblin, F.; Mongelard, G.; Fliniaux, O.; Corbin, C.; Marosevic, D.; Pilard, S.;
Demailly, H.; Gutierrez, L.; et al. RNAi-mediated pinoresinol lariciresinol reductase gene silencing in flax
(Linum usitatissimum L.) seed coat: Consequences on lignans and neolignans accumulation. J. Plant Physiol.
2014, 171, 1372–1377. [CrossRef] [PubMed]
41. Ghose, K.; Selvaraj, K.; McCallum, J.; Kirby, C.W.; Sweeney-Nixon, M.; Cloutier, S.J.; Deyholos, M.;
Datla, R.; Fofana, B. Identification and functional characterization of a flax UDP-glycosyltransferase
glucosylating secoisolariciresinol (SECO) into secoisolariciresinol monoglucoside (SMG) and diglucoside
(SDG). BMC Plant Biol. 2014, 14, 82. [CrossRef] [PubMed]
42. Fofana, B.; Ghose, K.; McCallum, J.; You, F.M.; Cloutier, S. UGT74S1 is the key player in controlling
secoisolariciresinol diglucoside (SDG) formation in flax. BMC Plant Biol. 2017, 17, 1–13. [CrossRef] [PubMed]
43. Ford, J.D.; Huang, K.; Wang, H.; Davin, L.B.; Lewis, N.G. Biosynthetic Pathway to the Cancer
Chemopreventive Secoisolariciresinol Diglucoside-Hydroxymethyl Glutaryl Ester-Linked Lignan Oligomers
in Flax (Linum usitatissimum) Seed. J. Nat. Prod. 2001, 2, 1388–1397. [CrossRef]
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Abstract: Lignans are polyphenolic compounds with a wide spectrum of biological functions including
antioxidant, anti-inflammatory, and anticarcinogenic activities, therefore, there is an increasing interest
in promoting the inclusion of lignan-rich foods in humans’ diets. Flaxseed is the richest source
of the lignan secoisolariciresinol diglucoside—a compound found in the outer fibrous-containing
layers of flax. The rumen appears to be the major site for the conversion of secoisolariciresinol
diglucoside to the enterolignans enterodiol and enterolactone, but only enterolactone has been
detected in milk of dairy cows fed flaxseed products (whole seeds, hulls, meal). However,
there is limited information regarding the ruminal microbiota species involved in the metabolism
of secoisolariciresinol diglucoside. Likewise, little is known about how dietary manipulation
such as varying the nonstructural carbohydrate profile of rations affects milk enterolactone in
dairy cows. Our review covers the gastrointestinal tract metabolism of lignans in humans and
animals and presents an in-depth assessment of research that have investigated the impacts
of flaxseed products on milk enterolactone concentration and animal health. It also addresses
the pharmacokinetics of enterolactone consumed through milk, which may have implications to
ruminants and humans’ health.
Keywords: animal health; cattle; enterolignan; human health; pharmacokinetic; ruminant;
secoisolariciresinol diglucoside
1. Introduction
Lignans are polyphenolic, phytoestrogenic compounds known to display a wide range of
biological functions, including weak estrogenic and cardioprotective activities, as well as antiestrogenic,
antioxidant, anti-inflammatory, and anticarcinogenic properties [1–3]. The weak and antiestrogenic
effects of lignans are caused by distinct transactivation activities of estrogen receptors between the
enterolignans enterodiol (ED) and enterolactone (EL) [4]. There is a growing interest in promoting
the consumption of lignan-rich foods because of the potential benefits to human health. The outer
fibrous-containing layers of flaxseed (Linum usitatissimum L.) is the richest source of the lignan
secoisolariciresinol diglucoside (SDG) [5], which accounts for over 95% of the total lignans found
in flax [6]. In ruminants, the rumen appears to be the main site for conversion of SDG into the
mammalian lignans ED and EL [7–10]. However, only EL was detected in milk of dairy cows fed
flaxseed meal (FM) [11] possibly because of ruminal dehydrogenation reactions converting ED to EL
like those occurring in humans [12]. This suggests that EL-enriched milk can be used as a source
of lignans for humans due to the following reasons: (1) milk is consumed by a large part of the
world population despite regional differences in per capita consumption [13], (2) global consumption
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of milk is projected to increase by 60% between 2005/2007 and 2050, particularly in regions where
the population traditionally consumes less milk such as East and North Africa, sub-Saharan Africa,
and South and East Asia [14], and (3) a poor and variable consumption of plant lignans worldwide [15].
Hulls, meal, and whole seeds are flaxseed products that have been used as sources of the lignan
SDG to improve the concentration of EL in milk of dairy cows [11,16–19]. It is important to note that
other ingredients (e.g., forages, cereal grains, protein supplements) used in diets of dairy cows also
provide lignans. Therefore, comparison of milk EL concentrations across experiments should consider
the contribution of lignans from non-flaxseed feedstuffs. Diets containing sources of nonstructural
carbohydrates (NSC) with different ruminal degradability (e.g., ground corn vs. liquid molasses)
also have been shown to affect the EL concentration in milk of dairy cows fed FM [18]. Despite the
growing knowledge regarding the impact of flaxseed supplementation on milk EL concentration in
the last 10 years, little is known about how dietary manipulation affects the ruminal microbiome and
EL production in dairy cows. Research in this area is needed to unravel dietary strategies suitable to
modulate the concentration of EL in dairy cows’ milk.
In addition to human health benefits, flaxseed lignans can be also used as natural antioxidants
to improve animal health via upregulation of antioxidant enzymes. Newborn dairy calves and
periparturient dairy cows are prone to oxidative stress and immune depression [20,21]. Previous
research revealed that the antioxidant activity of plant enterolignans is stronger than that of vitamin
E [22]. Furthermore, weanling albino rats receiving 10% flaxseed (1.5 g/kg of body weight) during 14 d
followed by a challenge with a toxin (i.e., carbon tetrachloride) known to downregulate the hepatic
expression of antioxidant enzymes were able to restore the activities of superoxide dismutase (SOD),
catalase (CAT), and glutathione peroxidase (GPx) by 95, 182, and 136%, respectively, compared with
the control treatment [23]. Altogether, these results are encouraging and open new opportunities
to explore the use of flaxseed products or flaxseed-derived lignans as bioactive sources to mitigate
oxidative stress in newborn, growing, and adult dairy cattle.
The primary objective of this review is to present an in-depth summary and evaluation of research
that have investigated the impacts of flaxseed hulls (FH), FM, and whole seeds flaxseed (WF) on milk
EL concentration and animal health. We also covered the metabolism of lignans in the gastrointestinal
tract of humans and animals and the pharmacokinetics of milk EL consumed by newborn dairy calves,
which may have implications to ruminants and humans’ health.
2. Metabolism of Lignans in the Gastrointestinal Tract
The flaxseed lignans SDG, secoisolariciresinol (SECO), pinoresinol, lariciresinol, and matairesinol
are converted by the gut microbiota of humans [6,24] and ruminants [7–10] to the enterolignans ED
and EL. In contrast, the lignan isolariciresinol, also derived from flaxseed, is not converted to ED
and EL [25]. Enterodiol and EL are named mammalian lignans or enterolignans because they are
produced in the gut of humans and other mammals and not found in plant tissues [26]. A simplified
pathway highlighting the conversion of plant lignans to enterolignans in humans is presented in
Figure 1. Consortia of gut microorganisms appear to be involved in the sequential catalytic reactions
reported in Figure 1, including 28 bacterial species belonging to 12 different genera such as Bacteroides,
Clostridium, Bifidobacterium, and Ruminococcus among others according to previous research [12,27–33].
After conversion of lignans into ED and EL, these enterolignans are absorbed in the large intestine
followed by conjugation as glucuronides and sulfates based on in vitro work using human colon
epithelial cells [34]. Conjugated EL and ED undergo extensive first-pass metabolism and enterohepatic
recirculation [34,35], as well as deconjugation by colonic bacterial β-glucuronidases and sulfatases
followed by reabsorption [36]. It has also been shown that conjugation of EL takes place not only in
the colon, but also in the small intestine and liver microsomes of humans and rats according to in vitro
enzymatic kinetic analysis of EL glucuronidation [35].
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Figure 1. Metabolic pathways for enterolignans production from flaxseed lignans by the gut microbiota
of humans. SDG = secoisolariciresinol diglucoside; SECO = secoisolariciresinol; ED = enterodiol;
EL = enterolactone. Adapted from [29].
An investigation of the relationship among the gut microbial community, urinary EL excretion,
and diet from a 3-d food record of 115 premenopausal American women (40–45 years old) revealed
a significant positive association between EL excretion and either the gut microbial community
or its diversity [37]. They also demonstrated that the gut microbial community associated with
high EL production was distinct and enriched in Moryella, Acetanaerobacterium, Fastidiosipila spp.,
and Streptobacillus spp. [37]. Interestingly, these 4 bacterial genera were not part of those typically
related to the sequential pathway of lignans catabolism [12,27–33]. However, despite these genera not
being previously linked to EL production, they are closely related to those involved in the metabolism of
lignans [37]. Recently, the complete metabolic pathway of pinoresinol and lariciresinol was unraveled
using comparative genomics and transcriptional profiling (RNAseq) prepared from stool samples,
thus indicating that the conversion of dietary lignans to bioactive enterolignans is a common route
adopted by the gut microbiota of humans [38]. These results are an important step for advancing
the molecular genetic understanding of the gut bioactivation of lignans and other plant secondary
compounds to downstream metabolites relevant to humans’ health [38].
In ruminants, it is conceivable that deglycosylation, demethylation, dehydroxylation,
and dehydrogenation reactions like those reported in humans (Figure 1) are also involved in the
metabolism of lignans, but little is known about which ruminal bacteria species or consortia participate
in these reactions. Lignans present in FH and WF were both converted to mammalian lignans by
ruminal and fecal microbiota of dairy cows during in vitro incubations [7]. While EL was the major
enterolignan produced by the ruminal microbiota, the fecal counterpart yielded primarily ED [7].
In a study conducted using ruminally-cannulated goats, the concentrations of SDG, ED, and EL
increased significantly in both rumen and serum following ruminal infusion of SDG (1 mg/kg of
body weight) [9]. These authors also observed that the ruminal and serum concentrations of EL were
approximately 2-fold greater than those of ED [9], indicating that EL is the predominant enterolignan
in the rumen, which agree with results from another study [7]. The role of the ruminal microbiota
and the effects of flaxseed oil (FO) in the metabolism of flaxseed-lignans and concentrations of EL in
biological fluids have been also investigated [8]. Flaxseed oil is a rich source of polyunsaturated fatty
311
Molecules 2019, 24, 41
acids (PUFA) [39], which are known to be toxic for certain species of ruminal microorganisms [40,41].
Therefore, feeding sources rich in PUFA may interfere with the ruminal metabolism of flaxseed-lignans
and ultimately affect the concentrations of EL in biological fluids. The concentrations of EL increased
by an average of 1,755% in urine, 238% in plasma, and 925% in milk of cows administered with FH in
the rumen compared with FO and FH infused in the abomasum [8]. However, no significant differences
in the concentrations of EL in urine, plasma, and milk were observed when FO was administered
in the rumen and FH infused in the abomasum [8], which confirm that rumen is the major site for
conversion of SDG to EL. In addition, the ruminal concentration of EL increased linearly and a strong
correlation (r = 0.76) between EL concentrations in ruminal fluid and milk was observed in dairy
cows fed incremental amounts of FM [0, 5, 10, and 15% of the diet dry matter (DM)] [10,42], further
reinforcing the key role of the ruminal microbiota in the metabolism of flaxseed-SDG.
It appears that in ruminants, ED and EL are absorbed in the rumen and intestines [10,43,44], possibly
as conjugated forms like other phytoestrogens including formononetin, daidzein, and equol [43].
Interestingly, sheep had a greater conjugative activity than cattle in most parts of the gastrointestinal
tract evaluated (i.e., rumen, reticulum, omasum) except in the small intestine [43]. In humans,
deconjugation performed by gut microbial β-glucuronidases and sulfatases is known to enhance
the reabsorption of ED and EL [36,45,46]. Studies conducted with lactating dairy cows showed no
relationship between flaxseed supplementation (FH or FM) and activity of microbial β-glucuronidase
in the rumen [8,10,47], thus suggesting that this enzyme has little or no involvement in the ruminal
absorption of EL, possibly because conjugation occurs during or after cell uptake of enterolignans [43].
In fact, when the ruminal activity of microbial β-glucuronidase decreased in dairy cows fed FH [48],
the concentrations of EL in rumen, plasma, urine, and milk increased compared with the control
diet. However, additional research is needed to elucidate the actual mechanisms involved in the
absorption of enterolignans in ruminant animals. Likewise, research investigating the potential effects
of intestinal β-glucuronidases on deconjugation of enterolignans before reabsorption in the large
intestine of ruminants is warranted.
Studies in which oil (FO or sunflower) was administered in the rumen or infused in the
abomasum also helped to shed light on the gastrointestinal tract metabolism of lignans in dairy
cows. Oil sources rich in n-3 PUFA such as FO are known to inhibit the growth of ruminal
microorganisms involved in fiber degradation (e.g., Butyrivibrio, Ruminococcus) and methanogenesis
(e.g., Methanobrevibacter) [40,41]. β-glucuronidase activity in humans has been attributed to colonic
bacteria belonging to the genera Ruminococcus, Bacteroides, Bifidobacterium, and Eubacterium [49],
which are also found in the rumen [50,51]. Thus, it is conceivable that FO may inhibit ruminal
bacteria with β-glucuronidase activity. In fact, FO reduced microbial β-glucuronidase activity when
it was administered in the rumen, but not during abomasal infusion in lactating dairy cows [8].
These results [8] imply that ruminal bacteria with predominant β-glucuronidase activity may be
more susceptible to the toxic effects of FO than those primarily involved in the conversion of SDG
to EL as the concentration of EL in the rumen was not affected by the site of FO supplementation
(rumen or abomasum). Compared with the control treatment, fecal β-glucuronidase activity tended to
increase in dairy cows fed FH and no change was detected with abomasal infusion of FO in another
experiment [48]. In contrast, it was found that feeding FM and infusing sunflower oil (n-6 PUFA
source) in the abomasum of lactating dairy cows decreased fecal β-glucuronidase activity relative
to the control treatment [47]. It has been shown that the ruminal microbiota can be modulated
by modifying the dietary PUFA profile and similar processes may also take place in the large
intestine of ruminants, which may explain to a certain extent these inconsistent results in fecal
β-glucuronidase activity [8,47,48]. Changes (increase or decrease) in 16S rRNA copy numbers of
ruminal microorganisms such as Butyrivibrio, ciliate protozoa, methanogens, Selenomonas ruminantium,
and Streptococcus bovis were detected during an in vitro rumen simulation technique study in which
fermenters were dosed with diets rich in n-6 PUFA (i.e., sunflower oil) or a n-6/n-3 PUFA mix (i.e.,
sunflower oil plus fish and algae oil) [52]. Overall, ruminal or fecal microbiota β-glucuronidase activity
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appears to have limited biological importance for the absorption of EL in lactating dairy cows fed
different flaxseed products or abomasally-infused with n-3 or n-6 PUFA oil sources.
As mentioned earlier, there is scarce information about the role of ruminal microbiota species in
the metabolism of plant-derived lignans. Ruminal supplementation of SDG stimulated the growth
of the bacterium Ruminococcus gnavus, which is likely involved with glucuronidase activity in the
rumen [9]. In fact, R. gnavus E1, an anaerobic bacterium belonging to the dominant human gut
microbiota, expresses the gene gnus known to encode for the β-glucuronidase enzyme [49]. In a more
recent study, the concentration of total ruminal bacteria 16S rRNA obtained using qPCR did not differ
in cows fed incremental amounts of FM [42]. However, additional PCR-DGGE and DNA extraction
analyses using bands from cows fed 15% FM showed that several genera contributed to the metabolism
of lignans, particularly Prevotella spp. [42]. Moreover, a follow-up in vitro pure culture assay revealed
that 11 ruminal bacteria species were able to metabolize SDG to SECO, with bacteria from the genus
Prevotella being the most efficient followed by Butyrivibrio fibrisolvens and Peptostreptococcus anaerobius,
whereas Ruminococcus albus, Eubacterium ruminantium, Butyrivibrio proteoclasticus, and Ruminococcus
flavefaciens showed the least conversion efficiency [42]. Their data also suggested that intermediate
compounds between the SDG to EL pathway were formed during in vitro pure culture incubations
due to the presence of unidentified peaks in the chromatograms [42]. Overall, the genus Prevotella
appears to be the most relevant in the metabolism of plant lignans to enterolignans in ruminants.
However, the current knowledge regarding ruminal microbiota diversity and function in young and
adult ruminants fed different sources of flaxseed is limited and warrants further research.
3. Effects of Flaxseed Products on Milk EL Concentration
Table 1 summarizes results from 15 studies in which milk EL concentration was measured in
dairy cows fed different flaxseed products (i.e., FH, FM, WF) and NSC sources. The nutritional profile
of flaxseed products used in studies summarized in Table 1 are presented in Table 2.
3.1. Dose-Response Studies and Milk EL Concentration
Four dose-response studies using FH (1 experiment) [17], FM (2 experiments) [10,11], and WF
(1 experiment) [53] have been conducted to date (Table 1). In three out of four experiments, the milk
concentration of EL increased linearly in response to incremental amounts (diet DM basis) of FH (0, 5,
10, and 20%) or FM (0, 5, 10, and 15%). Compared with the control diet, feeding 20% FH increased
the concentration of milk EL by approximately 250% [17]. The milk concentrations of EL increased
by approximately 110% [11] and 330% [10] relative to control treatments when cows were fed the
greatest amount of FM (i.e., 15%). In contrast, only a positive linear trend in milk EL concentration was
observed in response to increasing amounts of WF (0, 5, 10, and 15%) [53]. Flaxseed hulls (mean = 1%
SDG) and FM (mean = 1.6% SDG) contain greater concentrations of SDG than WF (mean = 0.6% SDG;
see Table 2), thus consistent with a more pronounced response in milk EL concentration with feeding
FH or FM versus WF. No curvilinear responses were detected in these four dose-response studies,
indicating that a theoretical maximum concentration of milk EL was not achieved in diets containing
up to 15% FM, 15% WF, or 20% FH. These results also suggest that ruminal and intestinal absorptive
mechanisms were not saturated by increased concentrations of EL. However, there are limitations
regarding the amount of flaxseed products that can be included in dairy diets due to environmental
and milk production concerns associated with excess intake of crude protein or crude fat depending on
the flax source used. As shown in Table 2, FM is a protein supplement (mean = 37.2% crude protein),
while FH can be used as both lipid (mean = 28.4% crude fat) and protein sources (mean = 22.4% crude
protein); likewise, WF contains high concentration of lipids (mean = 34.9% crude fat) and moderate
crude protein content (mean = 23.5%).
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Table 2. Nutritional profile (% of dry matter) of flaxseed products used in studies listed in Table 1 1.
Item
Flax Products
Flaxseed Hulls 2 (n = 5) Flaxseed Meal 3 (n = 6) Whole Flaxseed 4 (n = 1)
Crude protein 22.4 ± 2.41 37.2 ± 1.35 23.5
Neutral detergent fiber 20.6 ± 2.64 30.6 ± 4.61 20.7
Acid detergent fiber 15.8 ± 3.44 15.9 ± 1.39 13.7
Crude fat 28.4 ± 3.09 3.70 ± 4.11 34.9
SDG 1.00 ± 0.08 1.60 ± 0.21 0.60
1 Values are presented as mean ± standard deviation, unless otherwise noted. 2 Values were calculated using data
reported by [8,17,48,55,56]; 4 studies including [8,48,55,56] reported the same nutritional composition for flaxseed
hulls except for a different secoisolariciresinol diglucoside (SDG) concentration value reported by [55]; no SDG
concentration for flaxseed hulls was reported by [17]. 3 Values were calculated using data from [11,18,19,47,57,58];
SDG concentrations were not reported by [47] and [57]. 4 Values were calculated using data from [53].
High intake of crude protein can lead to excess N excretion to the environment and poor N use
efficiency in lactating dairy cows [59,60]. Excess consumption of fat (>5% of the diet DM) has been
associated with depressed DM intake, milk production, and ruminal fiber digestibility [59].
3.2. Comparison of Flaxseed Products and Animal Variation in Milk EL Concentration
We are aware of only one publication that compared, in the same experiment, the effect of flaxseed
products on milk EL concentration in dairy cows (i.e., [16]; see Table 1). In this study [16], 24 lactating
dairy cows were used in a randomized complete block design in which animals were assigned to a
control diet without flaxseed supplementation or 10% of the diet DM as FM or WF. It was observed
that relative to the control treatment, the milk concentration of EL increased by an average of 178%
in cows fed FM or WF. However, no differences in the concentration of milk EL was found between
FM and WF. Even though milk EL yield (mg/d) did not differ with feeding FM versus WF, only cows
supplemented with FM had a significant increase in milk EL output (+216%) compared with the control
animals. For the remaining studies summarized in Table 1, including the dose-response experiments
(discussed above) and the feeding trials that evaluated different NSC sources and FM supplementation
(discussed next section), milk EL concentration improved in all except one study (i.e., [47]). In their
experiment [47], 8 ruminally-cannulated dairy cows were used in a replicated 4 × 4 Latin square
design with a 2 × 2 factorial arrangement of treatments. The concentrations of milk EL averaged 75
and 122 nM in cows fed diets without and with FM supplementation, respectively. Despite an average
increase of 63% in milk EL concentration comparing FM- versus non-FM diets [47], this difference
did not reach statistical significance possibly because of the low number of animals used and the
large cow-to-cow variability in milk EL content. For instance, the 95% confidence interval for milk
EL concentration ranged from 32 to 161 nM (control), 35 to 175 nM (250 g/d abomasal infusion of
sunflower oil), 46 to 221 mM (13.7% FM), and 63 to 312 nM (13.7% FM plus 250 g/d abomasal infusion
of sunflower oil) [47].
A large interindividual variation in the concentration of the phytoestrogen equol in milk of
dairy cows has been reported, with values ranging from 400 to 2,600 μg/kg across treatments in two
experiments [61]. Similarly, we [19] observed a large interindividual variation in milk EL yield in
dairy cows fed varying levels of NSC sources and 15% FM (see Figure 2), which is consistent with
previous research [61]. This large cow-to-cow variability cannot be entirely explained by differences
in dietary composition or phytoestrogens intake so that other factors such as ruminal microbiota
profile, digesta passage rate, and dairy cattle genetics may be also involved [61]; however, the actual
biological mechanisms underpinning this wide interindividual variability are not well understood.
Previous researchers reported that EL is a transported substrate and likely a competitive inhibitor of the
ATP-binding cassette subfamily G2 (ABCG2) protein [62], which is known to transport phytoestrogens
and their conjugated metabolites [63–65]. It was further demonstrated that the milk-to-plasma ratio
of EL decreased significantly in the Abcg2(−/−) knockout female mice phenotype compared with the
315
Molecules 2019, 24, 41
wild-type group (0.4 vs. 6.4) [62]. A subsequent study showed that EL was used as substrate to the
bovine ABCG2 variant Y in vitro and was also actively secreted in milk resulting in a 2-fold increase
in its milk-to-plasma ratio in Y/S heterozygous versus Y/Y homozygous cows [66]. The bovine
ABCG2 Y581S variant has been described as a gain-of-function polymorphism that increases milk
secretion and decreases plasma levels of its substrates [67–69]. Taken together, the ABCG2 protein
and its variant Y581S appear to contribute to the interindividual variation of EL secretion in milk of
dairy cows opening the possibility for controlling, through genetic selection or other management
tools, the amount of enterolignans consumed by the population [61]. Improved knowledge of lignans
metabolism in ruminants is needed because high intake of phytoestrogens may result in adverse
health effects, particularly in critical stages of infant development [70,71] and during lactation and
pregnancy [72]. Therefore, timing of exposure to phytoestrogens is key for capitalizing on health
benefits while minimizing undesirable health outcomes [73]. In a recent literature review, the authors
stated that current evidences regarding the potential health benefits of phytoestrogens are not so
convincing that clearly outweigh the possible health risks (e.g., decreased fertility, increased risk of
cancer in estrogen-sensitive tissues) [74]. They concluded that data currently available are not sufficient
to support a more refined (semi) quantitative risk–benefit analysis, implying that a definite conclusion
on potential health benefit outcomes of phytoestrogens cannot be made [74].
Figure 2. Interindividual variation in milk enterolactone yield in dairy cows fed (% of diet dry matter)
diets in which ground corn was replaced by incremental amounts of liquid molasses (LM) (see [18] for
study details).
3.3. Impact of NSC Sources and FM on Milk EL Concentration
To the best of our knowledge, only three studies have investigated the impact of different NSC
sources on milk EL concentration in dairy cows fed FM (see Table 1). It is well established that in
relation to starch, sugars are more rapidly fermented in the rumen [75], implying that NSC sources
with different degradability in the rumen may change ruminal fermentation processes, digesta passage
rate, and microbiota growth and species composition. Compared with ground corn, liquid or dried
molasses has greater concentration of sucrose [18,76]. The effects of supplemental NSC (ground
corn vs. liquid molasses) and rumen-degradable protein (soybean meal-sunflower meal mix vs.
FM) on milk EL concentration have been evaluated in dairy cows fed grass hay-based diets [18].
No significant rumen-degradable protein by NSC source interaction was observed for milk EL
concentration. However, significant rumen-degradable protein and NSC source effects were detected;
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cows fed diets containing (DM basis) 16% FM and 12% liquid molasses had 288 and 53% more EL
in milk than those fed rations consisting of 16% soybean meal-sunflower meal mix and 12% ground
corn, respectively. Therefore, liquid molasses may select for ruminal microorganisms with better
capacity to convert FM-SDG to EL than ground corn [18]. A follow-up study evaluated the effects of
replacing ground corn with incremental amounts of liquid molasses (0, 4, 8, and 12% of the diet DM)
on milk EL concentration in dairy cows fed 15% FM [19]. It was hypothesized that the concentration
of EL in milk would be modulated by possible changes in DM intake (also affecting SDG intake)
when varying the dietary proportions of liquid molasses and ground corn. Only a cubic trend was
observed for milk EL concentration despite the linear decrease in SDG intake with replacing ground
corn by liquid molasses [19]. Although this cubic trend is difficult to explain biologically, the lack of a
precursor-product relationship suggests that the ruminal output of EL seems to be more affected by the
microbiota metabolism of SDG than by SDG supply. Milk EL yield did not differ and averaged 1.38,
1.61, 1.36, and 1.52 mg/d in diets containing 0, 4, 8, or 12% liquid molasses, respectively [19]. Prevotella
spp. have been reported to be one of the main converters of SDG to SECO, a lignan-derived metabolite
that is further metabolized to ED and EL, presumably by additional ruminal microbiota species [42].
Prevotella species are also capable of utilizing starch, other non-cellulosic polysaccharides, and simple
sugars as energy sources, yielding succinate as the major end-product of ruminal fermentation [77].
Therefore, it was not entirely surprising to obtain a curvilinear response for milk EL concentration with
feeding various dietary levels of liquid molasses [19] because Prevotella spp. can utilize both starch
and sugars [77].
Our laboratory conducted a third study evaluating the effect of sucrose and FO on milk EL
concentration of dairy cows fed 15% FM [58]. Specifically, 16 lactating dairy cows were used in a
replicated 4 × 4 Latin square design with the following arrangement of treatments (% of diet DM):
(1) 8% soybean meal (control); (2) 5% sucrose + 15% FM; (3) 3% FO + 15% FM; and (4) 5% sucrose + 3%
FO + 15% FM. As discussed above, Prevotella spp. have been shown to be involved in the metabolism of
SDG [42] and NSC [77]. In addition, the genus Prevotella dominated the ruminal bacterial community
when steers were fed diets containing 4% FO, suggesting that Prevotella species are possibly involved
in the metabolism of PUFA [78]. We hypothesized [58] that sucrose and FO could synergistically
interact to increase the concentration of EL in milk as sugars [77] and FO [78] have been shown to
promote growth of Prevotella spp. Compared with the control diet (mean = 76.8 nM of milk EL),
the average concentration of EL in milk increased 4-fold in cows fed 15% FM (mean = 321 nM).
However, no differences in milk EL concentration was observed among the treatments containing FM
supplemented with sucrose or FO or both [58]. Overall, our data [18,19,58] indicate that the use of
NSC sources with different ruminal degradability did not consistently improve milk EL concentration.
Differences in DM intake, milk production, type of forage, and forage-to-concentrate ratio may have
contributed to the inconsistent results in milk EL content across our studies.
3.4. Dairy Breed and Milk EL Concentration
Holstein cows were used in all studies presented in Table 1 except in two experiments where
Jerseys were selected [18,19]. A large interindividual variation for the milk concentration of equol has
been reported, but this variability was more pronounced in Swedish Red than Norwegian Red dairy
cows [61]. These results suggest that dairy cattle genetics may influence the output of phytoestrogens
in milk. It is well known that Jersey cows produce milk with greater concentrations of fat and protein
than Holsteins (e.g., [79]). However, we are not aware of any publication that has simultaneously
compared Holstein versus Jersey cows in terms of milk EL concentration and yield. Therefore,
data from [10,11,19,58] were used to make inferences regarding the concentration of milk EL between
breeds. In these four studies cows received 15% FM in at least one dietary treatment (see Table 1 for
details). The concentration of milk EL averaged 259 nM in Jerseys [19], and 78 nM [11], 650 nM [10],
and 321 nM [58] in Holsteins. Compared with one study using Holsteins [11], the concentration and
yield of milk EL in Jerseys increased by 3.3- and 2.8-fold, respectively [19]. Contrarily, the concentration
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and yield of milk EL were greater in two other studies with Holsteins [10,58] than Jerseys [19],
suggesting that no conclusive relationship between dairy breed and milk EL could be established.
It is important to note that this exercise is a gross evaluation of the potential effect of dairy breed on
milk EL concentration so that any association between breed and milk EL should be done cautiously.
Nevertheless, the mean concentration of milk EL ranged from 78 to 650 nM implying that genetics,
dietary composition, and even analytical methods may be involved in this variation in milk EL
across experiments [10,11,19,58]. For instance, a chromatographic method (i.e., HPLC) was used in one
(i.e., [11]) of the four studies resulting in the lowest milk EL content (i.e., 78 nM). The concentration of EL
in the remaining three studies [10,19,58] were analyzed colorimetrically using a commercial competitive
enzymatic immunoassay, which led to an average milk EL concentration 425% greater than that
obtained with HPLC [11]. Moreover, the ingredient composition of the basal diet, forage-to-concentrate
ratio, and forage source may have changed the ruminal environment among these four studies
ultimately impacting the concentration of EL in milk. Plant lignans such as matairesinol, pinoresinol,
and lariciresinol are also converted to enterolignans [6,24,80], with pinoresinol and lariciresinol present
in greater concentrations than SDG and matairesinol in several plant species [81]. Thus, it is conceivable
that dietary ingredients other than flaxseed may also supply lignans to the ruminal microbiota,
which can contribute to variation in milk EL concentration reported in the literature.
4. Pharmacokinetics of Milk EL and Potential Implications on Animal and Human Health
Elevated blood concentrations of ED and EL have been associated with reduced risk of coronary
diseases and colorectal adenoma in humans [82–84]. A dose-response relationship between flaxseed
intake and serum concentrations of ED or EL was observed in a study conducted with healthy young
women [85]. Moreover, a 5-fold increase in the urinary excretion of EL was found in rats fed pure
EL compared with those fed plant lignans [86]. These authors [86] hypothesized that EL may be
passively absorbed along the intestinal tract, while plant lignans must be first converted to EL by
colonic microorganisms followed by absorption in a limited segment of the gut. A large interindividual
variation in the blood concentration of enterolignans has been observed in humans, thus revealing
differences in the capacity of the colonic microbiota in converting plant lignans to ED and EL [46,85,87].
Therefore, EL-enriched milk has potential to be used as an enterolignan source for improving human
health, particularly because EL appears to be more bioavailable than plant lignans [86]. Periparturient
dairy cows, as well as newborn and nursing dairy calves could also benefit from the antioxidant
properties of EL due to their susceptibility to oxidative stress and depressed immune system [20,21].
However, there is limited information regarding the pharmacokinetics of EL derived from milk and
we are not aware of any published research that have instigated the effects on EL-enriched milk on
human or animal health.
Recently, we investigated the pharmacokinetics of EL in newborn dairy calves fed milk replacer
or EL-enriched milk [58]. In newborn calves, suckling stimulates the reflex closure of the esophageal
groove so that ingested milk or milk replacer bypass the reticulo-rumen down to the abomasum [50].
Thus, calves may be used as a translational model to make inferences about the pharmacokinetics of
EL in simple-stomach mammals including humans. We hypothesized that the area under the curve
and plasma concentration of EL would be greater in Holstein calves fed a single bolus of EL-enriched
milk versus milk replacer [58]. The EL-enriched milk was collected from a Jersey cow fed 15% FM.
On d 5 of life, 20 calves (10 males and 10 females) were administered 2 L of milk replacer (low-EL
treatment: 123 nM of EL) or 2 L of EL-enriched milk (high-EL treatment: 481 nM of EL) during the
morning feeding. The area under the curve for the plasma concentration of EL, which was determined
using the trapezoidal rule between 0 and 12 h after treatment administration was greater in high-
(26 nM × h) than low-EL calves (4.30 nM × h). Similarly, the maximum concentration of EL in plasma
was greater in high- (5.06 nM) versus low-EL calves (1.95 nM). Furthermore, the time after treatment
administration to reach maximum plasma concentration of EL was faster in the high- (4.31 h) compared
with the low-EL (4.44 h) treatment. Our results showed that newborn calves were able to absorb
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EL, suggesting that EL-enriched milk can potentially be used as a natural source of antioxidants to
pre-weaned ruminants. We also calculated the apparent efficiency of EL absorption between 0 and
12 h after the oral administration of treatments; calves fed EL-enriched milk tended to have lower
apparent efficiency of EL absorption than those fed milk replacer (1.31 vs. 1.80%, respectively). In a
study in which 12 healthy volunteers (6 men and 6 women) ingested a single dose of purified SDG
(1.31 μmol/kg of body weight), ED and EL reached their maximum plasma concentrations at 14.8
and 19.7 h after intake of SDG, respectively [87]. In addition, the area under the curve of EL (mean =
1762 nM × h) increased by 2-fold compared with that of ED (mean = 966 nM × h), indicating a greater
systemic exposure to EL than ED [87]. Although our study shed some light in the metabolism of milk
EL in vivo [58], future research using humans or animal models that better represent the anatomy
and physiology of humans’ gastrointestinal tract is warranted to provide further insights about the
pharmacokinetics of EL consumed through milk.
An association between serum EL concentration ≥ 10 nM and decreased mortality risk (i.e.,
all-causes and breast cancer-specific) after breast cancer surgery has been reported in women [88].
Milk concentration of EL averaged 395 nM in two studies in which Jersey cows received 15–16%
FM [18,19]. Thus, 1 daily serving (250 mL) of EL-enriched milk with a concentration of 395 nM of
EL would result in 1.3 nM of EL in plasma assuming an apparent efficiency of absorption of 1.31%
based on our previous work [58]. These results imply that EL-enriched milk needs to be consumed in
combination with other lignan-rich foods to reach EL concentration in blood that has been linked to
decreased mortality and positive health outcomes in humans [88]. However, our inferences should be
interpreted cautiously because calves were fed milk as the sole dietary source [58], which may have
increased digesta passage rate ultimately limiting the intestinal absorption of EL.
5. Antioxidant Activity of Flaxseed Products and Dairy Cow Health
Periparturient dairy cows mobilize triacylglycerols from the adipose tissue to support elevated
energy demand during early lactation [59,89]. As lactation advances, dairy cows also experience
extensive metabolic adaptations for maintenance and high milk production [90]. This increased
metabolic activity requires more oxygen consumption, which stimulates production of reactive oxygen
species (ROS) [91]. When ROS generation exceeds the endogenous antioxidant defense capacity,
animals are susceptible to oxidative damage to DNA, lipids, protein, and other cellular components [92].
Oxidative stress may also impair the immune system of dairy cows [91,93] so that they are likely more
vulnerable to a variety of metabolic disorders, including udder edema, milk fever, retained placenta,
mastitis, and reproductive issues [90,91]. It has been shown that newborn calves had greater blood
concentration of free radicals than pregnant cows, suggesting that they undergo a more severe oxidative
stress [20]. Therefore, mitigation of oxidative stress has great potential to improve dairy cattle health
and profitability of dairy enterprises. In recent years, several studies were conducted to investigate
the effects of flaxseed products on the activity of antioxidant enzymes in plasma and erythrocytes,
and their gene expression in mammary and hepatic tissues and results are discussed below.
Superoxide dismutase, CAT, and GPX are antioxidant enzymes commonly involved in combating
free radicals in animals’ blood and tissues. Superoxide dismutase catalyzes the reaction of highly
reactive superoxides to form less reactive peroxides [94]. Peroxides can then be converted to water
and oxygen under the catalyzation of CAT [95]. Glutathione peroxidase is an enzyme that facilitates
reduction reactions of hydroperoxides such as organic hydroperoxides and peroxides [94]. According
to previous work [96], CAT mainly works against free radicals when animals experience severe
oxidative stress, whereas GPX protects those with less oxidative stress pressure.
The activity of antioxidant enzymes in lactating dairy cows fed different flaxseed products
are summarized in Table 3. Overall, the activities of SOD, CAT, and GPx in plasma, erythrocytes,
and mammary and hepatic tissues were not affected by supplementation of FH, FM, WF, and whole
linola (see Table 3). Linola is a cultivar of flaxseed containing approximately 70% linoleic acid [97].
A potential explanation for the inability of flaxseed products to modify the activity of antioxidant
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enzymes in most studies listed in Table 3 may be due to the use of mid-lactation dairy cows experiencing
low oxidative stress. Contrarily, a study [98] reported that inclusion of 12.4% FM lowered plasma
CAT activity and tended to elevate that of erythrocytes. Likewise, a tendency for increased activity
of SOD in mammary tissues was observed with feeding 9.88% FH [56]. It is also important to note
that significant treatment by sampling time interactions were found for plasma CAT and GPx activity
with FM supplementation [99]. Plasma CAT and GPx activity responded quadratically and cubically
to increasing amounts of FM (0, 5, 10, 15%) when blood samples were collected before feeding, but no
treatments effect was observed with sampling 3 h post-feeding [99]. These interactions were probably
caused by a longer-lasting supply of antioxidants from the diet with the greatest intake of SDG (i.e.,
15% FM) compared with the lower levels [99].
The effect of flaxseed products on mRNA abundance of antioxidant enzymes genes in the
mammary gland of lactating dairy cows are summarized in Table 4. Feeding 9.88% FH [56] and
incremental amounts of FM (0, 5, 10, and 15%) [99] increased mRNA abundance of CAT gene,
whereas no changes were observed with inclusion of 13.7% FM [100]. Additionally, GPx1 and GPx3,
two isoforms of GPx, were not impacted with feeding varying amounts of FM [98–100]. However,
GPx1 and GPx3 were up- and downregulated, respectively, in dairy cows fed 9.88% FH compared
with those fed the control diet [56]. These contradictory effects on GPx1 and GPx3 mRNA abundance
with feeding 9.88% FH may be associated with different functions of GPx genes [101]. In addition
to CAT and GPx, the mRNA abundance of three isoforms of SOD genes including SOD1, SOD2,
and SOD3 were quantified. Both De Marchi et al. [100] and Schogor et al. [99] showed that the mRNA
abundance of SOD genes was not modified by FM supplementation to lactating dairy cows. In contrast,
an increase in the mRNA abundance of SOD1 and decreases in that of SOD2 and SOD3 were detected
in dairy cows fed 9.88% FH [56]. The promoter region of SOD1 contains an antioxidant response
element not found in SOD2 and SOD3, thereby consistent with the variable responses of SOD genes
to FH supplementation [102]. Collectively, the effects of flaxseed products on modifying antioxidant
enzymes or their expression in mammary or hepatic tissues were limited.
The nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) relative mRNA abundance in mammary
tissues increased linearly in cows fed incremental amounts of FM [99] (see Table 4). The NFE2L2
gene encodes for a transcription factor involved in activating the expression of a series of genes that
are transcribed and translated into antioxidant proteins [103,104]. It is noteworthy that increased
NFE2L2 [99] did not coincide with changes in mRNA abundance of most antioxidant enzymes as
discussed above. A trend was observed for decreased relative mRNA abundance of the nuclear
factor kappa-light-chain-enhancer of activated B cells subunit 1 (NF-κB1) gene with feeding 13.7%
FM to lactating dairy cows [100]; however, two other studies [98,99] did not detect changes in mRNA
abundances of NF-κB and NF-κB1, respectively, when similar amounts of FM were fed. The NF-κB1
gene is one of the five members of the NF-κB family, which regulates numerous genes involved in
inflammatory and immune responses, apoptosis, and tumor progression [105–107]. The polyphenolic
compound quercetin protected interstitial Leydig cells against atrazine-induced toxicity by decreasing
the expression of NF-κB and preventing oxidative stress [107]. As shown in Table 2, FM is the richest
source of the lignan SDG, a polyphenolic compound like quercetin, thus in line with the reduced
expression of NF-κB1 gene [100]. These results suggest that FM supplementation has potential to
decrease inflammation and cell death in mammary tissues [100]. Interestingly, decreased NF-κB1
was not associated with changes in the relative mRNA abundance of antioxidant enzymes [100],
possibly because FM supplementation did not affect the nuclear factor erythroid 2–related factor 2
(NRF2) mRNA abundance, which agrees with previous work [98]. As known, NRF2 is a transcription
factor that activates the expression of multiple genes holding an antioxidant response element in their
promoters for codifying antioxidant proteins and phase 2 detoxifying enzymes [105]. Future research
is needed to better understand how the relationship between flaxseed supplementation and expression
of antioxidant enzyme genes may interact to modulate inflammatory, immunological, and health
responses in dairy cows experiencing oxidative stress.
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Table 4. Relative mRNA abundance of oxidative stress-related genes in mammary tissues of lactating
dairy cows fed flaxseed products 1.
Items 3
Treatments 2 and References
Non-FH vs. 9.88%
FH diets [56]






CAT ↑ linear increase† NS −
GPX1 ↑ NS NS NS
GPX3 ↓ NS NS −
SOD1 ↑ NS NS −
SOD2 ↓ NS NS −
SOD3 ↓ NS NS −
NFE2L2 − linear increase − −
NF-κB − NS − −
NF-κB1 − − ↓, † NS
NRF2 − − NS NS
1 Significant differences in the cited references were declared at p ≤ 0.05 and trends at 0.05 < p ≤ 0.10; NS = not
significant (p > 0.10). 2 FH = flaxseed hulls; FM = flaxseed meal. 3 CAT = catalase; GPX = glutathione peroxidase;
SOD = superoxide dismutase; NFE2L2 = nuclear factor (erythroid-derived 2)-like 2; NF-κB1 = nuclear factor
Kappa-B1; NRF2 = nuclear factor (erythroid-derived 2)-like 2; ↑ = positive effect; ↓ = negative effect; † = tendency
for significance; − = no measurement.
Thiobarbituric acid-reactive substances (TBARS) are markers of oxidative status and mainly
used to estimate oxidative damage to lipids or lipoperoxidation [109]. Lipoperoxidation can cause
damages to cell membranes and membrane-bound enzymes [110]. The impact of flaxseed products
supplementation on TBARS concentration in milk, plasma, and ruminal fluid are summarized in Table 5.
Quadratic and cubic responses for milk TBARS production were observed in cows fed incremental
amounts of FM, with 5% FM and 10% FM resulting in the lowest values [99]. They [99] also reported a
significant treatment × sampling time interaction for ruminal TBARS concentration; a linear decrease
in TBARS was found with increasing FM supplementation at 2 h after feeding, but no changes were
detected at 0 (pre-feeding), 4, and 6 h post-feeding. It was hypothesized that the defense of FM-lignans
against oxidation in the rumen is a time-dependent process, with protection being more effective
within the first hours after feeding and weakening over time [99]. However, another study [111]
reported no changes in ruminal TBARS concentration at 0 (pre-feeding) and 2 h post-feeding but
decreased thereafter (4 and 6 h) with feeding 12.4% FM. A third experiment [112] showed a significant
decrease in ruminal TBARS concentration in dairy cows fed 13.7% FM despite no treatment × sampling
time interaction effect. None of the studies listed in Table 5 (i.e., [99,111,112]) reported effects of FM
on plasma TBARS concentration. Similarly, no effects of FM supplementation were observed for
the plasma peroxidizability index and total antioxidant capacity [111,112]. As pointed out earlier,
research using dairy cattle during stages of life (e.g., transition period, neonatal phase, weaning) more
conducive of oxidative stress is needed to better assess the role of flaxseed lignans on animal oxidative
status and overall health.
Table 5. Indicators of oxidative stress in lactating dairy cows fed flaxseed products 1.
Items 3
Treatments 2 and References






Milk TBARS Q,C 4 NS NS
Plasma TBARS NS NS NS
Ruminal TBARS NS 5 NS 6 ↑ 7
Plasma peroxidizability index − NS NS
Plasma total antioxidant capacity − NS NS
1 Significant differences in the cited references were declared at p ≤ 0.05 and trends at 0.05 < p ≤ 0.10; NS =
not significant (p > 0.10). 2 FM = flaxseed meal. 3 TBARS = thiobarbituric acid-reactive substances (nmol of
malondialdehyde equivalent/mL); plasma peroxidizability index = (% dienoic fatty acid × 1) + (% trienoic fatty acid
× 2) + (% tetraenoic fatty acid × 3) + (% pentaenoic fatty acid × 4) + (% hexaenoic fatty acid × 5) [113]; plasma total
antioxidant capacity expressed in mM. 4 Quadratic and cubic effects were observed. 5 no overall treatment effect,
but a significant treatment by sampling time interaction was reported [linear decrease at 2 h post-feeding; no changes
at 0 (pre-feeding), 4, and 6 h post-feeding]. 6 no overall treatment effect, but a significant treatment by sampling
time interaction was reported [no effects at 0 (pre-feeding) and 2 h post-feeding but decreased with FM at 4 and 6 h
post-feeding]. 7↑ = positive effect.
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6. Conclusions
Our review showed that flaxseed products, particularly FM and FH were effective in enhancing
the concentration of EL in milk. The metabolism of SDG to EL by the ruminal microbiota possibly
involves deglycosylation, demethylation, dehydroxylation, and dehydrogenation reactions. In vitro
work showed that ruminal bacteria from the genus Prevotella were the most efficient converters of SDG
to SECO. The large interindividual variation in milk EL yield suggests that the ruminal microbiota vary
in their effectiveness for metabolizing SDG to EL. This opens the possibility for controlling, through
genetic selection or other management tools, the amount of EL consumed by the population. Scientific
information related to the pharmacokinetics of EL consumed via milk is limited. Recent research
showed that EL is absorbed by newborn dairy calves, indicating that EL-enriched milk has potential to
be used as a natural source of antioxidants for pre-weaned ruminants.
We specifically call for future research to assess how the relationship between flaxseed
supplementation and expression of antioxidant enzyme genes may interact to modulate inflammatory,
immunological, and health responses in dairy cattle experiencing oxidative stress. Microbiome
work is also needed to elucidate the profile and function of the ruminal microbiota species and
genomes involved in the metabolism of lignans in ruminants. The impact of forage types (e.g.,
low- vs. high-lignan legumes), forage conservation methods, and different sources of NSC and fibrous
by-products (e.g., soyhulls, beet pulp, citrus pulp) on ruminal microbiome and milk EL concentration in
cows fed FM deserves specific attention. These complex research questions should be tackled through
collaborative efforts of laboratories with complementary expertise so that an in-depth understanding
of the opportunities and challenges of lignans research in dairy cattle can be successfully implemented.
To do so, the scientific community, dairy processors, and the population need to be informed and
engaged concerning the implications of phytoestrogens to animals and humans’ health.
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Abstract: The study aims to communicate the current status regarding the development and
management of the databases on dietary lignans; within the phytochemicals, the class of the lignan
compounds is of increasing interest because of their potential beneficial properties, i.e., anticancerogenic,
antioxidant, estrogenic, and antiestrogenic activities. Furthermore, an introductory overview of the
main characteristics of the lignans is described here. In addition to the importance of the general
databases, the role and function of a food composition database is explained. The occurrence of lignans
in food groups is described; the initial construction of the first lignan databases and their inclusion in
harmonized databases at national and/or European level is presented. In this context, some examples
of utilization of specific databases to evaluate the intake of lignans are reported and described.
Keywords: dietary lignans; national databases; food groups; dietary intake; harmonized databases
1. Introduction
Within phytochemicals, phenolic compounds called lignans have attracted the interest of food
chemists and nutrition researchers over the years. Lignans are vascular plant secondary metabolites,
with widespread occurrence in the plant kingdom, and which are ascribed a wide range of physiological
functions, positively affecting human health [1]. They are a class of secondary plant metabolites that
belong to the group of diphenolic compounds derived from the combination of two phenylpropanoid
C6–C3 units at the β and β’ carbon, and can be linked to additional ether, lactone, or carbon bonds;
they have a chemical structure like the 1,4-diarylbutan [2]. The range of their structures and biological
activities is broad. They are derived from the shikimic acid biosynthetic pathway [3]. The range relative
to structurally different forms of lignans and biological activities is broad [4,5]. The main commonly
studied and reported compounds are secoisolariciresinol, lariciresinol, matairesinol, pinoresinol,
medioresinol, and syringaresinol (shown in Figure 1), while, recently, the isolation and structure
elucidation of new lignan compounds have been carried out [6–8] and the spectrum of their attributing
properties has been widened [9–11].
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Figure 1. The chemical structure of main dietary lignans, (a) secoisolariciresinol, (b) matairesinol,
(c) lariciresinol, (d) pinoresinol, (e) medioresinol, and (f) syringaresinol.
Plant lignans give rise to metabolites, enterodiol, and enterolactone [12], generally called
enterolignans due to their colonic origin (named also mammalian lignans) (shown in Figure 2).
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Figure 2. The chemical structure of enterolignans, (a) enterodiol and (b) enterolactone.
Enterolignans, and some of their plant precursors, are reported to have several biological
activities—antitumorigenic [13], anticarcinogenic [14], estrogenic or anti-estrogenic [15,16], as well as
antioxidant properties [17].
Lignans, in line with other natural compounds, contribute in disease prevention and health
promotion [18,19]; several studies have showed the potential of lignan-rich diets against the
development of various diseases, particularly hormone-dependent cancer, cardiovascular diseases,
and diabetes [20–27].
Lignans are the basis for novel perspectives for health promotion and disease prevention as
nutraceuticals and functional foods [28–32]. Currently, Pilkington, [33], by using a chemometric
approach, have analyzed the physicochemical properties of classical lignans, neolignans, flavonolignans,
and carbohydrate–lignan conjugates to assess their absorption, distribution, metabolism, excretion
and toxic (ADMET) profiles, and establish if these compounds are lead-like/drug-like and, thus,
have potential to be, or act as, a driver in the development of future therapeutics; the results showed
how carbohydrate–lignan conjugates and flavonolignans are less drug-like, while lignans showed a
particularly high level of drug-likeness [33].
Nowadays, lignan species and their quantity in food products are determined. Different
methodologies have been defined for the extraction and identification of lignans [34–40]. The extraction
procedure from the food matrix represents a key issue and, in particular, the type of hydrolysis step
(alkaline, acid hydrolysis, enzymatic hydrolysis, or a mixture of them). The expanding demand
for lignans are stimulating the interest in identification of new sources and in improvement of
analytical and purification procedures. Analytical values using HPLC, as well as either gas or liquid
chromatography–mass spectrometry, were developed and carried out [41,42]. The development
and the assessment of methodologies for the extraction, identification, and determination of lignans
are achieved [17,43,44]. Also, the “new” emerging lignans, due to LC combined with HR-MS/MS,
have been, and will continue, broadening the view regarding dietary lignans [45]; simultaneously,
the synthesis [46,47] and the design [48] of new compounds are being carried out.
The complex relationship between food, nutrition, and health [49] is explored via nutrients
and bioactive compounds, i.e., beneficial food components [50], and via non-beneficial food
components [51]. In this direction, a directory of information about bioactive component databases,
specialized, at a national and European level, is being developed, and will be useful for the planning
and evaluation of clinical and epidemiological research studies on bioactive components. Databases
of lignans in food products are being creating in several countries (Finland, Netherlands, United
States, Canada, United Kingdom, Japan, and Spain), and represent the first step for establishing
comprehensive and harmonized dietary databases, including all or nearly all bioactive compounds [1].
Reliable methods of exposure measurement are essential for understanding the potential benefits of
lignans [52].
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2. Databases: Significance, Principles and Common Criteria/Measures
Databases, also called electronic databases, represent a system to generate and collect any data,
information, and documentation specially organized for rapid search and retrieval by a computer [53].
Databases are tools constructed to facilitate the storage, retrieval, modification, and deletion of data in
conjunction with various data-processing operations [54].
A comprehensive food composition database (FCDB) should be a repository of all numeric,
descriptive, and graphical information on the nutrient characteristics of foods [55]; the term food
composition data indicates all information referring to the description and identification of foods
and their food components (nutrient values, number of sample collections and analyses, analytical
methods, descriptive coding, photos, data source, value documentation, etc.) and include various
steps in the production, generation, compilation, and publication of data [55].
The EuroFIR project (European Food Information Resource Network of Excellence) was born
to develop and integrate a comprehensive, coherent, and validated network of databanks providing
a single, authoritative source of food composition data for Europe [56,57]. In this project, efforts in
developing procedures for defining and establishing a standardized approach of study have been
carried out from the various European partners within their FCDB [56,57].
The establishment of the “Project Committee—Food composition data” (CEN/TC 387,
2008–2013) [58] was an important milestone for the EuroFIR Network of Excellence to reach this
objective. A common European standard, established within the CEN-European Committee for
Standardization framework, represents a key tool enabling unambiguous identification and description
of food composition data and its quality in e.g. databases, for dissemination and interchange [58].
Generally, the use of database management system allows the administration of large volumes of
information and data by providing epidemiological research to store large varieties of food consumed
for each individual subject and the comparability of data, representing a basic tool for obtaining
reliable information on the relationship between nutrients and foods [59,60].
The utilization made by different users requires that FCDBs follow very specific compilation
criteria, such as representativeness, accuracy in the production and selection of analytical values,
traceability of data taken from other sources at the nutrient level, and clarity in the designation and
description of the food [60].
In this context, the food grouping systems in food composition databases represent a key tool.
Currently, Durazzo et al. [60] summarized and discussed how the food grouping systems of the
various international food composition databases (FCDBs), in terms of number, type and class of
consumed foods (e.g., ingredients, commercial products, cooked food, recipes, mixed dishes, etc.) vary
between different countries (usually, 10 and 25 food groups), and are constantly evolving according
to their changes and updates; the authors marked how these groupings are structured according to
the convenience of using the nutritional composition of specific foods and, therefore, there is not an
internationally standardized approach.
3. Distribution of Lignans in Food: Occurrence
Lignans are in a wide variety of plants from different origins, including the major edible plants.
Amongst the latter, flaxseed and sesame seeds represent rich sources of lignans [40,61–65], whereas
wood knots in coniferous trees, particularly Norway spruce, are identified as the most concentrated
lignan sources known so far [66].
The main sources of dietary lignans are oilseeds (i.e., flax, soy, rapeseed, and sesame), whole-grain
cereals (i.e., wheat, oats, rye, and barley), legumes, various vegetables and fruit (particularly berries),
as well as beverages, such as coffee, tea, and wine, and, recently, lignans are also reported in
dairy products, meat, and fish [64,65,67–84]. The types and amounts vary from one source to
another. The content of some lignans, as well as the degree of esterification of their glycosides,
could vary with different growing conditions, geographic location, climate, and genetic characteristics.
Some examples of profile and distribution of lignans in common food groups are here reported,
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from research in the literature applying different methodological approaches. As concluded by
Durazzo et al. [17], in a systematized assessment of lignans in cereals and cereal-based products for
grains studied in [65,73,76], the total average values in grains ranged between 23 and 401 μg/100 g
dry weight, with lariciresinol the most representative. As, for instance, for vegetables, Milder et al. [64]
reported a content of total lignans (as the sum of secoisolariciresinol, matairesinol, lariciresinol, and
pinoresinol, and expressed as μg/100 g fresh edible weight) of 1325 for broccoli, 185 for cauliflower,
787 for white cabbage, 171 for carrot, 58 for tomato, and 48 for chicory. Another example was given
by Penalvo et al. [65] that described, for asparagus, a following profile of lignan concentrations:
secoisolariciresinol 183 μg/100 g wet basis, syringaresinol 58 μg/100 g wet basis, pinoresinol
49 μg/100 g wet basis, lariciresinol 47 μg/100 g wet basis, medioresinol 5 μg/100 g wet basis,
matairesinol 2 μg/100 g wet basis whereas, for eggplant, tomato, and radish, the most representative
was lariciresinol [65]. For the fruit group, as reported in a work of Kuhnle [75] secoisolariciresinol
and matairesinol were identified, respectively, in orange (peel and pith removed, 21 and <1 μg/100 g
wet weight), nectarine (stoned, 24 and <1 μg/100 g wet weight), apricot (stoned, 51 and <1 μg/100 g
wet weight), mango (skinned and stoned, 17 and 1 μg/100 g wet weight), melon (cantaloupe, skin
and seeds removed, 16 and <1 μg/100 g wet weight), and others [75]. Moreover, Penalvo et al. [70]
showed for avocado, a profile of decreasing concentration of lignans, syringaresinol > pinoresinol
> medioresinol > secoisolariciresinol > lariciresinol > matairesinol and for pineapple, syringaresinol
> lariciresinol > matairesinol > secoisolariciresinol > pinoresinol > medioresinol, whereas, the most
representative lignan for navel orange was lariciresinol, and secoisolariciresinol for kiwifruit. In berries,
as reported by Smeds et al. [78], the most representative lignans among those studied were lariciresinol
for cloudberries (5008 μg/100 g dry weight); secoisolariciresinol for blackberries (2902 μg/100 g
dry weight), lingoberries (2319 μg/100 g dry weight), blackcurrants (446 μg/100 g dry weight);
syringaresinol for cranberries (2578 μg/100 g dry weight), sea buckthorns (1177 μg/100 g dry weight),
bilberries (801 μg/100 g dry weight), and red gooseberries (498 μg/100 g dry weight); and pinoresinol
for strawberries (1403 μg/100 g dry weight); for raspberries the most representatives were lariciresinol
(406 μg/100 g dry weight), syringaresinol (388 μg/100 g dry weight) and pinoresinol (377 μg/100 g
dry weight).
Within the beverage group, a recent work of Angeloni et al. [84] reported, for coffee samples from
different Countries, secoisolariciresinol from 27.9 to 52.0 μg L−1 and lariciresinol from 5.3 to 27.8 μg
L−1 respectively, contrary to matairesinol, that was not possible to detect it in each type of coffee.
For foods of animal origin, Kuhnle et al. [72] reported the content of lignans for the first
time; in milk and its derived products, the content of dietary lignans was reported (as the sum
of secoisolariciresinol, matairesinol, and shonanin) as follows: about 1 μg/100 g wet weight for
skimmed, semi-skimmed, or whole milk; in the cheese group, from <1 μg/100 g wet weight for feta
cheese derived from ewe’s and goat’s milk, to 4 μg/100 g wet weight for mascarpone, 5 μg/100 g wet
weight for parmesan, 6 μg/100 g wet weight for mozzarella (derived from buffalo milk), 13 μg/100 g
wet weight for soft Philadelphia cheese (full fat), and to 25 μg/100 g wet weight for Wensleydale
cheese. Moreover, cow milk, also condensed and evaporated, showed a content of enterolactone in a
range of 3–9 μg/100 g wet weight, and cheese in a range of 3–23 μg/100 g wet weight.
The same authors [72] reported a dietary lignan content for meat (including different meat cuts
and offal) at various cooking of 1–2 μg/100 g wet weight in chicken, 3–9 μg/100 g wet weight in
pork, 4–16 μg/100 g wet weight in beef, 4–17 μg/100 g wet weight in lamb; whereas, for eggs,
2–3 μg/100 g wet weight for egg whites and 6–10 μg/100 g wet weight for egg yolks. Small quantities
of enterolignans (<6 μg/100 g wet weight) were detected in some type of eggs and meat cuts.
Most of the foods are consumed after cooking or processing, depending on the type of food matrices
and the eating habits of the consumers, indeed, researches are moving in this direction [72,85,86]; indeed,
the evaluation of the effects of all type of factors on lignan content in different food matrices increase
the reliability of lignan intake estimations.
334
Molecules 2018, 23, 3251
At the same time, procedures to improve the content of lignans such as milling, parboiling,
or supplementation diet in animals [86–88] were optimized.
Nowadays, attention is paid to less common species and agro-industrial side streams [89–91],
in order to continually explore new sources of lignans.
4. Lignans and Databases: The Current Workflow
Studies that examine the relationship between diet and health have led to increased interest in
all biologically active constituents that are present together with nutrients in food, and data on these,
as well as other compounds, are increasingly required in the database system.
A complete and comprehensive harmonized databases on the content of lignans in foods are useful
in dietary assessment and in the evaluation of formulated diet, in order to be used in observational
studies as key elements for healthy nutritional patterns [92]. Knowledge of the dietary intake of lignans
is needed for understanding the relationship between a lignan-rich diet and the potential lower risk
of development of various diseases, that is, hormone-related cancers, heart diseases, menopausal
symptoms, and osteoporosis.
Detailed and accurate information on the lignans in foods is crucial in determining exposure and
to investigate health effects in vivo.
To reach this objective, limitations were given by numerous existing factors—from one side, the
diversity of the chemical features of compounds, the great number of dietary sources, and the large
variability in content from a specified source, to the other side, the different extraction procedures
and analytical techniques and methodologies [93]. Additional factors, in some cases, are given by the
fact that several studies have been focused only on few compounds within a class, and by the lack of
appropriate analytical methods.
In the last decade, researchers are addressing the identification and determination of lignan
profiles in main food groups and in food chain products; when a new dataset for nutritional values is
used, it is very important to evaluate the quality of the analytical information [55]. New experimental
and analytical data on lignan content are now available for updating and expanding food composition
databases [64,65,67–84]. In Table 1 the main national databases of lignans are described.












































































































































The first examples of databases including lignans were movements toward the development
of phytoestrogen databases [67,94]. Valsta et al. [67] reported on expansion of the Finnish
National Food Composition Database (Fineli®), compiling values for plant lignans, matairesinol,
and secoisolariciresinol (shown in Figure 1), and the isoflavones, daidzein and genistein.
Further, Milder et al. [64] developed a lignan database for 83 solid foods and 26 beverages
commonly consumed in the Netherlands: the amount of lignans in plant foods varied widely, from 0
to 301,129 μg/100 g fresh weight; in detail, the lignan values varied from 10 to 30,129 μg/100 g fresh
edible weight of oilseeds and nuts, from 7 to 12,474 μg/100 g fresh edible weight of grain products,
from 0 to 2321 μg/100 g fresh edible weight of vegetables, from 0 to 450 μg/100 g fresh edible weight
of fruits, from 26 to 37 μg/100 g fresh edible weight of legumes, and in beverages ranged from 0 to
91 μg/100 mL. Only five of the studied foods did not contain a measurable amount of lignans and,
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in most cases, the amount of lariciresinol and pinoresinol was larger than that of secoisolariciresinol
and matairesinol.
On the basis of above mentioned lignan databases, in another work, Milder et al. [68] have
assessed the lignan intake in a representative sample of 4660 Dutch adults (Dutch Food Consumption
Survey, carried out in 1997–1998), reporting the following contribution percentages to lignan intake:
lariciresinol and pinoresinol contributed 75%, whereas secoisolariciresinol and matairesinol contributed
25%; and the major food sources of lignans were beverages (37%), followed by vegetables (24%),
nuts and seeds (14%), bread (9%), and fruits (7%) [68].
Thompson et al. [69] developed a lignan database of foods consumed in Canada: nine
phytoestrogens were identified in 121 food products of Canada by GC–MS, including lignans;
decreasing amounts (on wet weight, μg per 100 g) of total lignans are reported in the following
order: nuts and oilseeds (25–379012), cereals and breads (2.0–7239.3), legumes (1.8–979.4), fruits
(0.3–61.8), vegetables (1.2–583.2), soy products (2.2–269.2), meat products and other processed foods
(0.2–415.1), alcoholic beverages (1.1–37.3), and non-alcoholic beverages (0.9–12). Matairesinol was
the least-concentrated lignan in most studied foods, whereas secoisolariciresinol reached the highest
concentration in 63 foods, lariciresinol in 44 foods, and pinoresinol in 14 foods [69].
Peñalvo et al. [70] have reported the content of six plant lignans (shown in Figure 1) in 86 food
items commonly consumed in Japan: the amount of plant lignans ranged from 0 to 1724 μg/100 g
(wet basis); in details, as for instance, considering the food group of vegetables, most of the lignans were
in the stems and leaves of Japanese parsley, asparagus, Japanese spinach, bitter oranges, and Chinese
citrus, and related concentrations in vegetables ranged from 19 to 1724 μg/100 g wet basis.
Moreno-Franco et al. [77] have developed the Aligna databases, by collecting data from scientific
publications for alkylresorcinols and lignans in common foods and beverages, and by analyzing foods
particularly consumed in Spain; moreover, the assess of lignans intake in Spain was evaluated and
reported as follows: 0.76 mg/day, with the major contributors, i.e. oils and fats (33 percent), fruits and
vegetables (30 percent), bread (14 percent), and wine and beer (10 percent) [77].
In several works, Kuhnle et al. [71,72,74,75] reported the content of secoisolariciresinol and
matairesinol in 115 foods of animal origin, 240 different foods based on fresh and processed fruit
and vegetables, 101 cereal and cereal-based foods including bread, breakfast cereals, biscuits, pasta,
and rice, and about 40 beverages, nuts, seeds, and oils. The study of Mulligan et al. [81] estimates
the average intakes of isoflavones, lignans, enterolignans, and coumestrol in the Norfolk arm of the
European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk) from 7-days food diaries,
and provides data on total isoflavone, lignan, and phytoestrogen consumption by food group—the
mean daily total lignan intake was 361 (SD 230) μg in soya-consuming men, and 311 (SD 178) μg in
non-soya-consuming men; the mean daily total lignans intake was 318 (SD 212) μg in soya-consuming
women and 251 (SD 141) μg in non-soya-consuming women [81].
It is worth mentioning the work of Tetens et al. [95] which estimated and evaluated the scale
of consumption and the main food sources of lignans in five European countries using the Finnish
databases [67], including lignans and Dutch lignan databases [64], respectively; in detail, 42 food groups
known to contribute to the total lignan intake were selected and a value attributed for secoisolariciresinol
and matairesinol from the Finnish lignan database (Fineli®) or for secoisolariciresinol, matairesinol,
lariciresinol, and pinoresinol from the Dutch database. The total intake of lignans was estimated from
food consumption data for adult men and women (19–79 years) from Denmark, Finland, Italy, Sweden,
United Kingdom, and the contribution of aggregated food groups calculated using the Dutch lignan
database [75]. The authors showed that, compared to the total lignan intakes among Dutch men and
women, the total lignan intakes were higher in Denmark and Sweden, and within similar range in
Finland, Italy, and United Kingdom [75].
Here, also, are some examples of utilization of lignan databases to investigate the association
between lignan intake and prevention of some chronic pathologies.
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A recent study was undertaken by Witkowska et al. [96] that examined the total and individual
lignan intakes and their dietary sources in postmenopausal Polish women: for lignan content, the Dutch
lignan database was used [64]; for beverages, nuts, seeds, and oils, data from Kuhnle et al. [71] were
taken, and when data on lignan content were missing, values were taken from Thompson et al. [69];
in women with cardiovascular disease (CVD), secoisolariciresinol accounted for 50.15% lignan intake
from plant foods, as compared to 44.8% in the control. Pinoresinol, lariciresinol, and matairesinol
contributed to the total lignan intakes of CVD and non-CVD women in 24.0% vs. 26.1%, 22.7% vs.
26.1%, and 3.1% vs. 2.9%, respectively [96].
Nowadays, the major core public databases that gather extensive data on the polyphenol
content of foods and beverages include lignans—Phenol-Explorer [97], the first comprehensive
database on polyphenol content in foods [98] and eBASIS (Bioactive Substances in Food Information
Systems) [99–101], published through the EuroFIR project.
Phenol-Explorer was the first comprehensive web-based database on polyphenol content in
foods and an open-access database and, now, throughout several updates [102,103], includes new
data on pharmacokinetic and metabolites, the effect of food processing and cooking and, in the
last update (version 3.6), 1451 new content values for lignans have been added (to the database).
The development of the Phenol-Explorer database included five main steps: literature search, data
compilation, data evaluation, data aggregation, and final data exportation to the MySQL database
which is used by the web interface. Composition data were collected from peer-reviewed scientific
publications, and evaluated before they were aggregated to produce final representative mean
content values.
The eBASIS database contains composition data and biological effects of over 300 major European
plant foods of 24 compound classes, such as glucosinolates, phytosterols, polyphenols, isoflavones,
glycoalkaloids, and xanthine alkaloids in 15 EU languages. EuroFIR eBASIS resource is a compilation of
expert critically evaluated data extracted from peer-reviewed literature as raw data. This could be seen
and considered as the first effort to establish a harmonized food composition information system in EU.
Indeed, eBASIS should be defined as the first EU harmonized food composition database. Currently,
2695 data points for lignans were inserted in eBASIS, in detail, 658 values for secoisolariciresinol,
550 values for matairesinol, 313 values for lariciresinol, 276 values for pinoresinol, 93 values for
medioresinol, and 86 values for syringaresinol [99,101].
Indeed, considering the importance of metabolic pathways and the benefits of bioactive
compounds in humans, it is worth mentioning the Human Metabolome Database or HMDB 4.0 [104],
a web metabolomic database on human metabolites including lignans and their metabolites [105],
as well as PhytoHub [106], a freely electronic database containing detailed information about all
phytochemicals and their metabolites commonly ingested in diets [107].
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Abstract: During barrel aging, spirits undergo organoleptic changes caused by the release of aroma
and taste compounds. Recently, studies have revealed the bitter properties of oak wood lignans,
such as (±)-lyoniresinol, and their contribution to wine taste. To evaluate the impact of lignans in
spirits, a targeted screening of 11 compounds was set up and served to validate their presence in this
matrix, implying their release by oak wood during aging. After development and validation of a
quantification method, the most abundant and the bitterest lignan, (±)-lyoniresinol, was assayed
by liquid chromatography–high resolution mass spectrometry (LC-HRMS) in spirits. Its gustatory
detection threshold was established at 2.6 mg/L in spirits. A large number of samples quantified
were above this detection threshold, which suggests its effect of increased bitterness in spirit taste.
Significant variations were observed in commercial spirits, with concentrations ranging from 0.2
to 11.8 mg/L, which could be related to differences in barrel aging processes. In “eaux-de-vie” of
cognac, concentrations of (±)-lyoniresinol were observed in the range from 1.6 mg/L to 12 mg/L.
Lower concentrations were measured for older vintages.
Keywords: Lignan; bitterness; taste-active compound; quantification; oak ageing
1. Introduction
Spirits are alcoholic beverages, traditionally consumed for human enjoyment. Their sensory
quality is strongly influenced by their different production stages [1]. First, the elaboration of spirits
needs a raw material with a high content of sugars naturally present in fruits (apple, pear, or grape) for
calvados, cognac, armagnac, and brandy; of carbohydrates and starch (corn, barley, or rye) for bourbon
and whiskey; or of sugarcane for rum. Thereafter, yeast fermentation, distillation techniques in pots or
column stills, maturation in oak barrels, and bottling play their own special part in aroma and taste
formation [2,3]. From a chemical point of view, spirits are a highly complex matrix characterized by
an ethanol concentration that is usually between 36% to 55% v/v and a high content of volatile and
nonvolatile compounds.
With the development of sensitive and resolutive analytical techniques, such as GC-olfactometry
and GC-MS, hundreds of volatile components have been identified in spirits over the last few
decades [3–7]. These compounds are mainly esters, alcohols, aldehydes, and volatile acids coming
from grapes or formed during fermentation.
Contrary to volatile compounds, nonvolatile molecules present in spirits are exclusively acquired
after distillation. Most of them are released from oak wood during aging. Indeed, barrel aging is a
crucial step during which the organoleptic properties of spirits are fine-tuned [8]. The color, structure,
aroma, and taste of spirits are modified during oak aging [9–12], and it is commonly acknowledged
that the overall quality improves. While the key aromatic compounds released from oak wood in
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spirits are well known [13,14], modifications to gustatory properties during this process have been only
partially explained. Recent studies have demonstrated the influence of oak wood on the softening of
wine and spirits with the discovery of natural sweet compounds called quercotriterpenosides [15,16].
Furthermore, the astringency and bitterness of ellagitannins, a major class of oak wood compounds,
have also been studied. Glabasnia and Hofmann showed that the detection thresholds (DTs) of the main
hydrolysable tannins were significantly higher than their concentrations in wines, suggesting their low
influence on wine bitterness [17]. So far, no correlation between bitterness and oak tannins has been
clearly established [18]. Moreover, a large number of studies have examined the phenolic composition
of spirits. Mainly nonflavonoids have been identified and quantified in aged spirits, most of them
of low molecular weight [19,20]. Phenolic acids such as gallic acid are the most abundant phenolic
compounds in spirits, followed by phenolic aldehydes (vanillin, sinapaldehyde, syringaldehyde),
lignans, phenyl ketones, and coumarins such as scopoletin [21–25].
Among these nonvolatile compounds present in spirits, lignans appear to be particularly interesting,
since previous studies have demonstrated the bitter properties of lyoniresinol [16] and various derivatives.
Lyoniresinol has been described as the most abundant lignin in sessile oak, and its detection threshold
has been established at 1.5 mg/L in wine [26]. A complementary study showed that only (+)-lyoniresinol
was bitter, with a detection threshold established at 0.5 mg/L in wines [27]. This enantiomer was
quantified in various wines at concentrations higher than this value, demonstrating its contribution to
wine bitterness [28]. Yet the sensory properties of a molecule, and in particular its detection threshold, can
be strongly influenced by the nature of the matrix from an olfactory or gustatory point of view [29–32].
Consequently, the contribution of lignans to spirit taste cannot be presumed from the results obtained
in wine. A better knowledge on oak wood and spirits composition appears particularly interesting to
improve the quality of these products with high economic interest.
Based on these observations, the present work aimed at studying the occurrence of oak wood
lignans in spirits and their taste contribution. First, samples of commercial spirits were screened by
liquid chromatography–high resolution mass spectrometry (LC-HRMS) to search for the presence
of targeted oak wood lignans. Considering the strong bitterness induced by (±)-lyoniresinol, the
detection threshold of this lignan was established in a spirit matrix. Finally, after development and
validation of an LC-HRMS method, a racemic mixture of lyoniresinol was quantified in various
samples of commercial and experimental spirits in order to investigate its sensory impact along with
the influence of oenological parameters on its content.
2. Results and Discussion
2.1. Chemical Diversity of Oak Lignans in Spirits
Previous studies have focused on the diversity and gustatory importance of lignans present in oak
wood [33]. Using an LC-HRMS guided purification protocol, 11 lignans (Compounds 1–11, Figure 1),
natural derivatives of lyoniresinol, were isolated and identified from an oak wood extract [26,34].
In addition, it has been proven that all these molecules are released in wine aged in oak barrels. In this
matrix, some of the galloyl, glucosyl, and xylosyl derivatives have been described as bitter but with a
lower intensity than lyoniresinol [26].
Their presence has not been reported in spirits until now, even though maturation in barrels
is crucial for fine-tuning their sensory properties. To determine whether these lignans were likely
to impact the taste of spirits, their presence was first investigated by screening a cognac aged for
23 years. Based on mass measurement accuracy, LC-HRMS is a powerful technique in screening
samples by targeting the characteristic m/z ions of specific empirical formulas. To this end, the
chromatographic and spectrometric conditions described by Marchal et al. [26] were applied. Extracted
ion chromatograms (XICs) were obtained in an oak wood extract (Figure 2a) and in a spirit (cognac,
Figure 2b) by considering the m/z ratios specific to the deprotonated ions ([M − H]−) of (±)-lyoniresinol
and lignans 1 to 11 with a 3-ppm tolerance window (Figure 2).
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Figure 1. Chemical structures of lignans 1–11. Xyl, Glu, and Gall correspond, respectively, to
β-xylopyranose, β-glucopyranose, and galloyl.
Figure 2. Negative LC-ESI-FTMS XIC of an (a) oak wood extract and (b) a spirit corresponding to
[M − H]− ions of lyoniresinol and lignans 1–11 (from top to bottom).
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Similar signals were detected in XICs of both samples. Moreover, analysis in higher energy
collision dissociation (HCD) fragmentation mode revealed the same main fragment ions in the two
matrices. Concomitantly with the specificity of mass measurement (<3 ppm) and retention time
similarity (<0.02 min), these results demonstrated that lignans 1–11 were present in the analyzed
spirits. The presence of lyoniresinol had already been established in oak wood extracts [35,36],
wines [21], and spirits [8,22,35,37]. Lignans 7 and 8 had also been identified in these three matrices [34].
However, lignans 1–6 and 9–11 had been described in wines [26,34], but never in spirits. A comparison
of the signal intensity of all the lignans suggested that (±)-lyoniresinol might be the most abundant of
them in spirits. These results confirmed recent studies, in which the combination of sensory analysis
and quantitative studies established that lyoniresinol is both the most abundant lignan released from
oak wood in wine and one of the bitterest.
The detection threshold of a compound is the concentration beyond which this molecule is
perceived by one half of a panel. In oenology, detection thresholds have been measured, mainly on
olfactory compounds, in different matrices such as water, wine, or spirits [29,30,32]. These studies
have shown that the nature of the matrix can have a significant impact on the olfactory properties of
a compound. In the same way, taste-active compounds can also be strongly affected by the matrix.
For instance, the detection threshold was calculated for a bitter compound, caffeine, in water and liquid
food at 94 and 184 mg/kg, respectively [31]. These results underline the importance of calculating a
detection threshold of (±)-lyoniresinol in a spirit matrix to determine its effective impact on spirit taste.
2.2. Sensory Impact and Quantification of (±)-Lyoniresinol in Spirits
Previous studies have demonstrated that lyoniresinol significantly contributes to the bitterness of
oaked wines [26]. However, depending on the studied matrix, the sensory properties of lyoniresinol
can change. For this reason, the detection threshold must be evaluated in “eau-de-vie” of cognac and
compared to quantitative values measured in spirits by LC-HRMS.
2.2.1. Determination of (±)-Lyoniresinol Detection Threshold in Spirits
The gustatory impact of (±)-lyoniresinol had been previously established in a white wine by
Marchal et al. [26]. The group taste threshold was calculated to be 1.5 mg/L, with a wide range of
individual detection thresholds from 0.125 to 11.3 mg/L. Furthermore, Cretin et al. demonstrated
that only (+)-lyoniresinol exhibited a bitter taste compared to its enantiomer, described as tasteless or
slightly sweet [27,28]. As not enough (+)-lyoniresinol was available in our laboratory to determine
its detection threshold, the sensory studies presented in this work were carried out with a racemic
mixture, which is naturally present in oak wood.
The detection threshold of lyoniresinol was determined using the 3AFC (three-alternative forced
choice) method [38,39]. Solutions of (±)-lyoniresinol at various concentrations were prepared according
to a geometric progression with a ratio of 2, and presented in 3AFC tests. Two sessions were organized
to avoid excessive tiredness among the tasters. The (±)-lyoniresinol group threshold was established
at 2.6 mg/L with strong inter-individual variability. Indeed, individual detection thresholds covered a
range from 0.35 mg/L to 32 mg/L. The same trends had been described in wine, but the gustatory
threshold values were significantly higher in “eau-de-vie”. These variations could be partly due to the
higher level of ethanol in the matrix. They confirmed the results of a preliminary study on “eau-de-vie”
of armagnac [35].
2.2.2. Development of an LC-HRMS Method to Quantitate Lyoniresinol in Spirits
Previous studies have shown the relevance of using LC-HRMS to quantify (±)-lyoniresinol in
spirits, wines, and oak wood macerates [26,28]. The same chromatographic conditions were used for
(±)-lyoniresinol quantification in spirits.
The LC-HRMS method previously described for quantification in wine involved an ionization
in negative mode [26]. However, preliminary tests were carried out in the same conditions and
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showed insufficient results regarding linearity and accuracy with the spirit samples. Consequently, a
quantification method based on a positive ionization mode was developed for this matrix. LC-HRMS
quantification was performed in full scan mode, the selectivity of the detection being ensured by
the mass accuracy measurement of the Orbitrap analyzer (<3 ppm) and the repeatability of the
retention time.
The full scan HRMS spectrum of (±)-lyoniresinol (C22H28O8) presented several ions
corresponding to adducts ([M + Na]+, [M + K]+, [M + NH4]+); pseudodimers ([2M + H]+, [2M +
Na]+); and fragments (C14H17O4+, C14H19O5+) (Figure 3), but the signal corresponding to protonated
ion (C22H29O8+) was very low, whatever the ionization parameters. Preliminary tests showed that
quantification was more reliable by using the fragment ion at m/z 249.11214 (C14H17O4+), which
was the most intense signal. This chemical species might result from a loss of a dimethoxyphenol
group (C8H10O3) jointly with dehydration. Such fragmentation reactions are well known for lignin
derivatives [40] and can be caused by high temperature [41]. Spectrometry parameters were tuned to
optimize the response of the m/z 249.11214 ion.
Figure 3. High resolution mass spectrometry (HRMS) spectrum of (±)-lyoniresinol in positive
ionization mode.
Absolute quantification was carried out by preparing calibration solutions of pure lyoniresinol
in a model solution at 8% v/v. Orbitrap analysis afforded high accuracy of mass measurement, so
extracted ion chromatograms were built with a 3-ppm window around the theoretical m/z of the
C14H17O4+ ion. Injection of pure lyoniresinol indicated a characteristic retention time of 2.90 min.
This tR was considered for automatic integration of the XIC.
Sensitivity
Given the high selectivity of the mass measurement, the notion of signal-to-noise is not suitable for
this technique. The detection limit of a molecule is defined as the lowest concentration of this molecule
for which a reliable and reproducible signal is observed. In addition, the signal must be different
from a blank made under the same conditions. In this study, the method described by De Paepe et
al. [42] was used. The lowest levels of the calibration curve (from 2 to 50 μg/L) were injected into five
replicates. Precision (relative standard deviation (RSD)%) and accuracy (recovery of back-calculated
concentrations) were obtained for each concentration. The instrumental detection limit (IDL) was
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defined as the standard deviation at the lowest concentration that could be measured with a precision
lower than, e.g., 10%, and an accuracy higher than, e.g., 90%. With this method, it was evaluated at
5 μg/L in spirits. The instrumental quantification limit (IQL) was defined as twice the corresponding
IDL (10 μg/L). Limits of detection (LOD) and quantification (LOQ), reassessed using the dilution
factor, were calculated at 25 μg/L and 50 μg/L, respectively.
Linearity and Accuracy
The working range was chosen taking into account the IQL previously determined. A quadratic
calibration curve (1/x statistical weight) was obtained with a good correlation coefficient (R2 of 0.9999)
for a range from 10 μg/L to 10 mg/L. The recovery of back-calculated concentrations was higher than
90% at each method calibration level, establishing the accuracy.
Specificity
Specificity was assessed by mass accuracy and the repeatability of retention times.
These parameters were checked for each injection of calibration solutions and samples. Low variations
in retention time (<0.04 min) and a mass deviation lower than 2.2 ppm between experimental and
theoretical values were observed for lyoniresinol, guaranteeing the specificity of the method. Moreover,
no signal was detected in non-oaked “eau-de-vie”.
Repeatability and Trueness
To determine intraday repeatability (RSD%), five replicates of two concentrations (100 μg/L and
1 mg/L) of the calibration curve were successively injected. Values lower than 4% were obtained for
both concentrations, guaranteeing the repeatability of the method.
Trueness was determined by calculating the recovery ratios of three different samples of cognac
spiked with stock solutions for additions of 100 μg/L and 1 and 2 mg/L. These recovery ratios ranged
from 85% to 98%. These slight variations could be explained by the highly complex matrix of spirits.
However, the results remained in accordance with common specifications [43] and established the
trueness of the method. Interday repeatability was estimated by injections of the same standard
solutions for five successive days. As usually observed for LC-ESI-MS analysis, the RSD values were
quite high. To overcome this issue, all the calibration solutions were injected for each quantitative
analysis of an unknown sample.
All of the results proved the ability of the LC-HRMS method to quantify lyoniresinol in spirits (Table 1).
Table 1. Validation parameters for HRMS quantitation of (±)-lyoniresinol in spirits.
Parameters Matrix/Spirits
Sensitivity
IDL (μg/L) IQL (μg/L) LOD (μg/L) LOQ (μg/L)
5 10 25 50
Linearity and Accuracy
Working Range R2
10 μg/L–10 mg/L 0.9999
Specificity
tR variation Mass Accuracy
<0.04 min <2.2 ppm
Repeatability and Trueness
Intraday Repeatability
100 μg/L 1 mg/L
3.35% 3.43%
Recovery
Samples 100 μg/L 1 mg/L 2 mg/L
EDV-C7 94% 91% 98%
EDV-C8 87% 85% 97%
EDV-1995 88% 86% 87%
IDL: Instrumental detection limit; IQL: Instrumental quantification limit; LOD: Limit of detection; LOQ: Limit of
quantification; EDV: eau-de-vie.
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2.2.3. Application of the Method to Quantitate Lyoniresinol in Spirits
Content of Lyoniresinol in Various Commercial Spirits
Twenty-four commercial spirits were analyzed to assess the range of lyoniresinol amounts in
some cognacs, but also whiskies, rums, and other brandies using the LC-HRMS method previously
validated. Lyoniresinol was detected in all samples, at concentrations ranging from 0.2 to 11.8 mg/L
with a mean value of 3.3 mg/L. The results are illustrated in Figure 4. There were not enough samples
to carry out a statistical study, but among the spirits richest in lyoniresinol, there was a majority of
cognacs (C-2 and C-5 to C-11), as well as two brandies (B-13 and B-14), one rum (R-19), and one
whiskey (W-22). A comparison to sensory data highlighted that the lyoniresinol concentration was
above the detection threshold in these 12 spirits, establishing the sensory relevance of this compound,




























































Figure 4. Variations in (±)-lyoniresinol content in 24 commercial spirits. The red line represents the
level of the gustatory detection threshold (DT).
Furthermore, the significant variations in lyoniresinol observed between these commercial spirits
could have been due to various factors, and some hypotheses can be evoked. First, the analyzed
commercial spirits were aged in contact with oak wood, so these observations could have been related
to aging conditions. The influence of the aging container on the lyoniresinol content of a white wine
has already been established, confirming that lyoniresinol is released from oak wood to wine [26].
Additionally, this study showed that new oak barrels contained more lyoniresinol. Thus, the variations
observed in the analyzed spirits could have been due to the proportion of new oak barrels used
during the aging of the spirits. Previous studies have also demonstrated that the concentrations of
molecules vary according to the use of new or used barrels, barrels previously used in a maturation
cycle [9]. Indeed, Piggott et al. noted differences in the levels of phenolic compounds depending
on three types of casks. The study showed an increase in concentrations of nonvolatile compounds,
such as vanillin, syringaldehyde, and syringic acid, as well as a reduction in coniferaldehyde and
sinapaldehyde concentrations in 36-month-old whiskey distillates [10]. As spirits are aged for a
longer period than wine [8], aging time and aging container could explain the significant variations in
lyoniresinol observed in these samples, but such information was not available for the commercial
spirits analyzed in this study. The potential influence of aging conditions on lyoniresinol concentrations
in spirits needs to be clarified in further studies.
Second, various cooperage parameters could have affected the chemical composition of oak wood.
Previous works have shown that the concentration of oak molecules released in wine or spirits could
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vary according to the botanical species or geographical origin of the oak [44–46]. However, Cretin et al.
demonstrated that there was no significant effect of oak species on lyoniresinol content [28].
In addition, during barrel making, the wood undergoes a series of stages that influence its
oenological quality, most notably seasoning and toasting of the staves. These technological features
affect the structure and the chemical composition of the wood, but also the future matrix with which it
will be in contact [47–51]. Indeed, Cretin et al. studied the influence of wood toasting temperature on
lyoniresinol and showed that this compound was slightly degraded at around 250 ◦C [28], in line with
another study [52].
Content of Lyoniresinol in Various Vintages of the Same Spirits
Lyoniresinol was quantified in a series of “eaux-de-vie” of cognac of 10 different vintages from
the same distillery and using similar aging conditions. The samples were not commercial cognac,
but “eaux-de-vie” still undergoes the aging process in barrels. They were matured in used barrels
(a 350-L coarse grain oak barrel). For each vintage, a sample was collected from five different barrels
and analyzed. The concentrations presented in Figure 5 correspond to the mean values of these
five replicates. The measured values ranged from 1.6 mg/L (2015) to 12 mg/L (1995). For each
vintage, the coefficient of variation between the five replicates was relatively low (from 5.7% to 33.2%),
revealing a good homogeneity between barrels. From 2015 to 1995, the results showed that the older
the “eau-de-vie”, the higher the level of lyoniresinol, confirming previous observations [27,35,37].
Conversely, for older vintages, lower concentrations were measured. This could suggest a degradation
of lyoniresinol in long-time barrel storage. Furthermore, aging in used barrels implies a lower
extractable potential of the compounds than in new oak barrels and can influence the lyoniresinol
content in these vintages. However, this hypothesis needs to be studied more deeply, since the




























Figure 5. Concentrations of (±)-lyoniresinol in 10 vintages of cognac “eaux-de-vie” coming from the
same distillery.
Despite the release of lyoniresinol, a bitter compound, spirits are known to improve during
oak wood aging. Research has highlighted the impact of other taste-active compounds such as
quercotriterpenosides [16], which could be released at the same time from oak wood and might
modulate the effect of lyoniresinol on the taste balance in spirits.
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3. Materials and Methods
3.1. Chemicals
D-(+)-glucose, D-(−)-fructose, and quinine sulfate were purchased from Sigma-Aldrich
(Saint-Quentin-Fallavier, France). Ultrapure water (Milli-Q purification system, Millipore, France) and
HPLC grade solvent (acetonitrile, ethanol, ethyl acetate, n-heptane, methanol, and propan-2-ol; VWR
International, Pessac, France) were used for sample preparation and lignan purification. Acetonitrile
(ACN) and water used for chromatographic separation were LC-MS grade and were purchased from
Fisher Chemical (Illkirch, France). Lignans were isolated as previously described by Marchal et al. [26].
3.2. LC Analysis
The HPLC appliance consisted of an HTC PAL autosampler (CTC Analytics AG, Zwingen,
Switzerland) and an Accela U-HPLC system with quaternary pumps. For (±)-lyoniresinol quantitation,
a C18 column (Hypersil Gold 2.1 × 100 mm, 1.9-μm particle size, Thermo Fisher Scientific) was used
with water (Eluent A) and ACN (Eluent B) as mobile phases. The flow rate was set at 600 μL/min,
and the injection volume was 5 μL. Eluent B varied as follows: 0 min, 14%; 0.5 min, 14%; 1.5 min, 19%;
2 min, 19%; 4.5 min, 38%; 4.6 min, 98%; 6.9 min, 98%; 7 min, 14%; 8.6 min, 14%.
3.3. HRMS
An Exactive Orbitrap mass spectrometer equipped with a heated electrospray ionization (HESI II)
probe (both from Thermo Fisher Scientific, Les Ulis, France) was used. The mass analyzer was calibrated
each week using Pierce®ESI Negative and Positive Ion Calibration solutions (Thermo Fisher Scientific).
3.3.1. Screening
To perform targeted screening, the ionization and spectrometric parameters, optimized in negative
mode, were previously described by Marchal et al. [26]. Table 2 summarizes all the data.
Table 2. Ionization and spectrometric conditions for HRMS analyses.
Mass Spectrometer Exactive
Use LC-MS Screening LC-MS Quantification
Ionization Mode Negative Positive
Sheath gas flow a 75 75
Auxiliary gas flow a 18 20
HESI probe temperature 320 ◦C 320 ◦C
Capillary temperature 350 ◦C 350 ◦C
Electrospray voltage −3 kV 3.5 kV
Capillary voltage −60 V 35 V
Tube lens voltage offset −135 V 120 V
Skimmer voltage −26 V 18 V
Mass range (in Th) 200–800 200–800
Resolution b 25 000 25 000
Automatic gain control value 106 106
a Sheath gas and auxiliary gas flows (both nitrogen) are expressed in arbitrary units. b Resolution m/Δm, fwhm at
m/z 200 Th.
3.3.2. Quantification
For quantitation of (±)-lyoniresinol in spirits, mass acquisitions were performed and optimized in
positive Fourier transform (FTMS) ionization mode. The ionization and spectrometric parameters are
described in Table 3. All data were processed using the Qual Browser and Quan Browser applications
of Xcalibur version 3.0 (Thermo Fisher Scientific) [45].
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Table 3. Features of commercial spirits.
Samples Brands Type Origin ABV (Alcohol by Volume)
C-1 Brand A Cognac France 40
C-2 Brand A Cognac France 40
C-3 Brand A Cognac France 40
C-4 Brand A Cognac France 40
C-5 Brand B Cognac France 40
C-6 Brand B Cognac France 40
C-7 Brand C Cognac France 40
C-8 Brand C Cognac France 40
C-9 Brand C Cognac France 40
C-10 Brand D Cognac France 40
C-11 Brand D Cognac France 40
C-12 Brand E Cognac France 42
B-13 Brand F Brandy SouthAfrica 38
B-14 Brand G Brandy France 40
B-15 Brand H Brandy Germany 38
B-16 Brand I Brandy France 40
R-17 Brand J Rum Jamaica 43
R-18 Brand K Rum Guyana 40
R-19 Brand L Rum Barbados 43
W-20 Brand M Whisky Ireland 40
W-21 Brand N Whisky Scotland 40
W-22 Brand O Whisky Scotland 40
W-23 Brand O Whisky Scotland 40
Bo-24 Brand P Bourbon UnitedStates 50
3.4. Spirits and Sample Preparation
Two series of spirits were used in this study. Lyoniresinol quantitation was assessed in
24 commercial spirits (including 12 cognacs, 4 grape brandies, 3 rums, 4 whiskies, and 1 bourbon).
All of these were aged in oak wood. Table 3 summarizes all the features of these spirits, which were
randomly chosen among spirits commercially available and well distributed in France.
The second set of spirits, supplied by Rémy-Martin, consisted of 10 vintages from 1970 to 2015,
with five replicates for each year. The samples came from the same distillery and used similar
aging conditions.
All concentrations were expressed in mg/L of spirits.
A spirit is a matrix with a high alcohol content, so a dilution is necessary before any injection.
This prevents deterioration of the chromatographic separation and allows all concentrations to be
included in the working range. For quantitative analysis, the percentage of alcohol ranged from 71
to 38% v/v, and the spirit samples were reduced to 8% alcohol with water and 0.45 μm filtered. The
diluted spirits were injected directly into LC-HRMS using the chromatographic and spectrometric
parameters described above.
3.5. Preparation of Calibration Solution for Lignan Quantitation
A stock solution of (±)-lyoniresinol (1 g/L) was prepared in ethanol. One range of calibration was
prepared by successive dilution of this solution in hydroethanolic solution (8%, v/v) in order to supply
calibration samples (10 mg/L, 5 mg/L, 2 mg/L, 1 mg/L, 500 μg/L, 200 μg/L, 100 μg/L, 50 μg/L,
20 μg/L, 10 μg/L, 5 μg/L, 2 μg/L). Detection of (±)-lyoniresinol was based on the theoretical exact
mass of the most intense ion, the fragment ion at m/z 249.11214, and its retention time at 2.90 min.
Peak areas were determined by automatic integration of extracted ion chromatograms built in a 3-ppm
window around the exact mass of the C14H17O4+ ion.
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3.6. Method Validation for Quantitation of Lyoniresinol on C18 Column
The quantitation method of (±)-lyoniresinol in spirits was validated by studying sensitivity,
linearity, specificity, intraday repeatability, and trueness. A calibration curve was established by
plotting the areas for each concentration level versus the nominal concentration. Quadratic regression
was chosen with a 1/x statistical weight.
The sensitivity of the LC-HRMS method was determined following the approach described by
De Paepe et al. [42]. Linearity was evaluated by correlation coefficient (R2) and by deviations of each
back-calculated standard concentration from the nominal value. To evaluate repeatability, the intraday
precision was determined by injecting five replicates of two intermediate calibration solutions (100
and 1000 μg/L), and the relative standard deviation (RSD%) was calculated. Trueness was checked by
calculating the recovery ratio (between measured and expected areas) from three samples of spirits
(C-7, C-8, EDV-1995). They were chosen among the analyzed samples and were spiked with calibration
solution corresponding to an addition of 100 μg/L and 1 and 2 mg/L of (±)-lyoniresinol. Specificity
was assessed by evaluating the mass accuracy and retention time repeatability. These parameters were
determined concomitantly with the precision and trueness analysis described above.
3.7. Sensory Analysis
Tasting sessions took place in a specific air-conditioned room at 20 ◦C equipped with individual
booths and normalized glasses. The “eau-de-vie” used for sensory analysis was a non-oaked spirit
adjusted to 40% v/v of ethanol with pure and demineralized water (eau de source de Montagne,
Laqueuille, France). The absence of (±)-lyoniresinol in this matrix was checked by LC-HRMS analysis.
Results obtained from the sensory tests were statistically interpreted following the norms
published by the International Organization for Standardization (ISO) [38].
3.7.1. Panel Training
The panel consisted of 24 wine tasters, 7 men and 17 women, aged from 20 to 45 years. The aim of
this training session was, first, to accustom the panel to sweet and bitter perceptions (glucose, fructose,
and quinine sulfate aqueous solutions), and in the second session to familiarize all panelists with a
new matrix with a higher alcohol concentration (40%, v/v).
First, two aqueous solutions containing, respectively, glucose and fructose at 10 g/L, and quinine
sulfate at 20 mg/L, were presented to the tasters to illustrate sweet and bitter tastes. These solutions
were made with demineralized water (eau de source de Montagne, Laqueuille, France).
In a second session, solutions containing these compounds at the same concentrations, but in
a non-oaked “eau-de-vie” (40%, v/v), were presented to the tasters. They were asked to rate the
sweetness and bitterness intensities of each solution on a 0–10 scale. The results were interpreted
by a one-way analysis of variance (ANOVA). For each parameter, the homogeneity of the variance
was assessed using the Levene test. ANOVA’s statistics were considerably below the p-value of 0.05.
Indeed, results were significant with a p-value of 0.0001 for the sweet solution and a p-value of 0.003
for the bitter solution. Training showed the reliability of the panel to distinguish sweet and bitter tastes
even in a complex matrix.
3.7.2. Determination of Lyoniresinol Taste Threshold in Spirits
The taste threshold of (±)-lyoniresinol was evaluated in a non-oaked “eau-de-vie” adjusted at
40% v/v. Due to the higher alcohol concentration present in this matrix and the remanence of the
bitter taste, two different sessions were planned to avoid tiredness among the panelists. In the first
session, three concentrations (2, 4, and 8 mg/L) were presented in ascending order. Each concentration
was displayed according to the 3AFC (three-alternative forced choice) described by ISO 4120:2007 [38].
Concentrations presented in the second session depended on the results from the first session for
each taster. If the panelist had given correct answers, three lower concentrations (0.5, 1, and 2 mg/L)
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were presented to him or her, following a geometric progression of ratio 2, starting with the lowest.
Conversely, tasters who did not give any correct answers during the first session received three higher
concentrations (8, 16, and 32 mg/L) in the other session.
Individual thresholds were estimated as the geometrical mean between the lowest concentration
of a continuous series of three correct answers and the concentration just below this level. The group
threshold was estimated as the geometrical mean between all the individual thresholds.
4. Conclusions
This study focused on the use of analytical and sensory techniques to highlight the presence of
lignans in spirits and the importance of lyoniresinol. First, an LC-HRMS targeted screening of spirits
aged in barrels revealed the presence of 11 lignans. Next, the study focused on the most abundant
and the bitterest lignan, (±)-lyoniresinol, to assess its sensory role in spirits. After development and
validation of the LC-HRMS method, a racemic mixture of lyoniresinol was quantified in 24 commercial
spirits and 10 different vintages of an “eau-de-vie” of cognac. Results showed that in various spirits,
(±)-lyoniresinol was above its detection threshold, which was estimated at 2.6 mg/L. This work
revealed that this lignan has a significant impact on the taste balance of spirits, as it increases its
bitterness. Additionally, high concentrations of (±)-lyoniresinol (up to 12 mg/L) were observed in
an oaked “eau-de-vie” of cognac, and its level was detected above the detection threshold for the
considered samples, covering a period of almost 50 years. Furthermore, in the analyzed commercial
spirits, significant variations were observed, ranging from 0.2 to 11.8 mg/L, and could be partly
explained by differences in aging modalities. A similar analytical strategy could be developed to
determine the importance of the dextrorotatory enantiomer of lyoniresinol, which exhibits a strong
bitter taste, in brandies. This work brings new insight into and a better understanding of the molecular
origin of spirit taste. From a practical point of view, studying the parameters likely to affect the level of
(+)-lyoniresinol in oak wood and spirits would open up interesting perspectives for better monitoring
of the organoleptic properties of spirits.
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Abstract: The dynamics of interactions to a solvent is a key factor in the proper characterization of
new molecular structures. In molecular dynamics simulations, the solvent molecules are explicitly
present, thereby defining a more accurate description on how the solvent molecules affect the
molecular conformation. Intermolecular interactions in chemical systems, e.g., hydrogen bonds,
can be considered as networks or graphs. Graph theoretical analyses can be an outstanding tool
in analyzing the changes in interactions between solvent and solute. In this study, the software
ChemNetworks is applied to interaction studies between TIP4P solvent molecules and organic
solutes, i.e., wood-derived lignan-based ligands called LIGNOLs, thereby supporting the research
of interaction networks between organic molecules and solvents. This new approach is established
by careful comparisons to studies using previously available tools. In the hydration studies,
tetramethyl 1,4-diol is found to be the LIGNOL which was most likely to form hydrogen bonds to the
TIP4P solvent.
Keywords: lignan; molecular dynamics; intermolecular interactions; graph theory
1. Introduction
Computational chemistry is of utmost importance in scientific research today. Theoretical methods
are frequently being used in most branches to explain and predict various chemical phenomena.
A shortcoming, especially in organic synthesis, is the proper characterization of new, molecular
structures at the atomic level. The key factor often affecting the molecular minimum energy
configuration is the solvent and especially the dynamics of hydrogen bonding to the solvent [1].
Traditional quantum chemical (QC) calculations usually do not account for the solvent and are
best suited for studies of single molecules. With continuum models [2], the solvent can be taken
into account as a bulk medium. However, in molecular dynamics (MD) simulations [3] the solvent
molecules are explicitly present, thereby defining a more accurate description of how the solvent
molecules affect the molecular conformation.
Intermolecular interactions in chemical systems can be considered as networks or graphs.
Graph theory is commonly used in mathematics and computer science to model pairwise relations
between objects making up a graph, consisting of vertices connected by edges. In chemistry,
the structure of the intermolecular interaction can be treated as a graph, wherein the molecules
are regarded as vertices, and the interactions are regarded as edges. Considering intramolecular
interactions, the atoms serve as vertices; the edges represent chemical bonds between different atoms,
and the number of edges associated with a given vertex is the valence of the atom. Graph theoretical
analyses can dissect complex local and global changes occurring within the chemical network over
Molecules 2018, 23, 1990; doi:10.3390/molecules23081990 www.mdpi.com/journal/molecules359
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multiple time and length scales, thereby making it an outstanding tool in analyzing the changes in
interactions, e.g., hydrogen bond topologies [4], between solvent and solute in MD simulations. Graph
theory’s similarities to statistical mechanical simulations make it a unique new tool for analysis of
large chemical systems, as has recently been shown [5–7]. The implementation of graph theory in
chemistry belongs to a suite of approaches called Intermolecular Network Theory.
ChemNetworks [8] is a software originating from the previous edition, moleculaRnetworks [5] for
analysis of statistical mechanical data on the hierarchical structure and dynamics of water. The purpose
of this software is to process coordinates of chemical systems into a graph formalism and apply
topological network analyses that include network neighborhood, determination of geodesic pathways
(the shortest edge path between two vertices, i.e., the shortest contiguous hydrogen bond pathway in
the systems), the vertex degree census (the average distribution of hydrogen bonds), direct structural
searches, and distribution of defect states of the network. The package enables a more comprehensive
overview of different conformers compared to classical approaches, as explained in more detail within
this study.
In this work, the ChemNetworks software has been applied to interaction studies between TIP4P
solvent molecules and organic solutes, which thus provides a new way of contemplating large chemical
systems. The software has been utilized to support the research of interaction networks between
organic molecules and solvents and applied to fit the trajectory data format of common MD simulation
programs, e.g., Gromacs. By utilizing ChemNetworks, the objective in this first study was to establish
the new approach by carefully comparing results of the analyses by ChemNetworks with previously
described analyses performed with Gromacs, and to investigate a more detailed treatment of the solvent
organization around the solutes than has been possible with previously available tools.
In this study, the ChemNetworks software has been applied to TADDOL-like lignan-based chiral
ligands (LIGNOLs) as shown in Figure 1. TADDOLs [9] have hindered structures containing two
adjacent stereocenters, resulting in a fixed angle between the metal-complexing hydroxyl groups,
and are often used as ligands for transition metal catalyzed asymmetric synthesis. The LIGNOL
structures have been studied extensively [10–14] and are known on a molecular level to a great extent.
LIGNOLs are a class of 1,4-diols based on the natural product group lignans, with the same catalytic
functionality as TADDOLs [9].
 
Figure 1. General structure and numbering of atoms of the LIGNOLs (R, R′ = phenyl, methyl or
hydrogen, which is explained in more detail in Table 1).
Table 1. Description of the investigated structures.
R R′
2Ph Phenyl H
3PhR Phenyl Phenyl, H
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2. Results and Discussion
2.1. Hydration
In the LIGNOLs, there are four hydrogen bonding acceptor oxygen atoms in methoxy groups.
However, the most interesting oxygens from the reaction point of view are those in the hydroxyl
groups, O9–H and O9′–H, see Figure 1. In those groups, there are also two hydrogen bonding donors,
which can be seen in Figure 2.
 
Figure 2. Hydrogen bonding of tetramethyl 1,4-diol with TIP4P water (hydrogen atoms white, carbon
atoms cyan, oxygen atoms red; red dashed lines indicate hydrogen bonds).
In order to understand the hydration effect more properly the g_hbond analyzing program [15–19]
implemented in Gromacs was used in a previous study [11] to get the number of hydrogen bonds
for the oxygen atoms O9 and O9′, and totally for each LIGNOL conformer, as well as the average
lifetime of the uninterrupted hydrogen bonds. The g_hbond routine calculates the hydrogen bond
correlation function (CHB(t)) by accounting for the hydrogen bonds between a specific donor–acceptor
pair at different times (t1, t2), even if the hydrogen bond is absent in the interval between t1 and t2.
By integrating the resulting hydrogen bond correlation function, the average lifetime of a hydrogen
bond (the term is explained in detail in Section 2.2) can be calculated [15–19].
These are shown for comparison in the uneven columns in Table 2. The g_hbond program
computes and analyses hydrogen bonds between all possible donors (D) and acceptors (A), but cannot
perform analyses in graph formalism, e.g., geodesics, nor identify water-mediated hydrogen
bond bridges.
In Table 2, the average number of hydrogen bonds per timeframe between the LIGNOLs and the
TIP4P solvent used in ref. [11], are compared to the average hydrogen bond degree between TIP4P
and the sites of interest in the LIGNOLs. For each property, a mean value was calculated for the three
conformers of each LIGNOL structure chosen from previous studies [11] to avoid individual deviations.
The notation for the LIGNOLs is taken from ref. [10], i.e., 2Ph meaning diphenyl 1,4-diol, 3Ph meaning
triphenyl 1,4-diol, 4Ph meaning tetraphenyl 1,4-diol, and 4Met meaning tetramethyl 1,4-diol, and are
summarized in Table 2. The numbers originally referred to the three quantum chemically most stable
conformers [10] of each of the LIGNOLs, but when used in simulations, they refer to different starting
points to cover more phase space.
The columns with a “g_” before contain the number of hydrogen bonds per timeframe calculated
in ref. [11] with Gromacs tools. “Deg” is a weighted average hydrogen bond degree, as the output of
ChemNetworks gives the number of observations (time frames) separately for each degree of a specific
site. The analysis takes both hydrogens of water into account separately, so if a water molecule arranges
itself to an interaction site such that both of the two H atoms are close to that site within the hydrogen
bond cutoff, then the degree will be counted as two. The actual number is divided by two to get the
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degree concerning the number of water molecules interacting with the LIGNOL, which is comparable
to the g_hbond analysis. The indication that the same water is counted twice (instead of a bifurcated
hydrogen bond) can also be seen in the bond distance section.
In general, Table 2 (and the visualized data in Figure 3) shows that the results from ChemNetworks
compared to the Gromacs analysis tool g_hbond are coherent, although slightly different hydrogen
bond definitions are employed, as described in the experimental section. It can be seen that O9 exhibits
a slightly higher affinity to form hydrogen bonds to the solvent molecules compared to O9′ [11].
The steric hindrance within the molecule strongly depends on the kind and number of substituents.
Phenyl fragments show a much higher impact on the configuration of the molecule and towards
restrictions to form hydrogen bonds.
Table 2. The average number of hydrogen bonds per timeframe (Gromacs) compared to the
average hydrogen bond degree between TIP4P water and the sites of interest in the LIGNOLs
(ChemNetworks = CNw).
Software Gromacs CNw Gromacs CNw Gromacs CNw
Conformation g_numO9 DegO9 g_numO9′ DegO9′ g_numtot Degtot
2Ph1 1.24 1.00 0.98 0.75 6.23 5.66
2Ph2 1.23 1.06 0.98 0.80 6.26 5.93
2Ph9 1.41 1.22 0.80 0.74 6.08 5.92
Mean 1.29 ± 0.08 1.09 ± 0.09 0.92 ± 0.08 0.76 ± 0.03 6.19 ± 0.08 5.83 ± 0.12
3PhR3 1.16 1.02 0.71 0.70 5.54 5.64
3PhR4 1.11 0.99 0.78 0.76 5.53 5.64
3PhR5 1.27 0.94 1.15 0.91 6.08 5.79
Mean 1.18 ± 0.07 0.98 ± 0.03 0.88 ± 0.19 0.79 ± 0.09 5.72 ± 0.26 5.69 ± 0.07
3PhS3 1.25 1.08 0.65 0.69 5.58 5.71
3PhS7 1.12 1.01 0.80 0.77 5.60 5.67
3PhS10 1.10 0.95 1.14 0.95 6.51 5.89
Mean 1.16 ±0.07 1.01 ± 0.05 0.86 ± 0.20 0.80 ± 0.11 5.90 ± 0.43 5.75 ± 0.10
4Met2 1.20 0.97 1.33 0.97 6.35 5.93
4Met3 1.37 1.13 1.24 0.99 7.05 6.13
4Met6 1.37 1.16 1.24 1.02 7.04 6.28
Mean 1.31 ± 0.08 1.08 ± 0.08 1.27 ± 0.04 0.99 ± 0.02 6.81 ± 0.33 6.11 ± 0.14
4Ph3 0.62 0.67 1.05 0.90 5.31 5.51
4Ph4 0.68 0.67 0.95 0.84 5.23 5.41
4Ph8 0.79 0.77 0.85 0.80 5.26 5.50
Mean 0.70 ± 0.07 0.70 ± 0.05 0.95 ± 0.08 0.84 ± 0.04 5.27 ± 0.03 5.47 ± 0.04
 
Figure 3. Comparision of the average total number of hydrogen bonds per timeframe derived from
ChemNetworks (Degtot) and Gromacs (g_numtot) analysis for different molecules.
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A fact which is even more obvious in the ChemNetworks analysis is that tetramethyl 1,4-diol is
more likely to form hydrogen bonds to TIP4P, and tetraphenyl less, mainly due to the small tendency
of O9 to form hydrogen bonds to TIP4P. Figure 2 shows hydrogen bonding of tetramethyl 1,4-diol with
TIP4P water and visualizes possible steric hindrance attributed to exchanging of the substituents.
2.2. Lifetime of Hydrogen Bonds
In Table 3, the average lifetime (in ps) of the uninterrupted hydrogen bonds between the LIGNOLs
and the TIP4P solvent used in ref. [11], are compared to the mean lifetimes of the hydrogen bonds
between water and the sites of interest in the LIGNOLs. The determined timeframe is usually referred
to as resident time in case of a molecule or conformation. In the case of a hydrogen bond, it is rather
called lifetime. Throughout the study, residence times of molecules were determined and interpreted as
lifetimes of hydrogen bonds. For each property, a mean value was calculated for the three conformers
of each LIGNOL structure to avoid separate deviations. The lifetimes calculated by ChemNetworks
are doubled due to the same reason that the degrees were divided in two in the previous section.
The water molecule stays in the vicinity of the referred site for a certain time, while, on average, half of
the time the first hydrogen of water is interacting, and the other half of the time, the other hydrogen is
interacting with the solute, meaning that the water molecule is dynamically mobile when it locates
near the LIGNOL. This was also confirmed by changing the analysis code such that only the water
molecule ID was traced instead of water hydrogen labels.
Table 3 summarizes the lifetimes of the uninterrupted hydrogen bonds between the LIGNOLs
and the TIP4P solvent molecules. The results are visualized in Figure 4a for the O9 and in Figure 4b
for the O9′ atom. The unexpectedly long lifetime observed for O9′ in ref. [11] cannot be found with
ChemNetworks, although the general trend is the same. However, a correlation can be seen to the number
of hydrogen bonds, as the lifetimes are longer for tetramethyl 1,4-diol and shorter for tetraphenyl.
Shorter lifetimes for a large average number of hydrogen bonds may imply that they are slightly weak,
meaning that the hydrogen bonds from O9′ in tetramethyl 1,4-diol might be stronger compared to
O9. These findings could be important for the application of these LIGNOLs as metal-binding agents,
as their bonding to a metal-atom catalyst is comparable to the hydrogen bonding of the diol to TIP4P
water. In other words, by changing the substituents of the LIGNOL molecules it is easily possible
to design molecules with a certain strength of coordinating bonds. A comprehensive prediction by
chemical simulations might then be advantageous over synthesizing different compounds in the lab
without knowing about their coordination properties.
Diphenyl 1,4-diol was the only LIGNOL with phenyls at C9′ and not at C9, thus the reason for
this phenomenon was concluded to be the electronic effects of the phenyl rings at C9′.
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Table 3. Lifetimes (in ps) of the uninterrupted hydrogen bonds between the LIGNOLs and the
TIP4P solvent.
Software Gromacs CNw Gromacs CNw
Conformation g_lifeO9 lifeO9 g_lifeO9′ lifeO9′
2Ph1 3.35 3.30 6.18 3.68
2Ph2 3.26 3.12 5.82 3.52
2Ph9 2.29 3.02 2.24 2.92
Mean 2.97 ± 0.48 3.15 ± 0.12 4.75 ± 1.78 3.37 ± 0.33
3PhR3 2.03 3.02 1.67 2.82
3PhR4 1.97 2.96 1.72 2.96
3PhR5 2.88 3.82 3.15 3.40
Mean 2.29 ± 0.42 3.27 ± 0.39 2.18 ± 0.69 3.06 ± 0.25
3PhS3 2.08 3.08 1.58 2.70
3PhS7 1.96 2.92 1.78 3.04
3PhS10 3.53 3.18 3.35 3.16
Mean 2.52 ± 0.71 3.06 ± 0.11 2.24 ± 0.79 2.97 ± 0.19
4Met2 3.95 3.38 3.63 4.10
4Met3 3.57 3.40 3.83 3.40
4Met6 3.56 3.36 3.86 3.44
Mean 3.69 ± 0.18 3.38 ± 0.02 3.77 ± 0.10 3.65 ± 0.32
4Ph3 1.57 2.56 2.07 3.58
4Ph4 1.82 2.82 2.00 3.34
4Ph8 1.88 2.98 1.77 3.14
Mean 1.76 ± 0.13 2.79 ± 0.17 1.95 ± 0.13 3.35 ± 0.18
The results from ChemNetworks shows very clearly the effect of steric hindrance in the activity of the
hydroxyl groups of interest. Tetramethyl 1,4-diol exhibits the least sterically demanding substituents,
with a lot of space for several water molecules to move close to O9 and O9′.
 
Figure 4. Comparison of the average lifetimes (in ps) of the uninterrupted hydrogen bonds of O9 (a)
and O9′ (b) derived from ChemNetworks (life) and Gromacs (g_life) analysis for different molecules.
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The steric hindrance of all molecules is most pronounced for the tetraphenyl 1,4-diol, which is by
far the least capable of forming hydrogen bonds combined with the shortest lifetimes especially in case
of O9. The lifetimes of the four hydrogen bonding acceptor oxygen atoms in methoxy groups were
also analyzed, and they varied between 1.04 and 1.18 ps in most cases with a few exceptions reaching
up to 1.29 ps for O4 in triphenyl(S) 1,4-diol.
2.3. Distance Distributions
In the previous study with g_hbond [11], the mean value of the hydrogen bond lengths was
calculated as 0.28 nm, which corresponds well with the general approximation of O···H hydrogen
bond length of 0.18 nm in addition to the O–H bond length of 0.10 nm. Figure 5 shows the distribution
of distances between tetramethyl 1,4-diol and TIP4P water for the whole solute and oxygen atom O9′
calculated by ChemNetworks.
As previously stated, in ChemNetworks, each interaction is treated separately for each site in every
molecule for every frame in the trajectory. The distance distribution shown in Figure 5 shows one peak
at around 0.18 nm corresponding to the water molecule that directly interacts with the LIGNOL site
(the first hydration shell), while the second partial peak at 0.3 nm may have contribution from the
first hydration shell (another hydrogen atom) and the second hydration shell (those water molecules
that are not directly interacting with the LIGNOL, but interacting with the first hydration shell water).
The second coordination shell usually gives broader distribution, and the reason for the illusionary
sharpness of the secondary peak is that it is truncated in this case. ChemNetworks does not include the
O–H bond length (approximately 0.1 nm) in the value of the hydrogen bond, so the average distance
to the closer hydrogen is approximately 0.18 nm. A hydrogen bond distance cutoff of 0.25 nm would
be enough for these systems since it is the minimum of this distribution which can exclude the second
shell water in the analysis. Besides, this supports the double-interaction from the two hydrogen atoms
of a water molecule, which can explain the difference in the degree and probably in the hydrogen
bond lifetime.
 
Figure 5. Distribution of distances between tetramethyl 1,4-diol and TIP4P water for the whole solute
(black squares) and oxygen atom O9′ (grey circles).
3. Materials and Methods
In the LIGNOLs, there are four hydrogen bonding acceptor oxygen atoms in methoxy groups.
However, the most interesting oxygens from the reaction point of view are those in the hydroxyl
groups, O9–H and O9′–H, see Figure 1. In those groups, there are also two hydrogen bonding donors,
which can be seen in Figure 2.
In order to understand the hydration effect more properly, the g_hbond analyzing program [15–19]
implemented in Gromacs (version 4.5.3) was used in a previous study [11] to get the number of hydrogen
bonds for the oxygen atoms O9 and O9′, and totally for each LIGNOL conformer, as well as the average
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lifetime of the uninterrupted hydrogen bonds. These are shown for comparison in the uneven columns
in Table 3. The g_hbond program computes and analyses hydrogen bonds between all possible donors
(D) and acceptors (A), but cannot perform analyses in graph formalism, e.g., geodesics, nor identify
water-mediated hydrogen bond bridges. The existence of a hydrogen bond was determined by a
geometrical criterion, i.e., r(DA) ≤ 0.35 nm and α(HDA) ≤ 30◦ [15–19].
The purpose of the ChemNetworks (version 2.2) software is to process Cartesian coordinates of the
chemical systems into a graph formalism and apply topological network analyses, thereby describing
intermolecular chemical networks of entire systems quantitatively at both the local and global levels
and as a function of time. In Scheme 1, the analysis steps are described schematically.
 
Scheme 1. Schematic flowchart for the ChemNetworks run (graph theoretical analysis).
Before the actual graph theoretical analysis, the Cartesian (.xyz) simulation data needs to be
converted into a graph (an output file called *.graph). This procedure is accomplished by defining
the system topology in an input file, where all atoms for each molecule as well as all internal
bonds are listed. In this study, the interactions were calculated with the geometric criteria of the
nonbonded distance r(O . . . H) < 0.30 nm and the hydrogen bond angle α(HO . . . H) unspecified,
which means that all the possible angles are accepted as intermolecular interactions to get a proper
calculation of the surrounding water molecules. Periodic boundary conditions (PBC) were applied in
the original simulations, and these can be accounted for in ChemNetworks so that the graph can cross
the PBC boundaries.
The first analysis includes determination of each vertex degree and the network neighborhood,
which gives the edge distributions. In the .graph file containing the intermolecular interactions, all pairs
of vertices sharing an edge are listed. In graph theory, the degree of a vertex is defined as a count of
the number of connections to that vertex. In this first-degree analysis step, the numbers of edges per
vertex are collected for a histogram of the edge distribution. The edge distribution is essentially the
same as the integrated pair distribution function but split into its intrinsic components.
The second analysis involves the determination of the geodesics, in this study meaning the shortest
contiguous hydrogen bond paths between every pair of vertices, and their lifetimes. This can be done
separately for each site specified in the system; in this case, different oxygen atoms. In chemical
systems, all possible paths for the intermolecular interaction graph are not that trivial to analyze
mathematically. However, the adjacency matrix can be converted to a geodesic distance (gd) matrix via
the Floyd–Warshall algorithm [20,21], which is not possible by Gromacs analysis tools. The gd matrix is
a square matrix with the dimension N, i.e., the total number of vertices. The entries of the matrix are
the geodesics [22] (geodesic distances), i.e., the number of edges in the shortest path connecting two
vertices (atoms) in a graph. The output of the geodesics analysis (.geopath) is a list for each graph of
all paths between all sets of vertices connected by edges.
The last part of the analysis in this study comprises the residence times of the solute–solvent
interactions, which are calculated as the average of all hydrogen bond durations weighted by the
relative concentration of each species with a specific residence time in solution. Considering all
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individual edges for the residence time determination might be too memory intensive for simple
spreadsheet programs. Thus, the geodesic-statistics.c code of ChemNetworks is strongly preferred.
To conclude the description of the analysis algorithms, the solute configurations with a
certain number of interactions (i) with solvent molecules are identified for every snapshot, and the
corresponding number of observed occurrences is recorded as N(i). The degree census is obtained as
the statistic histogram of N(i). The solute–solvent interaction is monitored concerning individual sites
from the solute molecule such that the degree per site can be resolved. Thus, the degree census depicts
the structure of solute–solvent interactions around each site. On the other hand, the solute–solvent
residence time is representative of the dynamic feature of the solute–solvent interaction. The continuous
persistence (ti) of every solute–solvent interaction is traced along the trajectory. Finally, the residence
time of solute–solvent interactions is calculated as the average interaction persistence weighted by its
relative occurrence probability P(ti). The residence time of the solute–solvent interaction is also labeled
concerning the interacting sites so that the residence time of each site can be obtained.
Data Format and Working Procedure
The trajectory data format of common MD simulation programs, e.g., Gromacs, is binary, and one
of the important practical tasks is to make a recipe for how to treat the trajectory data to be readable
by ChemNetworks. In this study, it has been done by applying the compressed and portable trajectory
format (.xtc) in combination with the structure format (.gro) and saving it as Cartesian coordinates
(.xyz) in VMD [23]. Although Gromacs tools (trj_conv) can convert trajectories to human readable
formats, this was found to be the most convenient way to make them ChemNetworks readable.
For each structure, a multi-level deterministic structural optimization was conducted in earlier
studies, including complementary QC calculations [10] (step 1 in Scheme 2), and MD simulations [11]
(step 2 in Scheme 2). The optimizations were performed using DFT [24] with the B3LYP hybrid
exchange-correlation functional [25–27] in combination with the MARI-J approximation [28–30] and
the TZVP basis set [31] for all atoms, as implemented in the Turbomole program package. The MD
simulations were performed using the Gromacs version 4.5.3 software [15–19]. Water was described
using the TIP4P model [32], and the LIGNOLs were modeled with the OPLS-AA force field [33]
implemented in Gromacs. The topologies of the LIGNOLs were constructed manually and they
comprised between 533 (4Ph) and 369 (4Met) internal coordinates, respectively. To get reasonable
atomic charges to help choose suitable atom types with the hand-tuned charges available in the
force field, electrostatic potential fit (ESP) charges were studied with GAMESS at HF/6-31G* level.
For O9 and O9′ (shown in Figure 1), the OPLS atom type opls_154 with the atomic charge −0.683
was found to be the most suitable, and for the other four oxygens (O3, O4, O4′, and O5′), the atom
type opls_179 with the atomic charge −0.285 was chosen. The parametrization is crucial information
when explaining differences in persistence by electronic effects which are not intrinsically described in
a force field. An important detail to consider is also that the sum of the atomic charges in a charge
group should be an integer or equal to zero. Each conformation was placed at the center of a cubic
box with the dimension between 5.2 and 5.6 nm (volume = 144–174 nm3) and solvated by 4802–5795
water molecules. The original simulations in ref. [11] were run for ten ns with a one fs time step at
298 K and 1 atm. The whole trajectory was used for the analysis. A cutoff of 0.9 nm was applied to
short-range nonbonded interactions, and for long-range electrostatic interactions, the particle mesh
Ewald (PME) method [34,35] was used with a grid spacing of 0.12 nm and fourth-order interpolation.
In all simulations, system snapshots were collected every 500 steps, i.e., every 0.5 ps, for subsequent
analysis. In this time, only electronic excitations and bonding vibrations will occur, but those can
be ignored when studying the conformational preferences of the system. It is important to get a
comprehensive view of all the studied systems to locate possible shortcomings and develop the
software to handle those. The flowchart for the working procedure is shown in Scheme 2.
367
Molecules 2018, 23, 1990
 
Scheme 2. Flowchart for the working procedure.
4. Conclusions
ChemNetworks gives a more detailed description of solvent organization around the solutes as
the output gives the number of observations separately for each degree of a specific site and both
hydrogens of the TIP4P solvent are taken into account separately. This result was confirmed in all
three parts of the performed analysis. The general objective of this study, i.e., to establish the new
approach by careful comparison of the analyses by ChemNetworks with previously described analyses
performed with Gromacs, was accomplished. A successful recipe was proposed for applying the graph
theoretical analysis software to molecular dynamics trajectories by Gromacs. In the hydration studies,
tetramethyl 1,4-diol was found to be most likely to form hydrogen bonds, which could be important
for application of the LIGNOL as a metal-binding agent. Also, the residence times for tetramethyl
1,4-diol were found to be longer, meaning that the hydrogen bonds might be strong. The results from
ChemNetworks show very clearly the effect of a steric hindrance in the activity of the hydroxyl groups
of interest. The hydration studies of the MD simulations confirm that several of these LIGNOLs,
produced from a renewable source, have great potential as chiral catalysts.
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